Characterization	O
of	O
the	O
cellular	O
transcription	B-protein
factors	I-protein
interacting	O
with	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV-I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O
	
Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
elements	I-DNA
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	B-cell_line
lines	I-cell_line
of	O
lymphocytic	B-cell_type
,	I-cell_type
monocytic	I-cell_type
,	I-cell_type
neuronal	I-cell_type
,	I-cell_type
and	I-cell_type
glial	I-cell_type
cell	I-cell_type
origin	I-cell_type
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	B-protein
factors	I-protein
to	O
the	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
(	O
1-4	O
)	O
.	O
	
ATF/CREB	B-protein
and	O
Sp	B-protein
family	I-protein
members	I-protein
interacted	O
with	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
to	O
form	O
DNA-protein	B-protein
complexes	I-protein
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O
	
However	O
,	O
a	O
unique	O
DNA-protein	B-protein
complex	I-protein
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	B-cell_line
MG	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
or	O
the	O
THP-1	B-cell_line
mature	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA-protein	B-protein
complex	I-protein
is	O
comprised	O
of	O
the	O
AP-1	B-protein
components	O
,	O
Fos	B-protein
and	O
Jun	B-protein
.	O
	
###MEDLINE:97248268	
	
HIV	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
CD3/CD28	B-protein
.	O
	
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
by	O
cross-linking	O
CD3	B-protein
and	O
CD28	B-protein
.	O
	
In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
in	O
the	O
same	O
way	O
.	O
	
Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	B-protein
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS-isolated	O
)	O
subsets	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
identified	O
by	O
expression	O
of	O
both	O
CD45RA	B-protein
and	O
CD62L	B-protein
.	O
	
Remixing	O
of	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
that	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B-protein
coreceptors	I-protein
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B-protein
factors	I-protein
,	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
activator	B-protein
protein-1	I-protein
.	O
	
The	O
inherent	O
resistance	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
HIV-infected	O
adults	O
.	O
	
###MEDLINE:97225991	
	
A	O
PMLRARalpha	B-DNA
transgene	I-DNA
initiates	O
murine	O
acute	O
promyelocytic	O
leukemia	O
.	O
	
The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O
	
To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B-protein
PMLRAR	I-protein
alpha	I-protein
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B-DNA
alpha	I-DNA
cDNA	I-DNA
in	O
myeloid	B-cell_type
cells	I-cell_type
of	O
transgenic	O
mice	O
.	O
	
PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O
	
Both	O
the	O
preleukemic	O
state	O
and	O
the	O
leukemia	O
could	O
be	O
transplanted	O
to	O
nontransgenic	O
mice	O
,	O
and	O
the	O
transplanted	O
preleukemia	O
could	O
progress	O
to	O
APL	O
.	O
	
The	O
APL	O
recapitulated	O
features	O
of	O
the	O
human	O
disease	O
,	O
including	O
a	O
response	O
to	O
retinoic	O
acid	O
.	O
	
Retinoic	O
acid	O
caused	O
the	O
leukemic	B-cell_type
cells	I-cell_type
to	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
eliciting	O
remissions	O
of	O
both	O
the	O
preleukemic	O
state	O
and	O
APL	O
in	O
mice	O
.	O
	
Our	O
results	O
demonstrate	O
that	O
PMLRAR	B-protein
alpha	I-protein
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O
	
The	O
transgenic	O
mice	O
described	O
here	O
provide	O
an	O
apparently	O
accurate	O
model	O
for	O
human	O
APL	O
that	O
includes	O
clear	O
evidence	O
of	O
tumor	O
progression	O
.	O
	
The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O
	
###MEDLINE:97276992	
	
DNA	O
methylation	O
changes	O
in	O
hematologic	O
malignancies	O
:	O
biologic	O
and	O
clinical	O
implications	O
.	O
	
DNA	O
methylation	O
changes	O
are	O
among	O
the	O
most	O
common	O
detectable	O
abnormalities	O
in	O
human	O
neoplasia	O
.	O
	
Hypermethylation	O
within	O
the	O
promoters	B-DNA
of	O
selected	O
genes	O
appears	O
to	O
be	O
especially	O
common	O
in	O
all	O
types	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
neoplasms	I-cell_type
,	O
and	O
is	O
usually	O
associated	O
with	O
inactivation	O
of	O
the	O
involved	O
gene	O
(	O
s	O
)	O
.	O
	
Such	O
hypermethylation-associated	O
silencing	O
of	O
gene	O
expression	O
has	O
been	O
shown	O
for	O
several	O
genes	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
the	O
estrogen	B-DNA
receptor	I-DNA
(	I-DNA
ER	I-DNA
)	I-DNA
gene	I-DNA
,	O
P15	O
,	O
P16	O
and	O
others	O
.	O
	
Hypermethylation	O
within	O
the	O
promoters	B-DNA
of	O
some	O
genes	O
appear	O
to	O
be	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
neoplasia	O
(	O
ER	B-DNA
,	O
P15	B-DNA
)	O
,	O
while	O
other	O
genes	O
seem	O
to	O
become	O
methylated	O
during	O
the	O
progression	O
of	O
leukemias	O
(	O
HIC1	O
,	O
c-abl	O
)	O
.	O
	
The	O
high	O
prevalence	O
of	O
promoter	O
methylation	O
suggests	O
that	O
this	O
molecular	O
abnormality	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
activity	O
during	O
therapy	O
.	O
	
In	O
addition	O
,	O
new	O
technology	O
allows	O
the	O
sensitive	O
identification	O
of	O
gene	O
hypermethylation	O
in	O
a	O
background	O
of	O
normal	B-cell_type
cells	I-cell_type
,	O
suggesting	O
possible	O
new	O
strategies	O
for	O
the	O
detection	O
of	O
minimal	O
residual	O
disease	O
.	O
	
Finally	O
,	O
reactivation	O
of	O
tumor-suppressor	O
gene	O
expression	O
through	O
pharmacologic	O
inhibition	O
of	O
DNA	B-protein
methyltransferase	I-protein
and	O
resultant	O
DNA	O
demethylation	O
appears	O
to	O
be	O
a	O
promising	O
new	O
avenue	O
of	O
therapy	O
in	O
acute	O
leukemia	O
.	O
	
###MEDLINE:97214626	
	
Redox	O
regulation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
during	O
lymphocyte	O
activation	O
.	O
	
We	O
have	O
previously	O
demonstrated	O
an	O
obligatory	O
requirement	O
for	O
intracellular	O
reactive	O
oxygen	O
species	O
generation	O
during	O
T	O
lymphocyte	O
activation	O
,	O
and	O
have	O
proposed	O
that	O
intracellular	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
signalling	O
agents	O
in	O
the	O
regulation	O
of	O
certain	O
cellular	O
processes	O
,	O
for	O
example	O
,	O
during	O
cell	O
cycle	O
entry	O
.	O
	
To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
been	O
interested	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
cell	O
cycle	O
entry	O
events	O
are	O
affected	O
by	O
oxidative	O
signalling	O
.	O
	
In	O
earlier	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
processes	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
have	O
shown	O
that	O
oxidative	O
signalling	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
early	O
changes	O
in	O
gene	O
expression	O
during	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
.	O
	
To	O
extend	O
these	O
initial	O
observations	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
the	O
activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
erk1	B-protein
and	O
erk2	B-protein
,	O
as	O
members	O
of	O
a	O
signal	O
transduction	O
pathway	O
known	O
to	O
directly	O
regulate	O
transcription	O
factor	O
function	O
.	O
	
Using	O
as	O
a	O
probe	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
both	O
antioxidant	O
and	O
antiproliferative	O
activity	O
,	O
we	O
have	O
identified	O
erk2	B-protein
,	O
a	O
key	O
element	O
of	O
the	O
MAP	O
kinase	O
pathway	O
,	O
as	O
being	O
responsive	O
to	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O
	
These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O
	
###MEDLINE:97184448	
	
Physical	O
and	O
functional	O
interaction	O
between	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax1	I-protein
protein	I-protein
and	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
.	O
	
Tax1	B-protein
,	O
a	O
potent	O
activator	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transcription	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
expression	O
of	O
many	O
cellular	B-DNA
genes	I-DNA
.	O
	
Tax1	B-protein
does	O
not	O
bind	O
DNA	O
directly	O
but	O
regulates	O
transcription	O
through	O
protein-protein	O
interactions	O
with	O
sequence-specific	B-protein
transcription	I-protein
factors	I-protein
.	O
	
Using	O
the	O
yeast	O
two-hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-protein
,	O
we	O
isolated	O
the	O
B	B-protein
subunit	I-protein
of	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
from	O
a	O
HeLa	B-DNA
cDNA	I-DNA
library	I-DNA
.	O
	
The	O
interaction	O
of	O
Tax1	B-protein
with	O
NF-YB	B-protein
was	O
specific	O
in	O
that	O
NF-YB	B-protein
did	O
not	O
interact	O
with	O
a	O
variety	O
of	O
other	O
transcription	B-protein
factors	I-protein
,	O
including	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
Tat	I-protein
,	O
human	B-protein
papillomavirus	I-protein
E6	I-protein
,	O
and	O
Bicoid	B-protein
,	O
or	O
with	O
the	O
M7	B-protein
(	I-protein
amino	I-protein
acids	I-protein
29CP-AS	I-protein
)	I-protein
Tax1	I-protein
mutant	I-protein
.	O
	
However	O
,	O
NF-YB	B-protein
did	O
interact	O
with	O
the	O
C-terminal	B-protein
Tax1	I-protein
mutants	I-protein
M22	B-protein
(	O
130TL-AS	B-protein
)	O
and	O
M47	B-protein
(	O
319LL-RS	B-protein
)	O
.	O
	
We	O
also	O
show	O
that	O
in	O
vitro-translated	O
NF-YB	B-protein
specifically	O
bound	O
to	O
a	O
glutathione	B-protein
S-transferase-Tax1	I-protein
fusion	I-protein
protein	I-protein
.	O
	
Further	O
,	O
Tax1	B-protein
coimmunoprecipitated	O
with	O
NF-Y	B-protein
from	O
nuclear	O
extracts	O
of	O
HTLV-1-transformed	B-cell_type
cells	I-cell_type
,	O
providing	O
evidence	O
for	O
in	O
vivo	O
interaction	O
of	O
Tax1	B-protein
and	O
NF-YB	B-protein
.	O
	
We	O
further	O
demonstrate	O
that	O
Tax1	B-protein
specifically	O
activated	O
the	O
NF-Y-responsive	B-DNA
DQbeta	I-DNA
promoter	I-DNA
,	O
as	O
well	O
as	O
a	O
minimal	B-DNA
promoter	I-DNA
which	O
contains	O
only	O
the	O
Y-box	B-DNA
element	I-DNA
.	O
	
In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O
	
Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
Tax1	B-protein
interacts	O
with	O
NF-Y	B-protein
through	O
the	O
B	B-protein
subunit	I-protein
and	O
that	O
this	O
interaction	O
results	O
in	O
activation	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
promoter	I-DNA
.	O
	
Through	O
activation	O
of	O
this	O
and	O
other	O
NF-Y	B-protein
driven	O
promoters	B-DNA
,	O
the	O
Tax1	B-protein
-NF-Y	B-protein
interaction	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
cellular	O
transformation	O
and	O
HTLV-1	O
pathogenesis	O
.	O
	
###MEDLINE:97265687	
	
High	O
levels	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
in	O
adult	O
T-cell	O
leukemia	O
and	O
human	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
virus	I-cell_type
type	I-cell_type
I-infected	I-cell_type
cells	I-cell_type
:	O
possible	O
enhancement	O
of	O
DNA-binding	O
of	O
E2F	B-protein
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
I	I-protein
transactivating	I-protein
protein	I-protein
,	O
Tax	B-protein
.	O
	
Transcription	B-protein
factor	I-protein
E2F	B-protein
binds	O
to	O
cellular	B-DNA
promoters	I-DNA
of	O
certain	O
growth-	B-DNA
and	I-DNA
cell	I-DNA
cycle-controlling	I-DNA
genes	I-DNA
and	O
forms	O
distinct	O
heteromeric	B-protein
complexes	I-protein
with	O
other	O
nuclear	B-protein
proteins	I-protein
.	O
	
It	O
has	O
therefore	O
been	O
proposed	O
that	O
E2F	B-protein
is	O
involved	O
in	O
cellular	O
proliferation	O
control	O
.	O
	
Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
	
We	O
show	O
here	O
by	O
mobility-shift	O
assay	O
that	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
were	O
detected	O
in	O
HTLV-I-infected	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
leukemic	B-cell_type
cells	I-cell_type
obtained	O
from	O
ATL	O
patients	O
but	O
not	O
in	O
an	O
uninfected	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
,	O
and	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
The	O
Tax	B-protein
protein	I-protein
,	O
encoded	O
by	O
HTLV-I	O
,	O
is	O
a	O
potent	O
transcription	O
activator	O
of	O
viral	O
and	O
several	O
cellular	B-DNA
genes	I-DNA
.	O
	
We	O
demonstrate	O
that	O
expression	O
of	O
Tax	B-protein
can	O
induce	O
the	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Thus	O
,	O
Tax	B-protein
,	O
through	O
enhancement	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
,	O
may	O
be	O
capable	O
of	O
regulating	O
cellular	O
gene	O
expression	O
implicated	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
ATL	O
.	O
	
This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV-I	O
which	O
does	O
not	O
contain	O
oncogenes	B-DNA
induces	O
neoplasia	O
.	O
	
###MEDLINE:97167598	
	
Dissociation	O
of	O
the	O
Jak	B-protein
kinase	I-protein
pathway	O
from	O
G-CSF	B-protein
receptor	I-protein
signaling	O
in	O
neutrophils	O
.	O
	
Activation	O
of	O
the	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
(	O
G-CSFR	B-protein
)	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
intracellular	B-protein
substrates	I-protein
in	O
proliferating	B-cell_type
cells	I-cell_type
and	O
nonproliferating	B-cell_type
,	I-cell_type
terminally	I-cell_type
differentiated	I-cell_type
neutrophils	I-cell_type
.	O
	
The	O
kinases	O
that	O
couple	O
ligand	O
binding	O
to	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
substrates	I-protein
by	O
the	O
G-CSFR	O
with	O
activation	O
of	O
specific	O
functional	O
programs	O
are	O
largely	O
unknown	O
.	O
	
In	O
this	O
study	O
,	O
we	O
examined	O
early	O
signaling	O
events	O
in	O
proliferating	B-cell_type
and	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
following	O
G-CSF	B-protein
stimulation	O
to	O
determine	O
whether	O
identical	O
signaling	O
cascades	O
are	O
activated	O
.	O
	
In	O
murine	B-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
transfected	O
with	O
the	O
human	B-protein
G-CSFR	I-protein
and	O
NFS-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
the	O
murine	B-protein
G-CSFR	I-protein
,	O
G-CSF	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Tyk2	B-protein
.	O
	
Tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Stat1	B-protein
was	O
also	O
detected	O
following	O
G-CSF	B-protein
stimulation	O
.	O
	
Using	O
a	O
mitogenically	B-protein
incompetent	I-protein
human	I-protein
G-CSFR	I-protein
mutant	I-protein
in	O
which	O
Pro639	O
and	O
Pro641	O
were	O
substituted	O
by	O
alanine	O
,	O
the	O
box	B-protein
1	I-protein
PDP	I-protein
motif	I-protein
was	O
found	O
to	O
be	O
required	O
for	O
activation	O
of	O
Jak	B-protein
kinases	I-protein
,	O
tyrosine	O
phosphorylation	O
of	O
the	O
G-CSFR	B-protein
,	O
and	O
recruitment	O
of	O
Stat	B-protein
proteins	I-protein
.	O
	
Notably	O
,	O
no	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
Tyk2	B-protein
,	O
Stat1	B-protein
,	O
or	O
Stat3	B-protein
was	O
observed	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
.	O
	
In	O
addition	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
in	O
neutrophils	B-cell_type
of	O
the	O
recently	O
cloned	O
Jak3	B-protein
kinase	I-protein
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
myeloid	B-cell_type
cells	I-cell_type
undergo	O
terminal	O
neutrophilic	O
maturation	O
.	O
	
These	O
results	O
indicate	O
a	O
lack	O
of	O
involvement	O
of	O
Jak	B-protein
kinases	I-protein
in	O
signaling	O
by	O
the	O
G-CSFR	B-protein
in	O
neutrophils	B-cell_type
,	O
and	O
suggest	O
utilization	O
of	O
alternative	O
signal	O
transduction	O
pathways	O
distinct	O
from	O
those	O
in	O
proliferating	B-cell_type
cells	I-cell_type
.	O
	
Activation	O
of	O
the	O
Jak	B-protein
-Stat	B-protein
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G-CSFR	B-protein
and	O
requires	O
the	O
membrane-proximal	B-protein
box	I-protein
1	I-protein
PXP	I-protein
motif	I-protein
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B-protein
receptor	I-protein
superfamily	I-protein
.	O
	
###MEDLINE:97167569	
	
Impaired	O
induction	O
of	O
c-fos/c-jun	B-DNA
genes	I-DNA
and	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
binding	O
distinct	O
c-fos/c-jun	B-DNA
promoter	I-DNA
elements	I-DNA
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
aging	O
.	O
	
The	O
activation	O
of	O
transcriptional	B-protein
factor	I-protein
c-Fos/c-Jun	O
AP-1	B-protein
is	O
essential	O
for	O
normal	O
T	B-cell_type
cell	I-cell_type
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	B-cell_type
cells	I-cell_type
during	O
aging	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c-fos/c-jun	B-DNA
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age-associated	O
impairments	O
of	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Whereas	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
stimulated	O
with	O
cross-linked	B-protein
anti-CD3epsilon	I-protein
mAb	I-protein
OKT3	B-protein
plus	O
PMA	O
or	O
with	O
the	O
lectin	B-protein
PHA	B-protein
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c-Fos	B-protein
protein	O
expression	O
,	O
the	O
expression	O
of	O
c-Fos	B-protein
but	O
not	O
c-Jun	B-protein
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
certain	O
elderly	O
subjects	O
.	O
	
In	O
addition	O
,	O
RNase	B-protein
protection	O
assays	O
revealed	O
that	O
anti-CD3/	O
PMA-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c-fos	B-RNA
and/or	I-RNA
c-jun	I-RNA
mRNA	I-RNA
compared	O
to	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
.	O
	
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	O
of	O
nuclear	B-protein
regulatory	I-protein
proteins	I-protein
recognizing	O
the	O
AP-1	B-DNA
consensus	I-DNA
TRE	I-DNA
motif	I-DNA
,	O
the	O
proximal	B-DNA
c-jun	I-DNA
TRE-like	I-DNA
promoter	I-DNA
element	I-DNA
,	O
and	O
the	O
c-fos	B-DNA
serum	I-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
were	O
determined	O
in	O
resting	B-cell_type
and	I-cell_type
stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Although	O
the	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	O
of	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
binding	O
the	O
AP-1	B-DNA
TRE	I-DNA
,	O
c-jun	B-DNA
TRE	I-DNA
,	O
and	O
c-fos	B-DNA
SRE	I-DNA
DNA	I-DNA
sequence	I-DNA
motifs	I-DNA
,	O
age-related	O
reductions	O
in	O
the	O
activation	O
of	O
AP-1	B-protein
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c-jun	B-protein
TRE	I-protein
and	I-protein
c-fos	I-protein
SRE	I-protein
binding	I-protein
complexes	I-protein
.	O
	
Furthermore	O
,	O
the	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
binding	O
the	O
SRE	B-DNA
motif	I-DNA
induced	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B-protein
response	I-protein
factor	I-protein
and	O
Elk-1	B-protein
pointing	O
toward	O
age-related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
distinct	O
from	O
c-jun/AP-1	B-protein
.	O
	
These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c-fos/c-jun	B-DNA
as	O
well	O
as	O
their	O
nuclear	B-protein
regulatory	I-protein
proteins	I-protein
may	O
contribute	O
to	O
the	O
age-related	O
impairments	O
of	O
AP-1	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:97276819	
	
Retinoic	O
acid-induced	O
modulation	O
of	O
IL-2	B-RNA
mRNA	I-RNA
production	O
and	O
IL-2	B-protein
receptor	O
expression	O
on	O
T	B-cell_type
cells	I-cell_type
.	O
	
BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune-modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O
	
Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	B-protein
(	O
Ig	O
)	O
response	O
.	O
	
Investigating	O
cytokines	B-protein
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	B-protein
production	O
is	O
augmented	O
by	O
RA	O
.	O
	
In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	B-RNA
mRNA	I-RNA
,	O
another	O
important	O
cytokine	B-protein
for	O
B	O
cell	O
immunoglobulin	B-protein
production	O
,	O
the	O
expression	O
of	O
IL-2	B-protein
receptors	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
RA	B-protein
nuclear	I-protein
receptors	I-protein
.	O
	
METHODS	O
:	O
Purified	O
T	B-cell_type
cells	I-cell_type
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent/media	O
control	O
for	O
0	O
,	O
6-8	O
,	O
and	O
24	O
h	O
.	O
	
Total	O
mRNA	B-RNA
was	O
extracted	O
from	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
using	O
RT-PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	B-protein
and	O
RA	B-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
-	O
alpha	B-RNA
,	O
beta	B-RNA
,	O
gamma	B-RNA
mRNA	I-RNA
were	O
determined	O
.	O
	
The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	B-cell_type
cells	I-cell_type
.	O
	
CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL-2	B-RNA
mRNA	I-RNA
production	O
by	O
T	B-cell_type
cells	I-cell_type
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL-2R-alpha	B-protein
expression	O
.	O
	
These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR-alpha	B-protein
.	O
	
Thus	O
,	O
IL-2	B-protein
may	O
be	O
another	O
important	O
cytokine	B-protein
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O
	
###MEDLINE:97263762	
	
Involvement	O
of	O
an	O
SAF-like	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
activation	O
of	O
serum	B-DNA
amyloid	I-DNA
A	I-DNA
gene	I-DNA
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
.	O
	
Serum	B-protein
amyloid	I-protein
A	I-protein
(	O
SAA	B-protein
)	O
has	O
been	O
linked	O
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high-density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	O
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	B-DNA
gene	I-DNA
in	O
THP-1	B-cell_line
monocyte/macrophage	I-cell_line
cells	I-cell_line
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O
	
We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B-protein
gene	O
is	O
induced	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
	
By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	B-DNA
promoter	I-DNA
sequence	I-DNA
between	O
-280	O
and	O
-226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O
	
Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA-binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O
	
Characterization	O
of	O
the	O
DNA-binding	B-protein
protein	I-protein
by	O
UV	O
cross-linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	B-protein
factor	I-protein
designated	O
SAF	B-protein
.	O
	
These	O
results	O
demonstrated	O
that	O
LPS-mediated	O
SAA	B-protein
gene	O
induction	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	B-protein
activity	O
.	O
	
###MEDLINE:97298895	
	
Cytomegalovirus	B-DNA
immediate	I-DNA
early	I-DNA
genes	I-DNA
upregulate	O
interleukin-6	B-protein
gene	O
expression	O
.	O
	
BACKGROUND	O
:	O
The	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
(	O
IE	B-DNA
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
are	O
known	O
to	O
regulate	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
.	O
	
Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O
	
Interleukin-6	B-protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O
	
The	O
regulation	O
of	O
IL-6	B-protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	B-protein
.	O
	
These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	B-protein
production	O
.	O
	
METHODS	O
:	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
.	O
	
Interleukin-6	B-protein
protein	O
and	O
IL-6	B-RNA
mRNA	I-RNA
were	O
measured	O
in	O
control	O
and	O
CMV	B-cell_type
immediate	I-cell_type
early	I-cell_type
transfected	I-cell_type
cells	I-cell_type
.	O
	
Cotransfection	O
of	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
IL-6	B-DNA
chloramphenicol	I-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
or	I-DNA
IL-6	I-DNA
luciferase	I-DNA
constructs	I-DNA
were	O
used	O
to	O
study	O
IL-6	B-protein
promoter	O
activity	O
.	O
	
RESULTS	O
:	O
Interleukin-6	B-protein
protein	I-protein
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS-stimulated	B-cell_line
control	I-cell_line
cells	I-cell_line
.	O
	
Cytomegalovirus	B-protein
IE	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	B-DNA
promoter	I-DNA
activity	O
in	O
both	O
IL-6	B-protein
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O
	
A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL-6	B-protein
luciferase	B-protein
activity	O
in	O
LPS-stimulated	B-cell_line
CMV	I-cell_line
transfected	I-cell_line
cells	I-cell_line
.	O
	
CONCLUSION	O
:	O
Cytomegalovirus	B-protein
immediate	I-protein
early	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
expression	O
of	O
IL-6	B-protein
in	O
LPS-stimulated	O
cells	O
.	O
	
The	O
increase	O
in	O
IL-6	B-protein
luciferase	B-protein
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
responsive	O
to	O
IL-1	B-protein
,	O
TNF	B-protein
alpha	I-protein
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
	
The	O
ability	O
of	O
CMV	B-protein
IE	I-protein
gene	I-protein
products	I-protein
to	O
enhance	O
IL-6	B-protein
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O
	
###MEDLINE:97255754	
	
Induction	O
of	O
relA	B-protein
(	I-protein
p65	I-protein
)	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
subunit	I-protein
expression	O
during	O
differentiation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
to	O
macrophages	B-cell_type
.	O
	
We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
subunits	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDMs	B-cell_type
)	O
.	O
	
Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	B-protein
homodimers	I-protein
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O
	
An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	I-protein
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	B-cell_type
.	O
	
Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	B-cell_type
and	O
MDMs	B-cell_type
.	O
	
In	O
contrast	O
,	O
the	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
was	O
barely	O
detectable	O
in	O
monocytes	B-cell_type
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	B-cell_type
.	O
	
Analysis	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
revealed	O
that	O
the	O
stability	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
significantly	O
higher	O
in	O
MDMs	B-cell_type
,	O
compared	O
with	O
monocytes	B-cell_type
.	O
	
In	O
MDMs	B-cell_type
,	O
an	O
upregulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
were	O
also	O
observed	O
.	O
	
These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	I-protein
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O
	
The	O
parallel	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
complexes	I-protein
that	O
are	O
readily	O
available	O
for	O
inducer-mediated	O
stimulation	O
.	O
	
###MEDLINE:97211823	
	
Nuclear	B-protein
Rel-A	I-protein
and	I-protein
c-Rel	I-protein
protein	I-protein
complexes	I-protein
are	O
differentially	O
distributed	O
within	O
human	B-cell_type
thymocytes	I-cell_type
.	O
	
Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
proteins	I-protein
are	O
inducible	O
transcriptional	B-protein
regulators	I-protein
of	O
numerous	O
cellular	B-DNA
genes	I-DNA
.	O
	
They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
	
We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	B-cell_type
thymocytes	I-cell_type
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O
	
In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50/p65	B-protein
and	I-protein
p50/c-Rel	I-protein
complexes	I-protein
.	O
	
Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	B-protein
Abs	I-protein
allowed	O
visualization	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
proteins	I-protein
in	O
both	O
thymocytes	B-cell_type
and	O
nonthymocyte	B-cell_type
cells	I-cell_type
.	O
	
This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50/c-Rel	B-protein
in	O
medullary	B-cell_type
thymocytes	I-cell_type
,	O
whereas	O
p50/p65	B-protein
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O
	
However	O
,	O
the	O
intensity	O
of	O
p65	B-protein
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	B-cell_type
from	O
the	O
medulla	O
.	O
	
p65	O
,	O
p50	O
,	O
and	O
c-Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	B-cell_type
and	I-cell_type
CD8-positive	I-cell_type
thymocytes	I-cell_type
.	O
	
These	O
observations	O
suggest	O
that	O
p65	B-protein
and	I-protein
c-Rel	I-protein
complexes	I-protein
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF-kappa	B-protein
B	I-protein
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:97230366	
	
ALY	B-protein
,	O
a	O
context-dependent	B-protein
coactivator	I-protein
of	O
LEF-1	B-protein
and	O
AML-1	B-protein
,	O
is	O
required	O
for	O
TCRalpha	B-DNA
enhancer	I-DNA
function	O
.	O
	
LEF-1	B-protein
is	O
a	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
T-cell	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
by	O
facilitating	O
the	O
assembly	O
of	O
multiple	B-protein
proteins	I-protein
into	O
a	O
higher	O
order	O
nucleoprotein	B-protein
complex	I-protein
.	O
	
The	O
function	O
of	O
LEF-1	B-protein
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B-protein
domain	I-protein
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B-protein
domain	I-protein
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer-binding	B-protein
proteins	I-protein
.	O
	
With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context-dependent	B-protein
activation	I-protein
domains	I-protein
,	O
we	O
cloned	O
ALY	B-protein
,	O
a	O
novel	O
LEF-1-interacting	B-protein
protein	I-protein
.	O
	
ALY	B-protein
is	O
a	O
ubiquitously	O
expressed	O
,	O
nuclear	O
protein	O
that	O
specifically	O
associates	O
with	O
the	O
activation	B-protein
domains	I-protein
of	O
LEF-1	B-protein
and	O
AML-1	B-protein
(	O
CBF	B-protein
alpha2	I-protein
,	O
PEBP2	B-protein
alpha	I-protein
(	O
B	O
)	O
,	O
which	O
is	O
another	O
protein	O
component	O
of	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
.	O
	
In	O
addition	O
,	O
ALY	B-protein
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B-protein
and	O
AML	B-protein
proteins	I-protein
.	O
	
Overexpression	O
of	O
ALY	B-protein
stimulates	O
the	O
activity	O
of	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
reconstituted	O
in	O
transfected	B-cell_line
nonlymphoid	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
,	O
whereas	O
down-regulation	O
of	O
ALY	B-protein
by	O
anti-sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Similar	O
to	O
LEF-1	B-protein
,	O
ALY	B-protein
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	B-protein
DNA-binding	I-protein
domain	I-protein
.	O
	
We	O
propose	O
that	O
ALY	B-protein
mediates	O
context-dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	B-protein
proteins	I-protein
in	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
.	O
	
###MEDLINE:97209374	
	
AML1a	B-protein
but	O
not	O
AML1b	B-protein
inhibits	O
erythroid	O
differentiation	O
induced	O
by	O
sodium	O
butyrate	O
and	O
enhances	O
the	O
megakaryocytic	O
differentiation	O
of	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O
	
AML1	B-protein
may	O
play	O
a	O
role	O
in	O
growth	O
and	O
differentiation	O
of	O
cells	O
along	O
erythroid	B-cell_type
and/or	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
,	O
because	O
a	O
significant	O
level	O
of	O
the	O
AML1	B-protein
gene	O
is	O
expressed	O
in	O
these	O
cells	O
.	O
	
We	O
overexpressed	O
AML1a	B-protein
(	O
without	O
the	O
transcription-activating	B-protein
domain	I-protein
)	O
and	O
AML1b	B-protein
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin-producing	B-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
.	O
	
The	O
AML1a-transfected	B-cell_line
K562	I-cell_line
cells	I-cell_line
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n-butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1-beta-D-arabinofuranosylcytosine	O
,	O
and	O
herbimycin	O
A	O
.	O
	
The	O
AML1	B-protein
antisense	O
oligodeoxynucleotide	O
but	O
not	O
the	O
sense	O
oligomer	O
recovered	O
its	O
differentiation-inducing	O
capacity	O
in	O
the	O
presence	O
of	O
butyrate	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
AML1b	B-protein
conferred	O
a	O
similar	O
differentiation-inducing	O
capacity	O
upon	O
K562	B-cell_line
cells	I-cell_line
transfected	O
with	O
vector	O
alone	O
.	O
	
AML1a	B-protein
expression	O
was	O
associated	O
with	O
enhanced	O
sensitivity	O
to	O
megakaryocytic	O
differentiation	O
induced	O
by	O
phorbol	O
ester	O
.	O
	
These	O
results	O
provide	O
evidence	O
that	O
AML1	B-protein
proteins	O
play	O
a	O
role	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
.	O
	
###MEDLINE:97218151	
	
Identification	O
of	O
sequence	O
alterations	O
in	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
estrogen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
an	O
ER-negative	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Given	O
the	O
important	O
role	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
the	O
development	O
and	O
physiology	O
of	O
the	O
breast	O
,	O
it	O
is	O
essential	O
to	O
delineate	O
the	O
mechanisms	O
responsible	O
for	O
its	O
failed	O
expression	O
in	O
some	O
breast	O
tumors	O
.	O
	
We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-protein
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	I-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O
	
From	O
this	O
,	O
we	O
identified	O
a	O
number	O
of	O
variations	O
between	O
the	O
sequences	O
,	O
two	O
of	O
which	O
were	O
determined	O
to	O
be	O
associated	O
with	O
a	O
50	O
%	O
decrease	O
in	O
CAT	B-protein
activity	O
.	O
	
###MEDLINE:97228922	
	
Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
involved	O
in	O
generation	O
of	O
cytokines	B-protein
and	O
nitric	O
oxide	O
.	O
	
The	O
influence	O
of	O
the	O
anti-allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	B-protein
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
cells	I-cell_type
.	O
	
Azeptin	O
dose-dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
(	O
HF	B-cell_type
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O
Generation	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin	B-protein
1-beta	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin-6	B-protein
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin-treated	O
PBL	B-cell_type
and	O
human	B-cell_type
monocytes	I-cell_type
(	O
HM	B-cell_type
)	O
was	O
decreased	O
to	O
approximately	O
1/3	O
to	O
2/3	O
of	O
the	O
control	O
levels	O
.	O
	
In	O
parallel	O
with	O
the	O
decreased	O
cytokine	B-protein
generation	O
,	O
each	O
cytokine	B-RNA
mRNA	I-RNA
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O
	
In	O
addition	O
,	O
both	O
inducible	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
-mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
were	O
suppressed	O
by	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O
	
Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
PBL	B-cell_type
,	O
HM	O
and	O
HF	B-cell_type
.	O
	
These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	B-protein
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
###MEDLINE:97166066	
	
Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE-I	B-DNA
enhancer	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
different	O
T	B-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O
	
The	O
immunomodulatory	O
cytokine	B-protein
IL-4	B-protein
affects	O
cells	O
of	O
most	O
hemopoietic	B-cell_type
lineages	I-cell_type
.	O
	
IL-4	B-protein
is	O
secreted	O
by	O
activated	O
Th2	B-cell_type
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	B-cell_type
Th	I-cell_type
cells	I-cell_type
toward	O
the	O
Th2	B-cell_type
phenotype	I-cell_type
.	O
	
We	O
have	O
previously	O
identified	O
an	O
enhancer	B-DNA
element	I-DNA
,	O
PRE-I	B-DNA
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O
	
To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue-specific	O
expression	O
of	O
the	O
IL-4	B-protein
gene	O
,	O
we	O
analyzed	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
PRE-I	B-DNA
site	I-DNA
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	B-protein
promoter	O
of	O
Th1	B-cell_type
and	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O
	
We	O
show	O
that	O
PRE-I	B-DNA
interacts	O
with	O
PMA	O
-and	O
PMA/ionomycin-inducible	O
,	O
cyclosporin	O
A-sensitive	O
nuclear	B-protein
factors	I-protein
.	O
	
Using	O
anti-C/EBPbeta	B-protein
(	O
NF-IL6	B-protein
)	O
,	O
anti-C/EBPdelta	B-protein
(	O
NF-IL6beta	B-protein
)	O
,	O
anti-NF-ATc	B-protein
,	O
anti-NF-ATp	B-protein
,	O
anti-Fos	B-protein
,	O
and	O
anti-Jun	B-protein
Abs	I-protein
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE-I	B-protein
binding	I-protein
factor	I-protein
POS-1	B-protein
is	O
composed	O
of	O
different	O
transcription	B-protein
factors	I-protein
in	O
different	O
Th	O
cell	O
subsets	O
.	O
	
In	O
the	O
IL-4-producing	B-cell_line
Th0-like	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
and	O
mouse	B-cell_line
EL-4	I-cell_line
cells	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1a	B-protein
)	O
contains	O
NF-IL6beta	B-protein
and	O
Jun	B-protein
.	O
	
In	O
the	O
mouse	B-cell_line
Th2	I-cell_line
D10	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
human	B-cell_line
Th2	I-cell_line
clones	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1b	B-protein
)	O
contains	O
NF-IL6beta	B-protein
,	O
Jun	B-protein
,	O
and	O
NF-ATc/p	B-protein
.	O
	
In	O
contrast	O
,	O
POS-1	B-protein
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	B-cell_line
Th1	I-cell_line
clones	I-cell_line
.	O
	
These	O
findings	O
suggest	O
that	O
PRE-I	B-DNA
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	B-DNA
gene	I-DNA
expression	O
levels	O
.	O
	
###MEDLINE:97276784	
	
Regulation	O
of	O
human	O
epsilon	O
germline	B-DNA
transcription	O
:	O
role	O
of	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
.	O
	
Germline	B-protein
transcripts	I-protein
initiate	O
from	O
promoters	B-DNA
upstream	O
of	O
the	O
immunoglobulin	B-DNA
switch	I-DNA
region	I-DNA
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O
	
Different	O
cytokines	B-protein
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	B-DNA
promoter	I-DNA
.	O
	
Because	O
binding	B-DNA
sites	I-DNA
for	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
cluster	I-DNA
,	O
BSAP	B-protein
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
and	O
isotype	O
switching	O
.	O
	
We	O
investigated	O
whether	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
Our	O
results	O
showed	O
that	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
both	O
IL-4	B-protein
-dependent	O
induction	O
and	O
CD40	B-protein
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	B-DNA
transcription	O
.	O
	
BSAP	B-protein
is	O
unique	O
among	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
epsilon	O
germline	B-DNA
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B-protein
switching	O
.	O
	
###MEDLINE:97263535	
	
Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B-protein
T-antigen	I-protein
.	O
	
A	O
molecular	O
basis	O
for	O
induction	O
of	O
antibodies	B-protein
to	O
DNA	O
and	O
eukaryotic	B-protein
transcription	I-protein
factors	I-protein
.	O
	
We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
expression	O
of	O
the	O
polyomavirus	B-protein
transcription	I-protein
factor	I-protein
T-antigen	I-protein
has	O
the	O
potential	O
to	O
induce	O
anti-DNA	B-protein
antibodies	I-protein
in	O
mice	O
.	O
	
Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O
	
First	O
,	O
we	O
describe	O
results	O
demonstrating	O
that	O
mice	O
inoculated	O
with	O
T-antigen-expressing	B-DNA
plasmids	I-DNA
produced	O
antibodies	B-protein
,	O
not	O
only	O
to	O
T-antigen	B-protein
and	O
DNA	O
,	O
but	O
also	O
to	O
the	O
DNA-binding	B-protein
eukaryotic	I-protein
transcription	I-protein
factors	I-protein
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
and	O
to	O
the	O
cAMP-response-element-binding	B-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O
	
Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
and	O
to	O
TBP	B-protein
and	O
CREB	B-protein
are	O
linked	O
to	O
such	O
events	O
.	O
	
Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O
	
Linked	O
to	O
these	O
events	O
,	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
TBP	B-protein
,	O
and	O
CREB	B-protein
were	O
detected	O
,	O
identical	O
to	O
what	O
we	O
observed	O
in	O
mice	O
.	O
	
Antibodies	O
recognizing	O
double-stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O
	
The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA-associated	B-protein
proteins	I-protein
and	O
T	B-cell_type
cells	I-cell_type
recognizing	O
T	B-protein
antigen	I-protein
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B-protein
ag	I-protein
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O
	
###MEDLINE:97278840	
	
Jak3	B-protein
is	O
associated	O
with	O
CD40	B-protein
and	O
is	O
critical	O
for	O
CD40	B-protein
induction	O
of	O
gene	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
CD40	B-protein
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
Although	O
CD40	B-protein
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	B-protein
-mediated	O
events	O
.	O
	
We	O
show	O
that	O
engagement	O
of	O
CD40	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	B-protein
as	O
well	O
as	O
of	O
STAT3	B-protein
.	O
	
Jak3	B-protein
is	O
constitutively	O
associated	O
with	O
CD40	B-protein
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline-rich	B-protein
sequence	I-protein
in	O
the	O
membrane-proximal	B-protein
region	I-protein
of	O
CD40	B-protein
.	O
	
Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	B-protein
to	O
induce	O
expression	O
of	O
CD23	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
lymphotoxin-alpha	B-DNA
genes	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	B-protein
is	O
activated	O
by	O
CD40	B-protein
and	O
plays	O
an	O
important	O
role	O
in	O
CD40	B-protein
-mediated	O
functions	O
.	O
	
###MEDLINE:98145608	
	
Transcription	B-protein
factors	I-protein
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O
	
Intimate	O
interactions	O
between	O
multipotential	O
hemopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
their	O
microenvironment	O
work	O
towards	O
redefining	O
the	O
identity	O
and	O
the	O
differentiative	O
fate	O
of	O
these	O
primitive	B-cell_type
cells	I-cell_type
.	O
	
Molecular	O
cues	O
delivered	O
by	O
the	O
microenvironment	O
frequently	O
act	O
in	O
an	O
instructive	O
fashion	O
by	O
initiating	O
intracellular	O
signaling	O
pathways	O
that	O
ultimately	O
target	O
a	O
select	O
group	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
These	O
transcriptional	O
regulators	O
in	O
turn	O
trigger	O
a	O
cascade	O
of	O
genetic	O
changes	O
that	O
ultimately	O
determine	O
the	O
course	O
of	O
the	O
cells	O
during	O
differentiation	O
.	O
	
Gene	O
inactivation	O
studies	O
on	O
the	O
PU.1	B-DNA
,	I-DNA
Ikaros	I-DNA
and	I-DNA
GATA-3	I-DNA
genes	I-DNA
have	O
revealed	O
that	O
their	O
encoded	O
factors	O
are	O
essential	O
for	O
the	O
earliest	O
commitment	O
step	O
into	O
the	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphoid	I-cell_type
lineages	I-cell_type
.	O
	
###MEDLINE:97207294	
	
Interleukin-4	B-protein
signaling	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
.	O
	
Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
is	O
an	O
important	O
cytokine	O
for	O
B	O
and	O
T	O
lymphocyte	O
function	O
and	O
mediates	O
its	O
effects	O
via	O
a	O
receptor	O
that	O
contains	O
gammac	B-protein
.	O
	
B	B-cell_type
cells	I-cell_type
derived	O
from	O
patients	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X-SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	B-protein
-mediated	O
signaling	O
.	O
	
We	O
found	O
that	O
although	O
IL-4	B-protein
stimulation	O
of	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
did	O
not	O
result	O
in	O
Janus	B-protein
tyrosine	I-protein
kinase-3	I-protein
(	O
JAK3	B-protein
)	O
phosphorylation	O
,	O
other	O
IL-4	B-protein
substrates	I-protein
including	O
JAK1	B-protein
and	O
IRS-1	B-protein
were	O
phosphorylated	O
.	O
	
Additionally	O
,	O
we	O
detected	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
6	I-protein
(	O
STAT6	B-protein
)	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
in	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
a	O
wide	O
range	O
of	O
gammac	B-protein
mutations	O
.	O
	
However	O
,	O
reconstitution	O
of	O
these	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
gammac	B-protein
enhanced	O
IL-4	B-protein
-mediated	O
responses	O
including	O
STAT6	B-protein
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	B-protein
expression	O
.	O
	
Thus	O
,	O
gammac	B-protein
is	O
not	O
necessary	O
to	O
trigger	O
IL-4	B-protein
-mediated	O
responses	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL-4	B-protein
-signaling	O
.	O
	
These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B-protein
signaling	O
pathways	O
exist	O
.	O
	
###MEDLINE:97234588	
	
Cell-to-cell	O
contact	O
activates	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	B-DNA
motif	I-DNA
.	O
	
Cell-to-cell	O
contact	O
between	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
transfected	B-cell_line
human	I-cell_line
colonic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
HT29	I-cell_line
activates	O
transcription	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTR	B-DNA
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O
	
HIV-1	B-DNA
LTR	I-DNA
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus-encoded	B-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O
	
Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV-1	B-DNA
LTR	I-DNA
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
located	O
in	O
the	O
U3	B-DNA
region	I-DNA
are	O
involved	O
in	O
cell-to-cell	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
.	O
	
Cell-to-cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
p50/p65	I-protein
heterodimer	I-protein
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O
	
Cell-to-cell	O
contact	O
activation	O
of	O
NF-kappaB	B-protein
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	B-protein
inhibitor	I-protein
kappaB	I-protein
alpha	I-protein
.	O
	
NF-kappaB	B-protein
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O
	
###MEDLINE:97184601	
	
Identification	O
of	O
nucleotide	B-DNA
sequences	I-DNA
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
region	O
downstream	O
of	O
the	O
enhancer	B-DNA
(	O
DEN	B-DNA
)	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
mink	O
cell	O
focus-forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O
	
Another	O
important	O
activity	O
of	O
DEN	B-DNA
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF-kappaB	B-protein
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O
	
###MEDLINE:97223498	
	
Possible	O
role	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
germline	B-DNA
C	O
epsilon	O
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF-kappa	B-protein
B	I-protein
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O
	
We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
or	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
participates	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
responsible	O
for	O
germline	B-DNA
C	O
epsilon	O
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DND39	B-cell_line
.	O
	
Both	O
IL-4	B-protein
and	O
anti-	O
CD40	B-protein
mAb	I-protein
induced	O
activation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-kinase	B-protein
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	B-protein
.	O
	
In	O
addition	O
,	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF-kappa	B-protein
B	I-protein
activation	O
caused	O
by	O
IL-4	B-protein
,	O
anti-CD40	B-protein
mAb	I-protein
,	O
or	O
their	O
combination	O
.	O
	
NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	B-DNA
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
than	O
in	O
those	O
stimulated	O
with	O
IL-4	B-protein
alone	O
.	O
	
These	O
results	O
indicate	O
that	O
IL-4	B-protein
and	O
ligation	O
of	O
CD40	B-protein
induce	O
NF-kappa	B-protein
B	I-protein
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3-kinase	B-protein
pathway	O
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O
	
###MEDLINE:97209911	
	
Differentiation	O
of	O
U-937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O
	
We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
of	O
two	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O
	
One	O
hour	O
pulse-treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	B-protein
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O
	
By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse-treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O
	
However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O
	
Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane-bound	B-protein
enzyme	I-protein
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane-bound	B-protein
and	I-protein
cytosolic	I-protein
enzyme	I-protein
.	O
	
By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O
	
When	O
used	O
at	O
differentiation-inducing	O
concentrations	O
,	O
both	O
topoisomerase	B-protein
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	B-protein
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide-treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	B-cell_type
cells	I-cell_type
.	O
	
By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF-kappa	B-protein
(	I-protein
B	I-protein
)	I-protein
and	O
EGR-1	B-protein
transcription	B-protein
factors	I-protein
was	O
little	O
affected	O
.	O
	
It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O
	
However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	B-protein
drugs	O
.	O
	
###MEDLINE:97153026	
	
GATA-1	B-protein
DNA	O
binding	O
activity	O
is	O
down-regulated	O
in	O
late	O
S	O
phase	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
set	O
out	O
to	O
test	O
a	O
model	O
for	O
tissue-specific	O
gene	O
expression	O
that	O
relies	O
on	O
the	O
early	O
replication	O
of	O
expressed	O
genes	O
to	O
sequester	O
limiting	O
activating	O
transcription	B-protein
factors	I-protein
.	O
	
Using	O
an	O
erythroid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
we	O
have	O
tested	O
the	O
changes	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
the	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
through	O
the	O
cell	O
cycle	O
.	O
	
We	O
find	O
that	O
GATA-1	B-protein
activity	O
is	O
low	O
in	O
G1	O
,	O
peaks	O
in	O
mid-S	O
phase	O
,	O
and	O
then	O
decreases	O
in	O
G2/M	O
.	O
	
In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
two	O
ubiquitous	O
transcription	B-protein
factors	I-protein
,	O
Oct1	B-protein
and	O
Sp1	B-protein
,	O
remain	O
high	O
in	O
G2/M	O
.	O
	
GATA-1	B-protein
protein	O
and	O
mRNA	B-RNA
vary	O
in	O
a	O
similar	O
manner	O
through	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
the	O
expression	O
of	O
the	O
gene	O
or	O
the	O
stability	O
of	O
its	O
message	O
is	O
regulated	O
.	O
	
Although	O
a	O
number	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
or	O
DNA	O
replication	O
have	O
been	O
shown	O
to	O
peak	O
in	O
S	O
phase	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
displaying	O
S	O
phase-specific	O
DNA	O
binding	O
activity	O
.	O
	
One	O
interpretation	O
of	O
these	O
data	O
leads	O
to	O
a	O
model	O
in	O
which	O
the	O
peak	O
in	O
GATA-1	B-protein
DNA	O
binding	O
amplifies	O
the	O
effect	O
of	O
early	O
replication	O
on	O
the	O
activation	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
at	O
the	O
same	O
time	O
as	O
preventing	O
activation	O
of	O
non-erythroid	B-DNA
genes	I-DNA
containing	O
GATA-responsive	B-DNA
elements	I-DNA
.	O
	
These	O
results	O
may	O
also	O
relate	O
to	O
recent	O
data	O
implicating	O
GATA-1	B-protein
function	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
	
###MEDLINE:97275156	
	
Activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O
	
Activated	B-cell_type
neutrophils	I-cell_type
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B-protein
and	O
chemokines	B-protein
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O
	
Although	O
little	O
is	O
known	O
to	O
date	O
concerning	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
,	O
it	O
is	O
noteworthy	O
that	O
many	O
of	O
these	O
genes	O
depend	O
on	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF-kappaB	B-protein
,	O
for	O
inducible	O
expression	O
.	O
	
We	O
therefore	O
investigated	O
whether	O
NF-kappaB/Rel	B-protein
proteins	I-protein
are	O
expressed	O
in	O
human	B-cell_type
neutrophils	I-cell_type
,	O
as	O
well	O
as	O
their	O
fate	O
on	O
cell	O
activation	O
.	O
	
We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	B-protein
NFkappaB1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and/or	O
c-Rel	B-protein
are	O
present	O
in	O
neutrophils	B-cell_type
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	B-protein
complexes	I-protein
is	O
physically	O
associated	O
with	O
cytoplasmic	B-protein
IkappaB-alpha	I-protein
in	O
resting	O
cells	O
.	O
	
Following	O
neutrophil	O
stimulation	O
with	O
proinflammatory	O
agonists	O
(	O
such	O
as	O
lipopolysaccharide	O
[	O
LPS	O
]	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
[	O
TNF-alpha	B-protein
]	O
,	O
and	O
fMet-Leu-Phe	O
)	O
that	O
induce	O
the	O
production	O
of	O
cytokines	B-protein
and	O
chemokines	B-protein
in	O
these	O
cells	O
,	O
NF-kappaB/Rel	B-protein
proteins	I-protein
translocated	O
to	O
nuclear	O
fractions	O
,	O
resulting	O
in	O
a	O
transient	O
induction	O
of	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O
	
The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB-alpha	B-protein
degradation	O
.	O
	
Proinflammatory	B-cell_type
neutrophil	I-cell_type
stimuli	O
also	O
promoted	O
the	O
accumulation	O
of	O
IkappaB-alpha	B-RNA
mRNA	I-RNA
transcripts	I-RNA
,	O
resulting	O
in	O
the	O
reexpression	O
of	O
the	O
IkappaB-alpha	B-protein
protein	I-protein
.	O
	
To	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
indication	O
that	O
NF-kappaB	B-protein
activation	O
may	O
underlie	O
the	O
action	O
of	O
proinflammatory	O
stimuli	O
towards	O
human	O
neutrophil	O
gene	O
expression	O
and	O
,	O
as	O
such	O
,	O
adds	O
a	O
new	O
facet	O
to	O
our	O
understanding	O
of	O
neutrophil	B-cell_type
biology	I-cell_type
.	O
	
###MEDLINE:97261995	
	
Two	O
distinct	O
pathways	O
of	O
interleukin-5	B-protein
synthesis	O
in	O
allergen-specific	B-cell_line
human	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
suppressed	O
by	O
glucocorticoids	O
.	O
	
Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O
	
The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
,	O
a	O
selective	B-protein
eosinophil-activating	I-protein
factor	I-protein
,	O
produced	O
by	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	B-protein
synthesis	O
,	O
we	O
established	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
from	O
asthmatic	O
patients	O
.	O
	
GC	O
efficiently	O
suppressed	O
IL-5	B-protein
synthesis	O
of	O
T-cell	O
clones	O
activated	O
via	O
either	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
or	O
IL-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
.	O
	
Induction	O
of	O
IL-5	B-RNA
mRNA	I-RNA
upon	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O
	
Human	O
IL-5	B-protein
promoter/enhancer-luciferase	O
gene	O
construct	O
transfected	O
to	O
T-cell	B-cell_line
clones	I-cell_line
was	O
transcribed	O
on	O
either	O
TCR	B-protein
or	O
IL-2R	B-protein
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	B-DNA
human	I-DNA
IL-5	I-DNA
gene	I-DNA
segment	I-DNA
located	O
5	B-DNA
'	I-DNA
upstream	I-DNA
of	O
the	O
coding	O
region	O
contains	O
activation-inducible	B-DNA
enhancer	I-DNA
elements	I-DNA
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O
	
Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
NF-AT	B-protein
and	O
NF-kappaB	B-protein
were	O
not	O
significantly	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O
	
Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL-5	B-protein
production	O
by	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T-cell	O
IL-5	B-protein
synthesis	O
.	O
	
###MEDLINE:97276939	
	
Itk	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
is	O
required	O
for	O
CD2-mediated	B-DNA
interleukin-2	I-DNA
promoter	I-DNA
activation	O
in	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
.	O
	
We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	B-protein
,	O
a	O
member	O
of	O
the	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
Tec	I-protein
family	I-protein
,	O
in	O
T	O
cell	O
activation	O
.	O
	
Stimulation	O
of	O
either	O
CD2	B-protein
or	O
T	O
cell	O
receptor	O
(	O
TCR	B-protein
)	O
/CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody-mediated	O
cross-linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Itk	B-protein
,	O
which	O
was	O
maximal	O
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O
	
The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti-	O
Itk	B-protein
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O
	
Interleukin-2	O
(	O
IL-2	B-protein
)	O
promoter	O
activity	O
stimulated	O
by	O
cross-linking	O
of	O
CD2	B-protein
,	O
TCR	B-protein
/CD3	O
,	O
and	O
CD28	B-protein
with	O
antibodies	B-protein
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	B-protein
mutant	I-protein
lacking	O
the	O
kinase	O
activity	O
.	O
	
The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	B-protein
wild-type	I-protein
Itk	I-protein
.	O
	
Stimulation	O
of	O
CD2	B-protein
or	O
TCR/CD3	B-protein
induced	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
the	O
binding	B-DNA
site	I-DNA
of	O
which	O
is	O
included	O
in	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O
	
The	O
activation	O
of	O
NFAT	B-protein
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	B-protein
mutant	I-protein
.	O
	
These	O
results	O
demonstrate	O
that	O
Itk	B-protein
plays	O
a	O
role	O
in	O
IL-2	B-protein
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	B-protein
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
.	O
	
###MEDLINE:97251018	
	
Expression	O
of	O
LAZ3/BCL6	B-protein
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC-derived	O
non-Hodgkin	O
lymphomas	O
.	O
	
Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3/BCL6	B-DNA
gene	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O
	
Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	B-protein
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O
	
In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O
	
The	O
LAZ3/BCL6	B-RNA
transcript	I-RNA
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O
	
In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3/BCL6	B-protein
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non-B	O
lymphomas	O
.	O
	
All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	B-protein
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O
	
A	O
follicular	O
expression	O
pattern	O
was	O
also	O
found	O
in	O
all	O
non-malignant	O
reactive	O
lymph	O
nodes	O
.	O
	
Hence	O
,	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	B-cell_type
cells	I-cell_type
from	O
the	O
germinal	O
centers	O
.	O
	
###MEDLINE:97197832	
	
Jak1	B-protein
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	B-protein
signaling	B-protein
molecules	I-protein
.	O
	
The	O
Jak1	B-protein
,	I-protein
Jak2	I-protein
,	I-protein
Jak3	I-protein
,	I-protein
and	I-protein
Fes	I-protein
tyrosine	I-protein
kinases	I-protein
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
stimulation	O
in	O
different	O
cell	O
systems	O
.	O
	
However	O
,	O
it	O
is	O
not	O
clear	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
kinases	O
are	O
responsible	O
for	O
initiating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
of	O
intracellular	B-protein
substrates	I-protein
in	O
vivo	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	B-cell_line
Jak1-deficient	I-cell_line
HeLa	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
E1C3	B-cell_line
,	O
and	O
its	O
parental	B-cell_line
Jak1-expressing	I-cell_line
counterpart	I-cell_line
,	O
1D4	B-cell_line
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	B-protein
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O
	
IL-4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
(	I-protein
IRS	I-protein
)	I-protein
-1	I-protein
and	O
IRS-2	B-protein
in	O
1D4	B-cell_line
but	O
not	O
in	O
E1C3	B-cell_line
cells	I-cell_line
.	O
	
IL-4	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
Stat6	B-protein
was	O
pronounced	O
in	O
1D4	B-cell_line
cells	I-cell_line
,	O
while	O
no	O
IL-4	B-protein
-induced	O
Stat6	B-protein
phosphorylation	O
was	O
detected	O
in	O
E1C3	B-cell_line
cells	I-cell_line
.	O
	
IL-4	B-protein
also	O
induced	O
Stat6	B-protein
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	B-cell_line
but	O
not	O
E1C3	B-cell_line
cells	I-cell_line
utilizing	O
a	O
radiolabeled	B-DNA
immunoglobulin	I-DNA
heavy	I-DNA
chain	I-DNA
germline	I-DNA
epsilon	I-DNA
promotor	I-DNA
sequence	I-DNA
(	O
Iepsilon	B-DNA
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
	
Reconstitution	O
of	O
Jak1	B-protein
expression	O
in	O
E1C3	B-cell_line
cells	I-cell_line
restored	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
induce	O
IRS	B-DNA
and	O
Stat6	B-protein
tyrosine	O
phosphorylation	O
.	O
	
These	O
results	O
provide	O
evidence	O
that	O
Jak1	B-protein
expression	O
is	O
required	O
for	O
mediating	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
crucial	O
molecules	O
involved	O
in	O
IL-4	B-protein
signal	O
transduction	O
.	O
	
###MEDLINE:97249714	
	
Oxidant-regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O
	
It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e.g.	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte-derived	O
oxidants	O
.	O
	
Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
beta	I-protein
.	O
	
Nuclear	B-protein
transcription	I-protein
factor	I-protein
kB	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
and	O
pleiotropic	B-protein
regulator	I-protein
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O
	
This	O
transcription	B-protein
factor	I-protein
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	B-protein
protein	I-protein
I-kB	I-protein
thereby	O
allowing	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	B-protein
molecules	I-protein
(	O
e.g	O
.	O
ICAM-1	B-protein
,	O
VCAM-1	B-protein
)	O
,	O
cytokines	B-protein
(	O
TNF	B-protein
,	O
IL-1	B-protein
,	O
IL-6	B-protein
)	O
and	O
enzymes	B-protein
(	O
iNOS	B-protein
)	O
.	O
	
The	O
proteolytic	O
degradation	O
of	O
the	O
post-translationally	O
modified	O
I-kappa	B-protein
B	I-protein
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	B-protein
proteasome	I-protein
complex	I-protein
.	O
	
Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro-inflammatory	B-protein
mediators	I-protein
and	O
adhesion	B-protein
molecules	I-protein
.	O
	
###MEDLINE:97184561	
	
Generation	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O
	
Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O
	
However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	B-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O
	
Since	O
the	O
CTL	B-cell_type
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B-protein
epitopes	I-protein
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B-protein
epitopes	I-protein
.	O
	
The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O
	
Three	O
mouse	O
strains	O
(	O
C57BL/10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB/FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB/cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild-type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B-protein
antigen	I-protein
(	O
s	O
)	O
,	O
and	O
the	O
CTL	B-cell_type
responses	O
were	O
measured	O
.	O
	
In	O
C57BL/10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	B-protein
antigen	I-protein
in	O
E1A	B-DNA
.	O
	
When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O
	
or	O
intranasally	O
with	O
wild-type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	B-DNA
region	I-DNA
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O
	
In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O
	
The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB/c	O
mice	O
was	O
more	O
complex	O
.	O
	
CTLs	B-cell_type
from	O
BALB/c	O
mice	O
inoculated	O
i.p.	O
with	O
wild-type	O
Ad	O
recognized	O
E1B	B-DNA
in	O
the	O
context	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
I	I-DNA
Dd	I-DNA
allele	I-DNA
and	O
a	O
region	O
outside	O
E1	B-DNA
associated	O
with	O
the	O
Kd	B-DNA
allele	I-DNA
.	O
	
When	O
BALB/c	O
mice	O
were	O
inoculated	O
with	O
E1	B-DNA
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B-protein
Kd-restricted	I-protein
epitope	I-protein
was	O
recognized	O
,	O
and	O
Dd-restricted	O
CTLs	B-cell_type
did	O
not	O
develop	O
.	O
	
This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	B-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	B-protein
-diverse	O
human	O
population	O
.	O
	
###MEDLINE:97180731	
	
Characterization	O
of	O
the	O
human	B-DNA
platelet/endothelial	I-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
promoter	I-DNA
:	O
identification	O
of	O
a	O
GATA-2	B-DNA
binding	I-DNA
element	I-DNA
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O
	
Platelet/endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
PECAM-1	B-protein
)	O
is	O
a	O
130-kD	B-protein
member	I-protein
of	O
the	O
Ig	B-DNA
gene	I-DNA
superfamily	I-DNA
that	O
is	O
expressed	O
on	O
platelets	B-cell_type
,	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
certain	O
leukocyte	B-cell_type
subsets	I-cell_type
.	O
	
To	O
examine	O
the	O
factors	O
controlling	O
vascular-specific	O
expression	O
of	O
PECAM-1	B-protein
,	O
we	O
cloned	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
PECAM-1	B-DNA
gene	I-DNA
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O
	
5'-Rapid	O
amplification	O
of	O
cDNA	B-DNA
ends	I-DNA
(	O
5'-RACE	B-DNA
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
.	O
	
Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
(	O
TIS	B-DNA
)	O
showed	O
no	O
canonical	O
TATA	B-DNA
or	O
CAAT	B-DNA
elements	I-DNA
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA-less	B-DNA
promoters	I-DNA
encompassed	O
the	O
TIS	B-DNA
.	O
	
5'-serially	B-DNA
truncated	I-DNA
PECAM-1	I-DNA
promoter	I-DNA
segments	I-DNA
cloned	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
drove	O
transcription	O
in	O
both	O
a	O
lineage-	O
and	O
orientation-specific	O
manner	O
.	O
	
Putative	O
cis-acting	B-DNA
control	I-DNA
elements	I-DNA
present	O
within	O
a	O
300-bp	B-DNA
core	I-DNA
promoter	I-DNA
included	O
two	O
ets	B-DNA
sites	I-DNA
,	O
an	O
Sp1	B-DNA
site	I-DNA
,	O
tandem	O
E-box	B-DNA
domains	I-DNA
,	O
two	O
GATA-associated	B-DNA
sites	I-DNA
(	O
CACCC	O
)	O
,	O
an	O
AP-2	B-DNA
binding	I-DNA
site	I-DNA
,	O
and	O
a	O
GATA	B-DNA
element	I-DNA
at	O
-24	B-DNA
.	O
	
Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	B-DNA
sequence	I-DNA
at	O
position	O
-24	B-DNA
,	O
and	O
gel-shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
,	O
but	O
not	O
GATA-1	B-protein
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM-1	B-DNA
promoter	I-DNA
.	O
	
Understanding	O
the	O
cis-	B-protein
and	I-protein
transacting	I-protein
factors	I-protein
that	O
regulate	O
the	O
tissue-specific	O
expression	O
of	O
PECAM-1	B-protein
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular-specific	O
gene	O
expression	O
is	O
achieved	O
.	O
	
###MEDLINE:97205231	
	
A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	B-DNA
response	I-DNA
element	I-DNA
(	O
nGRE	B-DNA
)	O
in	O
the	O
human	B-DNA
interleukin-1beta	I-DNA
gene	I-DNA
.	O
	
Interleukin-1	B-protein
beta	I-protein
(	O
IL-1beta	B-protein
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	B-protein
mediators	I-protein
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O
	
The	O
regulation	O
of	O
human	B-protein
IL-1beta	I-protein
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	B-DNA
elements	I-DNA
have	O
been	O
discovered	O
in	O
the	O
promoter	B-DNA
region	I-DNA
.	O
	
However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL-1beta	B-protein
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O
	
We	O
have	O
identified	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
in	O
the	O
region	O
between	O
-685	B-DNA
and	I-DNA
-395	I-DNA
.	O
	
Within	O
this	O
region	O
,	O
a	O
19-bp	B-DNA
nuclear	I-DNA
factor	I-DNA
binding	I-DNA
site	I-DNA
(	O
-570	B-DNA
to	I-DNA
-552	I-DNA
)	O
was	O
characterized	O
by	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O
	
A	O
consensus	B-DNA
sequence	I-DNA
for	O
a	O
negative	B-DNA
glucocorticoid	I-DNA
response	I-DNA
element	I-DNA
(	O
nGRE	B-DNA
)	O
and	O
a	O
transcription	B-DNA
activator	I-DNA
protein-2	I-DNA
binding	I-DNA
site	I-DNA
were	O
noted	O
within	O
this	O
footprint	O
.	O
	
Functional	O
studies	O
showed	O
a	O
2.5-fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19-bp	B-DNA
binding	I-DNA
site	I-DNA
was	O
deleted	O
in	O
the	O
reporter	B-DNA
constructs	I-DNA
IL-1beta	B-protein
/CAT	B-protein
and	O
IL-1beta	B-protein
/SV40	B-DNA
promoter	I-DNA
/CAT	B-protein
.	O
	
Dexamethasone	O
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild-type	B-DNA
fragment	I-DNA
but	O
not	O
in	O
a	O
deletion	B-DNA
mutant	I-DNA
lacking	O
the	O
19-bp	B-DNA
site	I-DNA
.	O
	
A	O
protein	O
of	O
about	O
150	B-protein
kD	I-protein
that	O
bound	O
to	O
this	O
negative	B-DNA
regulatory	I-DNA
sequence	I-DNA
was	O
identified	O
by	O
UV	O
cross-linking	O
.	O
	
This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	B-DNA
regulatory	I-DNA
region	I-DNA
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	B-DNA
gene	I-DNA
.	O
	
###MEDLINE:97170874	
	
Interaction	O
of	O
transcription	B-protein
factors	I-protein
RFX1	B-protein
and	O
MIBP1	B-protein
with	O
the	O
gamma	B-DNA
motif	I-DNA
of	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
core	I-DNA
promoter	I-DNA
.	O
	
The	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
of	O
the	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
(	I-DNA
HBV	I-DNA
)	I-DNA
core	I-DNA
promoter	I-DNA
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O
	
One	O
of	O
these	O
subregions	O
,	O
NRE	B-DNA
gamma	I-DNA
,	O
is	O
active	O
in	O
both	O
HeLa	B-cell_line
cervical	I-cell_line
carcinoma	I-cell_line
cells	I-cell_line
and	O
Huh7	B-cell_line
hepatoma	I-cell_line
cells	I-cell_line
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O
	
Here	O
we	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
RFX1	B-protein
can	O
bind	O
to	O
NRE	B-DNA
gamma	I-DNA
and	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
through	O
this	O
site	O
.	O
	
Mutations	O
which	O
abrogated	O
the	O
gene-suppressive	O
activity	O
of	O
NRE	B-DNA
gamma	I-DNA
prevented	O
RFX1	B-protein
from	O
binding	O
to	O
NRE	B-DNA
gamma	I-DNA
.	O
	
In	O
addition	O
,	O
RFX1	B-protein
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B-protein
,	O
with	O
the	O
transcription	B-protein
factor	I-protein
MIBP1	B-protein
to	O
NRE	B-DNA
gamma	I-DNA
.	O
	
In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	B-DNA
gene	I-DNA
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	B-protein
acts	O
with	O
MIBP1	B-protein
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	B-DNA
gamma	I-DNA
site	I-DNA
.	O
	
The	O
ability	O
of	O
RFX1	B-protein
to	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
raises	O
the	O
possibility	O
that	O
RFX1	B-protein
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
	
###MEDLINE:97275148	
	
Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O
	
Clinical	O
efficacy	O
and	O
pharmacokinetics	O
in	O
relapsed	O
patients	O
.	O
	
The	O
therapeutic	O
effect	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
was	O
evaluated	O
among	O
15	O
APL	O
patients	O
at	O
relapse	O
after	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
induced	O
and	O
chemotherapy	O
maintained	O
complete	O
remission	O
(	O
CR	O
)	O
.	O
	
As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg/d	O
.	O
	
Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low-dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O
	
During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O
	
Pharmacokinetic	O
studies	O
,	O
which	O
were	O
performed	O
in	O
eight	O
patients	O
,	O
showed	O
that	O
after	O
a	O
peak	O
level	O
of	O
5.54	O
micromol/L	O
to	O
7.30	O
micromol/L	O
,	O
plasma	O
arsenic	O
was	O
rapidly	O
eliminated	O
,	O
and	O
the	O
continuous	O
administration	O
of	O
As2O3	O
did	O
not	O
alter	O
its	O
pharmacokinetic	O
behaviors	O
.	O
	
In	O
addition	O
,	O
increased	O
amounts	O
of	O
arsenic	O
appeared	O
in	O
the	O
urine	O
,	O
with	O
a	O
daily	O
excretion	O
accounting	O
for	O
approximately	O
1	O
%	O
to	O
8	O
%	O
of	O
the	O
total	O
daily	O
dose	O
administered	O
.	O
	
Arsenic	O
contents	O
in	O
hair	O
and	O
nail	O
were	O
increased	O
,	O
and	O
the	O
peak	O
content	O
of	O
arsenic	O
could	O
reach	O
2.5	O
to	O
2.7	O
microg/g	O
tissue	O
at	O
CR	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
a	O
decline	O
of	O
the	O
arsenic	O
content	O
in	O
hair	O
and	O
nail	O
was	O
observed	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O
	
We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O
	
###MEDLINE:97268616	
	
Nucleolin	B-protein
is	O
one	O
component	O
of	O
the	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
and	O
switch	B-protein
region	I-protein
binding	I-protein
protein	I-protein
,	O
LR1	B-protein
.	O
	
LR1	B-protein
is	O
a	O
B	O
cell-specific	O
,	O
sequence-specific	O
DNA	O
binding	O
activity	O
that	O
regulates	O
transcription	O
in	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
LR1	B-protein
also	O
binds	O
Ig	B-protein
heavy	I-protein
chain	I-protein
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O
	
LR1	B-protein
contains	O
two	O
polypeptides	O
,	O
of	O
106	O
kDa	O
and	O
45	O
kDa	O
,	O
and	O
here	O
we	O
report	O
that	O
the	O
106-kDa	B-protein
component	I-protein
of	O
LR1	B-protein
is	O
nucleolin	B-protein
.	O
	
This	O
identification	O
,	O
initially	O
made	O
by	O
microsequence	O
analysis	O
,	O
was	O
verified	O
by	O
showing	O
that	O
(	O
i	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
increased	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
nucleolin	B-DNA
cDNA	I-DNA
expression	I-DNA
construct	I-DNA
;	O
(	O
ii	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
was	O
recognized	O
by	O
antibodies	O
raised	O
against	O
recombinant	B-protein
human	I-protein
nucleolin	I-protein
;	O
and	O
(	O
iii	O
)	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
epitope-tagged	B-DNA
nucleolin	I-DNA
expression	I-DNA
constructs	I-DNA
,	O
the	O
LR1-DNA	B-protein
complex	I-protein
was	O
recognized	O
by	O
the	O
anti-tag	B-protein
antibody	I-protein
.	O
	
Nucleolin	B-protein
is	O
an	O
abundant	B-protein
nucleolar	I-protein
protein	I-protein
which	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
rDNA	B-DNA
transcription	O
or	O
organization	O
,	O
or	O
rRNA	B-RNA
processing	O
.	O
	
Homology	O
between	O
nucleolin	B-protein
and	O
histone	B-protein
H1	I-protein
suggests	O
that	O
nucleolin	B-protein
may	O
alter	O
DNA	O
organization	O
in	O
response	O
to	O
cell	O
cycle	O
controls	O
,	O
and	O
the	O
nucleolin	B-protein
component	O
of	O
LR1	B-protein
may	O
therefore	O
function	O
to	O
organize	O
switch	B-DNA
regions	I-DNA
before	O
,	O
during	O
,	O
or	O
after	O
switch	O
recombination	O
.	O
	
The	O
demonstration	O
that	O
nucleolin	B-protein
is	O
a	O
component	O
of	O
a	O
B	B-protein
cell-specific	I-protein
complex	I-protein
that	O
binds	O
switch	O
region	O
sequences	O
suggests	O
that	O
the	O
G-rich	B-DNA
switch	I-DNA
regions	I-DNA
may	O
have	O
evolved	O
from	O
rDNA	B-DNA
.	O
	
###MEDLINE:97276244	
	
Glucocorticoid-resistance	O
in	O
peripheral-blood	B-cell_type
lymphocytes	I-cell_type
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid-receptors	B-protein
in	O
chronic	O
renal	O
failure	O
patients	O
.	O
	
Glucocorticoid	O
(	O
GC	O
)	O
resistance	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
seriously	O
impairs	O
successive	O
GC	O
therapy	O
after	O
renal	O
transplantation	O
.	O
	
We	O
examined	O
the	O
relationship	O
between	O
GC-receptor	O
(	O
GC-R	O
)	O
parameters	O
in	O
peripheral-blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
PBMC	B-cell_type
resistance	O
to	O
GC	O
in	O
21	O
CRF	O
patients	O
and	O
18	O
healthy	O
subjects	O
.	O
	
Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	B-cell_type
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng/mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng/mL	O
)	O
groups	O
.	O
	
In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
2.89	O
+/-	O
1.23	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+/-	O
2.24	O
nM	O
,	O
respectively	O
.	O
	
The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+/-	O
2.02	O
(	O
257.7	O
+/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O
	
The	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.33	O
+/-	O
1.37	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+/-	O
1.39	O
nM	O
,	O
respectively	O
.	O
	
Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	B-protein
stimulation	O
.	O
	
There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase-ratios	O
(	O
post/pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B-protein
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O
	
In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
6.04	O
+/-	O
2.35	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.13	O
+/-	O
2.31	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+/-	O
1.62	O
nM	O
,	O
respectively	O
.	O
	
The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	B-protein
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O
	
Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC-R	B-protein
parameters	O
in	O
CRF	O
.	O
	
We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	B-cell_type
capacity	O
to	O
amplify	O
GC-R	B-protein
numbers	O
in	O
response	O
to	O
mitogen	B-protein
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC-R	B-protein
parameters	O
.	O
	
An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC-resistance	O
of	O
CRF	O
.	O
	
###MEDLINE:97213977	
	
Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	B-protein
domain	I-protein
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O
	
The	O
ZEBRA	B-protein
protein	I-protein
from	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O
	
ZEBRA	B-protein
,	O
a	O
member	O
of	O
the	O
bZIP	B-protein
family	I-protein
of	O
DNA-binding	B-protein
proteins	I-protein
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	B-DNA
lytic	I-DNA
cycle	I-DNA
promoters	I-DNA
.	O
	
It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	B-protein
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O
	
We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	B-protein
,	O
Z	B-protein
(	I-protein
S186A	I-protein
)	I-protein
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O
	
The	O
mutant	O
,	O
containing	O
a	O
serine-to-alanine	O
substitution	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA-binding	B-DNA
sites	I-DNA
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA-responsive	B-DNA
promoters	I-DNA
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV-infected	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B-protein
protein	I-protein
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
ZEBRA	B-protein
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B-protein
protein	I-protein
in	O
disruption	O
of	O
EBV	O
latency	O
.	O
	
The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B-protein
protein	I-protein
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	B-DNA
viral	I-DNA
promoters	I-DNA
in	O
a	O
chromatinized	B-DNA
viral	I-DNA
episome	I-DNA
.	O
	
###MEDLINE:97197910	
	
Immune	O
hyperactivation	O
of	O
HIV-1-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
Tat	B-protein
and	O
the	O
CD28	B-protein
pathway	O
.	O
	
Human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O
	
Infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
HIV-1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	B-protein
and	I-protein
CD28	I-protein
receptors	I-protein
.	O
	
Expression	O
of	O
the	O
HIV-1	B-protein
transactivator	I-protein
Tat	B-protein
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL-2	B-protein
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	B-protein
plus	O
CD28	B-protein
.	O
	
IL-2	B-protein
superinduction	O
by	O
Tat	B-protein
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28-responsive	B-DNA
element	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	B-protein
amino	I-protein
acids	I-protein
encoded	O
by	O
the	O
second	B-DNA
exon	I-DNA
of	I-DNA
Tat	I-DNA
.	O
	
###MEDLINE:97242104	
	
Response	O
to	O
intranasal	O
fluticasone	O
propionate	O
in	O
perennial	O
allergic	O
rhinitis	O
not	O
associated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
.	O
	
BACKGROUND	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
treatment	O
with	O
corticosteroids	O
varies	O
among	O
patients	O
with	O
perennial	O
rhinitis	O
.	O
	
Most	O
patients	O
will	O
respond	O
but	O
a	O
few	O
patients	O
respond	O
less	O
to	O
these	O
drugs	O
.	O
	
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
association	O
in	O
reduction	O
of	O
symptoms	O
due	O
to	O
glucocorticoids	O
and	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
in	O
patients	O
with	O
perennial	O
allergic	O
rhinitis	O
,	O
in	O
vitro	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
studies	O
were	O
performed	O
with	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
using	O
dexamethasone	O
and	O
in	O
vitro	O
production	O
of	O
mediators	B-protein
were	O
measured	O
.	O
	
METHODS	O
:	O
During	O
a	O
double-blind	O
placebo-controlled	O
crossover	O
study	O
,	O
200	O
micrograms	O
fluticasone	O
propionate	O
aqueous	O
nasal	O
spray	O
(	O
in	O
the	O
active	O
treatment	O
period	O
)	O
and	O
placebo	O
(	O
in	O
the	O
placebo	O
treatment	O
period	O
)	O
were	O
administered	O
twice	O
daily	O
for	O
2	O
weeks	O
to	O
22	O
patients	O
allergic	O
to	O
house	O
dust	O
mite	O
.	O
	
At	O
the	O
end	O
of	O
both	O
treatment	O
periods	O
symptoms	O
were	O
scored	O
after	O
allergen	O
provocation	O
(	O
100	O
,	O
1000	O
,	O
10000	O
BU/mL	O
)	O
and	O
during	O
the	O
9.5	O
hours	O
after	O
this	O
challenge	O
.	O
	
Receptor	O
binding	O
studies	O
with	O
dexamethasone	O
were	O
performed	O
with	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
Leukotriene	O
B4	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
and	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
in	O
plasma	O
were	O
determined	O
.	O
	
RESULTS	O
:	O
No	O
significant	O
partial	O
correlations	O
of	O
the	O
number	O
of	O
the	O
peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
6821	O
+/-	O
5669	O
binding	O
sites	O
per	O
cell	O
)	O
and	O
the	O
affinity	O
(	O
Kd	O
:	O
16.5	O
+/-	O
13.51	O
nmol/L	O
)	O
for	O
the	O
glucocorticoid	B-protein
receptors	I-protein
with	O
the	O
symptom	O
score	O
(	O
placebo	O
:	O
4.3	O
+/-	O
2.45	O
pts	O
;	O
fluticasone	O
:	O
2.4	O
+/-	O
1.55	O
pts	O
)	O
after	O
active	O
treatment	O
were	O
found	O
.	O
	
Also	O
no	O
significant	O
partial	O
correlations	O
of	O
the	O
levels	O
of	O
leukotriene	O
B4	O
(	O
45.6	O
+/-	O
105.3	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
,	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
(	O
734	O
+/-	O
237	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
(	O
571	O
+/-	O
236	O
ng/mL	O
)	O
in	O
plasma	O
with	O
the	O
symptom	O
score	O
after	O
active	O
treatment	O
were	O
found	O
.	O
	
CONCLUSIONS	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
topical	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
rhinitis	O
and	O
allergy	O
to	O
house	O
dust	O
mite	O
is	O
not	O
correlated	O
with	O
the	O
characteristics	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
	
###MEDLINE:97184542	
	
Constitutive	O
expression	O
of	O
p50	B-protein
homodimer	I-protein
in	O
freshly	B-cell_type
isolated	I-cell_type
human	I-cell_type
monocytes	I-cell_type
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	B-cell_type
and	O
mature	O
macrophages	O
.	O
	
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	B-cell_type
macrophages	I-cell_type
than	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O
	
We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF-kappaB	B-protein
with	O
monocyte	O
differentiation	O
.	O
	
We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDMs	B-cell_type
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	B-cell_type
macrophages	I-cell_type
(	O
AMs	B-cell_type
)	O
.	O
	
Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	B-protein
inactive	I-protein
p50	I-protein
homodimer	I-protein
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50/p65	B-protein
and	I-protein
p50/RelB	I-protein
heterodimers	I-protein
.	O
	
As	O
in	O
MDMs	B-cell_type
,	O
AMs	B-cell_type
constitutively	O
expressed	O
p50/p65	B-protein
and	O
p50/RelB	B-protein
although	O
at	O
lower	O
levels	O
.	O
	
HIV	O
infection	O
of	O
fresh	O
monocytes	B-cell_type
failed	O
to	O
induce	O
p50/p65	B-protein
as	O
seen	O
in	O
MDMs	B-cell_type
.	O
	
The	O
replacement	O
of	O
p50	B-protein
homodimers	I-protein
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	B-cell_type
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O
	
The	O
change	O
in	O
NF-kappaB	B-protein
components	I-protein
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV-infected	O
individuals	O
.	O
	
###MEDLINE:97186415	
	
NF-kappa	B-protein
B	I-protein
-independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O
	
Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B-protein
cytokine	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O
	
To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O
	
Pretreatment	O
of	O
ACH-2	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	B-protein
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF-kappa	B-protein
B	I-protein
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH-2	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
following	O
TNF-alpha-	O
or	O
PMA-induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O
	
These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF-kappa	B-protein
B	I-protein
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O
	
###MEDLINE:97199263	
	
A	O
T	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
in	O
the	O
interleukin-3	B-DNA
locus	I-DNA
is	O
activated	O
cooperatively	O
by	O
Oct	B-DNA
and	I-DNA
NFAT	I-DNA
elements	I-DNA
within	O
a	O
DNase	B-DNA
I-hypersensitive	I-DNA
site	I-DNA
.	O
	
Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
is	O
expressed	O
primarily	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
identified	O
an	O
inducible	O
T	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
14	O
kb	O
upstream	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
that	O
responded	O
to	O
activation	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
signaling	O
pathways	O
.	O
	
The	O
IL-3	B-protein
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	B-DNA
A-sensitive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
found	O
only	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Four	O
NFAT-like	B-DNA
elements	I-DNA
exist	O
within	O
the	O
enhancer	O
.	O
	
The	O
two	O
most	O
active	O
NFAT-like	B-DNA
elements	I-DNA
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	B-DNA
I-hypersensitive	I-DNA
site	I-DNA
.	O
	
One	O
of	O
these	O
NFAT-like	B-DNA
elements	I-DNA
encompassed	O
overlapping	O
Oct-	B-DNA
and	I-DNA
NFATp/c-binding	I-DNA
sites	I-DNA
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O
	
We	O
suggest	O
that	O
the	O
T	O
cell-specific	O
expression	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B-protein
and	I-protein
NFAT	I-protein
family	I-protein
proteins	I-protein
.	O
	
###MEDLINE:97170849	
	
Adenovirus	B-protein
E1B	I-protein
19K	I-protein
protein	I-protein
is	O
required	O
for	O
efficient	O
DNA	O
replication	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
The	O
adenovirus	B-DNA
E1B	I-DNA
19K	I-DNA
gene	I-DNA
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	B-cell_type
rodent	I-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
E1A	B-protein
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O
	
It	O
has	O
been	O
shown	O
that	O
this	O
E1B	B-protein
19K	I-protein
protein	I-protein
is	O
not	O
necessary	O
for	O
viral	O
DNA	O
replication	O
in	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
such	O
as	O
HeLa	B-cell_line
and	O
KB	B-cell_line
.	O
	
We	O
reported	O
here	O
that	O
the	O
E1B	B-protein
19K	I-protein
mutant	O
viruses	O
were	O
unable	O
to	O
replicate	O
efficiently	O
in	O
a	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O
	
Viral	O
DNA	O
synthesis	O
and	O
late	O
gene	O
expression	O
were	O
found	O
to	O
be	O
defective	O
in	O
U937	B-cell_line
cells	I-cell_line
infected	O
with	O
E1B	B-protein
19K	I-protein
mutants	O
compared	O
with	O
wild-type	O
virus	O
.	O
	
Early	O
viral	O
RNA	O
splicing	O
patterns	O
also	O
differ	O
between	O
wild-type	B-cell_line
and	I-cell_line
dl337-infected	I-cell_line
cells	I-cell_line
.	O
	
Furthermore	O
,	O
the	O
defect	O
in	O
viral	O
replication	O
could	O
be	O
complemented	O
by	O
dl312	O
virus	O
defective	O
in	O
E1A	B-protein
expression	O
4	O
days	O
after	O
infection	O
with	O
E1B	O
mutants	O
,	O
suggesting	O
persistence	O
of	O
the	O
E1B	B-DNA
mutant	I-DNA
genome	I-DNA
in	O
the	O
infected	O
cells	O
despite	O
defective	O
onset	O
of	O
the	O
late	O
phase	O
of	O
replication	O
.	O
	
These	O
results	O
imply	O
that	O
E1B	B-protein
19K	I-protein
is	O
required	O
for	O
efficient	O
viral	O
DNA	O
replication	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
	
###MEDLINE:97272160	
	
Activation	O
of	O
Ras	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
by	O
terminal	B-protein
complement	I-protein
complexes	I-protein
is	O
G	B-protein
protein	I-protein
dependent	O
.	O
	
Assembly	O
of	O
terminal	B-protein
complement	I-protein
complexes	I-protein
(	O
TCC	B-protein
)	O
C5b-7	B-protein
,	O
C5b-8	B-protein
,	O
and	O
C5b-9	B-protein
on	O
target	O
cells	O
during	O
acute	O
and	O
chronic	O
inflammation	O
induces	O
hydrolysis	O
of	O
plasma	O
membrane	O
phospholipids	O
and	O
heterotrimeric	O
G	B-protein
protein	I-protein
activation	O
.	O
	
TCC	B-protein
also	O
stimulate	O
a	O
variety	O
of	O
cellular	O
activities	O
,	O
which	O
include	O
cytokine	B-protein
synthesis	O
,	O
proto-oncogene	B-DNA
activation	O
,	O
and	O
mitotic	O
signaling	O
.	O
	
Now	O
we	O
report	O
that	O
sublytic	O
TCC	B-protein
induced	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
1	I-protein
activation	O
in	O
JY25	O
B	O
cell	O
line	O
.	O
	
When	O
cells	O
were	O
exposed	O
to	O
C5b-9	B-protein
,	O
GTP-bound	B-protein
Ras	I-protein
in	O
anti-C5b-9	B-protein
immunoprecipitates	I-protein
was	O
increased	O
3.2-fold	O
at	O
2	O
min	O
,	O
while	O
GTP-bound	B-protein
Ras	I-protein
in	O
anti-Ras	B-protein
immunoprecipitates	I-protein
was	O
increased	O
2-fold	O
at	O
10	O
min	O
.	O
	
Both	O
C5b-9	B-protein
and	O
C5b-7	B-protein
,	O
but	O
not	O
C5b6	B-protein
,	O
increased	O
Raf-1	B-protein
kinase	O
activity	O
maximum	O
3.3-fold	O
at	O
2	O
min	O
and	O
2.8-fold	O
at	O
5	O
min	O
,	O
respectively	O
.	O
	
ERK1	B-protein
activity	O
was	O
2-fold	O
increased	O
by	O
C5b-9	B-protein
at	O
2	O
min	O
and	O
by	O
C5b-7	B-protein
at	O
10	O
min	O
,	O
over	O
the	O
C5b6	B-protein
level	O
.	O
	
The	O
role	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
on	O
TCC	B-protein
-inducible	O
mitotic	O
signaling	O
was	O
evaluated	O
by	O
assessing	O
DNA	O
synthesis	O
and	O
activator	B-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
DNA-binding	O
activity	O
.	O
	
The	O
MAPK/ERK-specific	O
inhibitor	O
PD	O
098	O
,	O
059	O
abolished	O
the	O
C5b-9	B-protein
-induced	O
DNA	O
synthesis	O
.	O
	
Involvement	O
of	O
G	B-protein
protein	I-protein
in	O
the	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
was	O
indicated	O
by	O
inhibition	O
of	O
Raf-1	B-protein
and	O
ERK1	B-protein
kinase	O
activity	O
,	O
as	O
well	O
as	O
the	O
DNA	O
synthesis	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B-protein
toxin	I-protein
.	O
	
Overexpression	O
of	O
beta-adrenergic	O
receptor	O
kinase	O
1	O
carboxyl-terminal	O
peptide	O
in	O
JY25	B-cell_line
cells	I-cell_line
also	O
inhibited	O
Raf-1	B-protein
and	O
ERK1	B-protein
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O
	
###MEDLINE:97288306	
	
Spontaneous	O
occurrence	O
of	O
early	O
region	O
1A	O
reiteration	O
mutants	O
of	O
type	O
5	O
adenovirus	O
in	O
persistently	B-cell_type
infected	I-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
.	O
	
Mutants	O
of	O
type	O
5	O
adenovirus	O
(	O
Ad5	O
)	O
with	O
reiterated	B-DNA
DNA	I-DNA
sequences	I-DNA
in	O
the	O
E1a	B-DNA
region	I-DNA
appeared	O
in	O
a	O
human	B-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Molt-4	B-cell_line
,	O
persistently	O
infected	O
with	O
H5sub304	O
,	O
a	O
deletion/substitution	O
mutant	O
that	O
has	O
a	O
wild-type	O
phenotype	O
in	O
viral	O
replication	O
.	O
	
Endonuclease	B-protein
analyses	O
and	O
DNA	O
sequencing	O
revealed	O
DNA	O
reiteration	O
in	O
each	O
mutant	O
.	O
	
In	O
the	O
four	O
representative	O
mutants	O
investigated	O
,	O
the	O
DNA	B-DNA
reiterations	I-DNA
all	O
started	O
within	O
a	O
six-base-pair	B-DNA
consensus	I-DNA
sequence	I-DNA
,	O
G	O
(	O
or	O
C	O
)	O
CTGTG	O
,	O
located	O
in	O
the	O
second	O
exon	B-DNA
of	O
the	O
E1a	B-DNA
region	I-DNA
(	O
at	O
nt	O
1333	O
,	O
1367	O
,	O
or	O
1419	O
)	O
.	O
	
There	O
was	O
not	O
any	O
DNA	O
homology	O
between	O
the	O
breakpoints	O
in	O
the	O
second	O
exon	B-DNA
and	O
the	O
inserting	B-DNA
sequences	I-DNA
(	O
starting	O
at	O
nt	O
532	O
,	O
710	O
,	O
or	O
792	O
)	O
.	O
	
Northern	O
analyses	O
suggested	O
that	O
the	O
reiterated	B-DNA
splicing	I-DNA
sites	I-DNA
of	O
the	O
representative	O
mutants	O
were	O
all	O
used	O
in	O
RNA	O
splicing	O
,	O
and	O
the	O
closest	O
donor	O
and	O
recipient	O
joints	O
were	O
used	O
most	O
frequently	O
.	O
	
These	O
observations	O
imply	O
that	O
during	O
persistent	O
infection	O
Ad5	O
underwent	O
spontaneous	O
mutations	O
by	O
sequence-specific	O
breakage	O
and	O
nonhomologous	O
end-end	O
joining	O
recombination	O
events	O
.	O
	
These	O
E1a	O
reiteration	O
mutants	O
could	O
be	O
propagated	O
in	O
HeLa	B-cell_line
,	O
A549	B-cell_line
,	O
and	O
KB	B-cell_line
cells	I-cell_line
;	O
they	O
were	O
genetically	O
stable	O
;	O
and	O
they	O
killed	O
CREF	B-cell_line
cells	I-cell_line
at	O
a	O
strikingly	O
high	O
frequency	O
.	O
	
Preliminary	O
observations	O
tend	O
to	O
correlate	O
this	O
CREF	O
cell	O
killing	O
with	O
the	O
accumulation	O
of	O
the	O
early	B-protein
viral	I-protein
proteins	I-protein
and/or	O
viral	B-DNA
DNA	I-DNA
in	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O
	
This	O
degree	O
of	O
cell	O
damage	O
was	O
not	O
observed	O
in	O
Ad5wt	O
or	O
H5sub304	O
infection	O
of	O
CREF	B-cell_line
cells	I-cell_line
.	O
	
The	O
observed	O
E1a	B-DNA
reiterations	I-DNA
provide	O
a	O
model	O
to	O
gain	O
insight	O
into	O
understanding	O
the	O
evolutionary	O
events	O
of	O
some	O
,	O
if	O
not	O
all	O
,	O
adenovirus	O
types	O
during	O
many	O
years	O
of	O
symbiotic	O
,	O
persistent	O
relationship	O
in	O
human	O
tonsils	O
and	O
adenoids	O
and	O
possibly	O
other	O
lymphoid	O
organs	O
.	O
	
###MEDLINE:97276226	
	
Preferential	O
presentation	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
T-cell	I-protein
antigen	I-protein
by	O
HLA	B-protein
DQA1*0501/DQB1*0201	I-protein
in	O
comparison	O
to	O
HLA	B-protein
DQA1*0201/DQB1*0201	I-protein
.	O
	
The	O
HLA	B-DNA
DQA1	I-DNA
locus	I-DNA
is	O
polymorphic	O
.	O
	
Haplotypes	O
containing	O
HLA	B-DNA
DQA1*0501	I-DNA
,	O
but	O
not	O
HLA	B-DNA
DQA1*0201	I-DNA
,	O
together	O
with	O
HLA	B-DNA
DQB1*0201	I-DNA
are	O
associated	O
with	O
Grave	O
's	O
disease	O
and	O
celiac	O
sprue	O
.	O
	
In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
functional	O
correlate	O
of	O
DQA1	O
polymorphism	O
.	O
	
T	B-cell_type
cells	I-cell_type
infiltrating	O
a	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
lesion	O
from	O
a	O
HLA	O
DQ	O
2	O
,	O
7	O
individual	O
yielded	O
a	O
virus-specific	B-cell_line
CD4+	I-cell_line
clone	I-cell_line
restricted	O
by	O
DQ2	B-protein
.	O
	
Presentation	O
of	O
viral	O
peptide	O
and	O
protein	O
segregated	O
with	O
DQA1	B-DNA
allele	I-DNA
,	O
because	O
cell	O
lines	O
bearing	O
DQA1*0501/DQB1*0201	B-protein
heterodimers	I-protein
presented	O
antigen	O
in	O
proliferation	O
and	O
cytotoxicity	O
assays	O
much	O
more	O
efficiently	O
than	O
cell	B-cell_line
lines	I-cell_line
bearing	O
DQA1*0201/DQB1*0201	B-protein
.	O
	
Binding	O
of	O
viral	O
peptide	O
to	O
cell	O
lines	O
bearing	O
DQA1*0201	B-protein
,	O
in	O
comparison	O
to	O
DQA1*0501	B-protein
,	O
was	O
only	O
moderately	O
reduced	O
and	O
may	O
not	O
explain	O
this	O
effect	O
.	O
	
Truncation	O
and	O
substitution	O
analyses	O
of	O
peptide	O
binding	O
and	O
T-cell	O
activation	O
were	O
performed	O
to	O
determine	O
which	O
viral	O
peptide	O
residues	O
contacting	O
TCR	B-protein
might	O
therefore	O
be	O
presented	O
in	O
an	O
altered	O
conformation	O
by	O
DQA1*0201/DQB1*0201	B-protein
.	O
	
Residues	O
432	O
,	O
435	O
,	O
437	O
,	O
438	O
,	O
and	O
440	O
(	O
position	B-DNA
P1	I-DNA
,	I-DNA
P4	I-DNA
,	I-DNA
P6	I-DNA
,	I-DNA
P7	I-DNA
,	I-DNA
and	I-DNA
P9	I-DNA
)	O
contributed	O
to	O
DQ2	B-protein
binding	O
,	O
whereas	O
residues	O
431	O
,	O
433	O
,	O
434	O
,	O
and	O
436	O
(	O
positions	B-DNA
P	I-DNA
1	I-DNA
,	I-DNA
P2	I-DNA
,	I-DNA
P3	I-DNA
,	I-DNA
and	I-DNA
P5	I-DNA
)	O
contributed	O
to	O
TCR	B-protein
contact	O
.	O
	
Differential	O
presentation	O
of	O
peptide	O
by	O
HLA	B-protein
DQ2	I-protein
heterodimers	I-protein
varying	O
at	O
the	O
DQA1	B-DNA
locus	I-DNA
may	O
have	O
relevance	O
to	O
host	O
defense	O
and	O
the	O
pathogenesis	O
of	O
HLA	O
DQ2	B-protein
-associated	O
autoimmune	O
diseases	O
.	O
	
###MEDLINE:97282709	
	
Inhibitor	O
(	O
IK	O
)	O
of	O
IFN-gamma	B-protein
induced	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
also	O
inhibits	O
HLA	B-protein
class	I-protein
II	I-protein
constitutive	O
expression	O
in	O
the	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
The	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
is	O
constitutive	O
in	O
professional	B-cell_type
antigen	I-cell_type
presenting	I-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	B-cell_type
APCs	I-cell_type
(	O
e.g	O
.	O
fibroblasts	B-cell_type
)	O
.	O
	
We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B-protein
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
.	O
	
Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B-protein
in	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
since	O
over-expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	B-RNA
class	I-RNA
II	I-RNA
mRNA	I-RNA
expression	O
.	O
	
The	O
class	B-DNA
II	I-DNA
transactivator	I-DNA
(	O
CIITA	B-DNA
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN-gamma	B-protein
induced	O
MHC	B-protein
class	I-protein
II	I-protein
expressions	O
.	O
	
Examination	O
of	O
CIITA	B-RNA
mRNA	I-RNA
in	O
IK	B-protein
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	B-RNA
mRNA	I-RNA
transcription	O
.	O
	
Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	B-protein
protein	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
that	O
inhibition	O
induced	O
by	O
IK	B-protein
is	O
upstream	O
of	O
CIITA	B-DNA
in	O
this	O
regulatory	O
pathway	O
.	O
	
###MEDLINE:97217364	
	
Selective	O
expression	O
of	O
an	O
interleukin-12	B-protein
receptor	I-protein
component	I-protein
by	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
cells	I-cell_type
.	O
	
Interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
heterodimeric	B-protein
cytokine	I-protein
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
and	O
in	O
the	O
generation	O
of	O
IFN-gamma-producing	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
show	O
that	O
the	O
IL-12	B-protein
receptor	I-protein
(	I-protein
IL-12R	I-protein
)	I-protein
beta	I-protein
2	I-protein
subunit	I-protein
,	O
a	O
recently	O
cloned	O
binding	B-protein
and	I-protein
signal	I-protein
transducing	I-protein
component	I-protein
of	O
the	O
IL-12R	B-protein
,	O
is	O
expressed	O
on	O
human	B-cell_line
Th1	I-cell_line
but	I-cell_line
not	I-cell_line
Th2	I-cell_line
clones	I-cell_line
and	O
is	O
induced	O
during	O
differentiation	O
of	O
human	B-cell_type
naive	I-cell_type
cells	I-cell_type
along	O
the	O
Th1	O
but	O
not	O
the	O
Th2	O
pathway	O
.	O
	
IL-12	B-protein
and	O
type	B-protein
I	I-protein
but	I-protein
not	I-protein
type	I-protein
II	I-protein
interferons	I-protein
induce	O
expression	O
of	O
the	O
IL-12R	B-protein
beta	I-protein
2	I-protein
chain	I-protein
during	O
in	O
vitro	O
T	O
cell	O
differentiation	O
after	O
antigen	O
receptor	O
triggering	O
.	O
	
The	O
selective	O
expression	O
and	O
regulation	O
of	O
the	O
IL-12R	B-protein
beta	I-protein
2	I-protein
subunit	I-protein
may	O
help	O
to	O
understand	O
the	O
basis	O
of	O
Th1/Th2	O
differentiation	O
and	O
may	O
provide	O
therapeutic	O
options	O
for	O
altering	O
the	O
Th1/Th2	O
balance	O
in	O
several	O
immuno-pathological	O
conditions	O
such	O
as	O
autoimmune	O
diseases	O
and	O
allergies	O
.	O
	
###MEDLINE:97230346	
	
The	O
T	B-protein
cell	I-protein
activation	I-protein
factor	I-protein
NF-ATc	B-protein
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O
	
T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O
	
The	O
hypothesis	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O
	
We	O
report	O
that	O
certain	O
NF-AT	B-protein
(	I-protein
Rel	I-protein
)	I-protein
family	I-protein
members	I-protein
productively	O
bind	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
,	O
synergize	O
with	O
NF-kappaB	B-protein
and	O
Tat	B-protein
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
link	O
regulatory	B-protein
factors	I-protein
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O
	
###MEDLINE:97184478	
	
Transcription	O
mediated	O
by	O
NFAT	B-protein
is	O
highly	O
inducible	O
in	O
effector	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
Th1	B-cell_type
cells	I-cell_type
.	O
	
Transcriptional	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	B-DNA
genes	I-DNA
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IL-4	B-protein
,	O
among	O
others	O
.	O
	
Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
pTh	I-cell_type
)	I-cell_type
cells	I-cell_type
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	B-cell_type
cells	I-cell_type
(	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	B-protein
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O
	
eTh2	B-cell_type
cells	I-cell_type
are	O
the	O
major	O
source	O
of	O
IL-4	B-protein
,	O
while	O
gamma	B-protein
interferon	I-protein
is	O
produced	O
by	O
eTh1	B-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	B-protein
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	B-cell_type
cells	I-cell_type
into	O
either	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
cells	I-cell_type
to	O
mediate	O
the	O
expression	O
of	O
IL-2	B-protein
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O
	
However	O
,	O
although	O
NFAT	B-protein
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
cells	I-cell_type
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	B-protein
complexes	I-protein
present	O
in	O
eTh2	B-cell_type
cells	I-cell_type
are	O
able	O
to	O
mediate	O
high-level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	B-protein
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	B-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
to	O
activated	O
pTh	B-cell_type
cells	I-cell_type
,	O
neither	O
eTh1	B-cell_type
nor	O
eTh2	B-cell_type
cells	I-cell_type
produced	O
significant	O
IL-2	B-protein
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	B-protein
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL-4	B-protein
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	B-cell_type
cells	I-cell_type
.	O
	
These	O
data	O
suggest	O
that	O
activated	O
NFAT	B-protein
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
failure	O
of	O
eTh1	B-cell_type
cells	I-cell_type
to	O
produce	O
IL-4	B-protein
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high-level	O
transcription	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
by	O
NFAT	B-protein
.	O
	
Regulation	O
of	O
NFAT	B-protein
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
.	O
	
###MEDLINE:97218076	
	
Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
lipopolysaccharide-stimulated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
	
During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte/macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O
	
Transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	B-protein
cytokines	I-protein
.	O
	
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF-kappaB	B-protein
by	O
LPS	O
in	O
a	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB-alpha	B-protein
inhibitor	O
hydrolysis	O
.	O
	
No	O
degradation	O
of	O
p105	B-protein
and	I-protein
p100	I-protein
inhibitors	I-protein
was	O
observed	O
under	O
these	O
conditions	O
.	O
	
The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	B-protein
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O
	
This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O
	
This	O
finding	O
indicates	O
that	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
are	O
also	O
involved	O
.	O
	
However	O
,	O
the	O
NF-kappaB	B-protein
activation	O
pathway	O
involving	O
the	O
acidic	B-protein
sphingomyelinase	I-protein
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:97199262	
	
c-Rel	B-protein
is	O
a	O
target	O
of	O
pentoxifylline-mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O
	
The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell-dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O
	
In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O
	
We	O
found	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
anti-CD3-induced	O
c-Rel	B-protein
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF-kappaB	B-protein
family	I-protein
members	I-protein
was	O
not	O
significantly	O
affected	O
.	O
	
However	O
,	O
induction	O
of	O
NF-AT	B-protein
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c-Rel	B-protein
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O
	
Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	B-protein
factors	I-protein
,	O
IL-2	B-RNA
mRNA	I-RNA
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	B-RNA
(	I-RNA
alpha	I-RNA
)	I-RNA
chain	I-RNA
mRNA	I-RNA
induction	O
was	O
not	O
affected	O
.	O
	
These	O
observations	O
implicated	O
c-Rel	B-protein
as	O
an	O
IL-2	B-protein
promoter	I-protein
factor	I-protein
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O
	
In	O
contrast	O
with	O
the	O
observation	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
c-Rel	B-protein
induction	O
was	O
not	O
blocked	O
by	O
PF	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O
	
###MEDLINE:97159684	
	
V3	B-protein
loop	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B-protein
2	I-protein
-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O
	
We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	B-protein
region	I-protein
of	O
the	O
HTLV-III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	B-protein
-driven	O
T	O
cell	O
proliferation	O
.	O
	
V3-BH10	B-protein
,	O
which	O
consists	O
of	O
42	B-protein
amino	I-protein
acids	I-protein
and	O
has	O
a	O
loop	B-protein
structure	I-protein
,	O
suppressed	O
IL-2	B-protein
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	B-cell_line
cells	I-cell_line
[	O
Kit225	B-cell_line
,	O
ED-40515	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	O
KT-3	B-cell_line
,	O
7-day	B-cell_line
PHA-blasts	I-cell_line
,	O
and	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
Hut102	B-cell_line
,	O
Molt-4	B-cell_line
,	O
and	O
Jurkat	B-cell_line
)	O
.	O
	
This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	B-protein
-driven	O
cell	O
growth	O
of	O
CD8-positive	B-cell_type
lymphocytes	I-cell_type
purified	O
from	O
7-day	B-cell_type
PHA-blasts	I-cell_type
,	O
indicating	O
that	O
CD4	B-protein
molecules	I-protein
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O
	
The	O
treatment	O
with	O
anti-V3	B-protein
loop	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
902	B-protein
antibody	I-protein
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3-BH10	B-protein
.	O
	
In	O
addition	O
,	O
V3-BH10	B-protein
generated	O
the	O
arrest	O
of	O
Kit225	B-cell_line
cells	I-cell_line
and	O
also	O
purified	B-cell_line
CD8-positive	I-cell_line
lymphocytes	I-cell_line
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	B-protein
.	O
	
Neither	O
chromatin	B-DNA
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	B-cell_line
cells	I-cell_line
cultured	O
with	O
V3-BH10	B-protein
and	O
IL-2	B-protein
.	O
	
V3-BH10	B-protein
neither	O
blocked	O
radiolabeled	O
IL-2	B-protein
binding	O
to	O
IL-2	B-protein
receptors	I-protein
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	B-protein
proteins	I-protein
(	O
p120	B-protein
,	O
p98	B-protein
,	O
p96	B-protein
,	O
p54	B-protein
,	O
and	O
p38	B-protein
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O
	
However	O
,	O
V3-BH10	B-protein
enhanced	O
IL-2	B-protein
-induced	B-RNA
mRNA	I-RNA
expression	O
of	O
c-fos	B-DNA
but	O
not	O
c-myc	B-DNA
or	O
junB	B-DNA
.	O
	
Thus	O
,	O
the	O
binding	O
of	O
V3	B-protein
loop	I-protein
of	O
gp120	B-protein
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	B-protein
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	B-protein
-induced	O
T	O
cell	O
growth	O
	
###MEDLINE:97277252	
	
A	O
negative	O
role	O
for	O
phosphoinositide	B-protein
3-kinase	I-protein
in	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
function	O
.	O
	
BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T-cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O
	
Phosphoinositide	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T-cell	O
function	O
,	O
including	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
the	O
costimulatory	B-protein
receptor	I-protein
CD28	I-protein
,	O
and	O
negative	B-protein
regulators	I-protein
of	O
T-cell	O
activation	O
such	O
as	O
CTLA-4	B-protein
.	O
	
PI	B-protein
3-kinase	I-protein
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T-cell	O
differentiation	O
and	O
lymphocyte	B-cell_type
proliferation	O
.	O
	
PI	B-protein
3-kinase	I-protein
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O
	
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
TCR	B-protein
-directed	O
T-cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	B-protein
3-kinase	I-protein
.	O
	
RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	B-protein
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	B-protein
and	O
serum	B-protein
response	I-protein
factor	I-protein
were	O
not	O
affected	O
by	O
expression	O
of	O
the	O
mutant	O
forms	O
of	O
PI	B-protein
3-kinase	I-protein
.	O
	
We	O
found	O
,	O
however	O
,	O
that	O
PI	B-protein
3-kinase	I-protein
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
'	O
(	O
NF-AT	B-protein
)	O
elicited	O
by	O
the	O
TCR	B-protein
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	B-protein
3-kinase	I-protein
inhibited	O
TCR	B-protein
-mediated	O
NF-AT	B-protein
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	B-protein
3-kinase	I-protein
potently	O
enhanced	O
TCR	B-protein
-controlled	O
NF-AT	B-protein
induction	O
.	O
	
These	O
effects	O
of	O
PI	B-protein
3-kinase	I-protein
were	O
not	O
mediated	O
by	O
previously	O
identified	O
PI	B-protein
3-kinase	I-protein
effectors	I-protein
,	O
such	O
as	O
protein	B-protein
kinase	I-protein
B	I-protein
,	O
a	O
positive	B-protein
regulator	I-protein
of	O
PI	B-protein
3-kinase	I-protein
,	O
or	O
the	O
GTPase	B-protein
Rac	I-protein
,	O
and	O
are	O
therefore	O
likely	O
to	O
involve	O
a	O
novel	O
,	O
as	O
yet	O
unknown	O
,	O
effector	B-protein
molecule	I-protein
.	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B-protein
3-kinase	I-protein
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T-cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B-protein
3-kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	B-protein
-signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T-cell	O
homeostasis	O
.	O
	
###MEDLINE:97248576	
	
The	O
Pax-5	B-DNA
gene	I-DNA
is	O
alternatively	O
spliced	O
during	O
B-cell	O
development	O
.	O
	
The	O
transcription	B-protein
factor	I-protein
Pax-5	I-protein
is	O
expressed	O
during	O
the	O
early	O
stages	O
of	O
B-cell	O
differentiation	O
and	O
influences	O
the	O
expression	O
of	O
several	O
B-cell-specific	B-DNA
genes	I-DNA
.	O
	
In	O
addition	O
to	O
the	O
existing	O
isoform	O
(	O
Pax-5	B-protein
,	O
which	O
we	O
have	O
named	O
Pax-5a	B-protein
)	O
,	O
we	O
have	O
isolated	O
three	O
new	O
isoforms	O
,	O
Pax-5b	B-protein
,	O
Pax-5d	B-protein
,	O
and	O
Pax-5e	B-protein
,	O
from	O
murine	O
spleen	O
and	O
B-lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
library	O
screenings	O
and	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O
	
Isoforms	O
Pax-5b	B-protein
and	O
Pax-5e	B-protein
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA-binding	B-protein
domain	I-protein
.	O
	
Isoforms	O
Pax-5d	O
and	O
Pax-5e	B-protein
have	O
deleted	O
the	O
3'-region	B-protein
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O
	
The	O
existence	O
of	O
alternative	O
Pax-5	B-RNA
transcripts	I-RNA
was	O
confirmed	O
using	O
RNase	B-protein
protection	O
assays	O
.	O
	
Furthermore	O
,	O
Pax-5a	B-protein
and	O
Pax-5b	B-protein
proteins	I-protein
were	O
detected	O
using	O
Western	O
blot	O
analysis	O
.	O
	
Pax-5a	B-protein
was	O
detectable	O
in	O
pro-	B-cell_line
,	I-cell_line
pre-	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax-5b	B-protein
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro-B-cell	B-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
Mobility	O
shift	O
assays	O
showed	O
that	O
in	O
vitro	O
translated	O
Pax-5a	B-protein
and	O
Pax-5d	B-protein
,	O
but	O
not	O
Pax-5b	B-protein
or	O
Pax-5e	B-protein
,	O
could	O
interact	O
with	O
a	O
B-cell-specific	B-DNA
activator	I-DNA
protein-binding	I-DNA
site	I-DNA
on	O
the	O
blk	B-DNA
promoter	I-DNA
.	O
	
Using	O
this	O
assay	O
,	O
we	O
also	O
showed	O
that	O
Pax-5d	B-protein
was	O
present	O
in	O
nuclear	O
extracts	O
of	O
some	O
(	O
but	O
not	O
all	O
)	O
B-lymphoid	B-cell_line
lines	I-cell_line
and	O
interacts	O
with	O
the	O
B-cell-specific	B-DNA
activator	I-DNA
protein-binding	I-DNA
site	I-DNA
.	O
	
The	O
pattern	O
of	O
differential	O
expression	O
of	O
alternatively	B-protein
spliced	I-protein
Pax-5	I-protein
isoforms	I-protein
suggests	O
that	O
they	O
may	O
be	O
important	O
regulators	B-protein
of	I-protein
transcription	I-protein
during	O
B-cell	O
maturation	O
.	O
	
###MEDLINE:97274642	
	
Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor-induced	O
Erk2	B-protein
kinase	I-protein
activation	O
in	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
by	O
Syk	B-protein
.	O
	
The	O
two	O
related	O
protein-tyrosine	B-protein
kinases	I-protein
Syk	B-protein
and	O
Zap	B-protein
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O
	
We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
Syk	B-protein
is	O
less	O
dependent	O
on	O
the	O
Src	B-protein
family	I-protein
kinase	I-protein
Lck	B-protein
than	O
the	O
activation	O
of	O
Zap	B-protein
.	O
	
Here	O
we	O
report	O
that	O
overexpression	O
of	O
Syk	B-protein
in	O
the	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
enabled	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor/CD3	I-protein
complex	I-protein
to	O
induce	O
a	O
normal	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
and	O
expression	O
of	O
a	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
reporter	O
construct	O
.	O
	
In	O
contrast	O
,	O
Zap	B-protein
and	O
other	O
protein-tyrosine	B-protein
kinases	I-protein
were	O
unable	O
to	O
reconstitute	O
these	O
signaling	O
pathways	O
when	O
expressed	O
at	O
the	O
same	O
levels	O
.	O
	
In	O
parallel	O
,	O
Syk	B-protein
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	B-protein
was	O
not	O
.	O
	
The	O
Syk	B-protein
-mediated	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
MAPK	B-protein
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3-5	O
min	O
.	O
	
The	O
capacity	O
of	O
Syk	B-protein
to	O
reconstitute	O
the	O
MAPK	B-protein
response	O
required	O
the	O
catalytic	O
activity	O
of	O
Syk	B-protein
,	O
an	O
intact	O
autophosphorylation	B-protein
site	I-protein
(	O
Y518	O
and	O
Y519	O
)	O
,	O
both	O
Src	B-protein
homology	I-protein
2	I-protein
domains	I-protein
and	O
it	O
was	O
blocked	O
by	O
the	O
inhibitory	B-protein
N17-mutated	I-protein
dominant-negative	I-protein
Ras	I-protein
construct	I-protein
.	O
	
A	O
Y341	O
--	O
>	O
F	B-protein
mutant	I-protein
of	O
Syk	B-protein
,	O
which	O
is	O
deficient	O
in	O
its	O
interaction	O
with	O
phospholipase	B-protein
Cy1	I-protein
and	O
Vav	B-protein
,	O
was	O
less	O
efficient	O
than	O
wild-type	B-protein
Syk	I-protein
.	O
	
Our	O
results	O
suggest	O
that	O
Syk	B-protein
,	O
in	O
contrast	O
to	O
Zap	B-protein
,	O
can	O
transduce	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
independently	O
of	O
Lck	B-protein
.	O
	
###MEDLINE:97222140	
	
Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
MEF2C	B-protein
by	O
the	O
MAP	B-protein
kinase	I-protein
p38	I-protein
in	O
inflammation	O
.	O
	
For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram-negative	O
bacteria	O
.	O
	
These	O
cellular	O
responses	O
require	O
intracellular	O
signalling	O
pathways	O
,	O
such	O
as	O
the	O
four	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathways	O
.	O
	
In	O
mammalian	O
cells	O
the	O
MAPK	B-protein
p38	I-protein
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B-protein
molecules	I-protein
.	O
	
One	O
means	O
of	O
understanding	O
the	O
role	O
of	O
p38	B-protein
in	O
these	O
responses	O
is	O
to	O
identify	O
proteins	O
with	O
functions	O
regulated	O
by	O
p38	B-protein
-catalysed	O
phosphorylation	O
.	O
	
Here	O
we	O
demonstrate	O
a	O
link	O
between	O
the	O
p38	B-protein
pathway	O
and	O
a	O
member	O
of	O
the	O
myocyte-enhancer	B-protein
factor	I-protein
2	I-protein
(	I-protein
MEF2	I-protein
)	I-protein
group	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
We	O
found	O
that	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
LPS	O
increases	O
the	O
transactivation	O
activity	O
of	O
MEF2C	B-protein
through	O
p38	B-protein
-catalysed	O
phosphorylation	O
.	O
	
One	O
consequence	O
of	O
MEF2C	B-protein
activation	O
is	O
increased	O
c-jun	B-DNA
gene	I-DNA
transcription	O
.	O
	
Our	O
results	O
show	O
that	O
p38	B-protein
may	O
influence	O
host	O
defence	O
and	O
inflammation	O
by	O
maintaining	O
the	O
balance	O
of	O
c-Jun	B-protein
protein	I-protein
consumed	O
during	O
infection	O
.	O
	
###MEDLINE:97300635	
	
Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
The	O
role	O
of	O
cellular	O
redox	O
status	O
in	O
both	O
cytotoxic	O
activity	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
was	O
investigated	O
.	O
	
The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O
	
Pretreatment	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
but	O
the	O
AP-1	B-protein
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O
	
The	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PDTC	O
paralleled	O
with	O
an	O
inhibition	O
of	O
spontaneous	O
cytotoxicity	O
mediated	O
by	O
NK	B-cell_type
cells	I-cell_type
.	O
	
Moreover	O
,	O
the	O
inhibitors	O
of	O
serine	B-protein
proteases	I-protein
,	O
N-alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
and	O
N-alpha-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
,	O
also	O
blocked	O
the	O
cytolytic	O
activity	O
of	O
NK	B-cell_type
cells	I-cell_type
against	O
the	O
sensitive	O
target	O
K562	B-cell_line
.	O
	
In	O
contrast	O
,	O
NK	O
activity	O
was	O
not	O
affected	O
by	O
pretreatment	O
of	O
the	O
effector	O
cells	O
with	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-leu-leu-norleucinal	O
which	O
selectively	O
inhibits	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	B-cell_type
cells	I-cell_type
involved	O
transcriptional	O
and	O
post-transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:97228330	
	
The	O
predominant	O
E2F	B-protein
complex	I-protein
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
in	O
AML	B-cell_type
blasts	I-cell_type
contains	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
.	O
	
The	O
E2F	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
progression	O
.	O
	
There	O
is	O
now	O
also	O
increasing	O
evidence	O
that	O
some	O
family	O
members	O
may	O
act	O
as	O
oncogenes	B-DNA
or	O
tumour	B-DNA
suppressor	I-DNA
genes	I-DNA
.	O
	
The	O
characterization	O
of	O
these	O
proteins	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
acute	B-cell_type
myeloid	I-cell_type
leukaemia	I-cell_type
(	I-cell_type
AML	I-cell_type
)	I-cell_type
blasts	I-cell_type
may	O
thus	O
give	O
an	O
insight	O
to	O
the	O
molecular	O
mechanisms	O
governing	O
proliferation	O
and	O
leukaemogenesis	O
in	O
these	O
cells	O
.	O
	
Therefore	O
we	O
analysed	O
the	O
expression	O
of	O
E2F	B-protein
-DNA	O
binding	O
activity	O
and	O
the	O
constituent	O
proteins	O
found	O
in	O
the	O
complexes	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
of	O
various	O
lineages	O
.	O
	
We	O
also	O
studied	O
blasts	O
from	O
18	O
patients	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
.	O
	
On	O
electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
a	O
single	O
E2F-DNA	B-protein
binding	I-protein
complex	I-protein
was	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
which	O
was	O
shown	O
to	O
contain	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
,	O
indicating	O
that	O
all	O
quiescent	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
have	O
the	O
same	O
complex	O
.	O
	
Examination	O
of	O
18	O
AML	O
samples	O
by	O
EMSA	O
revealed	O
the	O
presence	O
of	O
E2F	B-protein
binding	O
and	O
no	O
gross	O
abnormalities	O
were	O
detected	O
.	O
	
An	O
E2F-4/p130	B-protein
complex	I-protein
was	O
detected	O
in	O
representative	O
samples	O
of	O
all	O
FAB	B-protein
types	O
analysed	O
.	O
	
Thus	O
abnormalities	O
of	O
E2F	B-protein
function	O
are	O
unlikely	O
to	O
play	O
a	O
primary	O
pathogenic	O
role	O
in	O
AML	O
.	O
	
###MEDLINE:97184469	
	
Characterization	O
of	O
a	O
mutant	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
does	O
not	O
activate	O
NF-kappaB	B-protein
in	O
response	O
to	O
multiple	O
stimuli	O
.	O
	
Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O
	
Associated	O
with	O
its	O
inhibitor	O
,	O
I	B-protein
kappaB	I-protein
,	O
NF-kappaB	B-protein
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O
	
Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	B-protein
kappaB	I-protein
is	O
proteolyzed	O
and	O
NF-kappaB	B-protein
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O
	
The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B-protein
kappaB	I-protein
inactivation	O
remain	O
poorly	O
understood	O
.	O
	
In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70/Z3-derived	B-cell_line
1.3E2	I-cell_line
murine	I-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
that	O
does	O
not	O
activate	O
NF-kappaB	B-protein
in	O
response	O
to	O
several	O
stimuli	O
.	O
	
We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	B-protein
,	O
or	O
double-stranded	B-RNA
RNA	I-RNA
,	O
I	B-protein
kappaB	I-protein
alpha	I-protein
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O
	
Neither	O
a	O
mutation	O
in	O
I	B-protein
kappaB	I-protein
alpha	I-protein
nor	O
a	O
mutation	O
in	O
p50	B-protein
or	O
relA	B-protein
,	O
the	O
two	O
major	O
subunits	O
of	O
NF-kappaB	B-protein
in	O
this	O
cell	O
line	O
,	O
accounts	O
for	O
this	O
phosphorylation	O
defect	O
.	O
	
As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-protein
kappaB	I-protein
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	B-cell_line
cells	I-cell_line
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O
	
In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC-insensitive	O
pathways	O
,	O
induce	O
I	B-protein
kappaB	I-protein
alpha	O
degradation	O
in	O
1.3E2	B-cell_line
.	O
	
Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	B-cell_line
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild-type	B-cell_line
70Z/3	I-cell_line
.	O
	
We	O
also	O
report	O
that	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
-derived	I-protein
Tax	I-protein
trans-activator	I-protein
induces	O
NF-kappaB	B-protein
activity	O
in	O
1.3E2	B-cell_line
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O
	
Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	B-protein
kappaB	I-protein
molecules	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
and	O
the	O
recently	O
identified	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	B-cell_line
cell	O
line	O
following	O
stimulation	O
.	O
	
Our	O
results	O
demonstrate	O
that	O
1.3E2	B-cell_line
is	O
a	O
cellular	B-protein
transduction	I-protein
mutant	I-protein
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF-kappaB	B-protein
.	O
	
In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B-protein
kappaB	I-protein
alpha	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
,	O
and	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
degradation	O
.	O
	
###MEDLINE:97188782	
	
Involvement	O
of	O
Egr-1	B-protein
/RelA	B-protein
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
NF-kappa	B-protein
B1	I-protein
transcription	O
.	O
	
NF-kappa	B-protein
B	I-protein
is	O
an	O
important	O
transcription	B-protein
factor	I-protein
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O
	
The	O
NF-kappa	B-DNA
B1	I-DNA
gene	I-DNA
encodes	O
a	O
105-kD	B-protein
protein	I-protein
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	B-protein
component	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
regulates	O
the	O
NF-kappa	B-DNA
B1	I-DNA
gene	I-DNA
.	O
	
In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	B-protein
(	O
PHA	B-protein
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF-kappa	B-protein
B1	I-protein
encoding	O
transcripts	B-RNA
than	O
cells	O
stimulated	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O
	
Characterization	O
of	O
the	O
NF-kappa	B-DNA
B1	I-DNA
promoter	I-DNA
identified	O
an	O
Egr-1	B-DNA
site	I-DNA
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA/	O
PHA	B-protein
-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Egr-1	B-protein
.	O
	
Furthermore	O
,	O
Egr-1	B-protein
induction	O
was	O
required	O
for	O
endogenous	O
NF-kappa	B-DNA
B1	I-DNA
gene	O
expression	O
,	O
since	O
PMA/	O
PHA-stimulated	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
antisense	O
Egr-1	B-RNA
RNA	I-RNA
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF-kappa	O
B1	O
transcription	O
.	O
	
Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF-kappa	B-DNA
B1	I-DNA
gene	O
expression	O
.	O
	
###MEDLINE:97189104	
	
The	O
synthesis	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
glycoprotein	I-protein
E	I-protein
and	O
immediate-early	B-protein
protein	I-protein
(	O
IE62	B-protein
)	O
expressed	O
in	O
recombinant	O
herpes	O
simplex	O
virus-1	O
.	O
	
In	O
order	O
to	O
evaluate	O
the	O
conditions	O
for	O
optimal	O
expression	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
(	I-protein
VZV	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
herpes	O
simplex	O
virus-1	O
(	O
HSV-1	O
)	O
vector	O
,	O
we	O
selected	O
the	O
VZV	B-protein
glycoprotein	I-protein
E	I-protein
(	O
gE	B-protein
)	O
,	O
encoded	O
by	O
ORF	B-DNA
68	I-DNA
and	O
the	O
VZV	B-protein
product	I-protein
of	O
ORF	B-DNA
62	I-DNA
,	O
an	O
immediate-early	B-protein
major	I-protein
tegument	I-protein
protein	I-protein
(	O
IE62	B-protein
)	O
.	O
	
Three	O
HSV/VZV	B-DNA
recombinants	I-DNA
were	O
generated	O
:	O
(	O
1	O
)	O
VZV	B-DNA
gE	I-DNA
protein	I-DNA
coding	I-DNA
sequences	I-DNA
along	O
with	O
the	O
promoter	B-protein
region	I-protein
were	O
inserted	O
into	O
the	O
thymidine	B-DNA
kinase	I-DNA
(	I-DNA
TK	I-DNA
)	I-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
KOS	O
;	O
(	O
2	O
)	O
VZV	B-protein
gE	I-protein
expressed	O
from	O
the	O
HSV-1	B-DNA
ICP4	I-DNA
promoter	I-DNA
was	O
inserted	O
into	O
the	O
glycoprotein	B-DNA
C	I-DNA
(	I-DNA
gC	I-DNA
)	I-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
F	O
;	O
and	O
(	O
3	O
)	O
VZV	B-DNA
IE62	I-DNA
protein	I-DNA
coding	I-DNA
sequences	I-DNA
under	O
the	O
control	O
of	O
the	O
HSV-1	B-DNA
ICP4	I-DNA
promoter	I-DNA
were	O
inserted	O
into	O
the	O
gC	B-DNA
gene	I-DNA
of	O
HSV-1	O
strain	O
F	O
.	O
	
Immunoblot	O
analysis	O
and	O
immunoperoxidase	O
staining	O
of	O
infected	O
cell	O
monolayers	O
demonstrated	O
vector	O
expression	O
of	O
VZV	B-protein
proteins	I-protein
.	O
	
Following	O
intracranial	O
inoculation	O
in	O
mice	O
,	O
both	O
VZV	B-protein
gE-HSV	I-protein
(	O
TK	B-protein
)	O
and	O
VZV	B-protein
IE62-HSV	I-protein
(	O
gC	B-protein
)	O
induced	O
an	O
IgG	B-protein
response	O
against	O
VZV	B-protein
gE	I-protein
or	O
VZV	B-protein
IE62	I-protein
.	O
	
When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T-lymphocytes	B-cell_type
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T-lymphocytes	B-cell_type
that	O
recognized	O
VZV	B-protein
gE	I-protein
or	O
VZV	B-protein
IE62	I-protein
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV-1	O
or	O
a	O
vaccinia	O
vector	O
.	O
	
These	O
experiments	O
demonstrate	O
that	O
HSV-1	O
is	O
a	O
competent	O
vector	O
for	O
expression	O
of	O
these	O
VZV	B-protein
proteins	I-protein
and	O
support	O
the	O
feasibility	O
of	O
engineering	O
a	O
combined	O
vaccine	O
for	O
these	O
closely	O
related	O
alpha-herpesviruses	O
.	O
	
###MEDLINE:97153085	
	
Constitutive	O
dephosphorylation	O
and	O
activation	O
of	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
,	O
NF-AT1	B-protein
,	O
in	O
Tax-expressing	B-cell_type
and	I-cell_type
type	I-cell_type
I	I-cell_type
human	I-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
virus-infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
tax	O
gene	O
product	O
of	O
the	O
type	O
I	O
human	O
T-cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
transactivates	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
through	O
activation	O
of	O
an	O
enhancer	O
termed	O
CD28	B-DNA
responsive	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
.	O
	
Tax	B-protein
activation	O
of	O
the	O
CD28RE	B-DNA
is	O
partially	O
mediated	O
by	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
,	O
NF-AT1	B-protein
.	O
	
We	O
have	O
previously	O
shown	O
that	O
NF-AT1	B-protein
is	O
constitutively	O
active	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
Tax	B-DNA
cDNA	I-DNA
,	O
although	O
the	O
underlying	O
molecular	O
mechanism	O
and	O
physiological	O
relevance	O
of	O
this	O
finding	O
remain	O
unclear	O
.	O
	
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
active	O
form	O
of	O
NF-AT1	B-protein
is	O
also	O
present	O
in	O
the	O
nuclei	O
of	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
express	O
the	O
Tax	B-protein
protein	I-protein
.	O
	
Interestingly	O
,	O
the	O
constitutive	O
activation	O
of	O
NF-AT1	B-protein
in	O
these	O
T	B-cell_type
cells	I-cell_type
is	O
associated	O
with	O
its	O
dephosphorylation	O
.	O
	
Furthermore	O
,	O
the	O
dephosphorylated	O
NF-AT1	B-protein
can	O
be	O
rapidly	O
rephosphorylated	O
when	O
the	O
cells	O
are	O
incubated	O
with	O
cyclosporin	O
A	O
,	O
an	O
immunosuppressant	O
inhibiting	O
the	O
serine/threonine	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O
	
These	O
results	O
suggest	O
that	O
activation	O
of	O
NF-AT1	B-protein
in	O
Tax-expressing	B-cell_line
and	I-cell_line
HTLV-I-transformed	I-cell_line
T	I-cell_line
cells	I-cell_line
results	O
from	O
its	O
dephosphorylation	O
,	O
which	O
in	O
turn	O
may	O
be	O
due	O
to	O
deregulation	O
of	O
calcineurin	B-protein
	
###MEDLINE:97265379	
	
Expression	O
of	O
NFAT-family	B-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
NFAT	B-protein
proteins	I-protein
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
mediating	O
signal	O
transduction	O
.	O
	
Using	O
a	O
panel	O
of	O
specific	O
antisera	O
in	O
immunoprecipitation	O
assays	O
,	O
we	O
found	O
that	O
NFATp	B-protein
(	O
135	B-protein
kDa	I-protein
)	O
is	O
constitutively	O
expressed	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
synthesis	O
of	O
NFATc	B-protein
(	O
predominant	O
form	O
of	O
86	B-protein
kDa	I-protein
)	O
is	O
induced	O
by	O
ionomycin	O
treatment	O
.	O
	
NFAT4/x	B-protein
was	O
very	O
weakly	O
expressed	O
in	O
unstimulated	O
cells	O
,	O
and	O
its	O
level	O
did	O
not	O
increase	O
upon	O
treatment	O
with	O
activating	O
agents	O
.	O
	
NFAT3	B-protein
protein	I-protein
was	O
not	O
observed	O
under	O
any	O
conditions	O
.	O
	
Higher-molecular-weight	B-protein
species	I-protein
of	O
NFATc	B-protein
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O
	
In	O
addition	O
,	O
translation	O
of	O
NFATc	B-RNA
mRNA	I-RNA
apparently	O
initiates	O
at	O
two	O
different	O
AUG	B-DNA
codons	I-DNA
,	O
giving	O
rise	O
to	O
proteins	O
that	O
differ	O
in	O
size	O
by	O
36	O
amino	O
acids	O
.	O
	
Additional	O
size	O
heterogeneity	O
of	O
both	O
NFATc	B-protein
and	O
NFATp	B-protein
results	O
from	O
phosphorylation	O
.	O
	
In	O
contrast	O
to	O
ionomycin	O
treatment	O
,	O
exposure	O
of	O
cells	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
plus	O
anti-CD28	B-protein
did	O
not	O
induce	O
NFATc	B-protein
,	O
indicating	O
that	O
under	O
these	O
conditions	O
,	O
interleukin-2	B-protein
synthesis	O
by	O
these	O
cells	O
is	O
apparently	O
independent	O
of	O
NFATc	B-protein
.	O
	
In	O
DNA	O
binding	O
assays	O
,	O
both	O
PMA	O
plus	O
anti-CD28	B-protein
and	O
PMA	O
plus	O
ionomycin	O
resulted	O
in	O
nuclear	B-protein
NFAT	I-protein
.	O
	
Surprisingly	O
,	O
the	O
PMA-ionomycin-induced	O
synthesis	O
of	O
NFATc	B-protein
that	O
was	O
detected	O
by	O
immunoprecipitation	O
was	O
not	O
mirrored	O
in	O
the	O
DNA	O
binding	O
assays	O
:	O
nearly	O
all	O
of	O
the	O
activity	O
was	O
due	O
to	O
NFATp	B-protein
.	O
	
This	O
is	O
the	O
first	O
study	O
of	O
expression	O
of	O
all	O
family	O
members	O
at	O
the	O
protein	O
level	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:97353180	
	
Of	O
the	O
GATA-binding	B-protein
proteins	I-protein
,	O
only	O
GATA-4	B-protein
selectively	O
regulates	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
IL-5	B-cell_type
producing	I-cell_type
cells	I-cell_type
which	O
express	O
multiple	B-protein
GATA-binding	I-protein
proteins	I-protein
.	O
	
Interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
is	O
produced	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	B-cell_type
cells	I-cell_type
.	O
	
Using	O
ATL-16T	B-cell_line
cells	I-cell_line
which	O
express	O
IL-5	B-RNA
mRNA	I-RNA
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
,	O
that	O
regulates	O
IL-5	B-DNA
gene	I-DNA
transcription	O
.	O
	
This	O
cis-acting	B-DNA
sequence	I-DNA
contains	O
the	O
core	B-DNA
binding	I-DNA
motif	I-DNA
,	O
(	O
A/T	O
)	O
GATA	O
(	O
A/G	O
)	O
,	O
for	O
GATA-binding	B-protein
family	I-protein
proteins	I-protein
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O
	
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	B-protein
GATA-4	I-protein
(	O
hGATA-4	B-protein
)	O
and	O
show	O
that	O
hGATA-4	B-protein
selectively	O
interacts	O
with	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
within	O
the	O
IL-5	B-DNA
proximal	I-DNA
promoter	I-DNA
region	I-DNA
.	O
	
By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O
	
Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA-4	B-protein
and	O
PMA/A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL-5	B-DNA
promoter	I-DNA
activation	O
.	O
	
The	O
requirement	O
of	O
another	O
regulatory	B-DNA
element	I-DNA
called	O
CLE0	B-DNA
,	O
which	O
lies	O
downstream	O
of	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
,	O
was	O
also	O
demonstrated	O
.	O
	
ATL-16T	B-cell_line
cells	I-cell_line
express	O
mRNA	B-RNA
of	O
three	O
GATA-binding	B-protein
proteins	I-protein
,	O
hGATA-2	B-protein
,	O
hGATA-3	B-protein
and	O
hGATA-4	B-protein
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	O
to	O
the	O
consensus	B-DNA
(	I-DNA
A/T	I-DNA
)	I-DNA
GATA	I-DNA
(	I-DNA
G/	I-DNA
A	I-DNA
)	I-DNA
motif	I-DNA
.	O
	
However	O
,	O
using	O
ATL-16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	B-protein
is	O
the	O
only	O
GATA-binding	B-protein
protein	I-protein
that	O
forms	O
specific	O
DNA-protein	B-protein
complex	I-protein
with	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
.	O
	
The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	B-cell_line
cells	I-cell_line
expressing	O
GATA-binding	B-protein
proteins	I-protein
showed	O
that	O
GATA-4	B-protein
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
among	O
the	O
three	O
GATA-binding	B-protein
proteins	I-protein
.	O
	
When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA-4	B-protein
showed	O
the	O
highest	O
activity	O
.	O
	
These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA-4	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	B-DNA
gene	I-DNA
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA-binding	B-protein
proteins	I-protein
are	O
expressed	O
.	O
	
###MEDLINE:97219997	
	
Control	O
of	O
NFATx1	B-protein
nuclear	O
translocation	O
by	O
a	O
calcineurin-regulated	B-protein
inhibitory	I-protein
domain	I-protein
.	O
	
The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
regulates	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
cells	I-cell_type
through	O
cis-acting	B-DNA
elements	I-DNA
located	O
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokine	B-DNA
genes	I-DNA
.	O
	
NFATx1	B-protein
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	B-protein
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O
	
We	O
found	O
that	O
NFATx1	B-protein
DNA	O
binding	O
activity	O
and	O
interaction	O
with	O
AP-1	O
polypeptides	O
were	O
dependent	O
on	O
its	O
central	B-protein
Rel	I-protein
similarity	I-protein
region	I-protein
and	O
that	O
transcriptional	O
activation	O
was	O
reduced	O
by	O
deletions	O
of	O
either	O
its	O
N-terminal	B-protein
domain	I-protein
or	O
its	O
C-terminal	B-protein
domain	I-protein
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	B-protein
transcriptional	I-protein
activation	I-protein
motifs	I-protein
in	O
both	O
regions	O
.	O
	
We	O
also	O
identified	O
a	O
potent	O
inhibitory	B-protein
sequence	I-protein
within	O
its	O
N-terminal	B-protein
domain	I-protein
.	O
	
We	O
show	O
that	O
the	O
inactivation	O
of	O
the	O
inhibition	O
was	O
dependent	O
on	O
the	O
activity	O
of	O
calcineurin	B-protein
,	O
a	O
calcium-calmodulin-dependent	B-protein
phosphatase	I-protein
.	O
	
We	O
also	O
show	O
that	O
calcineurin	B-protein
associated	O
with	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
NFATx1	B-protein
at	O
multiple	B-protein
docking	I-protein
sites	I-protein
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	B-protein
.	O
	
We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	B-protein
residues	I-protein
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	B-protein
proteins	I-protein
.	O
	
Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	B-protein
of	O
the	O
mapped	O
60	B-protein
residues	I-protein
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O
	
Our	O
results	O
support	O
the	O
model	O
proposing	O
that	O
the	O
N-terminal	B-protein
domain	I-protein
confers	O
calcium-signaling	O
dependence	O
on	O
NFATx1	B-protein
transactivation	O
activity	O
by	O
regulating	O
its	O
intracellular	O
localization	O
through	O
a	O
protein	O
module	O
that	O
associates	O
with	O
calcineurin	B-protein
and	O
is	O
a	O
target	O
of	O
its	O
phosphatase	B-protein
activity	O
.	O
	
###MEDLINE:97226013	
	
Neuronal	B-protein
(	I-protein
type	I-protein
I	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
regulates	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activity	O
and	O
immunologic	B-protein
(	I-protein
type	I-protein
II	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
expression	O
.	O
	
Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O
	
NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	B-protein
synthase	I-protein
(	I-protein
NOS	I-protein
)	I-protein
isoforms	I-protein
:	O
neuronal	B-protein
NOS	I-protein
(	O
nNOS	B-protein
)	O
,	O
endothelial	B-protein
NOS	I-protein
,	O
and	O
immunologic	B-protein
NOS	I-protein
(	O
iNOS	B-protein
)	O
.	O
	
We	O
show	O
that	O
nNOS	B-protein
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	O
in	O
glia	B-cell_type
.	O
	
NO	O
derived	O
from	O
nNOS	B-protein
in	O
glia	B-cell_type
inhibits	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF	B-protein
kappaB	I-protein
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	B-protein
kappaB	I-protein
activation	O
.	O
	
Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	B-protein
kappaB	I-protein
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O
	
In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
a	O
human	O
T-cell	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
induces	O
NF	B-protein
kappaB	I-protein
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O
	
Contrary	O
to	O
the	O
results	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
NF	B-protein
kappaB	I-protein
activation	O
in	O
astrocytes	B-cell_type
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	B-protein
kappaB	I-protein
activation	O
in	O
astrocytes	B-cell_type
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O
	
In	O
astrocytes	B-cell_type
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	B-protein
kappaB-dependent	I-protein
enzyme	I-protein
,	O
iNOS	B-protein
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	B-protein
kappaB	I-protein
.	O
	
NF	B-protein
kappaB	I-protein
activation	O
in	O
glia	B-cell_type
from	O
mice	O
lacking	O
nNOS	B-protein
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	B-cell_type
from	O
wild-type	O
mice	O
.	O
	
Our	O
data	O
suggest	O
that	O
nNOS	B-protein
in	O
astrocytes	B-cell_type
regulates	O
NF	B-protein
kappaB	I-protein
activity	O
and	O
iNOS	B-protein
expression	O
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	B-protein
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	B-DNA
kappaB-regulated	I-DNA
genes	I-DNA
.	O
	
###MEDLINE:97300620	
	
Involvement	O
of	O
Stat3	B-protein
in	O
interleukin-6	B-protein
-induced	O
IgM	B-protein
production	O
in	O
a	O
human	B-cell_line
B-cell	I-cell_line
line	I-cell_line
.	O
	
Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
is	O
an	O
important	O
B-cell	B-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
.	O
	
IL-6	B-protein
treatment	O
of	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
SKW6.4	B-cell_line
,	O
leads	O
to	O
increased	O
IgM	B-protein
production	O
.	O
	
We	O
have	O
previously	O
shown	O
that	O
IL-6	B-protein
induces	O
activation	O
of	O
JAK1	B-protein
and	O
JAK2	B-protein
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
A	O
chimeric	O
IL-6	B-protein
receptor	I-protein
,	O
comprised	O
of	O
the	O
intracellular	B-protein
tail	I-protein
of	O
the	O
IL-6	B-protein
receptor	I-protein
subunit	I-protein
gp130	B-protein
fused	O
to	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	I-protein
EGF	I-protein
)	I-protein
receptor	I-protein
,	O
was	O
stably	O
transfected	O
into	O
SKW6.4	B-cell_line
cells	I-cell_line
.	O
	
EGF	O
treatment	O
induced	O
IgM	B-protein
production	O
in	O
cells	O
transfected	O
with	O
an	O
intact	O
gp130	B-protein
cytoplasmic	I-protein
tail	I-protein
,	O
but	O
not	O
in	O
untransfected	B-cell_line
cells	I-cell_line
or	O
cells	O
transfected	O
with	O
a	O
cytoplasmic	B-protein
tail	I-protein
lacking	O
all	O
four	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
binding	I-protein
sites	I-protein
.	O
	
Moreover	O
,	O
EGF	O
treatment	O
induced	O
Stat3	B-protein
phosphorylation	O
in	O
cells	O
transfected	O
with	O
the	O
intact	O
chimeric	B-protein
EGF-gp130	I-protein
receptor	I-protein
along	O
with	O
induction	O
of	O
DNA-mobility	O
shift	O
of	O
a	O
classical	B-DNA
interferon-gamma-activated	I-DNA
site	I-DNA
.	O
	
To	O
define	O
further	O
the	O
relation	O
between	O
Stat3	B-protein
activation	O
and	O
enhanced	O
IgM	B-protein
production	O
,	O
we	O
determined	O
the	O
effect	O
of	O
chimeric	O
gp130	O
on	O
the	O
transcriptional	O
activation	O
of	O
a	O
genetic	O
element	O
linked	O
to	O
immunoglobulin	B-protein
production	O
,	O
namely	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
(	O
IgH-enhancer	B-DNA
)	O
.	O
	
Parental	O
as	O
well	O
as	O
transfected	O
SKW6.4	B-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
an	O
IgH-enhancer-luciferase	B-DNA
construct	I-DNA
.	O
	
The	O
transcriptional	O
activity	O
of	O
the	O
IgH-luciferase	B-DNA
construct	I-DNA
was	O
induced	O
upon	O
ligation	O
of	O
the	O
full-length	B-protein
chimeric	I-protein
receptor	I-protein
but	O
not	O
by	O
truncated	B-protein
gp130	I-protein
receptors	I-protein
.	O
	
Moreover	O
,	O
the	O
gp130	B-protein
-induced	O
activity	O
of	O
this	O
reporter	B-DNA
gene	I-DNA
was	O
abrogated	O
by	O
Stat3EE	B-protein
,	O
a	O
mutant	O
Stat3	B-protein
incapable	O
of	O
binding	O
DNA	O
.	O
	
These	O
results	O
indicate	O
that	O
IL-6	B-protein
-induced	O
B-cell	O
differentiation	O
,	O
as	O
measured	O
by	O
IgM	B-protein
production	O
,	O
may	O
be	O
controlled	O
by	O
Stat3	B-protein
proteins	I-protein
.	O
	
###MEDLINE:97236919	
	
T-lymphocytes	B-cell_type
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O
	
The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	B-cell_type
filarial	I-cell_type
antigen-specific	I-cell_type
T-cells	I-cell_type
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O
	
Circulating	B-cell_type
T-cells	I-cell_type
from	O
individuals	O
with	O
filaria-induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	B-cell_type
monolayers	I-cell_type
than	O
did	O
T-cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0.04	O
)	O
.	O
	
In	O
contrast	O
to	O
the	O
MF	O
individuals	O
where	O
no	O
effect	O
was	O
seen	O
,	O
transendothelial	O
migration	O
of	O
48-hr	O
filarial	B-cell_type
antigen	I-cell_type
stimulated	I-cell_type
T-cells	I-cell_type
from	O
LP	O
individuals	O
was	O
significantly	O
(	O
P	O
=	O
0.01	O
)	O
greater	O
than	O
migration	O
of	O
48-hr	O
media-stimulated	B-cell_type
T-cells	I-cell_type
.	O
	
In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA-4/	O
VCAM-1	B-protein
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T-cells	B-cell_type
.	O
	
###MEDLINE:97184463	
	
Transcriptional	O
regulation	O
of	O
the	O
ferritin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
:	O
the	O
activity	O
of	O
the	O
CCAAT	B-protein
binding	I-protein
factor	I-protein
NF-Y	I-protein
is	O
modulated	O
in	O
heme-treated	B-cell_line
Friend	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O
	
The	O
ferritin	B-DNA
H-chain	I-DNA
gene	I-DNA
promoter	I-DNA
regulation	O
was	O
analyzed	O
in	O
heme-treated	B-cell_line
Friend	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
(	O
FLCs	B-cell_line
)	O
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O
	
In	O
the	O
majority	O
of	O
cell	B-cell_line
lines	I-cell_line
studied	O
,	O
the	O
regulation	O
of	O
ferritin	B-protein
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O
	
However	O
,	O
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	B-protein
synthesis	O
,	O
and	O
in	O
macrophages	B-cell_type
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O
	
We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	B-DNA
H-gene	I-DNA
promoter	I-DNA
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	B-cell_line
to	O
a	O
reporter	B-DNA
gene	I-DNA
is	O
77	B-DNA
nucleotides	I-DNA
upstream	I-DNA
of	O
the	O
TATA	B-DNA
box	I-DNA
.	O
	
This	O
cis	B-DNA
element	I-DNA
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	B-protein
(	O
heme-responsive	B-protein
factor	I-protein
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme-treated	O
FLCs	B-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O
	
The	O
CCAAT	B-DNA
element	I-DNA
present	O
in	O
reverse	O
orientation	O
in	O
this	O
promoter	O
region	O
of	O
the	O
ferritin	B-DNA
H-chain	I-DNA
gene	I-DNA
is	O
necessary	O
for	O
binding	O
and	O
for	O
gene	O
activity	O
,	O
since	O
a	O
single	O
point	O
mutation	O
is	O
able	O
to	O
abolish	O
the	O
binding	O
of	O
HRF	B-protein
and	O
the	O
transcriptional	O
activity	O
in	O
transfected	B-cell_line
cells	I-cell_line
.	O
	
By	O
competition	O
experiments	O
and	O
supershift	O
assays	O
,	O
we	O
identified	O
the	O
induced	O
HRF	B-protein
as	O
containing	O
at	O
least	O
the	O
ubiquitous	O
transcription	B-protein
factor	I-protein
NF-Y	B-protein
.	O
	
NF-Y	B-protein
is	O
formed	O
by	O
three	O
subunits	B-protein
,	O
A	B-protein
,	O
B	B-protein
,	O
and	O
C	B-protein
,	O
all	O
of	O
which	O
are	O
necessary	O
for	O
DNA	O
binding	O
.	O
	
Cotransfection	O
with	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
of	O
the	O
NF-YA	B-protein
subunit	I-protein
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	B-protein
,	O
indicating	O
that	O
NF-Y	B-protein
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O
	
We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF-YA	B-protein
subunit	I-protein
in	O
heme-treated	O
and	O
control	O
FLCs	B-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O
	
###MEDLINE:97332608	
	
Concomitant	O
downregulation	O
of	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
activity	O
and	O
c-myc	B-DNA
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c-myc	B-DNA
.	O
	
Regulation	O
of	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
expression	O
is	O
controlled	O
by	O
a	O
B	B-DNA
cell-specific	I-DNA
promoter	I-DNA
,	O
intronic	B-DNA
enhancer	I-DNA
and	O
additional	O
B	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
elements	I-DNA
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	B-DNA
locus	I-DNA
.	O
	
One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell-specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c-myc	B-DNA
oncogene	I-DNA
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	B-DNA
locus	I-DNA
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	B-DNA
gene	I-DNA
class	I-DNA
switch	O
recombination	O
.	O
	
We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
.	O
	
When	O
mouse	B-cell_line
MPC11	I-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
in	O
which	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	B-cell_type
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O
	
Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	B-cell_line
plasmacytoma	I-cell_line
x	I-cell_line
fibroblast	I-cell_line
environment	I-cell_line
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
transcriptionally	O
inactive	O
.	O
	
Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
,	O
essential	O
for	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
can	O
not	O
be	O
excluded	O
.	O
	
Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c-myc	B-DNA
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	B-cell_line
cells	I-cell_line
carrying	O
the	O
t	B-DNA
(	I-DNA
12	I-DNA
;	I-DNA
15	I-DNA
)	I-DNA
translocation	I-DNA
,	O
is	O
down-regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	B-cell_type
.	O
	
Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	B-protein
factors	I-protein
that	O
control	O
the	O
cell-specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	B-DNA
.	O
	
###MEDLINE:97184665	
	
Activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
in	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
by	O
hypochlorous	O
acid	O
.	O
	
Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
human	B-cell_type
cells	I-cell_type
.	O
	
During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	B-cell_type
polymorphonuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
Treatment	O
of	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
(	O
the	O
heterodimer	B-protein
p50/p65	I-protein
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O
	
Western	O
blot	O
analysis	O
of	O
the	O
NF-kappaB	B-protein
inhibitory	I-protein
subunits	I-protein
(	O
IkappaB	B-protein
)	O
demonstrated	O
that	O
both	O
IkappaB	B-protein
-alpha	O
proteolysis	O
and	O
p105	B-protein
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O
	
NF-kappaB	B-protein
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O
	
Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p-bromophenacyl-bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF-kappaB	B-protein
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O
	
Moreover	O
,	O
ACH-2	B-cell_line
cells	I-cell_line
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
the	O
supernatants	O
.	O
	
The	O
importance	O
of	O
TNF-alpha	B-protein
release	O
in	O
NF-kappaB	B-protein
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF-kappaB	B-protein
was	O
promoted	O
in	O
untreated	B-cell_line
cells	I-cell_line
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF-alpha	B-protein
and	O
HOCl	O
was	O
detected	O
.	O
	
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF-kappaB	B-protein
in	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long-distance	O
effect	O
through	O
subsequent	O
TNF-alpha	B-protein
release	O
.	O
	
###MEDLINE:97180928	
	
Rapid	O
Ca2+-mediated	O
activation	O
of	O
Rap1	B-protein
in	O
human	B-cell_type
platelets	I-cell_type
.	O
	
Rap1	B-protein
is	O
a	O
small	O
,	O
Ras-like	B-protein
GTPase	I-protein
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O
	
We	O
have	O
developed	O
a	O
novel	O
assay	O
to	O
monitor	O
the	O
active	O
,	O
GTP-bound	B-protein
form	I-protein
of	O
Rap1	B-protein
based	O
on	O
the	O
differential	O
affinity	O
of	O
Rap1GTP	B-protein
and	O
Rap1GDP	B-protein
for	O
the	O
Rap	B-protein
binding	I-protein
domain	I-protein
of	O
RalGDS	B-protein
(	O
RBD	B-protein
)	O
.	O
	
Stimulation	O
of	O
blood	B-cell_type
platelets	I-cell_type
with	O
alpha-thrombin	B-protein
or	O
other	O
platelet	O
activators	O
caused	O
a	O
rapid	O
and	O
strong	O
induction	O
of	O
Rap1	B-protein
that	O
associated	O
with	O
RBD	B-protein
in	O
vitro	O
.	O
	
Binding	O
to	O
RBD	B-protein
increased	O
from	O
undetectable	O
levels	O
in	O
resting	B-cell_type
platelets	I-cell_type
to	O
>	O
50	O
%	O
of	O
total	O
Rap1	B-protein
within	O
30	O
s	O
after	O
stimulation	O
.	O
	
An	O
increase	O
in	O
the	O
intracellular	O
Ca2+	O
concentration	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
Rap1	B-protein
activation	O
since	O
it	O
was	O
induced	O
by	O
agents	O
that	O
increase	O
intracellular	O
Ca2+	O
and	O
inhibited	O
by	O
a	O
Ca2+-chelating	O
agent	O
.	O
	
Neither	O
inhibition	O
of	O
translocation	O
of	O
Rap1	B-protein
to	O
the	O
cytoskeleton	O
nor	O
inhibition	O
of	O
platelet	O
aggregation	O
affected	O
thrombin	B-protein
-induced	O
activation	O
of	O
Rap1	B-protein
.	O
	
In	O
contrast	O
,	O
prostaglandin	O
I2	O
(	O
PGI2	O
)	O
,	O
a	O
strong	O
negative	O
regulator	O
of	O
platelet	B-cell_type
function	O
,	O
inhibited	O
agonist-induced	O
as	O
well	O
as	O
Ca2+-induced	O
activation	O
of	O
Rap1	B-protein
.	O
	
From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	B-protein
activation	O
in	O
platelets	B-cell_type
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist-induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2+	O
concentration	O
	
###MEDLINE:97248400	
	
Physical	O
interactions	O
between	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
transcriptional	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	I-DNA
contain	O
adjacent	O
or	O
overlapping	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
Similar	O
arrays	O
of	O
functionally	O
important	O
NF-kappaB/NFAT	B-DNA
and	I-DNA
Ets	I-DNA
binding	I-DNA
sites	I-DNA
are	O
present	O
in	O
the	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV-1	O
and	O
HIV-2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T-cell	O
gene	O
expression	O
that	O
has	O
been	O
co-opted	O
during	O
HIV	O
evolution	O
.	O
	
Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
cooperatively	O
regulate	O
inducible	O
T-cell	O
gene	O
expression	O
remained	O
unknown	O
.	O
	
In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
both	O
in	O
vitro	O
and	O
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	B-DNA
domain	I-DNA
of	O
Ets	B-protein
proteins	I-protein
and	O
the	O
C-terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF-kappaB/NFAT	B-protein
proteins	I-protein
.	O
	
In	O
addition	O
,	O
the	O
Ets	B-protein
-	O
NF-kappaB	B-protein
/	O
NFAT	B-protein
interaction	O
requires	O
the	O
presence	O
of	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	B-DNA
sites	I-DNA
for	O
Ets	B-protein
and	O
NF-kappaB	B-protein
proteins	I-protein
.	O
	
A	O
dominant-negative	O
mutant	O
of	O
NF-kappaB	B-protein
p50	I-protein
that	O
binds	O
DNA	O
but	O
fails	O
to	O
interact	O
with	O
Ets	B-protein
proteins	I-protein
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
by	O
NF-kappaB	B-protein
(	O
p50	B-protein
+	O
p65	B-protein
)	O
and	O
Ets-1	B-protein
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	B-protein
and	O
NF-kappaB	B-protein
proteins	I-protein
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
.	O
	
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T-cell	B-DNA
genes	I-DNA
and	O
viruses	O
.	O
	
These	O
interactions	O
represent	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
novel	O
immunosuppressive	O
and	O
antiviral	O
therapies	O
.	O
	
###MEDLINE:97353114	
	
An	O
acute	B-DNA
myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
,	O
AML1	B-DNA
,	O
regulates	O
transcriptional	O
activation	O
and	O
hemopoietic	O
myeloid	O
cell	O
differentiation	O
antagonistically	O
by	O
two	O
alternative	O
spliced	O
forms	O
.	O
	
The	O
AML1	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
21	I-DNA
is	O
disrupted	O
in	O
the	O
(	B-DNA
8	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
and	I-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
(	I-DNA
q26	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
translocations	I-DNA
associated	O
with	O
myelogenous	O
leukemias	O
and	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O
	
From	O
AML1	B-DNA
gene	I-DNA
,	O
two	O
representative	O
forms	O
of	O
proteins	O
,	O
AML1a	B-protein
and	O
AML1b	B-protein
,	O
are	O
produced	O
by	O
an	O
alternative	O
splicing	O
.	O
	
Both	O
forms	O
have	O
DNA-binding	B-protein
domain	I-protein
,	O
but	O
AML1a	B-protein
lacks	O
a	O
putative	O
transcriptional	O
activation	O
domain	O
which	O
AML1b	B-protein
has	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
AML1a	B-protein
,	O
which	O
solely	O
has	O
no	O
effects	O
as	O
a	O
transcriptional	O
regulator	O
,	O
dominantly	O
suppresses	O
transcriptional	O
activation	O
by	O
AML1b	B-protein
,	O
and	O
that	O
AML1a	B-protein
exhibits	O
the	O
higher	O
affinity	O
for	O
DNA-binding	O
than	O
AML1b	B-protein
.	O
	
Furthermore	O
a	O
dominant	B-protein
negative	I-protein
form	I-protein
of	O
AML1	B-protein
,	O
AML1a	B-protein
,	O
totally	O
suppressed	O
granulocytic	O
differentiation	O
otherwise	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
when	O
AML1a	B-protein
was	O
overexpressed	O
in	O
32Dc13	B-cell_type
murine	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O
	
Such	O
differentiation	O
block	O
by	O
AML1a	B-protein
was	O
canceled	O
by	O
the	O
concomitant	O
overexpression	O
of	O
AML1b	B-protein
.	O
	
These	O
data	O
strongly	O
suggest	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
AML1	B-protein
is	O
essential	O
for	O
the	O
myeloid	O
cell	O
differentiation	O
.	O
	
In	O
addition	O
,	O
we	O
observed	O
an	O
altered	O
expression	O
level	O
of	O
AML1	B-protein
along	O
with	O
the	O
myeloid	O
differentiation	O
in	O
several	O
hemopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
In	O
these	O
cases	O
,	O
at	O
least	O
,	O
the	O
AML1	B-protein
expression	O
level	O
is	O
a	O
potential	O
regulator	O
for	O
myeloid	O
cell	O
differentiation	O
.	O
	
###MEDLINE:97240797	
	
Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
potently	O
up-regulates	O
the	O
promoter	O
activity	O
of	O
RANTES	B-protein
,	O
a	O
chemokine	O
that	O
blocks	O
HIV	O
infection	O
.	O
	
The	O
complex	O
network	O
of	O
cytokines	B-protein
that	O
are	O
involved	O
in	O
inflammatory	O
and	O
immunoregulatory	O
responses	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O
	
RANTES	B-protein
(	O
regulated	B-protein
upon	I-protein
activation	I-protein
,	I-protein
normal	I-protein
T	I-protein
cell	I-protein
expressed	I-protein
and	I-protein
secreted	I-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
belongs	O
to	O
the	O
beta-chemokine	B-protein
family	I-protein
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+/CD45RO	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8+	B-cell_type
and	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
monocytes/macrophages	B-cell_type
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage-tropic	O
strains	O
of	O
HIV	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	B-protein
expression	O
,	O
the	O
RANTES	B-DNA
promoter	I-DNA
region	I-DNA
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel-mobility	O
shift	O
assays	O
.	O
	
We	O
demonstrate	O
that	O
:	O
1	O
)	O
RANTES	B-protein
promoter	O
activity	O
is	O
up-regulated	O
by	O
PMA	O
plus	O
ionomycin	O
,	O
coexpression	O
of	O
the	O
p65	B-protein
subunit	I-protein
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
,	O
the	O
proinflammatory	B-protein
cytokines	I-protein
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
,	O
and	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
;	O
2	O
)	O
the	O
RANTES	B-DNA
promoter	I-DNA
region	I-DNA
contains	O
four	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
at	O
positions	B-DNA
-30	I-DNA
,	I-DNA
-44	I-DNA
,	I-DNA
-213	I-DNA
,	I-DNA
and	I-DNA
-579	I-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
;	O
3	O
)	O
one	O
site	O
(	O
-213	O
)	O
is	O
an	O
NF-AT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
that	O
also	O
has	O
weak	O
affinity	O
to	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
most	O
distal	O
site	O
(	O
-579	O
)	O
also	O
serves	O
as	O
a	O
CD28-responsive	B-DNA
element	I-DNA
;	O
and	O
4	O
)	O
mutation	O
on	O
any	O
of	O
those	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
or	O
coexpression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
cytoplasmic	B-protein
inhibitor	I-protein
of	I-protein
NF-kappa	I-protein
B	I-protein
)	O
markedly	O
reduced	O
the	O
promoter	O
activity	O
.	O
	
Thus	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
HIV	O
expression	O
,	O
is	O
also	O
involved	O
in	O
the	O
expression	O
of	O
RANTES	B-protein
,	O
a	O
chemokine	B-protein
that	O
blocks	O
infection	O
by	O
macrophage-tropic	O
strains	O
of	O
HIV	O
.	O
	
###MEDLINE:97226001	
	
Pivotal	O
role	O
for	O
the	O
NFIL3/E4BP4	B-protein
transcription	I-protein
factor	I-protein
in	O
interleukin	B-protein
3	I-protein
-mediated	O
survival	O
of	O
pro-B	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
E2A-HLF	B-protein
(	I-protein
hepatic	I-protein
leukemia	I-protein
factor	I-protein
)	I-protein
oncoprotein	I-protein
,	O
generated	O
in	O
pro-B	B-cell_type
lymphocytes	I-cell_type
by	O
fusion	O
of	O
the	O
trans-activation	B-protein
domain	I-protein
of	O
E2A	B-protein
to	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
domain	I-protein
of	O
HLF	B-protein
,	O
functions	O
as	O
an	O
anti-apoptotic	B-protein
transcription	I-protein
factor	I-protein
in	O
leukemic	O
cell	O
transformation	O
.	O
	
When	O
introduced	O
into	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
-dependent	O
mouse	O
pro-B	B-cell_type
lymphocytes	I-cell_type
,	O
E2A-HLF	B-protein
prevents	O
apoptosis	O
induced	O
by	O
growth	B-protein
factor	I-protein
deprivation	O
,	O
suggesting	O
that	O
IL-3	B-protein
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	B-protein
oncoprotein	I-protein
.	O
	
We	O
considered	O
four	O
bZIP	B-protein
transcription	I-protein
factors	I-protein
as	O
candidates	O
for	O
this	O
putative	O
IL-3-regulated	B-protein
factor	I-protein
,	O
each	O
of	O
which	O
binds	O
avidly	O
to	O
the	O
DNA	B-DNA
consensus	I-DNA
sequence	I-DNA
recognized	O
by	O
E2A-HLF	B-protein
and	O
is	O
related	O
to	O
the	O
Caenorhabditis	B-protein
elegans	I-protein
CES-2	I-protein
(	O
cell	B-protein
death	I-protein
specification	I-protein
protein	I-protein
)	O
neuron-specific	B-protein
mediator	I-protein
of	I-protein
cell	I-protein
death	I-protein
.	O
	
The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B-protein
protein	I-protein
(	O
also	O
called	O
E4bp4	B-protein
)	O
,	O
but	O
not	O
of	O
Hlf	B-protein
,	O
Dbp	B-protein
,	O
or	O
Tef	B-protein
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	B-protein
in	O
mouse	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
Baf-3	B-cell_line
and	O
FL5.12	B-cell_line
)	O
.	O
	
Northern	O
blot	O
analysis	O
showed	O
that	O
Nfil3/E4bp4	B-protein
is	O
regulated	O
as	O
a	O
``	B-DNA
delayed-early	I-DNA
''	I-DNA
IL-3-responsive	I-DNA
gene	I-DNA
,	O
requiring	O
de	O
novo	O
protein	O
synthesis	O
.	O
	
In	O
the	O
absence	O
of	O
IL-3	B-protein
,	O
enforced	O
expression	O
of	O
the	O
human	B-DNA
NFIL3/E4BP4	I-DNA
cDNA	I-DNA
promoted	O
the	O
survival	O
but	O
not	O
the	O
growth	O
of	O
IL-3-dependent	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
.	O
	
Our	O
results	O
implicate	O
NFIL3/E4BP4	B-protein
(	O
nuclear	B-protein
factor	I-protein
regulated	I-protein
by	I-protein
IL-3/adenovirus	I-protein
E4	I-protein
promoter	I-protein
binding	I-protein
protein	I-protein
)	O
in	O
a	O
distinct	O
growth	O
factor-regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	B-cell_type
B-cell	I-cell_type
progenitors	I-cell_type
,	O
and	O
whose	O
alteration	O
by	O
E2A-HLF	B-protein
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O
	
###MEDLINE:97218353	
	
Detection	O
of	O
adenovirus	O
DNA	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O
	
Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O
	
Lymphocytes	B-cell_type
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	O
DNA	O
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O
	
To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	O
DNA	O
.	O
	
Two	O
sets	O
of	O
nested	O
primers	O
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	B-DNA
E1A	I-DNA
and	I-DNA
hexon	I-DNA
genes	I-DNA
.	O
	
The	O
E1A	B-DNA
and	I-DNA
hexon	I-DNA
primers	I-DNA
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A-F	O
)	O
.	O
	
Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	I-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O
	
None	O
of	O
33	O
PBMC	B-cell_type
specimens	I-cell_type
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	O
DNA	O
by	O
nested	O
PCR	O
assay	O
.	O
	
In	O
comparison	O
,	O
PBMC	B-cell_type
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	O
DNA	O
.	O
	
It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	B-cell_type
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O
	
In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O
	
###MEDLINE:97216066	
	
Common	O
and	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
human	B-cell_type
neutrophils	I-cell_type
utilized	O
by	O
platelet	B-protein
activating	I-protein
factor	I-protein
and	O
FMLP	B-protein
.	O
	
Stimulation	O
of	O
human	B-cell_type
neutrophils	I-cell_type
with	O
chemoattractants	B-protein
FMLP	B-protein
or	O
platelet	B-protein
activating	I-protein
factor	I-protein
(	O
PAF	B-protein
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O
	
We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O
	
Stimulation	O
with	O
either	O
PAF	B-protein
or	O
FMLP	B-protein
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
MAPk	I-protein
)	I-protein
homologue	I-protein
38-kD	B-protein
murine	I-protein
MAP	I-protein
kinase	I-protein
homologous	O
to	O
HOG-1	B-protein
(	I-protein
p38	I-protein
)	I-protein
MAPk	I-protein
.	O
	
Neither	O
FMLP	B-protein
nor	O
PAF	B-protein
activated	O
c-jun	B-protein
NH2-terminal	I-protein
MAPk	I-protein
(	O
JNKs	B-protein
)	O
.	O
	
Under	O
identical	O
conditions	O
,	O
FMLP	B-protein
but	O
not	O
PAF	B-protein
,	O
resulted	O
in	O
significant	O
p42/44	B-protein
(	I-protein
ERK	I-protein
)	I-protein
MAPk	I-protein
activation	O
.	O
	
Both	O
FMLP	B-protein
and	O
PAF	B-protein
activated	I-protein
MAP	I-protein
kinase	I-protein
kinase-3	I-protein
(	O
MKK3	B-protein
)	O
,	O
a	O
known	O
activator	O
of	O
p38	B-protein
MAPk	I-protein
.	O
	
Both	O
MAP	B-protein
ERK	I-protein
kinase	I-protein
kinase-1	I-protein
(	O
MEKK1	B-protein
)	O
and	O
Raf	B-protein
are	O
activated	O
strongly	O
by	O
FMLP	B-protein
,	O
but	O
minimally	O
by	O
PAF	B-protein
.	O
	
Pertussis	B-protein
toxin	I-protein
blocked	O
FMLP	B-protein
-induced	O
activation	O
of	O
the	O
p42/44	B-protein
(	I-protein
ERK	I-protein
)	I-protein
MAPk	I-protein
cascade	O
,	O
but	O
not	O
that	O
of	O
p38	B-protein
MAPk	I-protein
.	O
	
A	O
specific	O
p38	B-protein
MAPk	I-protein
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B-protein
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B-protein
or	O
FMLP	B-protein
.	O
	
These	O
results	O
demonstrate	O
distinct	O
patterns	O
of	O
intracellular	O
signaling	O
for	O
two	O
chemoattractants	B-protein
and	O
suggest	O
that	O
selective	O
activation	O
of	O
intracellular	O
signaling	O
cascades	O
may	O
underlie	O
different	O
patterns	O
of	O
functional	O
responses	O
.	O
	
###MEDLINE:97184462	
	
Cloning	O
of	O
the	O
novel	B-protein
human	I-protein
myeloid-cell-specific	I-protein
C/EBP-epsilon	I-protein
transcription	I-protein
factor	I-protein
.	O
	
Chicken	B-protein
NF-M	I-protein
transcription	I-protein
factor	I-protein
,	O
in	O
cooperation	O
with	O
either	O
c-Myb	B-protein
or	O
v-Myb	B-protein
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
in	O
heterologous	B-cell_type
cell	I-cell_type
types	I-cell_type
,	O
such	O
as	O
embryonic	B-cell_type
fibroblasts	I-cell_type
.	O
	
In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	B-protein
NF-M	I-protein
,	O
C/EBP-beta	B-protein
(	O
NF-IL6	B-protein
)	O
.	O
	
However	O
,	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	B-cell_type
cells	I-cell_type
.	O
	
By	O
using	O
a	O
reverse	O
transcription-PCR-based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA-binding	B-DNA
domains	I-DNA
of	O
highly	O
homologous	O
members	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
,	O
we	O
have	O
cloned	O
a	O
novel	B-DNA
human	I-DNA
gene	I-DNA
encoding	O
a	O
member	O
of	O
the	O
C/EBP	B-DNA
gene	I-DNA
family	I-DNA
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	B-protein
,	O
C/EBP-epsilon	B-protein
.	O
	
A	O
1.2-kb	B-DNA
cDNA	I-DNA
encoding	O
full-length	O
human	B-DNA
C/EBP-epsilon	I-DNA
was	O
cloned	O
from	O
a	O
promyelocyte-late	B-DNA
myeloblast-derived	I-DNA
lambda	I-DNA
gt11	I-DNA
library	I-DNA
.	O
	
Molecular	O
analysis	O
of	O
the	O
cDNA	O
and	O
genomic	O
clones	O
indicated	O
the	O
presence	O
of	O
two	O
exons	B-DNA
encoding	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
32	O
kDa	O
and	O
a	O
pI	O
of	O
9.5	O
.	O
	
Primer	O
extension	O
analysis	O
of	O
C/EBP-epsilon	B-RNA
mRNA	I-RNA
detected	O
a	O
single	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	B-DNA
codon	I-DNA
.	O
	
The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid-cell-specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	B-DNA
box	I-DNA
but	O
has	O
a	O
number	O
of	O
purine-rich	B-DNA
stretches	I-DNA
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
.	O
	
Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	B-cell_line
and	I-cell_line
late-myeloblast-like	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	B-protein
anti-C/EBP-epsilon	I-protein
antibodies	I-protein
raised	O
against	O
the	O
N-terminal	B-protein
portion	I-protein
of	O
C/EBP-epsilon	B-protein
(	O
amino	B-protein
acids	I-protein
1	I-protein
to	I-protein
115	I-protein
)	O
showed	O
that	O
C/EBP-epsilon	B-protein
is	O
a	O
32-kDa	B-protein
nuclear	I-protein
phosphoprotein	I-protein
.	O
	
The	O
human	O
C/EBP-epsilon	B-protein
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double-stranded	B-DNA
DNA	I-DNA
containing	I-DNA
consensus	I-DNA
C/EBP	I-DNA
sites	I-DNA
.	O
	
Cotransfection	O
of	O
the	O
C/EBP-epsilon	B-protein
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
vectors	I-DNA
containing	O
myeloid-cell-specific	B-DNA
c-mim	I-DNA
and	I-DNA
human	I-DNA
myeloperoxidase	I-DNA
promoters	I-DNA
suggested	O
a	O
role	O
for	O
C/EBP-epsilon	B-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
.	O
	
Transient	O
tranfection	O
of	O
a	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NB4	B-cell_line
)	O
with	O
a	O
C/EBP-epsilon	B-DNA
expression	I-DNA
plasmid	I-DNA
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	O
C/EBP-epsilon	B-protein
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O
	
###MEDLINE:97281244	
	
The	O
tumour	B-protein
associated	I-protein
cell	I-protein
surface	I-protein
antigen	I-protein
A6H	B-protein
is	O
costimulatory	O
for	O
human	B-cell_type
CD4+	I-cell_type
but	I-cell_type
not	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
A6H	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
recognizes	O
a	O
120	B-protein
,	I-protein
000-140	I-protein
,	I-protein
000	I-protein
MW	I-protein
antigen	I-protein
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85-90	O
%	O
of	O
human	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O
	
The	O
binding	O
of	O
the	O
A6H	B-protein
mAb	I-protein
induced	O
a	O
costimulatory	O
signal	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	B-protein
costimulated	O
cell	O
proliferation	O
and	O
cytokine	B-protein
production	O
in	O
purified	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Unexpectedly	O
,	O
the	O
CD8+	B-cell_type
T-cell	I-cell_type
subpopulation	I-cell_type
failed	O
to	O
respond	O
.	O
	
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
costimulated	O
with	O
the	O
A6H	B-protein
mAb	I-protein
upregulated	O
CD80	B-protein
,	O
CD86	B-protein
,	O
CD71	B-protein
,	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
R	I-protein
alpha	I-protein
,	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
,	O
while	O
no	O
corresponding	O
up-regulation	O
of	O
these	O
cell	B-protein
surface	I-protein
molecules	I-protein
was	O
seen	O
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	B-protein
mAb	I-protein
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
OCT-1	B-protein
,	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
which	O
are	O
known	O
to	O
be	O
transcriptional	B-protein
regulators	I-protein
of	O
several	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	O
genes	O
,	O
including	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2R	I-DNA
genes	I-DNA
.	O
	
Co-ligation	O
of	O
the	O
A6H	B-protein
antigen	O
and	O
the	O
CD3	B-protein
complex	I-protein
induced	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
no	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
and	O
octamer-binding	B-protein
(	I-protein
Oct	I-protein
)	I-protein
proteins	I-protein
was	O
seen	O
compared	O
to	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
anti-CD3	B-protein
alone	O
.	O
	
Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	B-protein
was	O
seen	O
in	O
A6H	B-protein
costimulated	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T-cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	B-protein
ligation	O
.	O
	
Molecular	O
differences	O
of	O
the	O
A6H	B-protein
molecule	I-protein
or	O
distinct	O
regulation	O
of	O
the	O
A6H	B-protein
transduced	O
AP-1	B-protein
activation	O
pathway	O
may	O
exist	O
in	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cell	I-cell_type
subpopulations	I-cell_type
.	O
	
###MEDLINE:97176699	
	
Cloning	O
and	O
expression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
from	O
the	O
squirrel	O
monkey	O
(	O
Saimiri	O
boliviensis	O
boliviensis	O
)	O
,	O
a	O
glucocorticoid-resistant	O
primate	O
.	O
	
New	O
World	O
primates	O
such	O
as	O
the	O
squirrel	O
monkey	O
have	O
elevated	O
cortisol	O
levels	O
and	O
glucocorticoid	O
resistance	O
.	O
	
We	O
have	O
shown	O
that	O
the	O
apparent	O
binding	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
squirrel	B-cell_type
monkey	I-cell_type
lymphocytes	I-cell_type
is	O
5-fold	O
lower	O
than	O
that	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
(	O
apparent	O
Kd	O
,	O
20.9	O
+/-	O
1.8	O
and	O
4.3	O
+/-	O
0.2	O
nmol/L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
consistent	O
with	O
previous	O
studies	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
isolated	O
from	O
the	O
two	O
species	O
.	O
	
As	O
a	O
first	O
step	O
in	O
understanding	O
the	O
mechanism	O
of	O
decreased	O
binding	O
affinity	O
in	O
New	O
World	O
primates	O
,	O
we	O
used	O
reverse	O
transcription-PCR	O
to	O
clone	O
the	O
glucocorticoid	B-protein
receptor	I-protein
from	O
squirrel	O
monkey	O
liver	O
and	O
have	O
compared	O
the	O
sequence	O
to	O
receptor	O
sequences	O
obtained	O
from	O
owl	O
monkey	O
liver	O
,	O
cotton-top	B-cell_line
tamarin	I-cell_line
B95-8	I-cell_line
cells	I-cell_line
,	O
and	O
human	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	I-protein
is	O
approximately	O
97	O
%	O
identical	O
in	O
nucleotide	O
and	O
amino	O
acid	O
sequence	O
to	O
the	O
human	B-protein
receptor	I-protein
.	O
	
The	O
ligand-binding	B-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
528-777	I-protein
)	O
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	I-protein
contains	O
four	O
amino	O
acid	O
differences	O
(	O
Ser551	O
to	O
Thr	O
,	O
Ser616	O
to	O
Ala	O
,	O
Ala618	O
to	O
Ser	O
,	O
and	O
Ile761	O
to	O
Leu	O
)	O
,	O
all	O
of	O
which	O
are	O
present	O
in	O
owl	B-protein
monkey	I-protein
and	I-protein
cotton-top	I-protein
tamarin	I-protein
receptors	I-protein
.	O
	
The	O
DNA-binding	B-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
421-486	I-protein
)	O
is	O
completely	O
conserved	O
among	O
human	B-protein
,	I-protein
squirrel	I-protein
monkey	I-protein
,	I-protein
owl	I-protein
monkey	I-protein
,	I-protein
and	I-protein
cotton-top	I-protein
tamarin	I-protein
receptors	I-protein
.	O
	
Twenty-two	O
differences	O
from	O
the	O
human	O
sequence	O
were	O
found	O
in	O
the	O
N-terminal	B-protein
region	I-protein
(	O
amino	B-protein
acids	I-protein
1-421	I-protein
)	O
of	O
the	O
squirrel	O
monkey	O
receptor	O
.	O
	
None	O
of	O
the	O
substitutions	O
in	O
the	O
ligand-binding	B-protein
domain	I-protein
matched	O
mutations	O
known	O
to	O
influence	O
binding	O
affinity	O
in	O
other	O
species	O
.	O
	
To	O
determine	O
whether	O
the	O
substitutions	O
per	O
se	O
were	O
responsible	O
for	O
decreased	O
affinity	O
,	O
squirrel	O
monkey	O
and	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
expressed	O
in	O
the	O
TNT	O
Coupled	O
Reticulocyte	O
Lysate	O
System	O
.	O
	
Expressions	O
of	O
human	O
and	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptors	I-protein
and	O
a	O
squirrel	B-protein
monkey	I-protein
receptor	I-protein
in	O
which	O
Phe774	O
was	O
mutated	O
to	O
Leu	O
(	O
F774L	O
)	O
were	O
similar	O
.	O
	
When	O
expressed	O
in	O
the	O
TNT	O
System	O
,	O
squirrel	O
monkey	O
and	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
had	O
similar	O
,	O
high	O
affinity	O
binding	O
for	O
dexamethasone	O
(	O
apparent	O
Kd	O
,	O
5.9	O
+/-	O
1.2	O
and	O
4.3	O
+/-	O
0.5	O
nmol/L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
whereas	O
the	O
squirrel	B-protein
monkey	I-protein
F774L	I-protein
receptor	I-protein
had	O
lower	O
affinity	O
binding	O
(	O
apparent	O
Kd	O
,	O
20.4	O
+/-	O
2.0	O
nmol/L	O
;	O
n	O
=	O
3	O
)	O
.	O
	
Thus	O
,	O
substitutions	O
within	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	I-protein
can	O
not	O
account	O
for	O
the	O
decreased	O
binding	O
affinity	O
of	O
these	O
receptors	O
in	O
squirrel	B-cell_type
monkey	I-cell_type
cells	I-cell_type
.	O
	
Rather	O
,	O
the	O
binding	O
affinity	O
is	O
probably	O
influenced	O
by	O
the	O
expression	O
of	O
cytosolic	B-protein
factors	I-protein
that	O
affect	O
glucocorticoid	B-protein
receptor	I-protein
function	O
.	O
	
###MEDLINE:97158624	
	
Shared	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
within	O
the	O
human	B-protein
interleukin-7	I-protein
receptor	I-protein
complex	I-protein
.	O
	
A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
.	O
	
Genetic	O
evidence	O
suggests	O
that	O
mutations	O
in	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
receptor	I-protein
subunit	I-protein
cause	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X-SCID	O
)	O
.	O
	
The	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
can	O
be	O
employed	O
in	O
receptor	B-protein
complexes	I-protein
for	O
IL-2	B-protein
,	I-protein
-4	I-protein
,	I-protein
-7	I-protein
,	I-protein
-9	I-protein
,	I-protein
and	I-protein
-15	I-protein
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
chain	I-protein
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X-SCID	O
patients	O
.	O
	
Interestingly	O
,	O
gene	O
disruption	O
of	O
either	O
IL-7	B-protein
or	O
the	O
IL-7	B-protein
receptor	I-protein
(	I-protein
IL-7R	I-protein
)	I-protein
alpha	I-protein
subunit	I-protein
in	O
mice	O
leads	O
to	O
immunological	O
defects	O
that	O
are	O
similar	O
to	O
human	O
X-SCID	O
.	O
	
These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
in	O
the	O
IL-7R	B-protein
complex	I-protein
.	O
	
In	O
the	O
present	O
study	O
,	O
structure/function	O
analyses	O
of	O
the	O
IL-7R	B-protein
complex	I-protein
using	O
a	O
chimeric	B-protein
receptor	I-protein
system	O
demonstrated	O
that	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
indeed	O
critical	O
for	O
IL-7R	B-protein
function	O
.	O
	
Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
necessary	O
for	O
IL-7R	B-protein
signal	O
transduction	O
.	O
	
Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
cytoplasmic	B-protein
domain	I-protein
by	O
a	O
severely	B-protein
truncated	I-protein
erythropoeitin	I-protein
receptor	I-protein
does	O
not	O
affect	O
measured	O
IL-7R	B-protein
signaling	O
events	O
.	O
	
These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	B-protein
complex	I-protein
,	O
while	O
IL-7R	B-protein
alpha	I-protein
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	B-protein
signaling	I-protein
molecules	I-protein
.	O
	
Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X-SCID	O
is	O
due	O
primarily	O
to	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
-mediated	O
defects	O
in	O
the	O
IL-7	B-protein
/IL-7R	B-protein
system	O
	
###MEDLINE:97343293	
	
S-allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O
	
We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S-allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	B-cell_type
pulmonary	I-cell_type
artery	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O
	
In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-	B-protein
alpha	I-protein
)	O
and	O
H2O2	O
.	O
	
Activated	O
NF-kappa	B-protein
B	I-protein
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P-labeled	B-DNA
probe	I-DNA
.	O
	
SAC	O
consistently	O
exhibited	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
both	O
TNF-alpha	B-protein
and	O
H2O2	O
.	O
	
Supershift	O
with	O
specific	O
antibodies	O
to	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65-p50	B-protein
heterodimer	I-protein
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
protein	I-protein
.	O
	
Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:97154704	
	
Elf-2	B-protein
,	O
a	O
rhombotin-2	B-protein
binding	I-protein
ets	I-protein
transcription	I-protein
factor	I-protein
:	O
discovery	O
and	O
potential	O
role	O
in	O
T	O
cell	O
leukemia	O
.	O
	
Rhombotin-2	B-DNA
(	O
RBTN-2	B-DNA
)	O
is	O
a	O
proto-oncogene	B-DNA
only	O
in	O
the	O
context	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
postulated	O
that	O
the	O
oncogenic	O
effect	O
of	O
RBTN-2	B-protein
in	O
T	O
cells	O
is	O
likely	O
mediated	O
by	O
binding	B-protein
protein	I-protein
(	O
s	O
)	O
with	O
T	O
cell-specific	O
expression	O
.	O
	
By	O
screening	O
a	O
T	O
cell	O
cDNA	B-DNA
library	I-DNA
,	O
we	O
identified	O
a	O
novel	B-protein
ets	I-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
RBTN-2	B-protein
.	O
	
This	O
protein	O
was	O
named	O
elf-2	B-protein
because	O
its	O
DNA-binding	B-protein
domain	I-protein
is	O
virtually	O
identical	O
to	O
that	O
of	O
ets	B-protein
family	I-protein
member	I-protein
elf-1	B-protein
.	O
	
Northern	O
analyses	O
showed	O
similar	O
levels	O
of	O
two	O
elf-2	B-RNA
transcripts	I-RNA
(	O
3.5	O
kb	O
and	O
3.8	O
kb	O
)	O
in	O
all	O
tissues	O
except	O
thymus	O
.	O
	
Thymocytes	B-cell_type
expressed	O
four-	O
to	O
10-fold	O
greater	O
amounts	O
of	O
the	O
3.5	B-RNA
kb	I-RNA
transcript	I-RNA
than	O
other	O
tissues	O
.	O
	
Sequence	O
analyses	O
of	O
cDNA	B-DNA
clones	I-DNA
indicated	O
that	O
these	O
transcripts	O
encode	O
proteins	O
differing	O
only	O
at	O
their	O
amino	B-protein
termini	I-protein
,	O
and	O
likely	O
represent	O
alternatively	O
spliced	O
isoforms	O
.	O
	
These	O
isoforms	O
(	O
elf-2a	B-protein
and	O
elf-2b	B-protein
)	O
contain	O
identical	O
RBTN-2	B-protein
binding	I-protein
regions	I-protein
and	O
DNA-binding	B-protein
domains	I-protein
.	O
	
Elf-2b	B-protein
lacks	O
a	O
putative	B-protein
transactivation	I-protein
domain	I-protein
.	O
	
The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	B-protein
normally	O
interacts	O
equally	O
with	O
elf-2a	B-protein
and	O
elf-2b	B-protein
.	O
	
In	O
contrast	O
,	O
when	O
RBTN-2	B-protein
is	O
inappropriately	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
RBTN-2	B-protein
would	O
interact	O
predominantly	O
with	O
elf-2b	B-protein
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O
	
###MEDLINE:99126331	
	
Transcription	B-protein
factor	I-protein
effects	O
on	O
chromosome	O
constitution	O
of	O
cell	B-cell_line
hybrids	I-cell_line
.	O
	
When	O
immunoglobulin	B-cell_line
(	I-cell_line
Ig	I-cell_line
)	I-cell_line
-secreting	I-cell_line
plasmacytomas	I-cell_line
are	O
fused	O
to	O
a	O
T-cell	B-cell_type
lymphoma	I-cell_type
,	O
Ig	B-DNA
gene	I-DNA
expression	O
ceases	O
in	O
greater	O
than	O
95	O
%	O
of	O
the	O
resulting	O
hybrids	O
.	O
	
In	O
the	O
rare	O
hybrids	O
that	O
continue	O
to	O
express	O
Ig	O
,	O
all	O
other	O
tested	O
B	B-DNA
lymphocyte-specific	I-DNA
genes	I-DNA
also	O
remain	O
active	O
.	O
	
The	O
low	O
frequency	O
with	O
which	O
these	O
Ig-expressing	B-cell_line
hybrids	I-cell_line
are	O
recovered	O
,	O
along	O
with	O
the	O
fact	O
that	O
cell	O
fusions	O
can	O
lead	O
to	O
chromosome	O
loss	O
,	O
led	O
us	O
to	O
propose	O
that	O
this	O
rare	O
phenotype	O
was	O
due	O
to	O
loss	O
of	O
a	O
T-cell-derived	B-protein
chromosome	I-protein
encoding	I-protein
a	I-protein
factor	I-protein
or	O
factors	O
with	O
gene	O
silencing	O
activity	O
.	O
	
To	O
identify	O
the	O
relevant	O
chromosome	O
,	O
we	O
have	O
used	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-assisted	O
method	O
of	O
chromosome	O
mapping	O
to	O
analyze	O
both	O
Ig-silenced	B-cell_line
(	I-cell_line
common	I-cell_line
)	I-cell_line
and	I-cell_line
Ig-expressing	I-cell_line
(	I-cell_line
rare	I-cell_line
)	I-cell_line
hybrids	I-cell_line
.	O
	
Although	O
no	O
single	O
chromosome	O
was	O
found	O
to	O
correlate	O
with	O
Ig	B-DNA
gene	I-DNA
silencing	O
,	O
we	O
discovered	O
that	O
the	O
two	O
types	O
of	O
hybrids	O
had	O
undergone	O
distinct	O
patterns	O
of	O
chromosome	O
loss	O
.	O
	
Moreover	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
a	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
Oct-2	B-protein
)	O
dramatically	O
altered	O
both	O
the	O
phenotype	O
and	O
chromosome	O
constitution	O
of	O
hybrids	O
arising	O
in	O
these	O
cell	O
fusions	O
.	O
	
###MEDLINE:99097434	
	
Reactivation	O
of	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B-protein
50	I-protein
transactivator	I-protein
,	O
a	O
homolog	O
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O
	
Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
-associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS-related	O
neoplasms	O
.	O
	
The	O
primary	O
reservoir	O
of	O
infection	O
consists	O
of	O
latently	O
infected	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
possibly	O
other	O
mononuclear	B-cell_type
cells	I-cell_type
.	O
	
Viral	O
reactivation	O
from	O
latency	O
and	O
spread	O
from	O
this	O
lymphoid	O
reservoir	O
is	O
presumably	O
required	O
for	O
development	O
of	O
nonlymphoid	O
tumors	O
like	O
KS	O
.	O
	
Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	B-DNA
gene	I-DNA
,	O
ORF	B-DNA
50	I-DNA
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed-early	B-DNA
viral	I-DNA
genes	I-DNA
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99077502	
	
Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
AP-1	B-protein
are	O
insufficient	O
for	O
IL-2	B-DNA
promoter	I-DNA
activation	O
:	O
requirement	O
for	O
CD28	B-protein
up-regulation	O
of	O
RE/AP	B-protein
.	O
	
IL-2	B-protein
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
requires	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O
	
IL-2	B-DNA
promoter	I-DNA
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	B-cell_line
B	I-cell_line
cells	I-cell_line
requires	O
CD28	B-protein
activation	O
.	O
	
The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	B-protein
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL-2	B-DNA
promoter	I-DNA
activation	O
by	O
>	O
80	O
%	O
.	O
	
Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
or	O
AP-1	B-DNA
reporters	I-DNA
.	O
	
Therefore	O
,	O
activation	O
of	O
NFAT	B-protein
and	O
AP-1	B-protein
is	O
insufficient	O
for	O
IL-2	B-DNA
promoter	I-DNA
activation	O
.	O
	
In	O
contrast	O
,	O
an	O
RE/AP	B-protein
reporter	O
was	O
blocked	O
by	O
CTLA4Ig	O
by	O
>	O
90	O
%	O
.	O
	
Thus	O
,	O
the	O
requirement	O
for	O
CD28	B-protein
in	O
IL-2	B-DNA
promoter	I-DNA
activation	O
appears	O
to	O
be	O
due	O
to	O
RE/AP	B-protein
and	O
not	O
the	O
NFAT	B-DNA
or	I-DNA
AP-1	I-DNA
sites	I-DNA
.	O
	
In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE/AP	B-protein
is	O
not	O
mediated	O
by	O
NFAT	B-protein
,	O
because	O
activation	O
of	O
a	O
NFAT	B-protein
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O
	
###MEDLINE:99074403	
	
The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein-Barr	O
virus	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
Review	O
)	O
.	O
	
Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O
	
Most	O
viruses	O
can	O
not	O
compete	O
with	O
the	O
various	O
immune	O
mechanisms	O
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O
	
Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O
	
A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O
	
This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation-dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O
	
Both	O
are	O
true	O
for	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O
	
B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O
	
The	O
former	O
can	O
become	O
latently	O
infected	O
and	O
are	O
thought	O
to	O
be	O
the	O
virus	O
reservoir	O
in	O
vivo	O
,	O
whereas	O
the	O
latter	O
were	O
shown	O
to	O
be	O
permissive	O
for	O
lytic	O
replication	O
.	O
	
However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	O
permissive	O
for	O
viral	O
replication	O
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	B-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	B-DNA
gene	I-DNA
regulatory	O
mechanisms	O
.	O
	
Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	B-DNA
gene	I-DNA
regulation	O
may	O
result	O
in	O
EBV-associated	O
disease	O
.	O
	
###MEDLINE:99060915	
	
Adaptor	O
function	O
for	O
the	O
Syk	B-protein
kinases-interacting	I-protein
protein	I-protein
3BP2	B-protein
in	O
IL-2	B-protein
gene	O
activation	O
.	O
	
Syk-family	B-protein
tyrosine	I-protein
kinases	I-protein
are	O
essential	O
for	O
lymphocyte	O
development	O
and	O
activation	O
.	O
	
Using	O
a	O
yeast	O
two-hybrid	O
screen	O
to	O
identify	O
Syk	B-protein
kinases-interacting	I-protein
proteins	I-protein
(	O
SKIPs	B-protein
)	O
,	O
we	O
isolated	O
3BP2	B-protein
,	O
an	O
Abl	B-protein
SH3-interacting	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O
	
3BP2	B-protein
was	O
selectively	O
expressed	O
in	O
hematopoietic/lymphoid	O
tissues	O
and	O
bound	O
via	O
its	O
SH2	B-protein
domain	I-protein
activated	I-protein
Syk-family	I-protein
kinases	I-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
,	O
including	O
in	O
antigen	B-cell_type
receptor-stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
addition	O
to	O
Zap-70	B-protein
,	O
the	O
3BP2	B-protein
SH2	I-protein
domain	I-protein
associated	O
in	O
vitro	O
with	O
LAT	B-protein
,	O
Grb2	B-protein
,	O
PLCgamma1	B-protein
,	O
and	O
Cbl	B-protein
from	O
activated	O
T	O
cell	O
lysates	O
.	O
	
Transient	O
3BP2	B-protein
overexpression	O
induced	O
transcriptional	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
its	O
NFAT	B-DNA
or	I-DNA
AP-1	I-DNA
elements	I-DNA
.	O
	
This	O
activity	O
was	O
dependent	O
on	O
the	O
SH2	B-protein
and	O
pleckstrin-homology	B-protein
domains	I-protein
of	O
3BP2	B-protein
,	O
and	O
required	O
functional	O
Syk	B-protein
kinases	I-protein
,	O
Ras	B-protein
,	O
and	O
calcineurin	B-protein
.	O
	
Thus	O
,	O
3BP2	B-protein
is	O
an	O
important	O
adaptor	O
that	O
may	O
couple	O
activated	O
Zap-70/Syk	B-protein
to	O
a	O
LAT-containing	B-protein
signaling	I-protein
complex	I-protein
involved	O
in	O
TCR-mediated	O
gene	O
transcription	O
.	O
	
###MEDLINE:99054996	
	
In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	B-protein
.	O
	
Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O
	
In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
BL	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B-protein
inhibitor	I-protein
of	I-protein
metalloproteinases	I-protein
(	I-protein
TIMP	I-protein
)	I-protein
-1	I-protein
.	O
	
Results	O
indicate	O
that	O
TIMP-1-positive	B-cell_line
BL	I-cell_line
lines	I-cell_line
show	O
resistance	O
to	O
cold-shock-induced	O
apoptosis	O
.	O
	
Furthermore	O
,	O
recombinant	O
TIMP-1	B-protein
,	O
but	O
not	O
TIMP-2	B-protein
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB-94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95-dependent	O
and	O
-independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma-radiation	O
)	O
pathways	O
in	O
TIMP-1-negative	B-cell_line
BL	I-cell_line
lines	I-cell_line
.	O
	
TIMP-1	B-protein
suppression	O
of	O
PCD	O
is	O
not	O
due	O
to	O
metalloproteinase	B-protein
inhibition	O
,	O
as	O
reduction	O
and	O
alkylation	O
of	O
the	O
TIMP-1	B-protein
did	O
not	O
abolish	O
this	O
activity	O
.	O
	
Retroviral	O
induction	O
of	O
TIMP-1	B-protein
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O
	
This	O
resistance	O
to	O
apoptosis	O
is	O
reversed	O
by	O
anti-TIMP-1	B-protein
antibodies	I-protein
,	O
demonstrating	O
that	O
secreted	O
TIMP-1	B-protein
is	O
active	O
in	O
blocking	O
apoptosis	O
.	O
	
Furthermore	O
,	O
TIMP-1	B-protein
upregulation	O
induced	O
expression	O
of	O
Bcl-XL	B-protein
but	O
not	O
Bcl-2	B-protein
as	O
well	O
as	O
decreased	O
NF-kappaB	B-protein
activity	O
as	O
compared	O
with	O
controls	O
.	O
	
These	O
results	O
demonstrate	O
that	O
TIMP-1	B-protein
suppresses	O
apoptosis	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
suggests	O
a	O
novel	O
activity	O
for	O
TIMP-1	B-protein
in	O
tissue	O
homeostasis	O
.	O
	
###MEDLINE:99045415	
	
Spi-1/PU.1	B-DNA
proto-oncogene	B-DNA
induces	O
opposite	O
effects	O
on	O
monocytic	O
and	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O
	
Spi-1/PU.1	B-protein
is	O
a	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
of	O
the	O
Ets	B-protein
family	I-protein
.	O
	
To	O
analyze	O
the	O
effects	O
of	O
ectopic	O
expression	O
of	O
spi-1	B-protein
on	O
the	O
proliferation/differentiation	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
K562	B-cell_line
cells	I-cell_line
were	O
stably	O
transfected	O
with	O
a	O
spi-1	B-DNA
expression	I-DNA
vector	I-DNA
.	O
	
The	O
transfected	B-cell_line
cell	I-cell_line
lines	I-cell_line
expressed	O
elevated	O
levels	O
of	O
spi-1	B-RNA
mRNA	I-RNA
and	O
protein	O
and	O
high	O
Spi-1	B-protein
-DNA	O
binding	O
activity	O
.	O
	
The	O
spi-1	B-cell_line
transfected	I-cell_line
cells	I-cell_line
showed	O
reduced	O
growth	O
rates	O
and	O
reduced	O
clonogenic	O
cell	O
growth	O
.	O
	
When	O
the	O
erythroid	O
and	O
monocytic	O
differentiation	O
markers	O
were	O
analyzed	O
,	O
spi-1	B-protein
overexpression	O
resulted	O
in	O
opposite	O
effects	O
:	O
erythroid	O
differentiation	O
was	O
significantly	O
inhibited	O
in	O
spi-1	B-cell_line
transfectants	I-cell_line
,	O
while	O
spi-1	B-protein
overexpression	O
increased	O
the	O
monocytic	O
differentiation	O
of	O
cells	O
.	O
	
These	O
results	O
indicate	O
a	O
differential	O
role	O
of	O
Spi-1	B-DNA
on	O
the	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99034605	
	
In	O
vivo	O
function	O
of	O
an	O
interleukin	B-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
(	B-protein
IL-2Rbeta	I-protein
)	I-protein
/IL-4Ralpha	I-protein
cytokine	I-protein
receptor	I-protein
chimera	I-protein
potentiates	O
allergic	O
airway	O
disease	O
.	O
	
Strength	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
,	O
coreceptors	B-protein
,	O
costimulation	O
,	O
antigen-presenting	B-cell_type
cell	I-cell_type
type	I-cell_type
,	O
and	O
cytokines	O
all	O
play	O
crucial	O
roles	O
in	O
determining	O
the	O
efficiency	O
with	O
which	O
type	B-cell_type
2	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
Th2	B-cell_type
,	O
Tc2	B-cell_type
)	O
develop	O
from	O
uncommitted	B-protein
precursors	I-protein
.	O
	
To	O
investigate	O
in	O
vivo	O
regulatory	O
mechanisms	O
that	O
control	O
the	O
population	O
of	O
type	B-cell_type
2	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
disease	O
susceptibility	O
,	O
we	O
have	O
created	O
lines	O
of	O
transgenic	O
mice	O
in	O
which	O
expression	O
of	O
a	O
chimeric	B-protein
cytokine	I-protein
receptor	I-protein
(	O
the	O
mouse	B-protein
interleukin	I-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
[	I-protein
IL-2Rbeta	I-protein
]	I-protein
extracellular	I-protein
domain	I-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
tail	I-protein
of	O
IL-4Ralpha	B-protein
)	O
is	O
targeted	O
to	O
the	O
T	B-cell_type
lymphoid	I-cell_type
lineage	I-cell_type
using	O
the	O
proximal	B-DNA
lck	I-DNA
promoter	I-DNA
.	O
	
This	O
chimera	O
transduced	O
IL-4	B-protein
-specific	O
signals	O
in	O
response	O
to	O
IL-2	B-protein
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
and	O
immunoglobulin	B-protein
E	I-protein
production	O
)	O
upon	O
in	O
vitro	O
TCR	B-protein
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O
	
Thus	O
,	O
type	O
2	O
effector	O
function	O
was	O
augmented	O
by	O
IL-4	B-protein
signals	O
transduced	O
through	O
a	O
chimeric	B-protein
receptor	I-protein
expressed	O
in	O
a	O
T	O
cell-specific	O
manner	O
.	O
	
This	O
influence	O
was	O
sufficient	O
for	O
establishment	O
of	O
antigen-induced	O
allergic	O
airway	O
hyperresponsiveness	O
on	O
a	O
disease-resistant	O
background	O
	
###MEDLINE:97148606	
	
Differentiation-dependent	O
expression	O
of	O
a	O
human	B-protein
carboxylesterase	I-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
transcription	B-protein
factor	I-protein
binding	O
to	O
the	O
promoter	B-DNA
.	O
	
Carboxylesterases	B-protein
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O
	
During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	B-protein
carboxylesterase	I-protein
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O
	
In	O
PMA-treated	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
we	O
could	O
detect	O
three	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	B-RNA
antisense	I-RNA
RNA	I-RNA
probes	I-RNA
.	O
	
We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	B-DNA
upstream	I-DNA
sequence	I-DNA
and	O
showed	O
its	O
basal	B-DNA
promoter	I-DNA
activity	O
in	O
CHO	B-cell_line
cells	I-cell_line
.	O
	
Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	B-DNA
region	I-DNA
spanning	O
base	B-DNA
pairs	I-DNA
-1	I-DNA
to	I-DNA
-275	I-DNA
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	B-protein
factors	I-protein
,	O
is	O
bound	O
by	O
nuclear	B-protein
factors	I-protein
Sp1	B-protein
and	O
IRBP	B-protein
but	O
not	O
by	O
C/EBPs	B-protein
.	O
	
Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B-protein
and	O
IRBP	B-protein
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation-dependent	O
transcription	O
of	O
this	O
human	B-DNA
carboxylesterase	I-DNA
gene	I-DNA
.	O
	
###MEDLINE:97288734	
	
The	O
role	O
of	O
the	O
Ikaros	B-DNA
gene	I-DNA
in	O
lymphocyte	O
development	O
and	O
homeostasis	O
.	O
	
The	O
Ikaros	B-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
family	O
of	O
hemopoietic-specific	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
,	O
is	O
described	O
as	O
a	O
central	O
regulator	O
of	O
lymphocyte	O
differentiation	O
.	O
	
During	O
fetal	O
development	O
,	O
it	O
is	O
required	O
at	O
the	O
earliest	O
stage	O
of	O
T	O
cell	O
and	O
B	O
cell	O
specification	O
.	O
	
In	O
the	O
adult	O
,	O
however	O
,	O
lymphoid	B-cell_type
lineages	I-cell_type
rely	O
on	O
Ikaros	B-DNA
at	O
distinct	O
phases	O
of	O
their	O
development	O
.	O
	
Its	O
activity	O
is	O
essential	O
for	O
the	O
generation	O
of	O
B	B-cell_type
cell	I-cell_type
but	O
not	O
of	O
T	B-cell_type
cell	I-cell_type
precursors	I-cell_type
,	O
although	O
the	O
differentiation	O
of	O
the	O
latter	O
is	O
not	O
normal	O
.	O
	
A	O
significant	O
increase	O
in	O
CD4	B-cell_type
thymocytes	I-cell_type
and	O
their	O
immediate	O
precursors	O
is	O
detected	O
,	O
and	O
because	O
these	O
cells	O
lack	O
markers	O
that	O
correlate	O
with	O
positive	O
selection	O
,	O
a	O
deregulation	O
in	O
their	O
maturation	O
process	O
is	O
suggested	O
.	O
	
Furthermore	O
,	O
Ikaros-null	B-cell_type
thymocytes	I-cell_type
hyperproliferate	O
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
;	O
within	O
days	O
after	O
their	O
appearance	O
in	O
the	O
thymus	O
,	O
clonally	O
expanding	O
populations	O
are	O
detected	O
.	O
	
Deregulated	O
TCR	B-protein
-mediated	O
responses	O
and	O
the	O
fast	O
kinetics	O
of	O
tumor	O
development	O
in	O
these	O
mutant	B-cell_type
thymocytes	I-cell_type
implicate	O
Ikaros	O
as	O
a	O
central	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
for	O
the	O
T	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O
	
In	O
addition	O
,	O
lack	O
of	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
selective	O
defects	O
in	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
dendritic	B-cell_type
antigen-presenting	I-cell_type
cells	I-cell_type
point	O
to	O
Ikaros	B-protein
as	O
an	O
essential	O
factor	O
for	O
the	O
establishment	O
of	O
early	O
branchpoints	O
of	O
the	O
T	O
cell	O
pathway	O
.	O
	
The	O
dominant	O
interference	O
activity	O
of	O
Ikaros	B-protein
isoforms	I-protein
unable	O
to	O
bind	O
DNA	O
and	O
their	O
effects	O
in	O
lymphocyte	O
development	O
suggest	O
that	O
Ikaros	B-protein
works	O
in	O
concert	O
with	O
other	O
factors	O
.	O
	
The	O
role	O
of	O
Aiolos	B-DNA
,	O
a	O
lymphoid-restricted	B-DNA
and	I-DNA
structurally	I-DNA
related	I-DNA
gene	I-DNA
,	O
in	O
lymphoid	O
differentiation	O
is	O
discussed	O
.	O
	
A	O
model	O
is	O
proposed	O
that	O
defines	O
Ikaros	B-protein
as	O
the	O
backbone	O
of	O
a	O
complex	B-protein
regulatory	I-protein
protein	I-protein
network	I-protein
that	O
controls	O
cell	O
fate	O
decisions	O
and	O
regulates	O
homeostasis	O
in	O
the	O
hemo-lymphoid	O
system	O
.	O
	
Changes	O
in	O
this	O
regulatory	O
network	O
may	O
reflect	O
differentiation	O
and	O
proliferation	O
adjustments	O
made	O
in	O
hemo-lymphoid	B-cell_type
progenitors	I-cell_type
and	O
precursors	B-cell_type
as	O
they	O
give	O
rise	O
to	O
the	O
cells	O
of	O
our	O
immune	O
system	O
.	O
	
###MEDLINE:97138389	
	
STAT1	B-protein
pathway	O
is	O
involved	O
in	O
activation	O
of	O
caprine	O
arthritis-encephalitis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
monocytes	B-cell_type
.	O
	
The	O
caprine	B-DNA
arthritis-encephalitis	I-DNA
virus	I-DNA
(	I-DNA
CAEV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
is	O
activated	O
by	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
in	O
promonocytic	B-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
previously	O
shown	O
that	O
a	O
70-bp	B-DNA
element	I-DNA
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
response	O
of	O
the	O
CAEV	B-DNA
LTR	I-DNA
to	O
this	O
cytokine	B-protein
.	O
	
At	O
the	O
5	B-DNA
'	I-DNA
end	I-DNA
,	O
this	O
70-bp	B-DNA
IFN-gamma	I-DNA
response	I-DNA
element	I-DNA
contains	O
sequence	O
similarity	O
to	O
the	O
gamma	B-DNA
activated	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
the	O
putative	O
GAS	B-DNA
element	I-DNA
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
binds	O
specifically	O
to	O
a	O
cellular	B-protein
factor	I-protein
induced	O
by	O
IFN-gamma	B-protein
in	O
promonocytic	B-cell_type
cells	I-cell_type
.	O
	
Substitution	O
mutations	O
in	O
this	O
consensus	B-DNA
sequence	I-DNA
eliminate	O
binding	O
of	O
the	O
inducible	B-protein
factor	I-protein
.	O
	
The	O
GAS	B-DNA
element	I-DNA
from	O
the	O
70-bp	B-DNA
motif	I-DNA
is	O
sufficient	O
to	O
confer	O
responsiveness	O
to	O
IFN-gamma	B-protein
using	O
a	O
heterologous	O
minimal	O
promoter	O
.	O
	
Consistent	O
with	O
the	O
binding	O
data	O
,	O
the	O
same	O
mutations	O
in	O
the	O
GAS	B-DNA
element	I-DNA
eliminate	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
the	O
context	O
of	O
both	O
a	O
functional	O
CAEV	B-DNA
LTR	I-DNA
and	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O
	
The	O
cellular	O
factor	O
that	O
binds	O
to	O
the	O
GAS	B-DNA
element	I-DNA
is	O
present	O
from	O
5	O
min	O
to	O
14	O
h	O
after	O
stimulation	O
with	O
IFN-gamma	B-protein
.	O
	
Binding	O
of	O
the	O
nuclear	O
factor	O
to	O
the	O
GAS	B-DNA
element	I-DNA
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
is	O
inhibited	O
by	O
antibody	O
directed	O
against	O
STAT1	B-protein
(	O
p91/84	B-protein
)	O
.	O
	
Thus	O
,	O
the	O
GAS	O
sequence	O
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
is	O
essential	O
for	O
the	O
response	O
to	O
IFN-gamma	B-protein
and	O
a	O
STAT1-like	B-protein
factor	I-protein
binds	O
to	O
this	O
site	O
.	O
	
The	O
STAT-1	O
signaling	O
pathway	O
provides	O
at	O
least	O
one	O
mechanism	O
for	O
activation	O
of	O
the	O
CAEV	B-DNA
LTR	I-DNA
by	O
IFN-gamma	B-protein
in	O
monocytes	B-cell_type
.	O
	
These	O
data	O
are	O
the	O
first	O
demonstration	O
of	O
a	O
role	O
for	O
a	O
STAT	B-protein
family	I-protein
member	I-protein
in	O
the	O
regulation	O
of	O
a	O
viral	B-DNA
promoter	I-DNA
.	O
	
###MEDLINE:99121740	
	
1	B-DNA
,	I-DNA
25-Dihydroxyvitamin	I-DNA
D3	I-DNA
receptors	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
renal	O
insufficiency	O
.	O
	
A	O
reduced	O
expression	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	O
)	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
and	O
humans	O
has	O
been	O
observed	O
.	O
	
Similar	O
results	O
have	O
been	O
obtained	O
by	O
our	O
own	O
group	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
patients	O
with	O
secondary	O
hyperparathyroidism	O
to	O
chronic	O
renal	O
failure	O
.	O
	
However	O
,	O
the	O
reasons	O
for	O
these	O
changes	O
are	O
not	O
clear	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
PBMC	B-cell_type
of	O
11	O
women	O
with	O
advanced	O
chronic	O
renal	O
failure	O
(	O
A-CRF	O
)	O
,	O
6	O
women	O
with	O
mild-moderate	O
renal	O
insufficiency	O
(	O
M-CRF	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O
	
The	O
mean	O
dissociation	O
constant	O
(	O
KD	O
)	O
was	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
A-CRF	O
:	O
0.7	O
+/-	O
0.5	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
M-CRF	O
:	O
1.1	O
+/-	O
0.9	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
:	O
1.0	O
+/-	O
0.6	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O
	
However	O
,	O
VDR	B-protein
concentration	O
was	O
significantly	O
decreased	O
in	O
A-CRF	O
(	O
0.8	O
+/-	O
0.5	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
,	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
M-CRF	O
(	O
1.7	O
+/-	O
0.7	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O
	
No	O
correlation	O
was	O
seen	O
between	O
VDR	B-protein
and	O
serum	O
calcitriol	O
or	O
PTH	O
levels	O
,	O
when	O
considering	O
both	O
groups	O
of	O
patients	O
together	O
or	O
separately	O
.	O
	
Conversely	O
,	O
a	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
VDR	B-protein
and	O
serum	O
creatinine	O
values	O
when	O
A-CRF	O
and	O
M-CRF	O
were	O
considered	O
altogether	O
(	O
r	O
=	O
-0.63	O
;	O
p	O
<	O
0.01	O
)	O
.	O
	
Treatment	O
with	O
two	O
different	O
schedules	O
of	O
oral	O
calcitriol	O
(	O
five	O
patients	O
with	O
0.5	O
microgram/day	O
for	O
1	O
month	O
and	O
four	O
patients	O
with	O
2	O
micrograms/day	O
for	O
7	O
days	O
)	O
did	O
not	O
change	O
VDR	B-protein
concentrations	O
.	O
	
We	O
conclude	O
that	O
the	O
low	O
levels	O
of	O
serum	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
of	O
uremia	O
are	O
not	O
responsible	O
for	O
the	O
decrease	O
in	O
VDR	B-protein
concentration	O
found	O
in	O
these	O
patients	O
.	O
	
###MEDLINE:99090715	
	
Transcription	B-protein
factor	I-protein
binding	O
to	O
the	O
core	B-DNA
promoter	I-DNA
of	O
the	O
human	B-DNA
monoamine	I-DNA
oxidase	I-DNA
B	I-DNA
gene	I-DNA
in	O
the	O
cerebral	O
cortex	O
and	O
in	O
blood	B-cell_type
cells	I-cell_type
.	O
	
Many	O
studies	O
show	O
that	O
monoamine	B-protein
oxidase	I-protein
B	I-protein
in	O
blood	B-cell_type
cells	I-cell_type
is	O
a	O
biological	O
marker	O
for	O
personality	O
characteristics	O
such	O
as	O
sensation	O
seeking	O
.	O
	
The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O
	
In	O
the	O
present	O
study	O
we	O
have	O
performed	O
electrophoretic	O
mobility-shift	O
assays	O
to	O
investigate	O
the	O
pattern	O
of	O
protein	O
binding	O
to	O
a	O
150	B-DNA
bp	I-DNA
fragment	I-DNA
of	O
the	O
proximal	B-DNA
5'-flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
monoamine	I-DNA
oxidase	I-DNA
B	I-DNA
gene	I-DNA
.	O
	
We	O
compared	O
the	O
pattern	O
using	O
nuclear	O
extracts	O
from	O
human	O
brain	O
and	O
lymphocytes	B-cell_type
.	O
	
Interestingly	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
monoamine	B-protein
oxidase	I-protein
B	I-protein
enzyme	O
activity	O
in	O
blood	B-cell_type
cells	I-cell_type
(	O
platelets	B-cell_type
)	O
and	O
the	O
binding	O
pattern	O
of	O
two	O
uncharacterized	O
transcription	B-protein
factors	I-protein
.	O
	
These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long-standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B-protein
monoamine	I-protein
oxidase	I-protein
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O
	
###MEDLINE:99075480	
	
Enhanced	O
differentiation	O
of	O
HL-60	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
to	O
macrophages	B-cell_type
induced	O
by	O
ciprofibrate	O
.	O
	
Ciprofibrate	O
,	O
an	O
hypolipidaemic	O
peroxisome	O
proliferator	O
,	O
induced	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
.	O
	
The	O
effect	O
was	O
greatly	O
potentiated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
at	O
a	O
concentration	O
where	O
neither	O
phorbol	O
ester	O
nor	O
ciprofibrate	O
alone	O
had	O
any	O
effect	O
on	O
these	O
cells	O
.	O
	
As	O
occurs	O
for	O
HL-60	O
cell	O
differentiation	O
induced	O
by	O
high	O
phorbol	O
ester	O
concentration	O
,	O
the	O
ciprofibrate-induced	O
phorbol	O
ester-dependent	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
proceeded	O
through	O
the	O
monocytic/macrophage	O
pathway	O
and	O
induced	O
the	O
phosphorylation	O
of	O
proteins	O
with	O
similar	O
molecular	O
weights	O
suggesting	O
that	O
increased	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
may	O
be	O
involved	O
in	O
the	O
effect	O
.	O
	
The	O
peroxisome	O
proliferator-activated	O
receptor	O
(	O
PPARalpha	O
)	O
transcription	B-protein
factor	I-protein
is	O
expressed	O
in	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
no	O
changes	O
were	O
observed	O
in	O
its	O
expression	O
upon	O
HL-60	O
cell	O
differentiation	O
.	O
	
###MEDLINE:99069401	
	
The	O
involvement	O
of	O
multiple	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	I-protein
TNFR	I-protein
)	I-protein
-associated	I-protein
factors	I-protein
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	B-protein
activator	I-protein
of	O
NF-kappaB	B-protein
,	O
a	O
member	O
of	O
the	O
TNFR	B-protein
superfamily	I-protein
.	O
	
Receptor	B-protein
activator	I-protein
of	I-protein
NF-kappaB	I-protein
(	O
RANK	B-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
expressed	O
on	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
.	O
	
Its	O
cognate	B-protein
ligand	I-protein
(	O
RANKL	B-protein
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O
	
We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B-protein
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
(	I-protein
TRAFs	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
5	I-protein
,	I-protein
and	I-protein
6	I-protein
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O
	
Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	B-protein
/RANK	B-protein
interaction	O
revealed	O
multiple	O
TRAF	B-protein
binding	I-protein
sites	I-protein
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	B-protein
cytoplasmic	I-protein
tail	I-protein
.	O
	
These	O
TRAF	B-protein
binding	I-protein
domains	I-protein
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	B-protein
-dependent	O
induction	O
of	O
NF-kappaB	B-protein
and	O
c-Jun	B-protein
NH2-terminal	B-protein
kinase	I-protein
activities	O
.	O
	
Site-directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	B-protein
binding	I-protein
sites	I-protein
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	B-protein
proteins	I-protein
.	O
	
In	O
particular	O
,	O
TRAF6	B-protein
interacted	O
with	O
membrane-proximal	B-protein
determinants	I-protein
distinct	O
from	O
those	O
binding	O
TRAFs	B-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
5	I-protein
.	O
	
When	O
this	O
membrane-proximal	B-protein
TRAF6	I-protein
interaction	I-protein
domain	I-protein
was	O
deleted	O
,	O
RANK	B-protein
-mediated	O
NF-kappaB	B-protein
signaling	O
was	O
completely	O
inhibited	O
while	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
activation	O
was	O
partially	O
inhibited	O
.	O
	
An	O
NH2-terminal	B-protein
truncation	I-protein
mutant	I-protein
of	O
TRAF6	B-protein
inhibited	O
RANKL	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	B-protein
in	O
ligand-induced	O
activation	O
events	O
.	O
	
###MEDLINE:99061768	
	
Stat6	B-protein
inhibits	O
human	O
interleukin-4	B-DNA
promoter	I-DNA
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
differentiation	O
of	O
naive	B-cell_type
T-helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cells	I-cell_type
into	O
cytokine-secreting	B-cell_type
effector	I-cell_type
Th	I-cell_type
cells	I-cell_type
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	B-protein
cytokines	I-protein
.	O
	
Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL-4	B-protein
-secreting	O
Th2	O
cells	O
.	O
	
In	O
Th2	O
cells	O
,	O
IL-4	B-protein
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	B-protein
factors	I-protein
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	B-DNA
region	I-DNA
.	O
	
Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
members	I-protein
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL-4	B-protein
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O
	
The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	B-protein
induces	O
expression	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	B-protein
transcription	I-protein
factor	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
6	I-protein
(	O
Stat6	B-protein
)	O
is	O
required	O
for	O
this	O
effect	O
.	O
	
We	O
report	O
here	O
that	O
Stat6	B-protein
interacts	O
with	O
three	O
binding	O
sites	O
in	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
These	O
sites	O
overlap	O
the	O
P1	B-DNA
,	I-DNA
P2	I-DNA
,	I-DNA
and	I-DNA
P4	I-DNA
NFAT	I-DNA
elements	I-DNA
.	O
	
To	O
investigate	O
the	O
role	O
of	O
Stat6	B-protein
in	O
regulating	O
IL-4	B-protein
transcription	O
,	O
we	O
used	O
Stat6	B-protein
-deficient	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
with	O
different	O
intact	O
IL-4	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
cotransfection	O
assays	O
.	O
	
We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	B-DNA
response	I-DNA
element	I-DNA
from	O
the	O
germline	B-DNA
IgE	I-DNA
promoter	I-DNA
was	O
highly	O
induced	O
by	O
IL-4	B-protein
in	O
Stat6-expressing	B-cell_type
Jurkat	I-cell_type
cells	I-cell_type
,	O
the	O
intact	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
was	O
repressed	O
under	O
similar	O
conditions	O
.	O
	
We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	B-protein
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL-4	B-protein
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O
	
###MEDLINE:99055586	
	
Epithelial	O
cell-initiated	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
early	O
tissue	O
damage	O
in	O
amebic	O
infection	O
of	O
human	O
intestine	O
.	O
	
BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O
	
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
role	O
of	O
the	O
host	O
inflammatory	O
response	O
in	O
the	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
and	O
the	O
role	O
of	O
the	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
in	O
initiating	O
that	O
response	O
.	O
	
METHODS	O
:	O
E.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID-HU-INT	O
)	O
mice	O
.	O
	
Human	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	B-protein
p65	I-protein
subunit	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	B-cell_type
from	O
SCID-HU-INT	O
mice	O
.	O
	
RESULTS	O
:	O
Administration	O
of	O
the	O
antisense	O
oligonucleotide	O
blocked	O
the	O
production	O
of	O
human	B-protein
interleukin	I-protein
1beta	I-protein
and	O
interleukin	B-protein
8	I-protein
by	O
intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
inhibited	O
neutrophil	O
influx	O
into	O
the	O
E.	O
histolytica-infected	O
intestinal	O
xenografts	O
.	O
	
Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	B-cell_type
from	O
SCID-HU-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O
	
CONCLUSIONS	O
:	O
Intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil-mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O
	
###MEDLINE:99041401	
	
Triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
.	O
	
Extract	O
of	O
Tripterygium	O
wilfordii	O
Hook.	O
f	O
(	O
TWHf	O
)	O
has	O
immunosuppressive	O
activity	O
and	O
has	O
been	O
used	O
as	O
anti-inflammatory	O
agent	O
in	O
traditional	O
Chinese	O
medicine	O
for	O
centuries	O
.	O
	
Recent	O
studies	O
have	O
demonstrated	O
that	O
triptolide	O
is	O
the	O
major	O
active	O
component	O
in	O
the	O
extract	O
that	O
inhibits	O
antigen	O
or	O
mitogen	B-protein
-induced	O
T	O
cell	O
proliferation	O
.	O
	
In	O
attempting	O
to	O
investigate	O
its	O
effect	O
on	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
found	O
triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
and	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
that	O
of	O
thymocytes	B-cell_type
.	O
	
The	O
triptolide-induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD-cleavable	O
caspases	B-protein
activity	O
and	O
degradation	O
of	O
caspase	B-protein
substrate	I-protein
poly	I-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	I-protein
(	O
PARP	B-protein
)	O
.	O
	
A	O
specific	O
inhibitor	O
of	O
caspases	B-protein
,	O
zVAD-FMK	O
,	O
prevents	O
triptolide-induced	O
PARP	B-protein
degradation	O
and	O
DNA	O
fragmentation	O
but	O
not	O
growth	O
arrest	O
.	O
	
Furthermore	O
,	O
enforced	O
expression	O
of	O
Bcl-2	B-protein
inhibited	O
triptolide-induced	O
degradation	O
of	O
PARP	B-protein
and	O
apoptosis	O
.	O
	
These	O
results	O
indicate	O
that	O
triptolide	O
induces	O
T	O
cell	O
apoptosis	O
through	O
activating	O
caspases	B-protein
,	O
and	O
suggest	O
the	O
growth	O
arrest	O
and	O
apoptotic	O
effect	O
of	O
triptolide	O
may	O
contribute	O
to	O
the	O
immunosuppressive	O
activity	O
of	O
TWHf	O
extract	O
	
###MEDLINE:97150708	
	
A	O
novel	O
transcription	B-protein
factor	I-protein
regulates	O
expression	O
of	O
the	O
vacuolar	B-protein
H+-ATPase	I-protein
B2	I-protein
subunit	I-protein
through	O
AP-2	B-DNA
sites	I-DNA
during	O
monocytic	O
differentiation	O
.	O
	
During	O
monocyte-to-macrophage	O
differentiation	O
,	O
the	O
cellular	O
content	O
of	O
vacuolar	B-protein
H+-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
increases	O
more	O
than	O
4-fold	O
.	O
	
We	O
have	O
shown	O
previously	O
that	O
amplified	O
expression	O
of	O
the	O
B2	B-protein
subunit	I-protein
of	O
the	O
V-ATPase	B-protein
occurs	O
solely	O
by	O
increased	O
transcription	O
,	O
and	O
that	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
B2	B-DNA
gene	I-DNA
,	O
containing	O
multiple	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factors	I-protein
AP-2	B-protein
and	O
Sp1	B-protein
,	O
is	O
required	O
for	O
this	O
expression	O
.	O
	
The	O
present	O
study	O
demonstrates	O
that	O
AP-2	B-DNA
binding	I-DNA
sequences	I-DNA
are	O
essential	O
for	O
increased	O
transcription	O
from	O
the	O
B2	B-DNA
promoter	I-DNA
during	O
monocyte-macrophage	O
differentiation	O
and	O
that	O
AP-2	B-protein
,	O
expressed	O
exogenously	O
in	O
THP-1	B-cell_line
and	O
other	O
cells	O
,	O
activates	O
transcription	O
from	O
the	O
B2	B-DNA
promoter	I-DNA
.	O
	
In	O
mobility	O
shift	O
assays	O
,	O
a	O
nuclear	B-protein
factor	I-protein
from	O
THP-1	B-cell_line
and	O
U-937	B-cell_line
cells	I-cell_line
was	O
identified	O
that	O
binds	O
to	O
several	O
AP-2	B-DNA
response	I-DNA
elements	I-DNA
within	O
the	O
B2	B-DNA
promoter	I-DNA
,	O
but	O
does	O
not	O
react	O
with	O
AP-2	B-protein
antibodies	I-protein
,	O
and	O
has	O
a	O
DNA	B-DNA
sequence	I-DNA
binding	O
affinity	O
profile	O
that	O
differs	O
from	O
AP-2	B-protein
.	O
	
These	O
findings	O
suggest	O
that	O
a	O
novel	O
AP-2-like	B-protein
transcription	I-protein
factor	I-protein
is	O
responsible	O
for	O
V-ATPase	B-protein
B	I-protein
subunit	I-protein
amplification	O
during	O
monocyte	O
differentiation	O
.	O
	
###MEDLINE:97261053	
	
c-Jun	O
and	O
GST-pi	O
expression	O
in	O
human	B-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O
	
Bone	O
marrow	O
samples	O
from	O
33	O
patients	O
affected	O
by	O
MM	O
and	O
MGUS	O
,	O
and	O
8	O
patients	O
not	O
affected	O
by	O
lymphoproliferative	O
diseases	O
were	O
studied	O
for	O
expression	O
of	O
c-Jun	B-protein
(	O
a	O
component	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
)	O
and	O
glutathione-S-transferase	B-protein
pi	I-protein
(	O
GST-pi	B-protein
)	O
using	O
immunocytochemical	O
methods	O
.	O
	
A	O
high	O
and	O
frequent	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
found	O
both	O
in	O
MM	O
and	O
MGUS	O
patients	O
(	O
31/33	O
patients	O
positive	O
for	O
c-Jun	B-protein
and	O
29/33	O
patients	O
positive	O
for	O
GST-pi	B-protein
)	O
and	O
in	O
controls	O
not	O
affected	O
by	O
monoclonal	O
gammopathy	O
(	O
7/8	O
patients	O
positive	O
for	O
both	O
c-Jun	B-protein
and	O
GST-pi	B-protein
)	O
.	O
	
No	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
c-Jun-	B-cell_line
and	I-cell_line
GST-pi-positive	I-cell_line
plasma	I-cell_line
cells	I-cell_line
.	O
	
The	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
not	O
related	O
to	O
clinical	O
or	O
laboratory	O
data	O
.	O
	
Our	O
results	O
seem	O
to	O
confirm	O
a	O
possible	O
role	O
of	O
the	O
transcriptional	B-protein
complex	I-protein
AP-1	B-protein
in	O
activating	O
GST-pi	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:97134898	
	
Activation	O
of	O
signaling	O
pathways	O
and	O
prevention	O
of	O
apoptosis	O
by	O
cytokines	B-protein
in	O
eosinophils	B-cell_type
.	O
	
Inhibition	O
of	O
apoptosis	O
in	O
eosinophils	B-cell_type
by	O
cytokines	B-protein
such	O
as	O
IL-5	B-protein
and	O
GM-CSF	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
and	O
parasitic	O
disorders	O
.	O
	
Recently	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
activated	O
by	O
these	O
cytokines	B-protein
in	O
eosinophils	B-cell_type
.	O
	
The	O
IL-3	B-protein
,	O
IL-5	B-protein
and	O
GM-CSF	B-protein
receptors	I-protein
share	O
a	O
common	B-protein
signal	I-protein
transducer	I-protein
that	O
possesses	O
no	O
intrinsic	B-protein
kinase	I-protein
domain	I-protein
.	O
	
It	O
has	O
been	O
shown	O
that	O
eosinophil	O
stimulation	O
by	O
these	O
cytokines	B-protein
is	O
associated	O
with	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
several	O
cellular	O
substrates	O
.	O
	
In	O
the	O
past	O
few	O
years	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
defining	O
the	O
tyrosine	O
kinases	O
that	O
are	O
activated	O
by	O
the	O
IL-3/IL-5/GM-CSF	B-protein
receptor	I-protein
beta-subunit	I-protein
in	O
eosinophils	B-cell_type
.	O
	
This	O
review	O
will	O
concentrate	O
on	O
this	O
topic	O
and	O
on	O
its	O
role	O
for	O
the	O
regulation	O
of	O
eosinophil	O
apoptosis	O
.	O
	
###MEDLINE:99119105	
	
Requirement	O
of	O
GATA-1	B-protein
and	O
p45	B-protein
NF-E2	I-protein
expression	O
in	O
butyric	O
acid-induced	O
erythroid	O
differentiation	O
.	O
	
Butyric	O
acid	O
(	O
BA	O
)	O
is	O
known	O
to	O
induce	O
overexpression	O
of	O
fetal	B-protein
hemoglobin	I-protein
and	O
then	O
erythroid	O
differentiation	O
.	O
	
Therefore	O
,	O
BA	O
is	O
currently	O
under	O
clinical	O
investigation	O
as	O
a	O
potential	O
therapy	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
disease	O
and	O
cancer	O
.	O
	
Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
BA-induced	O
differentiation	O
remain	O
largely	O
unknown	O
.	O
	
Previous	O
reports	O
have	O
shown	O
that	O
BA-induced	O
overexpression	O
of	O
erythroid	B-DNA
genes	I-DNA
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
suggesting	O
the	O
involvement	O
of	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
.	O
	
Here	O
,	O
we	O
intend	O
to	O
demonstrate	O
the	O
requirement	O
of	O
GATA-1	B-protein
and	O
NF-E2	B-protein
transcription	B-protein
factors	I-protein
in	O
the	O
BA-induced	O
erythroid	O
differentiation	O
of	O
human	B-cell_line
leukemic	I-cell_line
K562	I-cell_line
cells	I-cell_line
.	O
	
Time-course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA-1	B-protein
and	O
p45	B-protein
NF-E2	I-protein
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O
	
Moreover	O
,	O
antisense	O
oligodeoxynucleotides	O
targeting	O
either	O
GATA-1	B-protein
or	O
p45	B-protein
NF-E2	I-protein
proteins	O
inhibited	O
both	O
protein	O
expression	O
and	O
BA-induced	O
differentiation	O
.	O
	
In	O
contrast	O
,	O
BA-induced	O
cell	O
growth	O
inhibition	O
was	O
not	O
affected	O
.	O
	
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
requirement	O
of	O
GATA-1	B-protein
and	O
NF-E2	B-protein
in	O
BA-induced	O
differentiation	O
process	O
.	O
	
###MEDLINE:99092484	
	
Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
BamHI	I-DNA
W	I-DNA
promoter	I-DNA
.	O
	
Epstein-Barr	O
virus	O
,	O
a	O
human	O
gammaherpesvirus	O
,	O
possesses	O
a	O
unique	O
set	O
of	O
latent	B-DNA
genes	I-DNA
whose	O
constitutive	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
leads	O
to	O
cell	O
growth	O
transformation	O
.	O
	
The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	B-DNA
promoter	I-DNA
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O
	
Using	O
Wp	B-DNA
reporter	I-DNA
constructs	I-DNA
in	O
in	O
vitro	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
Wp	O
was	O
11-	O
to	O
190-fold	O
more	O
active	O
in	O
B	B-cell_line
cell	I-cell_line
than	O
in	O
non-B	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
that	O
three	O
regions	O
of	O
the	O
promoter	B-DNA
(	O
termed	O
UAS1	B-DNA
,	O
UAS2	B-DNA
,	O
and	O
UAS3	B-DNA
)	O
contributed	O
to	O
transcriptional	O
activation	O
.	O
	
The	O
upstream	O
regions	O
UAS3	B-DNA
(	O
-1168	B-DNA
to	I-DNA
-440	I-DNA
)	O
and	O
UAS2	B-DNA
(	O
-352	B-DNA
to	I-DNA
-264	I-DNA
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage-independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non-B	B-cell_type
cells	I-cell_type
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
in	O
UAS2	B-DNA
in	O
that	O
context	O
.	O
	
By	O
contrast	O
,	O
UAS1	B-DNA
(	O
-140	B-DNA
to	I-DNA
-87	I-DNA
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Mutational	O
analysis	O
of	O
UAS1	B-DNA
sequences	I-DNA
combined	O
with	O
in	O
vitro	O
bandshift	O
assays	O
revealed	O
the	O
presence	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
cellular	B-protein
factors	I-protein
in	O
this	O
region	O
.	O
	
When	O
mutations	O
that	O
abolished	O
factor	O
binding	O
in	O
bandshift	O
assays	O
were	O
introduced	O
into	O
a	O
Wp	B-DNA
reporter	I-DNA
construct	I-DNA
,	O
the	O
loss	O
of	O
any	O
one	O
of	O
the	O
three	O
UAS1	B-DNA
binding	I-DNA
sites	I-DNA
was	O
sufficient	O
to	O
reduce	O
promoter	O
activity	O
by	O
10-	O
to	O
30-fold	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
From	O
sequence	O
analysis	O
,	O
two	O
of	O
these	O
appear	O
to	O
be	O
novel	O
transcription	B-protein
factor	I-protein
binding	B-DNA
sites	I-DNA
,	O
whereas	O
the	O
third	O
was	O
identified	O
as	O
a	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O
	
Our	O
data	O
indicate	O
that	O
this	O
CRE	B-DNA
interacts	O
with	O
CREB	B-protein
and	I-protein
ATF1	I-protein
proteins	I-protein
present	O
in	O
B	O
cell	O
nuclear	O
extracts	O
and	O
that	O
this	O
interaction	O
is	O
important	O
for	O
Wp	O
activity	O
.	O
	
###MEDLINE:99075977	
	
In	O
situ	O
RT-PCR	O
detection	O
of	O
Epstein-Barr	B-RNA
virus	I-RNA
immediate-early	I-RNA
transcripts	I-RNA
in	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
AIDS-related	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O
	
The	O
pathway	O
whereby	O
EBV	O
infects	O
T	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	B-cell_type
cells	I-cell_type
has	O
not	O
been	O
established	O
.	O
	
In	O
order	O
to	O
shed	O
light	O
on	O
the	O
early	O
events	O
of	O
the	O
EBV	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
used	O
in	O
situ	O
reverse	O
transcription	O
based	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
to	O
study	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
homogeneous	B-cell_type
CD4+	I-cell_type
and	I-cell_type
CD8+	I-cell_type
lymphocytes	I-cell_type
.	O
	
Following	O
EBV	O
infection	O
,	O
Epstein-Barr	O
nuclear	O
antigen	O
(	O
EBNA	B-protein
)	O
expression	O
could	O
be	O
detected	O
in	O
T	B-cell_type
rosetting	I-cell_type
CD4+	I-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Only	O
a	O
few	O
cells	O
showed	O
viral	B-protein
capsid	I-protein
antigen	I-protein
(	O
VCA	B-protein
)	O
.	O
	
EBV	B-RNA
immediate-early	I-RNA
gene	I-RNA
transcripts	I-RNA
(	O
BZLF1	B-RNA
,	O
BRLF1	B-RNA
,	O
and	O
BMLF1	B-RNA
)	O
encoded	O
in	O
the	O
BamHI	O
Z	O
,	O
R	O
,	O
and	O
M	O
fragments	O
could	O
be	O
detected	O
by	O
in	O
situ	O
RT-PCR	O
in	O
the	O
EBV	O
producer	O
cell	O
line	O
B95.8	O
.	O
	
Both	O
BZLF1	B-RNA
and	I-RNA
BRLF1	I-RNA
immediate-early	I-RNA
transcripts	I-RNA
,	O
but	O
not	O
BMLF1	B-RNA
transcript	I-RNA
,	O
could	O
be	O
detected	O
in	O
individual	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
infected	O
with	O
EBV	O
.	O
	
Demonstration	O
of	O
EBV	B-RNA
mRNA	I-RNA
transcripts	I-RNA
encoding	O
immediate-early	B-protein
transcriptional	I-protein
transactivators	I-protein
in	O
EBV-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
provides	O
the	O
first	O
evidence	O
for	O
a	O
possible	O
mechanism	O
whereby	O
EBV	O
could	O
contribute	O
to	O
T	O
cell	O
proliferation	O
and	O
EBV-associated	O
T	O
cell	O
malignancies	O
.	O
	
###MEDLINE:99067836	
	
The	O
linkage	O
between	O
T-cell	O
and	O
dendritic	O
cell	O
development	O
in	O
the	O
mouse	O
thymus	O
.	O
	
Thymic	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
mediate	O
negative	O
selection	O
at	O
a	O
relatively	O
late	O
stage	O
of	O
the	O
T-cell	O
developmental	O
pathway	O
.	O
	
We	O
present	O
evidence	O
that	O
the	O
development	O
of	O
thymic	B-cell_type
DC	I-cell_type
and	O
of	O
T-lineage	B-cell_type
cells	I-cell_type
is	O
linked	O
via	O
a	O
common	O
precursor	O
at	O
an	O
early	O
stage	O
of	O
thymocyte	O
development	O
.	O
	
T-lineage	O
precursor	O
populations	O
from	O
the	O
adult	O
mouse	O
thymus	O
,	O
prior	O
to	O
T-cell	O
receptor	O
gene	O
rearrangement	O
,	O
display	O
a	O
capacity	O
to	O
produce	O
DC	B-cell_type
as	O
well	O
as	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
,	O
and	O
are	O
very	O
efficient	O
precursors	O
of	O
DC	B-cell_type
in	O
culture	O
.	O
	
These	O
lymphoid/DC	B-cell_type
precursors	I-cell_type
have	O
little	O
capacity	O
to	O
form	O
myeloid	B-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
thymic	B-cell_type
DC	I-cell_type
are	O
a	O
lymphoid-related	O
rather	O
than	O
myeloid-related	B-cell_type
lineage	I-cell_type
.	O
	
In	O
contrast	O
to	O
myeloid-related	B-cell_type
DC	I-cell_type
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
is	O
not	O
required	O
for	O
the	O
development	O
of	O
these	O
lymphoid-related	B-cell_type
DC	I-cell_type
in	O
vivo	O
or	O
in	O
vitro	O
.	O
	
DC	B-cell_type
can	O
develop	O
in	O
mutant	O
mice	O
lacking	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
provided	O
the	O
common	O
precursors	O
are	O
present	O
.	O
	
However	O
,	O
in	O
mutant	O
mice	O
lacking	O
functional	O
Ikaros	B-protein
transcription	B-protein
factors	I-protein
,	O
there	O
are	O
deficiencies	O
in	O
lymphoid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
,	O
in	O
mature	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
in	O
DC	B-cell_type
.	O
	
###MEDLINE:99059495	
	
Host	O
control	O
of	O
HIV-1	O
parasitism	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O
	
Post	O
HIV-1	O
entry	O
,	O
productive	O
HIV-1	O
infection	O
of	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
requires	O
overcoming	O
several	O
cellular	O
blocks	O
to	O
provirus	O
establishment	O
and	O
replication	O
.	O
	
Activation	O
of	O
unknown	O
host	O
intracellular	O
events	O
overcomes	O
such	O
inhibitory	O
steps	O
and	O
is	O
concomitant	O
with	O
HIV-1	O
replication	O
.	O
	
We	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
NFATc	B-protein
was	O
sufficient	O
as	O
a	O
cellular	O
factor	O
to	O
induce	O
a	O
highly	O
permissive	O
state	O
for	O
HIV-1	O
replication	O
in	O
primary	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
NFATc	B-protein
overcame	O
a	O
blockade	O
at	O
reverse	O
transcription	O
and	O
permitted	O
active	O
HIV-1	O
replication	O
.	O
	
Pharmacologic	O
blockade	O
of	O
endogenous	B-protein
NFAT	I-protein
activity	O
by	O
FK506	O
or	O
CsA	O
inhibited	O
synthesis	O
of	O
reverse	O
transcription	O
and	O
also	O
potently	O
blocked	O
HIV-1	O
replication	O
.	O
	
T	B-cell_type
cells	I-cell_type
therefore	O
can	O
become	O
competent	O
for	O
HIV-1	O
replication	O
by	O
control	O
of	O
regulated	B-protein
host	I-protein
factors	I-protein
such	O
as	O
the	O
NFATc	B-protein
transcription	B-protein
factor	I-protein
.	O
	
The	O
host	O
mechanisms	O
regulated	O
by	O
such	O
permissivity	O
factors	O
are	O
potential	O
targets	O
for	O
anti-HIV-1	O
therapy	O
.	O
	
###MEDLINE:99049838	
	
Regulation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT1	B-protein
nuclear	O
import	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	B-protein
localization	I-protein
sequence	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
.	O
	
Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
by	O
Ags	B-protein
or	O
cytokines	B-protein
results	O
in	O
translocation	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT	B-protein
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
.	O
	
The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	B-protein
localization	I-protein
sequence	I-protein
(	O
NLS	B-protein
)	O
within	O
the	O
karyophilic	B-protein
protein	I-protein
by	O
a	O
cytoplasmic	B-protein
receptor	I-protein
such	O
as	O
the	O
importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-alpha	I-protein
subunit	I-protein
.	O
	
The	O
NLSs	B-protein
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
and	O
NFAT	B-protein
differ	O
and	O
the	O
NLS	B-protein
of	O
STAT1	B-protein
has	O
not	O
yet	O
been	O
identified	O
.	O
	
Herein	O
we	O
demonstrate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
is	O
significantly	O
inhibited	O
by	O
a	O
cell-permeable	O
peptide	O
carrying	O
the	O
NLS	B-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
subunit	I-protein
.	O
	
NLS	B-protein
peptide-mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	B-protein
factors	I-protein
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL-2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
and	O
NFAT	B-protein
.	O
	
Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	B-protein
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	B-protein
NLS	I-protein
receptor	I-protein
complex	I-protein
comprised	O
of	O
the	O
Rch1/importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-beta	I-protein
heterodimer	I-protein
expressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
can	O
be	O
regulated	O
by	O
NLS	B-protein
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
to	O
target	O
members	O
of	O
the	O
importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-alpha	I-protein
beta	I-protein
NLS	B-protein
receptor	I-protein
complex	I-protein
.	O
	
###MEDLINE:99041167	
	
Membrane-associated	B-protein
lymphotoxin	I-protein
on	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
activates	O
endothelial	B-cell_type
cells	I-cell_type
via	O
an	O
NF-kappaB	B-protein
-dependent	O
pathway	O
.	O
	
BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
and	O
monocytes	O
associated	O
with	O
endothelial	B-cell_type
cell	I-cell_type
(	O
EC	B-cell_type
)	O
activation	O
.	O
	
We	O
have	O
previously	O
demonstrated	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
activate	O
porcine	O
EC	B-cell_type
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
cytokine	B-protein
secretion	O
.	O
	
In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	B-cell_line
cell	I-cell_line
line	I-cell_line
NK92	I-cell_line
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell-mediated	O
EC	B-cell_type
activation	O
.	O
	
METHODS	O
:	O
EC	B-cell_type
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	B-DNA
gene	I-DNA
driven	O
either	O
by	O
E-selectin	B-DNA
or	I-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-8	I-DNA
promoters	I-DNA
or	O
a	O
synthetic	O
NF-kappaB-dependent	B-DNA
promoter	I-DNA
.	O
	
In	O
addition	O
,	O
a	O
dominant-negative	B-DNA
mutant	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
receptor	I-DNA
I	I-DNA
(	I-DNA
TNFRI	I-DNA
)	I-DNA
expression	I-DNA
vector	I-DNA
was	O
co-transfected	O
in	O
inhibition	O
studies	O
.	O
	
Forty-eight	O
hours	O
after	O
transfection	O
,	O
EC	B-cell_type
were	O
stimulated	O
with	O
NK	B-cell_type
cells	I-cell_type
or	O
NK	B-cell_type
cell	I-cell_type
membrane	I-cell_type
extracts	I-cell_type
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	B-protein
assay	O
.	O
	
RESULTS	O
:	O
Co-culture	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
transfected	O
EC	B-cell_type
enhanced	O
E-selectin	B-protein
,	O
IL-8	B-protein
,	O
and	O
NF-kappaB	B-protein
-dependent	O
promoter	O
activity	O
.	O
	
NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	B-cell_type
and	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
(	O
p50	B-protein
and	O
p65	B-protein
)	O
.	O
	
Western	O
blotting	O
of	O
NK	B-cell_type
cell	I-cell_type
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin-alpha	B-protein
(	O
LTalpha	B-protein
)	O
but	O
not	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O
	
Furthermore	O
,	O
LTalpha	B-protein
was	O
secreted	O
in	O
NK	B-cell_line
:	I-cell_line
EC	I-cell_line
co-cultures	I-cell_line
.	O
	
Co-transfection	O
with	O
dominant-negative	B-protein
mutant	I-protein
TNFRI	I-protein
inhibited	O
EC	B-cell_type
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	B-cell_type
cells	I-cell_type
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O
	
The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti-human	O
LT	O
sera	O
.	O
	
CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane-bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B-protein
,	O
leading	O
to	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
transcription	O
of	O
E-selectin	B-protein
and	O
IL-8	B-protein
,	O
which	O
results	O
in	O
EC	B-cell_type
activation	O
.	O
	
The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	B-cell_type
cells	I-cell_type
with	O
mutant	B-protein
TNFRI	I-protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	B-cell_type
cells	I-cell_type
to	O
activate	O
EC	B-cell_type
	
###MEDLINE:97150707	
	
Ras	B-protein
-dependent	O
,	O
Ca2+-stimulated	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
by	O
a	O
constitutively	O
active	O
Cbl	B-protein
mutant	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
stimulation	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
proteins	I-protein
,	O
including	O
Cbl	B-protein
,	O
a	O
protooncogene	B-protein
product	I-protein
whose	O
function	O
remains	O
unclear	O
.	O
	
As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	B-protein
in	O
TCR	B-protein
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild-type	B-protein
Cbl	I-protein
or	O
a	O
transforming	O
Cbl	B-protein
mutant	I-protein
(	O
70Z/3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
element	I-DNA
derived	O
from	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL2	I-DNA
)	I-DNA
promoter	I-DNA
in	O
transiently	O
cotransfected	O
Jurkat-TAg	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
70Z/3	B-protein
,	O
but	O
not	O
Cbl	B-protein
,	O
caused	O
NFAT	B-protein
activation	O
which	O
was	O
significantly	O
enhanced	O
by	O
stimulation	O
with	O
calcium	O
ionophore	O
,	O
and	O
was	O
drastically	O
reduced	O
by	O
cyclosporin	O
A	O
pretreatment	O
.	O
	
A	O
point	O
mutation	O
of	O
a	O
potential	O
phosphatidylinositol	B-DNA
3-kinase	I-DNA
(	I-DNA
PI3-K	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
(	O
Y731EAM	B-DNA
to	O
Y731EAC	B-DNA
)	O
in	O
70Z/3	B-protein
disrupted	O
the	O
association	O
of	O
PI3-K	B-protein
with	O
70Z/3	B-protein
,	O
but	O
did	O
not	O
reduce	O
the	O
induction	O
of	O
NFAT	B-protein
activity	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
Cbl	B-protein
and	O
PI3-K	B-protein
is	O
not	O
required	O
in	O
the	O
70Z/3	B-protein
-mediated	O
induction	O
of	O
NFAT	B-protein
.	O
	
Additional	O
mapping	O
studies	O
indicated	O
that	O
defined	O
deletions	O
of	O
C-terminal	O
70Z/3	B-protein
sequences	O
affected	O
to	O
a	O
variable	O
degree	O
its	O
ability	O
to	O
stimulate	O
NFAT	B-protein
activity	O
.	O
	
Strikingly	O
,	O
deletion	O
of	O
346	B-protein
C-terminal	I-protein
residues	I-protein
augmented	O
this	O
activity	O
,	O
whereas	O
removal	O
of	O
20	O
additional	O
residues	O
abolished	O
it	O
.	O
	
Coexpression	O
of	O
dominant	B-protein
negative	I-protein
Ras	I-protein
abrogated	O
the	O
basal	O
or	O
ionomycin-stimulated	O
,	O
70Z/3	B-protein
-mediated	O
NFAT	B-protein
activation	O
,	O
suggesting	O
a	O
functional	B-protein
Ras	I-protein
is	O
required	O
for	O
this	O
activation	O
.	O
	
These	O
results	O
implicate	O
Cbl	B-protein
in	O
Ras	B-protein
-dependent	O
signaling	O
pathways	O
which	O
lead	O
to	O
NFAT	B-protein
activation	O
.	O
	
###MEDLINE:97259535	
	
Requirement	O
of	O
prestimulated	B-cell_line
THP-1	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
for	O
endothelial	B-cell_type
cell	I-cell_type
activation	O
.	O
	
Involvement	O
of	O
TNF	O
alpha	O
.	O
	
Blood	B-cell_type
monocytes	I-cell_type
spontaneously	O
activate	O
endothelial	B-cell_type
cells	I-cell_type
in	O
culture	O
,	O
leading	O
to	O
adhesion	O
of	O
monocytic	B-cell_type
cells	I-cell_type
onto	O
the	O
endothelial	O
surface	O
and	O
overproduction	O
of	O
endothelial	O
proteins	O
such	O
as	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWf	B-protein
)	O
and	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
type	I-protein
1	I-protein
(	O
PAI-1	B-protein
)	O
.	O
	
To	O
overcome	O
the	O
difficulty	O
in	O
obtaining	O
quiescent	B-cell_type
monocytes	I-cell_type
,	O
we	O
studied	O
the	O
ability	O
of	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
to	O
activate	O
endothelial	B-cell_type
cells	I-cell_type
.	O
	
Lipopolysaccharide	O
(	O
LPS	O
)	O
-prestimulated	O
and	O
untreated	O
THP-1	B-cell_line
cells	I-cell_line
were	O
cocultured	O
with	O
resting	B-cell_type
human	I-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVEC	B-cell_type
)	O
for	O
3	O
and	O
24	O
h	O
in	O
the	O
presence	O
of	O
colimycin	O
to	O
neutralize	O
LPS	O
traces	O
.	O
	
Addition	O
of	O
untreated	O
THP-1	B-cell_line
cells	I-cell_line
had	O
little	O
effect	O
on	O
HUVEC	B-cell_type
adhesiveness	O
.	O
	
Addition	O
of	O
prestimulated	O
THP-1	B-cell_line
cells	I-cell_line
was	O
followed	O
by	O
a	O
noticeable	O
adhesion	O
after	O
3	O
h	O
which	O
reversed	O
to	O
basal	O
values	O
within	O
24	O
h	O
.	O
	
Under	O
these	O
conditions	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
E-selectin	B-protein
,	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	B-protein
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O
	
Diffusible	B-protein
endothelial	I-protein
proteins	I-protein
such	O
as	O
soluble	O
E-selectin	B-protein
,	O
PAI-1	B-protein
and	O
vWf	B-protein
to	O
a	O
minimal	O
extent	O
,	O
increased	O
in	O
supernatants	O
from	O
HUVEC	B-cell_type
cocultured	O
for	O
24	O
h	O
with	O
prestimulated	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
In	O
those	O
cocultures	O
,	O
TNF	B-protein
alpha	I-protein
concentrations	O
peaked	O
at	O
3	O
h	O
whereas	O
IL-1	O
beta	O
levels	O
progressively	O
rose	O
until	O
24	O
h	O
.	O
	
Addition	O
of	O
an	O
anti-TNF	B-protein
alpha	I-protein
antibody	I-protein
decreased	O
by	O
40	O
%	O
E-selectin	B-protein
and	O
ICAM-1	B-protein
induction	O
and	O
suppressed	O
PAI-1	B-protein
overproduction	O
with	O
a	O
weak	O
effect	O
on	O
vWf	B-protein
.	O
	
An	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
had	O
negligible	O
effects	O
on	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
PAI-1	B-protein
or	O
vWf	B-protein
production	O
.	O
	
These	O
results	O
provide	O
evidence	O
that	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	B-cell_type
and	O
that	O
TNF	B-protein
alpha	I-protein
contributes	O
to	O
this	O
phenomenon	O
.	O
	
###MEDLINE:97132947	
	
Engagement	O
of	O
the	O
Lewis	O
X	O
antigen	O
(	O
CD15	O
)	O
results	O
in	O
monocyte	O
activation	O
.	O
	
We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	B-cell_line
necrosis	I-cell_line
factor-alpha	I-cell_line
(	I-cell_line
TNF-alpha	I-cell_line
)	I-cell_line
-treated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
increased	O
expression	O
of	O
tissue	O
factor	O
and	O
CD36	B-protein
on	O
monocytes	O
.	O
	
Using	O
immunological	O
cross-linking	O
to	O
mimic	O
receptor	O
engagement	O
by	O
natural	O
ligands	O
,	O
we	O
now	O
show	O
that	O
CD15	O
(	O
Lewis	O
X	O
)	O
,	O
a	O
monocyte	B-protein
counter-receptor	I-protein
for	O
endothelial	B-protein
selectins	I-protein
may	O
participate	O
in	O
this	O
response	O
.	O
	
We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross-linking	O
induced	O
TNF-alpha	B-protein
release	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
MM6	I-cell_line
.	O
	
Quantitative	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
showed	O
an	O
increase	O
in	O
steady-state	O
TNF-alpha	B-RNA
mRNA	I-RNA
after	O
3	O
to	O
4	O
hours	O
of	O
cross-linking	O
.	O
	
CD15	O
cross-linking	O
also	O
concomitantly	O
increased	O
interleukin-1	B-RNA
beta	I-RNA
(	I-RNA
IL-1	I-RNA
beta	I-RNA
)	I-RNA
mRNA	I-RNA
,	O
while	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
levels	O
of	O
beta-actin	B-RNA
mRNA	I-RNA
,	O
indicating	O
specificity	O
.	O
	
To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	B-DNA
beta	I-DNA
promoter/enhancer	I-DNA
sequences	I-DNA
was	O
introduced	O
into	O
MM6	B-cell_line
.	O
	
Subsequent	O
cross-linking	O
of	O
CD15	O
increased	O
CAT	B-protein
activity	O
.	O
	
CD15	O
engagement	O
by	O
monoclonal	B-protein
antibody	I-protein
also	O
attenuated	O
IL-1	B-protein
beta	I-protein
transcript	O
degradation	O
,	O
demonstrating	O
that	O
signaling	O
via	O
CD15	O
also	O
had	O
posttranscriptional	O
effects	O
.	O
	
Nuclear	O
extracts	O
of	O
anti-	O
CD15	B-cell_type
cross-linked	I-cell_type
cells	I-cell_type
demonstrated	O
enhanced	O
levels	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
activator	I-protein
protein-1	I-protein
,	O
minimally	O
changed	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
,	O
and	O
did	O
not	O
affect	O
SV40	B-protein
promoter	I-protein
specific	I-protein
protein-1	I-protein
.	O
	
We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O
	
In	O
addition	O
to	O
its	O
well-recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	B-cell_type
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O
	
###MEDLINE:99111421	
	
CD2	B-protein
signalling	O
induces	O
phosphorylation	O
of	O
CREB	B-protein
in	O
primary	B-cell_type
lymphocytes	I-cell_type
.	O
	
Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	B-DNA
genes	I-DNA
,	O
and	O
bind	O
transcription	B-protein
factors	I-protein
of	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	I-protein
/activating	I-protein
transcription	I-protein
factor-1	I-protein
(	I-protein
ATF-1	I-protein
)	I-protein
family	I-protein
.	O
	
We	O
have	O
used	O
a	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	B-DNA
promoter	I-DNA
.	O
	
We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross-linking	O
.	O
	
We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	B-protein
.	O
	
Therefore	O
,	O
we	O
investigated	O
CD2	B-protein
and	O
CD3	B-protein
receptor	I-protein
-mediated	O
signalling	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O
	
CD2	B-protein
,	O
but	O
not	O
CD3	B-protein
,	O
cross-linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O
	
CD2	B-protein
cross-linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B-protein
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O
	
Consistent	O
with	O
post-translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	B-protein
protein	O
was	O
observed	O
.	O
	
Phosphorylation	O
of	O
CREB	B-protein
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp-cAMP-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTK	B-protein
)	O
and	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O
	
Both	O
CD2	B-protein
and	O
CD3	B-protein
cross-linking	O
increased	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O
	
These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB/ATF-1	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
by	O
the	O
CD2	B-protein
signalling	O
pathway	O
and	O
suggest	O
CD2	B-protein
receptor	O
modulation	O
of	O
CRE	B-DNA
-mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell-to-cell	O
contact	O
)	O
.	O
	
###MEDLINE:99089911	
	
X-rays-induced	O
secretion	O
of	O
cellular	B-protein
factor	I-protein
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV-1	B-DNA
promoter	I-DNA
transcription	O
in	O
various	O
non-irradiated	B-cell_line
transfected	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-	O
1	O
)	O
replication	O
or	O
reporter	B-DNA
gene	I-DNA
expression	O
.	O
	
In	O
addition	O
,	O
extracellular	B-protein
factor	I-protein
(	O
s	O
)	O
released	O
by	O
X-ray-treated	B-cell_line
human	I-cell_line
colonic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
HT29	B-cell_line
)	O
might	O
activate	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
in	O
non-irradiated	B-cell_line
HT29	I-cell_line
cells	I-cell_line
.	O
	
In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	B-cell_line
transfected	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
X-ray	O
irradiation	O
up-regulates	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
through	O
the	O
kappaB	B-protein
regulatory	I-protein
elements	I-protein
.	O
	
A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non-irradiated	B-cell_type
cells	I-cell_type
of	O
either	O
X-ray-treated	B-cell_line
cells	I-cell_line
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	B-cell_line
cultures	I-cell_line
.	O
	
The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O
	
In	O
addition	O
,	O
X-ray	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
in	O
transiently	O
or	O
stably	O
transfected	O
cell	B-cell_line
lines	I-cell_line
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	B-protein
factors	I-protein
,	O
suramin	O
.	O
	
The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS-related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O
	
###MEDLINE:99073952	
	
Activation	O
of	O
the	O
human	B-DNA
delta-globin	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
primary	B-cell_type
adult	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O
	
Restoration	O
of	O
the	O
CCAAT	B-DNA
box	I-DNA
or	O
insertion	O
of	O
an	O
erythroid	B-DNA
Kruppel-like	I-DNA
factor	I-DNA
(	I-DNA
EKLF	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
delta	B-DNA
promoter	I-DNA
activates	O
its	O
expression	O
in	O
several	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
We	O
extended	O
these	O
studies	O
using	O
a	O
novel	O
primary	B-cell_line
human	I-cell_line
adult	I-cell_line
erythroid	I-cell_line
cell	I-cell_line
(	I-cell_line
hAEC	I-cell_line
)	I-cell_line
system	I-cell_line
to	O
investigate	O
these	O
effects	O
at	O
the	O
late	B-cell_type
erythroblast	I-cell_type
stage	I-cell_type
.	O
	
Restoration	O
of	O
the	O
CCAAT	B-DNA
box	I-DNA
at	O
-70	B-DNA
bp	I-DNA
,	O
or	O
insertion	O
of	O
an	O
EKLF	B-DNA
binding	I-DNA
site	I-DNA
at	O
-85	B-DNA
bp	I-DNA
or	O
-95	B-DNA
bp	I-DNA
in	O
the	O
promoter	B-DNA
significantly	O
increased	O
delta	O
globin	O
gene	O
expression	O
in	O
hAEC	O
.	O
	
Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	B-DNA
box	I-DNA
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	B-DNA
binding	I-DNA
site	I-DNA
in	O
delta-globin	B-protein
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	B-cell_line
model	I-cell_line
as	O
well	O
.	O
	
###MEDLINE:99065132	
	
Constitutive	O
association	O
of	O
JAK1	B-protein
and	O
STAT5	B-protein
in	O
pro-B	B-cell_type
cells	I-cell_type
is	O
dissolved	O
by	O
interleukin-4	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
both	O
proteins	O
.	O
	
The	O
bipartite	B-protein
human	I-protein
interleukin-4	I-protein
(	I-protein
IL-4	I-protein
)	I-protein
receptor	I-protein
was	O
functionally	O
expressed	O
in	O
murine	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
and	O
activated	O
by	O
human	B-protein
IL-4	I-protein
to	O
evoke	O
intracellular	O
signaling	O
.	O
	
Mutual	O
association	O
of	O
signal	B-protein
transducing	I-protein
proteins	I-protein
within	O
the	O
receptor	O
complex	O
was	O
then	O
studied	O
in	O
dependence	O
of	O
ligand	O
stimulation	O
.	O
	
Besides	O
ligand-induced	O
receptor	O
heterodimerization	O
and	O
contacts	O
of	O
the	O
two	O
IL-4	B-protein
receptor	I-protein
subunits	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
with	O
Janus	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK3	B-protein
a	O
prominent	O
constitutive	O
binding	O
between	O
JAK1	B-protein
and	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
STAT5	B-protein
was	O
detected	O
.	O
	
Since	O
both	O
these	O
proteins	O
become	O
phosphorylated	O
in	O
response	O
to	O
IL-4	B-protein
receptor	I-protein
stimulation	O
,	O
the	O
influence	O
of	O
tyrosine	O
phosphorylation	O
on	O
their	O
mutual	O
contact	O
was	O
analyzed	O
.	O
	
Association	O
of	O
JAK1	B-protein
and	O
STAT5	B-protein
was	O
found	O
to	O
occur	O
exclusively	O
between	O
unphosphorylated	B-protein
proteins	I-protein
.	O
	
###MEDLINE:99061637	
	
Activation	O
of	O
human	B-cell_type
macrophages	I-cell_type
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O
	
Positive-pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O
	
In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	B-cell_type
cells	I-cell_type
can	O
be	O
submitted	O
to	O
a	O
prolonged	B-cell_line
cyclic	I-cell_line
pressure-stretching	I-cell_line
strain	I-cell_line
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O
	
In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O
	
The	O
lung	B-cell_type
macrophage	I-cell_type
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
the	O
chemokines	B-protein
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
and	I-protein
-6	I-protein
,	O
and	O
matrix	B-protein
metalloproteinase-9	I-protein
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O
	
These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
,	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
,	O
and	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O
	
Nuclear	B-protein
factor-kappaB	I-protein
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	B-cell_type
macrophages	I-cell_type
.	O
	
Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	B-protein
endotoxin	I-protein
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O
	
Dexamethasone	O
prevented	O
IL-8	B-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
in	O
ventilated	B-cell_type
macrophages	I-cell_type
.	O
	
Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL-8	B-protein
secretion	O
by	O
alveolar	B-cell_type
type	I-cell_type
II-like	I-cell_type
cells	I-cell_type
.	O
	
Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	B-cell_type
cells	I-cell_type
,	O
bronchial	B-cell_type
cells	I-cell_type
,	O
and	O
fibroblasts	B-cell_type
failed	O
to	O
produce	O
IL-8	B-protein
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure-stretching	O
load	O
.	O
	
This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress-induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O
	
###MEDLINE:99049827	
	
Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF-	B-protein
and	I-protein
cytokine-receptor	I-protein
families	O
target	O
a	O
common	O
cis-element	B-DNA
of	O
the	O
IFN	B-DNA
regulatory	I-DNA
factor	I-DNA
1	I-DNA
promoter	I-DNA
.	O
	
CD40	B-protein
activation	O
of	O
B	B-cell_type
cells	I-cell_type
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	B-protein
.	O
	
However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O
	
IFN	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
(	O
IRF-1	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
either	O
CD40	B-protein
or	O
cytokines	B-protein
.	O
	
We	O
have	O
found	O
that	O
these	O
different	O
sets	O
of	O
signals	O
target	O
a	O
common	O
cis-acting	O
element	O
in	O
the	O
promoter	O
of	O
this	O
gene	O
,	O
the	O
IRF-1	B-DNA
gamma-activated	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
.	O
	
Targeting	O
of	O
the	O
IRF-1	B-DNA
GAS	I-DNA
is	O
not	O
confined	O
to	O
activation	O
via	O
CD40	B-protein
but	O
extends	O
to	O
other	O
stimuli	O
that	O
mimic	O
the	O
CD40	B-protein
signaling	O
cascade	O
,	O
like	O
TNF-alpha	B-protein
and	O
EBV	O
.	O
	
In	O
contrast	O
to	O
induction	O
of	O
STATs	B-protein
by	O
cytokines	B-protein
,	O
the	O
IRF-1	B-DNA
GAS	I-DNA
-binding	O
complex	O
activated	O
by	O
CD40	B-protein
,	O
TNF-alpha	B-protein
,	O
or	O
EBV	O
contains	O
Rel	B-protein
proteins	I-protein
,	O
specifically	O
p50	B-protein
and	O
p65	B-protein
.	O
	
In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	B-protein
together	O
with	O
either	O
IL-4	B-protein
or	O
IFN-gamma	B-protein
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel/STAT	B-protein
complexes	I-protein
.	O
	
Given	O
the	O
importance	O
of	O
IRF-1	B-protein
in	O
a	O
variety	O
of	O
biologic	O
functions	O
from	O
proliferation	O
to	O
apoptosis	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
modulation	O
of	O
IRF-1	B-protein
levels	O
may	O
be	O
a	O
critical	O
control	O
point	O
in	O
B	O
cell	O
activation	O
.	O
	
###MEDLINE:99069282	
	
Differential	O
effects	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitors	O
on	O
fibronectin	B-protein
-induced	O
interleukin-beta	B-DNA
gene	I-DNA
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
express	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
when	O
stimulated	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
glycoprotein	I-protein
,	O
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O
	
Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	B-protein
acts	O
upon	O
to	O
mediate	O
the	O
FN	B-protein
-induced	O
IL-1beta	B-protein
response	O
remain	O
unclear	O
.	O
	
We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	B-protein
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B-protein
-induced	O
IL-1beta	B-protein
response	O
.	O
	
Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	B-protein
protein	I-protein
into	O
the	O
media	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
exposed	O
to	O
FN	B-protein
.	O
	
Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	B-protein
protein	I-protein
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O
	
To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	B-cell_line
U937	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O
	
U937	O
cells	O
transfected	O
with	O
the	O
human	O
full-length	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
connected	O
to	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O
	
These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
activator	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	B-protein
induction	O
of	O
IL-1beta	B-protein
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL-1beta	B-DNA
gene	I-DNA
.	O
	
In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	B-protein
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O
	
Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	B-DNA
gene	I-DNA
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O
	
Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	B-protein
,	O
we	O
conclude	O
that	O
PKC	B-protein
is	O
necessary	O
for	O
FN	B-protein
-induced	O
IL-1beta	B-protein
protein	O
production	O
.	O
	
In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL-1beta	B-protein
by	O
unknown	O
mechanisms	O
	
###MEDLINE:97429889	
	
The	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
of	O
CD36	B-protein
is	O
required	O
for	O
oxidized	O
low-density	O
lipoprotein	O
modulation	O
of	O
NF-kappaB	B-protein
activity	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O
	
The	O
binding	O
of	O
oxidized	O
low-density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	B-cell_type
-macrophages	B-cell_type
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O
	
The	O
integral	O
membrane	O
glycoprotein	B-protein
CD36	I-protein
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte-macrophages	B-cell_type
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B-protein
-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O
	
To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	B-protein
transfected	O
Chinese	B-cell_type
hampster	I-cell_type
ovary	I-cell_type
(	I-cell_type
CHO	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O
	
We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF-kappaB	B-DNA
sequence	I-DNA
following	O
activation	O
of	O
CD36-producing	B-cell_line
CHO	I-cell_line
cells	I-cell_line
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O
	
This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	B-protein
transfected	O
cells	O
with	O
the	O
human	B-protein
CD36-specific	I-protein
antibody	I-protein
OKM5	B-protein
.	O
	
We	O
also	O
determined	O
that	O
activation	O
of	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
required	O
an	O
intact	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
segment	I-protein
on	O
CD36	B-protein
.	O
	
Our	O
results	O
support	O
the	O
idea	O
that	O
human	B-protein
CD36	I-protein
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O
	
###MEDLINE:97205335	
	
TRAMP	B-protein
,	O
a	O
novel	O
apoptosis-mediating	B-protein
receptor	I-protein
with	O
sequence	O
homology	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
1	I-protein
and	O
Fas	B-protein
(	O
Apo-1/CD95	B-protein
)	O
.	O
	
A	O
novel	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptor	I-protein
family	I-protein
,	O
designated	O
TRAMP	B-protein
,	O
has	O
been	O
identified	O
.	O
	
The	O
structural	O
organization	O
of	O
the	O
393	B-protein
amino	I-protein
acid	I-protein
long	I-protein
human	I-protein
TRAMP	I-protein
is	O
most	O
homologous	O
to	O
TNF	B-protein
receptor	I-protein
1	I-protein
.	O
	
TRAMP	B-protein
is	O
abundantly	O
expressed	O
on	O
thymocytes	B-cell_type
and	O
lymphocytes	B-cell_type
.	O
	
Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine-rich	B-protein
domains	I-protein
,	O
and	O
the	O
cytoplasmic	B-protein
region	I-protein
contains	O
a	O
death	B-protein
domain	I-protein
known	O
to	O
signal	O
apoptosis	O
.	O
	
Overexpression	O
of	O
TRAMP	B-protein
leads	O
to	O
two	O
major	O
responses	O
,	O
NF-kappaB	B-protein
activation	O
and	O
apoptosis	O
.	O
	
TRAMP	B-protein
-induced	O
cell	O
death	O
is	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
ICE-like	B-protein
proteases	I-protein
,	O
but	O
not	O
by	O
Bcl-2	B-protein
.	O
	
In	O
addition	O
,	O
TRAMP	B-protein
does	O
not	O
appear	O
to	O
interact	O
with	O
any	O
of	O
the	O
known	O
apoptosis-inducing	B-protein
ligands	I-protein
of	O
the	O
TNF	B-protein
family	I-protein
.	O
	
###MEDLINE:97131727	
	
The	O
state	O
of	O
maturation	O
of	O
monocytes	B-cell_type
into	O
macrophages	B-cell_type
determines	O
the	O
effects	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
on	O
HIV	O
replication	O
.	O
	
The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
on	O
HIV	O
infection	O
in	O
human	B-cell_type
monocytes	I-cell_type
as	O
they	O
matured	O
into	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV-1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O
	
IL-4	B-protein
and	O
IL-13	B-protein
up-regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	B-protein
Ag	I-protein
assay	O
.	O
	
Using	O
a	O
nuclear	O
run-on	O
assay	O
,	O
IL-4	B-protein
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two-	O
to	O
threefold	O
.	O
	
IL-4	B-protein
stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	B-RNA
RNA	I-RNA
expression	O
.	O
	
Conversely	O
,	O
IL-4	B-protein
and	O
IL-13	B-protein
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	B-protein
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O
	
The	O
reversal	O
from	O
stimulation	O
to	O
inhibition	O
occurred	O
after	O
3	O
to	O
5	O
days	O
of	O
adherence	O
to	O
plastic	O
.	O
	
IL-4	B-protein
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O
	
The	O
effect	O
of	O
both	O
cytokines	B-protein
on	O
the	O
monocyte	O
maturation/differentiation	O
(	O
CD11b	B-protein
,	O
CD13	B-protein
,	O
and	O
CD26	B-protein
)	O
and	O
other	O
macrophage	B-protein
markers	I-protein
(	O
CD14	B-protein
and	O
CD68	B-protein
)	O
was	O
examined	O
.	O
	
IL-4	B-protein
enhanced	O
CD11b	B-protein
,	O
but	O
inhibited	O
CD26	B-protein
expression	O
and	O
delayed	O
CD13	B-protein
loss	O
.	O
	
IL-13	B-protein
had	O
similar	O
effects	O
on	O
CD11b	B-protein
and	O
CD13	B-protein
,	O
but	O
no	O
effect	O
on	O
CD26	B-protein
.	O
	
Hence	O
,	O
these	O
cytokines	B-protein
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
translocation	O
.	O
	
###MEDLINE:99101008	
	
Mice	O
lacking	O
the	O
transcription	B-protein
factor	I-protein
CIITA	B-protein
--	O
a	O
second	O
look	O
.	O
	
We	O
have	O
generated	O
a	O
second	O
line	O
of	O
mice	O
lacking	O
a	O
transcription	B-protein
factor	I-protein
thought	O
to	O
be	O
a	O
critical	O
regulator	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
,	O
CIITA	B-protein
(	O
for	O
class	O
II	O
transactivator	B-protein
)	O
.	O
	
Our	O
and	O
the	O
previously	O
published	O
lines	O
differ	O
in	O
the	O
deletion	O
that	O
was	O
engineered	O
and	O
by	O
the	O
fact	O
that	O
we	O
removed	O
the	O
neomycin-resistance	B-DNA
promoter	I-DNA
and	O
structural	B-DNA
gene	I-DNA
via	O
the	O
cre-loxP	O
recombination	O
system	O
.	O
	
Characterization	O
of	O
our	O
line	O
led	O
to	O
two	O
new	O
findings	O
.	O
	
First	O
,	O
a	O
substantial	O
number	O
of	O
cells	O
can	O
express	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
the	O
absence	O
of	O
CIITA	B-protein
,	O
albeit	O
at	O
5-fold	O
reduced	O
levels	O
,	O
most	O
notably	O
dendritic	B-cell_type
cells	I-cell_type
in	O
s.c.	O
lymph	O
nodes	O
;	O
therefore	O
,	O
the	O
CIITA	B-DNA
gene	I-DNA
can	O
not	O
be	O
an	O
absolute	O
'	O
master	B-DNA
gene	I-DNA
'	O
controlling	O
the	O
expression	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
,	O
as	O
had	O
been	O
thought	O
.	O
	
Second	O
,	O
in	O
contrast	O
to	O
recent	O
results	O
on	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CIITA	B-protein
is	O
not	O
critically	O
involved	O
in	O
the	O
IFN-gamma	B-protein
-induced	O
up-regulation	O
of	O
MHC	B-DNA
class	I-DNA
I	I-DNA
genes	I-DNA
.	O
	
###MEDLINE:99087711	
	
Interleukin-10	B-protein
stabilizes	O
inhibitory	O
kappaB-alpha	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O
	
This	O
beneficial	O
effect	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibition	O
of	O
inflammatory	B-protein
cytokine	I-protein
production	O
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O
	
Evidence	O
suggests	O
that	O
IL-10	B-protein
may	O
inhibit	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
through	O
an	O
unknown	O
mechanism	O
.	O
	
NF-kappaB	B-protein
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	B-protein
kappaB-alpha	I-protein
(	O
IkappaB-alpha	B-protein
)	O
.	O
	
We	O
hypothesized	O
that	O
IL-10	B-protein
prevents	O
human	O
monocyte	O
NF-kappaB	B-protein
activation	O
and	O
resultant	O
TNF-alpha	B-protein
production	O
by	O
stabilization	O
of	O
IkappaB-alpha	B-protein
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
IL-10	B-protein
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
human	O
monocyte	O
TNF-alpha	B-protein
production	O
,	O
NF-kappaB	B-protein
activation	O
,	O
and	O
IkappaB-alpha	B-protein
degradation	O
.	O
	
Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O
	
Cells	O
were	O
stimulated	O
with	O
endotoxin	B-protein
(	O
LPS	O
,	O
100	O
ng/mL	O
)	O
with	O
and	O
without	O
human	O
IL-10	B-protein
(	O
10	O
ng/mL	O
)	O
.	O
	
Following	O
stimulation	O
,	O
TNF-alpha	B-protein
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF-kappaB	B-protein
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB-alpha	B-protein
levels	O
by	O
Western	O
blot	O
.	O
	
We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	B-cell_type
monocytes	I-cell_type
,	O
TNF-alpha	B-protein
increased	O
to	O
798+/-67	O
pg/mL	O
(	O
p	O
<	O
.001	O
versus	O
control	O
)	O
.	O
	
IL-10	B-protein
attenuated	O
LPS-stimulated	O
TNF-alpha	B-protein
production	O
(	O
297+/-54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O
	
After	O
LPS	O
stimulation	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
IkappaB-alpha	B-protein
protein	O
levels	O
decreased	O
,	O
and	O
NF-kappaB	B-protein
DNA	O
binding	O
increased	O
.	O
	
IL-10	B-protein
pretreatment	O
prevented	O
LPS-induced	O
decreases	O
in	O
IkappaB-alpha	B-protein
protein	O
levels	O
and	O
attenuated	O
NF-kappaB	B-protein
DNA	O
binding	O
.	O
	
IL-10	B-protein
appears	O
to	O
prevent	O
activation	O
of	O
NF-kappaB	B-protein
by	O
preserving	O
IkappaB-alpha	B-protein
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF-alpha	B-protein
release	O
.	O
	
###MEDLINE:99074319	
	
Down-regulation	O
of	O
human	O
granzyme	B-protein
B	I-protein
expression	O
by	O
glucocorticoids	O
.	O
	
Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	B-protein
and	O
AP-1	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
.	O
	
The	O
serine	B-protein
protease	I-protein
granzyme	I-protein
B	I-protein
is	O
an	O
essential	O
component	O
of	O
the	O
granule	O
exocytosis	O
pathway	O
,	O
a	O
major	O
apoptotic	O
mechanism	O
used	O
by	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
to	O
induce	O
target	O
cell	O
apoptosis	O
.	O
	
Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	B-cell_type
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	B-DNA
regions	I-DNA
including	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
Ikaros	B-DNA
binding	I-DNA
sites	I-DNA
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activation	O
.	O
	
Dexamethasone	O
,	O
a	O
glucocorticoid	O
that	O
is	O
widely	O
used	O
as	O
an	O
immunomodulatory	O
and	O
anti-inflammatory	O
agent	O
,	O
inhibits	O
granzyme	B-RNA
B	I-RNA
mRNA	I-RNA
transcript	I-RNA
in	O
phytohemagglutinin-activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
Transfection	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
-148	B-DNA
to	I-DNA
+60	I-DNA
region	I-DNA
of	O
the	O
human	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
demonstrated	O
that	O
this	O
region	O
was	O
the	O
target	O
for	O
dexamethasone	O
repression	O
.	O
	
Mutation	O
of	O
Ikaros	B-protein
or	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
context	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
demonstrated	O
that	O
both	O
sites	O
participate	O
in	O
dexamethasone-mediated	O
inhibition	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activity	O
.	O
	
Electromobility	O
shift	O
assay	O
revealed	O
that	O
dexamethasone	O
abolished	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
to	O
the	O
Ikaros	B-DNA
binding	I-DNA
site	I-DNA
and	O
reduced	O
AP-1	B-protein
binding	O
activity	O
.	O
	
These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	B-DNA
granzyme	I-DNA
B	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	B-protein
factors	I-protein
at	O
the	O
AP-1	B-DNA
and	I-DNA
Ikaros	I-DNA
sites	I-DNA
.	O
	
###MEDLINE:99064961	
	
Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
polycystic	O
ovary	O
syndrome	O
.	O
	
OBJECTIVE	O
:	O
Many	O
studies	O
have	O
suggested	O
that	O
there	O
is	O
a	O
possible	O
hormonal	O
dysregulation	O
of	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
an	O
increased	O
cortisol	O
clearance	O
in	O
patients	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O
	
Therefore	O
in	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
role	O
of	O
glucocorticoid	B-protein
receptor/s	I-protein
(	O
GR	B-protein
)	O
characteristics	O
in	O
the	O
developing	O
of	O
these	O
abnormalities	O
in	O
patients	O
with	O
PCOS	O
.	O
	
METHOD	O
:	O
For	O
this	O
purpose	O
,	O
the	O
number	O
and	O
affinity	O
of	O
GR	B-protein
in	O
peripheral	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	O
)	O
of	O
10	O
patients	O
with	O
PCOS	O
and	O
10	O
healthy	O
women	O
(	O
controls	O
)	O
were	O
determined	O
.	O
	
RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
number	O
(	O
6500+/-1001	O
sites/cell	O
and	O
6352+/-1697	O
sites/cell	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
and	O
affinity	O
(	O
3.93+/-0.89	O
nM	O
and	O
4.49+/-0.71	O
nM	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
of	O
GR	B-protein
between	O
the	O
PCOS	O
patients	O
and	O
the	O
controls	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
alterations	O
in	O
the	O
HPA	O
axis	O
and	O
in	O
the	O
cortisol	O
metabolism	O
observed	O
in	O
PCOS	O
are	O
not	O
related	O
to	O
GR	B-protein
deficiency	O
.	O
	
###MEDLINE:99057097	
	
Heterogeneous	O
expression	O
of	O
the	O
lipocalin	B-protein
NGAL	I-protein
in	O
primary	O
breast	O
cancers	O
.	O
	
We	O
have	O
previously	O
shown	O
that	O
neu	O
oncogene-initiated	O
rat	O
mammary	O
carcinomas	O
uniquely	O
over-express	O
neu-related	B-protein
lipocalin	I-protein
(	O
NRL	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
calycin	B-protein
protein	I-protein
superfamily	I-protein
.	O
	
Here	O
,	O
we	O
characterize	O
the	O
putative	B-protein
human	I-protein
homolog	I-protein
of	O
NRL	B-protein
,	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
(	O
NGAL	B-protein
)	O
.	O
	
ngal	O
gene	O
expression	O
was	O
found	O
at	O
moderate	O
levels	O
in	O
only	O
2	O
of	O
17	O
human	O
tissues	O
examined	O
,	O
breast	O
and	O
lung	O
.	O
	
When	O
breast	O
cancers	O
were	O
examined	O
for	O
NGAL	O
mRNA	O
and	O
protein	O
levels	O
,	O
they	O
were	O
found	O
to	O
exhibit	O
heterogeneous	O
expression	O
.	O
	
NGAL	B-protein
levels	O
varied	O
in	O
these	O
tumors	O
from	O
undetectable	O
to	O
exceeding	O
those	O
in	O
normal	O
breast	O
parenchyma	O
.	O
	
Immuno-histochemical	O
analysis	O
confirmed	O
the	O
presence	O
of	O
NGAL	B-protein
within	O
breast	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
but	O
detected	O
only	O
low	O
levels	O
of	O
this	O
protein	O
in	O
normal	O
ductal	O
epithelium	O
.	O
	
In	O
contrast	O
,	O
large	O
amounts	O
of	O
the	O
protein	O
were	O
localized	O
to	O
the	O
lumen	O
of	O
normal	O
breast	O
ducts	O
in	O
the	O
vicinity	O
of	O
NGAL	B-protein
-expressing	O
tumors	O
.	O
	
Interestingly	O
,	O
unlike	O
NRL	B-protein
in	O
rat	O
mammary	O
carcinomas	O
,	O
no	O
significant	O
association	O
between	O
NGAL	B-protein
expression	O
and	O
HER-2/neu	B-protein
activation	O
was	O
found	O
in	O
human	O
breast	O
tumors	O
.	O
	
In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
NGAL	B-protein
expression	O
in	O
breast	O
cancer	O
was	O
found	O
with	O
several	O
other	O
markers	O
of	O
poor	O
prognosis	O
,	O
including	O
estrogen	O
and	O
progesterone	B-protein
receptor	I-protein
-negative	O
status	O
and	O
high	O
proliferation	O
(	O
S-phase	O
fraction	O
)	O
.	O
	
NGAL	B-protein
levels	O
were	O
stratified	O
as	O
high	O
or	O
low	O
in	O
breast	O
cancers	O
from	O
a	O
cohort	O
of	O
node-positive	O
patients	O
with	O
known	O
outcome	O
.	O
	
No	O
significant	O
association	O
between	O
NGAL	B-protein
expression	O
and	O
disease-free	O
or	O
overall	O
survival	O
was	O
observed	O
.	O
	
###MEDLINE:99049801	
	
BASH	B-protein
,	O
a	O
novel	B-protein
signaling	I-protein
molecule	I-protein
preferentially	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
of	O
the	O
bursa	O
of	O
Fabricius	O
.	O
	
The	O
bursa	O
of	O
Fabricius	O
is	O
a	O
gut-associated	O
lymphoid	O
organ	O
that	O
is	O
essential	O
for	O
the	O
generation	O
of	O
a	O
diversified	O
B	B-cell_type
cell	I-cell_type
repertoire	I-cell_type
in	O
the	O
chicken	O
.	O
	
We	O
describe	O
here	O
a	O
novel	O
gene	O
preferentially	O
expressed	O
in	O
bursal	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
The	O
gene	O
encodes	O
an	O
85-kDa	B-protein
protein	I-protein
,	O
designated	O
BASH	B-protein
(	O
B	B-protein
cell	I-protein
adaptor	I-protein
containing	I-protein
SH2	I-protein
domain	I-protein
)	O
,	O
that	O
contains	O
N-terminal	B-protein
acidic	I-protein
domains	I-protein
with	O
SH2	B-protein
domain-binding	I-protein
phosphotyrosine-based	I-protein
motifs	I-protein
,	O
a	O
proline-rich	B-protein
domain	I-protein
,	O
and	O
a	O
C-terminal	B-protein
SH2	I-protein
domain	I-protein
.	O
	
BASH	B-protein
shows	O
a	O
substantial	O
sequence	O
similarity	O
to	O
SLP-76	B-protein
,	O
an	O
adaptor	O
protein	O
functioning	O
in	O
TCR	B-protein
-signal	O
transduction	O
.	O
	
BASH	B-protein
becomes	O
tyrosine-phosphorylated	O
with	O
the	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
cross-link	O
or	O
by	O
coexpression	O
with	O
Syk	B-protein
and	O
Lyn	B-protein
and	O
associates	O
with	O
signaling	B-protein
molecules	I-protein
including	O
Syk	B-protein
and	O
a	O
putative	B-protein
chicken	I-protein
Shc	I-protein
homologue	I-protein
.	O
	
Overexpression	O
of	O
BASH	B-protein
results	O
in	O
suppression	O
of	O
the	O
NF-AT	B-protein
activation	O
induced	O
by	O
BCR	B-protein
-cross-linking	O
.	O
	
These	O
findings	O
suggest	O
that	O
BASH	B-protein
is	O
involved	O
in	O
BCR	B-protein
-mediated	O
signal	O
transduction	O
and	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
development	O
in	O
the	O
bursa	O
.	O
	
###MEDLINE:99039380	
	
Granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
activates	O
a	O
72-kDa	B-protein
isoform	I-protein
of	O
STAT3	B-protein
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O
	
Granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
signaling	O
involves	O
activation	O
of	O
STATs	B-protein
,	O
proteins	O
that	O
serve	O
the	O
dual	O
function	O
of	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
.	O
	
We	O
previously	O
demonstrated	O
that	O
G-CSF	B-protein
activated	O
a	O
distinct	O
Stat3-like	B-protein
protein	I-protein
in	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
normal	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
StatG	B-protein
.	O
	
StatG	B-protein
in	O
normal	B-cell_type
immature	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
i.e	O
.	O
adult	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
was	O
composed	O
of	O
Stat3beta	B-protein
.	O
	
This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	B-protein
in	O
mature	B-cell_type
normal	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
i.e	O
.	O
polymorphonuclear	B-cell_type
neutrophilic	I-cell_type
granulocytes	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O
	
These	O
studies	O
revealed	O
that	O
the	O
major	B-protein
protein	I-protein
in	O
extracts	O
of	O
PMN	B-cell_type
activated	O
by	O
G-CSF	B-protein
to	O
bind	O
the	O
high-affinity	B-DNA
serum-inducible	I-DNA
element	I-DNA
(	O
hSIE	B-DNA
)	O
is	O
a	O
72-kDa	B-protein
protein	I-protein
that	O
cross-reacts	O
with	O
Stat3	B-protein
monoclonal	I-protein
antibody	I-protein
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	B-protein
.	O
	
Stat3gamma	B-protein
is	O
derived	O
from	O
Stat3alpha	B-protein
by	O
limited	O
proteolysis	O
and	O
lacks	O
the	O
carboxyl-terminal	B-protein
portion	I-protein
of	O
Stat3alpha	B-protein
.	O
	
Because	O
this	O
region	O
of	O
Stat3alpha	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	B-protein
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	B-protein
for	O
Stat3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
these	O
terminally	B-cell_type
differentiated	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
	
###MEDLINE:97362594	
	
Association	O
between	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
in	O
adult	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O
	
It	O
is	O
known	O
that	O
the	O
expression	O
levels	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
in	O
adult	B-cell_type
T	I-cell_type
cell	I-cell_type
leukemia	I-cell_type
(	I-cell_type
ATL	I-cell_type
)	I-cell_type
cells	I-cell_type
are	O
high	O
,	O
whereas	O
those	O
in	O
T-lymphoid	B-cell_type
cells	I-cell_type
are	O
not	O
.	O
	
In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM-1	B-protein
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM-1	B-RNA
mRNAs	I-RNA
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
provirus	O
were	O
done	O
.	O
	
The	O
levels	O
of	O
ICAM-1	B-RNA
mRNA	I-RNA
expression	O
of	O
ATL	B-cell_line
cells	I-cell_line
were	O
generally	O
higher	O
than	O
those	O
of	O
T-lymphoid	B-cell_type
cells	I-cell_type
.	O
	
However	O
,	O
ILT-mat	B-cell_line
cells	I-cell_line
and	O
ATL16T	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
although	O
they	O
were	O
ATL	B-cell_line
cells	I-cell_line
,	O
showed	O
rather	O
low	O
surface	O
ICAM-1	B-protein
expression	O
and	O
ICAM-1	B-RNA
mRNA	I-RNA
expression	O
.	O
	
Southern	O
blot	O
hybridization	O
showed	O
that	O
only	O
two	O
and	O
four	O
bands	O
were	O
found	O
in	O
ILT-mat	B-cell_line
and	O
ATL16T	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
whereas	O
>	O
10	O
bands	O
were	O
detected	O
in	O
other	O
ATL	B-cell_line
cells	I-cell_line
.	O
	
These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	B-cell_type
cell	I-cell_type
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	B-protein
molecules	I-protein
.	O
	
###MEDLINE:97196961	
	
Heat-shock	O
and	O
cadmium	O
chloride	O
increase	O
the	O
vimentin	O
mRNA	O
and	O
protein	O
levels	O
in	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O
	
Heat-shock	O
for	O
2	O
hours	O
at	O
42	O
degrees	O
C	O
,	O
or	O
the	O
administration	O
for	O
3	O
hours	O
of	O
100	O
or	O
150	O
microM	O
cadmium	O
chloride	O
,	O
inhibited	O
the	O
subsequent	B-cell_line
proliferation	I-cell_line
activity	I-cell_line
,	O
induced	O
the	O
expression	O
of	O
functional	O
differentiation	B-protein
markers	I-protein
,	O
and	O
caused	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
stress-responsive	B-protein
HSP70	I-protein
protein	I-protein
in	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
,	O
both	O
heat	O
and	O
cadmium	O
produced	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
intermediate	B-protein
filament	I-protein
protein	I-protein
vimentin	B-protein
,	O
as	O
determined	O
by	O
immunoblot	O
and	O
immunofluorescence	O
assays	O
.	O
	
By	O
contrast	O
,	O
the	O
amounts	O
of	O
actin	B-protein
and	O
beta-tubulin	B-protein
were	O
not	O
significantly	O
altered	O
.	O
	
The	O
amount	O
of	O
vimentin	B-RNA
mRNA	I-RNA
was	O
also	O
increased	O
during	O
recovery	O
from	O
stress	O
,	O
indicating	O
that	O
vimentin	B-protein
expression	O
was	O
not	O
exclusively	O
regulated	O
at	O
the	O
protein	O
level	O
.	O
	
Although	O
cadmium	O
caused	O
an	O
early	O
,	O
transient	O
stimulation	O
of	O
c-jun	B-DNA
and	O
c-fos	B-DNA
expression	O
and	O
AP-1	B-protein
binding	O
activity	O
,	O
heat-shock	O
failed	O
to	O
alter	O
both	O
protooncogene	B-DNA
expression	O
and	O
transcription	O
factor	O
binding	O
,	O
indicating	O
that	O
the	O
stress-induced	O
vimentin	B-protein
increase	O
was	O
not	O
the	O
result	O
of	O
AP-1	B-protein
-mediated	O
transcriptional	O
activation	O
.	O
	
Finally	O
,	O
it	O
was	O
observed	O
that	O
the	O
rate	O
of	O
decay	O
of	O
vimentin	B-RNA
mRNA	I-RNA
upon	O
actinomycin	O
D	O
administration	O
was	O
decreased	O
in	O
heat-	B-cell_line
and	I-cell_line
cadmium-pretreated	I-cell_line
cells	I-cell_line
in	O
comparison	O
to	O
untreated	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
indicate	O
that	O
stress	O
treatments	O
cause	O
an	O
increase	O
in	O
vimentin	B-protein
levels	O
in	O
promonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
may	O
be	O
explained	O
at	O
least	O
in	O
part	O
by	O
transcript	O
stabilization	O
.	O
	
###MEDLINE:99321124	
	
Ovarian	O
and	O
breast	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
can	O
recognize	O
peptides	O
from	O
the	O
amino	O
enhancer	O
of	O
split	O
protein	O
of	O
the	O
Notch	B-protein
complex	I-protein
.	O
	
In	O
this	O
study	O
we	O
investigated	O
recognition	O
by	O
ovarian	B-cell_type
tumor	I-cell_type
associated	I-cell_type
lymphocyte	I-cell_type
(	O
OVTAL	B-cell_type
)	O
,	O
and	O
breast	B-cell_type
tumor	I-cell_type
associated	I-cell_type
lymphocytes	I-cell_type
(	O
BRTAL	B-cell_type
)	O
,	O
of	O
peptides	O
corresponding	O
to	O
the	O
sequence	O
125-135	B-protein
of	I-protein
the	I-protein
Aminoenhancer	I-protein
of	I-protein
split	I-protein
(	I-protein
AES	I-protein
)	I-protein
protein	I-protein
.	O
	
Three	O
of	O
these	O
peptides	O
designated	O
as	O
G75	O
:	O
AES1/2	O
(	O
128-135	B-protein
)	O
,	O
G60	O
:	O
AES1/2	O
(	O
127-137	B-protein
)	O
and	O
G61	O
:	O
AES1/2	O
(	O
125-133	B-protein
)	O
correspond	O
to	O
the	O
wildtype	B-DNA
AES	I-DNA
sequence	I-DNA
,	O
while	O
the	O
fourth	O
G76	O
:	O
GPLTPLPV	O
,	O
AES1/2	B-protein
(	I-protein
128-135	I-protein
)	I-protein
corresponds	O
to	O
a	O
variant	O
sequence	O
of	O
the	O
peptide	O
G75	O
with	O
the	O
N-terminal	O
Leu	O
substituted	O
to	O
glycine	O
.	O
	
These	O
sequences	O
were	O
chosen	O
for	O
study	O
because	O
mass-spectrometric	O
analysis	O
(	O
MS	O
)	O
of	O
a	O
CTL	B-cell_type
active	O
HPLC	O
peptide	O
fraction	O
eluted	O
from	O
immunoaffinity	B-protein
precipitated	I-protein
HLA-A2	I-protein
molecule	I-protein
,	O
revealed	O
:	O
(	O
a	O
)	O
the	O
presence	O
of	O
an	O
ion	O
with	O
a	O
mass-to-charge	O
ratio	O
(	O
m/z	O
)	O
of	O
793	O
which	O
was	O
more	O
abundant	O
than	O
other	O
ions	O
of	O
similar	O
masses	O
;	O
(	O
b	O
)	O
the	O
tentatively	O
reconstituted	O
sequence	O
of	O
the	O
ion	O
793	O
matched	O
the	O
sequence	O
of	O
peptide	O
G76	O
.	O
	
We	O
found	O
that	O
AES	O
peptides	O
G75	O
(	O
128-135	B-protein
)	O
and	O
G76	O
(	O
128-135	B-protein
)	O
(	O
L128G	O
)	O
reconstituted	O
CTL	O
recognition	O
at	O
concentrations	O
ranging	O
between	O
200-500	O
nM	O
.	O
	
These	O
concentrations	O
are	O
lower	O
than	O
concentrations	O
reported	O
to	O
activate	O
effector	O
function	O
of	O
CTL	O
recognizing	O
other	O
epithelial	B-protein
tumor	I-protein
Ag	I-protein
.	O
	
Furthermore	O
,	O
analysis	O
with	O
cloned	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
indicated	O
that	O
G75	O
and	O
G76	O
were	O
not	O
cross-reactive	O
specificities	O
,	O
suggesting	O
a	O
key	O
role	O
for	O
the	O
N-terminal	B-protein
residues	I-protein
of	O
the	O
variant	O
peptide	O
in	O
dictating	O
specificities	O
.	O
	
Since	O
the	O
AES	B-protein
proteins	I-protein
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	B-DNA
of	I-DNA
split	I-DNA
[	I-DNA
E	I-DNA
(	I-DNA
spl	I-DNA
)	I-DNA
]	I-DNA
genes	I-DNA
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B-protein
receptors	I-protein
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self-antigens	B-protein
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B-protein
Ag	I-protein
in	O
epithelial	O
cancers	O
.	O
	
###MEDLINE:99098435	
	
Induction	O
of	O
the	O
pro-myelocytic	B-DNA
leukaemia	I-DNA
gene	I-DNA
by	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
interferons	I-protein
.	O
	
The	O
physiological	O
role	O
of	O
the	O
pro-myelocytic	B-protein
leukaemia	I-protein
(	I-protein
PML	I-protein
)	I-protein
gene	I-protein
product	I-protein
is	O
poorly	O
defined	O
.	O
	
Among	O
other	O
functions	O
,	O
PML	B-DNA
is	O
involved	O
in	O
haematopoietic	O
differentiation	O
and	O
in	O
control	O
of	O
cell	O
growth	O
and	O
tumorigenesis	O
.	O
	
We	O
investigated	O
the	O
regulation	O
of	O
human	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
(	O
IFNs	B-protein
)	O
and	O
IL-1	B-protein
in	O
various	O
human	B-cell_line
haematopoietic	I-cell_line
lines	I-cell_line
(	O
U937	B-cell_line
,	O
THP1	B-cell_line
,	O
HL60	B-cell_line
,	O
NB4	B-cell_line
)	O
,	O
in	O
human	B-cell_type
diploid	I-cell_type
fibroblasts	I-cell_type
and	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
leukocytes	I-cell_type
.	O
	
Cytokine-induced	O
modulation	O
of	O
PML	B-DNA
expression	O
was	O
assessed	O
by	O
Northern	O
blot	O
analyses	O
,	O
flow	O
cytometry	O
studies	O
and	O
in	O
situ	O
immunolabelling	O
.	O
	
Our	O
data	O
show	O
that	O
IFNs	B-protein
and	O
IL-1	B-protein
upregulate	O
PML	O
transcript	O
and	O
protein	O
expression	O
in	O
a	O
time	O
and	O
dose-dependent	O
manner	O
.	O
	
In	O
situ	O
immunolabelling	O
revealed	O
that	O
upregulation	O
of	O
protein	O
expression	O
by	O
IFN-alpha	B-protein
is	O
a	O
consequence	O
of	O
a	O
marked	O
increase	O
in	O
both	O
the	O
number	O
and	O
the	O
intensity	O
of	O
the	O
staining	O
of	O
so-called	O
PML	B-protein
nuclear	I-protein
bodies	I-protein
.	O
	
Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
and	O
IL-1	B-protein
may	O
account	O
for	O
upregulation	O
of	O
PML	B-protein
proteins	I-protein
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O
	
###MEDLINE:99086128	
	
The	O
position	O
of	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
does	O
not	O
influence	O
its	O
biological	O
activity	O
.	O
	
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
human	O
herpesvirus	O
which	O
latently	O
infects	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
EBV	O
encodes	O
a	O
unique	O
transcriptional	O
activator	O
,	O
known	O
as	O
ZEBRA	B-protein
,	O
which	O
can	O
disrupt	O
viral	O
latency	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
induce	O
lytic	O
viral	O
replication	O
.	O
	
Furthermore	O
,	O
ZEBRA	B-protein
has	O
been	O
shown	O
to	O
bind	O
at	O
the	O
EBV	O
origin	O
of	O
lytic	O
replication	O
,	O
and	O
is	O
necessary	O
for	O
viral	O
DNA	O
replication	O
to	O
occur	O
.	O
	
Previously	O
we	O
demonstrated	O
that	O
heterologous	B-protein
activation	I-protein
domains	I-protein
can	O
fully	O
substitute	O
for	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
.	O
	
Here	O
we	O
extend	O
those	O
results	O
by	O
showing	O
that	O
the	O
position	O
of	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
or	O
a	O
heterologous	O
replacement	O
domain	O
does	O
not	O
influence	O
its	O
ability	O
to	O
function	O
in	O
the	O
disruption	O
of	O
EBV	O
latency	O
.	O
	
In	O
this	O
study	O
three	O
novel	O
clones	O
were	O
constructed	O
in	O
which	O
the	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
repositioned	O
to	O
the	O
carboxy	B-protein
terminus	I-protein
of	O
the	O
protein	O
.	O
	
These	O
mutants	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
ability	O
of	O
ZEBRA	B-protein
's	I-protein
wild	I-protein
type	I-protein
domain	I-protein
to	O
function	O
in	O
the	O
complex	O
biological	O
process	O
of	O
virus	O
activation	O
is	O
not	O
compromised	O
by	O
altering	O
its	O
position	O
within	O
the	O
protein	O
.	O
	
###MEDLINE:99071844	
	
The	O
modulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
3-O-methyl-D-glucose	O
transport	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocyte	I-cell_type
in	O
obesity	O
.	O
	
Glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
and	O
3-O-methyl-D	O
glucose	O
(	O
3-O-MG	O
)	O
transport	O
were	O
determined	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
from	O
11	O
abdominal	O
obese	O
subjects	O
,	O
10	O
pituitary-dependent	O
Cushing	O
's	O
syndrome	O
(	O
Cushing	O
's	O
disease	O
)	O
and	O
10	O
healthy	O
controls	O
.	O
	
Using	O
a	O
whole-cell	O
competitive	O
binding	O
assay	O
and	O
3H-dexamethasone	O
as	O
tracer	O
,	O
MNL	B-cell_type
of	O
abdominal	O
obese	O
subjects	O
were	O
found	O
to	O
have	O
4855	O
+/-	O
1389	O
sites/cell	O
which	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
than	O
controls	O
(	O
6234	O
+/-	O
1568	O
sites/cell	O
)	O
,	O
although	O
no	O
significant	O
difference	O
was	O
found	O
in	O
the	O
mean	O
serum	O
cortisol	O
level	O
.	O
	
Their	O
mean	O
Kd	O
(	O
affinity	O
)	O
was	O
also	O
significantly	O
lower	O
than	O
that	O
found	O
in	O
the	O
healthy	O
controls	O
(	O
obese	O
Kd	O
:	O
2.92	O
+/-	O
0.84	O
nmol/l	O
,	O
control	O
Kd	O
:	O
4.55	O
+/-	O
0.67	O
nM	O
,	O
p	O
<	O
0.05	O
)	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
the	O
receptor	O
characteristics	O
in	O
Cushing	O
's	O
disease	O
patients	O
were	O
within	O
the	O
normal	O
range	O
.	O
	
At	O
the	O
same	O
time	O
,	O
3-O-MG	O
transport	O
was	O
determined	O
in	O
the	O
same	O
subjects	O
.	O
	
In	O
Cushing	O
's	O
disease	O
,	O
3-O-MG	O
transport	O
was	O
within	O
the	O
normal	O
range	O
,	O
whereas	O
in	O
abdominal	O
obesity	O
this	O
value	O
was	O
significantly	O
lower	O
than	O
the	O
healthy	O
controls	O
(	O
abdominal	O
obese	O
:	O
31.90	O
+/-	O
8.20	O
;	O
control	O
:	O
46.26	O
+/-	O
12.91	O
fmol/10	O
(	O
6	O
)	O
cell	O
,	O
min	O
,	O
p	O
<	O
0.05	O
)	O
.	O
	
We	O
also	O
found	O
a	O
positive	O
correlation	O
between	O
3-O-MG	O
transport	O
and	O
GR	B-protein
binding	O
capacity	O
in	O
abdominal	O
subjects	O
(	O
r	O
=	O
0.89	O
,	O
p	O
<	O
0.001	O
)	O
,	O
however	O
we	O
did	O
not	O
find	O
such	O
a	O
correlation	O
in	O
Cushing	O
's	O
disease	O
(	O
r	O
=	O
0.60	O
,	O
p	O
>	O
0.05	O
)	O
.	O
	
These	O
results	O
indicated	O
that	O
,	O
in	O
abdominal	O
obesity	O
,	O
the	O
GR	B-protein
binding	O
capacity	O
in	O
MNL	B-cell_type
is	O
influenced	O
by	O
the	O
changes	O
in	O
glucose	O
transport	O
.	O
	
###MEDLINE:99065678	
	
Interleukin-10	B-protein
and	O
transforming	B-DNA
growth	I-DNA
factor-beta	I-DNA
promoter	I-DNA
polymorphisms	I-DNA
in	O
allergies	O
and	O
asthma	O
.	O
	
Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
(	O
TGF-beta	B-protein
)	O
are	O
inhibitory	O
for	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
IgE	B-protein
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	B-cell_type
.	O
	
These	O
cytokines	B-protein
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O
	
We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL-10	B-DNA
and	I-DNA
TGF-beta	I-DNA
gene	I-DNA
promoters	I-DNA
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O
	
DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single-stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O
	
We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
IL-10	B-DNA
gene	I-DNA
and	O
four	O
in	O
the	O
TGF-beta	B-DNA
gene	I-DNA
promoters	I-DNA
(	O
3	O
in	O
TGF-beta1	B-DNA
and	O
1	O
in	O
TGF-beta2	B-DNA
)	O
.	O
	
The	O
IL-10	B-protein
gene	O
polymorphism	O
was	O
a	O
C-to-A	O
exchange	O
571	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
and	O
was	O
present	O
between	O
consensus	B-DNA
binding	I-DNA
sequences	I-DNA
for	O
Sp1	B-protein
and	O
elevated	O
total	O
serum	O
.	O
	
This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	B-protein
serum	I-protein
IgE	I-protein
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0.009	O
)	O
.	O
	
The	O
base	O
exchange	O
at	O
-509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF-beta	B-DNA
promoter	I-DNA
also	O
linked	O
to	O
elevated	O
total	O
IgE	B-protein
(	O
p	O
<	O
0.01	O
)	O
.	O
	
This	O
polymorphism	O
represented	O
a	O
C-to-T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	B-DNA
consensus	I-DNA
sequence	I-DNA
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O
	
###MEDLINE:99054659	
	
Tpl-2	B-protein
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	B-protein
and	O
NF-kappaB	B-protein
.	O
	
The	O
Tpl-2	B-protein
kinase	I-protein
activates	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
and	O
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
.	O
	
Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
is	O
inhibited	O
by	O
mutant	B-protein
signaling	I-protein
molecules	I-protein
that	O
inhibit	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
or	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B-protein
molecules	I-protein
that	O
activate	O
these	O
pathways	O
.	O
	
We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B-protein
and	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
.	O
	
The	O
activation	O
of	O
both	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	B-protein
.	O
	
However	O
,	O
it	O
was	O
only	O
the	O
IL-2	B-DNA
promoter	I-DNA
whose	O
activation	O
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
MEK1S218/222A	I-protein
and	O
the	O
MEK1/MEK2	O
inhibitor	O
PD098059	O
.	O
	
Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O
	
In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	B-protein
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	B-protein
-dependent	O
.	O
	
Experiments	O
in	O
COS-1	B-cell_line
and	O
EL-4	B-cell_line
cells	I-cell_line
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B-protein
is	O
NF-kappaB	B-protein
.	O
	
While	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
NFAT	B-protein
delta418	I-protein
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	B-protein
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	B-protein
-mediated	O
NFAT	B-protein
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O
	
Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	B-protein
or	O
Bcl-X	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O
	
###MEDLINE:99048705	
	
Differential	O
activation	O
of	O
functionally	O
distinct	O
STAT5	B-protein
proteins	I-protein
by	O
IL-5	B-protein
and	O
GM-CSF	B-protein
during	O
eosinophil	O
and	O
neutrophil	O
differentiation	O
from	O
human	B-cell_line
CD34+	I-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O
	
Interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
and	O
granulocyte	B-protein
macrophage-colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
are	O
important	O
cytokines	B-protein
for	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
myeloid	B-cell_type
lineages	I-cell_type
.	O
	
The	O
JAK	B-protein
/STAT	B-protein
pathway	O
is	O
one	O
of	O
the	O
signaling	O
pathways	O
implicated	O
in	O
mediating	O
biological	O
responses	O
induced	O
by	O
these	O
cytokines	B-protein
.	O
	
Previous	O
studies	O
have	O
demonstrated	O
that	O
these	O
cytokines	B-protein
predominantly	O
activate	O
an	O
80	B-protein
kDa	I-protein
STAT5	I-protein
isoform	I-protein
in	O
mature	O
granulocytes	O
.	O
	
To	O
better	O
understand	O
the	O
role	O
of	O
STAT	O
proteins	O
during	O
growth	O
and	O
differentiation	O
of	O
granulocytes	O
,	O
we	O
evaluated	O
differentiation	O
of	O
human	B-cell_line
CD34+	I-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
ex	O
vivo	O
toward	O
eosinophils	B-cell_type
and	O
neutrophils	O
.	O
	
Bandshift	O
experiments	O
showed	O
that	O
in	O
an	O
early	O
stage	O
of	O
both	O
differentiation	O
pathways	O
(	O
14	O
days	O
)	O
,	O
the	O
94	O
kDa	O
STAT5B	B-protein
protein	I-protein
was	O
activated	O
by	O
both	O
IL-5	B-protein
(	O
eosinophil	B-cell_type
lineage	I-cell_type
)	O
and	O
GM-CSF	B-protein
(	O
neutrophil	B-cell_type
lineage	I-cell_type
)	O
.	O
	
However	O
,	O
during	O
maturation	O
of	O
both	O
lineages	O
(	O
days	O
21	O
and	O
28	O
)	O
,	O
increased	O
expression	O
of	O
a	O
functionally	O
distinct	O
80	B-protein
kDa	I-protein
STAT5	I-protein
isoform	I-protein
was	O
observed	O
,	O
resulting	O
in	O
heterodimer	B-protein
DNA-binding	I-protein
complexes	I-protein
containing	O
both	O
the	O
94	O
and	O
80	O
kDa	O
STAT5	B-protein
proteins	I-protein
.	O
	
The	O
finding	O
that	O
functionally	O
distinct	O
isoforms	O
of	O
STAT5	B-protein
are	O
activated	O
during	O
the	O
early	O
and	O
late	O
differentiation	O
stages	O
of	O
granulocytes	O
suggests	O
that	O
they	O
might	O
be	O
involved	O
in	O
regulating	O
different	O
biological	O
functions	O
in	O
these	O
cells	O
.	O
	
###MEDLINE:99038208	
	
The	O
T-cell	B-protein
oncogenic	I-protein
protein	I-protein
HOX11	I-protein
activates	O
Aldh1	B-protein
expression	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
but	O
represses	O
its	O
expression	O
in	O
mouse	O
spleen	O
development	O
.	O
	
Hox11	B-DNA
is	O
a	O
homeobox	B-DNA
gene	I-DNA
essential	O
for	O
spleen	O
formation	O
in	O
mice	O
,	O
since	O
atrophy	O
of	O
the	O
anlage	O
of	O
a	O
developing	O
spleen	O
occurs	O
in	O
early	O
embryonic	O
development	O
in	O
Hox11	O
	O
mice	O
.	O
	
HOX11	B-protein
is	O
also	O
expressed	O
in	O
a	O
subset	O
of	O
T-cell	O
acute	O
leukemias	O
after	O
specific	O
chromosomal	O
translocations	O
.	O
	
Since	O
the	O
protein	O
has	O
a	O
homeodomain	B-DNA
and	O
can	O
activate	O
transcription	O
,	O
it	O
probably	O
exerts	O
at	O
least	O
some	O
of	O
its	O
effects	O
in	O
vivo	O
by	O
regulation	O
of	O
target	B-DNA
genes	I-DNA
.	O
	
Representational	O
difference	O
analysis	O
has	O
been	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	I-DNA
corresponding	O
to	O
mRNA	B-RNA
species	I-RNA
activated	O
following	O
stable	O
expression	O
of	O
HOX11	B-protein
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
.	O
	
The	O
gene	O
encoding	O
the	O
retinoic	B-protein
acid-synthesizing	I-protein
enzyme	I-protein
aldehyde	B-protein
dehydrogenase	I-protein
1	I-protein
(	O
Aldh1	B-protein
)	O
,	O
initially	O
called	O
Hdg-1	B-protein
,	O
was	O
found	O
to	O
be	O
ectopically	O
activated	O
by	O
HOX11	B-protein
in	O
this	O
system	O
.	O
	
Study	O
of	O
Aldh1	B-protein
gene	O
expression	O
during	O
spleen	O
development	O
showed	O
that	O
the	O
presence	O
of	O
Aldh1	B-RNA
mRNA	I-RNA
inversely	O
correlated	O
with	O
Hox11	B-protein
.	O
	
Hox11	B-protein
	O
mouse	O
embryos	O
have	O
elevated	O
Aldh1	B-RNA
mRNA	I-RNA
in	O
spleen	O
primordia	O
prior	O
to	O
atrophy	O
,	O
while	O
Aldh1	B-protein
seems	O
to	O
be	O
repressed	O
by	O
Hox11	B-protein
during	O
organogenesis	O
of	O
the	O
spleens	O
of	O
wild-type	O
mice	O
.	O
	
This	O
result	O
suggests	O
that	O
expression	O
of	O
Aldh1	B-protein
protein	I-protein
is	O
negatively	O
regulated	O
by	O
Hox11	B-protein
and	O
that	O
abnormal	O
expression	O
of	O
Aldh1	B-protein
in	O
Hox11	B-protein
	O
mice	O
may	O
cause	O
loss	O
of	O
splenic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
by	O
aberrant	O
retinoic	O
acid	O
metabolism	O
	
###MEDLINE:97364688	
	
Role	O
of	O
the	O
X2	B-DNA
box	I-DNA
in	O
activated	O
transcription	O
from	O
the	O
DRA	B-DNA
promoter	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	B-DNA
box	I-DNA
in	O
the	O
promoter	B-DNA
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
from	O
the	O
human	B-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
in	O
resting	O
and	O
activated	O
B	B-cell_type
cells	I-cell_type
.	O
	
NF-X2	B-DNA
,	O
which	O
contains	O
members	O
of	O
the	O
AP-1/ATF/CREB	B-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
interacts	O
with	O
the	O
X2	B-DNA
box	I-DNA
(	O
5'-TGCGTCA-3	O
'	O
)	O
from	O
positions	O
-97	O
to	O
-91	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
.	O
	
In	O
resting	O
Raji	B-cell_line
cells	I-cell_line
,	O
little	O
to	O
no	O
binding	O
to	O
the	O
X2	B-DNA
box	I-DNA
was	O
observed	O
.	O
	
In	O
sharp	O
contrast	O
,	O
in	O
B	B-cell_type
cells	I-cell_type
treated	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	B-DNA
box	I-DNA
and	O
NF-X2	B-DNA
containing	O
c-Fos	B-protein
were	O
observed	O
.	O
	
As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild-type	O
DRA	B-DNA
promoter	I-DNA
but	O
not	O
from	O
a	O
DRA	B-DNA
promoter	I-DNA
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	B-DNA
box	I-DNA
.	O
	
Since	O
the	O
co-expression	O
with	O
a	O
dominant	O
negative	O
c-Fos	B-protein
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	B-DNA
gene	I-DNA
depends	O
on	O
interactions	O
between	O
the	O
X2	B-DNA
box	I-DNA
and	O
NF-X2	B-DNA
,	O
which	O
contains	O
c-Fos	B-protein
.	O
	
###MEDLINE:97196870	
	
Thymocytes	O
control	O
the	O
CD4	B-DNA
gene	I-DNA
differently	O
from	O
mature	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	B-DNA
,	O
the	O
promoter	B-DNA
and	O
the	O
silencer	B-DNA
of	O
the	O
human	B-DNA
CD4	I-DNA
gene	I-DNA
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O
	
Immunofluorescence	O
studies	O
on	O
thymic	B-cell_type
populations	I-cell_type
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	B-DNA
DNA	I-DNA
elements	I-DNA
revealed	O
that	O
thymocytes	B-cell_type
control	O
the	O
CD4	B-DNA
gene	I-DNA
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
5'-positive	B-DNA
regulatory	I-DNA
unit	I-DNA
,	O
consisting	O
of	O
the	O
promoter	B-DNA
and	O
the	O
5	B-DNA
'	I-DNA
enhancer	I-DNA
,	O
is	O
already	O
active	O
at	O
the	O
CD4	B-protein
-	O
CD8	B-protein
-double-negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O
	
However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double-positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4+	B-cell_type
CD8int/-	I-cell_type
cell	I-cell_type
population	I-cell_type
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	B-DNA
or	I-DNA
the	I-DNA
third	I-DNA
intron	I-DNA
of	O
the	O
CD4	B-DNA
gene	I-DNA
,	O
is	O
required	O
for	O
CD4	B-DNA
gene	I-DNA
expression	O
in	O
this	O
population	O
.	O
	
The	O
other	O
studied	O
regulatory	B-DNA
element	I-DNA
is	O
the	O
minimal	B-DNA
CD4	I-DNA
silencer	I-DNA
which	O
inhibits	O
CD4	B-DNA
gene	I-DNA
expression	O
in	O
peripheral	B-cell_type
CD8	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	B-cell_type
DN	I-cell_type
thymocytes	I-cell_type
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down-regulate	O
CD4	B-DNA
gene	I-DNA
expression	O
.	O
	
Unexpectedly	O
,	O
the	O
CD4	B-DNA
silencer	I-DNA
is	O
also	O
active	O
in	O
CD4+	B-cell_type
CD8int/-	I-cell_type
cells	I-cell_type
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti-silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	B-protein
expression	O
in	O
this	O
cell	O
population	O
.	O
	
Altogether	O
,	O
the	O
CD4	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O
	
###MEDLINE:99201818	
	
[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O
	
Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti-inflammatory	O
,	O
immunosuppressive	O
or	O
anti-tumoral	O
agents	O
.	O
	
Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O
	
In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	B-protein
receptor	I-protein
belonging	O
to	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O
	
Once	O
activated	O
,	O
the	O
GR	B-protein
,	O
can	O
mediate	O
his	O
effects	O
through	O
direct	O
binding	O
on	O
the	O
DNA	O
or	O
via	O
protein/protein	O
interactions	O
with	O
transcription	B-protein
factors	I-protein
.	O
	
Depending	O
on	O
the	O
type	O
of	O
lymphocytes	B-cell_type
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
``	O
death	O
genes	O
''	O
by	O
the	O
activated	O
GR	B-protein
(	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
c-jun	B-protein
)	O
or	O
repression	O
of	O
survival	B-protein
factors	I-protein
(	O
AP-1	B-protein
,	O
c-Myc	B-protein
)	O
.	O
	
In	O
the	O
case	O
of	O
thymic	O
selection	O
the	O
mechanism	O
is	O
more	O
subtle	O
depending	O
on	O
the	O
mutual	O
repression	O
of	O
Nur77	B-protein
and	O
GR	B-protein
.	O
	
###MEDLINE:99096304	
	
Direct	O
suppression	O
of	O
Stat1	B-protein
function	O
during	O
adenoviral	O
infection	O
.	O
	
The	O
action	O
of	O
adenoviral	B-protein
E1A	I-protein
oncoprotein	I-protein
on	O
host	B-DNA
immune-response	I-DNA
genes	I-DNA
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300/CBP-type	B-protein
transcriptional	I-protein
coactivators	I-protein
in	O
competition	O
with	O
endogenous	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
.	O
	
However	O
,	O
we	O
show	O
that	O
mutant	O
forms	O
of	O
E1A	B-protein
that	O
no	O
longer	O
bind	O
p300/CBP	B-protein
can	O
still	O
interact	O
directly	O
with	O
Stat1	B-protein
(	O
via	O
E1A	B-protein
N-terminal	I-protein
and	I-protein
Stat1	I-protein
C-terminal	I-protein
residues	I-protein
)	O
and	O
block	O
IFNgamma-driven	O
,	O
Stat1	B-protein
-dependent	O
gene	O
activation	O
and	O
consequent	O
function	O
during	O
early-phase	O
infection	O
in	O
the	O
natural	B-cell_type
host	I-cell_type
cell	I-cell_type
.	O
	
The	O
results	O
provide	O
a	O
distinct	O
and	O
more	O
specific	O
mechanism	O
for	O
E1A	B-protein
-mediated	O
immune	O
suppression	O
and	O
an	O
alternative	O
model	O
of	O
IFNgamma	B-protein
-driven	O
enhanceosome	O
formation	O
that	O
may	O
allow	O
for	O
other	O
adaptors	O
(	O
in	O
addition	O
to	O
p300/CBP	B-protein
)	O
to	O
link	O
Stat1	B-protein
to	O
the	O
basal	B-protein
transcription	I-protein
complex	I-protein
.	O
	
###MEDLINE:99083144	
	
Effect	O
of	O
environmental	O
estrogens	O
on	O
IL-1beta	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Environmental	O
estrogens	O
or	O
estrogen	O
disrupters	O
have	O
recently	O
received	O
a	O
great	O
deal	O
of	O
attention	O
because	O
of	O
their	O
potential	O
health	O
impact	O
on	O
reproductive	O
tissues	O
.	O
	
Few	O
,	O
if	O
any	O
,	O
studies	O
have	O
been	O
made	O
on	O
the	O
impact	O
of	O
these	O
compounds	O
on	O
the	O
immune	O
system	O
.	O
	
We	O
sought	O
to	O
determine	O
the	O
activities	O
of	O
various	O
environmental	O
estrogens	O
on	O
the	O
modulation	O
of	O
the	O
interleukin-1beta	B-DNA
(	I-DNA
IL-1beta	I-DNA
)	I-DNA
gene	I-DNA
in	O
a	O
model	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
hER	B-cell_line
+	I-cell_line
IL-1beta-CAT+	I-cell_line
.	O
	
This	O
cell	O
line	O
stably	O
transfected	O
with	O
the	O
human	B-protein
estrogen	I-protein
receptor	I-protein
,	O
and	O
an	O
IL-1beta	B-DNA
promoter	I-DNA
construct	O
fused	O
to	O
the	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
allows	O
us	O
to	O
monitor	O
the	O
effect	O
of	O
estrogenic	O
compounds	O
on	O
IL-1beta	B-DNA
promoter	I-DNA
activity	O
.	O
	
17beta-estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL-1beta	B-DNA
promoter	I-DNA
-driven	O
CAT	B-protein
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
The	O
mycotoxins	O
alpha-zearalenol	O
and	O
zearalenone	O
both	O
exhibited	O
full	O
agonist	O
activity	O
,	O
but	O
at	O
lower	O
potencies	O
,	O
with	O
EC50	O
values	O
of	O
1.8	O
and	O
54	O
nM	O
,	O
respectively	O
,	O
compared	O
with	O
E2	O
at	O
0.5	O
nM	O
.	O
	
In	O
addition	O
,	O
genistein	O
was	O
a	O
very	O
low-potency	O
agonist	O
,	O
having	O
an	O
EC50	O
of	O
1.5	O
microM	O
.	O
	
Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O
	
The	O
activity	O
of	O
the	O
mycotoxins	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
estrogen	O
receptor	O
,	O
since	O
both	O
the	O
antiestrogens	O
H1285	O
and	O
ICI	O
182	O
,	O
780	O
effectively	O
inhibited	O
their	O
agonist	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
Representative	O
environmental	O
estrogenic	O
compounds	O
both	O
from	O
plant	O
and	O
industrial	O
sources	O
were	O
also	O
tested	O
.	O
	
Unlike	O
the	O
mycoestrogens	O
,	O
none	O
of	O
the	O
compounds	O
,	O
with	O
the	O
exception	O
of	O
genistein	O
,	O
synergized	O
with	O
LPS	O
to	O
enhance	O
IL-1beta	B-DNA
promoter	I-DNA
activity	O
.	O
	
When	O
tested	O
for	O
antiestrogenic	O
activity	O
,	O
the	O
industrial	O
compound	O
4-octylphenol	O
was	O
able	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
;	O
however	O
,	O
the	O
response	O
was	O
three	O
orders	O
of	O
magnitude	O
less	O
potent	O
than	O
H	O
1285	O
.	O
	
Naringenin	O
,	O
a	O
plant	O
flavonoid	O
,	O
showed	O
little	O
or	O
no	O
ability	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
.	O
	
Overall	O
,	O
the	O
results	O
show	O
that	O
some	O
environmental	O
estrogens	O
that	O
display	O
agonist	O
activity	O
in	O
reproductive	O
tissue	O
also	O
have	O
an	O
effect	O
on	O
IL-1	B-DNA
gene	I-DNA
expression	O
in	O
hemopoietic-derived	O
tissue	O
.	O
	
###MEDLINE:99070073	
	
Isolation	O
and	O
utilization	O
of	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
from	O
peripheral	O
blood	O
to	O
assay	O
an	O
in	O
vitro	O
primary	O
immune	O
response	O
to	O
varicella-zoster	O
virus	O
peptides	O
.	O
	
A	O
human	O
dendritic	O
cell-based	O
assay	O
used	O
to	O
monitor	O
a	O
T	O
cell	O
proliferation	O
response	O
to	O
viral	O
peptides	O
in	O
vitro	O
is	O
described	O
.	O
	
Dendritic	B-cell_type
cells	I-cell_type
and	O
autologous	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
a	O
series	O
of	O
density-gradient	O
centrifugations	O
or	O
magnetic	O
bead	O
separations	O
(	O
or	O
both	O
)	O
.	O
	
Peptides	O
corresponding	O
to	O
residues	O
of	O
the	O
immediate	B-protein
early	I-protein
protein	I-protein
,	O
IE62	B-protein
,	O
of	O
varicella-zoster	O
virus	O
(	O
VZV	O
)	O
were	O
used	O
as	O
stimulating	B-protein
antigens	I-protein
,	O
and	O
persons	O
with	O
no	O
history	O
of	O
varicella	O
and	O
no	O
humoral	O
or	O
cellular	O
immunity	O
to	O
VZV	O
served	O
as	O
naive	O
donors	O
for	O
the	O
assays	O
.	O
	
Three	O
VZV-susceptible	O
donors	O
were	O
tested	O
,	O
and	O
all	O
demonstrated	O
an	O
in	O
vitro	O
response	O
to	O
multiple	O
VZV	O
peptides	O
.	O
	
This	O
assay	O
has	O
potential	O
as	O
a	O
screen	O
to	O
establish	O
the	O
immunogenicity	O
of	O
viral	O
antigens	O
in	O
vitro	O
using	O
T	B-cell_type
cells	I-cell_type
from	O
naive	O
donors	O
.	O
	
###MEDLINE:98168578	
	
Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O
	
Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O
	
Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	B-protein
natural	I-protein
antibodies	I-protein
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O
	
Porcine	B-cell_line
aortic	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
PAEC	B-cell_line
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	B-cell_type
leukocytes	I-cell_type
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dynes/cm2	O
)	O
.	O
	
Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O
	
Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	B-cell_type
leukocytes	I-cell_type
as	O
compared	O
with	O
porcine	O
serum	O
.	O
	
A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U/ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	B-cell_type
cell	I-cell_type
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O
	
In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	B-cell_type
cell	I-cell_type
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	B-protein
molecules	I-protein
and	O
chemoattractants	B-protein
.	O
	
By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF-kappa	B-protein
B	I-protein
(	O
p65	B-protein
subunit	I-protein
)	O
in	O
the	O
nuclei	O
of	O
PAEC	B-cell_line
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
this	O
setting	O
.	O
	
At	O
variance	O
,	O
in	O
PAEC	B-cell_line
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF-kappa	B-protein
B	I-protein
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O
	
Treatment	O
of	O
PAEC	B-cell_line
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl-phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	B-cell_line
treated	O
with	O
human	O
serum	O
alone	O
.	O
	
Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte-endothelium	O
interaction	O
possibly	O
through	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O
	
###MEDLINE:99057586	
	
Anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
induce	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
	
The	O
anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O
	
In	O
this	O
study	O
the	O
capability	O
of	O
C5a	B-protein
and	O
C3a	B-protein
to	O
induce	O
transcription	O
factor	O
activation	O
was	O
examined	O
.	O
	
C5a	B-protein
and	O
C3a	B-protein
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	B-DNA
sequence	I-DNA
.	O
	
The	O
p50	B-protein
and	I-protein
p65	I-protein
proteins	I-protein
,	O
constituents	O
of	O
the	O
prototypic	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
,	O
were	O
identified	O
as	O
components	O
of	O
the	O
DNA-protein	O
complexes	O
by	O
anti-peptide	B-protein
antibodies	I-protein
in	O
gel	O
supershift	O
assays	O
.	O
	
C5a	B-protein
induced	O
kappaB	B-protein
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30-40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O
	
Binding	O
to	O
kappaB	B-DNA
sequence	I-DNA
was	O
accompanied	O
by	O
an	O
initial	O
decrease	O
and	O
subsequent	O
increase	O
in	O
the	O
cytoplasmic	O
IkappaBalpha	B-protein
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti-IkappaBalpha	B-protein
antibody	I-protein
.	O
	
Pertussis	O
toxin	O
treatment	O
markedly	O
decreased	O
kappaB	B-protein
binding	O
activities	O
induced	O
by	O
both	O
C5a	B-protein
and	O
C3a	B-protein
,	O
whereas	O
cholera	B-protein
toxin	I-protein
displayed	O
no	O
inhibitory	O
effect	O
.	O
	
Neither	O
of	O
the	O
two	O
toxins	O
affected	O
kappaB	B-protein
binding	O
activity	O
induced	O
by	O
TNFalpha	B-protein
in	O
the	O
same	O
cells	O
.	O
	
These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein-coupled	O
transcription	O
factor	O
activation	O
.	O
	
###MEDLINE:99047055	
	
Thrombopoietin	B-protein
and	O
its	O
receptor	O
.	O
	
Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
,	O
the	O
primary	O
physiological	O
regulator	O
of	O
platelet	O
production	O
,	O
was	O
initially	O
thought	O
to	O
be	O
a	O
lineage-specific	O
factor	O
acting	O
predominantly	O
on	O
megakaryocytopoiesis	O
.	O
	
Detailed	O
studies	O
establish	O
that	O
this	O
cytokine	O
mediates	O
biological	O
effects	O
on	O
a	O
broad	O
spectrum	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
,	O
including	O
stem	B-cell_type
cells	I-cell_type
.	O
	
TPO	B-protein
is	O
a	O
hormone	O
constitutively	O
produced	O
mainly	O
by	O
the	O
liver	O
and	O
kidney	O
.	O
	
Plasma	O
TPO	B-protein
levels	O
are	O
regulated	O
by	O
the	O
platelet	O
and	O
megakaryocyte	O
mass	O
through	O
Mpl	B-protein
receptor	I-protein
binding	O
,	O
internalization	O
and	O
degradation	O
.	O
	
The	O
Mpl	B-protein
receptor	I-protein
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
lacking	O
intrinsic	O
kinase	O
activity	O
.	O
	
Upon	O
ligand-induced	O
Mpl	O
homodimerization	O
,	O
the	O
major	O
signaling	O
events	O
for	O
proliferation	O
are	O
mediated	O
through	O
the	O
JAK2	B-protein
/STAT5	B-protein
pathway	O
,	O
while	O
differentiation	O
might	O
occur	O
through	O
a	O
prolonged	O
activation	O
of	O
the	O
MAPK	B-protein
pathway	O
.	O
	
Preclinical	O
and	O
clinical	O
studies	O
demonstrate	O
the	O
potential	O
use	O
of	O
TPO	B-protein
in	O
a	O
variety	O
of	O
contexts	O
,	O
but	O
it	O
is	O
too	O
early	O
to	O
evaluate	O
its	O
benefit	O
in	O
reducing	O
platelet	O
transfusion	O
.	O
	
###MEDLINE:99038200	
	
TAL1	B-protein
and	O
LIM-only	B-protein
proteins	I-protein
synergistically	O
induce	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
expression	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	B-protein
.	O
	
Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	B-protein
and	O
the	O
LIM-only	B-DNA
protein	I-DNA
gene	I-DNA
(	O
LMO	B-DNA
)	O
are	O
regularly	O
coactivated	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
.	O
	
This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	B-protein
and	O
LMO	B-protein
are	O
highly	O
synergistic	O
in	O
T-cell	O
tumorigenesis	O
in	O
double-transgenic	O
mice	O
.	O
	
To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	B-protein
and	O
LMO	B-protein
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	B-DNA
target	I-DNA
genes	I-DNA
regulated	O
by	O
TAL1	B-protein
and	O
LMO	B-protein
by	O
a	O
subtractive	O
PCR	O
method	O
.	O
	
One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
(	O
RALDH2	B-protein
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T-ALL	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
coexpressed	O
TAL1	B-protein
and	O
LMO	B-protein
.	O
	
Exogenously	O
transfected	O
TAL1	B-protein
and	O
LMO	B-protein
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	B-protein
expression	O
in	O
a	O
T-ALL	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HPB-ALL	B-cell_line
,	O
not	O
expressing	O
endogeneous	O
TAL1	B-protein
or	O
LMO	B-protein
.	O
	
The	O
RALDH2	B-RNA
transcripts	I-RNA
in	O
T-ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	B-RNA
intron	I-RNA
.	O
	
Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	B-DNA
site	I-DNA
in	O
a	O
cryptic	B-DNA
promoter	I-DNA
in	O
the	O
second	B-DNA
intron	I-DNA
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1-	O
and	O
LMO-dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	B-protein
binds	O
to	O
this	O
site	O
.	O
	
In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	B-protein
potentiated	O
the	O
induction	O
of	O
RALDH2	B-protein
by	O
TAL1	B-protein
and	O
LMO	B-protein
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O
	
Furthermore	O
,	O
a	O
TAL1	B-protein
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	B-protein
in	O
the	O
presence	O
of	O
LMO	B-protein
and	O
GATA3	B-protein
.	O
	
Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	B-DNA
gene	I-DNA
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	B-DNA
target	I-DNA
genes	I-DNA
regulated	O
by	O
TAL1	B-protein
and	O
LMO	B-protein
in	O
T-ALL	O
.	O
	
In	O
this	O
case	O
,	O
TAL1	B-protein
and	O
LMO	B-protein
act	O
as	O
cofactors	O
for	O
GATA3	B-protein
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	B-protein
	
###MEDLINE:97360262	
	
Glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
relation	O
to	O
age	O
and	O
to	O
sport	O
activity	O
.	O
	
Glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
are	O
ubiquitous	O
molecules	O
and	O
are	O
present	O
also	O
in	O
the	O
hippocampus	O
and	O
in	O
several	O
other	O
nervous	O
and	O
immune	O
tissues	O
.	O
	
Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
are	O
a	O
good	O
model	O
for	O
studies	O
of	O
GR	B-protein
in	O
humans	O
.	O
	
Glucocorticoids	O
are	O
important	O
for	O
maintaining	O
cellular	O
and	O
humoral	O
homeostasis	O
and	O
are	O
key	O
mediators	O
of	O
neuroendocrine-immune	O
regulatory	O
interactions	O
.	O
	
The	O
increase	O
of	O
cortisol	O
is	O
immunosuppressive	O
and	O
reduces	O
GR	B-protein
concentration	O
both	O
in	O
nervous	O
and	O
immune	O
systems	O
.	O
	
Variation	O
of	O
glucocorticoids	O
in	O
healthy	O
aged	O
subjects	O
and	O
athletes	O
has	O
been	O
shown	O
.	O
	
Prompted	O
by	O
these	O
results	O
,	O
we	O
have	O
investigated	O
in	O
man	O
a	O
possible	O
relationship	O
between	O
GR	B-protein
binding	O
capacity	O
in	O
the	O
PBMCs	B-cell_type
and	O
age	O
,	O
in	O
relation	O
also	O
to	O
plasma	O
testosterone	O
and	O
cortisol	O
.	O
	
The	O
same	O
parameters	O
have	O
been	O
examined	O
in	O
a	O
group	O
of	O
soccer	O
players	O
for	O
comparison	O
with	O
the	O
sedentary	O
group	O
.	O
	
GR	B-protein
binding	O
capacity	O
was	O
higher	O
in	O
younger	O
subjects	O
than	O
in	O
older	O
ones	O
,	O
and	O
lower	O
in	O
the	O
group	O
of	O
athletes	O
than	O
in	O
the	O
younger	O
and	O
older	O
sedentary	O
subjects	O
.	O
	
In	O
the	O
sedentary	O
group	O
a	O
negative	O
correlation	O
was	O
present	O
between	O
GR	B-protein
binding	O
capacity	O
and	O
age	O
.	O
	
Plasma	O
cortisol	O
was	O
higher	O
and	O
testosterone	O
lower	O
in	O
the	O
athletes	O
;	O
they	O
were	O
negatively	O
correlated	O
in	O
athletes	O
and	O
positively	O
correlated	O
in	O
the	O
sedentary	O
subjects	O
.	O
	
The	O
results	O
for	O
athletes	O
agree	O
with	O
their	O
lower	O
anabolic/catabolic	O
balance	O
.	O
	
The	O
mechanism	O
of	O
reduced	O
GR	B-protein
levels	O
in	O
relation	O
to	O
age	O
and	O
sport	O
activity	O
could	O
involve	O
a	O
loss	O
or	O
an	O
involution	O
of	O
receptor	O
synthesis	O
.	O
	
However	O
other	O
possibilities	O
,	O
such	O
as	O
altered	O
distribution	O
of	O
lymphocyte	O
subpopulations	O
with	O
different	O
receptor	O
concentrations	O
and	O
with	O
different	O
cytokine	B-protein
production	O
,	O
can	O
not	O
be	O
excluded	O
.	O
	
Several	O
neuroendocrine-immune	O
interactions	O
could	O
be	O
responsible	O
for	O
reduced	O
GR	B-protein
levels	O
with	O
age	O
and	O
sport	O
activity	O
in	O
man	O
.	O
	
###MEDLINE:97148782	
	
Glycation-dependent	O
,	O
reactive	O
oxygen	O
species-mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	B-cell_type
cells	I-cell_type
.	O
	
Prolonged	O
poor	O
glycemic	O
control	O
in	O
non-insulin-dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	O
secretion	O
from	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O
	
As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so-called	O
glucose	O
toxicity	O
to	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
we	O
induced	O
glycation	O
in	O
HIT-T15	B-cell_type
cells	I-cell_type
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D-ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O
	
The	O
results	O
of	O
reporter	B-DNA
gene	I-DNA
analyses	O
revealed	O
that	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	I-DNA
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta-actin	B-DNA
gene	I-DNA
promoter	I-DNA
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	I-DNA
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D-ribose	O
,	O
respectively	O
.	O
	
In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	B-RNA
mRNA	I-RNA
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation-induced	B-cell_type
cells	I-cell_type
.	O
	
Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA-binding	O
activity	O
of	O
an	O
insulin	B-protein
gene	I-protein
transcription	I-protein
factor	I-protein
,	O
PDX-1/IPF1/STF-1	B-protein
.	O
	
These	O
effects	O
of	O
D-ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N-acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O
	
These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O
	
###MEDLINE:99169427	
	
Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O
	
OBJECTIVE	O
:	O
The	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
distinctive	O
patterns	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
are	O
seen	O
in	O
different	O
forms	O
of	O
joint	O
disease	O
.	O
	
METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	B-protein
was	O
examined	O
in	O
purified	O
synovial	B-cell_type
and	I-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O
	
RESULTS	O
:	O
Electrophoretic	O
mobility	O
shift	O
assays	O
disclosed	O
two	O
specific	O
complexes	O
bound	O
to	O
a	O
NF-kappa	B-protein
B	I-protein
specific	O
32P-labelled	O
oligonucleotide	O
in	O
nucleoproteins	B-protein
extracted	O
from	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
synovial	O
fluid	O
and	O
peripheral	O
blood	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O
	
The	O
complexes	B-protein
consisted	O
of	O
p50/p50	B-protein
homodimers	I-protein
and	O
p50/p65	O
heterodimers	O
.	O
	
Increased	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
DNA	O
in	O
synovial	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
observed	O
relative	O
to	O
peripheral	O
T	O
cells	O
.	O
	
In	O
non-rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
synovial	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
exclusively	O
mediated	O
by	O
p50/p50	B-protein
homodimers	I-protein
.	O
	
CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O
	
The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
that	O
in	O
other	O
forms	O
of	O
non-rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O
	
###MEDLINE:99097163	
	
X	B-DNA
chromosome	I-DNA
inactivation	O
patterns	O
in	O
normal	O
females	O
.	O
	
Since	O
one	O
of	O
the	O
two	O
X	B-DNA
chromosomes	I-DNA
is	O
randomly	O
inactivated	O
at	O
an	O
early	O
stage	O
of	O
female	O
embryonic	O
development	O
,	O
X-linked	B-protein
markers	I-protein
have	O
been	O
used	O
to	O
study	O
the	O
origin	O
and	O
development	O
of	O
various	O
neoplastic	O
disorders	O
in	O
affected	O
heterozygous	O
women	O
;	O
clonality	O
assays	O
have	O
provided	O
a	O
useful	O
tool	O
to	O
the	O
understanding	O
of	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
neoplasia	O
.	O
	
Recently	O
,	O
a	O
technique	O
of	O
clonal	O
analysis	O
has	O
been	O
devised	O
that	O
takes	O
advantage	O
of	O
a	O
highly	O
polymorphic	O
short	B-DNA
tandem	I-DNA
repeat	I-DNA
within	O
the	O
X-linked	B-DNA
human	I-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
gene	I-DNA
,	O
resulting	O
in	O
a	O
heterozygosity	O
rate	O
approaching	O
90	O
%	O
.	O
	
The	O
rapid	O
expansion	O
of	O
the	O
number	O
of	O
women	O
now	O
suitable	O
for	O
X	O
inactivation	O
analysis	O
has	O
however	O
given	O
rise	O
to	O
new	O
controversies	O
,	O
one	O
of	O
the	O
more	O
troublesome	O
being	O
the	O
possibility	O
of	O
a	O
modification	O
of	O
the	O
pattern	O
of	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
in	O
blood	B-cell_type
cells	I-cell_type
of	O
elderly	O
women	O
.	O
	
In	O
the	O
present	O
study	O
we	O
analyze	O
with	O
the	O
AR	O
assay	O
a	O
group	O
of	O
166	O
healthy	O
females	O
aged	O
between	O
8	O
and	O
94	O
years	O
,	O
with	O
no	O
history	O
of	O
genetic	O
or	O
neoplastic	O
familial	O
disorders	O
.	O
	
We	O
failed	O
to	O
find	O
any	O
correlation	O
between	O
age	O
and	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
(	O
r	O
=	O
0.17	O
)	O
,	O
even	O
subdividing	O
the	O
subjects	O
in	O
different	O
age	O
groups	O
according	O
to	O
the	O
criteria	O
used	O
by	O
other	O
researchers	O
,	O
and	O
therefore	O
reaffirm	O
that	O
,	O
when	O
tested	O
for	O
with	O
well-standardized	O
and	O
accurate	O
criteria	O
,	O
extremely	O
unbalanced	O
inactivation	O
of	O
the	O
X	B-DNA
chromosome	I-DNA
is	O
a	O
truly	O
uncommon	O
phenomenon	O
in	O
normal	O
women	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99077519	
	
The	O
role	O
of	O
Stat4	B-protein
in	O
species-specific	O
regulation	O
of	O
Th	O
cell	O
development	O
by	O
type	B-protein
I	I-protein
IFNs	I-protein
.	O
	
Type	B-protein
I	I-protein
IFNs	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
,	O
in	O
addition	O
to	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	B-cell_type
cells	I-cell_type
.	O
	
We	O
show	O
here	O
that	O
IFN-alpha/beta	B-protein
act	O
directly	O
on	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
drive	O
Th1	O
development	O
,	O
bypassing	O
the	O
need	O
for	O
IL-12	B-protein
-induced	O
signaling	O
,	O
whereas	O
IFN-alpha	B-protein
can	O
not	O
substitute	O
IL-12	B-protein
for	O
mouse	O
Th1	O
development	O
.	O
	
The	O
molecular	O
basis	O
for	O
this	O
species	O
specificity	O
is	O
that	O
IFN-alpha/beta	B-protein
activate	O
Stat4	B-protein
in	O
differentiating	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	B-cell_type
cells	I-cell_type
.	O
	
Unlike	O
IL-12	B-protein
,	O
which	O
acts	O
only	O
on	O
Th1	B-cell_type
cells	I-cell_type
,	O
IFN-alpha/beta	B-protein
can	O
activate	O
Stat4	B-protein
not	O
only	O
in	O
human	B-cell_type
Th1	I-cell_type
,	O
but	O
also	O
in	O
Th2	B-cell_type
cells	I-cell_type
.	O
	
However	O
,	O
restimulation	O
of	O
human	B-cell_line
Th2	I-cell_line
lines	I-cell_line
and	O
clones	O
in	O
the	O
presence	O
of	O
IFN-alpha	B-protein
does	O
not	O
induce	O
the	O
production	O
of	O
IFN-gamma	B-protein
.	O
	
These	O
results	O
suggest	O
that	O
activation	O
of	O
Stat4	B-protein
,	O
which	O
is	O
necessary	O
for	O
the	O
differentiation	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
into	O
polarized	O
Th1	B-cell_type
cells	I-cell_type
,	O
is	O
not	O
sufficient	O
to	O
induce	O
phenotype	O
reversal	O
of	O
human	B-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:99070060	
	
Molecular	O
cloning	O
of	O
FKHRL1P2	B-protein
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	B-protein
head	I-protein
domain	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O
	
Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	B-protein
head	I-protein
domain	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
.	O
	
We	O
cloned	O
and	O
characterized	O
a	O
fork	B-DNA
head	I-DNA
cDNA	I-DNA
from	O
human	B-RNA
T	I-RNA
helper	I-RNA
cell	I-RNA
mRNA	I-RNA
using	O
differential	O
display	O
RT-PCR	O
.	O
	
The	O
cDNA	O
contains	O
a	O
546-nucleotide	B-DNA
(	I-DNA
nt	I-DNA
)	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
(	O
ORF	B-DNA
)	O
that	O
codes	O
for	O
the	O
carboxyl-terminal	B-protein
180	I-protein
amino	I-protein
acids	I-protein
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	B-DNA
gene	I-DNA
.	O
	
This	O
ORF	B-DNA
does	O
not	O
contain	O
the	O
characteristic	O
DNA-binding	B-DNA
domain	I-DNA
found	O
in	O
members	O
of	O
the	O
forkhead	B-protein
protein	I-protein
family	I-protein
.	O
	
In-vitro	O
transcription/translation	O
of	O
this	O
cDNA	B-DNA
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O
	
We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in-vitro-translated	B-protein
20-kDa	I-protein
protein	I-protein
.	O
	
This	O
antibody	O
also	O
recognizes	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
a	O
70-kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	B-DNA
gene	I-DNA
product	O
.	O
	
The	O
mRNA	O
levels	O
for	O
fkhrl1	B-DNA
is	O
elevated	O
in	O
T	B-cell_type
helper-induced	I-cell_type
lymphocytes	I-cell_type
in	O
comparison	O
to	O
PHA-stimulated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Further	O
characterization	O
of	O
FKHRL1	B-DNA
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	B-DNA
head	I-DNA
gene	I-DNA
subfamily	I-DNA
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O
	
###MEDLINE:99060929	
	
Inhibition	O
of	O
Th1	O
development	O
mediated	O
by	O
GATA-3	B-protein
through	O
an	O
IL-4-independent	O
mechanism	O
.	O
	
Recently	O
,	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	B-protein
was	O
shown	O
to	O
be	O
selectively	O
expressed	O
in	O
Th2	O
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
to	O
augment	O
Th2-specific	B-protein
cytokines	I-protein
.	O
	
Here	O
,	O
we	O
show	O
that	O
loss	O
of	O
GATA-3	B-protein
expression	O
by	O
developing	O
Th1	B-cell_type
cells	I-cell_type
requires	O
IL-12	B-protein
signaling	O
through	O
Stat4	B-protein
and	O
does	O
not	O
simply	O
result	O
from	O
an	O
absence	O
of	O
IL-4	B-protein
.	O
	
Moreover	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
GATA-3	B-protein
in	O
directly	O
repressing	O
Th1	O
development	O
distinct	O
from	O
its	O
positive	O
actions	O
on	O
Th2-specific	B-protein
cytokines	I-protein
.	O
	
GATA-3	B-protein
inhibits	O
Th1	B-protein
cytokines	I-protein
by	O
a	O
cell-intrinsic	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
IL-4	B-protein
and	O
that	O
may	O
involve	O
repression	O
of	O
IL-12	B-protein
signaling	O
.	O
	
Thus	O
,	O
GATA-3	B-protein
expression	O
and	O
IL-12	B-protein
signaling	O
are	O
mutually	O
antagonistic	O
,	O
which	O
facilitates	O
rapid	O
dominance	O
of	O
one	O
pathway	O
during	O
early	O
Th	O
development	O
,	O
producing	O
a	O
stable	O
divergence	O
in	O
cytokine	B-protein
profiles	O
.	O
	
###MEDLINE:99058080	
	
Conserved	B-DNA
elements	I-DNA
containing	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
GATA	I-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
erythroid-specific	O
chromatin	O
structure	O
reorganization	O
within	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O
	
Proper	O
expression	O
of	O
the	O
genes	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
locus	I-DNA
requires	O
the	O
associated	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
.	O
	
Structurally	O
,	O
the	O
LCR	B-DNA
is	O
defined	O
by	O
the	O
presence	O
of	O
four	O
domains	O
of	O
erythroid-specific	O
chromatin	O
structure	O
.	O
	
These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HSs	B-DNA
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	B-DNA
.	O
	
The	O
major	O
focus	O
of	O
this	O
research	O
is	O
to	O
define	O
the	O
cis	B-DNA
-acting	I-DNA
elements	I-DNA
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
these	O
domains	O
of	O
unique	O
chromatin	O
structure	O
.	O
	
Our	O
previous	O
investigations	O
on	O
the	O
formation	O
of	O
LCR	B-DNA
HS4	I-DNA
demonstrated	O
that	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
,	I-DNA
inverted	I-DNA
GATA	I-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
native	B-DNA
HS	I-DNA
.	O
	
Similarly	O
arranged	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
GATA	I-DNA
sites	I-DNA
are	O
present	O
within	O
the	O
core	B-DNA
regions	I-DNA
of	O
the	O
other	O
human	B-DNA
LCR	I-DNA
HSs	I-DNA
and	O
are	O
evolutionarily	O
conserved	O
.	O
	
Using	O
site-directed	O
mutagenesis	O
of	O
human	B-DNA
HSs	I-DNA
2	I-DNA
and	I-DNA
3	I-DNA
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
these	O
NF-E2	B-DNA
and	I-DNA
GATA	I-DNA
sites	I-DNA
are	O
common	O
requirements	O
for	O
the	O
formation	O
of	O
all	O
LCR	B-DNA
HSs	I-DNA
.	O
	
We	O
find	O
that	O
mutation	O
of	O
these	O
elements	O
,	O
and	O
particularly	O
the	O
GATA	B-DNA
elements	I-DNA
,	O
results	O
in	O
a	O
decrease	O
or	O
complete	O
loss	O
of	O
DNase	B-protein
I	I-protein
hypersensitivity	O
.	O
	
These	O
data	O
imply	O
the	O
presence	O
of	O
common	O
structural	O
elements	O
within	O
the	O
core	O
of	O
each	O
LCR	B-DNA
HS	I-DNA
which	O
are	O
required	O
for	O
erythroid-specific	O
chromatin	O
structure	O
reorganization	O
.	O
	
###MEDLINE:99047534	
	
Cloning	O
of	O
ARE-containing	B-DNA
genes	I-DNA
by	O
AU-motif-directed	O
display	O
.	O
	
A	O
procedure	O
suitable	O
for	O
cloning	B-RNA
labile	I-RNA
mRNAs	I-RNA
that	O
contain	O
AU	O
motifs	O
is	O
presented	O
(	O
AU-DD	O
)	O
.	O
	
These	O
motifs	O
are	O
regulatory	B-DNA
sequences	I-DNA
within	O
the	O
so-called	O
AU-rich	B-DNA
elements	I-DNA
(	O
AREs	B-DNA
)	O
often	O
found	O
in	O
3	B-DNA
'	I-DNA
untranslated	I-DNA
regions	I-DNA
of	O
genes	O
such	O
as	O
cytokines	B-protein
,	O
proto-oncogenes	B-DNA
,	O
and	O
transcription	B-protein
factors	I-protein
.	O
	
AU-DD	B-DNA
is	O
an	O
AU-motif-directed	B-DNA
differential	I-DNA
display	I-DNA
that	O
permits	O
the	O
identification	O
of	O
ARE-containing	B-DNA
genes	I-DNA
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O
	
It	O
has	O
been	O
applied	O
to	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
a	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
to	O
isolate	O
59	B-DNA
cDNA	I-DNA
fragments	I-DNA
associated	O
to	O
activation	O
.	O
	
Fourteen	O
percent	O
of	O
isolated	O
fragments	O
belong	O
to	O
already	O
known	O
genes	O
that	O
certainly	O
are	O
cytokines	B-protein
and	O
transduction/transcription	B-protein
factors	I-protein
.	O
	
The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	B-DNA
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O
	
These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	B-DNA
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99034460	
	
Transcription	O
factor	O
NF-kappaB	B-protein
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O
	
Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O
	
To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O
	
The	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O
	
This	O
review	O
discusses	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
in	O
general	O
and	O
the	O
association	O
of	O
NF-kappaB	B-protein
activation	O
with	O
cellular/molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O
	
###MEDLINE:97358652	
	
Expression	O
of	O
transcription	B-protein
factors	I-protein
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O
	
During	O
15	O
days	O
of	O
treatment	O
of	O
K562	B-cell_line
cells	I-cell_line
with	O
sodium	O
phenylacetate	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cellular	O
hemoglobin	B-protein
concentration	O
with	O
a	O
similar	O
increase	O
in	O
the	O
expression	O
of	O
gamma-globin	B-RNA
mRNA	I-RNA
.	O
	
Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O
	
At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	B-protein
surface	I-protein
antigenes	I-protein
CD33	B-protein
,	O
CD34	B-protein
,	O
CD45	B-protein
,	O
CD71	B-protein
and	O
glycophorin	B-protein
A	I-protein
.	O
	
Likewise	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
NF-E2	B-protein
,	O
SCL	B-protein
and	O
RBTN2	B-protein
,	O
all	O
expressed	O
in	O
untreated	O
K562	B-cell_line
cells	I-cell_line
,	O
did	O
not	O
increase	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
.	O
	
The	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
Evi-1	B-protein
and	O
c-myb	B-protein
,	O
known	O
to	O
inhibit	O
erythroid	O
differentiation	O
,	O
did	O
not	O
decrease	O
.	O
	
We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	B-cell_line
cells	I-cell_line
increases	O
gamma-globin	B-RNA
mRNA	I-RNA
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta-like	B-DNA
globin	I-DNA
genes	I-DNA
.	O
	
###MEDLINE:97155934	
	
Isolation	O
of	O
a	O
B-cell-specific	B-DNA
promoter	I-DNA
for	O
the	O
human	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
.	O
	
The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
is	O
essential	O
for	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
.	O
	
The	O
tissular	O
patterns	O
of	O
CIITA	O
and	O
MHC	O
class	O
II	O
gene	O
expression	O
are	O
tightly	O
correlated	O
:	O
CIITA	B-RNA
mRNA	I-RNA
is	O
highly	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
is	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
in	O
macrophage	B-cell_line
and	I-cell_line
epithelial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
We	O
first	O
isolated	O
two	O
overlapping	O
cosmids	B-DNA
encoding	O
human	B-protein
CIITA	I-protein
which	O
,	O
when	O
co-transfected	O
,	O
are	O
able	O
to	O
restore	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
in	O
a	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
B-LCL	B-cell_line
)	O
defective	O
for	O
CIITA	B-protein
.	O
	
Subsequently	O
,	O
a	O
1.8	B-DNA
kilobase	I-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
fragment	I-DNA
of	O
the	O
CIITA	B-DNA
promoter	I-DNA
was	O
isolated	O
and	O
sequenced	O
.	O
	
A	O
motif	O
presenting	O
a	O
strong	O
similarity	O
to	O
an	O
initiator	O
was	O
detected	O
,	O
as	O
well	O
as	O
putative	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
GATA-2	B-protein
,	O
LyF-1	B-protein
,	O
ets-1	B-protein
,	O
AP1	B-protein
,	O
and	O
MZF1	B-protein
transcription	B-protein
factors	I-protein
,	O
and	O
two	O
GAS	B-DNA
motifs	I-DNA
.	O
	
When	O
introduced	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
this	O
promoter	O
is	O
able	O
to	O
direct	O
a	O
high	O
luciferase	B-protein
activity	O
in	O
a	O
human	B-cell_line
B-LCL	I-cell_line
.	O
	
In	O
contrast	O
,	O
luciferase	B-protein
expression	O
was	O
not	O
stimulated	O
after	O
IFN-gamma	B-protein
treatment	O
when	O
the	O
construct	O
was	O
transfected	O
in	O
macrophage	O
or	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
However	O
,	O
an	O
induction	O
of	O
the	O
human	B-DNA
CIITA	I-DNA
gene	I-DNA
was	O
observed	O
in	O
mouse	B-cell_line
macrophage	I-cell_line
and	I-cell_line
fibrosarcoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
when	O
the	O
cells	O
were	O
transfected	O
with	O
a	O
cosmid	B-DNA
containing	O
the	O
human	B-DNA
CIITA	I-DNA
gene	I-DNA
,	O
but	O
lacking	O
the	O
1.8	B-DNA
kb	I-DNA
promoter	I-DNA
described	O
above	O
.	O
	
Taken	O
together	O
,	O
these	O
data	O
suggest	O
the	O
existence	O
of	O
an	O
intragenic	O
promoter	O
driving	O
an	O
IFN-gamma	B-protein
-inducible	O
expression	O
of	O
CIITA	B-protein
.	O
	
###MEDLINE:99149869	
	
Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	B-cell_type
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O
	
The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O
	
These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	B-cell_type
populations	I-cell_type
,	O
steroid	B-protein
hormone	I-protein
receptor	I-protein
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B-protein
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O
	
Significantly	O
increased	O
oestrogen	B-protein
receptor	I-protein
expression	O
,	O
bcl-2	B-protein
expression	O
and	O
numbers	O
of	O
CD8+	O
leukocytes	B-cell_type
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O
	
Apoptotic	B-cell_type
cells	I-cell_type
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O
	
In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	B-protein
hormone	I-protein
receptor	I-protein
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B-protein
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O
	
The	O
unusual	O
CD56+	B-cell_type
CD16-	I-cell_type
eGLs	I-cell_type
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O
	
Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	B-cell_type
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	B-cell_type
from	O
non-pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56+	B-cell_type
CD16+	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
eGLs	B-cell_type
from	O
non-pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U/ml	O
interleukin-2	B-protein
over	O
48-h	O
and	O
120-h	O
time	O
courses	O
.	O
	
eGLs	B-cell_type
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O
	
Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD+8	B-cell_type
T-cell	I-cell_type
numbers	O
and	O
increased	O
oestrogen	B-protein
receptor	I-protein
and	O
bcl-2	B-protein
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O
	
###MEDLINE:99097447	
	
Regulation	O
of	O
interleukin-1beta	B-protein
transcription	O
by	O
Epstein-Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	B-protein
proteins	I-protein
via	O
their	O
interaction	O
with	O
RBP	B-protein
.	O
	
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	B-cell_type
cells	I-cell_type
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCLs	B-cell_line
)	O
.	O
	
Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
is	O
expressed	O
in	O
LCLs	B-cell_line
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	B-protein
proteins	I-protein
on	O
the	O
expression	O
of	O
IL-1beta	B-protein
.	O
	
Using	O
RT-PCR	O
,	O
IL-1beta	B-protein
was	O
shown	O
to	O
be	O
up-regulated	O
in	O
EBV-transformed	B-cell_line
LCLs	I-cell_line
as	O
well	O
as	O
in	O
group	B-cell_line
III	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
BL	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
compared	O
with	O
group	B-cell_line
I	I-cell_line
BL	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
up-regulation	O
of	O
IL-1beta	B-protein
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
,	O
EBV	B-DNA
nuclear	I-DNA
proteins	I-DNA
2	I-DNA
,	I-DNA
3	I-DNA
,	I-DNA
4	I-DNA
,	I-DNA
and	I-DNA
6	I-DNA
genes	I-DNA
.	O
	
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-300	O
region	O
of	O
the	O
IL-1beta	B-protein
promoter	O
,	O
which	O
contains	O
a	O
nuclear	B-DNA
factor-kappaB	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
,	O
contained	O
a	O
functional	B-DNA
RBP	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B-protein
nuclear	I-protein
proteins	I-protein
3	I-protein
and	I-protein
6	I-protein
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	B-protein
from	O
its	O
recognition	B-DNA
sequence	I-DNA
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O
	
In	O
group	B-cell_line
I	I-cell_line
BL	I-cell_line
cells	I-cell_line
,	O
containing	O
low	O
levels	O
of	O
NF-kappaB	B-protein
,	O
only	O
RBP	B-protein
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF-kappaB	B-protein
binding	O
could	O
be	O
demonstrated	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
high	O
levels	O
of	O
activated	O
NF-kappaB	B-protein
.	O
	
In	O
addition	O
,	O
the	O
expression	O
of	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
led	O
to	O
activation	O
of	O
NF-kappaB	B-protein
that	O
was	O
capable	O
of	O
binding	O
the	O
IL-1beta	B-DNA
promoter	I-DNA
.	O
	
The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up-regulate	O
IL-1beta	B-protein
expression	O
,	O
possibly	O
by	O
using	O
RBP	B-protein
,	O
NF-kappaB	B-protein
,	O
or	O
both	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99077509	
	
CD27	B-protein
/CD70	O
interaction	O
augments	O
IgE	B-protein
secretion	O
by	O
promoting	O
the	O
differentiation	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
into	O
plasma	B-cell_type
cells	I-cell_type
.	O
	
The	O
induction	O
of	O
IgE	B-protein
switching	O
in	O
B	B-cell_type
cells	I-cell_type
requires	O
several	O
signals	O
given	O
by	O
cytokines	B-protein
and	O
cell	O
contact-delivered	O
signals	O
.	O
	
Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	B-protein
/CD70	O
interaction	O
in	O
B	O
cell	O
IgE	B-protein
synthesis	O
.	O
	
The	O
addition	O
of	O
CD27	O
ligand	O
(	O
CD70	O
)	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
increased	O
the	O
IgE	B-protein
synthesis	O
synergistically	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
plus	O
anti-CD40	B-protein
mAb	I-protein
(	O
anti-CD40	B-protein
)	O
.	O
	
The	O
effect	O
of	O
CD70	B-cell_line
transfectants	I-cell_line
was	O
dose	O
dependent	O
and	O
was	O
completely	O
blocked	O
by	O
anti-CD70	B-protein
mAb	I-protein
.	I-protein
	
CD27+	B-cell_type
B	I-cell_type
cells	I-cell_type
had	O
the	O
ability	O
to	O
produce	O
IgE	B-protein
,	O
which	O
was	O
increased	O
by	O
contact	O
with	O
CD70	O
transfectants	O
,	O
whereas	O
CD27-	O
B	O
cells	O
did	O
not	O
produce	O
IgE	B-protein
.	O
	
CD27	B-protein
/CD70	O
interaction	O
enhanced	O
B	B-cell_type
cell	I-cell_type
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
or	O
IL-4	B-protein
plus	O
anti-CD40	B-protein
.	O
	
The	O
augmentation	O
of	O
B	O
cell	O
proliferation	O
by	O
CD70	O
transfectants	O
was	O
apparent	O
in	O
CD27+	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
was	O
mild	O
in	O
CD27-	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
The	O
helper	O
activity	O
for	O
IgE	B-protein
synthesis	O
by	O
the	O
CD27	B-protein
/CD70	O
interaction	O
did	O
not	O
contribute	O
to	O
the	O
enhancement	O
of	O
germline	B-RNA
epsilon	I-RNA
transcripts	I-RNA
.	O
	
Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
remarkably	O
promoted	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
.	O
	
Finally	O
,	O
CD27	B-protein
cross-linking	O
resulted	O
in	O
the	O
up-regulation	O
of	O
positive	B-protein
regulatory	I-protein
domain	I-protein
I-binding	I-protein
factor-1	I-protein
.	O
	
Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
signaling	O
via	O
CD27	B-protein
on	O
B	B-cell_type
cells	I-cell_type
induces	O
IgE	B-protein
synthesis	O
,	O
in	O
cooperation	O
with	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
,	O
by	O
promoting	O
the	O
generation	O
of	O
plasma	B-cell_type
cells	I-cell_type
through	O
up-regulation	O
of	O
positive	B-protein
regulatory	I-protein
domain	I-protein
I-binding	I-protein
factor-1	I-protein
.	O
	
###MEDLINE:99074502	
	
Human	O
immunodeficiency	O
virus	O
type-1	O
transcription	O
:	O
role	O
of	O
the	O
5'-untranslated	O
leader	O
region	O
(	O
review	O
)	O
.	O
	
Human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
transcription	O
is	O
dependent	O
on	O
the	O
interaction	O
of	O
host-cell	B-protein
transcription	I-protein
factors	I-protein
with	O
cis-regulatory	B-DNA
DNA	I-DNA
elements	I-DNA
within	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
including	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
binding	B-DNA
sites	I-DNA
.	O
	
Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	B-DNA
leader	I-DNA
region	I-DNA
(	O
5'-UTR	B-DNA
)	O
also	O
contains	O
important	O
transcriptional	B-DNA
elements	I-DNA
.	O
	
These	O
regulatory	B-DNA
elements	I-DNA
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B-protein
factors	I-protein
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O
	
The	O
5'-UTR	B-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factors	I-protein
AP-1	O
,	O
NF-kappaB	B-protein
,	O
NF-AT	B-protein
,	O
IRF	B-protein
,	O
and	O
Sp1	B-protein
.	O
	
Mutations	O
in	O
these	O
binding	B-DNA
sites	I-DNA
can	O
interfere	O
with	O
the	O
viral	O
response	O
to	O
cell	O
activation	O
signals	O
,	O
decrease	O
LTR	B-DNA
transcription	O
,	O
and	O
inhibit	O
viral	O
replication	O
.	O
	
The	O
5'-UTR	B-DNA
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	B-protein
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O
	
We	O
propose	O
that	O
the	O
inducible	B-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
5'-UTR	B-DNA
comprise	O
a	O
downstream	B-DNA
enhancer	I-DNA
domain	I-DNA
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	B-DNA
promoter	I-DNA
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O
	
In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host-cell	B-protein
transcription	I-protein
factors	I-protein
that	O
interact	O
with	O
the	O
5'-UTR	B-DNA
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV-1	O
gene	O
expression	O
.	O
	
###MEDLINE:99060916	
	
Regulation	O
of	O
PAK	O
activation	O
and	O
the	O
T	O
cell	O
cytoskeleton	O
by	O
the	O
linker	B-protein
protein	I-protein
SLP-76	B-protein
.	O
	
Tyrosine	O
phosphorylation	O
of	O
linker	B-protein
proteins	I-protein
enables	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-associated	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
to	O
phosphorylate	O
and	O
regulate	O
effector	B-protein
molecules	I-protein
that	O
generate	O
second	B-protein
messengers	I-protein
.	O
	
We	O
demonstrate	O
here	O
that	O
the	O
SLP-76	B-protein
linker	O
protein	O
interacts	O
with	O
both	O
nck	B-protein
,	O
an	O
adaptor	B-protein
protein	I-protein
,	O
and	O
Vav	B-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
for	O
Rho-family	B-protein
GTPases	I-protein
.	O
	
The	O
assembly	O
of	O
this	O
tri-molecular	B-protein
complex	I-protein
permits	O
the	O
activated	O
Rho-family	B-protein
GTPases	I-protein
to	O
regulate	O
target	O
effectors	O
that	O
interact	O
through	O
nck	B-protein
.	O
	
In	O
turn	O
,	O
assembly	O
of	O
this	O
complex	O
mediates	O
the	O
enzymatic	O
activation	O
of	O
the	O
p21-activated	B-protein
protein	I-protein
kinase	I-protein
1	I-protein
and	O
facilitates	O
actin	B-protein
polymerization	O
.	O
	
Hence	O
,	O
phosphorylation	O
of	O
linker	B-protein
proteins	I-protein
not	O
only	O
bridges	O
the	O
TCR-associated	B-protein
PTK	I-protein
,	O
ZAP-70	B-protein
,	O
with	O
downstream	O
effector	O
proteins	O
,	O
but	O
also	O
provides	O
a	O
scaffold	O
to	O
integrate	O
distinct	O
signaling	B-protein
complexes	I-protein
to	O
regulate	O
T	B-cell_type
cell	I-cell_type
function	O
.	O
	
###MEDLINE:99057540	
	
Interleukin-12	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
transformation	O
with	O
Epstein-Barr	O
virus	O
.	O
	
Although	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-12	I-protein
was	O
originally	O
purified	O
from	O
an	O
Epstein-Barr	B-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
the	O
high	O
correlation	O
of	O
EBV	O
infection	O
and	O
IL-12	B-protein
expression	O
has	O
been	O
suggested	O
,	O
no	O
study	O
has	O
reported	O
whether	O
EBV	O
infection	O
is	O
directly	O
linked	O
to	O
IL-12	B-protein
expression	O
.	O
	
To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL-12	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O
	
Human	B-cell_type
peripheral	I-cell_type
B	I-cell_type
cells	I-cell_type
became	O
capable	O
of	O
constitutively	O
producing	O
p40	O
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	O
of	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
of	O
EBV	O
.	O
	
These	O
B	B-cell_type
cells	I-cell_type
expressed	O
p40	B-RNA
and	I-RNA
p35	I-RNA
mRNA	I-RNA
,	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
strongly	O
enhanced	O
p40	O
and	O
p70	O
production	O
.	O
	
Furthermore	O
,	O
transfection	O
with	O
LMP1	B-DNA
expression	I-DNA
vector	I-DNA
into	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Daudi	B-cell_line
,	O
led	O
to	O
p40	B-protein
production	O
with	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
activation	O
.	O
	
These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
EBV	O
induces	O
IL-12	B-protein
expression	O
potentially	O
through	O
LMP1	B-protein
expression	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99047525	
	
The	O
human	B-DNA
gene	I-DNA
encoding	O
the	O
lectin-type	B-protein
oxidized	I-protein
LDL	I-protein
receptor	I-protein
(	O
OLR1	B-protein
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O
	
LOX-1	B-protein
is	O
an	O
endothelial	B-protein
receptor	I-protein
for	O
oxidized	B-protein
low-density	I-protein
lipoprotein	I-protein
that	O
plays	O
essential	O
roles	O
in	O
atherogenesis	O
.	O
	
LOX-1	B-protein
has	O
the	O
highest	O
homology	O
with	O
C-type	B-protein
lectin	I-protein
receptors	I-protein
expressed	O
on	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
(	O
HGMW-approved	B-protein
symbol	I-protein
OLR1	I-protein
)	O
.	O
	
The	O
gene	O
structure	O
of	O
LOX-1	B-protein
resembles	O
that	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
.	O
	
Fluorescence	O
in	O
situ	O
hybridization	O
and	O
analyses	O
of	O
a	O
yeast	O
artificial	O
chromosome	O
contig	O
revealed	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
located	O
in	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
on	O
chromosome	B-DNA
12p12-p13	I-DNA
,	O
where	O
the	O
genes	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
cluster	O
.	O
	
In	O
contrast	O
,	O
the	O
expression	O
pattern	O
of	O
LOX-1	B-protein
is	O
different	O
from	O
that	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
;	O
LOX-1	B-protein
is	O
expressed	O
in	O
vascular-rich	O
organs	O
,	O
but	O
not	O
in	O
lymphocytes	B-cell_type
.	O
	
A	O
1753-bp	B-DNA
fragment	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
LOX-1	B-DNA
gene	I-DNA
had	O
a	O
functional	O
promoter	O
activity	O
.	O
	
This	O
region	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
the	O
STAT	B-protein
family	I-protein
and	O
NF-IL6	B-protein
,	O
and	O
the	O
expression	O
of	O
LOX-1	B-protein
was	O
upregulated	O
by	O
several	O
cytokines	B-protein
.	O
	
These	O
results	O
demonstrate	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
a	O
new	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99032541	
	
Transcriptional	O
regulation	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
by	O
cytokines	B-protein
:	O
cross-talk	O
between	O
STAT5	B-protein
and	O
other	O
signaling	B-protein
molecules	I-protein
.	O
	
The	O
beta-casein	B-DNA
promoter	I-DNA
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
5	I-protein
since	O
STAT5	B-protein
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL-inducible	O
beta-casein	B-protein
expression	O
.	O
	
However	O
,	O
not	O
only	O
is	O
expression	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
regulated	O
by	O
STAT5	B-protein
but	O
it	O
is	O
also	O
affected	O
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	B-protein
.	O
	
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	O
regulation	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
by	O
cytokines	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
found	O
that	O
the	O
beta-casein	B-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
cytotoxic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
CTLL-2	B-cell_line
,	O
in	O
response	O
to	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
which	O
activates	O
STAT5	B-protein
.	O
	
While	O
IL-4	B-protein
does	O
not	O
activate	O
STAT5	B-protein
,	O
it	O
induces	O
expression	O
of	O
STAT5-regulated	B-DNA
genes	I-DNA
in	O
CTLL-2	B-cell_line
,	O
i.e	O
.	O
beta-casein	B-protein
,	O
a	O
cytokine-inducible	B-protein
SH2-containing	I-protein
protein	I-protein
(	O
CIS	B-protein
)	O
,	O
and	O
oncostatin	B-protein
M	I-protein
(	O
OSM	B-protein
)	O
,	O
suggesting	O
that	O
STAT6	O
activated	O
by	O
IL-4	B-protein
substitutes	O
for	O
the	O
function	O
of	O
STAT5	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
IL-2	B-protein
-induced	O
beta-casein	B-protein
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-155	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O
	
Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL-2	B-protein
-induced	O
expression	O
of	O
beta-casein	B-protein
.	O
	
Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	B-protein
,	O
Ras	B-protein
(	I-protein
G12V	I-protein
)	I-protein
,	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
beta-casein	B-protein
and	O
OSM	B-protein
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	B-protein
is	O
mediated	O
by	O
the	O
region	O
between	O
-105	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O
	
In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	B-protein
,	O
RasN17	B-protein
,	O
also	O
inhibited	O
IL-2	B-protein
-induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta-casein	B-DNA
STAT5	I-DNA
element	I-DNA
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	B-protein
and	O
OSM	B-protein
.	O
	
In	O
addition	O
,	O
Ras	B-protein
(	I-protein
G12V	I-protein
)	I-protein
complemented	O
signaling	O
by	O
an	O
erythropoietin	B-protein
receptor	I-protein
mutant	I-protein
defective	O
in	O
Ras	B-protein
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta-casein	B-DNA
promoter	I-DNA
by	O
the	O
mutant	B-protein
erythropoietin	I-protein
receptor	I-protein
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	B-protein
in	O
Stat5	B-protein
-mediated	O
gene	O
expression	O
.	O
	
These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	B-protein
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O
	
###MEDLINE:99015774	
	
GATA-3	B-protein
represses	O
gp91phox	B-DNA
gene	I-DNA
expression	O
in	O
eosinophil-committed	B-cell_line
HL-60-C15	I-cell_line
cells	I-cell_line
.	O
	
To	O
study	O
the	O
regulatory	O
mechanism	O
of	O
gp91phox	B-DNA
gene	I-DNA
expression	O
in	O
eosinophils	O
,	O
we	O
transiently	O
transfected	O
eosinophil-committed	B-cell_line
HL-60-C15	I-cell_line
cells	I-cell_line
with	O
gp91phox	B-DNA
promoter	I-DNA
constructs	I-DNA
,	O
and	O
identified	O
a	O
negative	B-DNA
element	I-DNA
from	O
bp	O
-267	B-DNA
to	I-DNA
-246	I-DNA
of	O
the	O
gp91phox	B-DNA
gene	I-DNA
,	O
the	O
deletion	O
of	O
which	O
caused	O
an	O
83	O
%	O
increase	O
in	O
promoter	O
activity	O
.	O
	
Electrophoresis	O
mobility	O
shift	O
assays	O
demonstrated	O
GATA-3	B-protein
binds	O
to	O
the	O
GATA	B-DNA
consensus	I-DNA
site	I-DNA
from	O
bp	O
-256	B-DNA
to	I-DNA
-250	I-DNA
.	I-DNA
	
An	O
81	O
%	O
increment	O
in	O
promoter	O
activity	O
was	O
obtained	O
when	O
a	O
mutation	O
was	O
introduced	O
in	O
the	O
GATA-3	B-DNA
binding	I-DNA
site	I-DNA
of	O
the	O
bp	B-DNA
-267	I-DNA
to	I-DNA
+12	I-DNA
construct	I-DNA
,	O
which	O
is	O
comparable	O
to	O
that	O
of	O
the	O
bp	B-DNA
-245	I-DNA
to	I-DNA
+12	I-DNA
construct	I-DNA
.	O
	
We	O
therefore	O
conclude	O
that	O
GATA-3	B-protein
specifically	O
binding	O
to	O
the	O
GATA	B-DNA
site	I-DNA
negatively	O
regulates	O
the	O
expression	O
of	O
the	O
gene	O
in	O
HL-60-C15	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:99008506	
	
Uncoupling	O
activation-dependent	O
HS1	B-protein
phosphorylation	O
from	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
transcriptional	O
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
:	O
differential	O
signaling	O
through	O
CD3	B-protein
and	O
the	O
costimulatory	O
receptors	O
CD2	B-protein
and	O
CD28	B-protein
.	O
	
CD3	B-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
are	O
functionally	O
distinct	O
receptors	O
on	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
,	O
including	O
Vav	B-protein
,	O
Cbl	B-protein
,	O
p85	B-protein
phosphoinositide	I-protein
3-kinase	I-protein
,	O
and	O
the	O
Src	B-protein
family	I-protein
kinases	I-protein
Lck	B-protein
and	O
Fyn	B-protein
.	O
	
Ligation	O
of	O
CD3	B-protein
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
,	O
a	O
75-kDa	B-protein
hematopoietic	I-protein
cell-specific	I-protein
intracellular	I-protein
signaling	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O
	
We	O
have	O
examined	O
changes	O
in	O
HS1	B-protein
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	B-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
to	O
elucidate	O
its	O
role	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O
	
Unlike	O
ligation	O
of	O
CD3	B-protein
,	O
stimulation	O
with	O
anti-CD28	B-protein
mAb	I-protein
or	O
CHO	B-cell_line
cells	I-cell_line
expressing	O
the	O
CD28	B-protein
ligands	I-protein
CD80	B-protein
or	O
CD86	B-protein
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
was	O
induced	O
by	O
mitogenic	B-cell_type
pairs	I-cell_type
of	O
anti-CD2	B-protein
mAbs	I-protein
capable	O
of	O
activating	O
the	O
transcription	B-protein
factor	I-protein
NFAT	I-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
.	O
	
Costimulation	O
through	O
CD28	B-protein
and/or	O
CD2	B-protein
did	O
not	O
modulate	O
the	O
CD3	B-protein
-dependent	O
phosphorylation	O
of	O
HS1	B-protein
.	O
	
In	O
vivo	O
studies	O
indicated	O
that	O
CD3	B-protein
-induced	O
HSI	B-protein
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
Lck	B-protein
and	O
the	O
tyrosine	B-protein
phosphatase	I-protein
CD45	B-protein
,	O
did	O
not	O
require	O
MEK1	B-protein
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
activation	O
.	O
	
Thus	O
,	O
although	O
CD3	B-protein
,	O
CD28	B-protein
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	B-protein
molecules	I-protein
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	B-protein
.	O
	
Furthermore	O
,	O
activation-dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
was	O
not	O
required	O
for	O
NFAT	B-protein
transcriptional	O
activation	O
.	O
	
###MEDLINE:99003459	
	
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
in	O
activated	B-cell_type
cord	I-cell_type
and	I-cell_type
adult	I-cell_type
lymphocytes	I-cell_type
:	O
an	O
analysis	O
by	O
Northern	O
hybridization	O
.	O
	
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
further	O
analyze	O
the	O
neonatal	O
immune	O
response	O
to	O
an	O
antigenic	O
challenge	O
such	O
as	O
blood	O
transfusion	O
,	O
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
were	O
analyzed	O
in	O
twelve	O
in-vitro-stimulated	O
normal	O
cord	O
blood	O
and	O
ten	O
in-vitro-stimulated	B-cell_type
normal	I-cell_type
adult	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
samples	I-cell_type
.	O
	
MATERIALS	O
AND	O
METHODS	O
:	O
Lymphocyte	B-cell_type
samples	I-cell_type
were	O
stimulated	O
by	O
either	O
the	O
mitogen	B-protein
phytohemagglutinin	I-protein
(	O
PHA	B-protein
)	O
or	O
the	O
monoclonal	O
antibody	O
alphaCD3	B-protein
.	O
	
Proliferation	O
rate	O
and	O
Northern	O
blot	O
hybridization	O
were	O
employed	O
.	O
	
RESULTS	O
:	O
Cord	O
lymphocytes	O
revealed	O
a	O
greater	O
proliferation	O
rate	O
with	O
PHA	B-protein
and	O
alphaCD3	B-protein
than	O
adult	O
lymphocytes	O
(	O
p	O
=	O
0.0081	O
and	O
0.0023	O
,	O
respectively	O
)	O
.	O
	
In	O
addition	O
,	O
Northern	O
blot	O
analysis	O
of	O
cord	O
and	O
adult	O
samples	O
revealed	O
similar	O
maximal	O
increases	O
in	O
c-fos	B-RNA
(	O
99+/-15	O
and	O
126+/-11	O
%	O
,	O
p	O
=	O
0.0126	O
)	O
and	O
c-jun	B-RNA
(	I-RNA
123+/-9	I-RNA
and	I-RNA
185+/-38	I-RNA
%	I-RNA
,	I-RNA
p	I-RNA
=	I-RNA
0.0291	I-RNA
)	I-RNA
mRNA	I-RNA
expression	O
,	O
respectively	O
,	O
as	O
early	O
as	O
15	O
min	O
post-	O
alphaCD3	B-protein
stimulation	O
.	O
	
Adult	O
lymphocytes	O
showed	O
an	O
equivalent	O
increase	O
in	O
mRNA	O
expression	O
of	O
c-fos	B-DNA
and	O
c-jun	B-DNA
(	O
140+/-25	O
and	O
155+/-31	O
%	O
)	O
at	O
30	O
min	O
post-	O
PHA	B-protein
stimulation	O
,	O
while	O
cord	B-cell_type
lymphocyte	I-cell_type
maximum	O
c-fos	O
and	O
c-jun	O
expression	O
(	O
82+/-6	O
and	O
142+/-12	O
%	O
)	O
occurred	O
at	O
15	O
min	O
post-	O
PHA	B-protein
stimulation	O
(	O
c-fos	B-DNA
,	O
p	O
=	O
0.0354	O
;	O
c-jun	B-DNA
,	O
p	O
=	O
0.0112	O
)	O
.	O
	
CONCLUSION	O
:	O
Although	O
cord	B-cell_type
lymphocyte	I-cell_type
proliferation	O
rates	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
adult	O
lymphocytes	O
following	O
stimulation	O
,	O
lymphocyte	O
activation	O
,	O
as	O
analyzed	O
by	O
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
,	O
appears	O
similar	O
in	O
both	O
cord	O
and	O
adult	O
samples	O
.	O
	
We	O
conclude	O
that	O
cord	O
lymphocyte	O
activation	O
exhibits	O
an	O
adult-type	O
profile	O
.	O
	
###MEDLINE:98438540	
	
Fcgamma	B-protein
receptor	I-protein
-mediated	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
in	O
monocytes	B-cell_type
is	O
independent	O
of	O
Ras	B-protein
.	O
	
Receptors	O
for	O
the	O
Fc	B-protein
portion	I-protein
of	O
immunoglobulin	B-protein
molecules	I-protein
(	O
FcR	B-protein
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O
	
Cross-linking	O
of	O
FcR	B-protein
with	O
immune	B-protein
complexes	I-protein
leads	O
,	O
first	O
to	O
activation	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
.	O
	
The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O
	
We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	B-protein
in	O
monocytes	B-cell_type
.	O
	
Cross-linking	O
of	O
FcR	B-protein
,	O
on	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
by	O
immune	B-protein
complexes	I-protein
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	O
interleukin	B-protein
1	I-protein
production	O
.	O
	
These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	B-protein
kinase	I-protein
inhibitors	O
.	O
	
In	O
contrast	O
,	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutants	I-protein
of	O
Ras	B-protein
and	O
Raf-1	B-protein
,	O
in	O
these	O
cells	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
FcR	B-protein
-mediated	O
nuclear	B-protein
factor	I-protein
activation	O
,	O
suggesting	O
that	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
was	O
not	O
used	O
by	O
these	O
receptors	O
.	O
	
However	O
,	O
MAPK	B-protein
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	B-protein
cross-linking	O
with	O
immune	B-protein
complexes	I-protein
.	O
	
Using	O
the	O
specific	O
MAPK	B-protein
/extracellular	O
signal-regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	B-protein
activation	O
is	O
necessary	O
for	O
FcR	B-protein
-dependent	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	B-protein
kinases	I-protein
and	O
requires	O
MAPK	B-protein
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	B-protein
kinase	I-protein
receptors	I-protein
,	O
FcR	B-protein
-mediated	O
MAPK	B-protein
activation	O
does	O
not	O
involve	O
Ras	B-protein
and	O
Raf	B-protein
.	O
	
###MEDLINE:98426236	
	
BCL-6	B-protein
mutations	O
in	O
normal	B-cell_type
germinal	I-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
:	O
evidence	O
of	O
somatic	O
hypermutation	O
acting	O
outside	O
Ig	B-DNA
loci	I-DNA
.	O
	
The	O
molecular	O
mechanism	O
involved	O
in	O
the	O
process	O
of	O
antigen-driven	O
somatic	O
hypermutation	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
unknown	O
,	O
but	O
it	O
is	O
commonly	O
believed	O
that	O
this	O
mechanism	O
is	O
restricted	O
to	O
the	O
Ig	B-DNA
loci	I-DNA
.	O
	
B	B-cell_type
cell	I-cell_type
lymphomas	I-cell_type
commonly	O
display	O
multiple	O
somatic	O
mutations	O
clustering	O
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
BCL-6	B-protein
,	O
a	O
proto-oncogene	B-DNA
encoding	O
for	O
a	O
POZ/Zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
required	O
for	O
GC	O
formation	O
.	O
	
To	O
determine	O
whether	O
BCL-6	B-protein
mutations	O
represent	O
a	O
tumor-associated	O
phenomenon	O
or	O
reflect	O
a	O
physiologic	O
mechanism	O
,	O
we	O
screened	O
single	O
human	B-cell_type
tonsillar	I-cell_type
GC	I-cell_type
B	I-cell_type
cells	I-cell_type
for	O
mutations	O
occurring	O
in	O
the	O
BCL-6	B-DNA
5'-noncoding	I-DNA
region	I-DNA
and	O
in	O
the	O
Ig	B-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O
	
Thirty	O
percent	O
of	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
displayed	O
mutations	O
in	O
the	O
742	B-DNA
bp	I-DNA
region	I-DNA
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL-6	B-protein
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-4	O
)	O
/bp	O
)	O
.	O
	
Accordingly	O
,	O
an	O
expanded	O
survey	O
in	O
lymphoid	O
malignancies	O
showed	O
that	O
BCL-6	B-protein
mutations	O
are	O
restricted	O
to	O
B	O
cell	O
tumors	O
displaying	O
GC	O
or	O
post-GC	O
phenotype	O
and	O
carrying	O
mutated	B-DNA
Ig	I-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O
	
These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
physiologically	O
targets	O
non-Ig	B-DNA
sequences	I-DNA
.	O
	
###MEDLINE:98414619	
	
The	O
AD1	B-protein
and	O
AD2	B-protein
transactivation	O
domains	O
of	O
E2A	B-protein
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	B-protein
oncoprotein	I-protein
E2A-HLF	B-protein
.	O
	
The	O
chimeric	B-protein
oncoprotein	I-protein
E2A-HLF	B-protein
,	O
generated	O
by	O
the	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
chromosomal	I-DNA
translocation	I-DNA
in	O
pro-B-cell	O
acute	O
lymphoblastic	O
leukemia	O
,	O
incorporates	O
the	O
transactivation	B-protein
domains	I-protein
of	O
E2A	B-protein
and	O
the	O
basic	B-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
DNA-binding	I-protein
and	I-protein
protein	I-protein
dimerization	I-protein
domain	I-protein
of	O
HLF	B-protein
(	O
hepatic	B-protein
leukemic	I-protein
factor	I-protein
)	O
.	O
	
The	O
ability	O
of	O
E2A-HLF	B-protein
to	O
prolong	O
the	O
survival	O
of	O
interleukin-3	B-cell_line
(	I-cell_line
IL-3	I-cell_line
)	I-cell_line
-dependent	I-cell_line
murine	I-cell_line
pro-B	I-cell_line
cells	I-cell_line
after	O
IL-3	B-protein
withdrawal	O
suggests	O
that	O
it	O
disrupts	O
signaling	O
pathways	O
normally	O
responsible	O
for	O
cell	O
suicide	O
,	O
allowing	O
the	O
cells	O
to	O
accumulate	O
as	O
transformed	B-cell_type
lymphoblasts	I-cell_type
.	O
	
To	O
determine	O
the	O
structural	O
motifs	O
that	O
contribute	O
to	O
this	O
antiapoptotic	O
effect	O
,	O
we	O
constructed	O
a	O
panel	O
of	O
E2A-HLF	B-protein
mutants	I-protein
and	O
programmed	O
their	O
expression	O
in	O
IL-3-dependent	B-cell_line
murine	I-cell_line
pro-B	I-cell_line
cells	I-cell_line
(	O
FL5.12	B-cell_line
line	I-cell_line
)	O
,	O
using	O
a	O
zinc-inducible	O
vector	O
.	O
	
Neither	O
the	O
E12	B-protein
nor	O
the	O
E47	B-protein
product	O
of	O
the	O
E2A	B-DNA
gene	I-DNA
nor	O
the	O
wild-type	B-protein
HLF	I-protein
protein	I-protein
was	O
able	O
to	O
protect	O
the	O
cells	O
from	O
apoptosis	O
induced	O
by	O
IL-3	B-protein
deprivation	O
.	O
	
Surprisingly	O
,	O
different	O
combinations	O
of	O
disabling	O
mutations	O
within	O
the	O
HLF	B-protein
bZIP	I-protein
domain	I-protein
had	O
little	O
effect	O
on	O
the	O
antiapoptotic	O
property	O
of	O
the	O
chimeric	B-protein
protein	I-protein
,	O
so	O
long	O
as	O
the	O
amino-terminal	O
portion	O
of	O
E2A	B-protein
remained	O
intact	O
.	O
	
In	O
the	O
context	O
of	O
a	O
bZIP	B-protein
domain	I-protein
defective	O
in	O
DNA	O
binding	O
,	O
mutants	O
retaining	O
either	O
of	O
the	O
two	O
transactivation	B-protein
domains	I-protein
of	O
E2A	B-protein
were	O
able	O
to	O
extend	O
cell	O
survival	O
after	O
growth	B-protein
factor	I-protein
deprivation	O
.	O
	
Thus	O
,	O
the	O
block	O
of	O
apoptosis	O
imposed	O
by	O
E2A-HLF	B-protein
in	O
pro-B	B-cell_type
lymphocytes	I-cell_type
depends	O
critically	O
on	O
the	O
transactivating	B-protein
regions	I-protein
of	O
E2A	B-protein
.	O
	
Since	O
neither	O
DNA	O
binding	O
nor	O
protein	O
dimerization	O
through	O
the	O
bZIP	B-protein
domain	I-protein
of	O
HLF	B-protein
is	O
required	O
for	O
this	O
effect	O
,	O
we	O
propose	O
mechanisms	O
whereby	O
protein-protein	O
interactions	O
with	O
the	O
amino-terminal	O
region	O
of	O
E2A	B-protein
allow	O
the	O
chimera	B-protein
to	O
act	O
as	O
a	O
transcriptional	O
cofactor	O
to	O
alter	O
the	O
expression	O
of	O
genes	O
regulating	O
the	O
apoptotic	O
machinery	O
in	O
pro-B	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98400847	
	
Induction	O
of	O
Mn	B-protein
SOD	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
without	O
inflammatory	B-protein
cytokine	I-protein
production	O
by	O
a	O
mutant	B-protein
endotoxin	I-protein
.	O
	
Endotoxin	B-protein
selectively	O
induces	O
monocyte	B-protein
Mn	I-protein
superoxide	I-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
without	O
affecting	O
levels	O
of	O
Cu	O
,	O
Zn	B-protein
SOD	I-protein
,	O
catalase	B-protein
,	O
or	O
glutathione	B-protein
peroxidase	I-protein
.	O
	
However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure-activity	O
relationship	O
and	O
the	O
mechanism	O
by	O
which	O
endotoxin	O
induces	O
Mn	B-protein
SOD	I-protein
.	O
	
In	O
this	O
study	O
we	O
demonstrated	O
that	O
a	O
mutant	O
Escherichia	O
coli	O
endotoxin	O
lacking	O
myristoyl	O
fatty	O
acid	O
at	O
the	O
3	O
'	O
R-3-hydroxymyristate	O
position	O
of	O
the	O
lipid	O
A	O
moiety	O
retained	O
its	O
full	O
capacity	O
to	O
coagulate	O
Limulus	O
amoebocyte	O
lysate	O
compared	O
with	O
the	O
wild-type	O
E.	O
coli	O
endotoxin	O
and	O
markedly	O
stimulated	O
the	O
activation	O
of	O
human	B-protein
monocyte	I-protein
nuclear	I-protein
factor-kappaB	I-protein
and	O
the	O
induction	O
of	O
Mn	B-RNA
SOD	I-RNA
mRNA	I-RNA
and	O
enzyme	O
activity	O
.	O
	
However	O
,	O
in	O
contrast	O
to	O
the	O
wild-type	O
endotoxin	O
,	O
it	O
failed	O
to	O
induce	O
significant	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
and	O
macrophage	B-protein
inflammatory	I-protein
protein-1alpha	I-protein
by	O
monocytes	B-cell_type
and	O
did	O
not	O
induce	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
.	O
	
These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	B-protein
cytokine	I-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B-protein
SOD	I-protein
,	O
2	O
)	O
endotoxin	B-protein
-mediated	O
induction	O
of	O
Mn	B-protein
SOD	I-protein
and	O
inflammatory	O
cytokines	B-protein
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	B-protein
endotoxin	I-protein
to	O
induce	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
.	O
	
###MEDLINE:98389282	
	
Regulation	O
of	O
the	O
vitellogenin	B-DNA
gene	I-DNA
B1	I-DNA
promoter	I-DNA
after	O
transfer	O
into	O
hepatocytes	B-cell_type
in	O
primary	O
cultures	O
.	O
	
The	O
estrogen-dependent	O
and	O
tissue-specific	O
regulation	O
of	O
the	O
Xenopus	O
laevis	O
vitellogenin	B-DNA
gene	I-DNA
B1	I-DNA
promoter	I-DNA
has	O
been	O
studied	O
by	O
lipid-mediated	O
DNA	O
transfer	O
into	O
Xenopus	B-cell_type
hepatocytes	I-cell_type
in	O
primary	O
culture	O
.	O
	
Hepatocytes	O
achieve	O
an	O
efficient	O
hormonal	O
control	O
of	O
this	O
promoter	O
through	O
a	O
functional	O
interaction	O
between	O
the	O
estrogen	B-DNA
responsive	I-DNA
elements	I-DNA
and	O
a	O
promoter	B-DNA
proximal	I-DNA
region	I-DNA
upstream	O
of	O
the	O
TATA	B-DNA
box	I-DNA
,	O
which	O
is	O
characterized	O
by	O
a	O
high	O
density	O
of	O
binding	O
sites	O
for	O
the	O
transcription	B-protein
factors	I-protein
CTF/NF-1	B-protein
,	O
C/EBP	B-protein
and	O
HNF3	B-protein
.	O
	
DNA	O
accessibility	O
to	O
restriction	B-protein
enzymes	I-protein
within	O
the	O
chromosomal	O
copy	O
of	O
the	O
vitellogenin	B-DNA
gene	I-DNA
B1	I-DNA
promoter	I-DNA
shows	O
that	O
the	O
estrogen	B-DNA
responsive	I-DNA
unit	I-DNA
and	O
the	O
promoter	B-DNA
proximal	I-DNA
region	I-DNA
are	O
sensitive	O
to	O
digestion	O
in	O
uninduced	O
and	O
estrogen-induced	B-cell_type
hepatocytes	I-cell_type
but	O
not	O
in	O
erythrocyte	O
nuclei	O
.	O
	
Together	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
chromatin	B-DNA
configuration	O
as	O
well	O
as	O
the	O
interplay	O
of	O
promoter	B-DNA
elements	I-DNA
mediate	O
proper	O
hormone-dependent	O
and	O
tissue-specific	O
expression	O
of	O
the	O
B1	B-DNA
vitellogenin	I-DNA
gene	I-DNA
.	O
	
###MEDLINE:98380997	
	
Characterization	O
of	O
cytokine	B-protein
differential	O
induction	O
of	O
STAT	B-protein
complexes	I-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O
	
Cytokines	B-protein
,	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-6	B-protein
,	O
IL-7	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O
	
Recent	O
studies	O
reveal	O
that	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
,	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
directly	O
mediate	O
many	O
cytokine	B-protein
signals	O
.	O
	
We	O
analyzed	O
the	O
activation	O
of	O
STATs	B-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
by	O
a	O
variety	O
of	O
specific	O
cytokines	B-protein
.	O
	
We	O
demonstrate	O
that	O
IL-12	B-protein
induces	O
STAT4	B-protein
only	O
in	O
freshly	O
isolated	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
consistent	O
with	O
the	O
lack	O
of	O
the	O
IL-12	B-protein
receptor	I-protein
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
,	O
IL-4	B-protein
induces	O
different	O
C	B-protein
epsilon	I-protein
GAS	I-protein
DNA-protein	I-protein
binding	I-protein
complexes	I-protein
in	O
both	O
T	O
and	O
NK	B-cell_type
cells	I-cell_type
.	O
	
Moreover	O
,	O
IL-4	B-protein
costimulation	O
with	O
IL-2	B-protein
or	O
IL-12	B-protein
does	O
not	O
alter	O
their	O
own	O
preferential	O
GAS	B-DNA
-like	O
DNA	O
binding	O
patterns	O
when	O
C	B-DNA
epsilon-	I-DNA
,	I-DNA
Fc	I-DNA
gamma	I-DNA
RI-	I-DNA
,	I-DNA
and	I-DNA
SIE	I-DNA
GAS	I-DNA
motif	I-DNA
containing	O
oligonucleotide	O
probes	O
are	O
compared	O
,	O
suggesting	O
that	O
induction	O
of	O
GAS-like	B-protein
DNA-protein	I-protein
binding	I-protein
complexes	I-protein
by	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-12	B-protein
is	O
highly	O
selective	O
and	O
represents	O
one	O
important	O
factor	O
in	O
determining	O
specific	O
gene	O
activation	O
.	O
	
In	O
addition	O
,	O
IL-6	B-protein
and	O
IL-2	B-protein
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
in	O
both	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	B-DNA
gene	I-DNA
expression	O
.	O
	
We	O
further	O
demonstrated	O
that	O
IL-2	B-protein
,	I-protein
-7	I-protein
,	I-protein
and	I-protein
-15	I-protein
induce	O
multiple	B-protein
STAT	I-protein
proteins	I-protein
,	O
including	O
STAT5a	B-protein
,	O
STAT5b	B-protein
,	O
STAT1	B-protein
alpha	I-protein
,	O
STAT3	B-protein
,	O
and	O
another	O
unidentified	O
Fc	B-protein
gamma	I-protein
RI	I-protein
GAS	I-protein
DNA-binding	I-protein
protein	I-protein
.	O
	
Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B-protein
and	O
STAT5b	B-protein
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O
	
Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	B-protein
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:98373989	
	
A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
CD95	B-DNA
(	I-DNA
APO-1/Fas	I-DNA
)	I-DNA
ligand	I-DNA
promoter	I-DNA
is	O
essential	O
for	O
responsiveness	O
to	O
TCR	B-protein
-mediated	O
activation	O
.	O
	
Expression	O
of	O
the	O
CD95	B-protein
(	I-protein
APO-1/Fas	I-protein
)	I-protein
ligand	I-protein
(	O
CD95L	B-protein
)	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
major	O
cause	O
of	O
T	O
cell	O
activation-induced	O
apoptosis	O
.	O
	
To	O
study	O
the	O
molecular	O
mechanisms	O
of	O
transcriptional	O
control	O
of	O
CD95L	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
investigated	O
the	O
human	B-DNA
CD95L	I-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Deletion	O
studies	O
revealed	O
that	O
the	O
CD95L	B-DNA
proximal	I-DNA
promoter	I-DNA
sequence	I-DNA
from	O
-220	B-DNA
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
is	O
essential	O
for	O
T	O
cell	O
stimulation-induced	O
expression	O
of	O
CD95L	B-protein
.	O
	
In	O
this	O
study	O
,	O
we	O
discovered	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
located	O
at	O
-120	B-DNA
of	O
the	O
CD95L	B-DNA
promoter	I-DNA
which	O
contains	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
SP-1	B-protein
and	O
a	O
yet	O
unknown	O
inducible	B-protein
factor	I-protein
.	O
	
Mutation	O
analysis	O
demonstrated	O
that	O
binding	O
of	O
the	O
inducible	O
factor	O
to	O
the	O
-120	B-DNA
region	I-DNA
is	O
crucial	O
for	O
the	O
biological	O
function	O
of	O
the	O
CD95L	B-DNA
promoter	I-DNA
upon	O
T	O
cell	O
stimulation	O
.	O
	
The	O
DNA	O
sequence	O
at	O
-120	B-DNA
also	O
contains	O
two	O
DNA	B-DNA
motifs	I-DNA
homologous	O
to	O
the	O
binding	O
site	O
for	O
NF-AT	B-protein
.	O
	
NF-AT	B-protein
does	O
not	O
directly	O
bind	O
to	O
this	O
element	O
.	O
	
However	O
,	O
cotransfection	O
studies	O
with	O
an	O
NF-AT	B-DNA
expression	I-DNA
vector	I-DNA
showed	O
that	O
NF-AT	B-protein
may	O
confer	O
a	O
strong	O
inducible	O
activity	O
to	O
the	O
CD95L	B-DNA
promoter	I-DNA
at	O
this	O
regulatory	B-DNA
region	I-DNA
.	O
	
Our	O
data	O
also	O
show	O
that	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
down-regulates	O
CD95L	B-protein
transcription	O
by	O
inhibiting	O
the	O
function	O
of	O
this	O
positive	O
regulatory	B-DNA
element	I-DNA
	
###MEDLINE:99021680	
	
A	O
nongenomic	O
mechanism	O
for	O
progesterone-mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
,	O
Ca2+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O
	
Using	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage-gated	B-protein
and	I-protein
calcium-activated	I-protein
K+	I-protein
channels	I-protein
(	O
KV	B-protein
and	O
KCa	B-protein
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O
	
As	O
a	O
result	O
,	O
Ca2+	O
signaling	O
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
-driven	O
gene	O
expression	O
are	O
inhibited	O
.	O
	
Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2+	O
signals	O
,	O
but	O
not	O
the	O
Ca2+	O
transient	O
after	O
TCR	B-protein
stimulation	O
.	O
	
K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	B-protein
and	O
KCa	B-protein
channels	O
.	O
	
Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B-protein
channels	I-protein
,	O
reducing	O
both	O
Kv1.3	B-protein
and	O
charybdotoxin-resistant	B-protein
components	I-protein
of	O
KV	B-protein
current	O
and	O
KCa	B-protein
current	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B-protein
KV	I-protein
channels	I-protein
expressed	O
in	O
cell	B-cell_line
lines	I-cell_line
.	O
	
Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	B-protein
voltage-gated	I-protein
Na+	I-protein
channel	I-protein
,	O
an	O
inward	O
rectifier	O
K+	B-protein
channel	I-protein
,	O
or	O
on	O
lymphocyte	B-protein
Ca2+	I-protein
and	I-protein
Cl-	I-protein
channels	I-protein
.	O
	
We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
in	O
T	B-cell_type
cells	I-cell_type
by	O
progesterone	O
contributes	O
to	O
progesterone-induced	O
immunosuppression	O
.	O
	
###MEDLINE:99008517	
	
A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
Transgenic	O
mice	O
with	O
human	B-DNA
CD3epsilon	I-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
exhibit	O
early	O
arrest	O
of	O
T	O
cell	O
development	O
in	O
the	O
thymus	O
.	O
	
The	O
present	O
study	O
shows	O
that	O
,	O
instead	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
are	O
generated	O
in	O
the	O
thymus	O
of	O
a	O
line	O
,	O
tg	O
epsilon26	O
,	O
of	O
the	O
human	O
CD3epsilon	O
transgenic	O
mice	O
.	O
	
The	O
accumulation	O
of	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
was	O
found	O
only	O
in	O
tg	O
epsilon26	O
mice	O
,	O
not	O
in	O
other	O
human	B-cell_line
CD3epsilon	I-cell_line
transgenic	I-cell_line
mouse	I-cell_line
lines	I-cell_line
or	O
other	O
T	O
cell-deficient	O
mice	O
,	O
including	O
CD3-epsilon	O
knockout	O
mice	O
and	O
TCR-beta/TCR-delta	O
double	O
knockout	O
mice	O
.	O
	
Hanging	O
drop-mediated	O
transfer	O
into	O
2-deoxyguanosine-treated	O
thymus	O
lobes	O
showed	O
that	O
lymphoid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
rather	O
than	O
thymus	O
stromal	O
cells	O
were	O
responsible	O
for	O
abnormal	O
B	O
cell	O
development	O
in	O
tg	B-protein
epsilon26	I-protein
thymus	O
,	O
and	O
that	O
tg	B-cell_type
epsilon26	I-cell_type
fetal	I-cell_type
liver	I-cell_type
cells	I-cell_type
were	O
destined	O
to	O
become	O
B	B-cell_type
cells	I-cell_type
in	O
normal	O
thymus	O
even	O
in	O
the	O
presence	O
of	O
normal	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
undergoing	O
T	O
cell	O
development	O
.	O
	
These	O
results	O
indicate	O
that	O
lymphoid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
tg	B-protein
epsilon26	I-protein
mice	O
are	O
genetically	O
defective	O
in	O
thymic	O
choice	O
between	O
T	B-cell_type
cells	I-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
generating	O
B	B-cell_type
cells	I-cell_type
even	O
in	O
normal	O
thymus	O
environment	O
.	O
	
Interestingly	O
,	O
tg	B-cell_type
epsilon26	I-cell_type
thymocytes	I-cell_type
expressed	O
GATA-3	B-protein
and	O
TCF-1	B-protein
,	O
but	O
not	O
LEF-1	B-protein
and	O
PEBP-2alpha	B-protein
,	O
among	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
that	O
are	O
involved	O
in	O
early	O
T	O
cell	O
development	O
,	O
indicating	O
that	O
GATA-3	B-protein
and	O
TCF-1	B-protein
expressed	O
during	O
thymocyte	O
development	O
do	O
not	O
necessarily	O
determine	O
the	O
cell	O
fate	O
into	O
T	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O
	
Thus	O
,	O
tg	B-protein
epsilon26	I-protein
mice	O
provide	O
a	O
novel	O
mouse	O
model	O
in	O
that	O
lineage	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
is	O
genetically	O
defective	O
.	O
	
###MEDLINE:99003230	
	
Downstream	O
activation	O
of	O
a	O
TATA-less	B-DNA
promoter	I-DNA
by	O
Oct-2	B-protein
,	O
Bob1	O
,	O
and	O
NF-kappaB	B-protein
directs	O
expression	O
of	O
the	O
homing	B-protein
receptor	I-protein
BLR1	I-protein
to	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
The	O
chemokine	B-protein
receptor	I-protein
,	O
BLR1	B-protein
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
lymphoid	O
organs	O
.	O
	
In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA-less	B-DNA
blr1	I-DNA
core	I-DNA
promoter	I-DNA
that	O
confer	O
cell	O
type-	O
and	O
differentiation-specific	O
expression	O
in	O
the	O
B	B-cell_type
cells	I-cell_type
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	B-DNA
promoter	I-DNA
region	I-DNA
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
)	O
,	O
a	O
NF-kappaB	B-DNA
motif	I-DNA
(	O
+44	O
)	O
,	O
and	O
a	O
noncanonical	B-DNA
octamer	I-DNA
motif	I-DNA
(	O
+157	O
)	O
.	O
	
The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene-targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	B-protein
,	O
Bob1	B-protein
,	O
or	O
both	O
NF-kappaB	B-protein
subunits	O
p50	O
and	O
p52	O
.	O
	
In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	O
of	O
BLR1	B-protein
was	O
reduced	O
or	O
absent	O
.	O
	
In	O
mice	O
deficient	O
only	O
of	O
p52/NF-kappaB	B-protein
,	O
BLR1	B-protein
expression	O
was	O
unaffected	O
.	O
	
Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	B-protein
is	O
a	O
target	O
gene	O
for	O
Oct-2	B-protein
,	O
Bob1	B-protein
,	O
and	O
members	O
of	O
the	O
NF-kappaB/Rel	B-protein
family	I-protein
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	O
for	O
these	O
factors	O
.	O
	
###MEDLINE:98440543	
	
CD4	B-DNA
promoter	I-DNA
transactivation	O
by	O
human	O
herpesvirus	O
6	O
.	O
	
The	O
observation	O
that	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
induce	O
CD4	B-DNA
gene	I-DNA
transcription	O
and	O
expression	O
in	O
CD4	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
was	O
reported	O
several	O
years	O
ago	O
(	O
P.Lusso	O
,	O
A.De	O
Maria	O
,	O
M.Malnati	O
,	O
F.Lori	O
,	O
S.E.DeRocco	O
,	O
M.	O
Baseler	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
349	O
:	O
533-535	O
,	O
1991	O
)	O
and	O
subsequently	O
confirmed	O
(	O
P.Lusso	O
,	O
M.S.Malnati	O
,	O
A.Garzino-Demo	O
,	O
R.W.Crowley	O
,	O
E.	O
O.Long	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
362	O
:	O
458-462	O
,	O
1993	O
;	O
G.Furlini	O
,	O
M.	O
Vignoli	O
,	O
E.Ramazzotti	O
,	O
M.C.Re	O
,	O
G.Visani	O
,	O
and	O
M.LaPlaca	O
,	O
Blood	O
87	O
:	O
4737-4745	O
,	O
1996	O
)	O
.	O
	
Our	O
objective	O
was	O
to	O
identify	O
the	O
mechanisms	O
underlying	O
such	O
phenomena	O
.	O
	
Using	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
driven	O
by	O
the	O
CD4	B-DNA
promoter	I-DNA
,	O
we	O
report	O
that	O
HHV-6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	B-DNA
elements	I-DNA
.	O
	
Activation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
occurs	O
in	O
the	O
presence	O
of	O
the	O
viral	O
DNA	O
polymerase	O
inhibitor	O
phosphonoformic	O
acid	O
,	O
which	O
limits	O
expression	O
to	O
the	O
immediate-early	B-DNA
and	I-DNA
early	I-DNA
classes	I-DNA
of	I-DNA
viral	I-DNA
genes	I-DNA
.	O
	
Using	O
deletion	O
mutants	O
and	O
specific	O
CD4	B-DNA
promoter	I-DNA
mutants	I-DNA
,	O
we	O
identified	O
an	O
ATF/CRE	B-DNA
binding	I-DNA
site	I-DNA
located	O
at	O
nucleotides	B-DNA
-67	I-DNA
to	I-DNA
-60	I-DNA
upstream	I-DNA
of	O
the	O
CD4	B-DNA
gene	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
that	O
is	O
important	O
for	O
HHV-6	O
transactivation	O
.	O
	
The	O
ATF/CRE	B-DNA
site	I-DNA
is	O
also	O
essential	O
for	O
CD4	B-DNA
promoter	I-DNA
activation	O
by	O
forskolin	O
,	O
an	O
activator	O
of	O
adenylate	O
cyclase	O
.	O
	
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
specific	O
antibodies	O
,	O
we	O
showed	O
that	O
CREB-1	B-protein
binds	O
specifically	O
to	O
the	O
-79	B-DNA
to	I-DNA
-52	I-DNA
region	I-DNA
of	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O
	
Last	O
,	O
we	O
have	O
identified	O
two	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
of	O
HHV-6	O
,	O
U86	B-DNA
and	O
U89	B-DNA
from	O
the	O
immediate-early	O
locus	O
A	O
,	O
that	O
can	O
transactivate	O
the	O
CD4	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
transactivation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
by	O
ORFs	B-DNA
U86	B-DNA
and	O
U89	B-DNA
is	O
independent	O
of	O
the	O
CRE	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
additional	O
HHV-6	B-DNA
ORFs	I-DNA
are	O
likely	O
to	O
contribute	O
to	O
CD4	B-DNA
gene	I-DNA
activation	O
.	O
	
Taken	O
together	O
,	O
our	O
results	O
will	O
help	O
to	O
understand	O
the	O
complex	O
interactions	O
occurring	O
between	O
HHV-6	O
and	O
the	O
CD4	B-DNA
promoter	I-DNA
and	O
provide	O
additional	O
information	O
regarding	O
the	O
class	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
CD4	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:98426244	
	
The	O
PEBP2betaMYH11	B-protein
fusion	O
created	O
by	O
Inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
in	O
myeloid	O
leukemia	O
impairs	O
neutrophil	O
maturation	O
and	O
contributes	O
to	O
granulocytic	O
dysplasia	O
.	O
	
Chromosomal	O
translocations	O
involving	O
the	O
genes	O
encoding	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
of	O
the	O
Pebp2/Cbf	B-protein
transcription	I-protein
factor	I-protein
have	O
been	O
associated	O
with	O
human	O
acute	O
myeloid	O
leukemia	O
and	O
the	O
preleukemic	O
condition	O
,	O
myelodysplasia	O
.	O
	
Inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
fuses	O
the	O
gene	O
encoding	O
the	O
beta	B-protein
subunit	I-protein
of	O
Pebp2	B-protein
to	O
the	O
MYH11	B-DNA
gene	I-DNA
encoding	O
a	O
smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
(	O
Smmhc	B-protein
)	O
.	O
	
To	O
examine	O
the	O
effect	O
of	O
the	O
inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
on	O
myelopoiesis	O
,	O
we	O
used	O
the	O
hMRP8	B-DNA
promoter	I-DNA
element	I-DNA
to	O
generate	O
transgenic	O
mice	O
expressing	O
the	O
Pebp2beta	B-protein
Smmhc	B-protein
chimeric	I-protein
fusion	I-protein
protein	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O
	
Neutrophil	O
maturation	O
was	O
impaired	O
in	O
PEBP2betaMYH11	B-protein
transgenic	O
mice	O
.	O
	
Although	O
the	O
transgenic	O
mice	O
had	O
normal	O
numbers	O
of	O
circulating	B-cell_type
neutrophils	I-cell_type
,	O
their	O
bone	O
marrow	O
contained	O
increased	O
numbers	O
of	O
immature	B-cell_type
neutrophilic	I-cell_type
cells	I-cell_type
,	O
which	O
exhibited	O
abnormal	O
characteristics	O
.	O
	
In	O
addition	O
,	O
PEBP2betaMYH11	B-protein
inhibited	O
neutrophilic	O
differentiation	O
in	O
colonies	O
derived	O
from	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O
	
Coexpression	O
of	O
both	O
PEBP2betaMYH11	B-protein
and	O
activated	B-protein
NRAS	I-protein
induced	O
a	O
more	O
severe	O
phenotype	O
characterized	O
by	O
abnormal	O
nuclear	O
morphology	O
indicative	O
of	O
granulocytic	O
dysplasia	O
.	O
	
These	O
results	O
show	O
that	O
PEBP2betaMYH11	B-protein
can	O
impair	O
neutrophil	O
development	O
and	O
provide	O
evidence	O
that	O
alterations	O
of	O
Pebp2	B-protein
can	O
contribute	O
to	O
the	O
genesis	O
of	O
myelodysplasia	O
.	O
	
###MEDLINE:98414302	
	
Human	O
T	O
cell	O
leukemia	O
virus-I	O
(	O
HTLV-I	O
)	O
Tax	B-protein
-mediated	O
apoptosis	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
requires	O
an	O
enhanced	O
intracellular	O
prooxidant	O
state	O
.	O
	
We	O
have	O
shown	O
that	O
an	O
estradiol-dependent	O
activation	O
of	O
human	O
T	O
cell	O
leukemia	O
virus-I	O
Tax	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
and	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O
	
The	O
present	O
study	O
demonstrates	O
that	O
a	O
hormone-dependent	O
activation	O
of	O
Tax	B-protein
promotes	O
an	O
enhanced	O
prooxidant	O
state	O
in	O
stably	B-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
as	O
measured	O
by	O
changes	O
in	O
the	O
intracellular	O
levels	O
of	O
glutathione	O
and	O
H2O2	O
;	O
these	O
changes	O
are	O
followed	O
by	O
apoptotic	O
cell	O
death	O
.	O
	
Additional	O
stimulation	O
of	O
the	O
CD3	B-protein
/TCR	B-protein
pathway	O
enhances	O
the	O
oxidative	O
and	O
apoptotic	O
effects	O
.	O
	
Both	O
Tax	B-protein
-mediated	O
apoptosis	O
and	O
oxidative	O
stress	O
can	O
be	O
potently	O
suppressed	O
by	O
antioxidants	O
,	O
as	O
is	O
seen	O
with	O
the	O
administration	O
of	O
recombinant	B-protein
thioredoxin	I-protein
(	O
adult	B-protein
T	I-protein
cell	I-protein
leukemia-derived	I-protein
factor	I-protein
)	O
or	O
pyrrolidine	O
dithiocarbamate	O
.	O
	
Hormone-induced	O
Tax	B-protein
activation	O
induces	O
a	O
long-lasting	O
activation	O
of	O
NF-kappaB	B-protein
,	O
which	O
is	O
a	O
major	O
target	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O
	
The	O
long-term	O
exposure	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
to	O
hormone	O
eventually	O
results	O
in	O
a	O
selection	O
of	O
cell	B-cell_line
clones	I-cell_line
that	O
have	O
lost	O
Tax	B-protein
activity	O
.	O
	
A	O
subsequent	O
transfection	O
of	O
these	O
apparently	O
``	B-cell_line
nonresponsive	I-cell_line
''	I-cell_line
clones	I-cell_line
allows	O
the	O
recovery	O
of	O
Tax	B-protein
responses	O
in	O
these	O
cells	O
.	O
	
Our	O
observations	O
indicate	O
that	O
changes	O
in	O
the	O
intracellular	O
redox	O
status	O
may	O
be	O
a	O
determining	O
factor	O
in	O
Tax	B-protein
-mediated	O
DNA	O
damage	O
,	O
apoptosis	O
,	O
and	O
selection	O
against	O
the	O
long-term	O
expression	O
of	O
Tax	B-protein
function	O
.	O
	
###MEDLINE:98401161	
	
An	O
allosteric	O
drug	O
,	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
,	O
suppresses	O
HIV-1	O
replication	O
through	O
prevention	O
of	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	B-protein
Tat	I-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O
	
The	O
efficacy	O
of	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV-1	O
laboratory	O
isolates	O
(	O
HTLV-IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O
	
BMT	O
inhibited	O
the	O
replication	O
of	O
HIV-1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O
	
In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O
	
Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans-disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'-bismyristoyl	O
esterification	O
of	O
TDS	O
.	O
	
BMT	O
inhibits	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	B-protein
transactivator	I-protein
(	O
TAT	B-protein
)	O
and	O
the	O
cellular	B-protein
transcriptional	I-protein
nuclear	I-protein
factor-KB	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV-1	O
replication	O
.	O
	
###MEDLINE:98389427	
	
Glucocorticoid-induced	O
apoptosis	O
and	O
regulation	O
of	O
NF-kappaB	B-protein
activity	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Glucocorticoid-induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
and	O
resistant	B-cell_line
ICR27TK.3	I-cell_line
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Following	O
glucocorticoid	O
treatment	O
of	O
6TG1.1	B-cell_line
cells	I-cell_line
,	O
chromatin	B-DNA
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O
	
Fragmentation	O
was	O
not	O
observed	O
in	O
ICR27TK.3	B-cell_line
cells	I-cell_line
containing	O
mutant	B-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
L753F	B-cell_line
)	O
that	O
are	O
activation-deficient	O
but	O
retain	O
the	O
ability	O
to	O
repress	O
AP-1	B-protein
activity	O
.	O
	
Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP-1	B-protein
activity	O
is	O
not	O
involved	O
.	O
	
As	O
described	O
in	O
other	O
systems	O
,	O
fragmentation	O
required	O
ongoing	O
protein	O
synthesis	O
.	O
	
However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O
	
Dexamethasone	O
treatment	O
completely	O
blocked	O
12-O-tetradecanoylphorbol	O
13-acetate	O
induction	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
activity	O
and	O
elicited	O
an	O
increase	O
in	O
the	O
amount	O
of	O
immunoreactive	B-protein
IkappaB	I-protein
alpha	I-protein
in	O
sensitive	O
6TG1.1	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
resistant	O
ICR27TK.3	B-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
,	O
mild	O
detergent	O
treatment	O
of	O
cell	O
extracts	O
indicated	O
that	O
a	O
substantial	O
amount	O
of	O
cytoplasmic	B-protein
NF-kappaB	I-protein
is	O
complexed	O
with	O
IkappaB	B-protein
alpha	I-protein
or	O
some	O
other	O
inhibitory	O
factor.	O
These	O
results	O
suggest	O
that	O
induction	O
of	O
a	O
labile	B-protein
inhibitory	I-protein
factor	I-protein
such	O
as	O
IkappaB	B-protein
alpha	I-protein
may	O
contribute	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O
	
###MEDLINE:98379695	
	
Inhibition	O
of	O
HIV-1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF-alpha	B-protein
with	O
AZT	O
.	O
	
The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O
	
S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3'-azido-3'-deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	B-protein
reverse	I-protein
transcriptase	I-protein
.	O
	
Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV-1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	B-cell_type
infected	I-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
(	O
SupT	B-cell_line
)	O
in	O
culture	O
and	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
infected	O
with	O
a	O
primary	O
HIV-1	O
isolate	O
.	O
	
S9a	O
inhibited	O
TNF-alpha	B-protein
promoter-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O
	
It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	B-protein
transcription	O
via	O
a	O
Tat	B-protein
-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	B-protein
activation	O
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure-based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O
	
This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	B-DNA
genes	I-DNA
.	O
	
###MEDLINE:98376488	
	
Highly	O
polarized	O
HLA	B-protein
class	I-protein
II	I-protein
antigen	I-protein
processing	O
and	O
presentation	O
by	O
human	B-cell_type
intestinal	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O
	
The	O
high	O
concentration	O
of	O
foreign	B-protein
antigen	I-protein
in	O
the	O
lumen	B-cell_type
of	O
the	O
gastrointestinal	O
tract	O
is	O
separated	O
from	O
the	O
underlying	O
lymphocytes	B-cell_type
by	O
a	O
single	O
cell	O
layer	O
of	O
polarized	O
epithelium	O
.	O
	
Intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
can	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
may	O
function	O
as	O
antigen-presenting	B-cell_type
cells	I-cell_type
to	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
within	O
the	O
intestinal	O
mucosa	O
.	O
	
Using	O
tetanus	B-cell_type
toxoid	I-cell_type
specific	I-cell_type
and	I-cell_type
HLA-DR-restricted	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
show	O
that	O
polarized	B-cell_type
intestinal	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
directed	O
to	O
express	O
HLA-DR	B-protein
molecules	I-protein
are	O
able	O
to	O
initiate	O
class	O
II	O
processing	O
only	O
after	O
internalization	O
of	O
antigen	O
from	O
their	O
apical	O
surface	O
.	O
	
Coexpression	O
of	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
CIITA	I-protein
in	O
these	O
cells	O
,	O
which	O
stimulates	O
highly	O
efficient	O
class	O
II	O
processing	O
without	O
the	O
characteristic	O
decline	O
in	O
barrier	O
function	O
seen	O
in	O
polarized	O
monolayers	O
treated	O
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
gamma-IFN	I-protein
,	O
facilitates	O
antigen	O
processing	O
from	O
the	O
basolateral	O
surface	O
.	O
	
In	O
both	O
cases	O
,	O
peptide	O
presentation	O
to	O
T	B-cell_type
cells	I-cell_type
via	O
class	B-protein
II	I-protein
molecules	I-protein
was	O
restricted	O
to	O
the	O
basolateral	O
surface	O
.	O
	
These	O
data	O
indicate	O
a	O
highly	O
polarized	O
functional	O
architecture	O
for	O
antigen	O
processing	O
and	O
presentation	O
by	O
intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
the	O
functional	O
outcome	O
of	O
antigen	O
processing	O
by	O
the	O
intestinal	O
epithelium	O
is	O
both	O
dependent	O
on	O
the	O
cellular	O
surface	O
at	O
which	O
the	O
foreign	O
antigen	O
is	O
internalized	O
and	O
by	O
the	O
underlying	O
degree	O
of	O
mucosal	O
inflammation	O
	
###MEDLINE:99032837	
	
Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	B-protein
and	O
inhibition	O
of	O
NFkappaB	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
effects	O
on	O
TNFalpha	B-protein
release	O
.	O
	
Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	B-cell_type
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	B-protein
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
alpha	I-protein
.	O
	
TS	O
induces	O
the	O
synthesis	O
of	O
heat	B-protein
shock	I-protein
(	I-protein
HS	I-protein
)	I-protein
/stress	I-protein
proteins	I-protein
(	O
HSP	B-protein
)	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
Hsp70	B-protein
.	O
	
We	O
determined	O
whether	O
Hsp70	B-protein
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B-protein
transcription	I-protein
factor	I-protein
,	O
HSF	B-protein
.	O
	
HSF	B-protein
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	B-protein
.	O
	
Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	B-protein
.	O
	
U937	B-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	B-protein
factors	I-protein
were	O
analyzed	O
,	O
and	O
Hsp70	B-protein
expression	O
and	O
TNFalpha	B-protein
release	O
were	O
determined	O
in	O
parallel	O
.	O
	
TS	O
activated	O
HSF	B-protein
,	O
which	O
was	O
associated	O
with	O
Hsp70	B-protein
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	B-protein
binding	O
activity	O
and	O
TNFalpha	B-protein
release	O
.	O
	
The	O
altered	O
cytokine	B-protein
profile	I-protein
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF	B-protein
/	O
Hsp70	B-protein
-mediated	O
inhibition	O
of	O
NFkappaB	B-protein
activity	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99016857	
	
[	O
Molecular	O
mechanism	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
Th1	B-cell_line
and	O
Th2	B-cell_line
]	O
	
Upon	O
activation	O
by	O
antigens	B-protein
,	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
differentiate	O
into	O
one	O
of	O
several	O
subsets	O
,	O
characterized	O
by	O
their	O
distinct	O
cytokine	B-protein
-production	O
patterns	O
.	O
	
Among	O
these	O
subsets	O
,	O
Th1	B-cell_line
cells	I-cell_line
are	O
known	O
to	O
activate	O
cellular	O
immunity	O
resulting	O
in	O
inflammatory	O
response	O
,	O
whereas	O
Th2	B-cell_line
cells	I-cell_line
induce	O
humoral	O
and	O
allergic	O
responses	O
and	O
suppress	O
inflammation	O
.	O
	
Th1	O
and	O
Th2	O
effector	O
functions	O
and	O
their	O
development	O
are	O
attributable	O
to	O
their	O
distinct	O
cytokine	B-protein
expression	O
patterns	O
.	O
	
Recent	O
reports	O
have	O
demonstrated	O
that	O
differential	O
expression	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
adhesion	B-protein
molecule	I-protein
and	O
chemokine	B-protein
receptor	I-protein
,	O
is	O
involved	O
in	O
their	O
recruitment	O
into	O
target	O
tissues	O
.	O
	
It	O
is	O
,	O
therefore	O
,	O
suggested	O
that	O
clarification	O
of	O
the	O
mechanisms	O
of	O
differential	O
gene	O
expression	O
in	O
Th1/Th2	B-cell_line
should	O
lead	O
to	O
rational	O
strategies	O
for	O
manipulating	O
pathological	O
immune	O
responses	O
.	O
	
Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O
	
Among	O
them	O
,	O
both	O
the	O
activation	O
of	O
PKC/Ras-	O
and	O
CaM/CN-mediated	O
pathways	O
play	O
a	O
central	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O
	
Closer	O
examination	O
using	O
non-transformed	B-cell_line
murine	I-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
suggested	O
that	O
a	O
balance	O
between	O
the	O
activities	O
of	O
the	O
two	O
signaling	O
pathways	O
contributes	O
to	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O
	
We	O
propose	O
that	O
one	O
of	O
the	O
targets	O
of	O
PGE2	O
,	O
whose	O
effect	O
distinguishes	O
Th1	B-cell_line
from	O
Th2	O
,	O
resides	O
in	O
the	O
downstream	O
PKC/Ras	B-protein
-mediated	O
pathway	O
.	O
	
###MEDLINE:99008372	
	
Signalling	O
into	O
the	O
T-cell	O
nucleus	O
:	O
NFAT	B-protein
regulation	O
.	O
	
The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
plays	O
an	O
important	O
role	O
in	O
T-cell	O
biology	O
.	O
	
Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	B-protein
-dependent	O
translocation	O
of	O
NFAT	B-protein
transcription	B-protein
factors	I-protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O
	
This	O
translocation	O
process	O
coupled	O
to	O
the	O
subsequent	O
active	O
maintenance	O
of	O
NFAT	B-protein
in	O
the	O
nucleus	O
compartment	O
is	O
critical	O
for	O
the	O
induction	O
of	O
expression	O
of	O
several	O
genes	O
encoding	O
cytokines	B-protein
and	O
membrane	B-protein
proteins	I-protein
that	O
modulate	O
immune	O
responses	O
.	O
	
The	O
molecular	O
cloning	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
facilitated	O
rapid	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signalling	O
mechanisms	O
that	O
control	O
the	O
activity	O
of	O
NFAT	B-protein
.	O
	
###MEDLINE:98455230	
	
Differential	O
RNA	O
display	O
identifies	O
novel	B-DNA
genes	I-DNA
associated	O
with	O
decreased	O
vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
.	O
	
To	O
characterize	O
further	O
the	O
function	O
of	O
the	O
intracellular	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
we	O
have	O
developed	O
stable	B-cell_line
transfectant	I-cell_line
variants	I-cell_line
of	O
a	O
vitamin	B-cell_line
D-responsive	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
which	O
express	O
either	O
decreased	O
or	O
increased	O
numbers	O
of	O
VDR	B-protein
.	O
	
In	O
this	O
study	O
we	O
have	O
analyzed	O
changes	O
in	O
gene	O
expression	O
associated	O
with	O
this	O
variable	O
VDR	B-protein
expression	O
.	O
	
Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	B-protein
levels	O
was	O
associated	O
with	O
a	O
2-fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
.	O
	
Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O
	
Sequence	O
analysis	O
of	O
DD	B-protein
products	I-protein
revealed	O
two	O
cDNAs	B-DNA
with	O
identity	O
to	O
known	B-protein
gene	I-protein
products	I-protein
:	O
the	O
catalytic	B-protein
sub-unit	I-protein
of	I-protein
DNA-protein	I-protein
kinase	I-protein
(	O
DNA-PK	B-protein
(	I-protein
CS	I-protein
)	I-protein
)	O
,	O
and	O
the	O
peroxisomal	B-protein
enzyme	I-protein
17beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
type	I-protein
IV	I-protein
(	O
17beta-HSD	B-protein
IV	I-protein
)	O
.	O
	
Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	B-RNA
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	B-protein
.	O
	
Down-regulation	O
of	O
17beta-HSD	B-protein
IV	I-protein
mRNA	O
expression	O
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O
	
Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta-HSD	B-protein
IV	I-protein
or	O
DNA-PK	B-RNA
(	I-RNA
CS	I-RNA
)	I-RNA
mRNA	I-RNA
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O
	
These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone-dependent	B-protein
trans-activator	I-protein
,	O
VDR	B-protein
may	O
influence	O
gene	O
expression	O
by	O
ligand-independent	O
mechanisms	O
.	O
	
###MEDLINE:98438501	
	
Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
gene	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O
	
Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B-protein
and	I-protein
host	I-protein
cellular	I-protein
factors	I-protein
.	O
	
Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	B-protein
immunomodulatory	I-protein
molecule	I-protein
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O
	
In	O
1G5	B-cell_line
,	O
a	O
Jurkat-derived	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
stably	O
transfected	O
with	O
a	O
luciferase	B-DNA
gene	I-DNA
driven	O
by	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	B-DNA
LTR	I-DNA
-mediated	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O
	
Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	B-protein
messengers	I-protein
involved	O
in	O
this	O
PGE2-dependent	O
up-regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O
	
In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
Ca2+	O
.	O
	
Experiments	O
conducted	O
with	O
different	O
HIV-1	B-DNA
LTR-based	I-DNA
vectors	I-DNA
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O
	
The	O
involvement	O
of	O
NF-kappaB	B-protein
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB-regulated	B-DNA
luciferase	I-DNA
encoding	I-DNA
vector	I-DNA
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
studied	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
is	O
transduced	O
via	O
the	O
EP4	B-protein
receptor	I-protein
subtype	I-protein
.	O
	
These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	B-cell_type
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	B-cell_type
cells	I-cell_type
latently	O
infected	O
with	O
HIV-1	O
.	O
	
###MEDLINE:98422270	
	
Activation	O
of	O
distinct	O
transcription	B-protein
factors	I-protein
in	O
neutrophils	B-cell_type
by	O
bacterial	O
LPS	O
,	O
interferon-gamma	B-protein
,	O
and	O
GM-CSF	B-protein
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	B-protein
proteases	I-protein
.	O
	
Human	O
neutrophils	B-cell_type
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early-response	B-DNA
genes	I-DNA
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B-protein
,	O
chemokines	B-protein
,	O
and	O
the	O
high-affinity	O
surface	O
receptor	O
for	O
IgG	B-protein
,	O
FcgammaRI	B-protein
.	O
	
Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
members	O
of	O
the	O
NF-kappaB	B-protein
and	O
STAT	B-protein
families	I-protein
.	O
	
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	B-protein
factors	I-protein
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O
	
Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF-kappaB/Rel	B-protein
and	O
STAT	B-protein
proteins	I-protein
.	O
	
To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	B-cell_type
,	O
LPS	O
and	O
TNFalpha	B-protein
induce	O
a	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50/RelA	B-protein
dimers	I-protein
,	O
and	O
that	O
IFNgamma	B-protein
promotes	O
the	O
binding	O
of	O
STAT1	B-protein
homodimers	I-protein
to	O
the	O
IFNgamma	B-DNA
response	I-DNA
region	I-DNA
of	O
the	O
FcgammaRI	B-DNA
promoter	I-DNA
.	O
	
Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM-CSF	B-protein
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	B-protein
-containing	O
DNA-binding	O
activity	O
.	O
	
Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O
	
In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	B-protein
proteases	I-protein
.	O
	
###MEDLINE:98413772	
	
Low	O
CD3+CD28-induced	O
interleukin-2	B-protein
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
capacity	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
secrete	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O
	
We	O
analysed	O
IL-2	B-protein
production	O
in	O
purified	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor-mediated	O
anti-CD3	B-protein
/anti-CD3+	O
anti-CD28	B-protein
stimulation	O
.	O
	
PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL-2	B-protein
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate-bound	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
,	O
the	O
IL-2	B-protein
secretion	O
by	O
neonatal	B-cell_type
cells	I-cell_type
was	O
undetectable	O
and	O
adult	B-cell_type
cells	I-cell_type
produced	O
low	O
amounts	O
of	O
IL-2	B-protein
(	O
mean	O
331	O
+/-	O
86	O
pg/ml	O
)	O
.	O
	
The	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3-stimulated	B-cell_line
cells	I-cell_line
markedly	O
increased	O
IL-2	B-protein
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	B-protein
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
respective	O
mean	O
values	O
:	O
385	O
+/-	O
109	O
pg/ml	O
and	O
4494	O
+/-	O
1199	O
pg/ml	O
)	O
.	O
	
As	O
NF-kappa	B-protein
B	I-protein
is	O
a	O
critical	O
transcription	B-protein
factor	I-protein
in	O
the	O
control	O
of	O
IL-2	B-protein
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI-reactive	O
fluorochrome	O
DCFH-DA	O
and	O
flow	O
cytometry	O
.	O
	
In	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
NF-kappa	B-protein
B	I-protein
activation	O
and	O
ROI	O
formation	O
after	O
anti-CD3	B-protein
stimulation	O
were	O
low	O
compared	O
with	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
,	O
although	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
increased	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
ROI	O
formation	O
,	O
levels	O
similar	O
to	O
those	O
of	O
adults	O
were	O
not	O
achieved	O
.	O
	
After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL-2	B-protein
secretion	O
.	O
	
Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	B-protein
production	O
by	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
specific	O
for	O
anti-CD3	B-protein
and	O
anti-CD3	B-protein
+	O
anti-CD28	B-protein
-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98397262	
	
CD30	B-protein
is	O
a	O
CD40-inducible	B-protein
molecule	I-protein
that	O
negatively	O
regulates	O
CD40-mediated	B-protein
immunoglobulin	I-protein
class	O
switching	O
in	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O
	
We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B-protein
in	O
human	O
B	O
cell	O
differentiation	O
.	O
	
CL-01	B-cell_line
cells	I-cell_line
are	O
IgM	B-protein
+	O
IgD	B-protein
+	O
CD30	B-protein
+	O
and	O
switch	O
to	O
IgG	B-protein
,	O
IgA	B-protein
,	O
and	O
IgE	B-protein
when	O
exposed	O
to	O
CD40L	B-protein
and	O
IL-4	B-protein
.	O
	
Switching	O
is	O
hampered	O
by	O
CD30	B-protein
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
downstream	B-DNA
C	I-DNA
(	I-DNA
H	I-DNA
)	I-DNA
genes	I-DNA
.	O
	
The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	B-protein
-mediated	O
effects	O
in	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
Expression	O
of	O
CD30	B-protein
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B-protein
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	B-protein
and	O
IL-12	B-protein
.	O
	
Our	O
data	O
suggest	O
that	O
CD30	B-protein
critically	O
regulates	O
the	O
CD40	B-protein
-mediated	O
differentiation	O
of	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:98390872	
	
Calcineurin	B-protein
and	O
the	O
biological	O
effect	O
of	O
cyclosporine	O
and	O
tacrolimus	O
.	O
	
The	O
mechanism	O
of	O
the	O
immunosuppressive	O
effect	O
of	O
CyA	O
and	O
FK	O
506	O
can	O
be	O
monitored	O
in	O
vivo	O
in	O
humans	O
.	O
	
The	O
picture	O
emerging	O
is	O
of	O
a	O
close	O
relationship	O
between	O
drug	O
concentrations	O
and	O
CN	O
inhibition	O
.	O
	
But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O
	
What	O
is	O
the	O
role	O
of	O
CyA	O
in	O
the	O
activation	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
,	O
particularly	O
in	O
relationship	O
to	O
nephrotoxicity	O
and	O
fibrogenesis	O
?	O
	
How	O
important	O
are	O
the	O
anti-inflammatory	O
(	O
non	O
T	O
)	O
effects	O
of	O
CyA	O
,	O
and	O
which	O
cells	O
do	O
they	O
operate	O
in	O
?	O
	
Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
?	O
	
Finally	O
,	O
it	O
would	O
be	O
useful	O
to	O
know	O
what	O
the	O
inhibitory	O
effects	O
of	O
CyA	O
are	O
on	O
tolerance	O
and	O
negative	O
regulatory	O
events	O
.	O
	
###MEDLINE:98380286	
	
Stimulation	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
activates	O
expression	O
of	O
transcription	B-protein
and	I-protein
differentiation	I-protein
factors	I-protein
.	O
	
During	O
B	O
and	O
T	O
cell	O
differentiation	O
and	O
proliferation	O
many	O
genes	O
are	O
induced	O
or	O
repressed	O
while	O
certain	O
genes	O
are	O
constitutively	O
expressed	O
.	O
	
To	O
investigate	O
processes	O
related	O
to	O
B	O
and	O
T	O
cell	O
activation	O
,	O
the	O
gene	O
expression	O
of	O
stimulated	O
and	O
nonstimulated	B-cell_line
Ramos	I-cell_line
and	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
was	O
studied	O
using	O
cDNA	O
microarray	O
technology	O
.	O
	
Simultaneous	O
analysis	O
of	O
close	O
to	O
600	B-DNA
genes	I-DNA
indicated	O
highest	O
increase	O
in	O
the	O
expression	O
of	O
certain	O
transcription	B-protein
,	I-protein
differentiation	I-protein
and	I-protein
proliferation	I-protein
factors	I-protein
.	O
	
Many	O
of	O
these	O
genes	O
have	O
not	O
previously	O
been	O
shown	O
to	O
funcion	O
in	O
the	O
stimulated	B-cell_type
lymphocytes	I-cell_type
.	O
	
Also	O
genes	O
encoding	O
proteins	O
involved	O
in	O
DNA	O
replication	O
,	O
binding	O
,	O
transcription	O
and	O
translation	O
were	O
induced	O
.	O
	
Large	O
part	O
of	O
the	O
activated	B-DNA
genes	I-DNA
were	O
under	O
very	O
stringent	O
regulation	O
being	O
expressed	O
only	O
after	O
stimulation	O
.	O
	
The	O
mechanism	O
and	O
function	O
of	O
the	O
expressed	B-DNA
genes	I-DNA
during	O
lymphocyte	O
differentiation	O
and	O
in	O
disorders	O
is	O
discussed	O
.	O
	
###MEDLINE:99030136	
	
Interleukin	B-protein
2	I-protein
and	I-protein
15	I-protein
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
(	O
Stat3	B-protein
)	O
has	O
recently	O
been	O
shown	O
to	O
exist	O
in	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
a	O
short	O
form	O
,	O
Stat3beta	B-protein
,	O
and	O
a	O
longer	O
form	O
,	O
Stat3alpha	B-protein
,	O
displaying	O
differences	O
in	O
transcriptional	O
activity	O
.	O
	
It	O
is	O
unknown	O
which	O
Stat3	B-protein
isoform	I-protein
(	O
s	O
)	O
is	O
activated	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
and	O
IL-15	B-protein
.	O
	
Here	O
,	O
cytokine	B-protein
-induced	O
activation	O
of	O
Stat3	B-protein
in	O
previously	O
activated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
examined	O
using	O
Stat3	B-protein
antibodies	O
directed	O
against	O
different	O
regions	O
of	O
Stat3	B-protein
.	O
	
As	O
determined	O
by	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
and	O
binding	O
to	O
an	O
hSIE-oligonucleotide	O
probe	O
,	O
IL-2	B-protein
and	O
IL-15	B-protein
activated	O
the	O
slowly	O
migrating	O
isoform	O
,	O
Stat3alpha	B-protein
.	O
	
In	O
contrast	O
,	O
minimal	O
or	O
no	O
activation	O
of	O
Stat3beta	B-protein
was	O
observed	O
,	O
suggesting	O
that	O
IL-2	B-protein
and	O
IL-15	B-protein
predominantly	O
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
this	O
way	O
,	O
diversity	O
in	O
the	O
expression	O
and	O
activation	O
of	O
Stat3	B-protein
proteins	I-protein
may	O
provide	O
additional	O
means	O
of	O
regulating	O
cytokine	B-protein
-induced	O
T	O
cell	O
responses	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:99018025	
	
Transcriptional	O
regulation	O
of	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
AP-2	B-protein
.	O
	
Human	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
(	O
LAL	B-protein
)	O
is	O
a	O
hydrolase	B-protein
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O
	
It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL-mRNA	B-RNA
is	O
induced	O
.	O
	
This	O
induction	O
is	O
dependent	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
and	O
protein	O
synthesis	O
.	O
	
The	O
cell	O
type-specific	O
increase	O
in	O
LAL	B-protein
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O
	
The	O
human	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
differentiates	O
into	O
macrophage-like	B-cell_type
cells	I-cell_type
when	O
treated	O
with	O
phorbol	O
esters	O
.	O
	
In	O
order	O
to	O
determine	O
the	O
cis-acting	B-DNA
elements	I-DNA
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate-13	O
acetate	O
(	O
PMA	O
)	O
-enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	B-DNA
gene	I-DNA
assays	O
.	O
	
A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
has	O
been	O
identified	O
between	O
-182	B-DNA
bp	I-DNA
and	O
-107	B-DNA
bp	I-DNA
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O
	
Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	B-protein
and	O
AP-2	B-protein
to	O
the	O
LAL	B-DNA
promoter	I-DNA
is	O
increased	O
by	O
PMA	O
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
Co-transfections	O
with	O
expression	B-DNA
plasmids	I-DNA
for	O
Sp1	B-protein
and	O
AP-2	B-protein
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	B-protein
factors	I-protein
in	O
both	O
basal	O
and	O
PMA-enhanced	O
LAL	B-protein
expression	O
.	O
	
Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
(	O
LAL	B-protein
)	O
expression	O
in	O
THP-1	B-cell_line
cells	I-cell_line
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	B-protein
and	O
AP-2	B-protein
.	O
	
###MEDLINE:99008340	
	
Relationship	O
between	O
IkappaBalpha	B-protein
constitutive	O
expression	O
,	O
TNFalpha	B-protein
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV-infected	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
.	O
	
In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B-protein
into	O
lymphoblastoid	B-cell_type
cells	I-cell_type
.	O
	
Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF-kappaB	B-protein
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B-protein
.	O
	
Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O
	
Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	B-protein
cell	O
cycle	O
analysis	O
after	O
BrdU	B-protein
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O
	
Percentage	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
was	O
determined	O
by	O
in-situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O
	
No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O
	
In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	B-cell_line
clones	I-cell_line
.	O
	
Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	B-cell_line
transfected	I-cell_line
cells	I-cell_line
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	B-protein
treatment	O
.	O
	
This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B-protein
treatment	O
.	O
	
No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	B-cell_line
cells	I-cell_line
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O
	
Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B-DNA
gene	I-DNA
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF-kappaB	B-protein
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF-kappaB	B-cell_type
protects	I-cell_type
EBV-infected	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B-protein
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	B-protein
.	O
	
###MEDLINE:98455033	
	
Seminoma	O
in	O
a	O
postmenopausal	O
woman	O
with	O
a	O
Y	B-DNA
;	I-DNA
15	I-DNA
translocation	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
a	O
t	O
(	O
Y	O
;	O
15	O
)	O
/45	O
,	O
X	O
Turner	O
mosaic	O
pattern	O
in	O
skin	B-cell_type
fibroblasts	I-cell_type
.	O
	
We	O
report	O
an	O
unusual	O
case	O
of	O
a	O
55	O
year	O
old	O
Japanese	O
woman	O
with	O
a	O
seminoma	O
but	O
relatively	O
normal	O
menses	O
.	O
	
The	O
patient	O
was	O
a	O
phenotypic	O
female	O
with	O
late	O
onset	O
menarche	O
(	O
18	O
years	O
of	O
age	O
)	O
,	O
who	O
was	O
amenorrhoeic	O
for	O
the	O
first	O
year	O
,	O
followed	O
by	O
menses	O
of	O
one	O
to	O
three	O
days	O
'	O
slight	O
flow	O
with	O
dysmenorrhoea	O
,	O
but	O
an	O
otherwise	O
normal	O
menstrual	O
history	O
.	O
	
A	O
typical	O
seminoma	O
was	O
removed	O
from	O
the	O
left	O
adnexal	O
region	O
and	O
an	O
immature	O
testis	O
was	O
identified	O
separately	O
as	O
an	O
associated	O
right	O
adnexal	O
mass	O
.	O
	
Repeated	O
karyotypic	O
studies	O
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
cultures	I-cell_type
showed	O
only	O
46	O
,	O
X	O
,	O
-Y	O
,	O
t	O
(	O
Y	O
;	O
15	O
)	O
(	O
q12	O
;	O
p13	O
)	O
.	O
	
Cytogenetic	O
examination	O
of	O
the	O
patient	O
's	O
younger	O
brother	O
,	O
who	O
had	O
fathered	O
three	O
healthy	O
children	O
,	O
showed	O
an	O
identical	O
karyotype	O
.	O
	
Mosaicism	O
of	O
46	B-cell_line
,	I-cell_line
X	I-cell_line
,	I-cell_line
-Y	I-cell_line
,	I-cell_line
t	I-cell_line
(	I-cell_line
Y	I-cell_line
;	I-cell_line
15	I-cell_line
)	I-cell_line
(	I-cell_line
q12	I-cell_line
;	I-cell_line
p13	I-cell_line
)	I-cell_line
/45	I-cell_line
,	I-cell_line
X	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
found	O
in	O
skin	O
samples	O
from	O
the	O
patient	O
's	O
elbow	O
and	O
genital	O
regions	O
,	O
although	O
there	O
were	O
no	O
clinical	O
stigmata	O
of	O
Turner	O
syndrome	O
.	O
	
An	O
androgen	O
receptor	O
binding	O
assay	O
of	O
cultured	B-cell_line
genital	I-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
was	O
negative	O
.	O
	
Molecular	O
analysis	O
using	O
Southern	O
blot	O
hybridisation	O
,	O
PCR	O
,	O
and	O
direct	O
DNA	O
sequencing	O
showed	O
that	O
neither	O
the	O
patient	O
nor	O
her	O
brother	O
had	O
a	O
detectable	O
deletion	O
or	O
other	O
abnormalities	O
of	O
Y	O
chromosome	O
sequences	O
,	O
including	O
the	O
SRY	B-DNA
(	I-DNA
sex	I-DNA
determining	I-DNA
region	I-DNA
of	I-DNA
the	I-DNA
Y	I-DNA
chromosome	I-DNA
)	I-DNA
gene	I-DNA
sequence	I-DNA
.	O
	
These	O
findings	O
suggest	O
that	O
Turner	O
mosaicism	O
of	O
the	O
45	B-cell_line
,	I-cell_line
X	I-cell_line
cell	I-cell_line
line	I-cell_line
may	O
have	O
contributed	O
to	O
this	O
atypical	O
presentation	O
in	O
an	O
XY	O
female	O
,	O
although	O
we	O
can	O
not	O
exclude	O
abnormalities	O
of	O
other	O
genes	O
related	O
to	O
sex	O
differentiation	O
.	O
	
###MEDLINE:98435936	
	
Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	B-cell_type
infected	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O
	
As	O
several	O
inflammatory	B-protein
cytokines	I-protein
and	O
oxidative	O
stresses	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B-protein
)	O
-	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
HIV-1	O
replication	O
in	O
chronically	B-cell_line
infected	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Two	O
chronically	B-cell_line
HIV-1-infected	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
U1	B-cell_line
(	O
monocytic	O
)	O
and	O
ACH-2	B-cell_line
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF-alpha	B-protein
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O
	
HIV-1	O
replication	O
was	O
determined	O
by	O
p24	B-protein
antigen	I-protein
level	O
.	O
	
The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
gene	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
activation	O
were	O
also	O
examined	O
.	O
	
Cepharanthine	O
dose	O
dependently	O
inhibited	O
HIV-1	O
replication	O
in	O
TNF-alpha-	B-cell_line
and	I-cell_line
PMA-stimulated	I-cell_line
U1	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
ACH-2	B-cell_line
cells	I-cell_line
.	O
	
Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0.016	O
and	O
2.2	O
microg/ml	O
in	O
PMA-stimulated	B-cell_line
U1	I-cell_line
cells	I-cell_line
,	O
respectively	O
.	O
	
Cepharanthine	O
was	O
found	O
to	O
suppress	O
HIV-1	B-DNA
LTR	I-DNA
-driven	O
gene	O
expression	O
through	O
the	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
.	O
	
These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV-1	O
replication	O
in	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Since	O
biscoclaurine	O
alkaloids	O
,	O
containing	O
cepharanthine	O
as	O
a	O
major	O
component	O
,	O
are	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
various	O
inflammatory	O
diseases	O
in	O
Japan	O
,	O
cepharanthine	O
should	O
be	O
further	O
pursued	O
for	O
its	O
chemotherapeutic	O
potential	O
in	O
HIV-1-infected	O
patients	O
.	O
	
###MEDLINE:98418492	
	
NF-kappaB	B-protein
only	O
partially	O
mediates	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
activation	O
of	O
B	O
cells	O
.	O
	
The	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV-induced	O
immortalization	O
of	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	B-cell_line
lines	I-cell_line
.	O
	
LMP1	B-protein
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up-regulation	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	I-protein
.	O
	
LMP1	B-protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
one	O
through	O
interactions	O
with	O
TRAF	B-protein
proteins	I-protein
and	O
the	O
other	O
with	O
the	O
TRADD	B-protein
protein	I-protein
.	O
	
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF-kappaB	B-protein
induction	O
in	O
the	O
up-regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	B-protein
and	O
CD71	B-protein
by	O
LMP1	B-protein
.	O
	
This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B-protein
activates	O
transcription	O
from	O
p50/p65-	B-DNA
and	I-DNA
c-Rel-	I-DNA
responsive	I-DNA
promoters	I-DNA
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	B-protein
IkappaB	I-protein
mutant	I-protein
.	O
	
ICAM-1	B-protein
and	O
CD71	B-protein
are	O
nevertheless	O
up-regulated	O
by	O
LMP1	B-protein
in	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
cell	O
lines	O
expressing	O
the	O
dominant	B-protein
IkappaB	I-protein
.	O
	
Furthermore	O
,	O
LMP1	B-protein
-induced	O
cell	O
size	O
increase	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
was	O
unaffected	O
by	O
IkappaB	B-protein
expression	O
.	O
	
It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-protein
is	O
unable	O
to	O
activate	O
NF-kappaB	B-protein
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
strongly	O
suggesting	O
that	O
LMP1	B-protein
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF-kappaB	B-protein
.	O
	
###MEDLINE:98407711	
	
Models	O
of	O
lineage	O
switching	O
in	O
hematopoietic	O
development	O
:	O
a	O
new	O
myeloid-committed	B-cell_line
eosinophil	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
YJ	B-cell_line
)	O
demonstrates	O
trilineage	O
potential	O
.	O
	
A	O
new	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
an	O
eosinophilic	O
phenotype	O
,	O
designated	O
YJ	B-cell_line
,	O
was	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
a	O
patient	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMMoL	O
)	O
with	O
eosinophilia	O
.	O
	
When	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
most	O
YJ	B-cell_line
cells	I-cell_line
were	O
myeloblastoid	O
with	O
a	O
small	O
number	O
of	O
the	O
cells	O
having	O
eosinophilic	O
granules	O
.	O
	
Cell	B-protein
surface	I-protein
markers	I-protein
in	O
the	O
YJ	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
CD33	B-protein
and	O
were	O
negative	O
for	O
CD34	B-protein
,	O
CD16	B-protein
and	O
CD23	B-protein
.	O
	
The	O
eosinophilic	O
characteristics	O
of	O
YJ	B-cell_line
cells	I-cell_line
were	O
confirmed	O
by	O
histochemical	O
staining	O
with	O
Fast-Green/Neutral-Red	O
and	O
by	O
the	O
expression	O
of	O
mRNAs	B-RNA
for	O
eosinophil-associated	B-protein
granule	I-protein
proteins	I-protein
,	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
(	O
ECP	B-protein
)	O
,	O
eosinophil-derived	B-protein
neurotoxin	I-protein
(	O
EDN	B-protein
)	O
,	O
eosinophil	B-protein
peroxidase	I-protein
(	O
EPO	B-protein
)	O
,	O
and	O
major	B-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
,	O
and	O
for	O
the	O
Charcot-Leyden	B-protein
crystal	I-protein
(	I-protein
CLC	I-protein
)	I-protein
protein	I-protein
.	O
	
The	O
YJ	B-cell_line
cells	I-cell_line
could	O
be	O
induced	O
towards	O
monocytic	O
differentiation	O
by	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
	
The	O
monocytic	O
characteristics	O
of	O
YJ	B-cell_line
cells	I-cell_line
treated	O
with	O
PMA	O
were	O
confirmed	O
by	O
morphological	O
analysis	O
with	O
alpha-naphthyl	O
butyrate	O
esterase	O
staining	O
,	O
by	O
CD14	B-protein
expression	O
,	O
and	O
by	O
increased	O
expression	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
.	O
	
Furthermore	O
,	O
YJ	B-cell_line
cells	I-cell_line
could	O
be	O
differentiated	O
towards	O
the	O
neutrophil	B-cell_type
lineage	I-cell_type
by	O
stimulation	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O
	
YJ	B-cell_line
cells	I-cell_line
treated	O
in	O
vitro	O
with	O
2	O
microM	O
RA	O
differentiated	O
into	O
metamyelocytes	B-cell_type
and	O
band	B-cell_type
neutrophils	I-cell_type
,	O
and	O
increased	O
the	O
number	O
of	O
nitroblue	B-cell_line
tetrazolium	I-cell_line
(	I-cell_line
NBT	I-cell_line
)	I-cell_line
-positive	I-cell_line
cells	I-cell_line
and	O
increased	O
gp91phox	B-RNA
mRNA	I-RNA
expression	O
.	O
	
Thus	O
,	O
the	O
YJ	B-cell_line
cell	I-cell_line
line	I-cell_line
exhibited	O
eosinophilic	O
characteristics	O
,	O
but	O
was	O
able	O
to	O
differentiate	O
to	O
the	O
monocytic	B-cell_type
or	I-cell_type
neutrophilic	I-cell_type
lineages	I-cell_type
in	O
response	O
to	O
PMA	O
or	O
RA	O
,	O
respectively	O
.	O
	
The	O
expression	O
of	O
genes	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
myeloid	O
differentiation	O
was	O
evaluated	O
by	O
Northern	O
blot	O
analysis	O
.	O
	
Increased	O
expression	O
of	O
Egr-1	B-protein
was	O
observed	O
with	O
macrophage	O
differentiation	O
.	O
	
In	O
contrast	O
,	O
increased	O
expressions	O
of	O
C/EBPbeta	B-protein
and	O
MZF-1	B-RNA
mRNA	I-RNA
occurred	O
with	O
neutrophilic	O
differentiation	O
.	O
	
The	O
YJ	B-cell_line
cell	I-cell_line
line	I-cell_line
should	O
be	O
useful	O
for	O
elucidating	O
the	O
molecular	O
mechanisms	O
governing	O
lineage	O
switching	O
from	O
the	O
eosinophil	B-cell_type
to	O
monocytic	B-cell_type
or	I-cell_type
neutrophil	I-cell_type
lineages	I-cell_type
.	O
	
###MEDLINE:98400938	
	
Interleukin-6	B-protein
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O
	
Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	B-protein
and	O
recruitment	O
of	O
neutrophils	B-cell_type
(	O
PMN	B-cell_type
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O
	
To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	B-protein
and	O
activation	O
of	O
Stat3	B-protein
.	O
	
Using	O
semiquantitative	O
RT-PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	B-RNA
mRNA	I-RNA
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O
	
Increased	O
IL-6	B-protein
protein	O
expression	O
was	O
localized	O
to	O
bronchial	B-cell_type
and	I-cell_type
alveolar	I-cell_type
cells	I-cell_type
.	O
	
Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B-protein
activation	O
with	O
kinetics	O
similar	O
to	O
IL-6	B-RNA
mRNA	I-RNA
.	O
	
In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B-protein
activation	O
predominantly	O
within	O
alveoli	O
.	O
	
Intratracheal	O
instillation	O
of	O
IL-6	B-protein
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet-to-dry	O
ratio	O
.	O
	
These	O
findings	O
indicate	O
that	O
IL-6	B-protein
production	O
and	O
Stat3	B-protein
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN-mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O
	
###MEDLINE:98391735	
	
The	O
MHC	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
requires	O
conserved	O
leucine	B-protein
charged	I-protein
domains	I-protein
for	O
interactions	O
with	O
the	O
conserved	O
W	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
.	O
	
The	O
class	B-protein
II	I-protein
transactivator	I-protein
CIITA	B-protein
is	O
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O
	
Aside	O
from	O
an	O
N-terminal	B-DNA
acidic	I-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
,	O
little	O
is	O
known	O
about	O
how	O
this	O
factor	O
functions	O
.	O
	
Extensive	O
mutagenesis	O
of	O
CIITA	B-protein
was	O
undertaken	O
to	O
identify	O
structural	O
motifs	O
required	O
for	O
function	O
.	O
	
The	O
ability	O
of	O
mutants	O
to	O
activate	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
conserved	O
W-X-Y	B-DNA
or	I-DNA
X-Y	I-DNA
regulatory	I-DNA
elements	I-DNA
was	O
determined	O
.	O
	
Two	O
mutants	O
displayed	O
differential	O
activity	O
between	O
the	O
two	O
promoters	B-DNA
,	O
activating	O
transcription	O
with	O
the	O
W-X-Y	B-DNA
but	I-DNA
not	I-DNA
the	I-DNA
X-Y	I-DNA
elements	I-DNA
.	O
	
All	O
mutants	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interfere	O
with	O
wild-type	O
CIITA	B-protein
activity	O
.	O
	
Five	O
CIITA	B-DNA
mutant	I-DNA
constructions	I-DNA
were	O
able	O
to	O
down-regulate	O
wild-type	O
CIITA	B-protein
activity	O
.	O
	
Three	O
of	O
these	O
mutants	O
contained	O
targeted	O
disruptions	O
of	O
potential	O
functional	O
motifs	O
:	O
the	O
acidic	B-protein
activation	I-protein
domain	I-protein
,	O
a	O
putative	O
GTP-binding	B-protein
motif	I-protein
and	O
two	O
leucine	B-protein
charged	I-protein
domains	I-protein
(	O
LCD	B-protein
motifs	I-protein
)	O
.	O
	
The	O
other	O
two	O
contained	O
mutations	O
in	O
regions	O
that	O
do	O
not	O
have	O
homology	O
to	O
described	O
proteins	O
.	O
	
The	O
characterization	O
of	O
CIITA	B-protein
mutants	I-protein
that	O
are	O
able	O
to	O
discriminate	O
between	O
promoters	O
with	O
or	O
without	O
the	O
W	B-DNA
box	I-DNA
strongly	O
suggests	O
that	O
CIITA	B-protein
requires	O
such	O
interactions	O
for	O
function	O
.	O
	
The	O
identification	O
of	O
LCD	B-protein
motifs	I-protein
required	O
for	O
CIITA	B-protein
function	O
brings	O
to	O
light	O
a	O
previously	O
undefined	O
role	O
of	O
these	O
motifs	O
in	O
CIITA	B-protein
function	O
.	O
	
###MEDLINE:98380268	
	
The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
alpha	I-protein
(	O
PPARalpha	B-protein
)	O
ligand	O
WY	O
14	O
,	O
643	O
does	O
not	O
interfere	O
with	O
leukotriene	O
B4	O
induced	O
adhesion	O
of	O
neutrophils	B-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
.	O
	
Peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPAR	B-protein
)	O
control	O
discrete	O
genes	O
involved	O
in	O
fatty	O
acid	O
and	O
lipid	O
metabolism	O
.	O
	
Recently	O
,	O
it	O
was	O
suggested	O
that	O
activation	O
of	O
the	O
alpha	B-protein
isoform	I-protein
of	O
PPAR	B-protein
by	O
the	O
potent	O
proinflammatory	O
mediator	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
enhanced	O
degradation	O
of	O
this	O
eicosanoid	O
,	O
offersuggesting	O
a	O
new	O
aspect	O
of	O
down-regulation	O
of	O
inflammation	O
.	O
	
Here	O
,	O
we	O
studied	O
whether	O
PPARalpha	B-protein
activation	O
(	O
by	O
means	O
of	O
the	O
selective	O
agonist	O
WY	O
14	O
,	O
643	O
)	O
of	O
endothelial	B-cell_type
cells	I-cell_type
,	O
pivotal	O
in	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
,	O
interfered	O
with	O
LTB4	O
induced	O
adhesion	O
of	O
PMN	B-cell_type
neutrophil	I-cell_type
granulocytes	I-cell_type
in	O
vitro	O
.	O
	
When	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
WY	O
14	O
,	O
643	O
prior	O
to	O
activation	O
with	O
LTB4	O
(	O
or	O
fMLP	B-protein
,	O
IL-1beta	B-protein
or	O
TNFalpha	B-protein
,	O
as	O
controls	O
)	O
we	O
could	O
not	O
document	O
any	O
effect	O
on	O
the	O
number	O
of	O
adhering	B-cell_type
PMN	I-cell_type
or	O
duration	O
of	O
the	O
response	O
.	O
	
Thus	O
,	O
this	O
study	O
provides	O
no	O
evidence	O
indicating	O
a	O
regulatory	O
function	O
of	O
PPARalpha	B-protein
in	O
LTB4	O
induced	O
adhesive	O
interactions	O
between	O
endothelial	B-cell_type
cells	I-cell_type
and	O
neutrophils	B-cell_type
	
###MEDLINE:99025966	
	
Interaction	O
of	O
sickle	B-cell_type
erythrocytes	I-cell_type
with	O
endothelial	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
.	O
	
The	O
abnormal	O
adherence	O
of	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
SS	B-cell_type
RBC	I-cell_type
)	O
to	O
endothelial	B-cell_type
cells	I-cell_type
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O
	
We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
with	O
cultured	O
endothelial	B-cell_type
cells	I-cell_type
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
(	O
CAMs	B-protein
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	B-cell_type
and	O
the	O
adherence	O
of	O
SS	B-cell_type
reticulocytes	I-cell_type
.	O
	
We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWf	B-protein
)	O
,	O
derived	O
from	O
endothelial	O
cell-derived	O
conditioned	O
medium	O
(	O
E-CM	O
)	O
with	O
cultured	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid-reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O
	
Normal	B-cell_type
RBC	I-cell_type
show	O
none	O
of	O
these	O
phenomena	O
.	O
	
The	O
oxidant	O
stress-induced	O
signaling	O
resulted	O
in	O
an	O
increased	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	B-protein
,	O
ICAM-1	B-protein
,	O
E-selectin	B-protein
,	O
and	O
VCAM-1	B-protein
in	O
HUVEC	B-cell_line
.	O
	
The	O
addition	O
of	O
oxygen	B-protein
radical	I-protein
scavenger	I-protein
enzymes	I-protein
(	O
catalase	B-protein
,	O
superoxide	B-protein
dismutase	I-protein
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	O
these	O
events	O
.	O
	
Additionally	O
,	O
preincubation	O
of	O
HUVEC	B-cell_line
with	O
a	O
synthetic	O
peptide	O
Arg-Gly-Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	B-protein
-mediated	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	B-protein
and	O
NF-kB	B-protein
activation	O
.	O
	
Furthermore	O
,	O
SS	B-cell_type
RBC	I-cell_type
-induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
and	O
approximately	O
a	O
sixfold	O
increase	O
in	O
platelet-endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
PECAM-1	B-protein
)	O
phosphorylation	O
,	O
each	O
of	O
which	O
was	O
blocked	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
and	O
antioxidants	O
.	O
	
These	O
results	O
suggest	O
that	O
the	O
adherence/contact	O
of	O
SS	B-cell_type
RBC	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	B-cell_type
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	B-cell_type
reticulocytes	I-cell_type
,	O
indicating	O
that	O
injury/activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso-occlusion	O
in	O
SCD	O
.	O
	
###MEDLINE:99010987	
	
Signal	O
transduction	O
abnormalities	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	B-protein
therapy	O
.	O
	
Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3/T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O
	
Diminished	O
expression	O
of	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
that	O
are	O
associated	O
with	O
the	O
TCR	B-protein
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	B-protein
containing	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NFkappaB	I-protein
)	I-protein
complexes	I-protein
have	O
been	O
noted	O
.	O
	
These	O
defects	O
have	O
been	O
described	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O
	
Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O
	
To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	B-protein
,	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
,	O
T	B-cell_type
lymphocytes	I-cell_type
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	B-protein
therapy	O
[	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IFN	B-protein
alpha	I-protein
-containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O
	
In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
determined	O
by	O
Western	O
blots	O
of	O
T-cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O
	
Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O
	
In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	B-protein
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
.	O
	
Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	B-protein
treatment	O
were	O
also	O
investigated	O
.	O
	
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
detected	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O
	
When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B-protein
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	B-protein
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O
	
In	O
patients	O
treated	O
with	O
IL-2/	O
IFN	B-protein
alpha	I-protein
-based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	B-protein
increased	O
significantly	O
(	O
P	O
=	O
0.002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O
	
Correlations	O
of	O
TCRzeta	B-protein
or	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B-protein
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O
	
Abnormal	O
NFkappaB	B-protein
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
and/or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O
	
Activation	O
of	O
NFkappaB	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
inducible	O
during	O
cytokine	B-protein
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	B-protein
activity	O
prior	O
to	O
therapy	O
.	O
	
Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-protein
levels	O
were	O
present	O
although	O
kappaB	B-protein
binding	O
was	O
not	O
inducible	O
.	O
	
In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
express	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B-protein
associated	I-protein
molecules	I-protein
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	B-protein
-based	O
therapy	O
.	O
	
Abnormal	O
activation	O
of	O
NFkappaB	B-protein
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL-2/	O
IFN	B-protein
alpha	I-protein
-based	O
treatment	O
.	O
	
This	O
alteration	O
in	O
NFkappaB	B-protein
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta-associated	B-DNA
signaling	I-DNA
elements	I-DNA
.	O
	
The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O
	
###MEDLINE:99006780	
	
Identification	O
of	O
transcription	B-protein
factors	I-protein
expressed	O
during	O
ATRA-induced	O
neutrophil	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O
	
A	O
recent	O
clinical	O
therapeutic	O
initiative	O
has	O
been	O
the	O
use	O
of	O
chemical	O
agents	O
which	O
induce	O
the	O
leukaemic	B-cell_type
cells	I-cell_type
to	O
overcome	O
their	O
block	O
in	O
differentiation	O
.	O
	
In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O
	
Haemopoietic	O
differentiation	O
is	O
ultimately	O
controlled	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
which	O
is	O
mediated	O
by	O
an	O
array	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
Many	O
transcription	B-protein
factors	I-protein
contain	O
similar	O
structural	B-protein
protein	I-protein
sequences	I-protein
,	O
and	O
we	O
have	O
used	O
an	O
RT-PCR-based	O
approach	O
to	O
isolate	O
sequences	O
,	O
from	O
transcription	B-protein
factor	I-protein
gene	O
families	O
which	O
share	O
similar	O
domains	O
.	O
	
Degenerate	O
primers	O
corresponding	O
to	O
the	O
TFIIIA	B-DNA
zinc-finger	I-DNA
consensus	I-DNA
amino	I-DNA
acid	I-DNA
sequences	I-DNA
and	O
to	O
the	O
POU-homeodomain	B-protein
and	O
POU-specific	B-protein
domain	I-protein
were	O
used	O
to	O
amplify	O
genes	O
on	O
the	O
basis	O
that	O
they	O
contained	O
similarities	O
in	O
structural	O
motifs	O
shared	O
within	O
these	O
families	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
A	O
serum-independent	B-cell_line
HL60	I-cell_line
cell	I-cell_line
line	I-cell_line
was	O
induced	O
towards	O
the	O
neutrophil	O
lineage	O
by	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
24	O
h	O
.	O
	
CD38+	B-cell_type
cells	I-cell_type
committed	O
towards	O
this	O
lineage	O
were	O
enriched	O
and	O
a	O
population	O
of	O
these	O
cells	O
treated	O
with	O
dihydroxyvitamin	O
D3	O
to	O
induce	O
neutrophil	O
maturation	O
.	O
	
RNA	O
extracted	O
from	O
uninduced	O
,	O
ATRA-induced	B-cell_line
CD38+	I-cell_line
cells	I-cell_line
,	O
and	O
vitamin	B-cell_line
D3	I-cell_line
treated	I-cell_line
maturing	I-cell_line
cell	I-cell_line
cultures	I-cell_line
were	O
amplified	O
using	O
the	O
degenerate	O
primers	O
.	O
	
PCR	B-DNA
fragments	I-DNA
were	O
cloned	O
,	O
sequenced	O
,	O
clustered	O
into	O
homologous	O
groups	O
,	O
and	O
the	O
group	O
sequences	O
searched	O
on	O
the	O
GenBank	O
database	O
.	O
	
The	O
Oct	O
1	O
transcription	B-protein
factor	I-protein
,	O
and	O
a	O
very	O
close	O
homologue	O
,	O
KIAA0144	B-DNA
,	O
was	O
identified	O
using	O
the	O
POU	O
family	O
primers	O
.	O
	
The	O
zinc-finger	O
primers	O
identified	O
three	O
zinc-finger	O
genes	O
.	O
	
The	O
pattern	O
of	O
gene	O
expression	O
was	O
suggested	O
from	O
the	O
number	O
of	O
clones	O
in	O
each	O
group	O
at	O
neutrophil	O
commitment	O
and	O
maturation	O
.	O
	
The	O
differential	O
expression	O
of	O
the	O
genes	O
in	O
the	O
zinc	B-protein
finger	I-protein
and	I-protein
POU	I-protein
families	I-protein
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
cascade	O
of	O
gene	O
expression	O
which	O
occurs	O
following	O
ATRA-induced	O
differentiation	O
.	O
	
###MEDLINE:98451426	
	
GATA-3	B-protein
-dependent	O
enhancer	O
activity	O
in	O
IL-4	B-DNA
gene	I-DNA
regulation	O
.	O
	
Previously	O
,	O
we	O
analyzed	O
the	O
proximal	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
directing	O
Th2-specific	O
activity	O
.	O
	
An	O
800-base	B-DNA
pair	I-DNA
proximal	I-DNA
promoter	I-DNA
conferred	O
some	O
Th2-selective	O
expression	O
in	O
transgenic	O
mice	O
.	O
	
However	O
,	O
this	O
region	O
directed	O
extremely	O
low	O
reporter	O
mRNA	O
levels	O
relative	O
to	O
endogenous	O
IL-4	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
full	O
gene	O
activity	O
requires	O
additional	O
enhancer	B-DNA
elements	I-DNA
.	O
	
Here	O
,	O
we	O
analyzed	O
large	O
genomic	B-DNA
IL-4	I-DNA
regions	I-DNA
for	O
enhancer	O
activity	O
and	O
interaction	O
with	O
transcription	B-protein
factors	I-protein
.	O
	
The	O
proximal	O
IL-4	B-DNA
promoter	I-DNA
is	O
only	O
moderately	O
augmented	O
by	O
GATA-3	B-protein
,	O
but	O
certain	O
genomic	B-DNA
regions	I-DNA
significantly	O
enhanced	O
GATA-3	B-DNA
promoter	I-DNA
transactivation	O
.	O
	
Some	O
enhancing	O
regions	O
contained	O
consensus	O
,	O
GATA	B-DNA
sites	I-DNA
that	O
bound	O
Th2-specific	B-protein
complexes	I-protein
.	O
	
However	O
,	O
retroviral	O
transduction	O
of	O
GATA-3	B-protein
into	O
developing	B-cell_type
T	I-cell_type
cells	I-cell_type
induced	O
IL-5	B-protein
to	O
full	O
Th2	B-protein
levels	O
,	O
but	O
only	O
partially	O
restored	O
IL-4	B-protein
production	O
.	O
	
Thus	O
,	O
we	O
propose	O
that	O
GATA-3	B-protein
is	O
permissive	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
full	O
IL-4	B-protein
enhancement	O
and	O
may	O
act	O
through	O
GATA	B-DNA
elements	I-DNA
surrounding	O
the	O
IL-13/IL-4	B-DNA
gene	I-DNA
locus	I-DNA
.	O
	
###MEDLINE:98438422	
	
Position	O
effect	O
of	O
translocations	O
involving	O
the	O
inactive	B-DNA
X	I-DNA
chromosome	I-DNA
:	O
physical	O
linkage	O
to	O
XIC/XIST	B-DNA
does	O
not	O
lead	O
to	O
long-range	O
de	O
novo	O
inactivation	O
in	O
human	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
.	O
	
Given	O
the	O
reported	O
long-range	O
cis-inactivating	O
effect	O
of	O
the	O
XIST	B-DNA
gene	I-DNA
in	O
early	O
embryonic	O
development	O
and	O
the	O
lack	O
of	O
requirement	O
of	O
X-chromosome-specific	B-DNA
elements	I-DNA
for	O
propagating	O
the	O
inactive	O
state	O
,	O
there	O
exists	O
the	O
possibility	O
of	O
cis	O
inactivation	O
of	O
autosomal	O
material	O
after	O
de	O
novo	O
translocation	O
to	O
an	O
inactive	B-DNA
X	I-DNA
chromosome	I-DNA
(	O
Xi	B-DNA
)	O
in	O
differentiated	B-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
analyzed	O
de	O
novo	O
radiation-induced	O
translocations	O
between	O
the	O
Xi	B-DNA
and	O
autosomes	B-DNA
to	O
study	O
the	O
maintenance	O
and	O
spreading	O
of	O
X-chromosome	B-DNA
inactivation	O
(	O
X	O
inactivation	O
)	O
in	O
relation	O
to	O
the	O
position	O
of	O
the	O
X-inactivation	O
center	O
(	B-DNA
XIC	I-DNA
)	I-DNA
/XIST	I-DNA
in	O
differentiated	B-cell_type
cells	I-cell_type
.	O
	
Autosome/	O
Xi	B-DNA
translocations	O
were	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
	
The	O
activation	O
status	O
of	O
the	O
chromosomes	B-DNA
involved	O
in	O
the	O
translocation	O
was	O
determined	O
by	O
simultaneous	O
immunocytogenetic	O
studies	O
using	O
antibodies	B-protein
against	O
either	O
BrdU	B-protein
incorporated	O
at	O
late	O
S	O
phase	O
or	O
acetylated	B-protein
histone	I-protein
H4	I-protein
.	O
	
The	O
position	O
of	O
XIC/XIST	B-DNA
in	O
the	O
reciprocal	O
products	O
of	O
the	O
translocation	O
was	O
determined	O
by	O
XIST-specific	O
FISH	O
and	O
computer	O
enhancement	O
.	O
	
In	O
other	O
experiments	O
,	O
the	O
Xq13	B-DNA
region	I-DNA
carrying	O
XIC/XIST	B-DNA
was	O
localized	O
by	O
computer	O
enhancement	O
of	O
the	O
DAPI	O
banding	O
pattern	O
.	O
	
Our	O
study	O
in	O
differentiated	B-cell_type
cells	I-cell_type
provides	O
a	O
visual	O
demonstration	O
that	O
physical	O
separation	O
from	O
XIC/XIST	B-DNA
does	O
not	O
result	O
in	O
reactivation	O
of	O
inactive	B-DNA
X-chromosome	I-DNA
material	O
and	O
that	O
X	O
inactivation	O
is	O
not	O
spread	O
to	O
the	O
translocated	B-DNA
autosomes	I-DNA
irrespective	O
of	O
the	O
position	O
of	O
XIC/XIST	B-DNA
.	O
	
This	O
observation	O
suggests	O
that	O
physical	O
linkage	O
to	O
XIC/XIST	B-DNA
does	O
not	O
lead	O
to	O
de	O
novo	O
inactivation	O
of	O
autosomal	O
material	O
.	O
	
###MEDLINE:98421396	
	
Interleukin-4	B-protein
and	I-protein
-13	I-protein
induce	O
upregulation	O
of	O
the	O
murine	O
macrophage	O
12/15-lipoxygenase	B-protein
activity	I-protein
:	O
evidence	O
for	O
the	O
involvement	O
of	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O
	
When	O
human	O
monocytes	B-cell_type
or	O
alveolar	B-cell_type
macrophages	I-cell_type
are	O
cultured	O
in	O
the	O
presence	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
or	O
IL-13	B-protein
,	O
the	O
expression	O
of	O
the	O
reticulocyte-type	B-protein
15-lipoxygenase	I-protein
is	O
induced	O
.	O
	
In	O
mice	O
a	O
15-lipoxygenase	B-protein
is	O
not	O
expressed	O
,	O
but	O
a	O
leukocyte-type	B-protein
12-lipoxygenase	I-protein
is	O
present	O
in	O
peritoneal	B-cell_type
macrophages	I-cell_type
.	O
	
To	O
investigate	O
whether	O
both	O
lipoxygenase	B-protein
isoforms	I-protein
exhibit	O
a	O
similar	O
regulatory	O
response	O
toward	O
cytokine	B-protein
stimulation	O
,	O
we	O
studied	O
the	O
regulation	O
of	O
the	O
leukocyte-type	B-protein
12-lipoxygenase	I-protein
of	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
by	O
interleukins	B-protein
and	O
found	O
that	O
the	O
activity	O
of	O
this	O
enzyme	B-protein
is	O
upregulated	O
in	O
a	O
dose-dependent	O
manner	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IL-4	B-protein
or	O
IL-13	B-protein
but	O
not	O
by	O
IL-10	B-protein
.	O
	
When	O
peripheral	O
murine	O
monocytes	B-cell_type
that	O
do	O
not	O
express	O
the	O
lipoxygenase	B-protein
were	O
treated	O
with	O
IL-4	B-protein
expression	O
of	O
12/15-lipoxygenase	B-RNA
mRNA	I-RNA
was	O
induced	O
,	O
suggesting	O
pretranslational	O
control	O
mechanisms	O
.	O
	
In	O
contrast	O
,	O
no	O
upregulation	O
of	O
the	O
lipoxygenase	B-protein
activity	O
was	O
observed	O
when	O
the	O
macrophages	B-cell_type
were	O
prepared	O
from	O
homozygous	O
STAT6	B-protein
-deficient	O
mice	O
.	O
	
Peritoneal	B-cell_type
macrophages	I-cell_type
of	O
transgenic	O
mice	O
that	O
systemically	O
overexpress	O
IL-4	B-protein
exhibited	O
a	O
threefold	O
to	O
fourfold	O
higher	O
12-lipoxygenase	B-protein
activity	O
than	O
cells	O
prepared	O
from	O
control	O
animals	O
.	O
	
A	O
similar	O
upregulation	O
of	O
12-lipoxygenase	B-protein
activity	O
was	O
detected	O
in	O
heart	O
,	O
spleen	O
,	O
and	O
lung	O
of	O
the	O
transgenic	O
animals	O
.	O
	
Moreover	O
,	O
a	O
strong	O
induction	O
of	O
the	O
enzyme	O
was	O
observed	O
in	O
red	B-cell_type
cells	I-cell_type
during	O
experimental	O
anemia	O
in	O
mice	O
.	O
	
The	O
data	O
presented	O
here	O
indicate	O
that	O
(	O
1	O
)	O
the	O
12-lipoxygenase	B-protein
activity	O
of	O
murine	O
macrophages	O
is	O
upregulated	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
IL-4	B-protein
and/or	O
IL-13	B-protein
,	O
(	O
2	O
)	O
this	O
upregulation	O
requires	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
,	O
and	O
(	O
3	O
)	O
the	O
constitutive	O
expression	O
of	O
the	O
enzyme	O
appears	O
to	O
be	O
STAT6	B-protein
independent	O
.	O
	
The	O
cytokine	B-protein
-dependent	O
upregulation	O
of	O
the	O
murine	B-protein
macrophage	I-protein
12-lipoxygenase	I-protein
and	O
its	O
induction	O
during	O
experimental	O
anemia	O
suggests	O
its	O
close	O
relatedness	O
with	O
the	O
human	B-protein
reticulocyte-type	I-protein
15-lipoxygenase	I-protein
despite	O
their	O
differences	O
in	O
the	O
positional	O
specificity	O
of	O
arachidonic	O
acid	O
oxygenation	O
.	O
	
###MEDLINE:98405747	
	
Interferon-gamma-induced	B-protein
factor	I-protein
binding	O
to	O
the	O
interleukin-4-responsive	B-DNA
element	I-DNA
of	O
CD23b	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
tonsillar	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
role	O
in	O
transient	O
up-regulation	O
of	O
the	O
interleukin-4-induced	B-RNA
CD23b	I-RNA
mRNA	I-RNA
.	O
	
Stimulation	O
of	O
human	B-cell_type
tonsillar	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
rapidly	O
induced	O
the	O
activation	O
of	O
distinct	O
nuclear	B-protein
factors	I-protein
with	O
different	O
mobilities	O
,	O
both	O
of	O
which	O
bind	O
the	O
IL-4	B-DNA
response	I-DNA
element	I-DNA
(	O
IL-4RE	B-DNA
)	O
of	O
CD23b	B-DNA
promoter	I-DNA
as	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O
	
Co-treatment	O
of	O
IL-4	B-protein
and	O
IFN-gamma	B-protein
induced	O
,	O
in	O
addition	O
to	O
the	O
two	O
distinct	O
complexes	O
,	O
a	O
new	O
complex	O
with	O
an	O
intermediate	O
mobility	O
.	O
	
The	O
IL-4-induced	B-protein
complex	I-protein
reacted	O
with	O
anti-STAT	B-protein
(	I-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
6	I-protein
,	O
resulting	O
in	O
a	O
supershift	O
whereas	O
the	O
formation	O
of	O
the	O
IFN-gamma-induced	B-protein
complex	I-protein
was	O
inhibited	O
by	O
anti-STAT	B-protein
1	I-protein
.	O
	
The	O
intermediate	O
complex	O
appeared	O
to	O
react	O
with	O
both	O
anti-STAT	B-protein
6	I-protein
and	O
anti-STAT	B-protein
1	I-protein
.	O
	
Although	O
IFN-gamma	B-protein
alone	O
did	O
not	O
induce	O
CD23	B-RNA
mRNA	I-RNA
transcription	O
,	O
Northern	O
blot	O
analysis	O
revealed	O
a	O
transient	O
up-regulation	O
of	O
the	O
IL-4-induced	B-RNA
CD23	I-RNA
mRNA	I-RNA
by	O
IFN-gamma	B-protein
within	O
2	O
h	O
of	O
IFN-gamma	B-protein
treatment	O
in	O
these	O
tonsillar	B-cell_type
cells	I-cell_type
.	O
	
The	O
results	O
suggest	O
that	O
the	O
IL-4RE	B-DNA
of	O
the	O
IL-4-inducible	B-DNA
gene	I-DNA
can	O
accommodate	O
both	O
IL-4-	B-protein
and	I-protein
IFN-gamma-activated	I-protein
factors	I-protein
,	O
such	O
as	O
STAT	B-protein
6	I-protein
and	O
STAT	B-protein
1	I-protein
,	O
either	O
in	O
homodimeric	B-protein
or	I-protein
heterodimeric	I-protein
forms	I-protein
and	O
the	O
binding	O
of	O
these	O
different	O
proteins	O
to	O
the	O
respective	O
promoter	O
may	O
play	O
a	O
potential	O
regulatory	O
role	O
in	O
the	O
IL-4	B-protein
-inducible	O
gene	O
expression	O
.	O
	
###MEDLINE:98395152	
	
A	O
p56lck	B-protein
-independent	O
pathway	O
of	O
CD2	B-protein
signaling	O
involves	O
Jun	B-protein
kinase	I-protein
.	O
	
The	O
p56	B-protein
Src	I-protein
family	I-protein
non-receptor	I-protein
tyrosine	I-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
T	O
lymphocyte	O
differentiation	O
and	O
activation	O
.	O
	
Hence	O
in	O
the	O
absence	O
of	O
p56	B-protein
,	O
T	B-protein
cell	I-protein
receptor	I-protein
triggered	O
activation	O
does	O
not	O
occur	O
.	O
	
We	O
now	O
provide	O
evidence	O
for	O
a	O
CD2	B-protein
-based	O
signaling	O
pathway	O
which	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
,	O
is	O
independent	O
of	O
p56	B-protein
.	O
	
CD2	B-protein
-mediated	O
interleukin-2	B-protein
production	O
occurs	O
via	O
activation	O
of	O
Jun	B-protein
kinase	I-protein
in	O
cell	O
lines	O
lacking	O
p56	B-protein
.	O
	
Jun	B-protein
kinase	I-protein
then	O
facilitates	O
the	O
binding	O
of	O
c-Jun/c-Fos	B-protein
heterodimers	I-protein
to	O
the	O
AP-1	B-DNA
consensus	I-DNA
site	I-DNA
and	O
the	O
subsequent	O
transcriptional	O
activity	O
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O
	
These	O
data	O
elucidate	O
differences	O
between	O
TCR	B-protein
and	O
CD2	B-protein
signaling	O
pathways	O
in	O
the	O
same	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98389801	
	
Activation	O
of	O
E2F	B-protein
-mediated	O
transcription	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
Tax	I-protein
protein	I-protein
in	O
a	O
p16	B-cell_line
(	I-cell_line
INK4A	I-cell_line
)	I-cell_line
-negative	I-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O
	
The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O
	
Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV-I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	B-protein
protein	I-protein
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O
	
This	O
40-kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	B-protein
suppressor	I-protein
p16	B-protein
(	I-protein
INK4A	I-protein
)	I-protein
.	O
	
Consequently	O
,	O
Tax	B-protein
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	B-protein
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O
	
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	B-protein
can	O
also	O
activate	O
E2F	B-protein
-mediated	O
transcription	O
independently	O
of	O
p16	B-protein
(	I-protein
INK4A	I-protein
)	I-protein
.	O
	
Indeed	O
,	O
when	O
Tax	B-protein
is	O
coexpressed	O
with	O
the	O
E2F-1	B-protein
transcription	B-protein
factor	I-protein
in	O
CEM	B-cell_line
T-cells	I-cell_line
,	O
which	O
lack	O
expression	O
of	O
p16	B-protein
(	I-protein
INK4A	I-protein
)	I-protein
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	B-protein
-dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	B-DNA
binding	I-DNA
sites	I-DNA
.	O
	
This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F-binding	B-DNA
sites	I-DNA
.	O
	
In	O
addition	O
,	O
Tax	B-protein
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F-1	B-DNA
gene	I-DNA
itself	O
.	O
	
Using	O
Tax	B-protein
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	B-protein
-or	O
NF-kappaB-dependent	B-DNA
promoters	I-DNA
and	O
different	O
5	B-DNA
'	I-DNA
truncation	I-DNA
mutants	I-DNA
of	O
the	O
E2F-1	B-DNA
promoter	I-DNA
,	O
we	O
show	O
that	O
the	O
Tax	B-protein
-dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	B-DNA
gene	I-DNA
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	B-DNA
binding	I-DNA
site	I-DNA
located	O
in	O
the	O
E2F-1	B-DNA
promoter	I-DNA
.	O
	
###MEDLINE:98375886	
	
Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O
	
Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	B-cell_type
wall	I-cell_type
cells	I-cell_type
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O
	
In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O
	
We	O
find	O
that	O
iNO	O
produced	O
by	O
murine	B-cell_line
macrophage-like	I-cell_line
cells	I-cell_line
,	O
RAW264.7	B-cell_line
,	O
can	O
inhibit	O
cytokine	B-protein
-induced	O
endothelial	O
cell	O
activation	O
in	O
a	O
separated	O
and	O
mixed	O
endothelial-RAW264.7	B-cell_line
coculture	I-cell_line
system	I-cell_line
.	O
	
Both	O
iNO	O
production	O
and	O
endothelial	O
VCAM-1	B-protein
expression	O
were	O
induced	O
simultaneously	O
with	O
bacterial	O
LPS	O
and	O
murine-specific	B-protein
IFN-gamma	I-protein
.	O
	
Inhibition	O
of	O
iNO	B-protein
synthase	I-protein
(	O
iNOS	B-protein
)	O
activity	O
with	O
N	O
omega-monomethyl-L-arginine	O
in	O
endothelial-RAW264.7	B-cell_line
cocultures	I-cell_line
,	O
stimulated	O
with	O
murine-specific	B-protein
IFN-gamma	I-protein
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM-1	B-protein
and	O
iNOS	B-protein
expression	O
in	O
endothelial	O
and	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O
	
Transient	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
constructs	O
demonstrated	O
that	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
VCAM-1	B-protein
gene	O
transcription	O
were	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	B-DNA
B	I-DNA
cis-acting	I-DNA
elements	I-DNA
.	O
	
Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
of	O
nuclear	O
factor-kappa	B-protein
B	I-protein
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O
	
These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B-protein
expression	O
in	O
macrophages	B-cell_type
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O
	
###MEDLINE:99023607	
	
Detection	O
of	O
oestrogen	B-protein
receptor	I-protein
variants	I-protein
in	O
endometrium	O
,	O
myometrium	O
,	O
leiomyoma	O
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
comparison	O
to	O
variants	O
present	O
in	O
breast	O
cancer	O
.	O
	
Oestradiol	O
has	O
mitogenic	O
and	O
regulatory	O
effects	O
on	O
various	O
organs	O
and	O
cells	O
,	O
mediated	O
mainly	O
by	O
its	O
nuclear	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
.	O
	
The	O
presence	O
of	O
aberrant	O
ER	B-protein
forms	O
in	O
Oestrogen-dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O
	
ER	B-protein
variants	O
,	O
generated	O
by	O
alternative	O
splicing	O
,	O
have	O
been	O
detected	O
in	O
human	O
breast	O
cancer	O
,	O
but	O
also	O
in	O
normal	O
mammary	O
glands	O
,	O
therefore	O
their	O
role	O
in	O
tumorigenesis	O
has	O
been	O
questioned	O
.	O
	
We	O
have	O
investigated	O
,	O
by	O
the	O
use	O
of	O
the	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
amplification	O
technique	O
,	O
the	O
possible	O
existence	O
of	O
ER	B-protein
variants	O
in	O
other	O
normal	O
oestrogen	O
target	O
organs	O
and	O
cells	O
,	O
such	O
as	O
uterus	O
(	O
myometrium	O
and	O
endometrium	O
)	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
in	O
a	O
benign	O
uterus	O
tumour	O
(	O
leiomyoma	O
)	O
.	O
	
We	O
have	O
detected	O
variant	O
ER	B-protein
in	O
these	O
samples	O
and	O
have	O
compared	O
the	O
variant	O
profile	O
to	O
that	O
observed	O
in	O
breast	O
cancer	O
.	O
	
All	O
tissues	O
and	O
cells	O
studied	O
expressed	O
both	O
wild-type	B-protein
ER	I-protein
and	O
variant	B-protein
species	I-protein
.	O
	
Variant	O
forms	O
encompassed	O
ER	B-protein
with	O
deletions	O
of	O
exons	B-DNA
2	I-DNA
,	I-DNA
5	I-DNA
and	I-DNA
7	I-DNA
.	O
	
Variants	O
with	O
exon	B-DNA
5	I-DNA
deleted	O
were	O
detected	O
only	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
in	O
breast	O
cancer	O
.	O
	
Variants	O
with	O
exons	B-DNA
2	I-DNA
and	I-DNA
7	I-DNA
deleted	O
were	O
present	O
in	O
all	O
specimens	O
tested	O
.	O
	
These	O
results	O
corroborate	O
previous	O
findings	O
that	O
the	O
presence	O
of	O
ER	B-protein
variants	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O
	
The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	B-protein
forms	O
remain	O
to	O
be	O
elucidated	O
.	O
	
###MEDLINE:99010726	
	
p21ras	B-protein
initiates	O
Rac-1	B-protein
but	O
not	O
phosphatidyl	B-protein
inositol	I-protein
3	I-protein
kinase/PKB	I-protein
,	O
mediated	O
signaling	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
p21ras	B-protein
is	O
activated	O
by	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
then	O
co-ordinates	O
important	O
signaling	O
pathways	O
for	O
T	B-protein
lymphocyte	I-protein
activation	O
.	O
	
Effector	O
pathways	O
for	O
this	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
in	O
T	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
the	O
serine/threonine	B-protein
kinase	I-protein
Raf-1	B-protein
and	O
the	O
Ras-related	B-protein
GTPase	I-protein
Rac-1	B-protein
.	O
	
In	O
fibroblasts	B-cell_type
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	B-DNA
oncogene	I-DNA
is	O
Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PtdIns	B-protein
3-kinase	I-protein
)	O
.	O
	
Activation	O
of	O
this	O
lipid	B-protein
kinase	I-protein
is	O
able	O
to	O
induce	O
critical	O
Rac-1	B-protein
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B-protein
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine/threonine	B-protein
kinase	I-protein
Akt/PKB	I-protein
.	O
	
The	O
role	O
of	O
PtdIns	B-protein
3-kinase	I-protein
in	O
Ras	B-protein
signaling	O
in	O
T	B-cell_type
cells	I-cell_type
has	O
not	O
been	O
explored	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	B-protein
3-kinase	I-protein
to	O
initiate	O
the	O
Rac-1	B-protein
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O
	
We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt/PKB	B-protein
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
results	O
show	O
that	O
Ras	B-protein
can	O
initiate	O
a	O
Rac-1	B-protein
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	B-protein
complexes	I-protein
.	O
	
PtdIns	B-protein
3-kinase	I-protein
signals	O
can	O
not	O
mimic	O
p21ras	B-protein
and	O
induce	O
the	O
Rac	B-protein
mediated	O
responses	O
of	O
AP-1	B-protein
transcriptional	O
activation	O
.	O
	
Moreover	O
,	O
neither	O
TCR	B-protein
or	O
Ras	B-protein
activation	O
of	O
AP-1	B-protein
is	O
dependent	O
on	O
PtdIns	B-protein
3-kinase	I-protein
.	O
	
PKB	B-protein
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
;	O
PtdIns	B-protein
3-kinase	I-protein
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	B-protein
response	O
.	O
	
In	O
contrast	O
,	O
p21ras	B-protein
signals	O
are	O
unable	O
to	O
induce	O
Akt/PKB	B-protein
activity	O
in	O
T	B-cell_type
cell	I-cell_type
nor	O
is	O
Ras	B-protein
function	O
required	O
for	O
Akt/PKB	B-protein
activation	O
in	O
response	O
to	O
the	O
TCR	B-protein
.	O
	
The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	B-protein
3-kinase	I-protein
and	O
Akt/PKB	B-protein
are	O
not	O
universal	O
Ras	B-protein
effector	I-protein
molecules	I-protein
.	O
	
Ras	B-protein
can	O
initiate	O
Rac-1	B-protein
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
function	O
independently	O
of	O
PtdIns	B-protein
3-kinase	I-protein
activity	O
.	O
	
###MEDLINE:99006628	
	
Interleukin	B-protein
1beta	I-protein
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	B-cell_type
on	O
LNCaP	B-cell_type
human	I-cell_type
prostate	I-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O
	
Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen-sensitive	B-cell_type
prostate	I-cell_type
cancer	I-cell_type
LNCaP	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation-promoting	O
substances	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
that	O
exhibit	O
anti-tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
For	O
this	O
purpose	O
,	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
incubated	O
with	O
monocyte-conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	B-protein
receptor	I-protein
(	O
AR	B-protein
)	O
and	O
secretion	O
of	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
were	O
assessed	O
.	O
	
Conditioned	O
medium	O
from	O
monocytes	B-cell_type
reduced	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
Incubation	O
with	O
40	O
%	O
MCM	O
caused	O
a	O
50	O
%	O
reduction	O
in	O
cell	O
proliferation	O
.	O
	
AR	B-protein
protein	I-protein
decreased	O
by	O
70	O
%	O
and	O
PSA	B-protein
levels	O
in	O
supernatants	O
from	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O
	
We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	B-cell_type
,	O
prostaglandin	O
E2	O
and	O
interleukin	B-protein
1beta	I-protein
(	O
IL-1beta	B-protein
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O
	
LNCaP	B-cell_line
cells	I-cell_line
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O
	
The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	B-protein
protein	I-protein
and	O
PSA	B-protein
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti-IL-1beta	B-protein
antibody	I-protein
.	O
	
In	O
addition	O
,	O
recombinant	O
IL-1beta	B-protein
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
proteins	O
.	O
	
LNCaP	B-cell_line
cells	I-cell_line
were	O
shown	O
to	O
express	O
the	O
IL-1beta	B-protein
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	B-protein
signal	O
.	O
	
Our	O
findings	O
reveal	O
that	O
monocyte-derived	B-protein
IL-1beta	I-protein
inhibits	O
the	O
proliferation	O
of	O
androgen-responsive	B-cell_type
prostate	I-cell_type
tumour	I-cell_type
cells	I-cell_type
and	O
reduces	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O
	
###MEDLINE:98451425	
	
Differential	O
responsiveness	O
of	O
the	O
IL-5	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
to	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
.	O
	
The	O
cytokines	B-protein
IL-4	B-protein
and	O
IL-5	B-protein
are	O
often	O
coordinately	O
produced	O
by	O
Th2	B-cell_line
cells	I-cell_line
as	O
in	O
asthma	O
.	O
	
However	O
,	O
it	O
is	O
unclear	O
whether	O
similar	O
molecular	O
mechanisms	O
underlie	O
transcription	O
of	O
the	O
two	O
genes	B-DNA
.	O
	
We	O
have	O
previously	O
shown	O
that	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
is	O
expressed	O
in	O
Th2	B-cell_line
but	I-cell_line
not	I-cell_line
Th1	I-cell_line
cells	I-cell_line
and	O
is	O
crucial	O
for	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
by	O
different	O
stimuli	O
.	O
	
In	O
a	O
different	O
study	O
,	O
GATA-3	B-protein
was	O
shown	O
to	O
be	O
sufficient	O
for	O
the	O
expression	O
of	O
IL-4	B-protein
and	O
other	O
Th2	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
	
Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
GATA-3	B-protein
is	O
sufficient	O
to	O
drive	O
IL-5	B-protein
but	O
not	O
IL-4	B-protein
gene	O
expression	O
.	O
	
Also	O
,	O
in	O
Th2	B-cell_line
cells	I-cell_line
,	O
antisense	O
GATA-3	B-protein
RNA	O
inhibits	O
IL-5	B-protein
but	O
not	O
IL-4	B-protein
promoter	O
activation	O
.	O
	
The	O
induction	O
of	O
IL-5	B-DNA
gene	I-DNA
expression	O
by	O
GATA-3	B-protein
involves	O
high	O
affinity	O
binding	O
of	O
GATA-3	B-protein
to	O
an	O
inverted	O
GATA	B-DNA
repeat	I-DNA
in	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O
	
###MEDLINE:98438586	
	
The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha	I-DNA
chain/CD25	I-DNA
promoter	I-DNA
is	O
a	O
target	O
for	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O
	
The	O
expression	O
of	O
the	O
murine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
receptor	I-protein
alpha	I-protein
chain/CD25	I-protein
is	O
strongly	O
induced	O
at	O
the	O
transcriptional	O
level	O
after	O
T	O
cell	O
activation	O
.	O
	
We	O
show	O
here	O
that	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	I-protein
NF-AT	I-protein
)	I-protein
factors	I-protein
are	O
involved	O
in	O
the	O
control	O
of	O
CD25	B-DNA
promoter	I-DNA
induction	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
NF-ATp	B-protein
and	O
NF-ATc	B-protein
bind	O
to	O
two	O
sites	O
around	O
positions	B-DNA
-585	I-DNA
and	I-DNA
-650	I-DNA
located	O
upstream	O
of	O
the	O
proximal	B-DNA
CD25	I-DNA
promoter	I-DNA
.	O
	
Immediately	O
3	O
'	O
from	O
these	O
NF-AT	B-DNA
motifs	I-DNA
,	O
nonconsensus	B-DNA
sites	I-DNA
are	O
located	O
for	O
the	O
binding	O
of	O
AP-1-like	B-protein
factors	I-protein
.	O
	
Mutations	O
of	O
sites	O
that	O
suppress	O
NF-AT	B-protein
binding	O
impair	O
the	O
induction	O
and	O
strong	O
NF-ATp	B-protein
-mediated	O
transactivation	O
of	O
the	O
CD25	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
In	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
NF-ATp	B-protein
-deficient	O
mice	O
,	O
the	O
expression	O
of	O
CD25	B-protein
is	O
severely	O
impaired	O
,	O
leading	O
to	O
a	O
delayed	O
IL-2	B-protein
receptor	I-protein
expression	O
after	O
T	O
cell	O
receptor	O
(	O
TCR	B-protein
)	O
/	O
CD3	B-protein
stimulation	O
.	O
	
Our	O
data	O
indicate	O
an	O
important	O
role	O
for	O
NF-AT	B-protein
in	O
the	O
faithful	O
expression	O
of	O
high	B-protein
affinity	I-protein
IL-2	I-protein
receptors	I-protein
and	O
a	O
close	O
link	O
between	O
the	O
TCR	B-protein
-mediated	O
induction	O
of	O
IL-2	B-protein
and	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
promoters	I-DNA
,	O
both	O
of	O
which	O
are	O
regulated	O
by	O
NF-AT	B-protein
factors	I-protein
.	O
	
###MEDLINE:98421365	
	
A	O
novel	O
mutation	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
FY*B	B-DNA
allele	I-DNA
of	O
the	O
Duffy	B-DNA
chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
is	O
associated	O
with	O
an	O
altered	O
erythrocyte	O
phenotype	O
.	O
	
The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O
	
Antibodies	B-protein
to	O
Duffy	B-protein
antigens	I-protein
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O
	
The	O
Duffy	B-protein
protein	I-protein
is	O
a	O
receptor	O
for	O
the	O
Plasmodium	B-protein
vivax	I-protein
erythrocyte-binding	I-protein
protein	I-protein
and	O
is	O
also	O
a	O
receptor	O
for	O
various	O
chemokines	B-protein
(	O
thus	O
renamed	O
Duffy	B-protein
Antigen	I-protein
Receptor	I-protein
for	I-protein
Chemokines	I-protein
[	O
DARC	B-protein
]	O
)	O
.	O
	
The	O
two	O
Duffy	B-protein
polymorphic	I-protein
antigens	I-protein
,	O
Fya	B-protein
and	O
Fyb	B-protein
(	O
coded	O
by	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
)	O
,	O
are	O
present	O
on	O
erythrocyte	B-protein
membranes	I-protein
.	O
	
The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non-Ashkenazi	O
Jewish	O
groups	O
.	O
	
The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
FY*B	B-DNA
promoter	I-DNA
at	O
the	O
GATA	B-DNA
box	I-DNA
that	O
abolishes	O
the	O
expression	O
of	O
erythrocyte	B-protein
Duffy	I-protein
protein	I-protein
.	O
	
We	O
describe	O
here	O
a	O
novel	O
mutation	O
,	O
present	O
in	O
the	O
FY*B	B-DNA
coding	I-DNA
sequence	I-DNA
(	O
271C	O
--	O
>	O
T	O
)	O
,	O
that	O
is	O
associated	O
with	O
some	O
Fy	O
(	O
b-	O
)	O
phenotypes	O
among	O
non-Ashkenazi	O
Jews	O
and	O
among	O
Brazilian	O
blacks	O
.	O
	
The	O
mutation	O
is	O
present	O
in	O
Fy	O
(	O
b-	O
)	O
individuals	O
,	O
who	O
have	O
wild-type	B-DNA
FY*B	I-DNA
GATA	I-DNA
and	O
carry	O
the	O
previously	O
described	O
304G	O
--	O
>	O
A	O
substitution	O
.	O
	
The	O
271C	O
--	O
>	O
T	O
and	O
304G	O
--	O
>	O
A	O
can	O
be	O
identified	O
by	O
restriction	B-DNA
enzyme-generated	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
.	O
	
The	O
271C	O
--	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
--	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	B-protein
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O
	
The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	B-protein
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O
	
###MEDLINE:98403730	
	
Establishment	O
and	O
characterization	O
of	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
primary	I-cell_line
effusion	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
harbouring	O
human	O
herpesvirus	O
type-8	O
.	O
	
In	O
this	O
study	O
we	O
report	O
on	O
the	O
establishment	O
and	O
characterization	O
of	O
two	O
novel	O
lymphoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
)	O
which	O
carry	O
infection	O
by	O
human	O
herpesvirus	O
type-8	O
(	O
HHV-8	O
)	O
and	O
have	O
derived	O
from	O
AIDS-related	O
primary	O
effusion	O
lymphoma	O
(	O
PEL	B-cell_line
)	O
.	O
	
These	O
two	O
cell	B-cell_line
lines	I-cell_line
are	O
representative	O
of	O
different	O
virologic	O
subtypes	O
of	O
PEL	B-cell_line
,	O
i.e	O
.	O
HHV-8+/EBV-	B-cell_line
PEL	I-cell_line
in	O
the	O
case	O
of	O
CRO-AP/3	B-cell_line
and	I-cell_line
HHV-8+/EBV+	I-cell_line
PEL	I-cell_line
in	O
the	O
case	O
of	O
CRO-AP/5	B-cell_line
.	O
	
Consistent	O
with	O
the	O
diagnosis	O
of	O
PEL	B-cell_line
,	O
both	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
expressed	O
indeterminate	O
(	O
i.e.	O
non-B	O
,	O
non-T	O
)	O
phenotypes	O
although	O
immunogenotypic	O
studies	O
documented	O
their	O
B-cell	B-cell_type
origin	I-cell_type
.	O
	
Both	O
cell	B-cell_line
lines	I-cell_line
are	O
devoid	O
of	O
genetic	O
lesions	O
of	O
c-MYC	B-protein
,	O
BCL-2	B-protein
and	O
p53	B-protein
as	O
well	O
as	O
gross	O
rearrangements	O
of	O
BCL-6	B-protein
.	O
	
Detailed	O
histogenetic	O
characterization	O
of	O
these	O
novel	O
PEL	B-cell_line
cell	I-cell_line
lines	I-cell_line
suggests	O
that	O
PEL	B-cell_line
may	O
derive	O
from	O
a	O
post-germinal	B-cell_line
centre	I-cell_line
B	I-cell_line
cell	I-cell_line
which	O
has	O
undergone	O
pre-terminal	O
differentiation	O
.	O
	
The	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
cell	I-cell_line
lines	I-cell_line
may	O
provide	O
a	O
valuable	O
model	O
for	O
clarifying	O
the	O
pathogenesis	O
of	O
PEL	B-cell_line
.	O
	
In	O
particular	O
,	O
these	O
cell	B-cell_line
lines	I-cell_line
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	B-cell_line
.	O
	
###MEDLINE:98395103	
	
Two-site	O
interaction	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
with	O
activated	O
calcineurin	B-protein
.	O
	
Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
regulate	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
inducible	O
genes	O
during	O
the	O
immune	O
response	O
.	O
	
The	O
functions	O
of	O
NFAT	B-protein
proteins	I-protein
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-	I-protein
dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
.	O
	
Here	O
we	O
show	O
that	O
the	O
binding	O
of	O
calcineurin	B-protein
to	O
NFAT	B-protein
is	O
substantially	O
increased	O
when	O
calcineurin	B-protein
is	O
activated	O
with	O
calmodulin	B-protein
and	O
calcium	O
.	O
	
FK506.FKBP12	O
drug-immunophilin	O
complexes	O
inhibited	O
the	O
interaction	O
of	O
NFAT	B-protein
with	O
activated	O
calcineurin	B-protein
much	O
more	O
effectively	O
than	O
they	O
inhibited	O
the	O
interaction	O
with	O
inactive	O
calcineurin	B-protein
,	O
suggesting	O
that	O
part	O
of	O
the	O
interaction	O
with	O
activated	O
calcineurin	B-protein
involved	O
the	O
enzyme	B-DNA
active	I-DNA
site	I-DNA
.	O
	
We	O
have	O
previously	O
shown	O
that	O
NFAT	B-protein
is	O
targeted	O
to	O
inactive	O
calcineurin	B-protein
at	O
a	O
region	O
distinct	O
from	O
the	O
calcineurin	B-DNA
active	I-DNA
site	I-DNA
(	O
Aramburu	O
,	O
J.	O
,	O
Garcia-Cozar	O
,	O
F.	O
J.	O
,	O
Raghavan	O
,	O
A.	O
,	O
Okamura	O
,	O
H.	O
,	O
Rao	O
,	O
A.	O
,	O
and	O
Hogan	O
,	O
P.	O
G.	O
(	O
1998	O
)	O
Mol.	O
Cell	O
1	O
,	O
627-637	O
)	O
;	O
this	O
region	O
is	O
also	O
involved	O
in	O
NFAT	B-protein
binding	O
to	O
activated	O
calcineurin	B-protein
,	O
since	O
binding	O
is	O
inhibited	O
by	O
an	O
NFAT	O
peptide	O
spanning	O
the	O
calcineurin	B-protein
docking	O
site	O
on	O
NFAT	B-protein
.	O
	
The	O
interacting	O
surfaces	O
are	O
located	O
on	O
the	O
catalytic	B-protein
domain	I-protein
of	O
the	O
calcineurin	B-protein
A	I-protein
chain	I-protein
and	O
on	O
an	O
86-amino	B-protein
acid	I-protein
fragment	I-protein
of	O
the	O
NFAT	B-protein
regulatory	I-protein
domain	I-protein
.	O
	
NFAT	B-protein
binding	O
to	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
was	O
inhibited	O
by	O
the	O
calcineurin	B-protein
autoinhibitory	I-protein
domain	I-protein
and	O
the	O
RII	O
substrate	O
peptide	O
,	O
which	O
bind	O
in	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
as	O
well	O
as	O
by	O
the	O
NFAT	B-protein
docking	O
site	O
peptide	O
,	O
which	O
binds	O
to	O
a	O
region	O
of	O
calcineurin	B-protein
distinct	O
from	O
the	O
active	B-protein
site	I-protein
.	O
	
We	O
propose	O
that	O
,	O
in	O
resting	B-cell_type
cells	I-cell_type
,	O
NFAT	B-protein
is	O
targeted	O
to	O
a	O
region	O
of	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
that	O
does	O
not	O
overlap	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
.	O
	
Upon	O
cell	O
activation	O
,	O
displacement	O
of	O
the	O
autoinhibitory	B-protein
domain	I-protein
by	O
calmodulin	B-protein
binding	O
allows	O
NFAT	B-protein
to	O
bind	O
additionally	O
to	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
thus	O
positioning	O
NFAT	B-protein
for	O
immediate	O
dephosphorylation	O
at	O
functional	O
phosphoserine	O
residues	O
.	O
	
###MEDLINE:98385602	
	
Nuclear	B-protein
factor-kappaB	I-protein
induction	O
in	O
CD45RO+	B-cell_type
and	I-cell_type
CD45RA+	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
during	O
aging	O
.	O
	
An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	B-cell_type
to	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O
	
Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
in	O
activated	O
memory	B-cell_type
(	I-cell_type
CD45RO+	I-cell_type
)	I-cell_type
and	I-cell_type
naive	I-cell_type
(	I-cell_type
CD45RA+	I-cell_type
)	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF-alpha	B-protein
-mediated	O
induction	O
of	O
NFkappaB	B-protein
.	O
	
Although	O
treatment	O
with	O
TNF-alpha	B-protein
induced	O
nuclear	O
localization	O
of	O
NFkappaB	B-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	B-protein
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O
	
Examination	O
of	O
IkappaB	B-protein
alpha	I-protein
regulation	O
revealed	O
that	O
TNF-alpha	B-protein
-mediated	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	B-protein
.	O
	
In	O
addition	O
,	O
this	O
age-related	O
decrease	O
in	O
induction	O
of	O
nuclear	B-protein
NFkappaB	I-protein
correlated	O
with	O
decrease	O
in	O
intracellular	O
IL-2	B-protein
receptor	O
expression	O
and	O
anti-CD3	B-protein
-induced	O
proliferation	O
of	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
subsets	I-cell_type
.	O
	
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age-related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O
	
###MEDLINE:98375865	
	
Cyclosporin	O
A-resistant	O
transactivation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
requires	O
activity	O
of	O
okadaic	B-protein
acid-sensitive	I-protein
serine/threonine	I-protein
phosphatases	I-protein
.	O
	
Expression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
requires	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
stimulation	O
of	O
the	O
TCR	B-protein
and	O
costimulation	O
through	O
accessory	B-protein
receptors	I-protein
.	O
	
We	O
have	O
found	O
recently	O
that	O
okadaic	B-protein
acid-sensitive	I-protein
Ser/Thr	I-protein
phosphatases	I-protein
are	O
involved	O
in	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O
	
In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O
	
In	O
both	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
activated	B-cell_line
tumorigenic	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IL-2	B-protein
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O
	
The	O
transcription	B-protein
factors	I-protein
active	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
were	O
differentially	O
influenced	O
:	O
upon	O
down-modulation	O
of	O
okadaic	B-protein
acid-sensitive	I-protein
phosphatases	I-protein
,	O
transactivation	O
by	O
octamer	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
proteins	I-protein
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP-1	B-protein
proteins	I-protein
was	I-protein
even	I-protein
enhanced	I-protein
.	I-protein
	
###MEDLINE:99023506	
	
YM268	O
increases	O
the	O
glucose	O
uptake	O
,	O
cell	O
differentiation	O
,	O
and	O
mRNA	O
expression	O
of	O
glucose	B-protein
transporter	I-protein
in	O
3T3-L1	B-cell_type
adipocytes	I-cell_type
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
bis	O
[	O
4-	O
[	O
2	O
,	O
4-dioxo-5-thiazolidinyl	O
)	O
methyl	O
]	O
phenyl	O
]	O
methane	O
(	O
YM-268	O
)	O
,	O
a	O
thiazolidinedione	O
derivative	O
,	O
on	O
glucose	O
uptake	O
,	O
adipocyte	B-cell_type
differentiation	O
through	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
activity	O
in	O
cultured	B-cell_line
cells	I-cell_line
.	O
	
YM268	O
and	O
pioglitazone	O
dose-dependently	O
increased	O
the	O
2-deoxyglucose	O
uptake	O
in	O
3T3-L1	B-cell_line
cells	I-cell_line
.	O
	
YM268	O
facilitated	O
the	O
insulin-stimulated	O
triglyceride	O
accumulation	O
in	O
3T3-L1	B-cell_type
adipocytes	I-cell_type
and	O
increased	O
the	O
mRNA	O
expression	O
of	O
fatty	B-protein
acid-binding	I-protein
protein	I-protein
.	O
	
YM268	O
,	O
with	O
and	O
without	O
insulin	O
,	O
increased	O
the	O
mRNA	O
expression	O
of	O
glucose	B-protein
transporter	I-protein
isoforms	O
such	O
as	O
GLUT1	B-protein
and	O
GLUT4	B-protein
,	O
indicating	O
enhancement	O
of	O
adipocyte	B-cell_type
differentiation	O
.	O
	
Additionally	O
,	O
YM268	O
and	O
pioglitazone	O
showed	O
activity	O
of	O
the	O
PPARgamma	B-protein
ligand	I-protein
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	I-protein
responsible	O
for	O
adipogenesis	O
.	O
	
To	O
examine	O
the	O
possible	O
involvement	O
of	O
the	O
increased	O
activity	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
YM268-stimulated	O
glucose	O
uptake	O
,	O
the	O
enzyme	O
activity	O
was	O
estimated	O
by	O
measuring	O
the	O
phosphatidylinositol-3	O
,	O
4	O
,	O
5-trisphosphate	O
(	O
PI-3	O
,	O
4	O
,	O
5-P3	O
)	O
concentration	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Insulin	O
dose-dependently	O
increased	O
the	O
PI-3	O
,	O
4	O
,	O
5-P3	O
production	O
but	O
YM268	O
had	O
no	O
significant	O
effect	O
on	O
the	O
insulin-dependent	O
and	O
-independent	O
PI	O
3-kinase	O
activation	O
.	O
	
These	O
results	O
indicate	O
that	O
the	O
mechanism	O
by	O
which	O
YM268	O
increased	O
glucose	O
uptake	O
,	O
may	O
be	O
accounted	O
for	O
in	O
part	O
by	O
the	O
enhancement	O
of	O
GLUT1	B-protein
and	O
GLUT4	B-protein
expression	O
through	O
PPARgamma	B-protein
activation	O
.	O
	
###MEDLINE:99014176	
	
The	O
nuclear	B-protein
receptor	I-protein
PPARgamma	B-protein
-	O
bigger	O
than	O
fat	O
.	O
	
Work	O
reported	O
over	O
the	O
past	O
year	O
has	O
provided	O
insights	O
into	O
the	O
mechanisms	O
whereby	O
ligand	O
activation	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
regulates	O
systemic	O
glucose	O
and	O
lipid	O
homeostasis	O
.	O
	
PPARgamma	B-protein
has	O
also	O
been	O
implicated	O
recently	O
in	O
the	O
biology	O
of	O
monocytes	O
and	O
in	O
cell-cycle	O
regulation	O
and	O
cancer	O
.	O
	
Polyunsaturated	O
fatty	O
acids	O
and	O
eicosanoids	O
bind	O
and	O
activate	O
PPARgamma	B-protein
,	O
suggesting	O
that	O
these	O
lipids	O
may	O
serve	O
as	O
hormonal	O
regulators	O
of	O
a	O
variety	O
of	O
biological	O
processes	O
.	O
	
###MEDLINE:99007753	
	
The	O
role	O
of	O
caspases	O
in	O
T	O
cell	O
development	O
and	O
the	O
control	O
of	O
immune	O
responses	O
.	O
	
Apoptosis	O
is	O
responsible	O
for	O
the	O
removal	O
of	O
potentially	O
autoreactive	O
or	O
useless	O
T	O
cells	O
during	O
thymic	O
selection	O
and	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
the	O
periphery	O
.	O
	
Specific	O
families	O
of	O
receptors	B-protein
,	O
kinases	B-protein
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
cysteine	B-protein
proteases	I-protein
,	O
termed	B-protein
caspases	I-protein
,	O
are	O
involved	O
in	O
the	O
apoptotic	O
cascade	O
leading	O
to	O
proteolysis	O
of	O
specific	O
substrates	O
and	O
to	O
morphological	O
changes	O
associated	O
with	O
programmed	O
cell	O
death	O
.	O
	
Although	O
common	O
members	O
of	O
the	O
apoptotic	O
cascade	O
are	O
shared	O
between	O
different	O
cell	O
types	O
,	O
it	O
appears	O
that	O
cell-specific	B-protein
factors	I-protein
can	O
influence	O
the	O
response	O
to	O
a	O
given	O
apoptotic	O
stimuli	O
.	O
	
Characterization	O
and	O
understanding	O
of	O
the	O
basic	O
mechanisms	O
involved	O
in	O
the	O
different	O
pathways	O
protecting	O
or	O
leading	O
to	O
cell	O
death	O
may	O
provide	O
novel	O
ways	O
to	O
control	O
inappropriate	O
apoptosis	O
involved	O
in	O
several	O
diseases	O
.	O
	
###MEDLINE:98451423	
	
Cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
does	O
not	O
require	O
antigenic	O
peptides	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O
	
It	O
has	O
been	O
proposed	O
that	O
the	O
cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
involves	O
the	O
transfer	O
to	O
host	O
APCs	B-cell_type
of	O
heat	B-protein
shock	I-protein
protein	I-protein
glycoprotein	I-protein
96	I-protein
-chaperoned	O
antigenic	O
peptides	O
released	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
of	O
dying	B-cell_type
or	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
tested	O
this	O
possibility	O
directly	O
using	O
TAP-deficient	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
antigenic	O
ER	O
peptides	O
derived	O
from	O
two	O
model	O
Ags	B-protein
,	O
the	O
human	B-protein
adenovirus	I-protein
type	I-protein
5	I-protein
early	I-protein
regions	I-protein
E1A	I-protein
and	I-protein
E1B	I-protein
.	O
	
Although	O
both	O
proteins	O
were	O
well	O
expressed	O
,	O
the	O
cells	O
were	O
not	O
recognized	O
by	O
E1A-	B-cell_type
or	I-cell_type
E1B-specific	I-cell_type
CTLs	I-cell_type
unless	O
the	O
relevant	O
epitope	O
was	O
either	O
provided	O
exogenously	O
as	O
a	O
synthetic	O
peptide	O
or	O
targeted	O
to	O
the	O
ER	O
in	O
a	O
TAP-independent	O
fashion	O
.	O
	
Despite	O
the	O
absence	O
of	O
these	O
ER	O
peptides	O
,	O
the	O
TAP1-/-	B-cell_type
cells	I-cell_type
were	O
able	O
to	O
efficiently	O
cross-prime	B-cell_type
E1A-	I-cell_type
and	I-cell_type
E1B-specific	I-cell_type
CTLs	I-cell_type
following	O
immunization	O
of	O
syngeneic	O
mice	O
.	O
	
These	O
results	O
indicate	O
that	O
,	O
although	O
purified	O
peptide/glycoprotein	B-protein
96	I-protein
complexes	I-protein
are	O
potent	O
immunogens	O
,	O
the	O
mechanism	O
of	O
CTL	O
cross-priming	O
in	O
vivo	O
does	O
not	O
depend	O
upon	O
antigenic	O
peptides	O
in	O
the	O
ER	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98438583	
	
A	O
critical	O
role	O
of	O
the	O
p75	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
p75TNF-R	B-protein
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
.	I-protein
	
Despite	O
overwhelming	O
evidence	O
that	O
enhanced	O
production	O
of	O
the	O
p75	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
p75TNF-R	B-protein
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi-organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O
	
We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	B-protein
p75TNF-R	I-protein
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF-kappaB	B-protein
activity	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
compartment	O
.	O
	
This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
,	O
although	O
coexpression	O
of	O
a	O
human	B-DNA
TNF	I-DNA
transgene	I-DNA
accelerated	O
pathology	O
.	O
	
These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF-R	B-protein
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O
	
###MEDLINE:98421363	
	
Expression	O
status	O
of	O
BCL-6	B-protein
and	O
syndecan-1	B-protein
identifies	O
distinct	O
histogenetic	O
subtypes	O
of	O
Hodgkin	O
's	O
disease	O
.	O
	
The	O
tumor	B-cell_type
cells	I-cell_type
in	O
most	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
have	O
been	O
recently	O
recognized	O
to	O
originate	O
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
,	O
but	O
their	O
precise	O
differentiation	O
stage	O
is	O
not	O
fully	O
clarified	O
.	O
	
Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
B-cell	B-cell_type
lymphomas	I-cell_type
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
CD138/syndecan-1	B-protein
(	O
syn-1	B-protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post-GC	O
,	O
terminal	O
B-cell	O
differentiation	O
.	O
	
In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HD	O
histogenesis	O
.	O
	
We	O
have	O
found	O
that	O
in	O
nodular	O
lymphocyte	O
predominance	O
HD	O
(	O
NLPHD	O
)	O
tumor	B-cell_type
cells	I-cell_type
consistently	O
display	O
the	O
BCL-6	B-protein
(	O
+	O
)	O
/	O
syn-1	B-protein
(	O
-	O
)	O
phenotype	O
,	O
indicating	O
their	O
derivation	O
from	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
Conversely	O
,	O
classic	O
HD	O
(	O
CHD	O
)	O
is	O
heterogeneous	O
because	O
the	O
tumor	B-cell_type
cells	I-cell_type
of	O
a	O
fraction	O
of	O
CHD	O
display	O
the	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
syn-1	B-protein
(	O
+	O
)	O
phenotype	O
of	O
post-GC	O
B-cells	O
,	O
whereas	O
another	O
fraction	O
of	O
CHD	O
is	O
constituted	O
by	O
a	O
mixture	O
of	O
tumor	B-cell_type
cells	I-cell_type
reflecting	O
the	O
GC	O
(	O
BCL-6	B-protein
(	O
+	O
)	O
/	O
syn-1	B-protein
(	O
-	O
)	O
)	O
or	O
post-GC	O
(	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
syn-1	B-protein
(	O
+	O
)	O
)	O
phenotypes	O
.	O
	
BCL-6	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
/syn-1	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
tumor	I-cell_line
cells	I-cell_line
of	O
CHD	O
are	O
mostly	O
found	O
surrounded	O
by	O
T	B-cell_type
cells	I-cell_type
expressing	O
CD40L	B-protein
,	O
consistent	O
with	O
the	O
observation	O
that	O
CD40	B-protein
signaling	O
downregulates	O
BCL-6	B-protein
expression	O
.	O
	
These	O
data	O
indicate	O
that	O
tumor	B-cell_type
cells	I-cell_type
of	O
NLPHD	O
uniformly	O
display	O
a	O
GC	O
B-cell	O
phenotype	O
,	O
whereas	O
the	O
phenotype	O
of	O
tumor	B-cell_type
cells	I-cell_type
of	O
CHD	O
appears	O
to	O
be	O
modulated	O
by	O
the	O
surrounding	O
cellular	O
background	O
,	O
particularly	O
CD40L+	B-cell_type
reactive	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98406210	
	
Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus-induced	O
apoptosis	O
in	O
lymphoblastoid	B-protein
T-cell-line-expressing	I-protein
wild-type	I-protein
and	I-protein
mutated	I-protein
CD4	I-protein
receptors	I-protein
.	O
	
We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	B-protein
cytoplasmic	I-protein
tail	I-protein
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-induced	O
apoptosis	O
(	O
J.Corbeil	O
,	O
M.Tremblay	O
,	O
and	O
D.D.Richman	O
,	O
J.Exp.Med.183	O
:	O
39-48	O
,	O
1996	O
)	O
.	O
	
We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	B-protein
transduction	O
pathway	O
in	O
HIV-induced	O
apoptosis	O
.	O
	
To	O
do	O
this	O
,	O
wild-type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	B-protein
cytoplasmic	I-protein
tail	I-protein
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
line	I-cell_line
A2.01	B-cell_line
.	O
	
Apoptosis	O
was	O
prevented	O
when	O
CD4	B-protein
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
(	O
mutated	O
at	O
the	O
dicysteine	B-protein
motif	I-protein
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	B-protein
tail	I-protein
underwent	O
apoptosis	O
like	O
wild-	B-protein
type	I-protein
CD4	I-protein
.	O
	
The	O
differences	O
between	O
wild-type	B-protein
and	I-protein
mutated	I-protein
receptors	I-protein
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
or	O
NF-	B-protein
kappaB	I-protein
activation	O
.	O
	
Initial	O
signaling	O
through	O
the	O
CD4	B-protein
receptor	I-protein
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
undergo	O
apoptosis	O
.	O
	
Incubation	O
of	O
HIV-infected	B-cell_type
cells	I-cell_type
with	O
monoclonal	B-protein
antibody	I-protein
(	I-protein
MAb	I-protein
)	I-protein
13B8-2	I-protein
,	O
which	O
binds	O
to	O
CD4	B-protein
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O
	
Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	B-protein
-Fas	B-protein
ligand	I-protein
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti-Fas	O
MAb	O
(	O
ZB-4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
without	O
inducing	O
apoptosis	O
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O
	
These	O
observations	O
demonstrate	O
that	O
CD4	B-protein
signaling	O
mediates	O
HIV-induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B-protein
-Fas	B-protein
ligand	I-protein
interaction	O
,	O
does	O
not	O
require	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B-protein
dimerization	O
.	O
	
###MEDLINE:98395073	
	
p130	B-protein
,	O
p107	B-protein
,	O
and	O
pRb	B-protein
are	O
differentially	O
regulated	O
in	O
proliferating	B-cell_type
cells	I-cell_type
and	O
during	O
cell	O
cycle	O
arrest	O
by	O
alpha-interferon	B-protein
.	O
	
We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
family	I-protein
(	O
pRb	B-protein
,	O
p107	B-protein
,	O
and	O
p130	B-protein
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	B-cell_line
B-cells	I-cell_line
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha-interferon	B-protein
(	O
alpha-IFN	B-protein
)	O
.	O
	
alpha-IFN	B-protein
causes	O
dephosphorylation	O
of	O
pRb	B-protein
and	O
loss	O
of	O
p130	B-protein
phosphorylated	I-protein
Form	I-protein
3	I-protein
.	O
	
However	O
,	O
the	O
change	O
in	O
p130	B-protein
phosphorylation	O
in	O
response	O
to	O
alpha-IFN	B-protein
occurs	O
before	O
dephosphorylation	O
of	O
pRb	B-protein
is	O
complete	O
because	O
loss	O
of	O
p130	B-protein
Form	I-protein
3	I-protein
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	B-protein
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O
	
In	O
contrast	O
,	O
p107	B-protein
is	O
dephosphorylated	O
and	O
is	O
then	O
depleted	O
from	O
cells	O
as	O
they	O
exit	O
the	O
cell	O
cycle	O
.	O
	
p130	B-protein
,	O
predominantly	O
in	O
Form	O
1	O
,	O
and	O
hypophosphorylated	B-protein
pRb	I-protein
bind	O
an	O
E2F	B-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
;	O
p130	B-protein
complexes	O
E2F-4	B-protein
,	O
whereas	O
pRb	B-protein
binds	O
both	O
E2F-4	O
and	O
E2F-1	B-protein
.	O
	
The	O
phosphorylated	O
forms	O
of	O
E2F-4	B-protein
that	O
bind	O
to	O
the	O
E2F	B-DNA
DNA	I-DNA
site	I-DNA
are	O
different	O
from	O
hyperphosphorylated	O
E2F-4	B-protein
,	O
which	O
predominates	O
in	O
primary	B-cell_type
hemopoietic	I-cell_type
cells	I-cell_type
in	O
G0	O
.	O
	
We	O
conclude	O
that	O
although	O
cell	O
cycle	O
arrest	O
induced	O
by	O
alpha-IFN	B-protein
may	O
be	O
mediated	O
in	O
part	O
by	O
formation	O
of	O
a	O
complex	O
containing	O
p130	B-protein
and	O
E2F-4	B-protein
,	O
alpha-IFN	B-protein
does	O
not	O
induce	O
hyperphosphorylation	O
of	O
E2F-4	B-protein
,	O
which	O
characterizes	O
primary	B-cell_type
hemopoietic	I-cell_type
cells	I-cell_type
in	O
G0	O
.	O
	
###MEDLINE:98383419	
	
The	O
transcription	B-protein
factors	I-protein
c-myb	B-protein
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
the	O
monocytic/myeloic	B-DNA
gene	I-DNA
MRP14	B-DNA
.	O
	
The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O
	
During	O
this	O
process	O
a	O
sequence	O
of	O
cellular	O
,	O
humoral	O
,	O
non-specific	O
and	O
specific	O
actions	O
are	O
evoked	O
to	O
combat	O
the	O
infection	O
.	O
	
Macrophages	B-cell_type
and	O
granulocytes	B-cell_type
,	O
which	O
are	O
developed	O
from	O
a	O
common	O
progenitor	O
cell	O
,	O
are	O
the	O
cellular	O
components	O
of	O
the	O
specific	O
and	O
non-specific	O
immunoreaction	O
.	O
	
MRP14	B-DNA
(	O
Macrophage	B-protein
migration	I-protein
inhibitory	I-protein
related	I-protein
protein	I-protein
)	O
and	O
MRP8	B-protein
,	O
two	O
S-100	B-protein
proteins	I-protein
contained	O
in	O
high	O
concentrations	O
in	O
these	O
cells	O
are	O
obviously	O
essential	O
for	O
adhesion	O
and	O
migration	O
of	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O
	
To	O
investigate	O
the	O
transcriptional	O
regulation	O
of	O
these	O
genes	O
we	O
cotransfected	O
constructs	O
expressing	O
CAT	B-protein
under	O
control	O
of	O
the	O
MRP14	B-DNA
promoter	I-DNA
and	O
expression	O
constructs	O
of	O
C/EBP	B-protein
alpha	I-protein
and	O
v-myb	B-protein
,	O
two	O
transcription	B-protein
factors	I-protein
involved	O
in	O
myeloid/monocytic	O
differentiation	O
.	O
	
Transfection	O
with	O
C/EBP	B-protein
alpha	I-protein
revealed	O
a	O
massive	O
enhancement	O
of	O
the	O
MRP14	B-DNA
promoter	I-DNA
in	O
both	O
,	O
HL	B-cell_type
60	I-cell_type
cells	I-cell_type
(	O
granulocytic	O
differentiated	O
)	O
and	O
L132	B-cell_type
fibroblasts	I-cell_type
.	O
	
In	O
contrast	O
,	O
v-myb	B-protein
reduces	O
MRP14	B-DNA
promoter	I-DNA
activity	O
.	O
	
Northern	O
blot	O
analysis	O
of	O
L132	B-cell_type
cells	I-cell_type
transfected	O
with	O
the	O
C/EBP	B-protein
alpha	I-protein
expression	O
vector	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
is	O
sufficient	O
to	O
enhance	O
MRP14	B-protein
expression	O
in	O
the	O
context	O
of	O
the	O
whole	O
genome	O
.	O
	
###MEDLINE:98375844	
	
A	O
CD28	B-protein
-associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	B-DNA
gene	I-DNA
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	B-protein
engagement	O
.	O
	
Stimulation	O
of	O
resting	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
the	O
CD28-specific	B-protein
mAb	I-protein
BW	I-protein
828	I-protein
induces	O
proliferation	O
and	O
cytokine	B-protein
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	B-protein
coengagement	O
.	O
	
This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	B-protein
signal	O
)	O
can	O
activate	O
T	B-cell_type
cells	I-cell_type
.	O
	
To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	B-protein
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	B-cell_type
cells	I-cell_type
by	O
the	O
stimulatory	B-protein
mAb	I-protein
BW	I-protein
828	I-protein
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	B-protein
CD28	I-protein
mAb	I-protein
9.3	I-protein
.	O
	
Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
BW	B-protein
828	I-protein
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2+	O
,	O
but	O
did	O
not	O
lead	O
to	O
detectable	O
activation	O
of	O
the	O
protein	B-protein
kinases	I-protein
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
c-Raf-1	B-protein
.	O
	
This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	B-protein
response	O
element	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
mAb	B-protein
9.3	I-protein
increased	O
the	O
level	O
of	O
intracellular	O
Ca2+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
c-Raf-1	B-protein
,	O
but	O
was	O
unable	O
to	O
induce	O
the	O
binding	O
of	O
transcription	B-protein
factors	I-protein
to	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B-protein
828	I-protein
and	O
9.3	B-protein
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_type
cells	I-cell_type
(	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
activation	O
,	O
association	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	B-protein
changes	O
with	O
activation	O
.	O
	
These	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
through	O
CD28	B-protein
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O
	
###MEDLINE:99023375	
	
Decreased	O
IL-12	B-protein
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid-mediated	O
inhibition	O
of	O
NF-kappaB	B-protein
.	O
	
IL-12	B-protein
is	O
a	O
75-kDa	B-protein
heterodimeric	I-protein
cytokine	I-protein
composed	O
of	O
two	O
covalently	O
linked	O
p35	B-protein
and	I-protein
p40	I-protein
chains	I-protein
.	O
	
This	O
pro-inflammatory	B-protein
cytokine	I-protein
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell-mediated	O
immune	O
responses	O
.	O
	
Th1	O
cell-mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O
	
Thus	O
,	O
IL-12	B-protein
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O
	
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti-inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL-12	B-protein
production	O
and	O
Th1	O
cell	O
development	O
.	O
	
ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL-12	B-protein
heterodimer	I-protein
as	O
well	O
as	O
p40	B-protein
monomer	I-protein
by	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
This	O
was	O
associated	O
with	O
the	O
down-regulation	O
of	O
IL-12p40	B-RNA
mRNA	I-RNA
expression	O
.	O
	
Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	B-DNA
gene	I-DNA
promoter	I-DNA
revealed	O
that	O
ASA	O
inhibited	O
NF-kappaB	B-protein
activation	O
and	O
binding	O
to	O
the	O
p40-kappaB	B-DNA
site	I-DNA
in	O
the	O
p40	B-DNA
promoter	I-DNA
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	B-DNA
gene	I-DNA
.	O
	
Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti-inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
by	O
ASA	O
leads	O
to	O
down-regulation	O
of	O
IL-12	B-protein
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O
	
###MEDLINE:99008553	
	
Attenuation	O
of	O
HLA-DR	B-protein
expression	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Mycobacterium	O
tuberculosis	O
is	O
related	O
to	O
intracellular	O
sequestration	O
of	O
immature	B-protein
class	I-protein
II	I-protein
heterodimers	I-protein
.	O
	
MHC	B-protein
class	I-protein
II	I-protein
expression	O
was	O
examined	O
in	O
macrophages	B-cell_type
infected	O
with	O
Mycobacterium	O
tuberculosis	O
.	O
	
IFN-gamma	B-protein
increased	O
the	O
surface	O
expression	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
and	O
this	O
was	O
markedly	O
reduced	O
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O
	
Despite	O
this	O
effect	O
,	O
steady	O
state	O
levels	O
of	O
HLA-DRalpha	B-protein
,	O
HLA-DRbeta	B-protein
,	O
and	O
invariant	B-protein
(	I-protein
Ii	I-protein
)	I-protein
chains	I-protein
were	O
equivalent	O
in	O
control	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O
	
Metabolic	O
labeling	O
combined	O
with	O
pulse-chase	O
experiments	O
and	O
biochemical	O
analysis	O
showed	O
that	O
the	O
majority	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
infected	O
cells	O
became	O
resistant	O
to	O
endoglycosidase	B-protein
H	I-protein
,	O
consistent	O
with	O
normal	O
Golgi	O
processing	O
.	O
	
However	O
,	O
results	O
of	O
intracellular	O
staining	O
and	O
dual	O
color	O
confocal	O
microscopy	O
revealed	O
a	O
significant	O
defect	O
in	O
transport	O
of	O
newly	O
synthesized	O
class	B-protein
II	I-protein
molecules	I-protein
through	O
the	O
endocytic	O
compartment	O
.	O
	
Thus	O
,	O
compared	O
with	O
findings	O
in	O
control	O
cells	O
,	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
infected	B-cell_type
cells	I-cell_type
colocalized	O
to	O
a	O
minimal	O
extent	O
with	O
a	O
lysosomal-associated	B-protein
membrane	I-protein
protein-1	I-protein
+	O
endosomal	O
compartment	O
.	O
	
In	O
addition	O
,	O
in	O
contrast	O
to	O
control	B-cell_type
cells	I-cell_type
,	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
infected	B-cell_type
cells	I-cell_type
failed	O
to	O
colocalize	O
with	O
endocytosed	B-protein
BSA	I-protein
under	O
conditions	O
where	O
this	O
marker	O
is	O
known	O
to	O
label	O
late	O
endosomes	O
,	O
lysosomes	O
,	O
and	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
compartment	O
.	O
	
Consistent	O
with	O
defective	O
transport	O
along	O
the	O
endocytic	O
pathway	O
,	O
the	O
maturation	O
of	O
SDS-stable	B-protein
class	I-protein
II	I-protein
alphabeta	I-protein
dimers	I-protein
--	O
dependent	O
upon	O
removal	O
of	O
Ii	B-protein
chain	I-protein
and	O
peptide	O
loading	O
of	O
class	B-protein
II	I-protein
dimers	I-protein
in	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
compartment	O
--	O
was	O
markedly	O
impaired	O
in	O
M.	O
tuberculosis	O
-infected	B-cell_type
cells	I-cell_type
.	O
	
These	O
findings	O
indicate	O
that	O
defective	O
transport	O
and	O
processing	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
through	O
the	O
endosomal/lysosomal	O
system	O
is	O
responsible	O
for	O
diminished	O
cell	O
surface	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O
	
###MEDLINE:99187985	
	
Identification	O
of	O
upstream	B-DNA
regulatory	I-DNA
elements	I-DNA
that	O
repress	O
expression	O
of	O
adult	B-DNA
beta-like	I-DNA
globin	I-DNA
genes	I-DNA
in	O
a	O
primitive	O
erythroid	O
environment	O
.	O
	
Our	O
investigations	O
have	O
focused	O
on	O
localizing	O
cis-elements	B-DNA
responsible	O
for	O
the	O
down	O
regulation	O
of	O
the	O
adult	B-DNA
beta-like	I-DNA
globin	I-DNA
genes	I-DNA
(	O
delta	B-DNA
and	O
beta	B-DNA
)	O
in	O
immature	O
,	O
or	O
primitive	O
erythroid	O
tissues	O
.	O
	
We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
an	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
an	O
embryonic-fetal	O
phenotype	O
.	O
	
Analyzed	O
DNA	B-DNA
sequences	I-DNA
included	O
delta	B-DNA
and	I-DNA
beta	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
regions	I-DNA
extending	O
from	O
approximately	O
-500	B-DNA
to	I-DNA
+50bp	I-DNA
(	O
promoter	B-DNA
regions	I-DNA
)	O
,	O
truncated	O
delta	O
and	O
beta	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
regions	I-DNA
extending	O
from	O
approximately	O
-250	B-DNA
to	I-DNA
+50	I-DNA
bp	I-DNA
,	O
and	O
chimeric	B-DNA
promoter	I-DNA
constructions	I-DNA
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	B-DNA
or	I-DNA
beta	I-DNA
fragment	I-DNA
fused	O
to	O
a	O
proximal	B-DNA
beta	I-DNA
or	I-DNA
delta	I-DNA
sequence	I-DNA
.	O
	
In	O
CAT	B-DNA
reporter	I-DNA
constructions	I-DNA
no	O
appreciable	O
level	O
of	O
CAT	B-protein
activity	O
was	O
supported	O
by	O
the	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	B-DNA
promoter	I-DNA
.	O
	
Truncation	O
of	O
the	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
led	O
to	O
a	O
2-3	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O
	
In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
delta	B-DNA
promoter	I-DNA
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O
	
Coupling	O
of	O
the	O
upstream	B-DNA
beta	I-DNA
globin	I-DNA
sequence	I-DNA
from	O
approximately	O
-500	O
to	O
-250	O
bp	O
to	O
the	O
truncated	O
delta	B-DNA
promoter	I-DNA
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	B-DNA
globin	I-DNA
gene	I-DNA
upstream	I-DNA
element	I-DNA
(	O
s	O
)	O
.	O
	
Fusion	O
of	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
delta	B-DNA
promoter	I-DNA
to	O
the	O
truncated	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	B-DNA
beta	I-DNA
gene	I-DNA
promoter	I-DNA
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	B-DNA
transcriptional	I-DNA
element	I-DNA
(	O
s	O
)	O
in	O
the	O
upstream	B-DNA
delta	I-DNA
globin	I-DNA
regulatory	I-DNA
region	I-DNA
.	O
	
Site-directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	B-protein
proteins	I-protein
BP1	I-protein
and	I-protein
BP2	I-protein
in	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
beta	B-DNA
globin	I-DNA
gene	I-DNA
flanking	I-DNA
region	I-DNA
led	O
to	O
a	O
4-6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O
	
DNase	B-protein
I	I-protein
footprinting	O
of	O
the	O
upstream	B-DNA
delta-globin	I-DNA
region	I-DNA
revealed	O
protected	B-DNA
sequences	I-DNA
corresponding	O
to	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
GATA-1	B-protein
and	O
BP2	B-protein
.	O
	
These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
of	O
the	O
adult	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
contribute	O
to	O
its	O
factor-mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O
	
###MEDLINE:98439530	
	
Analysis	O
of	O
cytokine	B-protein
signaling	O
in	O
patients	O
with	O
extrinsic	O
asthma	O
and	O
hyperimmunoglobulin	O
E	O
.	O
	
BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	B-protein
by	O
cytokines	B-protein
is	O
mediated	O
by	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
	
The	O
induction	O
of	O
IgE	B-protein
by	O
IL-4	B-protein
and	O
IL-13	B-protein
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	B-protein
signal-transducing	I-protein
protein	I-protein
Stat6	I-protein
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	B-protein
class	O
switching	O
by	O
interferon-y	B-protein
(	O
IFN-gamma	B-protein
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	B-protein
.	O
	
OBJECTIVE	O
:	O
We	O
hypothesized	O
that	O
in	O
extrinsic	O
asthma	O
or	O
in	O
cases	O
of	O
markedly	O
elevated	O
IgE	B-protein
(	O
ie	O
,	O
hyperimmunoglobulin	O
E	O
[	O
HIE	O
]	O
)	O
increased	O
levels	O
of	O
IgE	B-protein
may	O
be	O
associated	O
with	O
alterations	O
in	O
the	O
cytokine	B-protein
levels	O
or	O
the	O
activation	O
of	O
Stat6	B-protein
.	O
	
METHODS	O
:	O
PBMCs	B-cell_type
and	O
sera	O
from	O
8	O
patients	O
with	O
extrinsic	O
asthma	O
(	O
mean	O
IgE	B-protein
,	O
285+/-100	O
IU/mL	O
)	O
,	O
3	O
patients	O
with	O
HIE	O
(	O
mean	O
IgE	B-protein
,	O
7050+/-1122	O
IU/mL	O
)	O
,	O
and	O
14	O
nonatopic	O
control	O
subjects	O
(	O
mean	O
IgE	B-protein
,	O
112+/-28	O
IU/mL	O
)	O
were	O
analyzed	O
.	O
	
RESULTS	O
:	O
The	O
mean	O
IL-4	B-protein
level	O
detected	O
by	O
ELISA	O
was	O
much	O
greater	O
in	O
patients	O
with	O
HIE	O
than	O
control	O
subjects	O
(	O
88.6+/-11.5	O
pg/mL	O
vs	O
11.5+/-7.1	O
pg/mL	O
,	O
P	O
=	O
.005	O
)	O
,	O
and	O
increased	O
IL-4	B-protein
levels	O
among	O
patients	O
with	O
both	O
asthma	O
and	O
HIE	O
correlated	O
with	O
the	O
increased	O
IgE	B-protein
levels	O
.	O
	
In	O
contrast	O
,	O
IL-13	B-protein
levels	O
were	O
not	O
elevated	O
.	O
	
Levels	O
of	O
Stat6	B-protein
protein	O
present	O
in	O
PBMCs	B-cell_type
did	O
not	O
differ	O
in	O
the	O
patients	O
and	O
control	O
subjects	O
.	O
	
Examination	O
of	O
Stat6	B-protein
DNA-binding	O
activity	O
demonstrated	O
no	O
activation	O
of	O
IL-4	B-protein
signaling	O
in	O
patients	O
with	O
either	O
HIE	O
or	O
acute	O
asthma	O
.	O
	
Interestingly	O
,	O
evidence	O
for	O
the	O
presence	O
of	O
B	B-cell_type
cells	I-cell_type
that	O
have	O
already	O
switched	O
to	O
IgE	B-protein
was	O
seen	O
in	O
PBMCs	B-cell_type
of	O
several	O
patients	O
with	O
asthma	O
or	O
HIE	O
.	O
	
CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
(	O
1	O
)	O
IgE	B-protein
production	O
in	O
asthma	O
and	O
HIE	O
usually	O
is	O
associated	O
with	O
elevated	O
levels	O
of	O
IL-4	B-protein
,	O
but	O
not	O
IL-13	B-protein
,	O
in	O
the	O
peripheral	O
blood	O
;	O
(	O
2	O
)	O
the	O
increased	O
sera	O
IL-4	B-protein
levels	O
in	O
asthma	O
and	O
HIE	O
are	O
not	O
sufficient	O
to	O
induce	O
Stat6	B-protein
activation	O
in	O
PBMCs	B-cell_type
;	O
and	O
(	O
3	O
)	O
evidence	O
of	O
switch	O
recombination	O
to	O
epsilon	O
may	O
be	O
detected	O
in	O
isolated	O
cases	O
of	O
elevated	O
IgE	B-protein
.	O
	
This	O
implies	O
that	O
high	O
levels	O
of	O
IgE	B-protein
in	O
these	O
patients	O
either	O
results	O
from	O
B	B-cell_type
cells	I-cell_type
that	O
have	O
already	O
undergone	O
class	O
switching	O
,	O
from	O
Ig	O
class	O
switching	O
that	O
is	O
localized	O
to	O
target	O
tissues	O
,	O
or	O
both	O
.	O
	
###MEDLINE:98430664	
	
Carboxyl-terminal	B-protein
15-amino	I-protein
acid	I-protein
sequence	I-protein
of	O
NFATx1	B-protein
is	O
possibly	O
created	O
by	O
tissue-specific	O
splicing	O
and	O
is	O
essential	O
for	O
transactivation	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
NFAT	B-protein
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
and	O
other	O
immunoregulatory	B-DNA
genes	I-DNA
.	O
	
We	O
have	O
isolated	O
NFATx	B-protein
,	O
which	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
and	O
an	O
isoform	O
of	O
NFATx	B-protein
,	O
NFATx1	B-protein
.	O
	
Here	O
we	O
provide	O
evidence	O
showing	O
that	O
15	O
amino	O
acids	O
in	O
the	O
carboxyl-terminal	B-protein
end	I-protein
of	O
NFATx1	B-protein
are	O
required	O
for	O
its	O
maximum	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
A	O
fusion	O
between	O
these	O
15	O
amino	O
acids	O
and	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
was	O
capable	O
of	O
transactivating	O
reporters	O
driven	O
by	O
the	O
GAL4	B-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
Interestingly	O
,	O
this	O
15-amino	B-protein
acid	I-protein
transactivation	I-protein
sequence	I-protein
is	O
well	O
conserved	O
in	O
NFAT	B-protein
family	I-protein
proteins	I-protein
,	O
although	O
the	O
sequences	O
contiguous	O
to	O
the	O
carboxyl-terminal	B-protein
regions	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
are	O
much	O
less	O
conserved	O
.	O
	
We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	B-protein
,	O
designated	O
NFATx2	B-protein
,	O
NFATx3	B-protein
,	O
and	O
NFATx4	B-protein
.	O
	
This	O
transactivation	O
sequence	O
is	O
altered	O
by	O
tissue-specific	O
alternative	O
splicing	O
in	O
newly	O
isolated	O
NFATx	B-protein
isoforms	I-protein
,	O
resulting	O
in	O
lower	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
NFATx1	B-protein
is	O
expressed	O
predominantly	O
in	O
the	O
thymus	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocyte	I-cell_type
,	O
while	O
the	O
skeletal	O
muscle	O
expressed	O
primarily	O
NFATx2	B-protein
.	O
	
In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
transcription	O
from	O
the	O
NFAT	B-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
activated	O
strongly	O
by	O
NFATx1	B-protein
but	O
only	O
weakly	O
by	O
NFATx2	B-protein
.	O
	
These	O
data	O
demonstrate	O
that	O
the	O
15-amino	B-protein
acid	I-protein
sequence	I-protein
of	O
NFATx1	B-protein
is	O
a	O
major	B-protein
transactivation	I-protein
sequence	I-protein
required	O
for	O
induction	O
of	O
genes	O
by	O
NFATx1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
possibly	O
regulates	O
NFAT	B-protein
activity	O
through	O
tissue-specific	O
alternative	O
splicing	O
.	O
	
###MEDLINE:98417611	
	
Altered	B-protein
DNA-binding	I-protein
specificity	I-protein
mutants	I-protein
of	O
EKLF	B-protein
and	O
Sp1	O
show	O
that	O
EKLF	B-protein
is	O
an	O
activator	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
in	O
vivo	O
.	O
	
The	O
locus	B-DNA
control	I-DNA
region	I-DNA
of	O
the	O
beta-globin	B-DNA
cluster	I-DNA
contains	O
five	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
5'HS1-5	B-DNA
)	O
required	O
for	O
locus	O
activation	O
.	O
	
5'HS3	B-DNA
contains	O
six	O
G-rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O
	
Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	B-protein
fingers	I-protein
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
interact	O
with	O
these	O
motifs	O
.	O
	
Because	O
point	O
mutagenesis	O
can	O
not	O
distinguish	O
between	O
family	O
members	O
,	O
it	O
is	O
not	O
known	O
which	O
protein	O
activates	O
5'HS3	B-DNA
.	O
	
We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	B-DNA
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	B-protein
fingers	I-protein
of	O
Sp1	B-protein
and	O
EKLF	B-protein
.	O
	
Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	B-protein
is	O
a	O
direct	O
activator	O
of	O
5'HS3	B-DNA
.	O
	
###MEDLINE:98406200	
	
The	O
Epstein-Barr	B-protein
virus	I-protein
Rta	I-protein
protein	I-protein
activates	O
lytic	B-DNA
cycle	I-DNA
genes	I-DNA
and	O
can	O
disrupt	O
latency	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
transition	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
from	O
latency	O
into	O
the	O
lytic	O
cycle	O
is	O
associated	O
with	O
the	O
expression	O
of	O
two	O
immediate-early	B-DNA
viral	I-DNA
genes	I-DNA
,	O
BZLF1	B-DNA
and	O
BRLF1	B-DNA
.	O
	
Overexpression	O
of	O
ZEBRA	O
,	O
the	O
product	O
of	O
BZLF1	B-DNA
,	O
is	O
sufficient	O
to	O
disrupt	O
latency	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
by	O
stimulating	O
expression	O
of	O
lytic	B-DNA
cycle	I-DNA
genes	I-DNA
,	O
including	O
BRLF1	B-DNA
.	O
	
The	O
BRLF1	B-protein
product	I-protein
Rta	I-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
both	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O
	
However	O
,	O
Rta	B-protein
has	O
recently	O
been	O
reported	O
to	O
disrupt	O
latency	O
in	O
an	O
epithelial	O
specific	O
manner	O
(	O
S.	O
Zalani	O
,	O
E.	O
Holley-Guthrie	O
,	O
and	O
S.	O
Kenney	O
,	O
Proc.	O
Natl.	O
Acad.	O
Sci.	O
USA	O
93	O
:	O
9194-9199	O
,	O
1996	O
)	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
expression	O
of	O
Rta	B-protein
is	O
also	O
sufficient	O
for	O
disruption	O
of	O
latency	O
in	O
a	O
permissive	B-cell_line
B-cell	I-cell_line
line	I-cell_line
.	O
	
In	O
HH514-16	B-cell_line
cells	I-cell_line
,	O
transfection	O
of	O
Rta	B-protein
leads	O
to	O
synthesis	O
of	O
ZEBRA	B-protein
,	O
viral	O
DNA	O
replication	O
,	O
and	O
late	O
gene	O
expression	O
.	O
	
However	O
,	O
Rta	B-protein
by	O
itself	O
is	O
less	O
potent	O
than	O
ZEBRA	B-protein
in	O
the	O
ability	O
to	O
activate	O
most	O
early	O
and	O
late	O
lytic	B-DNA
cycle	I-DNA
genes	I-DNA
.	O
	
In	O
light	O
of	O
previous	O
work	O
implicating	O
ZEBRA	B-protein
in	O
the	O
activation	O
of	O
Rta	B-protein
,	O
we	O
suggest	O
a	O
cooperative	O
model	O
for	O
EBV	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O
	
Expression	O
of	O
either	O
BZLF1	B-DNA
or	O
BRLF1	B-DNA
triggers	O
expression	O
of	O
the	O
other	O
immediate-early	B-protein
factor	I-protein
,	O
and	O
together	O
these	O
activators	O
act	O
individually	O
or	O
in	O
synergy	O
on	O
downstream	B-DNA
targets	I-DNA
to	O
activate	O
the	O
viral	O
lytic	O
cycle	O
.	O
	
###MEDLINE:98391036	
	
Transcription	O
of	O
a	O
minimal	B-DNA
promoter	I-DNA
from	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
CREB/ATF	B-protein
and	O
SP1	B-protein
proteins	I-protein
in	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O
	
NF-IL6	B-protein
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	B-cell_type
monocytes/macrophages	I-cell_type
,	O
and	O
NF-IL6	B-protein
is	O
the	O
only	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	I-protein
member	O
whose	O
steady-state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	B-cell_type
(	O
1	O
)	O
.	O
	
We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF-IL6	B-RNA
mRNA	I-RNA
following	O
activation	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O
	
We	O
have	O
identified	O
a	O
104-bp	B-DNA
minimal	I-DNA
promoter	I-DNA
region	I-DNA
of	O
the	O
NF-IL6	B-DNA
gene	I-DNA
that	O
is	O
sufficient	O
for	O
basal	O
and	O
activation-dependent	O
induction	O
of	O
transcription	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
This	O
region	O
contains	O
binding	O
sites	O
for	O
the	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein/activation	I-protein
transcription	I-protein
factor	I-protein
(	O
CREB/ATF	B-protein
)	O
and	O
Sp1	B-protein
families	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
Each	O
site	O
is	O
functionally	O
important	O
and	O
contributes	O
independently	O
to	O
transcription	O
of	O
the	O
NF-IL6	B-DNA
gene	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:98384373	
	
CIITA	B-protein
B-cell-specific	B-DNA
promoter	I-DNA
suppression	O
in	O
MHC	B-cell_line
class	I-cell_line
II-silenced	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
.	O
	
In	O
this	O
study	O
,	O
various	O
sets	O
of	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
,	O
generated	O
by	O
the	O
fusion	O
of	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
with	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
.	O
	
We	O
first	O
demonstrate	O
,	O
in	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
intraspecies	I-cell_line
hybrids	I-cell_line
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
,	O
Ii	B-protein
(	O
invariant	B-protein
chain	I-protein
)	O
and	O
HLA-DM	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	B-protein
gamma	I-protein
.	O
	
Using	O
interspecies	O
hybrids	O
,	O
the	O
segregation	O
of	O
human	B-DNA
chromosomes	I-DNA
allowed	O
us	O
to	O
establish	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
extinction	O
is	O
linked	O
to	O
the	O
presence	O
in	O
the	O
hybrids	O
of	O
the	O
chromosomes	B-DNA
from	O
the	O
epithelial	B-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O
	
Moreover	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
the	O
expression	O
pattern	O
of	O
MHC	B-RNA
class	I-RNA
II	I-RNA
mRNA	I-RNA
is	O
correlated	O
with	O
that	O
of	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
,	O
suggesting	O
that	O
CIITA	B-protein
is	O
the	O
actual	O
target	O
of	O
the	O
silencing	O
.	O
	
To	O
gain	O
further	O
insight	O
into	O
the	O
suppression	O
phenomenon	O
we	O
performed	O
luciferase	O
assays	O
which	O
show	O
that	O
silencing	O
affects	O
the	O
activity	O
of	O
the	O
B-cell-specific	B-DNA
promoter	I-DNA
of	O
CIITA	B-protein
.	O
	
These	O
results	O
therefore	O
demonstrate	O
that	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
silencing	O
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
due	O
to	O
an	O
active	O
suppression	O
of	O
one	O
of	O
the	O
promoters	B-DNA
of	O
the	O
CIITA	B-DNA
gene	I-DNA
,	O
mediated	O
by	O
the	O
epithelial	B-cell_type
cell	I-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O
	
###MEDLINE:98375837	
	
Class	O
II	O
transactivator-independent	O
endothelial	O
cell	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
activation	O
induced	O
by	O
lymphocyte	O
adhesion	O
.	O
	
NK	O
cells	O
induce	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	O
on	O
the	O
surface	O
of	O
allogeneic	O
endothelial	O
cells	O
in	O
an	O
adhesion-dependent	O
,	O
IFN-gamma	B-protein
-independent	O
manner	O
.	O
	
Here	O
,	O
we	O
demonstrate	O
that	O
NK	B-cell_line
cells	I-cell_line
induce	O
HLA-DR	B-protein
on	O
the	O
surface	O
of	O
a	O
mutant	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
is	O
defective	O
in	O
IFN-gamma	B-protein
-induced	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O
	
RNA	O
analysis	O
in	O
these	O
cells	O
and	O
in	O
a	O
cell	O
line	O
that	O
is	O
defective	O
in	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
demonstrates	O
that	O
NK	O
cell-induced	O
HLA-DR	B-RNA
alpha	I-RNA
mRNA	I-RNA
expression	O
is	O
also	O
CIITA	B-protein
-independent	O
.	O
	
The	O
Janus	B-cell_line
kinase-1-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
U4A	I-cell_line
expresses	O
HLA-DR	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
NK	O
cell	O
activation	O
,	O
and	O
HLA-DR	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
transfected	O
into	O
these	O
cells	O
are	O
induced	O
by	O
NK	B-cell_line
cells	I-cell_line
but	O
not	O
IFN-gamma	B-protein
.	O
	
These	O
data	O
indicate	O
that	O
the	O
IFN-gamma	B-protein
-independent	O
component	O
of	O
the	O
target	O
cell	O
HLA-DR	B-protein
expression	O
induced	O
by	O
lymphocyte	O
adhesion	O
uses	O
a	O
signaling	O
pathway	O
that	O
is	O
distinct	O
from	O
the	O
IFN-gamma	B-protein
-dependent	O
mechanism	O
and	O
also	O
suggest	O
that	O
CIITA	B-protein
is	O
not	O
required	O
.	O
	
###MEDLINE:99023364	
	
Effects	O
of	O
overexpression	O
of	O
IL-1	B-protein
receptor-associated	I-protein
kinase	I-protein
on	O
NFkappaB	B-protein
activation	O
,	O
IL-2	B-protein
production	O
and	O
stress-activated	O
protein	O
kinases	O
in	O
the	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL4	I-cell_line
.	O
	
The	O
association	O
and	O
activation	O
of	O
the	O
IL-1	B-protein
receptor-associated	I-protein
protein	I-protein
kinase	I-protein
(	O
IRAK	B-protein
)	O
to	O
the	O
IL-1	B-protein
receptor	I-protein
complex	I-protein
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL-1	B-protein
signal	O
transduction	O
.	O
	
We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL4	I-cell_line
6.1	I-cell_line
overexpressing	O
human	B-protein
(	I-protein
h	I-protein
)	I-protein
IRAK	I-protein
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL-1	B-protein
signaling	O
.	O
	
Overexpression	O
of	O
hIRAK	B-protein
enhanced	O
IL-1	B-protein
-stimulated	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFkappaB	I-protein
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N-IRAK	B-protein
)	O
specifically	O
inhibited	O
IL-1	B-protein
-dependent	O
NFkappaB	B-protein
activity	O
.	O
	
In	O
clones	O
stably	O
overexpressing	O
hIRAK	B-protein
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	B-protein
correlated	O
with	O
a	O
low	O
basal	O
IL-2	B-protein
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL-1	B-protein
-dependent	O
manner	O
.	O
	
Compared	O
to	O
the	O
parental	B-cell_line
cell	I-cell_line
line	I-cell_line
the	O
dose-response	O
curve	O
of	O
IL-1	B-protein
-induced	O
IL-2	B-protein
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O
	
These	O
results	O
demonstrate	O
that	O
IRAK	B-protein
directly	O
triggers	O
NFkappaB	B-protein
-mediated	O
gene	O
expression	O
in	O
EL4	B-cell_line
cells	I-cell_line
.	O
	
Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL-1	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
(	I-protein
SAP	I-protein
)	I-protein
kinases	I-protein
:	O
permanent	O
overexpression	O
of	O
IRAK	B-protein
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL-1	B-protein
-induced	O
activation	O
of	O
SAP	B-protein
kinases	I-protein
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O
	
###MEDLINE:99008545	
	
The	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
in	O
activated	O
DRA	B-DNA
transcription	O
.	O
	
Expression	O
of	O
human	B-DNA
MHC	I-DNA
HLA-DRA	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
can	O
be	O
up-regulated	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
Ig	O
cross-linking	O
as	O
well	O
as	O
by	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O
	
Induced	O
DRA	B-DNA
expression	O
involves	O
activation	O
of	O
restricted	B-protein
protein	I-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoforms	I-protein
,	O
resulting	O
in	O
activated	O
activator	O
protein-1	B-protein
-dependent	O
transcription	O
.	O
	
In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B-protein
were	O
analyzed	O
in	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O
	
Transient	O
transfection	O
analysis	O
with	O
target	B-DNA
plasmids	I-DNA
containing	O
either	O
DRA	B-DNA
promoter	I-DNA
(	O
wild-type	O
or	O
mutated	O
)	O
or	O
TPA	B-DNA
response	I-DNA
elements	I-DNA
demonstrated	O
that	O
pretreatment	O
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF	O
109203X	O
repressed	O
TPA-mediated	O
activation	O
.	O
	
Western	O
analysis	O
performed	O
on	O
cellular	O
fractions	O
of	O
resting	B-cell_type
cells	I-cell_type
and	O
of	O
TPA-activated	B-cell_type
cells	I-cell_type
revealed	O
abundant	O
expression	O
of	O
classical	B-protein
PKC-alpha	I-protein
(	O
cPKC-alpha	B-protein
)	O
,	O
cPKC-betaII	B-protein
,	O
and	O
atypical	B-protein
PKC-zeta	I-protein
isoforms	I-protein
and	O
identified	O
a	O
sustained	O
translocation	O
of	O
cPKC-alpha	B-protein
and	O
cPKC-betaII	B-protein
from	O
the	O
cytosolic	O
compartment	O
to	O
membranes	O
.	O
	
As	O
expected	O
,	O
the	O
distribution	O
of	O
atypical	B-protein
PKC-zeta	I-protein
was	O
unaffected	O
by	O
TPA	O
treatment	O
and	O
displayed	O
an	O
even	O
distribution	O
between	O
cytosol	O
and	O
membranes	O
.	O
	
This	O
finding	O
was	O
confirmed	O
by	O
immunofluorescence	O
microscopy	O
.	O
	
The	O
TPA-mediated	O
translocation	O
of	O
cPKC-alpha	B-protein
and	O
cPKC-betaII	B-protein
was	O
not	O
influenced	O
by	O
pretreatment	O
with	O
GF	O
109203X	O
.	O
	
Finally	O
,	O
functional	O
activation	O
and	O
translocation	O
of	O
PKC	B-protein
were	O
investigated	O
with	O
a	O
selective	O
in	O
vitro	O
kinase	O
assay	O
.	O
	
Together	O
,	O
these	O
results	O
show	O
that	O
activated	O
HLA-DRA	B-protein
expression	O
in	O
response	O
to	O
TPA	O
treatment	O
is	O
strictly	O
dependent	O
on	O
PKC	B-protein
activation	O
acting	O
on	O
the	O
X2	B-DNA
box	I-DNA
of	O
the	O
DRA	B-DNA
promoter	I-DNA
and	O
that	O
selective	O
inhibition	O
of	O
PKC	B-protein
enzymatic	O
activity	O
does	O
not	O
influence	O
subcellular	O
localization	O
of	O
expressed	O
PKC	B-protein
isoenzymes	I-protein
.	O
	
Thus	O
,	O
the	O
translocation	O
event	O
per	O
se	O
occurs	O
independently	O
of	O
PKC	B-protein
activation	O
in	O
these	O
cells	O
.	O
	
###MEDLINE:99007236	
	
Inhibition	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
in	O
human	B-cell_type
cells	I-cell_type
by	O
synthetic	O
DNA-binding	O
ligands	O
[	O
see	O
comments	O
]	O
	
Sequence-specific	O
DNA-binding	O
small	O
molecules	O
that	O
can	O
permeate	O
human	B-cell_type
cells	I-cell_type
potentially	O
could	O
regulate	O
transcription	O
of	O
specific	O
genes	O
.	O
	
Multiple	O
cellular	B-protein
DNA-binding	I-protein
transcription	I-protein
factors	I-protein
are	O
required	O
by	O
HIV	O
type	O
1	O
for	O
RNA	O
synthesis	O
.	O
	
Two	O
pyrrole-imidazole	O
polyamides	O
were	O
designed	O
to	O
bind	O
DNA	O
sequences	O
immediately	O
adjacent	O
to	O
binding	O
sites	O
for	O
the	O
transcription	B-protein
factors	I-protein
Ets-1	B-protein
,	O
lymphoid-enhancer	B-protein
binding	I-protein
factor	I-protein
1	I-protein
,	O
and	O
TATA-box	B-protein
binding	I-protein
protein	I-protein
.	O
	
These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA-binding	O
of	O
each	O
transcription	B-protein
factor	I-protein
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell-free	O
assays	O
.	O
	
When	O
used	O
in	O
combination	O
,	O
the	O
polyamides	O
inhibit	O
virus	O
replication	O
by	O
>	O
99	O
%	O
in	O
isolated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
,	O
with	O
no	O
detectable	O
cell	O
toxicity	O
.	O
	
The	O
ability	O
of	O
small	O
molecules	O
to	O
target	O
predetermined	O
DNA	B-DNA
sequences	I-DNA
located	O
within	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
suggests	O
a	O
general	O
approach	O
for	O
regulation	O
of	O
gene	O
expression	O
,	O
as	O
well	O
as	O
a	O
mechanism	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
.	O
	
###MEDLINE:98440284	
	
musculin	B-DNA
:	O
a	O
murine	B-DNA
basic	I-DNA
helix-loop-helix	I-DNA
transcription	I-DNA
factor	I-DNA
gene	I-DNA
expressed	O
in	O
embryonic	O
skeletal	O
muscle	O
.	O
	
We	O
describe	O
the	O
embryonic	O
expression	O
of	O
musculin	B-protein
,	O
a	O
new	O
murine	O
member	O
of	O
the	O
bHLH	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
Musculin	O
protein	O
is	O
closely	O
related	O
to	O
human	B-protein
ABF-1	I-protein
,	O
which	O
is	O
expressed	O
in	O
activated	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
to	O
epicardin/capsulin/Pod-1	B-protein
,	O
which	O
is	O
expressed	O
in	O
branchial	B-cell_type
myoblasts	I-cell_type
,	O
visceral	O
and	O
urogenital	O
mesoderm	O
and	O
epicardium	O
.	O
	
In	O
situ	O
hybridisation	O
revealed	O
musculin	B-protein
expression	O
in	O
embryos	O
was	O
largely	O
restricted	O
to	O
the	O
embryonic	B-cell_type
skeletal	I-cell_type
muscle	I-cell_type
lineage	I-cell_type
.	O
	
While	O
all	O
skeletal	O
muscles	O
expressed	O
the	O
gene	O
,	O
only	O
a	O
subset	O
of	O
myocytes	O
within	O
each	O
muscle	O
were	O
positive	O
,	O
indicating	O
molecular	O
heterogeneity	O
within	O
fetal	O
muscle	O
.	O
	
Copyright	O
1998	O
Elsevier	O
Science	O
Ireland	O
Ltd	O
.	O
	
All	O
Rights	O
Reserved	O
.	O
	
###MEDLINE:98437269	
	
Induction	O
of	O
T	O
cell	O
anergy	O
by	O
high	O
concentrations	O
of	O
immunodominant	O
native	O
peptide	O
is	O
accompanied	O
by	O
IL-10	B-protein
production	O
and	O
a	O
block	O
in	O
JNK	B-protein
activity	O
.	O
	
The	O
ability	O
to	O
induce	O
anergy	O
in	O
antigen-specific	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
potential	O
therapeutic	O
value	O
for	O
altering	O
pathologic	O
immune	O
responses	O
.	O
	
This	O
study	O
was	O
undertaken	O
to	O
further	O
analyze	O
changes	O
in	O
cytokine	B-protein
production	O
and	O
intracellular	O
signaling	O
during	O
anergy	O
induction	O
using	O
high	O
concentrations	O
of	O
native	O
peptide	O
ligand	O
of	O
tetanus	B-cell_line
toxoid	I-cell_line
(	I-cell_line
TT	I-cell_line
)	I-cell_line
-	I-cell_line
and	I-cell_line
myelin	I-cell_line
basic	I-cell_line
protein	I-cell_line
(	I-cell_line
MBP	I-cell_line
)	I-cell_line
-specific	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
TT-selected	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
could	O
be	O
rendered	O
unresponsive	O
to	O
its	O
dominant	O
epitope	O
in	O
a	O
dose-dependent	O
manner	O
(	O
IC50	O
=	O
0.03	O
microg/ml	O
)	O
.	O
	
The	O
TT-selected	B-cell_line
line	I-cell_line
,	O
as	O
well	O
as	O
three	O
T	O
cell	O
clones	O
established	O
from	O
this	O
line	O
,	O
continued	O
to	O
produce	O
IFN-gamma	B-protein
and	O
significantly	O
increased	O
IL-4	B-protein
and	O
IL-10	B-protein
production	O
when	O
anergy	O
was	O
induced	O
with	O
high	O
concentrations	O
of	O
the	O
immunodominant	O
epitope	O
.	O
	
JNK	B-protein
enzymatic	O
activity	O
was	O
blocked	O
in	O
anergized	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
The	O
MBP	B-protein
-selected	O
line	O
could	O
likewise	O
be	O
rendered	O
unresponsive	O
by	O
incubation	O
with	O
supraoptimal	O
concentrations	O
of	O
immunodominant	O
peptide	O
and	O
anergy	O
induction	O
was	O
accompanied	O
by	O
IL-10	B-protein
release	O
.	O
	
Both	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
be	O
anergized	O
by	O
the	O
autopresentation	O
of	O
native	O
peptide	O
since	O
anergy	O
was	O
induced	O
in	O
cultures	O
lacking	O
fresh	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O
	
This	O
study	O
shows	O
that	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
cascade	O
is	O
blocked	O
when	O
anergy	O
is	O
induced	O
to	O
high	O
concentrations	O
of	O
soluble	O
peptide	O
.	O
	
Copyright	O
1998	O
Academic	O
Press	O
.	O
	
###MEDLINE:98416180	
	
Upregulation	O
of	O
interleukin	B-protein
6	I-protein
and	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
receptors	I-protein
by	O
transcription	B-protein
factor	I-protein
CCAAT	B-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
alpha	I-protein
(	O
C/EBP	B-protein
alpha	I-protein
)	O
is	O
critical	O
for	O
granulopoiesis	O
.	O
	
Cytokines	O
stimulate	O
granulopoiesis	O
through	O
signaling	O
via	O
receptors	O
whose	O
expression	O
is	O
controlled	O
by	O
lineage-specific	O
transcription	B-protein
factors	I-protein
.	O
	
Previously	O
,	O
we	O
demonstrated	O
that	O
granulocyte	B-RNA
colony-stimulating	I-RNA
factor	I-RNA
(	I-RNA
G-CSF	I-RNA
)	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
undetectable	O
and	O
granulocyte	O
maturation	O
blocked	O
in	O
CCAAT	B-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
alpha	I-protein
(	O
C/EBPalpha	B-protein
)	O
-deficient	O
mice	O
.	O
	
This	O
phenotype	O
is	O
distinct	O
from	O
that	O
of	O
G-CSF	O
receptor-/-	O
mice	O
,	O
suggesting	O
that	O
other	O
genes	O
are	O
likely	O
to	O
be	O
adversely	O
affected	O
by	O
loss	O
of	O
C/EBPalpha	B-protein
.	O
	
Here	O
we	O
demonstrate	O
loss	O
of	O
interleukin	B-protein
6	I-protein
(	I-protein
IL-6	I-protein
)	I-protein
receptor	I-protein
and	O
IL-6-responsive	B-protein
colony-forming	I-protein
units	I-protein
(	O
CFU-IL6	B-protein
)	O
in	O
C/EBPalpha	B-protein
-/-	O
mice	O
.	O
	
The	O
observed	O
failure	O
of	O
granulopoiesis	O
could	O
be	O
rescued	O
by	O
the	O
addition	O
of	O
soluble	O
IL-6	B-protein
receptor	I-protein
and	O
IL-6	B-protein
or	O
by	O
retroviral	O
transduction	O
of	O
G-CSF	B-protein
receptors	I-protein
,	O
demonstrating	O
that	O
loss	O
of	O
both	O
of	O
these	O
receptors	O
contributes	O
to	O
the	O
absolute	O
block	O
in	O
granulocyte	O
maturation	O
observed	O
in	O
C/EBPalpha-deficient	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O
	
The	O
results	O
of	O
these	O
and	O
other	O
studies	O
suggest	O
that	O
additional	O
C/EBPalpha	B-DNA
target	I-DNA
genes	I-DNA
,	O
possibly	O
other	O
cytokine	O
receptors	O
,	O
are	O
also	O
important	O
for	O
the	O
block	O
in	O
granulocyte	O
differentiation	O
observed	O
in	O
vivo	O
in	O
C/EBPalpha	B-protein
-deficient	O
mice	O
.	O
	
###MEDLINE:98406066	
	
Phosphatidylinositides	O
bind	O
to	O
plasma	B-protein
membrane	I-protein
CD14	I-protein
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O
	
Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B-protein
(	O
membrane	B-protein
CD14	I-protein
)	O
,	O
a	O
cell-surface	O
receptor	O
found	O
principally	O
on	O
monocytes	B-cell_type
and	O
neutrophils	B-cell_type
,	O
host-derived	O
mCD14	B-protein
ligands	O
are	O
poorly	O
defined	O
.	O
	
We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4-phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	B-protein
.	O
	
Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	B-protein
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O
	
LPS-binding	B-protein
protein	I-protein
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	O
both	O
PS	O
-and	O
PtdIns-	O
mCD14	B-protein
binding	O
.	O
	
PtdIns	O
binding	O
to	O
mCD14	B-protein
can	O
be	O
blocked	O
by	O
anti-CD14	B-protein
monoclonal	I-protein
antibodies	I-protein
that	O
inhibit	O
LPS	O
-mCD14	B-protein
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS	O
-mCD14	B-protein
binding	O
and	O
LPS-induced	O
responses	O
in	O
monocytes	B-cell_type
.	O
	
Serum-equilibrated	B-cell_type
PtdIns	I-cell_type
also	I-cell_type
binds	I-cell_type
to	I-cell_type
mCD14-expressing	I-cell_type
cells	I-cell_type
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	B-protein
ligands	O
in	O
vivo	O
.	O
	
###MEDLINE:98391028	
	
Protein	B-protein
kinase	I-protein
C	I-protein
regulates	O
Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
expression	O
.	O
	
Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
is	O
a	O
transmembrane	B-protein
protein	I-protein
of	O
the	O
TNF/neuron	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
.	O
	
Ligation	O
of	O
Fas	B-protein
by	O
specific	B-protein
Abs	I-protein
or	O
Fas	B-protein
ligand	I-protein
(	O
FasL/CD95	B-protein
ligand	I-protein
)	O
induces	O
rapid	O
apoptotic	O
cell	O
death	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O
	
Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	B-protein
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	B-protein
expression	O
is	O
regulated	O
.	O
	
Using	O
our	O
previously	O
established	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
model	I-cell_line
A1.1	B-cell_line
,	O
we	O
show	O
that	O
specific	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
inhibitors	O
could	O
block	O
activation-induced	O
Fas	B-protein
expression	O
and	O
apoptosis	O
.	O
	
The	O
activation	O
of	O
PKC	B-protein
with	O
PMA	O
or	O
1-oleoyl-2-acetyl-sn-glycerol	O
could	O
mimic	O
the	O
TCR	B-protein
signal	O
by	O
inducing	O
the	O
expression	O
of	O
Fas	B-protein
but	O
not	O
FasL	O
.	O
	
PKC	B-protein
-dependent	O
Fas	B-protein
expression	O
was	O
also	O
observed	O
in	O
several	O
murine	B-cell_line
and	I-cell_line
human	I-cell_line
tumor	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Since	O
the	O
inhibition	O
of	O
Ca2+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR-induced	B-protein
FasL	I-protein
but	O
not	O
Fas	B-protein
,	O
the	O
expression	O
of	O
Fas	B-protein
appears	O
to	O
be	O
independent	O
of	O
Ca2+	O
mobilization	O
.	O
	
Significantly	O
,	O
expression	O
of	O
the	O
newly	O
identified	O
Fas-regulatory	B-DNA
gene	I-DNA
,	O
TDAG51	B-DNA
,	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
activity	O
of	O
PKC	B-protein
.	O
	
PKC	B-protein
activation	O
only	O
induced	O
Fas	B-protein
expression	O
in	O
cells	O
expressing	O
wild-type	O
TDAG51	B-DNA
.	O
	
Thus	O
,	O
Fas	B-protein
expression	O
is	O
likely	O
mediated	O
by	O
PKC	B-protein
through	O
TDAG51	B-DNA
.	O
	
###MEDLINE:98384235	
	
Retinoic	O
acid	O
inhibits	O
CD40	B-protein
+	O
interleukin-4	B-protein
-mediated	O
IgE	B-protein
production	O
in	O
vitro	O
.	O
	
To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti-CD40	B-protein
+	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
-mediated	O
B-cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti-CD40	B-protein
(	O
1	O
microgram/mL	O
)	O
+	O
IL-4	B-protein
(	O
5	O
ng/mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
healthy	O
donors	O
.	O
	
Anti-CD40	B-protein
+	O
IL-4	B-protein
-mediated	O
proliferation	O
of	O
PBMC	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+/-	O
5	O
%	O
in	O
PBMC	B-cell_type
and	O
55	O
%	O
+/-	O
4.4	O
%	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
all-trans	O
RA	O
,	O
and	O
58	O
%	O
+/-	O
6.7	O
%	O
and	O
51	O
%	O
+/-	O
4.7	O
%	O
,	O
respectively	O
by	O
13-cis	O
RA	O
.	O
	
IgE	B-protein
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-14	O
)	O
mol/L	O
for	O
B	B-cell_type
cells	I-cell_type
and	O
>	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
PBMC	B-cell_type
.	O
	
Maximal	O
inhibition	O
of	O
IgE	B-protein
production	O
for	O
B	B-cell_type
cells	I-cell_type
was	O
at	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
all-trans	O
RA	O
(	O
94	O
%	O
+/-	O
1.8	O
%	O
)	O
and	O
96	O
%	O
+/-	O
3.2	O
%	O
for	O
13-cis	O
RA	O
.	O
	
Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	B-protein
synthesis	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
affected	O
neither	O
B-cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	B-protein
,	O
IgG	B-protein
,	O
and	O
IgM	B-protein
.	O
	
Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	B-protein
production	O
shows	O
that	O
epsilon	O
germline	B-DNA
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O
	
To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	B-protein
receptors	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
and	I-protein
gamma	I-protein
,	O
the	O
expression	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
was	O
examined	O
by	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O
	
The	O
data	O
show	O
that	O
unstimulated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
B	I-cell_type
cells	I-cell_type
express	O
mRNA	O
of	O
the	O
RA	B-protein
receptor	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
and	I-protein
gamma	I-protein
.	O
	
Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose-dependent	O
inhibition	O
of	O
IgE	B-protein
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	B-protein
receptor	I-protein
with	O
high	O
specificity	O
.	O
	
Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	B-protein
production	O
of	O
anti-CD40	B-cell_line
+	I-cell_line
IL-4-stimulated	I-cell_line
B	I-cell_line
cells	I-cell_line
in	O
vitro	O
.	O
	
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O
	
###MEDLINE:98378528	
	
Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-protein
induction	O
of	O
NF-kappaB	B-protein
involves	O
activation	O
of	O
the	O
IkappaB	B-protein
kinase	I-protein
alpha	I-protein
(	O
IKKalpha	B-protein
)	O
and	O
IKKbeta	B-protein
cellular	B-protein
kinases	I-protein
.	O
	
Tax	B-protein
corresponds	O
to	O
a	O
40-kDa	B-protein
transforming	I-protein
protein	I-protein
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
by	O
an	O
unknown	O
mechanism	O
.	O
	
Tax	B-protein
expression	O
promotes	O
N-terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O
	
Our	O
studies	O
now	O
demonstrate	O
that	O
HTLV-1	O
Tax	B-protein
activates	O
the	O
recently	O
identified	O
cellular	B-protein
kinases	I-protein
IkappaB	B-protein
kinase	I-protein
alpha	I-protein
(	O
IKKalpha	B-protein
)	O
and	O
IKKbeta	B-protein
,	O
which	O
normally	O
phosphorylate	O
IkappaB	B-protein
alpha	I-protein
on	O
both	O
of	O
its	O
N-terminal	O
regulatory	O
serines	O
in	O
response	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
stimulation	O
.	O
	
In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-protein
termed	O
M22	B-protein
,	O
which	O
does	O
not	O
induce	O
NF-kappaB	B-protein
,	O
fails	O
to	O
activate	O
either	O
IKKalpha	B-protein
or	O
IKKbeta	B-protein
.	O
	
Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV-1-infected	B-cell_line
and	I-cell_line
Tax-expressing	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
Transfection	O
of	O
kinase-deficient	O
mutants	O
of	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
into	O
either	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
or	I-cell_line
293	I-cell_line
cells	I-cell_line
also	O
inhibits	O
NF-kappaB	B-protein
-dependent	O
reporter	B-DNA
gene	I-DNA
expression	O
induced	O
by	O
Tax	B-protein
.	O
	
Similarly	O
,	O
a	O
kinase-deficient	B-protein
mutant	I-protein
of	O
NIK	B-protein
(	O
NF-kappaB-inducing	B-protein
kinase	I-protein
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF-alpha	O
and	O
IL-1	O
signaling	O
pathways	O
leading	O
to	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
activation	O
,	O
blocks	O
Tax	B-protein
induction	O
of	O
NF-kappaB	B-protein
.	O
	
However	O
,	O
plasma	B-DNA
membrane-proximal	I-DNA
elements	I-DNA
in	O
these	O
proinflammatory	B-protein
cytokine	I-protein
pathways	O
are	O
apparently	O
not	O
involved	O
since	O
dominant	O
negative	O
mutants	O
of	O
the	O
TRAF2	B-protein
and	I-protein
TRAF6	I-protein
adaptors	I-protein
,	O
which	O
effectively	O
block	O
signaling	O
through	O
the	O
cytoplasmic	B-protein
tails	I-protein
of	O
the	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
receptors	O
,	O
respectively	O
,	O
do	O
not	O
inhibit	O
Tax	B-protein
induction	O
of	O
NF-kappaB	B-protein
.	O
	
Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV-1	O
Tax	B-protein
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	B-protein
cytokine	I-protein
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF-kappaB	B-protein
.	O
	
The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
by	O
Tax	B-protein
may	O
play	O
a	O
central	O
role	O
in	O
HTLV-1-mediated	O
transformation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T-cell	O
leukemia	O
	
###MEDLINE:99023967	
	
Role	O
of	O
IKK1	B-protein
and	O
IKK2	B-protein
in	O
lipopolysaccharide	O
signaling	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Mononuclear	B-cell_type
phagocytes	I-cell_type
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
	
Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	B-cell_type
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF-kappaB/Rel	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O
	
Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
interleukin	B-protein
1	I-protein
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	B-protein
and	O
IKK2	B-protein
.	O
	
Phosphorylation	O
of	O
the	O
IkappaB	B-protein
cytoplasmic	I-protein
inhibitors	I-protein
,	O
IkappaBalpha	B-protein
,	O
IkappaBbeta	B-protein
,	O
and	O
IkappaBepsilon	B-protein
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
into	O
the	O
nucleus	O
.	O
	
At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O
	
Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O
	
The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	B-cell_type
cells	I-cell_type
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	B-protein
and	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
.	O
	
In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	B-protein
,	O
a	O
dominant	B-protein
negative	I-protein
mutant	I-protein
IKK1	I-protein
(	O
K44M	B-protein
)	O
,	O
or	O
wild	B-protein
type	I-protein
IKK2	I-protein
did	O
not	O
affect	O
LPS-induced	O
kappaB	B-protein
-dependent	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B-protein
inhibited	O
LPS	O
induction	O
of	O
kappaB	B-protein
-dependent	O
transcription	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB-dependent	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
requires	O
activation	O
of	O
IKK2	B-protein
.	O
	
###MEDLINE:99008520	
	
IL-7	B-protein
reconstitutes	O
multiple	O
aspects	O
of	O
v-Abl	B-protein
-mediated	O
signaling	O
.	O
	
The	O
mechanism	O
by	O
which	O
early	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
are	O
selectively	O
transformed	O
by	O
v-Abl	B-protein
is	O
currently	O
unknown	O
.	O
	
Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
1	I-protein
,	O
JAK3	B-protein
,	O
STAT5	B-protein
,	O
and	O
STAT6	B-protein
,	O
in	O
pre-B	B-cell_type
cells	I-cell_type
transformed	O
by	O
v-Abl	B-protein
.	O
	
To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v-Abl	B-protein
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
on	O
pre-B	B-cell_type
cells	I-cell_type
transformed	O
with	O
a	O
temperature-sensitive	B-protein
v-Abl	I-protein
mutant	I-protein
were	O
examined	O
.	O
	
Whereas	O
IL-4	B-protein
had	O
little	O
or	O
no	O
effect	O
,	O
IL-7	B-protein
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v-Abl	B-protein
kinase	O
inactivation	O
.	O
	
IL-7	B-protein
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c-Myc	B-protein
,	O
Bcl-2	B-protein
,	O
and	O
Bcl-xL	B-protein
that	O
occur	O
upon	O
loss	O
of	O
v-Abl	B-protein
kinase	O
activity	O
.	O
	
IL-7	B-protein
did	O
not	O
maintain	O
v-Abl	B-protein
-mediated	O
differentiation	O
arrest	O
of	O
the	O
pre-B	B-cell_type
cells	I-cell_type
,	O
as	O
activation	O
of	O
NF-kappaB	B-protein
and	O
RAG	B-DNA
gene	I-DNA
transcription	O
was	O
unaffected	O
by	O
IL-7	B-protein
.	O
	
These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL-7	B-protein
signaling	O
pathways	O
in	O
transformation	O
by	O
v-Abl	B-protein
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
signaling	O
can	O
not	O
substitute	O
for	O
an	O
active	O
v-Abl	B-protein
kinase	O
in	O
transformed	B-cell_type
pre-B	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:99005376	
	
Differential	O
regulation	O
of	O
coproporphyrinogen	B-DNA
oxidase	I-DNA
gene	I-DNA
between	O
erythroid	B-cell_type
and	I-cell_type
nonerythroid	I-cell_type
cells	I-cell_type
.	O
	
Coproporphyrinogen	B-protein
oxidase	I-protein
(	O
CPO	B-protein
)	O
catalyzes	O
the	O
sixth	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O
	
To	O
assess	O
the	O
tissue-specific	O
regulation	O
of	O
the	O
CPO	B-DNA
gene	I-DNA
promoter	I-DNA
,	O
mouse	B-DNA
genomic	I-DNA
DNA	I-DNA
clones	I-DNA
for	O
CPO	B-protein
were	O
isolated	O
.	O
	
Structural	O
analysis	O
demonstrated	O
that	O
the	O
mouse	B-DNA
CPO	I-DNA
gene	I-DNA
spans	O
approximately	O
11	O
kb	O
and	O
consists	O
of	O
seven	B-DNA
exons	I-DNA
,	O
just	O
like	O
its	O
human	O
counterpart	O
.	O
	
Functional	O
analysis	O
of	O
the	O
promoter	O
by	O
transient	O
transfection	O
assays	O
indicated	O
that	O
synergistic	O
action	O
between	O
an	O
SP-1-like	B-DNA
element	I-DNA
at	O
-21/-12	O
,	O
a	O
GATA	B-DNA
site	I-DNA
at	O
-59/-54	O
,	O
and	O
a	O
novel	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
CPRE	B-DNA
(	O
-	O
GGACTACAG	B-DNA
-	O
)	O
at	O
-49/-41	O
,	O
is	O
essential	O
for	O
the	O
promoter	O
activity	O
in	O
murine	B-cell_type
erythroleukemia	I-cell_type
(	I-cell_type
MEL	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O
	
In	O
nonerythroid	B-cell_line
NIH3T3	I-cell_line
cells	I-cell_line
,	O
however	O
,	O
the	O
GATA	B-DNA
site	I-DNA
is	O
not	O
required	O
.	O
	
Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
specific	O
DNA-protein	B-protein
complexes	I-protein
can	O
be	O
formed	O
with	O
each	O
element	O
,	O
and	O
that	O
there	O
are	O
cell-specific	O
differences	O
in	O
factors	O
,	O
which	O
bind	O
to	O
the	O
SP-1-like	B-DNA
element	I-DNA
between	O
MEL	B-cell_line
and	I-cell_line
NIH3T3	I-cell_line
cells	I-cell_line
.	O
	
These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	B-protein
gene	O
between	O
erythroid	B-cell_type
and	I-cell_type
nonerythroid	I-cell_type
cells	I-cell_type
.	O
	
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
	
###MEDLINE:98438043	
	
Tumor	B-protein
suppressor	I-protein
proteins	I-protein
as	O
regulators	O
of	O
cell	O
differentiation	O
.	O
	
The	O
products	O
of	O
the	O
tumor	B-DNA
suppressor	I-DNA
genes	I-DNA
are	O
considered	O
to	O
function	O
as	O
specific	O
inhibitors	O
of	O
tumor	O
cell	O
growth	O
.	O
	
In	O
this	O
communication	O
,	O
we	O
present	O
evidence	O
to	O
show	O
that	O
these	O
proteins	O
inhibit	O
tumor	O
cell	O
proliferation	O
by	O
participating	O
in	O
the	O
activation	O
of	O
tumor	O
cell	O
differentiation	O
.	O
	
The	O
ML-1	B-cell_line
human	I-cell_line
myeloblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
used	O
in	O
this	O
study	O
proliferate	O
when	O
treated	O
with	O
insulin-like	B-protein
growth	I-protein
factor	I-protein
I	I-protein
and	O
transferrin	B-protein
but	O
differentiate	O
to	O
monocytes	B-cell_type
when	O
exposed	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta1	I-protein
,	O
or	O
to	O
macrophage-like	B-cell_type
cells	I-cell_type
when	O
treated	O
with	O
both	O
these	O
cytokines	B-protein
.	O
	
Initiation	O
of	O
proliferation	O
but	O
not	O
of	O
differentiation	O
was	O
followed	O
by	O
a	O
20-	O
to	O
25-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
DNA	B-protein
polymerase-associated	I-protein
processivity	I-protein
factor	I-protein
PCNA	I-protein
and	O
of	O
the	O
proliferation-specific	B-protein
transcription	I-protein
factor	I-protein
E2F1	I-protein
.	O
	
In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
p53	I-protein
(	O
wild	O
type	O
)	O
,	O
pRb	B-protein
,	O
and	O
p130/Rb2	B-protein
and	O
of	O
the	O
p53-dependent	B-protein
cyclin	I-protein
kinase	I-protein
inhibitor	I-protein
p21/Cip1	B-protein
.	O
	
p53	B-protein
and	O
p21/Cip1	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
PCNA	B-protein
,	O
whereas	O
p130	B-protein
and	O
pRb	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
E2F1	B-protein
.	O
	
As	O
a	O
result	O
,	O
G1-S-associated	B-DNA
DNA	I-DNA
and	O
mRNA	O
synthesis	O
is	O
inhibited	O
,	O
growth	O
uncoupled	O
from	O
differentiation	O
,	O
and	O
maturation	O
enabled	O
to	O
proceed	O
.	O
	
Where	O
this	O
function	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
is	O
impaired	O
,	O
the	O
capacity	O
for	O
differentiation	O
is	O
lost	O
,	O
which	O
leads	O
to	O
the	O
sustained	O
proliferation	O
that	O
is	O
characteristic	O
of	O
the	O
cancer	B-cell_type
cell	I-cell_type
.	O
	
###MEDLINE:98427848	
	
Transcription	B-protein
factor	I-protein
activation	O
in	O
lymphokine	O
activated	O
killer	B-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
from	O
patients	O
receiving	O
IL-2	B-protein
immunotherapy	O
.	O
	
Administration	O
of	O
the	O
cytokine	B-protein
interleukin-2	I-protein
(	O
IL-2	B-protein
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O
	
Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP-1	O
,	O
Sp1	O
,	O
NF-kappaB	B-protein
,	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STAT	B-protein
)	O
in	O
cancer	B-cell_type
patients	I-cell_type
'	I-cell_type
lymphocytes	I-cell_type
before	O
and	O
after	O
IL-2	B-protein
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel-shift	O
assay	O
.	O
	
An	O
in	O
vitro	O
surrogate	O
of	O
IL-2	B-protein
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
healthy	O
individuals	O
in	O
IL-2	B-protein
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	B-protein
-activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O
	
One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O
	
Prior	O
to	O
in	O
vivo	O
IL-2	B-protein
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	B-protein
factors	I-protein
in	O
PBMC	B-cell_type
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	B-cell_type
from	O
healthy	O
individuals	O
.	O
	
Over	O
a	O
3-week	O
course	O
of	O
IL-2	B-protein
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	O
patterns	O
of	O
AP-1	B-protein
,	O
Sp1	B-protein
,	O
and	O
NF-kappaB	B-protein
proteins	O
changed	O
to	O
resemble	O
those	O
seen	O
in	O
PBMC	B-cell_type
activated	O
by	O
IL-2	B-protein
in	O
vitro	O
.	O
	
However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	B-protein
-treated	O
patients	O
did	O
not	O
have	O
low-level	O
constitutive	O
expression	O
of	O
STAT	B-protein
binding	I-protein
factors	I-protein
as	O
did	O
LAK	B-protein
cells	I-protein
.	O
	
When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL-2	B-protein
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	B-protein
induction	O
patterns	O
were	O
noted	O
.	O
	
These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	B-cell_type
cells	I-cell_type
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	B-protein
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	B-cell_type
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	B-protein
.	O
	
###MEDLINE:98416141	
	
Activated	B-cell_type
platelets	I-cell_type
induce	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
on	O
endothelial	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O
	
BACKGROUND	O
:	O
Platelet/endothelium	O
interaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
inflammation	O
and	O
atherosclerosis	O
.	O
	
The	O
role	O
of	O
platelets	O
for	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
(	O
ICAM-1	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
has	O
been	O
assessed	O
.	O
	
METHODS	O
AND	O
RESULTS	O
:	O
Monolayers	O
of	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
were	O
incubated	O
with	O
nonstimulated	O
or	O
ADP-activated	B-cell_type
platelets	I-cell_type
for	O
6	O
hours	O
,	O
and	O
secretion	O
of	O
MCP-1	B-protein
and	O
surface	O
expression	O
of	O
ICAM-1	B-protein
were	O
determined	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O
	
In	O
the	O
presence	O
of	O
ADP-activated	B-cell_type
platelets	I-cell_type
,	O
both	O
MCP-1	B-protein
secretion	O
and	O
ICAM-1	B-protein
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	B-cell_type
platelets	I-cell_type
(	O
P	O
<	O
0.02	O
)	O
.	O
	
Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	B-protein
-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	B-cell_type
platelets	I-cell_type
.	O
	
In	O
addition	O
,	O
ADP-activated	B-cell_type
platelets	I-cell_type
induced	O
MCP-1	O
and	O
ICAM-1	O
promoter-dependent	O
transcription	O
.	O
	
Liposomal	O
transfection	O
of	O
a	O
double-stranded	O
kappaB	O
phosphorothioate	O
oligonucleotide	O
,	O
but	O
not	O
of	O
the	O
mutated	O
form	O
,	O
inhibited	O
MCP-1	B-protein
secretion	O
and	O
surface	O
expression	O
of	O
ICAM-1	B-protein
on	O
activated	O
endothelium	O
(	O
P	O
<	O
0.05	O
)	O
.	O
	
CONCLUSIONS	O
:	O
The	O
present	O
study	O
indicates	O
that	O
activated	B-cell_type
platelets	I-cell_type
modulate	O
chemotactic	O
(	O
MCP-1	B-protein
)	O
and	O
adhesive	O
(	O
ICAM-1	B-protein
)	O
properties	O
of	O
endothelial	B-cell_type
cells	I-cell_type
via	O
an	O
NF-kappaB	B-protein
-dependent	O
mechanism	O
.	O
	
Platelet-induced	O
activation	O
of	O
the	O
NF-kappaB	B-protein
system	O
might	O
contribute	O
to	O
early	O
inflammatory	O
events	O
in	O
atherogenesis	O
.	O
	
###MEDLINE:98400423	
	
Retinoid	B-protein
X	I-protein
receptor	I-protein
and	O
c-cerbA/thyroid	B-protein
hormone	I-protein
receptor	I-protein
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O
	
Nuclear	B-protein
receptors	I-protein
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O
	
Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
,	O
and	O
of	O
the	O
c-erbA/thyroid	B-protein
hormone	I-protein
(	I-protein
T3	I-protein
)	I-protein
receptor	I-protein
(	O
c-erbA/TR	B-protein
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	B-cell_type
cells	I-cell_type
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	B-cell_type
cell	I-cell_type
factor-dependent	I-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
.	O
	
RXR	B-protein
,	O
RAR	B-protein
,	O
and	O
c-erbA/TR	B-protein
-specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid-specific	B-DNA
gene	I-DNA
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O
	
Furthermore	O
,	O
while	O
ligand-activated	O
c-erbA/TR	B-protein
accelerated	O
differentiation	O
,	O
unliganded	O
c-erbA/TR	B-protein
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O
	
Thus	O
,	O
c-erbA/TR	B-protein
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	B-cell_type
cell	I-cell_type
fate	I-cell_type
:	O
unliganded	O
c-erbA/TR	B-protein
supports	O
growth	O
while	O
ligand-activated	O
c-erbA/TR	B-protein
induces	O
differentiation	O
.	O
	
Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	B-protein
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	B-protein
RXRs	I-protein
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF-1	B-protein
and	O
AF-2	B-protein
,	O
or	O
AF-2	B-protein
only	O
,	O
or	O
the	O
entire	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
were	O
introduced	O
into	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	B-protein
-specific	O
effects	O
.	O
	
It	O
was	O
found	O
that	O
expression	O
of	O
wild-type	B-protein
RXR	I-protein
and	O
of	O
the	O
RXR	B-protein
mutants	I-protein
devoid	O
of	O
AF-1	B-protein
and/or	O
AF-2	B-protein
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	B-protein
interfering	I-protein
deltaDNA-binding	I-protein
domain	I-protein
RXR	B-protein
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	B-protein
for	O
erythroid	O
cell	O
development	O
.	O
	
###MEDLINE:98389481	
	
Peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	B-protein
signaling	I-protein
molecules	I-protein
.	O
	
We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O
	
In	O
6	O
of	O
14	O
patients	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
displayed	O
an	O
impaired	O
ability	O
to	O
translocate	O
NFeB	B-protein
p65	I-protein
(	O
Rel-A	B-protein
)	O
following	O
activation	O
by	O
anti-CD3	O
and	O
IL-2	B-protein
.	O
	
This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel-A	B-protein
protein	I-protein
.	O
	
We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	B-protein
molecules	I-protein
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-zeta	I-protein
,	O
ZAP-70	B-protein
and	O
p56lck	B-protein
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T-cell	B-protein
signaling	I-protein
molecules	I-protein
.	O
	
T	B-cell_type
lymphocytes	I-cell_type
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B-protein
phosphatase	I-protein
,	O
map	B-protein
kinase	I-protein
phosphatase-1	I-protein
(	O
MKP-1	B-protein
)	O
.	O
	
MKP-1	B-protein
inactivates	O
MAP	B-protein
kinase	I-protein
and	O
therefore	O
may	O
interfere	O
with	O
the	O
activation	O
of	O
c-jun	B-DNA
and	O
c-fos	B-DNA
.	O
	
Abnormalities	O
of	O
I	O
or	O
more	O
signaling	B-protein
molecules	I-protein
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	B-cell_type
cells	I-cell_type
that	O
exhibited	O
all	O
5	O
defects	O
.	O
	
Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	B-cell_type
cells	I-cell_type
in	O
patients	O
with	O
cancer	O
.	O
	
For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	B-protein
molecule	I-protein
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T-cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O
	
Finally	O
,	O
despite	O
impaired	O
Rel-A	B-protein
translocation	O
,	O
T	B-cell_type
cells	I-cell_type
were	O
capable	O
of	O
transcribing	O
IL-2	B-protein
.	O
	
Impairments	O
in	O
the	O
translocation	O
of	O
Rel-B	B-protein
and	O
c-Rel	B-protein
further	O
suggest	O
that	O
the	O
NFKB	B-protein
family	I-protein
members	I-protein
Rel-A	B-protein
,	O
Rel-B	B-protein
and	O
c-Rel	B-protein
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL-2	B-protein
in	O
the	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
breast	O
cancer	O
.	O
	
###MEDLINE:98379823	
	
Specific	O
glucocorticoid	O
binding	O
at	O
different	O
levels	O
of	O
human	O
motor	O
activity	O
.	O
	
We	O
studied	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
dissociation	O
constant	O
in	O
isolated	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
as	O
well	O
as	O
blood	O
concentrations	O
of	O
hormones	O
produced	O
by	O
the	O
hypothalamic-hypophyseal-adrenocortical	O
system	O
in	O
three	O
experimental	O
series	O
:	O
at	O
normal	O
(	O
17	O
subjects	O
)	O
,	O
decreased	O
(	O
10	O
subjects	O
,	O
a	O
360-d	O
head-down	O
bed	O
rest	O
)	O
and	O
increased	O
(	O
8	O
subjects	O
,	O
physical	O
exercise	O
on	O
bicycle	O
ergometer	O
)	O
levels	O
of	O
motor	O
activity	O
.	O
	
In	O
the	O
first	O
series	O
we	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
dissociation	O
constant	O
did	O
not	O
depend	O
on	O
the	O
season	O
,	O
on	O
the	O
age	O
of	O
subjects	O
nor	O
on	O
cortisol	O
concentrations	O
in	O
blood	O
.	O
	
In	O
the	O
second	O
series	O
we	O
observed	O
the	O
following	O
:	O
at	O
the	O
end	O
of	O
the	O
first	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
receptor	O
affinity	O
significantly	O
increased	O
;	O
at	O
the	O
beginning	O
of	O
the	O
third	O
month	O
of	O
bed	O
rest	O
specific	O
glucocorticoid	O
binding	O
significantly	O
decreased	O
and	O
circadian	O
rhythms	O
of	O
adrenocorticotropin	O
and	O
cortisol	O
in	O
blood	O
varied	O
markedly	O
;	O
at	O
the	O
end	O
of	O
the	O
sixth	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
returned	O
to	O
prebed	O
rest	O
levels	O
and	O
dissociation	O
constant	O
decreased	O
.	O
	
In	O
the	O
third	O
series	O
physical	O
exercises	O
that	O
induced	O
an	O
activation	O
of	O
the	O
hypothalamic-hypophyseal-adrenocortical	O
system	O
(	O
maximal	O
physical	O
exercises	O
and	O
prolonged	O
submaximal	O
exercises	O
at	O
70	O
%	O
of	O
maximal	O
oxygen	O
uptake	O
)	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
without	O
changes	O
of	O
dissociation	O
constant	O
.	O
	
These	O
results	O
indicate	O
that	O
both	O
a	O
decrease	O
and	O
an	O
increase	O
of	O
human	O
motor	O
activity	O
resulted	O
in	O
significant	O
changes	O
of	O
specific	O
glucocorticoid	O
binding	O
which	O
were	O
not	O
influenced	O
by	O
changes	O
of	O
circulating	O
hormone	O
concentrations	O
in	O
blood	O
but	O
by	O
some	O
other	O
factors	O
affected	O
by	O
physical	O
activity	O
.	O
	
###MEDLINE:98378510	
	
The	O
small	B-protein
GTP-binding	I-protein
protein	I-protein
Rho	I-protein
potentiates	O
AP-1	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
Rho	B-protein
family	O
of	O
small	B-protein
GTP-binding	I-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O
	
We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	B-protein
enhances	O
AP-1	B-protein
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	B-protein
(	O
V14Rho	B-protein
)	O
has	O
little	O
or	O
no	O
effect	O
on	O
NFAT	B-protein
,	O
Oct-1	B-protein
,	O
and	O
NF-kappaB	B-DNA
enhancer	I-DNA
element	I-DNA
activities	O
under	O
similar	O
conditions	O
.	O
	
Overexpression	O
of	O
a	O
V14Rho	B-DNA
construct	I-DNA
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	B-DNA
deleted	I-DNA
)	O
abolishes	O
PMA-induced	O
AP-1	B-protein
transcriptional	O
activation	O
.	O
	
The	O
effect	O
of	O
Rho	B-protein
on	O
AP-1	B-protein
is	O
independent	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
,	O
as	O
a	O
dominant-negative	B-protein
MEK	I-protein
and	O
a	O
MEK	B-protein
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B-protein
-induced	O
AP-1	B-protein
activity	O
.	O
	
V14Rho	B-protein
binds	O
strongly	O
to	O
protein	B-protein
kinase	I-protein
Calpha	I-protein
(	O
PKCalpha	B-protein
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	B-DNA
site	I-DNA
on	O
V14Rho	B-protein
severely	O
diminished	O
this	O
association	O
.	O
	
Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	B-protein
as	O
an	O
effector	O
of	O
Rho	B-protein
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	O
of	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
PKCalpha	B-protein
blocked	O
the	O
effects	O
of	O
activated	O
Rho	B-protein
plus	O
PMA	O
on	O
AP-1	B-protein
transcriptional	O
activity	O
.	O
	
These	O
data	O
suggest	O
that	O
Rho	B-protein
potentiates	O
AP-1	B-protein
transcription	O
during	O
T-cell	O
activation	O
	
###MEDLINE:98365377	
	
Changes	O
in	O
PKC	B-protein
isoforms	I-protein
in	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
compared	O
with	O
blood	B-cell_type
monocytes	I-cell_type
.	O
	
Alveolar	O
macrophages	O
play	O
an	O
important	O
role	O
in	O
host	O
defense	O
and	O
in	O
other	O
types	O
of	O
inflammatory	O
processes	O
in	O
the	O
lung	O
.	O
	
These	O
cells	O
exhibit	O
many	O
alterations	O
in	O
function	O
compared	O
with	O
their	O
precursor	B-cell_type
cells	I-cell_type
,	O
blood	B-cell_type
monocytes	I-cell_type
.	O
	
To	O
evaluate	O
a	O
potential	O
mechanism	O
for	O
these	O
differences	O
in	O
function	O
,	O
we	O
evaluated	O
expression	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoforms	I-protein
.	O
	
We	O
found	O
an	O
increase	O
in	O
Ca2+-dependent	B-protein
PKC	I-protein
isoforms	I-protein
in	O
monocytes	O
compared	O
with	O
alveolar	O
macrophages	O
.	O
	
We	O
also	O
found	O
differential	O
expression	O
of	O
the	O
Ca2+-independent	B-protein
isoforms	I-protein
in	O
alveolar	B-cell_type
macrophages	I-cell_type
compared	O
with	O
monocytes	B-cell_type
.	O
	
One	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B-protein
can	O
be	O
increased	O
expression	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
pathways	O
.	O
	
Therefore	O
,	O
we	O
also	O
evaluated	O
activation	O
of	O
the	O
MAP	B-protein
kinase	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
2	I-protein
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
	
PMA	O
activated	O
ERK2	B-protein
kinase	I-protein
in	O
both	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
monocytes	B-cell_type
;	O
however	O
,	O
monocytes	B-cell_type
consistently	O
showed	O
a	O
significantly	O
greater	O
activation	O
of	O
ERK2	B-protein
kinase	I-protein
by	O
PMA	O
compared	O
with	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O
	
Another	O
known	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B-protein
and	O
subsequent	O
activation	O
of	O
ERK	B-protein
kinase	I-protein
is	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
activator	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O
	
We	O
evaluated	O
the	O
activation	O
of	O
AP-1	B-protein
by	O
PMA	O
in	O
both	O
monocytes	B-cell_type
and	O
macrophages	O
.	O
	
We	O
found	O
very	O
little	O
detectable	O
activation	O
of	O
AP-1	B-protein
,	O
as	O
assessed	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
,	O
whereas	O
monocytes	B-cell_type
showed	O
a	O
substantial	O
activation	O
of	O
AP-1	B-protein
by	O
PMA	O
.	O
	
These	O
studies	O
show	O
that	O
the	O
differential	O
expression	O
of	O
PKC	B-protein
isoforms	I-protein
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
blood	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
important	O
functional	O
alterations	O
in	O
the	O
cells	O
.	O
	
###MEDLINE:98353227	
	
Expression	O
of	O
gamma-IFN	B-DNA
responsive	I-DNA
genes	I-DNA
in	O
scavenger	O
receptor	O
over-expressing	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
xanthomatosis	O
.	O
	
We	O
have	O
recently	O
described	O
an	O
inherited	O
over-expression	O
of	O
the	O
macrophage	B-protein
scavenger	I-protein
receptor	I-protein
(	O
SR	B-protein
)	O
in	O
blood	B-cell_type
monocytes	I-cell_type
from	O
members	O
of	O
a	O
kindred	O
,	O
only	O
two	O
of	O
whom	O
displayed	O
extensive	O
xanthomatosis	O
.	O
	
Using	O
mRNA	O
differential	O
display	O
we	O
demonstrated	O
abnormally	O
high	O
expression	O
of	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	O
STAT1alpha	B-protein
)	O
in	O
monocytes	B-cell_type
from	O
the	O
proband	B-cell_line
II-2	I-cell_line
.	O
	
Expression	O
of	O
gamma-interferon	B-protein
inducible	I-protein
protein	I-protein
10	I-protein
(	O
IP-10	B-protein
)	O
,	O
a	O
STAT1alpha-responsive	B-DNA
gene	I-DNA
and	O
mediator	O
of	O
inflammatory	O
response	O
,	O
was	O
also	O
abnormally	O
expressed	O
in	O
the	O
monocytes	B-cell_type
from	O
II-2	B-cell_line
.	O
	
Over-expression	O
of	O
both	O
genes	O
was	O
restricted	O
to	O
monocytes	B-cell_type
from	O
II-2	B-cell_line
and	O
was	O
not	O
observed	O
in	O
monocytes	B-cell_type
from	O
the	O
clinically	O
unaffected	O
family	O
members	O
,	O
unlike	O
that	O
of	O
SR	B-protein
.	O
	
Gel	O
retardation	O
assays	O
with	O
THP-1	B-cell_line
cell	I-cell_line
extracts	O
identified	O
gamma-IFN	B-protein
inducible	O
DNA	O
binding	O
activity	O
to	O
three	O
potential	O
STATI	B-DNA
DNA	I-DNA
binding	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
IP-10	I-DNA
promoter	I-DNA
region	I-DNA
from	O
nucleotides	B-DNA
-	I-DNA
245	I-DNA
to	I-DNA
-	I-DNA
188	I-DNA
.	O
	
Taken	O
together	O
these	O
results	O
suggest	O
that	O
gamma-interferon	O
mediated	O
cell	O
activation	O
is	O
responsible	O
for	O
STAT1alpha	B-protein
-induced	O
transcription	O
of	O
the	O
IP-10	B-protein
gene	O
in	O
THP-1	B-cell_line
macrophages	I-cell_line
as	O
well	O
as	O
in	O
monocytes	B-cell_type
from	O
II-2	B-cell_line
.	O
	
Analysis	O
of	O
monocytes	B-cell_type
from	O
familial	O
hypercholesterolemic	O
(	O
FH	O
)	O
subjects	O
,	O
who	O
frequently	O
develop	O
xanthomatosis	O
,	O
revealed	O
a	O
significant	O
number	O
of	O
subjects	O
with	O
elevated	O
STAT1alpha	O
and	O
IP-10	O
expression	O
.	O
	
Our	O
data	O
suggest	O
that	O
the	O
inflammatory	O
effects	O
of	O
gamma-IFN	B-protein
signaling	O
could	O
play	O
a	O
role	O
in	O
foam	O
cell	O
formation	O
and	O
xanthomatosis	O
.	O
	
###MEDLINE:98343775	
	
Redox	O
signals	O
and	O
NF-kappaB	B-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O
	
The	O
activation	O
of	O
NF-kappaB	B-protein
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL-2	B-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
and	O
several	O
T	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
.	O
	
Diminished	O
NF-kappaB	B-protein
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF-kappaB	B-protein
might	O
occur	O
during	O
cellular	O
senescence	O
.	O
	
In	O
addition	O
,	O
aberrancies	O
in	O
NF-kappaB	B-protein
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV-1	O
infection	O
.	O
	
The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF-kappaB	B-protein
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O
	
Additionally	O
,	O
proposed	O
pathways	O
of	O
NF-kappaB	B-protein
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF-kappaB	B-protein
formation	O
.	O
	
Further	O
,	O
complete	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O
	
Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF-kappaB	B-protein
requires	O
dual	O
signals	O
.	O
	
The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF-kappaB	B-protein
to	O
redox	O
changes	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
examined	O
.	O
	
Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF-kappaB	B-protein
activation	O
may	O
be	O
relevant	O
to	O
immune-related	O
diseases	O
and	O
to	O
aging	O
.	O
	
###MEDLINE:98332778	
	
Uncoupling	O
of	O
nonreceptor	O
tyrosine	B-protein
kinases	I-protein
from	O
PLC-gamma1	B-protein
in	O
an	O
SLP-76-deficient	O
T	O
cell	O
.	O
	
Activation	O
of	O
nonreceptor	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTKs	B-protein
)	O
is	O
essential	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
responsiveness	O
;	O
however	O
,	O
the	O
function	O
of	O
individual	O
PTK	B-protein
substrates	I-protein
is	O
often	O
uncertain	O
.	O
	
A	O
mutant	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
was	O
isolated	O
that	O
lacked	O
expression	O
of	O
SLP-76	B-protein
(	O
SH2	B-protein
domain-containing	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kilodaltons	O
)	O
,	O
a	O
hematopoietically	B-protein
expressed	I-protein
adaptor	I-protein
protein	I-protein
and	O
PTK	B-protein
substrate	I-protein
.	O
	
SLP-76	B-protein
was	O
not	O
required	O
for	O
TCR	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
most	O
proteins	O
,	O
but	O
was	O
required	O
for	O
optimal	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
phospholipase	B-protein
C-gamma1	I-protein
(	O
PLC-gamma1	B-protein
)	O
,	O
as	O
well	O
as	O
Ras	B-protein
pathway	O
activation	O
.	O
	
TCR	B-protein
-inducible	O
gene	O
expression	O
was	O
dependent	O
on	O
SLP-76	B-protein
.	O
	
Thus	O
,	O
coupling	O
of	O
TCR-regulated	B-protein
PTKs	I-protein
to	O
downstream	O
signaling	O
pathways	O
requires	O
SLP-76	B-protein
.	O
	
###MEDLINE:98322151	
	
A	O
novel	O
function	O
of	O
Stat1	B-protein
and	O
Stat3	B-protein
proteins	O
in	O
erythropoietin	B-protein
-induced	O
erythroid	O
differentiation	O
of	O
a	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
We	O
recently	O
determined	O
that	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
activates	O
3	O
members	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
,	O
Stat1alpha	B-protein
,	O
Stat3	B-protein
,	O
and	O
Stat5	B-protein
,	O
in	O
the	O
human	B-cell_line
EPO-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
UT-7	B-cell_line
and	O
UT-7/EPO	B-cell_line
(	O
Kirito	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
16507	O
,	O
1997	O
)	O
.	O
	
In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
Stat1alpha	B-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
is	O
involved	O
in	O
EPO	B-protein
-induced	O
cellular	O
proliferation	O
.	O
	
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
in	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
.	O
	
UT-7/GM	B-cell_line
was	O
used	O
as	O
a	O
model	O
system	O
,	O
because	O
this	O
cell	O
line	O
can	O
differentiate	O
into	O
erythroid-lineage	B-cell_type
cells	I-cell_type
with	O
EPO	B-protein
treatment	O
(	O
Komatsu	O
et	O
al	O
,	O
Blood	O
89	O
:	O
4021	O
,	O
1997	O
)	O
.	O
	
We	O
found	O
that	O
EPO	B-protein
did	O
not	O
activate	O
Stat1alpha	B-protein
or	O
Stat3	B-protein
in	O
UT-7/GM	B-cell_line
cells	I-cell_line
.	O
	
Transfection	O
experiments	O
showed	O
that	O
both	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
inhibited	O
the	O
induction	O
by	O
EPO	B-protein
of	O
gamma-globin	B-RNA
and	I-RNA
erythroid-specific	I-RNA
5-aminolevulinate	I-RNA
synthetase	I-RNA
transcripts	I-RNA
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
percentage	O
of	O
hemoglobin-positive	B-cell_type
cells	I-cell_type
.	O
	
Dominant	O
negative	O
forms	O
of	O
Stat1alpha	B-protein
or	O
Stat3	B-protein
promoted	O
the	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
of	O
UT-7/GM	B-cell_line
cells	I-cell_line
,	O
even	O
in	O
the	O
presence	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
although	O
this	O
cytokine	O
never	O
induced	O
erythroid	O
differentiation	O
of	O
the	O
parent	B-cell_line
UT-7/GM	I-cell_line
cells	I-cell_line
with	O
or	O
without	O
EPO	B-protein
.	O
	
A	O
cell	O
cycle	O
analysis	O
showed	O
that	O
the	O
constitutive	O
activation	O
of	O
Stat1alpha	B-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
shortened	O
the	O
period	O
of	O
G0/G1	O
prolongation	O
caused	O
by	O
EPO	B-protein
stimulation	O
.	O
	
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
act	O
as	O
negative	O
regulators	O
in	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
.	O
	
Specifically	O
,	O
Stat1alpha	B-protein
may	O
activate	O
a	O
cell	B-DNA
cycle-associated	I-DNA
gene	I-DNA
(	O
s	O
)	O
,	O
leading	O
to	O
the	O
entry	O
of	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O
	
###MEDLINE:98313295	
	
Ro	O
09-2210	O
exhibits	O
potent	O
anti-proliferative	O
effects	O
on	O
activated	O
T	B-cell_type
cells	I-cell_type
by	O
selectively	O
blocking	O
MKK	B-protein
activity	O
.	O
	
By	O
using	O
high	O
throughput	O
screening	O
of	O
microbial	O
broths	O
,	O
we	O
have	O
identified	O
a	O
compound	O
,	O
designated	O
Ro	O
09-2210	O
,	O
which	O
is	O
able	O
to	O
block	O
anti-CD3	B-protein
induced	O
peripheral	O
blood	O
T	O
cell	O
activation	O
with	O
an	O
IC50	O
=	O
40	O
nM	O
.	O
	
Ro	O
09-2210	O
was	O
also	O
able	O
to	O
block	O
antigen-induced	O
IL-2	B-protein
secretion	O
with	O
an	O
IC50	O
=	O
30	O
nM	O
,	O
but	O
was	O
considerably	O
less	O
potent	O
at	O
blocking	O
Ca2+	O
flux	O
stimulated	O
by	O
anti-CD3	B-protein
treatment	O
.	O
	
To	O
determine	O
the	O
mechanism	O
of	O
action	O
of	O
Ro	O
09-2210	O
,	O
we	O
set	O
up	O
a	O
transient	O
expression	O
system	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
using	O
a	O
variety	O
of	O
reporter	O
gene	O
constructs	O
and	O
showed	O
effective	O
inhibition	O
of	O
phorbol	O
ester/ionomycin-induced	O
NF-AT	B-protein
activation	O
and	O
anti-CD3	O
induced	O
NF-AT	B-protein
with	O
IC50	O
=	O
7.7	O
and	O
10	O
nM	O
,	O
respectively	O
.	O
	
Ro	O
09-2210	O
was	O
also	O
able	O
to	O
inhibit	O
phorbol	O
ester/ionomycin-induced	O
activation	O
of	O
AP1	B-protein
with	O
IC50	O
=	O
<	O
10	O
nM	O
.	O
	
We	O
further	O
showed	O
that	O
Ro	O
09-2210	O
was	O
unable	O
to	O
inhibit	O
c-jun	B-DNA
induced	O
expression	O
of	O
AP1-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
(	O
IC50	O
>	O
500	O
nM	O
)	O
,	O
but	O
was	O
able	O
to	O
potently	O
inhibit	O
ras-induced	O
AP1	B-protein
activation	O
(	O
IC50	O
=	O
20	O
nM	O
)	O
.	O
	
This	O
suggested	O
that	O
Ro	O
09-2210	O
was	O
inhibiting	O
an	O
activator	O
of	O
AP-1	B-protein
which	O
was	O
upstream	O
of	O
c-jun	B-DNA
and	O
downstream	O
of	O
ras	B-protein
signaling	O
.	O
	
To	O
investigate	O
further	O
,	O
we	O
then	O
purified	O
a	O
number	O
of	O
different	O
kinases	O
,	O
including	O
PKC	B-protein
,	O
PhK	B-protein
,	O
ZAP-70	B-protein
,	O
ERK	B-protein
,	O
and	O
MEK	B-protein
1	I-protein
(	O
a	O
MKK	B-protein
)	O
,	O
and	O
showed	O
that	O
Ro	O
09-2210	O
was	O
a	O
selective	O
inhibitor	O
of	O
MEK1	B-protein
in	O
vitro	O
(	O
IC50	O
=	O
59	O
nM	O
)	O
.	O
	
###MEDLINE:98298224	
	
Coactivation	O
by	O
OCA-B	B-protein
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O
	
Molecular	O
dissection	O
of	O
the	O
B-cell-specific	O
transcription	O
coactivator	O
OCA-B	B-protein
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	B-DNA
promoters	I-DNA
through	O
interaction	O
with	O
octamer-bound	B-protein
Oct-1	I-protein
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O
	
Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	B-protein
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct-1	O
and	O
OCA-B	O
function	O
in	O
a	O
cell-free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O
	
Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	B-protein
and	O
the	O
PC4	B-protein
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	B-protein
and	O
another	O
,	O
USA-derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	B-protein
/OCA-B	B-protein
in	O
the	O
reconstituted	O
system	O
.	O
	
Indeed	O
,	O
USA-derived	B-protein
PC2	I-protein
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	B-protein
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O
	
Consistent	O
with	O
the	O
requirement	O
for	O
PC4	B-protein
in	O
the	O
reconstituted	O
system	O
,	O
OCA-B	B-protein
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	B-protein
.	O
	
Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	B-protein
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA-B	B-protein
/	O
Oct-1	B-protein
-dependent	O
transcription	O
.	O
	
These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct-1	B-protein
and	O
OCA-B	B-protein
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	B-protein
coactivators	I-protein
.	O
	
###MEDLINE:98241397	
	
Activation	O
of	O
Stat-3	B-protein
is	O
involved	O
in	O
the	O
induction	O
of	O
apoptosis	O
after	O
ligation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
molecules	I-protein
on	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Activation	O
of	O
Janus	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
and	O
Signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
)	O
after	O
ligation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
(	O
MHC-I	B-protein
)	O
was	O
explored	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Cross-linking	O
of	O
MHC-I	B-protein
mediated	O
tyrosine	O
phosphorylation	O
of	O
Tyk2	B-protein
,	O
but	O
not	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Jak3	B-protein
.	O
	
In	O
addition	O
,	O
the	O
transcription	B-protein
factor	I-protein
Stat-3	B-protein
was	O
tyrosine	O
phosphorylated	O
in	O
the	O
cytoplasm	O
and	O
subsequently	O
translocated	O
to	O
the	O
cell	O
nucleus	O
.	O
	
Data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
suggested	O
that	O
the	O
activated	B-protein
Stat-3	I-protein
protein	I-protein
associates	O
with	O
the	O
human	B-DNA
serum-inducible	I-DNA
element	I-DNA
(	I-DNA
hSIE	I-DNA
)	I-DNA
DNA-probe	I-DNA
derived	O
from	O
the	O
interferon-gamma	B-DNA
activated	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
in	O
the	O
c-fos	B-DNA
promoter	I-DNA
,	O
a	O
common	O
DNA	O
sequence	O
for	O
Stat	B-protein
protein	I-protein
binding	O
.	O
	
An	O
association	O
between	O
hSIE	B-DNA
and	O
Stat-3	B-protein
after	O
MHC-I	B-protein
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat-3	B-protein
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	B-DNA
probe	I-DNA
and	O
avidin	B-protein
-coupled	O
agarose	O
.	O
	
To	O
investigate	O
the	O
function	O
of	O
the	O
activated	O
Stat-3	B-protein
,	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
Stat-3	B-protein
isoform	I-protein
lacking	O
the	O
transactivating	B-protein
domain	I-protein
.	O
	
This	O
dominant-negative	B-protein
acting	I-protein
Stat-3	I-protein
isoform	I-protein
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC-I	B-protein
.	O
	
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
the	O
involvement	O
of	O
the	O
Jak/Stat	B-protein
signal	O
pathway	O
in	O
MHC-I	B-protein
-induced	O
signal	O
transduction	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98281217	
	
IL-2	B-protein
-induced	O
growth	O
of	O
CD8+	B-cell_type
T	I-cell_type
cell	I-cell_type
prolymphocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
mediated	O
by	O
NF-kappaB	B-protein
induction	O
and	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
expression	O
.	O
	
The	O
binding	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	B-cell_type
cells	I-cell_type
induces	O
nuclear	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
activation	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
(	I-DNA
IL-2R	I-DNA
)	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
,	O
and	O
cell	O
proliferation	O
.	O
	
In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL-2R	B-protein
signaling	O
in	O
the	O
growth	O
of	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
prolymphocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
T-PLL	I-cell_line
)	I-cell_line
cells	I-cell_line
has	O
been	O
investigated	O
.	O
	
Flow	O
cytometry	O
revealed	O
that	O
primary	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
from	O
a	O
patient	O
with	O
CD8+	O
T-PLL	O
expressed	O
IL-2Ralpha	B-protein
and	I-protein
beta	I-protein
chains	I-protein
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL-2Ralpha	B-protein
expression	O
on	O
culture	O
with	O
exogeneous	O
IL-2	B-protein
.	O
	
Northern	O
blot	O
analysis	O
failed	O
to	O
detect	O
IL-2	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
IL-2	B-protein
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O
	
Electrophoretic	O
mobility-shift	O
assays	O
revealed	O
that	O
recombinant	O
IL-2	B-protein
increased	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	B-cell_type
cells	I-cell_type
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL-2	B-protein
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF-kappaB	B-protein
components	O
c-Rel	B-protein
and	O
KBF1	B-protein
in	O
these	O
cells	O
.	O
	
IL-2	B-protein
binding	O
analysis	O
demonstrated	O
that	O
IL-2	B-protein
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL-2Rs	B-protein
on	O
the	O
leukemia	B-cell_type
cells	I-cell_type
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high-affinity	B-protein
IL-2Rs	I-protein
.	O
	
These	O
results	O
show	O
that	O
IL-2	B-protein
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_line
CD8+	I-cell_line
T-PLL	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
	
###MEDLINE:98373923	
	
Dimethyldithiocarbamate	O
inhibits	O
in	O
vitro	O
activation	O
of	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Dithiocarbamates	O
(	O
DTC	O
)	O
,	O
a	O
diverse	O
group	O
of	O
industrial	O
and	O
therapeutic	O
chemicals	O
,	O
have	O
been	O
reported	O
to	O
inhibit	O
,	O
enhance	O
or	O
have	O
no	O
effect	O
on	O
the	O
immune	O
system	O
.	O
	
These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and/or	O
specific	O
compound	O
tested	O
.	O
	
The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O
	
We	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
TNF-alpha	B-protein
-induced	O
activation	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O
	
The	O
inhibition	O
of	O
NF-kappaB	B-protein
is	O
apparently	O
permanent	O
as	O
DMDTC-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
did	O
not	O
regain	O
normal	O
TNF-alpha	B-protein
activation	O
,	O
even	O
after	O
72	O
h	O
in	O
culture	O
.	O
	
DMDTC	O
does	O
not	O
appear	O
to	O
alter	O
NF-kappaB	B-protein
directly	O
as	O
pre-incubation	O
of	O
nuclear	O
extracts	O
with	O
DMDTC	O
does	O
not	O
diminish	O
binding	O
activity	O
of	O
this	O
protein	O
.	O
	
We	O
further	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL-2	B-protein
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	B-protein
(	O
the	O
alpha	B-protein
subunit	I-protein
of	O
the	O
IL-2	B-protein
receptor	I-protein
)	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
phorbol	O
ester	O
.	O
	
These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O
	
###MEDLINE:98363633	
	
Human	B-DNA
15-lipoxygenase	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
analysis	O
and	O
identification	O
of	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
IL-13-induced	B-protein
regulatory	I-protein
factors	I-protein
in	O
monocytes	B-cell_type
.	O
	
In	O
order	O
to	O
study	O
the	O
transcriptional	O
control	O
of	O
15-LO	B-protein
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	B-DNA
15-LO	I-DNA
promoter	I-DNA
region	I-DNA
.	O
	
The	O
15-LO	B-protein
promoter	O
is	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
5'-end	B-DNA
of	O
the	O
gene	O
,	O
and	O
sequence	O
analysis	O
reveals	O
putative	O
Sp1	B-DNA
and	I-DNA
Ap2	I-DNA
binding	I-DNA
site/s	I-DNA
and	O
absence	O
of	O
TATA	B-DNA
or	I-DNA
CAAT	I-DNA
motifs	I-DNA
.	O
	
Transcription	O
is	O
initiated	O
at	O
one	O
major	O
site	O
.	O
	
Using	O
deletion	B-DNA
constructs	I-DNA
,	O
we	O
have	O
defined	O
an	O
active	B-DNA
promoter	I-DNA
region	I-DNA
of	O
1056	O
bp	O
.	O
	
Gel-shift	O
assays	O
revealed	O
that	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
induced	O
only	O
in	O
response	O
to	O
IL-13	B-protein
treatment	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
bind	O
to	O
the	O
15-LO	B-DNA
promoter	I-DNA
DNA	I-DNA
.	O
	
Two	O
regions	O
,	O
DP1	B-DNA
(	O
-140	B-DNA
to	I-DNA
-92	I-DNA
bp	I-DNA
)	O
and	O
DP2	B-DNA
(	O
-353	B-DNA
to	I-DNA
-304	I-DNA
bp	I-DNA
)	O
of	O
the	O
promoter	O
were	O
essential	O
for	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O
	
Hela	O
nuclear	O
extracts	O
contained	O
a	O
specific	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
s	I-protein
)	I-protein
binding	O
to	O
15-LO	B-DNA
promoter	I-DNA
DNA	I-DNA
which	O
are	O
distinct	O
from	O
those	O
derived	O
from	O
IL-13-treated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
monocyte	I-cell_line
nuclear	O
extracts	O
.	O
	
In	O
addition	O
,	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
results	O
refined	O
the	O
previous	O
localization	O
of	O
15-LO	B-protein
to	O
human	B-DNA
chromosome	I-DNA
17p13.3	I-DNA
.	O
	
###MEDLINE:98352765	
	
Ex	O
vivo	O
activation	O
of	O
tumor-draining	B-cell_type
lymph	I-cell_type
node	I-cell_type
T	I-cell_type
cells	I-cell_type
reverses	O
defects	O
in	O
signal	B-protein
transduction	I-protein
molecules	I-protein
.	O
	
The	O
adoptive	O
transfer	O
of	O
tumor-draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	B-cell_type
cells	I-cell_type
activated	O
ex	O
vivo	O
with	O
anti-CD3	B-protein
and	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O
	
The	O
efficacy	O
of	O
the	O
activated	B-cell_type
LN	I-cell_type
cells	I-cell_type
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	B-cell_line
modified	I-cell_line
variant	I-cell_line
(	O
designated	O
D5G6	B-cell_line
)	O
that	O
secretes	O
granulocyte/macrophage-colony-stimulating	B-protein
factor	I-protein
.	O
	
In	O
contrast	O
to	O
anti-CD3/IL-2-activated	B-cell_line
LN	I-cell_line
cells	I-cell_line
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor-draining	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	I-cell_type
has	O
no	O
therapeutic	O
activity	O
.	O
	
To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	B-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
proteins	O
of	O
the	O
NF-kappaB	B-protein
family	I-protein
were	O
analyzed	O
in	O
tumor-draining	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
levels	O
of	O
p56lck	B-protein
and	O
p59fyn	B-protein
were	O
lower	O
in	O
tumor-draining	O
than	O
in	O
normal	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
production	O
of	O
tyrosine-phosphorylated	B-protein
substrates	I-protein
was	O
markedly	O
depressed	O
following	O
anti-CD3	B-protein
stimulation	O
.	O
	
After	O
5-day	O
anti-CD3	B-protein
/IL-2	B-protein
activation	O
,	O
levels	O
of	O
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O
	
Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	B-protein
,	O
p59fyn	B-protein
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O
	
In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c-Rel	B-protein
and	O
Rel	B-protein
A	I-protein
were	O
normal	O
in	O
freshly	O
isolated	O
tumor-draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	B-protein
DNA-binding	O
activity	O
induced	O
by	O
anti-CD3	B-protein
mAb	I-protein
or	O
phorbol	O
myristate	O
acetate	O
.	O
	
Stimulation	O
of	O
activated	B-cell_type
LN	I-cell_type
cells	I-cell_type
with	O
D5	B-cell_type
tumor	I-cell_type
cells	I-cell_type
induced	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
.	O
	
These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
in	O
LN	B-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O
	
###MEDLINE:98343423	
	
Suppression	O
of	O
human	O
anti-porcine	O
T-cell	O
immune	O
responses	O
by	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
transactivator	I-DNA
constructs	I-DNA
lacking	O
the	O
amino	O
terminal	O
domain	O
.	O
	
BACKGROUND	O
:	O
The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
is	O
a	O
bi-	B-protein
or	I-protein
multifunctional	I-protein
domain	I-protein
protein	I-protein
that	O
acts	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O
	
We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	B-DNA
CIITA	I-DNA
gene	I-DNA
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	B-protein
terminal	I-protein
151	I-protein
amino	I-protein
acids	I-protein
,	O
acts	O
as	O
a	O
potent	O
dominant-negative	O
suppressor	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
expression	O
.	O
	
Porcine	B-protein
MHC	I-protein
class	I-protein
II	I-protein
antigens	I-protein
are	O
potent	O
stimulators	O
of	O
direct	O
T-cell	O
recognition	O
by	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
are	O
,	O
therefore	O
,	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
rejection	O
responses	O
to	O
transgenic	O
pig	O
donors	O
in	O
clinical	O
xenotransplantation	O
.	O
	
We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
examining	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
for	O
their	O
effect	O
on	O
porcine	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O
	
METHODS	O
:	O
Stable	O
transfectants	O
of	O
the	O
porcine	B-cell_line
vascular	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
line	I-cell_line
PIEC	B-cell_line
with	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
were	O
tested	O
for	O
SLA-DR	B-protein
and	O
SLA-DQ	B-protein
induction	O
by	O
recombinant	B-protein
porcine	I-protein
interferon-gamma	I-protein
.	O
	
Transient	O
transfectants	O
of	O
the	O
porcine	B-cell_line
B-cell	I-cell_line
line	I-cell_line
L23	I-cell_line
with	O
the	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA-DR	O
and	O
SLA-DQ	O
expression	O
.	O
	
T-cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
RESULTS	O
:	O
In	O
preliminary	O
studies	O
,	O
we	O
demonstrated	O
that	O
transfection	O
of	O
the	O
PIEC	B-cell_line
line	I-cell_line
with	O
full-length	O
human	O
CIITA	B-DNA
constructs	I-DNA
resulted	O
in	O
strong	O
expression	O
of	O
SLA-DR	B-protein
and	O
SLA-DQ	B-protein
antigens	O
,	O
thus	O
establishing	O
the	O
cross-species	O
effectiveness	O
of	O
human	B-protein
CIITA	I-protein
in	O
the	O
pig	O
.	O
	
The	O
mutated	B-DNA
human	I-DNA
CIITA	I-DNA
constructs	I-DNA
were	O
,	O
therefore	O
,	O
tested	O
in	O
the	O
pig	O
.	O
	
PIEC	B-cell_line
clones	I-cell_line
stably	O
transfected	O
with	O
one	O
of	O
these	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
SLA-DR	B-protein
and	O
SLA-DQ	B-protein
antigen	O
induction	O
and	O
marked	O
suppression	O
of	O
SLA-DRA	B-RNA
mRNA	I-RNA
induction	O
.	O
	
Moreover	O
,	O
transient	O
transfection	O
of	O
the	O
porcine	B-cell_line
B-cell	I-cell_line
line	I-cell_line
L23	I-cell_line
showed	O
up	O
to	O
90	O
%	O
suppression	O
of	O
constitutive	O
SLA-DR	O
and	O
SLA-DQ	O
antigen	O
expression	O
in	O
5-8	O
days	O
.	O
	
In	O
functional	O
studies	O
,	O
interferon-gamma-stimulated	B-cell_line
PIEC	I-cell_line
clones	I-cell_line
transfected	O
with	O
this	O
mutated	B-protein
CIITA	I-protein
construct	O
failed	O
to	O
stimulate	O
purified	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
CONCLUSION	O
:	O
Mutated	B-DNA
human	I-DNA
CIITA	I-DNA
constructs	I-DNA
are	O
potent	O
suppressors	O
of	O
porcine	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O
	
###MEDLINE:98328397	
	
Macrophages	B-cell_type
in	O
human	O
atheroma	O
contain	O
PPARgamma	B-protein
:	O
differentiation-dependent	B-protein
peroxisomal	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	B-protein
activity	O
through	O
PPARgamma	B-protein
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O
	
Mononuclear	B-cell_type
phagocytes	I-cell_type
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B-protein
metalloproteinases	I-protein
(	O
MMPs	B-protein
)	O
,	O
including	O
MMP-9	B-protein
.	O
	
Peroxisomal	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O
	
The	O
role	O
of	O
PPARgamma	B-protein
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O
	
We	O
report	O
here	O
that	O
monocytes/macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	B-protein
PPARgamma	I-protein
.	O
	
Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	B-protein
immunoreactive	I-protein
PPARgamma	I-protein
.	O
	
Human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	B-RNA
mRNA	I-RNA
and	O
protein	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O
	
In	O
addition	O
,	O
PPARgamma	B-RNA
mRNA	I-RNA
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate-induced	O
differentiation	O
.	O
	
Stimulation	O
of	O
PPARgamma	B-protein
with	O
troglitazone	O
or	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
inhibited	O
MMP-9	B-protein
gelatinolytic	O
activity	O
in	O
a	O
concentration-dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O
	
This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	B-protein
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O
	
Thus	O
,	O
PPARgamma	B-protein
is	O
present	O
in	O
macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	B-protein
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O
	
PPARgamma	B-protein
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte/macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O
	
###MEDLINE:98322149	
	
Erythropoietin	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
,	O
STAT5A	B-protein
,	O
and	O
STAT5B	B-protein
in	O
primary	B-cell_type
cultured	I-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
.	O
	
We	O
examined	O
signaling	O
by	O
erythropoietin	B-protein
in	O
highly	B-cell_type
purified	I-cell_type
human	I-cell_type
colony	I-cell_type
forming	I-cell_type
unit-erythroid	I-cell_type
cells	I-cell_type
,	O
generated	O
in	O
vitro	O
from	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O
	
We	O
found	O
that	O
erythropoietin	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
,	O
STAT5A	B-protein
,	O
and	O
STAT5B	B-protein
.	O
	
Tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
reaches	O
a	O
peak	O
around	O
10	O
minutes	O
after	O
stimulation	O
and	O
is	O
maximum	O
at	O
5	O
U/mL	O
of	O
erythropoietin	B-protein
.	O
	
Tyrosine	O
phosphorylation	O
of	O
STAT5	B-protein
is	O
accompanied	O
by	O
the	O
translocation	O
of	O
activated	O
STAT5	B-protein
to	O
the	O
nucleus	O
as	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
using	O
32Pi-labeled	O
STAT5	B-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O
	
Tyrosine	O
phosphorylation	O
STAT1	B-protein
or	O
STAT3	B-protein
was	O
not	O
detected	O
in	O
human	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
after	O
stimulation	O
with	O
erythropoietin	B-protein
.	O
	
Crkl	B-protein
,	O
an	O
SH2/SH3	B-protein
adapter	I-protein
protein	I-protein
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	B-protein
from	O
erythropoietin-stimulated	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c-Cbl	B-protein
in	O
the	O
studies	O
using	O
cell	B-cell_line
lines	I-cell_line
.	O
	
Thus	O
,	O
human	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
can	O
be	O
expanded	O
in	O
vitro	O
in	O
sufficient	O
numbers	O
and	O
purity	O
to	O
allow	O
its	O
usage	O
in	O
signal	O
transduction	O
studies	O
.	O
	
This	O
report	O
sets	O
a	O
basis	O
for	O
further	O
studies	O
on	O
signaling	O
in	O
primary	B-cell_type
cultured	I-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
,	O
which	O
in	O
turn	O
contribute	O
to	O
our	O
better	O
understanding	O
in	O
the	O
differentiation	O
processes	O
of	O
erythrocytes	B-cell_type
and	O
their	O
precursors	O
.	O
	
###MEDLINE:98311520	
	
Oxidative	O
stress	O
suppresses	O
transcription	B-protein
factor	I-protein
activities	O
in	O
stimulated	B-cell_type
lymphocytes	I-cell_type
.	O
	
Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation-dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	B-protein
expression	O
,	O
were	O
studied	O
.	O
	
Purified	B-cell_type
quiescent	I-cell_type
human	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O
	
The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O
	
DNA-binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B-protein
factors	I-protein
:	O
NFkappaB	B-protein
,	O
AP-1	B-protein
and	O
NFAT	B-protein
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	B-cell_type
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O
	
The	O
lymphocytes	B-cell_type
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O
	
All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	B-protein
activity	O
in	O
the	O
lymphocytes	B-cell_type
.	O
	
The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	B-protein
activity	O
.	O
	
We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	B-protein
factor	I-protein
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	B-cell_type
lymphocytes	I-cell_type
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	B-protein
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	B-protein
factor	I-protein
DNA-binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O
	
###MEDLINE:98299642	
	
IL-4	B-protein
-dependent	O
regulation	O
of	O
TGF-alpha	O
and	O
TGF-beta1	O
expression	O
in	O
human	B-cell_type
eosinophils	I-cell_type
.	O
	
TGFs	B-protein
play	O
important	O
roles	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O
	
We	O
have	O
previously	O
demonstrated	O
that	O
eosinophils	B-cell_type
infiltrating	O
into	O
different	O
pathologic	O
processes	O
elaborate	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
.	O
	
Eosinophils	B-cell_type
infiltrating	O
hamster	O
cutaneous	O
wounds	O
were	O
found	O
to	O
express	O
TGFs	B-protein
sequentially	O
.	O
	
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
biologic	O
mediators	O
that	O
may	O
regulate	O
the	O
expression	O
of	O
TGF-alpha	B-protein
and	I-protein
-beta1	I-protein
by	O
eosinophils	B-cell_type
.	O
	
Eosinophils	B-cell_type
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
and	O
cultured	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL-3	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-5	B-protein
.	O
	
Cells	O
were	O
analyzed	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O
	
Supernatants	O
from	O
these	O
cultures	O
were	O
assayed	O
for	O
secreted	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
using	O
TGF	B-protein
-specific	O
ELISAs	O
.	O
	
IL-3	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-5	B-protein
independently	O
up-regulated	O
TGF-beta1	B-RNA
mRNA	I-RNA
and	O
product	O
expression	O
by	O
eosinophils	B-cell_type
in	O
all	O
donors	O
.	O
	
Interestingly	O
,	O
TGF-alpha	B-protein
production	O
by	O
eosinophils	B-cell_type
was	O
up-regulated	O
by	O
IL-3	B-protein
and	O
IL-5	B-protein
but	O
was	O
down-regulated	O
by	O
IL-4	B-protein
.	O
	
Consistent	O
with	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
regulate	O
eosinophil	O
responses	O
,	O
IL-4	B-protein
signaling	I-protein
molecules	I-protein
are	O
present	O
in	O
human	B-cell_type
eosinophils	I-cell_type
.	O
	
The	O
observation	O
that	O
IL-4	B-protein
can	O
differentially	O
regulate	O
the	O
expression	O
of	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
suggests	O
that	O
IL-4	B-protein
may	O
serve	O
as	O
a	O
physiologic	O
molecular	O
switch	O
of	O
TGF	B-protein
expression	O
by	O
the	O
infiltrating	O
eosinophils	B-cell_type
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O
	
###MEDLINE:98282210	
	
MLL	O
and	O
CALM	B-DNA
are	O
fused	O
to	O
AF10	B-DNA
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
with	O
translocation	B-DNA
t	I-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
:	O
both	O
rearrangements	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
	
The	O
translocation	B-DNA
t	I-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q14	I-DNA
)	I-DNA
has	O
been	O
observed	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O
	
A	O
recent	O
study	O
showed	O
a	O
MLL/AF10	B-DNA
fusion	I-DNA
in	O
all	O
cases	O
of	O
AML	O
with	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
and	O
various	O
breakpoints	O
on	O
chromosome	B-DNA
11	I-DNA
ranging	O
from	O
q13	B-DNA
to	O
q23	B-DNA
.	O
	
We	O
recently	O
cloned	O
CALM	B-DNA
(	O
Clathrin	B-DNA
Assembly	I-DNA
Lymphoid	I-DNA
Myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
)	O
,	O
the	O
fusion	O
partner	O
of	O
AF10	B-DNA
at	O
11q14	B-DNA
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O
	
To	O
further	O
define	O
the	O
role	O
of	O
these	O
genes	O
in	O
acute	O
leukemias	O
,	O
10	O
cases	O
(	O
9	O
AML	O
and	O
1	O
ALL	O
)	O
with	O
cytogenetically	O
proven	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p12-14	I-DNA
;	I-DNA
q13-21	I-DNA
)	I-DNA
and	O
well-characterized	O
morphology	O
,	O
immunophenotype	O
,	O
and	O
clinical	O
course	O
were	O
analyzed	O
.	O
	
Interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
was	O
performed	O
with	O
2	O
YACs	B-DNA
flanking	O
the	O
CALM	B-DNA
region	I-DNA
,	O
a	O
YAC	B-DNA
contig	I-DNA
of	O
the	O
MLL	B-DNA
region	I-DNA
,	O
and	O
a	O
YAC	B-DNA
spanning	O
the	O
AF10	B-DNA
breakpoint	O
.	O
	
Rearrangement	O
of	O
at	O
least	O
one	O
of	O
these	O
genes	O
was	O
detected	O
in	O
all	O
cases	O
with	O
balanced	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
.	O
	
In	O
4	O
cases	O
,	O
including	O
3	O
AML	O
with	O
immature	O
morphology	O
(	O
1	O
AML-M0	O
and	O
2	O
AML-M1	O
)	O
and	O
1	O
ALL	O
,	O
the	O
signals	O
of	O
the	O
CALM	B-DNA
YACS	I-DNA
were	O
separated	O
in	O
interphase	O
cells	O
,	O
indicating	O
a	O
translocation	O
breakpoint	O
within	O
the	O
CALM	B-DNA
region	I-DNA
.	O
	
MLL	O
was	O
rearranged	O
in	O
3	O
AML	O
with	O
myelomonocytic	O
differentiation	O
(	O
2	O
AML-M2	O
and	O
1	O
AML-M5	O
)	O
,	O
including	O
1	O
secondary	O
AML	O
.	O
	
In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4+	B-protein
,	O
CD13	B-protein
-	O
,	O
CD33+	O
,	O
CD65s+	O
)	O
.	O
	
AF-10	O
was	O
involved	O
in	O
5	O
of	O
6	O
evaluable	O
cases	O
,	O
including	O
1	O
case	O
without	O
detectable	O
CALM	B-DNA
or	O
MLL	O
rearrangement	O
.	O
	
In	O
2	O
complex	O
translocations	O
,	O
none	O
of	O
the	O
three	O
genes	O
was	O
rearranged	O
.	O
	
All	O
cases	O
had	O
a	O
remarkably	O
poor	O
prognosis	O
,	O
with	O
a	O
mean	O
survival	O
of	O
9.6	O
+/-	O
6.6	O
months	O
.	O
	
For	O
the	O
7	O
AML	O
cases	O
that	O
were	O
uniformly	O
treated	O
according	O
to	O
the	O
AMLCG86/92	O
protocols	O
,	O
disease-free	O
and	O
overall	O
survival	O
was	O
significantly	O
worse	O
than	O
for	O
the	O
overall	O
study	O
group	O
(	O
P	O
=	O
.03	O
and	O
P	O
=	O
.01	O
,	O
respectively	O
)	O
.	O
	
We	O
conclude	O
that	O
the	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q14	I-DNA
)	I-DNA
indicates	O
CALM	B-DNA
and	I-DNA
MLL	I-DNA
rearrangements	I-DNA
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
and	O
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
	
###MEDLINE:98282482	
	
The	O
role	O
of	O
E-proteins	B-protein
in	O
B-	O
and	O
T-lymphocyte	O
development	O
.	O
	
Department	O
of	O
lymphocytes	B-cell_type
from	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
is	O
controlled	O
,	O
in	O
part	O
,	O
by	O
the	O
activity	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
.	O
	
In	O
particular	O
,	O
one	O
class	O
of	O
helix-loop-helix	B-protein
proteins	I-protein
,	O
termed	O
E-proteins	B-protein
,	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
B-cell	O
development	O
.	O
	
Recent	O
analysis	O
of	O
gene-targeted	O
mice	O
has	O
allowed	O
a	O
direct	O
assessment	O
of	O
the	O
functional	O
roles	O
of	O
several	B-protein
E-protein	I-protein
family	I-protein
members	I-protein
in	O
hematopoiesis	O
.	O
	
In	O
this	O
review	O
we	O
describe	O
the	O
defects	O
in	O
B-	O
and	O
T-	O
lymphocyte	O
development	O
in	O
mice	O
carrying	O
targeted	O
mutations	O
in	O
the	O
E-protein	B-DNA
genes	I-DNA
and	O
discuss	O
our	O
current	O
understanding	O
of	O
the	O
role	O
of	O
these	O
proteins	O
in	O
lymphoid	O
development	O
	
###MEDLINE:98374313	
	
Epstein-Barr	B-protein
virus-transforming	I-protein
protein	I-protein
latent	B-protein
infection	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
activates	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF-kappaB-inducing	B-protein
kinase	I-protein
and	O
the	O
IkappaB	B-protein
kinases	I-protein
IKKalpha	B-protein
and	O
IKKbeta	B-protein
.	O
	
The	O
Epstein-Barr	B-protein
virus	I-protein
oncoprotein	I-protein
latent	B-protein
infection	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
is	O
a	O
constitutively	O
aggregated	O
pseudo-tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR	B-protein
)	O
that	O
activates	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
through	O
two	O
sites	O
in	O
its	O
C-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O
	
One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	B-protein
in	O
associating	O
with	O
TNFR-associated	B-protein
factors	I-protein
TRAF1	B-protein
and	O
TRAF2	B-protein
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	B-protein
in	O
associating	O
with	O
the	O
TNFRI	B-protein
death	I-protein
domain	I-protein
interacting	I-protein
protein	I-protein
TRADD	B-protein
.	O
	
TNFRI	B-protein
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF-kappaB	B-protein
through	O
association	O
with	O
TRADD	B-protein
,	O
RIP	B-protein
,	O
and	O
TRAF2	B-protein
;	O
activation	O
of	O
the	O
NF-kappaB-inducing	B-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
;	O
activation	O
of	O
the	O
IkappaB	B-protein
alpha	I-protein
kinases	I-protein
(	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O
	
IkappaB	B-protein
alpha	I-protein
phosphorylation	O
on	O
Ser-32	O
and	O
Ser-36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF-kappaB	B-protein
activation	O
.	O
	
In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
and	O
IKKbeta	B-protein
.	O
	
Dominant	B-protein
negative	I-protein
mutants	I-protein
of	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
or	O
IKKbeta	B-protein
substantially	O
inhibited	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
.	O
	
###MEDLINE:98361309	
	
Targeted	O
disruption	O
of	O
the	O
MyD88	B-DNA
gene	I-DNA
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O
	
MyD88	B-protein
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	B-DNA
response	I-DNA
gene	I-DNA
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	B-protein
receptor	I-protein
complex	I-protein
and	O
IL-1	B-protein
receptor-associated	I-protein
kinase	I-protein
(	O
IRAK	B-protein
)	O
.	O
	
Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	B-protein
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	B-protein
in	O
response	O
to	O
IL-1	B-protein
.	O
	
Increases	O
in	O
interferon-gamma	B-protein
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	B-protein
are	O
abrogated	O
.	O
	
In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O
	
Furthermore	O
,	O
IL-18	B-protein
-induced	O
activation	O
of	O
NF-kappaB	B-protein
and	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
is	O
blocked	O
in	O
MyD88-/-	B-cell_line
Th1-developing	I-cell_line
cells	I-cell_line
.	O
	
Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B-protein
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B-protein
receptor	I-protein
as	O
well	O
as	O
IL-18	B-protein
receptor	I-protein
.	O
	
###MEDLINE:98353313	
	
Ciprofloxacin	O
induces	O
an	O
immunomodulatory	O
stress	O
response	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Exposure	O
of	O
cells	O
to	O
adverse	O
environmental	O
conditions	O
invokes	O
a	O
genetically	O
programmed	O
series	O
of	O
events	O
resulting	O
in	O
the	O
induction	O
of	O
specific	B-DNA
genes	I-DNA
.	O
	
The	O
fluoroquinolone	O
antibiotic	O
ciprofloxacin	O
has	O
recently	O
been	O
reported	O
to	O
upregulate	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
gene	O
induction	O
.	O
	
In	O
the	O
present	O
investigation	O
,	O
the	O
effect	O
of	O
ciprofloxacin	O
at	O
supratherapeutic	O
concentrations	O
on	O
immediate-early	O
(	O
<	O
2	O
h	O
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
was	O
studied	O
with	O
Northern	O
blots	O
.	O
	
In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL-2	B-protein
and	O
metallothionein	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
regions	I-DNA
and	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
NF-AT	B-protein
were	O
analyzed	O
by	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O
	
The	O
concentration	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
c-myc	I-RNA
,	I-RNA
junB	I-RNA
,	I-RNA
and	I-RNA
fra-1	I-RNA
mRNAs	I-RNA
was	O
increased	O
in	O
activated	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O
	
Ciprofloxacin	O
increased	O
CAT	B-protein
activity	O
in	O
stimulated	O
lymphocytes	O
transfected	O
with	O
plasmids	B-cell_type
containing	O
either	O
the	O
IL-2	B-protein
or	O
metallothionein	B-DNA
enhancer	I-DNA
.	O
	
Furthermore	O
,	O
among	O
the	O
transcription	B-protein
factors	I-protein
tested	O
,	O
AP-1	B-protein
activity	O
was	O
increased	O
in	O
stimulated	B-cell_type
purified	I-cell_type
T	I-cell_type
helper	I-cell_type
lymphocytes	I-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
drug-free	B-cell_type
controls	I-cell_type
.	O
	
Taken	O
together	O
,	O
ciprofloxacin	O
increased	O
the	O
levels	O
of	O
immediate-early	B-RNA
transcripts	I-RNA
,	O
enhanced	O
IL-2	B-protein
and	O
metallothionein	B-protein
promoter	O
induction	O
,	O
and	O
upregulated	O
AP-1	B-protein
concentrations	O
in	O
primary	B-cell_type
lymphocytes	I-cell_type
,	O
reflecting	O
a	O
program	O
commonly	O
observed	O
in	O
mammalian	O
stress	O
responses	O
.	O
	
###MEDLINE:98341858	
	
A	O
novel	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
-selective	O
antagonist	O
inhibits	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	B-cell_line
cells	I-cell_line
:	O
implications	O
of	O
RARalpha	B-protein
-mediated	O
signals	O
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
	
Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL-60	B-cell_line
cells	I-cell_line
to	O
differentiate	O
terminally	O
into	O
mature	B-cell_type
granulocytes	I-cell_type
,	O
which	O
subsequently	O
die	O
by	O
apoptosis	O
.	O
	
The	O
biological	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcription	B-protein
factors	I-protein
:	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
.	O
	
RARs	B-protein
and	O
RXRs	B-protein
form	O
heterodimers	B-protein
and	O
regulate	O
retinoid-mediated	O
gene	O
expression	O
.	O
	
We	O
have	O
recently	O
developed	O
a	O
novel	O
RAR	B-protein
-selective	O
antagonist	O
(	O
ER27191	O
)	O
which	O
prevents	O
RAR	B-protein
activation	O
by	O
retinoids	O
.	O
	
Using	O
this	O
RAR-selective	O
antagonist	O
,	O
and	O
RXR	B-protein
and	O
RAR	B-protein
agonist	O
,	O
we	O
demonstrate	O
the	O
RAR	B-protein
-mediated	O
signaling	O
pathway	O
is	O
important	O
for	O
differentiation	O
and	O
apoptosis	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
	
Simple	O
activation	O
of	O
RXRs	B-protein
is	O
not	O
sufficient	O
to	O
induce	O
apoptosis	O
of	O
the	O
cells	O
.	O
	
Interestingly	O
,	O
the	O
combination	O
of	O
the	O
RAR-selective	O
antagonist	O
and	O
9-cis	O
RA	O
resulted	O
in	O
partial	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	B-cell_line
and	I-cell_line
NB4	I-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
RAR	B-protein
antagonist	O
completely	O
blocked	O
all-trans	O
RA-induced	O
differentiation	O
and	O
apoptosis	O
of	O
the	O
cells	O
.	O
	
Additional	O
experiments	O
showed	O
that	O
levels	O
of	O
BCL-2	B-protein
protein	I-protein
decreased	O
during	O
differentiation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
	
Furthermore	O
,	O
HL-60	B-cell_line
cells	I-cell_line
transduced	O
with	O
a	O
bcl-2	B-DNA
expression	I-DNA
vector	I-DNA
showed	O
the	O
same	O
differentiation	O
response	O
to	O
retinoids	O
as	O
did	O
parental	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
even	O
though	O
apoptosis	O
was	O
inhibited	O
in	O
these	O
bcl-2-transduced	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
differentiation	O
and	O
apoptosis	O
are	O
regulated	O
independently	O
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:98326600	
	
Thrombopoietin	B-protein
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c-Mpl	B-protein
in	O
a	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7/GMT	B-cell_line
,	O
from	O
the	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
UT-7/GM	I-cell_line
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021-4033	O
,	O
1997	O
)	O
.	O
	
A	O
small	O
population	O
of	O
UT-7/GM	B-cell_line
cells	I-cell_line
positively	O
stained	O
for	O
hemoglobin	B-protein
(	O
Hb	B-protein
)	O
after	O
a	O
7-day	O
exposure	O
to	O
TPO	B-protein
.	O
	
More	O
than	O
50	O
%	O
of	O
TPO-treated	B-cell_line
UT-7/GMT	I-cell_line
cells	I-cell_line
positively	O
stained	O
for	O
Hb	B-protein
.	O
	
Using	O
UT-7/GMT	B-cell_line
cells	I-cell_line
,	O
we	O
examined	O
how	O
TPO	B-protein
promotes	O
hemoglobinization	O
.	O
	
TPO	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	B-protein
receptor	O
but	O
not	O
the	O
erythropoietin	B-protein
(	I-protein
EPO	I-protein
)	I-protein
receptor	I-protein
.	O
	
There	O
was	O
no	O
competition	O
between	O
TPO	B-protein
and	O
EPO	B-protein
for	O
binding	O
to	O
EPO	B-protein
receptor	I-protein
.	O
	
These	O
findings	O
suggest	O
that	O
TPO	B-protein
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT-7/GMT	B-cell_line
cells	I-cell_line
.	O
	
Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	B-protein
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	B-protein
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O
	
Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	B-protein
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O
	
###MEDLINE:98322148	
	
Role	O
of	O
GATA-1	B-protein
in	O
proliferation	O
and	O
differentiation	O
of	O
definitive	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O
	
To	O
elucidate	O
the	O
contributions	O
of	O
GATA-1	B-protein
to	O
definitive	O
hematopoiesis	O
in	O
vivo	O
,	O
we	O
have	O
examined	O
adult	O
mice	O
that	O
were	O
rendered	O
genetically	O
defective	O
in	O
GATA-1	B-protein
synthesis	O
(	O
Takahashi	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
12611	O
,	O
1997	O
)	O
.	O
	
Because	O
the	O
GATA-1	B-DNA
gene	I-DNA
is	O
located	O
on	O
the	O
X	B-DNA
chromosome	I-DNA
,	O
which	O
is	O
randomly	O
inactivated	O
in	O
every	O
cell	O
,	O
heterozygous	O
females	O
can	O
bear	O
either	O
an	O
active	O
wild-type	O
or	O
mutant	O
(	O
referred	O
to	O
as	O
GATA-1.05	B-DNA
)	O
GATA-1	B-protein
allele	O
,	O
consequently	O
leading	O
to	O
variable	O
anemic	O
severity	O
.	O
	
These	O
heterozygous	O
mutant	O
mice	O
usually	O
developed	O
normally	O
,	O
but	O
they	O
began	O
to	O
die	O
after	O
5	O
months	O
.	O
	
These	O
affected	O
animals	O
displayed	O
marked	O
splenomegaly	O
,	O
anemia	O
,	O
and	O
thrombocytopenia	O
.	O
	
Proerythroblasts	B-cell_type
and	O
megakaryocytes	B-cell_type
massively	O
accumulated	O
in	O
the	O
spleens	O
of	O
the	O
heterozygotes	O
,	O
and	O
we	O
showed	O
that	O
the	O
neomycin	B-DNA
resistance	I-DNA
gene	I-DNA
(	O
which	O
is	O
the	O
positive	O
selection	O
marker	O
in	O
ES	B-cell_type
cells	I-cell_type
)	O
was	O
expressed	O
profusely	O
in	O
the	O
abnormally	O
abundant	O
cells	O
generated	O
in	O
the	O
GATA-1.05	B-protein
mutant	O
females	O
.	O
	
We	O
also	O
observed	O
hematopoiesis	O
outside	O
of	O
the	O
bone	O
marrow	O
in	O
the	O
affected	O
mutant	O
mice	O
.	O
	
These	O
data	O
suggest	O
that	O
a	O
small	O
number	O
of	O
GATA-1.05	B-cell_line
mutant	I-cell_line
hematopoietic	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
begin	O
to	O
proliferate	O
vigorously	O
during	O
early	O
adulthood	O
,	O
but	O
because	O
the	O
cells	O
are	O
unable	O
to	O
terminally	O
differentiate	O
,	O
this	O
leads	O
to	O
progenitor	O
proliferation	O
in	O
the	O
spleen	O
and	O
consequently	O
death	O
.	O
	
Thus	O
,	O
GATA-1	B-protein
plays	O
important	O
in	O
vivo	O
roles	O
for	O
directing	O
definitive	O
hematopoietic	B-cell_type
progenitors	I-cell_type
to	O
differentiate	O
along	O
both	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O
	
The	O
GATA-1	B-protein
heterozygous	O
mutant	O
mouse	O
shows	O
a	O
phenotype	O
that	O
is	O
analogous	O
to	O
human	O
myelodysplastic	O
syndrome	O
and	O
thus	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
this	O
disorder	O
.	O
	
###MEDLINE:98309442	
	
Differential	O
regulation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
-STAT	B-protein
pathway	O
and	O
biologic	O
function	O
of	O
IL-13	B-protein
in	O
primary	B-cell_type
human	I-cell_type
NK	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
:	O
a	O
comparative	O
study	O
with	O
IL-4	B-protein
.	O
	
IL-13	B-protein
,	O
a	O
cytokine	O
similar	O
to	O
IL-4	B-protein
,	O
is	O
a	O
regulator	O
of	O
human	O
B	O
cell	O
and	O
monocyte	O
functions	O
.	O
	
Biologic	O
effects	O
of	O
IL-13	B-protein
on	O
primary	B-cell_type
human	I-cell_type
NK	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
well	O
defined	O
.	O
	
We	O
demonstrate	O
that	O
,	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
IL-13	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
may	O
induce	O
low	O
levels	O
of	O
IFN-gamma	B-protein
secretion	O
.	O
	
When	O
NK	B-cell_type
cells	I-cell_type
were	O
costimulated	O
with	O
IL-13	B-protein
and	O
IL-2	B-protein
,	O
IL-13	B-protein
generally	O
resulted	O
in	O
two	O
types	O
of	O
reactivity	O
:	O
IL-13	B-protein
synergized	O
with	O
IL-2	B-protein
to	O
stimulate	O
IFN-gamma	B-protein
production	O
or	O
it	O
modestly	O
inhibited	O
IL-2	B-protein
-mediated	O
IFN-gamma	B-protein
production	O
.	O
	
In	O
both	O
types	O
of	O
donors	O
,	O
the	O
effect	O
of	O
IL-13	B-protein
on	O
IL-2	B-protein
-induced	O
IFN-gamma	B-protein
production	O
was	O
in	O
marked	O
contrast	O
to	O
the	O
strong	O
inhibition	O
seen	O
with	O
IL-4	B-protein
in	O
NK	B-cell_type
cells	I-cell_type
.	O
	
Additionally	O
,	O
IL-13	B-protein
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	B-protein
.	O
	
In	O
T	B-cell_type
cells	I-cell_type
,	O
IL-13	B-protein
inhibits	O
anti-CD3	O
mAb/IL-2-	O
or	O
PHA-mediated	O
IFN-gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O
	
Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	B-protein
,	O
like	O
IL-4	B-protein
,	O
induces	O
distinct	O
STAT6-DNA	B-protein
binding	I-protein
complexes	I-protein
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	B-protein
and	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
in	O
NK	O
and	O
T	B-cell_type
cells	I-cell_type
.	O
	
We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	B-protein
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
NK	B-cell_type
cells	I-cell_type
,	O
suggesting	O
different	O
STAT6	B-protein
isoforms	I-protein
.	O
	
These	O
findings	O
show	O
that	O
IL-13	B-protein
and	O
IL-4	B-protein
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B-protein
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B-protein
and	O
JAK3	B-protein
in	O
these	O
cell	O
types	O
.	O
	
###MEDLINE:98290745	
	
The	O
human	O
toll	O
signaling	O
pathway	O
:	O
divergence	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
and	O
JNK	B-protein
/SAPK	B-protein
activation	O
upstream	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
(	O
TRAF6	B-protein
)	O
.	O
	
The	O
human	O
homologue	O
of	O
Drosophila	B-protein
Toll	I-protein
(	O
hToll	B-protein
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	B-protein
1	I-protein
receptor	I-protein
(	I-protein
IL-1R	I-protein
)	I-protein
superfamily	I-protein
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O
	
Signaling	O
by	O
hToll	B-protein
is	O
shown	O
to	O
occur	O
through	O
sequential	O
recruitment	O
of	O
the	O
adapter	B-protein
molecule	I-protein
MyD88	B-protein
and	O
the	O
IL-1R-associated	B-protein
kinase	I-protein
.	O
	
Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-activated	I-protein
factor	I-protein
6	I-protein
(	O
TRAF6	B-protein
)	O
and	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
-inducing	I-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF-kappaB	B-protein
activation	O
.	O
	
Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B-protein
failed	O
to	O
block	O
hToll	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
kinase/c-Jun	I-protein
NH2-terminal	I-protein
kinases	I-protein
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O
	
###MEDLINE:98282206	
	
Inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
Death-inducing	B-protein
ligands	I-protein
(	O
DILs	B-protein
)	O
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
-dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O
	
We	O
demonstrate	O
here	O
that	O
TRAIL	B-protein
(	O
TNF-related	B-protein
apoptosis-inducing	I-protein
ligand	I-protein
)	O
,	O
a	O
recently	O
identified	O
DIL	B-protein
,	O
also	O
activates	O
NFkappaB	B-protein
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	B-protein
.	O
	
NFkappaB	B-protein
activity	O
is	O
independent	O
from	O
FADD	B-protein
,	O
caspases	B-protein
,	O
and	O
apoptosis	O
induction	O
.	O
	
To	O
study	O
the	O
influence	O
of	O
NFkappaB	B-protein
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B-protein
,	O
CD95	O
,	O
TNFalpha	B-protein
,	O
or	O
doxorubicin	O
,	O
NFkappaB	B-protein
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B-protein
IkappaBalpha	I-protein
.	O
	
Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	B-cell_line
lines	I-cell_line
.	O
	
Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	B-protein
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	B-protein
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O
	
These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	B-protein
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O
	
###MEDLINE:98282481	
	
Loss-	O
and	O
gain-of-function	O
mutations	O
reveal	O
an	O
important	O
role	O
of	O
BSAP	B-protein
(	O
Pax-5	B-protein
)	O
at	O
the	O
start	O
and	O
end	O
of	O
B	O
cell	O
differentiation	O
.	O
	
Pax-5	B-protein
codes	O
for	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
which	O
is	O
expressed	O
throughout	O
B	O
cell	O
development	O
except	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O
	
Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B-lymphopoiesis	O
on	O
this	O
transcription	B-protein
factor	I-protein
.	O
	
BSAP	B-protein
is	O
required	O
for	O
B-lineage	O
commitment	O
in	O
the	O
fetal	O
liver	O
and	O
for	O
progression	O
beyond	O
an	O
early	O
pro-B	O
cell	O
stage	O
in	O
adult	O
bone	O
marrow	O
.	O
	
The	O
characterization	O
of	O
Pax-5-deficient	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
demonstrated	O
an	O
important	O
role	O
of	O
BSAP	B-protein
in	O
the	O
regulation	O
of	O
the	O
CD19	B-protein
,	O
mb-1	B-protein
(	O
Ig	B-protein
alpha	I-protein
)	O
and	O
N-myc	B-DNA
genes	I-DNA
as	O
well	O
as	O
in	O
the	O
developmental	O
pathway	O
controlling	O
VH-to-DHJH	O
recombination	O
at	O
the	O
immunoglobulin	B-protein
heavy-chain	I-protein
(	I-protein
IgH	I-protein
)	I-protein
locus	I-protein
.	O
	
The	O
human	B-DNA
PAX-5	I-DNA
gene	I-DNA
was	O
recently	O
shown	O
to	O
participate	O
together	O
with	O
the	O
IgH	B-DNA
locus	I-DNA
in	O
the	O
chromosomal	O
translocation	O
t	B-DNA
(	I-DNA
9	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q32	I-DNA
)	I-DNA
.	O
	
This	O
translocation	O
is	O
characteristic	O
of	O
a	O
small	O
subset	O
of	O
non-Hodgkin	O
lymphomas	O
exhibiting	O
plasmacytoid	O
differentiation	O
.	O
	
The	O
translocated	B-DNA
PAX-5	I-DNA
gene	I-DNA
is	O
deregulated	O
by	O
the	O
insertion	O
of	O
IgH	B-DNA
regulatory	I-DNA
elements	I-DNA
into	O
its	O
5	B-DNA
'	I-DNA
region	I-DNA
,	O
which	O
may	O
contribute	O
to	O
tumorigenesis	O
by	O
interfering	O
with	O
the	O
shut-down	O
of	O
PAX-5	B-protein
transcription	O
and	O
thus	O
with	O
the	O
completion	O
of	O
plasma	B-cell_type
cell	I-cell_type
differentiation	O
	
###MEDLINE:98374270	
	
Acetylation	O
and	O
modulation	O
of	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
activity	O
by	O
interaction	O
with	O
histone	B-protein
acetyltransferases	I-protein
.	O
	
Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
is	O
a	O
red	B-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta-globin	B-protein
expression	O
during	O
erythroid	O
ontogeny	O
.	O
	
EKLF	B-protein
is	O
required	O
for	O
integrity	O
of	O
the	O
chromatin	O
structure	O
at	O
the	O
beta-like	B-DNA
globin	I-DNA
locus	I-DNA
,	O
and	O
it	O
interacts	O
with	O
a	O
positive-acting	B-protein
factor	I-protein
in	O
vivo	O
.	O
	
We	O
find	O
that	O
EKLF	B-protein
is	O
an	O
acetylated	B-protein
transcription	I-protein
factor	I-protein
,	O
and	O
that	O
it	O
interacts	O
in	O
vivo	O
with	O
CBP	B-protein
,	O
p300	B-protein
,	O
and	O
P/CAF	B-protein
.	O
	
However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	O
equivalent	O
,	O
as	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
utilize	O
EKLF	B-protein
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans-	O
activation	B-protein
region	I-protein
.	O
	
The	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
enhance	O
EKLF	B-protein
's	O
transcriptional	O
activation	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
establish	O
EKLF	B-protein
as	O
a	O
tissue-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	B-protein
is	O
able	O
to	O
alter	O
chromatin	B-DNA
structure	O
and	O
induce	O
beta-globin	B-protein
expression	O
within	O
the	O
beta-like	B-DNA
globin	I-DNA
cluster	I-DNA
.	O
	
###MEDLINE:98362153	
	
Recognition	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
tegument	I-protein
proteins	I-protein
by	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O
	
The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O
	
The	O
antiviral	O
functions	O
of	O
infiltrating	B-cell_type
CD4-bearing	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	B-protein
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O
	
The	O
antigens	O
recognized	O
by	O
many	O
HSV-specific	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O
	
T	B-cell_type
cells	I-cell_type
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	B-DNA
DNA	I-DNA
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O
	
Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	B-protein
protein	I-protein
VP22	B-protein
and	O
the	O
viral	B-protein
dUTPase	I-protein
,	O
encoded	O
by	O
genes	B-DNA
UL49	I-DNA
and	I-DNA
UL50	I-DNA
,	O
respectively	O
,	O
are	O
T-cell	B-protein
antigens	I-protein
.	O
	
Separate	O
epitopes	B-protein
in	O
VP22	B-protein
were	O
defined	O
for	O
T-cell	B-cell_line
clones	I-cell_line
from	O
each	O
of	O
three	O
patients	O
.	O
	
Reactivity	O
with	O
the	O
tegument	B-protein
protein	I-protein
encoded	O
by	O
UL21	B-DNA
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O
	
Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	B-protein
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
VP22	B-protein
.	O
	
Some	O
tegument-specific	B-cell_line
CD4	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
exhibited	O
cytotoxic	O
activity	O
against	O
HSV-infected	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O
	
###MEDLINE:98349401	
	
Fibrinogen	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O
	
Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O
	
Mononuclear	B-cell_type
phagocytes	I-cell_type
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
.	O
	
U937	B-cell_line
cells	I-cell_line
differentiated	O
with	O
PMA	O
in	O
nonadherent	B-cell_line
culture	I-cell_line
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	B-protein
integrins	I-protein
,	O
predominately	O
CD11b/CD18	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	B-protein
.	O
	
Cells	O
stimulated	O
with	O
fibrinogen	B-protein
(	O
10-100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
	
NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O
	
Fibrinogen	B-protein
also	O
caused	O
activation	O
of	O
AP-1	B-protein
,	O
but	O
not	O
SP1	B-protein
or	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	I-protein
CREB	I-protein
)	I-protein
factors	I-protein
.	O
	
Blocking	O
mAbs	B-protein
against	O
CD18	B-protein
and	O
CD11b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	B-cell_line
cells	I-cell_line
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
(	O
bearing	O
two	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
)	O
coupled	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
.	O
	
Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	B-protein
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen	B-protein
/Mn2+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	B-protein
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	B-protein
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	B-protein
activity	O
induced	O
by	O
PMA	O
alone	O
.	O
	
We	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	B-protein
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	O
NF-kappa	B-protein
B	I-protein
.	O
	
###MEDLINE:98339383	
	
Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O
	
OBJECTIVE	O
:	O
To	O
identify	O
and	O
characterize	O
estrogen	B-RNA
receptor	I-RNA
(	I-RNA
ER	I-RNA
)	I-RNA
transcripts	I-RNA
expressed	O
in	O
immune	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
healthy	O
donors	O
.	O
	
METHODS	O
:	O
Peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
were	O
prepared	O
from	O
patients	O
with	O
SLE	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
8	O
)	O
.	O
	
T	B-cell_type
cells	I-cell_type
were	O
separated	O
into	O
CD4	B-cell_type
and	O
CD8	B-cell_type
.	O
	
Some	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O
	
Epstein-Barr	O
virus-transformed	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
n	O
=	O
7	O
)	O
and	O
B	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
(	O
n	O
=	O
2	O
)	O
established	O
from	O
patients	O
with	O
SLE	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
B	O
cell	O
source	O
.	O
	
These	O
cells	O
were	O
examined	O
for	O
ER	B-RNA
mRNA	I-RNA
by	O
reverse	O
transcription	O
nested	O
polymerase	O
chain	O
reaction	O
.	O
	
Amplified	O
cDNA	B-DNA
were	O
sequenced	O
by	O
standard	O
methods	O
.	O
	
RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	B-RNA
mRNA	I-RNA
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O
	
Partial	O
sequences	O
from	O
exons	B-DNA
1-8	I-DNA
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	B-RNA
ER	I-RNA
mRNA	I-RNA
.	O
	
There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B-RNA
transcripts	I-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O
	
Variant	O
receptor	O
transcripts	O
lacking	O
exon	B-DNA
5	I-DNA
or	O
exon	B-DNA
7	I-DNA
,	O
which	O
encodes	O
the	O
hormone	O
binding	O
domain	O
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O
	
Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O
	
Whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	O
receptor	O
proteins	O
remains	O
to	O
be	O
determined	O
.	O
	
In	O
vitro	O
stimulation	O
did	O
not	O
affect	O
ER	B-RNA
mRNA	I-RNA
expression	O
.	O
	
The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O
	
CONCLUSION	O
:	O
Monocytes	B-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	B-protein
type	I-protein
ER	I-protein
and	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
variants	I-protein
in	O
vivo	O
.	O
	
###MEDLINE:98325368	
	
DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
and	O
subsequent	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
.	O
	
Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O
	
We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	B-protein
is	O
crucially	O
involved	O
in	O
FasL	B-protein
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O
	
A	O
nondegradable	O
mutant	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
blocked	O
both	O
FasL	B-protein
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	B-protein
ligation	O
.	O
	
These	O
stimuli	O
also	O
induced	O
the	O
stress-activated	O
kinase	O
pathway	O
(	O
SAPK	B-protein
/JNK	B-protein
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O
	
A	O
1.2	O
kb	O
FasL	B-DNA
promoter	I-DNA
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B-protein
Rel	I-protein
or	O
Fos/Jun	B-protein
.	O
	
Mutations	O
in	O
the	O
relevant	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
eliminated	O
these	O
responses	O
.	O
	
Thus	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
contributes	O
to	O
stress-induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	B-protein
.	O
	
###MEDLINE:98322350	
	
A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
[	O
see	O
commetns	O
]	O
	
A	O
nonpeptidyl	O
small	O
molecule	O
SB	O
247464	O
,	O
capable	O
of	O
activating	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
signal	O
transduction	O
pathways	O
,	O
was	O
identified	O
in	O
a	O
high-throughput	O
assay	O
in	O
cultured	B-cell_type
cells	I-cell_type
.	O
	
Like	O
G-CSF	B-protein
,	O
SB	O
247464	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
signaling	I-protein
proteins	I-protein
and	O
stimulated	O
primary	B-cell_type
murine	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
to	O
form	O
granulocytic	B-cell_type
colonies	I-cell_type
in	O
vitro	O
.	O
	
It	O
also	O
elevated	O
peripheral	B-cell_type
blood	I-cell_type
neutrophil	I-cell_type
counts	O
in	O
mice	O
.	O
	
The	O
extracellular	O
domain	O
of	O
the	O
murine	B-protein
G-CSF	I-protein
receptor	I-protein
was	O
required	O
for	O
the	O
activity	O
of	O
SB	O
247464	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O
	
The	O
results	O
indicate	O
that	O
a	O
small	O
molecule	O
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	O
ligand	O
.	O
	
###MEDLINE:98305722	
	
Minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
PML/RAR	B-RNA
alpha	I-RNA
or	I-RNA
AML1/ETO	I-RNA
mRNA	I-RNA
and	O
phenotypic	O
analysis	O
of	O
possible	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
.	O
	
Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	B-protein
alpha	I-protein
or	O
AML1/ETO	B-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	B-cell_type
subsets	I-cell_type
involved	O
in	O
antitumor	O
immunity	O
.	O
	
Eight	O
patients	O
in	O
long-term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short-term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O
	
Using	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML/RAR	B-RNA
alpha	I-RNA
transcript	I-RNA
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1/ETO	B-RNA
transcript	I-RNA
.	O
	
Simultaneously	O
,	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
and	O
NK	B-cell_type
cells	I-cell_type
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O
	
Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD-positive	O
.	O
	
Although	O
all	O
MRD-positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	O
the	O
7	O
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O
	
The	O
total	O
populations	O
of	O
CD4	B-protein
+	O
,	O
CD8	B-protein
+	O
and	O
CD56	B-protein
+	O
[	O
possible	O
T-cell	B-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
(	O
T/NK	B-cell_type
)	O
populations	O
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+/LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O
	
The	O
CD8	B-protein
+	O
CD28	B-protein
+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O
	
The	O
T/NK	B-cell_type
subsets	I-cell_type
in	O
the	O
BM	O
of	O
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O
	
Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4+	B-cell_type
,	I-cell_type
CD8+	I-cell_type
and	I-cell_type
CD56+	I-cell_type
cell	I-cell_type
populations	I-cell_type
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-/LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+/LT	O
patients	O
and	O
MRD+	O
or	O
-/ST	O
patients	O
.	O
	
The	O
percentages	O
of	O
the	O
T/NK-cell	B-cell_type
subsets	I-cell_type
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O
	
Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T/NK-cell	B-cell_type
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O
	
These	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti-tumor	O
immunity	O
of	O
T/NK	B-cell_type
cells	I-cell_type
of	O
AML	O
in	O
remission	O
.	O
	
###MEDLINE:98295832	
	
Mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	B-protein
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O
	
The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	B-cell_type
cell	I-cell_type
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O
	
These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4-expressing	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O
	
Using	O
the	O
1G5	B-cell_line
cell	I-cell_line
line	I-cell_line
harbouring	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	B-DNA
LTR-dependent	I-DNA
gene	I-DNA
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O
	
The	O
implication	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
s	I-protein
)	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	B-DNA
LTR-driven	I-DNA
gene	I-DNA
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O
	
It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
.	O
	
M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	B-DNA
gene	I-DNA
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	B-DNA
,	I-DNA
but	I-DNA
not	I-DNA
the	I-DNA
kappaB-mutated	I-DNA
,	I-DNA
HIV-1	I-DNA
LTR	I-DNA
region	I-DNA
.	O
	
Finally	O
,	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	B-protein
TNF-alpha	I-protein
.	O
	
The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O
	
###MEDLINE:98230439	
	
Human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
quasispecies	I-DNA
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	B-protein
factor	I-protein
recruitment	O
in	O
human	B-cell_type
glial	I-cell_type
cells	I-cell_type
and	I-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	B-DNA
genome	I-DNA
.	O
	
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
sequence	O
diversity	O
on	O
LTR-directed	B-DNA
gene	I-DNA
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	B-DNA
from	O
proviral	B-DNA
DNA	I-DNA
in	O
HIV-1-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
.	O
	
Sequence	O
analysis	O
of	O
nineteen	O
LTRs	B-DNA
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	B-DNA
LTR	I-DNA
)	O
within	O
the	O
455-bp	B-DNA
U3	I-DNA
region	I-DNA
.	O
	
Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	B-DNA
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	B-DNA
LTR	I-DNA
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
(	O
an	O
astrocytoma	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
as	O
well	O
as	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
CD4-positive	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O
	
While	O
LTRs	B-DNA
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	B-DNA
were	O
generally	O
more	O
active	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
when	O
compared	O
to	O
the	O
LAI	B-DNA
LTR	I-DNA
.	O
	
Differences	O
in	O
LTR	B-DNA
sequence	I-DNA
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis-acting	B-DNA
sites	I-DNA
within	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	B-protein
factor	I-protein
binding	O
to	O
an	O
activating	B-DNA
transcription	I-DNA
factor/cAMP	I-DNA
response	I-DNA
element	I-DNA
binding	I-DNA
(	I-DNA
ATF/CREB	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
(	O
located	O
between	O
the	O
LEF-1	B-DNA
and	I-DNA
distal	I-DNA
NF-kappaB	I-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O
	
These	O
findings	O
suggest	O
that	O
LTR	B-DNA
sequence	I-DNA
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	B-DNA
function	O
and	O
transcription	B-protein
factor	I-protein
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O
	
###MEDLINE:98282480	
	
HMG	B-protein
box	I-protein
containing	O
transcription	B-protein
factors	I-protein
in	O
lymphocyte	B-cell_type
differentiation	O
.	O
	
The	O
identification	O
of	O
the	O
mammalian	B-DNA
sex-determining	I-DNA
gene	I-DNA
Sry	I-DNA
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
family	O
of	O
related	O
(	O
'	O
HMG	B-protein
box	I-protein
'	O
)	O
transcription	B-protein
factors	I-protein
that	O
control	O
developmental	O
events	O
in	O
yeast	O
,	O
C.	O
elegans	O
,	O
Drosophila	O
and	O
vertebrates	O
.	O
	
In	O
lymphocyte	B-cell_type
differentiation	O
,	O
several	O
HMG	B-protein
box	I-protein
proteins	I-protein
play	O
a	O
decisive	O
role	O
.	O
	
Sox-4	B-protein
is	O
important	O
for	O
very	O
early	O
B-cell	O
differentiation	O
,	O
while	O
TCF-1/LEF-1	B-protein
play	O
a	O
crucial	O
role	O
in	O
early	O
thymocyte	O
development	O
.	O
	
TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless/Wnt	O
signal	O
transduction	O
pathway	O
.	O
	
In	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
Xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O
	
Deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	O
tumors	O
.	O
	
These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF/LEF	B-protein
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B-protein
box	I-protein
proteins	I-protein
in	O
lymphoid	O
development	O
	
###MEDLINE:93315600	
	
Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
mutations	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
:	O
application	O
for	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
therapy	O
.	O
	
Recent	O
studies	O
indicate	O
that	O
mutations	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
are	O
associated	O
with	O
androgen	O
insensitivity	O
syndromes	O
,	O
a	O
heterogeneous	O
group	O
of	O
related	O
disorders	O
involving	O
defective	O
sexual	O
differentiation	O
in	O
karyotypic	O
males	O
.	O
	
In	O
this	O
report	O
,	O
we	O
address	O
the	O
possibility	O
of	O
rapid	O
mutational	O
analysis	O
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
for	O
initial	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
molecular	O
subclassification	O
of	O
affected	O
patients	O
and	O
their	O
families	O
.	O
	
DNA	O
from	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
of	O
six	O
patients	O
from	O
five	O
families	O
with	O
various	O
degrees	O
of	O
androgen	O
insensitivity	O
was	O
studied	O
.	O
	
Exons	B-DNA
2	I-DNA
to	I-DNA
8	I-DNA
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
were	O
analyzed	O
using	O
a	O
combination	O
of	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
DNA	O
sequencing	O
.	O
	
Female	O
family	O
members	O
were	O
also	O
studied	O
to	O
identify	O
heterozygote	O
carriers	O
.	O
	
Point	O
mutations	O
in	O
the	O
AR	B-DNA
gene	I-DNA
were	O
identified	O
in	O
all	O
six	O
patients	O
,	O
and	O
all	O
mutations	O
caused	O
amino	O
acid	O
substitutions	O
.	O
	
One	O
patient	O
with	O
incomplete	O
androgen	O
insensitivity	O
was	O
a	O
mosaic	O
for	O
the	O
mutation	O
.	O
	
Four	O
of	O
the	O
five	O
mothers	O
,	O
as	O
well	O
as	O
a	O
young	O
sister	O
of	O
one	O
patient	O
,	O
were	O
carriers	O
of	O
the	O
mutation	O
present	O
in	O
the	O
affected	O
child	O
.	O
	
Our	O
data	O
show	O
that	O
new	O
mutations	O
may	O
occur	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
leading	O
to	O
sporadic	O
androgen	O
insensitivity	O
syndrome	O
.	O
	
Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	B-DNA
allele	I-DNA
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O
	
The	O
identification	O
of	O
carriers	O
is	O
of	O
substantial	O
clinical	O
importance	O
for	O
genetic	O
counseling	O
.	O
	
###MEDLINE:93284506	
	
Proliferation	O
index	O
as	O
a	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O
	
BACKGROUND	O
.	O
	
The	O
proliferative	O
activity	O
of	O
tumors	O
has	O
been	O
extensively	O
investigated	O
with	O
different	O
approaches	O
,	O
among	O
which	O
the	O
use	O
of	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	I-protein
represents	O
an	O
easy	O
and	O
reliable	O
means	O
of	O
assessing	O
cell	O
proliferation	O
.	O
	
In	O
this	O
study	O
,	O
the	O
proliferative	O
activity	O
of	O
129	O
primary	O
breast	O
cancers	O
was	O
investigated	O
,	O
and	O
the	O
results	O
were	O
related	O
to	O
prognosis	O
.	O
	
METHODS	O
.	O
	
Tumor	O
samples	O
,	O
obtained	O
from	O
129	O
patients	O
who	O
underwent	O
surgery	O
between	O
January	O
1987	O
and	O
December	O
1988	O
,	O
were	O
processed	O
for	O
staining	O
by	O
an	O
immunohistochemical	O
procedure	O
(	O
avidin-biotin	B-protein
complex	I-protein
)	O
.	O
	
The	O
median	O
time	O
of	O
observation	O
was	O
42	O
months	O
(	O
range	O
,	O
31-55	O
months	O
)	O
.	O
	
Life-table	O
analysis	O
(	O
Mantel-Cox	O
)	O
was	O
used	O
to	O
assess	O
the	O
probability	O
of	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
RESULTS	O
.	O
	
Tumors	O
with	O
high	O
Ki-67	B-protein
proliferation	O
indices	O
(	O
>	O
20	O
%	O
)	O
were	O
associated	O
with	O
a	O
higher	O
4-year	O
probability	O
of	O
relapse	O
of	O
disease	O
(	O
55.3	O
%	O
versus	O
79.1	O
%	O
;	O
P	O
=	O
0.003	O
)	O
and	O
death	O
(	O
71	O
%	O
versus	O
95.6	O
%	O
;	O
P	O
=	O
0.00005	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
low	O
Ki-67	B-protein
values	O
.	O
	
In	O
addition	O
,	O
this	O
proliferative	O
parameter	O
maintained	O
its	O
prognostic	O
significance	O
when	O
the	O
patients	O
were	O
stratified	O
according	O
to	O
lymph	O
node	O
involvement	O
,	O
menopausal	O
status	O
,	O
and	O
nuclear	B-protein
estrogen	I-protein
receptor	I-protein
content	O
.	O
	
CONCLUSIONS	O
.	O
	
Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	I-protein
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O
	
###MEDLINE:93262492	
	
Regulation	O
of	O
the	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
Elf-1	B-protein
by	O
binding	O
to	O
the	O
retinoblastoma	B-protein
protein	I-protein
.	O
	
The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
is	O
a	O
nuclear	B-protein
phosphoprotein	I-protein
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O
	
Elf-1	B-protein
is	O
a	O
lymphoid-specific	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
	
In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf-1	B-protein
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	B-protein
binding	I-protein
sites	I-protein
of	O
several	O
viral	O
oncoproteins	B-protein
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
Elf-1	B-protein
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	B-protein
and	O
fails	O
to	O
bind	O
to	O
Rb	B-protein
mutants	I-protein
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O
	
Co-immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf-1	B-protein
and	O
Rb	B-protein
in	O
resting	B-cell_type
normal	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	O
of	O
Rb	B-protein
results	O
in	O
the	O
release	O
of	O
Elf-1	B-protein
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf-1	B-protein
-mediated	O
transcription	O
.	O
	
Overexpression	O
of	O
a	O
phosphorylation-defective	O
form	O
of	O
Rb	B-protein
inhibited	O
Elf-1	B-protein
-dependent	O
transcription	O
during	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
	
These	O
results	O
demonstrate	O
that	O
Rb	B-protein
interacts	O
specifically	O
with	O
a	O
lineage-restricted	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
.	O
	
This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage-specific	O
effector	O
functions	O
such	O
as	O
lymphokine	B-protein
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:93238864	
	
Human	B-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
cells	I-cell_line
express	O
the	O
hGATA-3	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
and	O
an	O
unrearranged	O
2.3-kb	B-protein
TcR	I-protein
delta	I-protein
transcript	I-protein
.	O
	
In	O
this	O
study	O
we	O
analyzed	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TcR	I-protein
)	I-protein
delta	I-protein
transcripts	I-protein
expressed	O
by	O
CD3-CD16+	B-cell_line
cells	I-cell_line
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA-3	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
and	O
the	O
recombination-activating	B-DNA
gene	I-DNA
(	I-DNA
RAG	I-DNA
)	I-DNA
-1	I-DNA
.	O
	
Multiple	O
TcR	B-protein
delta	I-protein
transcripts	I-protein
deriving	O
from	O
an	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
were	O
detected	O
in	O
both	O
polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Two	O
unrearranged	O
TcR	B-protein
delta	I-protein
transcripts	I-protein
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	B-RNA
delta	I-RNA
mRNA	I-RNA
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	O
in	O
TcR	B-cell_line
gamma/delta+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Sequence	O
analysis	O
of	O
nine	O
different	O
2.3-kb	O
cDNA	O
clones	O
obtained	O
from	O
NK-derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
.	O
	
These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
J	B-DNA
delta	I-DNA
1	I-DNA
segment	I-DNA
.	O
	
The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	B-DNA
delta	I-DNA
1	I-DNA
segment	I-DNA
corresponded	O
to	O
the	O
previously	O
reported	O
germ-line	O
sequence	O
.	O
	
The	O
J	B-DNA
delta	I-DNA
1	I-DNA
segment	I-DNA
was	O
correctly	O
spliced	O
to	O
C	B-DNA
delta	I-DNA
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O
	
Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	B-DNA
C	I-DNA
delta	I-DNA
exon	I-DNA
.	O
	
However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3-kb	B-DNA
cDNA	I-DNA
.	O
	
The	O
expression	O
of	O
hGATA-3	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
factor	I-protein
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	B-DNA
delta	I-DNA
locus	I-DNA
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	B-cell_line
cell	I-cell_line
population	I-cell_line
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O
	
All	O
NK	B-cell_line
clones	I-cell_line
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
hGATA-3	B-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
expression	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O
	
Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	B-DNA
gene	I-DNA
could	O
be	O
detected	O
in	O
all	O
NK	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
clones	O
analyzed	O
.	O
	
###MEDLINE:93232271	
	
Negative	O
transcriptional	O
regulation	O
of	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O
	
IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
affected	O
by	O
several	O
nuclear	B-protein
proteins	I-protein
.	O
	
We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL-2	B-DNA
gene	I-DNA
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
IL-2	O
promoter	O
.	O
	
Nuclear	O
extracts	O
from	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O
	
Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	B-protein
and	O
NF-AT	B-protein
,	O
but	O
not	O
of	O
NF-kB	B-protein
and	O
OCT-1/OAF	B-protein
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O
	
To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL-2	B-DNA
promoter	I-DNA
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O
	
Jurkat	B-cell_line
cells	I-cell_line
were	O
transfected	O
with	O
plasmids	B-DNA
containing	O
either	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
or	O
its	O
AP-1	B-DNA
,	I-DNA
NF-AT	I-DNA
,	I-DNA
and	I-DNA
NF-kB	I-DNA
motifs	I-DNA
.	O
	
Dex	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
AP-1	B-DNA
,	O
but	O
not	O
the	O
NF-AT	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O
	
In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
NF-AT	B-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O
	
These	O
results	O
suggest	O
that	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL-2	B-DNA
gene	I-DNA
transcription	O
through	O
interference	O
with	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O
	
We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	B-protein
factors	I-protein
,	O
AP-1	B-protein
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O
	
###MEDLINE:93322080	
	
Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O
	
Exposure	O
of	O
certain	O
cell	O
types	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
an	O
inducible	B-protein
transcription	I-protein
factor	I-protein
.	O
	
One	O
of	O
NF-kappa	B-protein
B	I-protein
's	O
unique	O
properties	O
is	O
its	O
posttranslational	O
activation	O
via	O
release	O
of	O
an	O
inhibitory	B-protein
subunit	I-protein
,	O
called	O
inhibitor	B-protein
of	I-protein
NF-kappa	I-protein
B	I-protein
(	O
I	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
from	O
a	O
sequestered	O
cytoplasmic	O
form	O
.	O
	
This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O
	
Other	O
bacterial	O
toxins	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
,	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
T	B-protein
cell	I-protein
mitogens	I-protein
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
.	O
	
The	O
activated	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
rapidly	O
taken	O
up	O
into	O
nuclei	O
,	O
initiates	O
transcription	O
from	O
immediate	O
early	O
genes	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O
	
Most	O
of	O
the	O
target	O
genes	O
for	O
NF-kappa	B-protein
B	I-protein
are	O
of	O
relevance	O
for	O
the	O
immune	O
response	O
and	O
can	O
be	O
grouped	O
into	O
those	O
encoding	O
cytokines	B-protein
,	O
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
acute	B-protein
phase	I-protein
proteins	I-protein
and	O
viral	B-DNA
genomes	I-DNA
,	O
such	O
as	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O
	
We	O
will	O
discuss	O
recent	O
experimental	O
evidences	O
suggesting	O
that	O
LPS	O
might	O
share	O
a	O
pathway	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
with	O
other	O
inducers	O
of	O
the	O
factor	O
.	O
	
This	O
common	O
pathway	O
may	O
involve	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
as	O
messenger	O
molecules	O
.	O
	
###MEDLINE:93260875	
	
[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	B-cell_type
]	O
	
Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	B-cell_type
biology	O
since	O
genes	O
association	O
with	O
eosinophils	B-cell_type
such	O
as	O
interleukin-5	B-protein
or	O
eosinophil	B-protein
granule	I-protein
proteins	I-protein
(	O
EPO	B-protein
,	O
ECP	B-protein
,	O
EDN	B-protein
,	O
MBP	B-protein
,	O
and	O
CLC	B-protein
)	O
,	O
were	O
isolated	O
.	O
	
However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	B-cell_type
lineage	I-cell_type
has	O
not	O
been	O
determined	O
.	O
	
The	O
mechanism	O
by	O
which	O
eosinophil-specific	B-DNA
genes	I-DNA
encoding	O
primary	O
and	O
secondary	B-protein
granule	I-protein
proteins	I-protein
(	O
e.g	O
.	O
ECP	B-protein
,	O
EDN	B-protein
,	O
EPO	B-protein
,	O
MBP	B-protein
,	O
and	O
CLC	B-protein
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O
	
In	O
this	O
paper	O
,	O
I	O
described	O
the	O
characterization	O
of	O
genes	O
encoding	O
eosinophil	B-protein
granule	I-protein
proteins	I-protein
and	O
the	O
mRNA	O
expression	O
of	O
GATA-1	B-protein
binding	I-protein
transcription	I-protein
factor	I-protein
during	O
eosinophil	O
differentiation	O
.	O
	
###MEDLINE:93155114	
	
Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid-specific	B-protein
nuclear	I-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NF-AT	B-protein
)	O
complex	O
.	O
	
The	O
lymphoid-specific	B-protein
transcription	I-protein
complex	I-protein
,	O
NF-AT	B-protein
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
is	O
assembled	O
from	O
a	O
pre-existing	O
,	O
T	B-protein
cell	I-protein
restricted	I-protein
cytoplasmic	I-protein
factor	I-protein
and	O
an	O
inducible	O
ubiquitous	B-protein
nuclear	B-protein
component	I-protein
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	B-protein
receptor	I-protein
.	O
	
Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	B-protein
factors	I-protein
as	O
components	O
of	O
the	O
murine	B-protein
NF-AT	I-protein
complex	I-protein
.	O
	
Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	B-protein
NF-AT	I-protein
contains	O
the	O
phorbol	B-protein
ester-inducible	I-protein
transcription	I-protein
factor	I-protein
AP1	I-protein
(	O
Jun/Fos	B-protein
)	O
.	O
	
We	O
further	O
characterize	O
which	O
AP1	B-protein
family	I-protein
members	I-protein
can	O
assume	O
this	O
role	O
.	O
	
Antisera	O
to	O
Fos	B-protein
inhibits	O
NF-AT	B-protein
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	B-DNA
site	I-DNA
for	I-DNA
AP1	I-DNA
.	O
	
Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra-1	B-protein
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF-AT	B-protein
-directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O
	
Overexpression	O
of	O
cJun	B-protein
or	O
JunD	B-protein
,	O
but	O
not	O
JunB	B-protein
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	O
that	O
many	O
but	O
not	O
all	O
Jun-	B-protein
and	I-protein
Fos-related	I-protein
proteins	I-protein
functionally	O
activate	O
NF-AT	B-protein
-dependent	O
transcription	O
in	O
the	O
presence	O
of	O
the	O
cytoplasmic	O
component	O
.	O
	
NF-AT	B-protein
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi-purified	B-protein
AP1	I-protein
proteins	I-protein
mixed	O
with	O
cytosol	O
from	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	B-protein
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF-AT	B-protein
DNA	I-protein
binding	I-protein
complex	I-protein
.	O
	
Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF-AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O
	
###MEDLINE:93289270	
	
Glucocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
sepsis	O
.	O
	
Glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
hormone-binding	O
activity	O
was	O
studied	O
by	O
a	O
whole-cell	O
method	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
MNC	B-cell_type
)	O
from	O
peripheral	O
blood	O
of	O
7	O
patients	O
during	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O
	
4	O
patients	O
were	O
receiving	O
dopamine	O
,	O
which	O
did	O
not	O
affect	O
the	O
GR	B-protein
count	O
.	O
	
The	O
patients	O
'	O
plasma	O
cortisol	O
concentrations	O
were	O
normal	O
or	O
slightly	O
elevated	O
.	O
	
Despite	O
a	O
wide	O
range	O
,	O
the	O
mean	O
GR	B-protein
count	O
and	O
affinity	O
in	O
MNC	B-cell_type
from	O
septic	O
patients	O
did	O
not	O
differ	O
from	O
those	O
in	O
normal	O
controls	O
,	O
suggesting	O
that	O
glucocorticoids	O
could	O
still	O
be	O
effective	O
in	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O
	
###MEDLINE:94026053	
	
The	O
impaired	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
DNA	O
binding	O
activity	O
in	O
lymphocytes	B-cell_type
derived	O
from	O
subjects	O
with	O
some	O
symptoms	O
of	O
premature	O
aging	O
.	O
	
The	O
study	O
of	O
human	O
disorders	O
known	O
as	O
premature	O
aging	O
syndromes	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
cellular	O
senescence	O
.	O
	
The	O
main	O
feature	O
of	O
cellular	O
senescence	O
in	O
vitro	O
is	O
cessation	O
of	O
cell	O
proliferation	O
.	O
	
Down	O
syndrome	O
(	O
DS	O
)	O
and	O
neuronal	O
ceroid-lypofuscinosis	O
(	O
NCL	O
)	O
are	O
clinically	O
characterized	O
by	O
the	O
premature	O
onset	O
of	O
numerous	O
features	O
normally	O
associated	O
with	O
human	O
aging	O
.	O
	
Phytohemagglutinin	B-protein
stimulated	O
lymphocytes	B-cell_type
derived	O
from	O
DS	O
subjects	O
showed	O
a	O
statistically	O
significant	O
diminished	O
proliferation	O
capacity	O
in	O
comparison	O
with	O
lymphocytes	B-cell_type
derived	O
from	O
NCL	O
and	O
healthy	O
individuals	O
.	O
	
We	O
demonstrated	O
,	O
by	O
applying	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
slightly	O
impaired	O
AP-1	B-protein
DNA	O
binding	O
activity	O
in	O
NCL	B-cell_type
lymphocytes	I-cell_type
and	O
strong	O
in	O
DS	B-cell_type
ones	I-cell_type
.	O
	
Our	O
results	O
showed	O
that	O
the	O
same	O
molecular	O
mechanisms	O
of	O
proliferation	O
cessation	O
could	O
exist	O
in	O
fibroblasts	B-cell_type
characterized	O
by	O
replicative	O
senescence	O
and	O
in	O
lymphocytes	B-cell_type
derived	O
from	O
individuals	O
with	O
premature	O
aging	O
syndromes	O
(	O
Down	O
	
###MEDLINE:93287269	
	
Differential	O
contribution	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
1	I-protein
gene	I-protein
products	I-protein
and	O
cellular	B-protein
factors	I-protein
to	O
the	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
provirus	O
.	O
	
We	O
have	O
previously	O
reported	O
that	O
infection	O
with	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
activates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
provirus	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Activation	O
of	O
the	O
HIV-1	O
provirus	O
correlated	O
with	O
the	O
activation	O
of	O
binding	O
of	O
55-	B-protein
and	I-protein
85-kDa	I-protein
proteins	I-protein
to	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
and	O
binding	O
of	O
the	O
50-kDa	B-protein
HLP-1	I-protein
protein	I-protein
to	O
the	O
LBP-1	B-DNA
sequences	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
Further	O
examination	O
of	O
this	O
system	O
has	O
shown	O
that	O
the	O
inhibition	O
of	O
HSV-1	O
replication	O
by	O
the	O
antiviral	O
drug	O
acyclovir	O
does	O
not	O
inhibit	O
HSV-1-mediated	O
induction	O
of	O
HIV-1	O
provirus	O
.	O
	
Surprisingly	O
,	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
HLP-1	O
binding	O
activities	O
were	O
substantially	O
inhibited	O
in	O
acyclovir-treated	B-cell_line
cells	I-cell_line
.	O
	
In	O
the	O
transient-transfection	O
assay	O
,	O
ICP0	B-protein
,	O
but	O
not	O
ICP4	B-protein
,	O
activated	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
promoter	I-DNA
region	I-DNA
and	O
the	O
effect	O
of	O
ICP0	B-protein
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
,	O
suggesting	O
that	O
induction	O
of	O
the	O
HIV-1	O
provirus	O
involves	O
cooperation	O
between	O
the	O
HSV-1-activated	B-protein
cellular	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
virus-encoded	B-protein
transactivator	I-protein
,	O
ICP0	B-protein
.	O
	
###MEDLINE:93294310	
	
Transcriptional	O
activation	O
of	O
the	O
macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
protein	I-protein
by	O
monocytes	B-cell_type
and	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O
	
Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
Mo	B-cell_type
)	O
constitutively	O
display	O
the	O
beta-chain	O
of	O
the	O
receptor	O
for	O
IL-2	B-protein
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	B-protein
.	O
	
Here	O
we	O
report	O
that	O
binding	O
of	O
human	B-protein
IL-2	I-protein
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	B-DNA
CSF	I-DNA
(	I-DNA
M-CSF	I-DNA
)	I-DNA
gene	I-DNA
in	O
Mo	B-cell_type
resulting	O
in	O
accumulation	O
of	O
M-CSF	B-RNA
mRNA	I-RNA
and	O
subsequent	O
release	O
of	O
bioactive	O
M-CSF	B-protein
protein	I-protein
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL-2	B-protein
induced	O
release	O
of	O
an	O
activity-stimulating	O
growth	O
of	O
monocyte-type	B-cell_line
colonies	I-cell_line
by	O
a	O
neutralizing	O
anti-M-CSF	B-protein
antibody	I-protein
.	O
	
Transcriptional	O
activation	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
.	O
	
Moreover	O
,	O
using	O
a	O
heterologous	B-DNA
promoter	I-DNA
(	I-DNA
herpes	I-DNA
thymidine	I-DNA
kinase	I-DNA
)	I-DNA
construct	I-DNA
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sequence	I-DNA
,	O
it	O
is	O
shown	O
that	O
NF-kappa	B-protein
B	I-protein
binding	O
by	O
an	O
IL-2-induced	B-protein
monocyte-derived	I-protein
nuclear	I-protein
protein	I-protein
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O
	
Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL-2	B-protein
induces	O
gene	O
expression	O
of	O
M-CSF	B-protein
in	O
human	B-cell_type
blood-derived	I-cell_type
Mo	I-cell_type
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O
	
###MEDLINE:93268332	
	
Regulation	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
(	I-DNA
IL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
by	O
mycobacterial	B-protein
components	I-protein
and	O
lipopolysaccharide	O
is	O
mediated	O
by	O
two	O
nuclear	B-DNA
factor-IL6	I-DNA
motifs	I-DNA
.	O
	
The	O
cytokines	O
interleukin-1	O
beta	O
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B-protein
)	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
in	O
vitro	O
after	O
stimulation	O
with	O
mycobacteria	O
and	O
are	O
considered	O
to	O
mediate	O
pathophysiologic	O
events	O
,	O
including	O
granuloma	O
formation	O
and	O
systemic	O
symptoms	O
.	O
	
We	O
demonstrated	O
that	O
the	O
Mycobacterium	O
tuberculosis	O
cell	O
wall	O
component	O
lipoarabinomannan	O
(	O
LAM	O
)	O
is	O
a	O
very	O
potent	O
inducer	O
of	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
investigated	O
the	O
mechanism	O
of	O
this	O
effect	O
.	O
	
We	O
localized	O
the	O
LAM-	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
,	O
and	O
TNF-alpha	B-protein
-inducible	B-DNA
promoter	I-DNA
activity	O
to	O
a	O
-131/+15	O
(	O
positions	O
-131	O
to	O
+15	O
)	O
DNA	O
fragment	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
.	O
	
Within	O
this	O
DNA	O
fragment	O
,	O
there	O
were	O
two	O
novel	O
9-bp	O
motifs	O
(	O
-90/-82	O
and	O
-40/-32	O
)	O
with	O
high	O
homology	O
to	O
the	O
nuclear	B-DNA
factor-IL6	I-DNA
(	I-DNA
NF-IL6	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
Site-directed	O
mutagenesis	O
demonstrated	O
that	O
the	O
two	O
NF-IL-6	B-DNA
motifs	I-DNA
could	O
be	O
independently	O
activated	O
by	O
LAM	O
,	O
LPS	O
,	O
or	O
TNF-alpha	B-protein
and	O
that	O
they	O
acted	O
in	O
an	O
orientation-independent	O
manner	O
.	O
	
DNA	O
mobility	O
shift	O
assay	O
revealed	O
specific	O
binding	O
of	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
from	O
LAM-	B-cell_line
,	I-cell_line
LPS-	I-cell_line
,	I-cell_line
or	I-cell_line
TNF-alpha-	I-cell_line
stimulated	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
to	O
the	O
NF-IL6	O
motifs	O
.	O
	
We	O
conclude	O
that	O
the	O
two	O
NF-IL6	B-DNA
sites	I-DNA
mediate	O
induction	O
of	O
IL-1	B-protein
beta	I-protein
in	O
response	O
to	O
the	O
stimuli	O
LAM	O
,	O
LPS	O
,	O
and	O
TNF-alpha	B-protein
.	O
	
###MEDLINE:93242763	
	
HIV-1	B-protein
Nef	I-protein
protein	I-protein
inhibits	O
the	O
recruitment	O
of	O
AP-1	B-protein
DNA-binding	O
activity	O
in	O
human	B-cell_type
T-cells	I-cell_type
.	O
	
The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
HIV-1-LTR	B-DNA
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV-1	B-DNA
gene	I-DNA
expression	O
.	O
	
Our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
the	O
HIV-1-encoded	B-protein
Nef	I-protein
protein	I-protein
suggested	O
that	O
Nef	B-protein
may	O
be	O
an	O
inhibitor	O
HIV-1	O
transcription	O
.	O
	
To	O
determine	O
whether	O
Nef	B-protein
affects	O
the	O
binding	O
of	O
cellular	B-protein
factors	I-protein
implicated	O
in	O
HIV-1	O
regulation	O
,	O
32P-labeled	O
oligonucleotides	O
corresponding	O
to	O
the	O
binding	O
sites	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
prepared	O
from	O
Nef-expressing	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
that	O
were	O
not	O
stimulated	O
or	O
were	O
stimulated	O
with	O
T-cell	B-protein
mitogens	I-protein
.	O
	
We	O
found	O
that	O
Nef	B-protein
inhibited	O
the	O
recruitment	O
of	O
AP-1	B-protein
DNA-binding	O
activity	O
in	O
mitogen-stimulated	O
human	B-cell_type
T-cells	I-cell_type
.	O
	
Additionally	O
,	O
Nef	B-cell_line
expressing	I-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV-1	B-DNA
AP-1	I-DNA
DNA	I-DNA
recognition	I-DNA
sequences	I-DNA
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
.	O
	
Mitogen-mediated	O
transcriptional	O
activation	O
of	O
the	O
CAT	B-DNA
gene	I-DNA
in	O
this	O
construct	O
was	O
inhibited	O
in	O
Nef-expressing	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
control	O
cells	O
.	O
	
These	O
studies	O
suggest	O
that	O
,	O
by	O
inhibiting	O
AP-1	B-protein
activation	O
,	O
Nef	B-protein
may	O
play	O
a	O
role	O
in	O
regulating	O
HIV-1	B-DNA
gene	I-DNA
expression	O
in	O
infected	B-cell_type
T-cells	I-cell_type
.	O
	
###MEDLINE:93278095	
	
Regulation	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
.	O
	
Transcription	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
cluster	I-DNA
depends	O
upon	O
upstream	B-DNA
regulatory	I-DNA
sequences	I-DNA
,	O
which	O
are	O
collectively	O
termed	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
.	O
	
Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	O
through	O
development	O
.	O
	
The	O
crux	O
of	O
transcriptional	O
activation	O
is	O
how	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
communicates	O
with	O
the	O
gene-proximal	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O
	
###MEDLINE:93346062	
	
Enhancing	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
human	O
NK	O
cell	O
activity	O
.	O
	
The	O
in	O
vitro	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
NK	O
activity	O
was	O
studied	O
.	O
	
The	O
proliferation	O
and	O
NK	O
activity	O
of	O
YT-N17	B-cell_line
(	O
a	O
human	B-cell_line
NK-like	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
were	O
enhanced	O
by	O
17	O
beta-estradiol	O
(	O
E2	O
)	O
,	O
and	O
the	O
enhancement	O
was	O
blocked	O
by	O
tamoxifen	O
(	O
Tx	O
)	O
,	O
an	O
antagonist	O
of	O
E2	O
.	O
	
On	O
the	O
contrary	O
,	O
other	O
steroid	O
hormones	O
such	O
as	O
Tx	O
,	O
progesterone	O
,	O
and	O
testosterone	O
had	O
no	O
effect	O
.	O
	
YT-N17	B-cell_line
contained	O
11.8	O
fmol/mg	O
protein	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
mean	O
of	O
two	O
independent	O
assays	O
)	O
,	O
a	O
value	O
which	O
was	O
5-10-fold	O
higher	O
than	O
that	O
of	O
other	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
An	O
enhancement	O
of	O
NK	O
activity	O
by	O
E2	O
was	O
also	O
seen	O
in	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
obtained	O
from	O
normal	O
subjects	O
,	O
and	O
it	O
was	O
again	O
suppressed	O
by	O
Tx	O
.	O
	
These	O
data	O
suggest	O
that	O
E2	O
is	O
one	O
of	O
the	O
activating	O
factors	O
for	O
NK/LGL	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:93186809	
	
A	O
serum	B-DNA
response	I-DNA
element	I-DNA
and	O
a	O
binding	B-DNA
site	I-DNA
for	I-DNA
NF-Y	I-DNA
mediate	O
the	O
serum	O
response	O
of	O
the	O
human	B-DNA
thrombospondin	I-DNA
1	I-DNA
gene	I-DNA
.	O
	
The	O
expression	O
of	O
thrombospondin	B-protein
1	I-protein
(	O
TSP	B-protein
1	I-protein
)	O
,	O
a	O
member	O
of	O
the	O
TSP	B-DNA
gene	I-DNA
family	I-DNA
,	O
is	O
rapidly	O
induced	O
by	O
growth	O
factors	O
.	O
	
We	O
tested	O
the	O
ability	O
of	O
human	B-DNA
TSP	I-DNA
1-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
to	O
respond	O
to	O
serum	O
in	O
stably	O
transfected	O
NIH-3T3	O
cells	O
.	O
	
Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	B-protein
1	I-protein
promoter	O
,	O
a	O
distal	O
element	O
at	O
-1280	O
and	O
a	O
proximal	O
element	O
at	O
-65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O
	
The	O
distal	O
element	O
contains	O
the	O
5'-CC	O
(	O
A	O
+	O
T	O
)	O
6GG-3	O
'	O
consensus	O
sequence	O
characteristic	O
of	O
a	O
serum-response	O
element	O
(	O
SRE	O
)	O
.	O
	
Deletions	O
or	O
mutations	O
in	O
this	O
element	O
reduced	O
the	O
serum	O
response	O
of	O
the	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
by	O
80-90	O
%	O
.	O
	
In	O
gel-shift	O
assays	O
,	O
the	O
-1280	B-DNA
element	I-DNA
and	O
the	O
c-fos	B-DNA
SRE	I-DNA
cross	I-DNA
-competed	O
,	O
whereas	O
their	O
functional	O
and	O
binding	B-DNA
mutants	I-DNA
did	O
not	O
.	O
	
The	O
proximal	B-DNA
element	I-DNA
contains	O
the	O
sequence	O
5'-GGCCAATGGG-3	O
'	O
,	O
which	O
closely	O
resembles	O
the	O
consensus	O
binding	O
motif	O
for	O
the	O
CCAAT-binding	B-DNA
factor	I-DNA
NF-Y	B-protein
(	O
CBF	B-protein
,	O
CP1	B-protein
,	O
alpha	B-protein
CP1	I-protein
)	O
.	O
	
Deletions	O
or	O
mutations	O
in	O
this	O
element	O
also	O
reduced	O
the	O
serum	O
response	O
by	O
80-90	O
%	O
.	O
	
Methylation	O
interference	O
analysis	O
of	O
the	O
-65	B-DNA
region	I-DNA
identified	O
a	O
pattern	O
of	O
contacts	O
with	O
nuclear	B-protein
factors	I-protein
resembling	O
that	O
for	O
NF-Y	B-protein
,	O
and	O
an	O
NF-Y-binding	B-DNA
site	I-DNA
and	O
the	O
proximal	B-DNA
TSP	I-DNA
1	I-DNA
element	I-DNA
cross-competed	O
in	O
gel-shift	O
assays	O
,	O
whereas	O
their	O
binding	B-DNA
mutants	I-DNA
did	O
not	O
.	O
	
Finally	O
,	O
an	O
abbreviated	B-DNA
TSP	I-DNA
1	I-DNA
promoter/5'-flank	I-DNA
,	O
containing	O
the	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
sites	I-DNA
,	O
mediated	O
a	O
serum	O
response	O
that	O
was	O
close	O
in	O
magnitude	O
to	O
that	O
of	O
the	O
parent	B-DNA
promoter	I-DNA
.	O
	
We	O
conclude	O
that	O
the	O
serum	O
response	O
of	O
the	O
human	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
requires	O
the	O
coordinated	O
function	O
of	O
an	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
site	I-DNA
.	O
	
###MEDLINE:93152870	
	
Cell-type-specific	O
transactivation	O
of	O
the	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
tax	I-protein
and	O
HTLV-II	B-protein
tax	I-protein
proteins	I-protein
.	O
	
The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
and	I-protein
HTLV-II	I-protein
Tax	I-protein
proteins	I-protein
are	O
potent	O
transactivators	B-protein
of	O
viral	O
and	O
cellular	O
gene	O
expression	O
.	O
	
Using	O
deletion	B-DNA
mutants	I-DNA
,	O
the	O
downstream	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
(	I-DNA
PTHrP	I-DNA
)	I-DNA
promoter	I-DNA
is	O
shown	O
to	O
be	O
responsive	O
to	O
both	O
HTLV-I	B-protein
and	I-protein
HTLV-II	I-protein
Tax	I-protein
as	O
well	O
as	O
the	O
AP1/c-jun	B-DNA
proto-oncogene	I-DNA
.	O
	
Transactivation	O
of	O
PTHrP	B-protein
by	O
Tax	B-protein
was	O
seen	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
B-cell	B-cell_line
lines	I-cell_line
or	O
fibroblasts	B-cell_line
.	O
	
A	O
carboxy	B-DNA
terminal	I-DNA
Tax	I-DNA
deletion	I-DNA
mutant	I-DNA
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	B-DNA
and	I-DNA
IL2R	I-DNA
alpha	I-DNA
promoters	I-DNA
but	O
not	O
the	O
HTLV-I	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
Exogenous	O
provision	O
of	O
NFkB	B-protein
rescued	O
IL2R	B-protein
alpha	O
expression	O
but	O
not	O
the	O
PTHrP	B-DNA
promoter	I-DNA
.	O
	
Thus	O
,	O
HTLV-I	B-protein
Tax	I-protein
,	O
HTLV-II	B-protein
Tax	I-protein
,	O
and	O
c-jun	B-protein
transactivate	O
PTHrP	B-protein
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T-cell	O
leukemia	O
.	O
	
###MEDLINE:93123257	
	
Involvement	O
of	O
Alu	B-DNA
sequences	I-DNA
in	O
the	O
cell-specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	B-protein
chain	I-protein
of	O
Fc	B-protein
and	O
T	B-protein
cell	I-protein
receptors	I-protein
.	O
	
The	O
Fc	B-protein
epsilon	I-protein
RI-gamma	I-protein
chains	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O
	
They	O
are	O
part	O
of	O
the	O
high	B-protein
affinity	I-protein
IgE	I-protein
receptor	I-protein
in	O
mast	B-cell_type
cells	I-cell_type
,	O
basophils	B-cell_type
,	O
Langerhans	B-cell_type
cells	I-cell_type
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
or	O
CD16	B-protein
)	O
in	O
natural	O
killer	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
;	O
and	O
part	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
in	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	B-protein
chain	I-protein
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	B-DNA
sequence	I-DNA
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O
	
This	O
sequence	O
contains	O
a	O
promoter	B-DNA
specific	O
to	O
cells	B-cell_type
of	I-cell_type
hematopoietic	I-cell_type
lineage	I-cell_type
.	O
	
However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B-DNA
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	B-cell_type
cells	I-cell_type
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	O
Fc	O
epsilon	O
RI-	O
gamma	B-protein
chain	I-protein
transcripts	O
.	O
	
We	O
have	O
identified	O
two	O
adjacent	O
cis-acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O
	
The	O
first	O
(	O
-445/-366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
second	O
(	O
-365/-264	O
)	O
binds	O
to	O
nuclear	B-protein
factors	I-protein
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	B-cell_type
and	O
as	O
a	O
positive	O
one	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Thus	O
,	O
this	O
Alu	B-DNA
repeat	I-DNA
(	O
90	O
%	O
identical	O
to	O
Alu	B-DNA
consensus	I-DNA
sequences	I-DNA
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O
	
###MEDLINE:94077003	
	
Chlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
and	O
the	O
human	O
immune	O
system	O
.	O
	
1	O
.	O
Blood	B-protein
cell	I-protein
receptors	I-protein
in	O
volunteers	O
with	O
moderately	O
increased	O
body	O
burdens	O
.	O
	
Using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAbs	B-protein
)	O
and	O
flow	O
cytometry	O
,	O
we	O
studied	O
a	O
variety	O
of	O
surface	B-protein
receptors	I-protein
on	O
lymphocyte	B-cell_type
subpopulations	I-cell_type
of	O
workers	O
with	O
moderately	O
increased	O
body	O
burdens	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
and	O
of	O
other	O
polychlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
(	O
PCDD/PCDF	O
)	O
,	O
expressed	O
here	O
as	O
International-Toxicity	O
Equivalencies	O
(	O
I-TE	O
)	O
.	O
	
The	O
hypothesis	O
to	O
be	O
tested	O
was	O
whether	O
or	O
not	O
humans	O
exhibit	O
a	O
similar	O
susceptibility	O
to	O
PCDDs/PCDFs	O
with	O
respect	O
to	O
the	O
surface	B-protein
receptors	I-protein
found	O
previously	O
to	O
respond	O
to	O
small	O
doses	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
in	O
Callithrix	O
jacchus	O
.	O
	
These	O
are	O
:	O
helper-inducer	B-cell_type
(	I-cell_type
memory	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
(	O
CD4+CD45R0+CD45RA-CD29highCD11a+	B-cell_type
)	O
,	O
CD20+	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
CD8+CD56+/CD57+	B-cell_type
)	O
.	O
	
Furthermore	O
,	O
68	O
triple-labellings	O
with	O
mAbs	B-protein
were	O
performed	O
on	O
the	O
cells	O
of	O
each	O
volunteer	O
to	O
possibly	O
generate	O
further	O
hypotheses	O
.	O
	
It	O
was	O
evaluated	O
whether	O
any	O
of	O
the	O
variables	O
might	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
effects	O
for	O
this	O
class	O
of	O
compounds	O
.	O
	
There	O
were	O
two	O
main	O
goals	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
whether	O
workers	O
with	O
a	O
moderately	O
increased	O
PCDD/PCDF-body	O
burden	O
[	O
25-140	O
ppt	O
TCDD	O
or	O
104-522	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
exhibit	O
changes	O
in	O
the	O
surface	B-protein
receptors	I-protein
of	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
as	O
observed	O
in	O
previous	O
studies	O
in	O
non-human	O
primates	O
,	O
and	O
(	O
2	O
)	O
to	O
clarify	O
whether	O
persons	O
at	O
the	O
upper	O
range	O
[	O
10-23	O
ppt	O
TCDD	O
or	O
30-90	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
of	O
the	O
body	O
burden	O
reference	O
values	O
of	O
a	O
not	O
particularly	O
exposed	O
population	O
show	O
detectable	O
deviations	O
in	O
these	O
immunological	O
variables	O
,	O
when	O
compared	O
with	O
persons	O
at	O
the	O
lower	O
and	O
medium	O
range	O
[	O
1-3	O
ppt	O
TCDD	O
or	O
9-29	O
ppt	O
I-TE	O
]	O
of	O
these	O
body	O
burden	O
reference	O
values	O
.	O
	
Regression	O
analysis	O
of	O
our	O
data	O
revealed	O
slight	O
trends	O
for	O
some	O
of	O
the	O
biomarkers	O
(	O
e.g.	O
CD45R0+	O
)	O
.	O
	
With	O
one	O
exception	O
,	O
these	O
were	O
all	O
increases	O
.	O
	
None	O
of	O
the	O
alterations	O
observed	O
are	O
of	O
medical	O
relevance	O
.	O
	
The	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
CD4+CD45R0+	B-cell_type
cells	I-cell_type
remained	O
significant	O
even	O
after	O
covariant	O
analysis	O
taking	O
age-related	O
changes	O
into	O
account	O
.	O
	
Altogether	O
,	O
the	O
data	O
do	O
not	O
provide	O
any	O
evidence	O
to	O
support	O
an	O
assumption	O
that	O
moderately	O
increased	O
body	O
burdens	O
of	O
PCDDs/PCDFs	O
in	O
adults	O
induce	O
decreases	O
in	O
the	O
cellular	O
components	O
of	O
the	O
human	O
immune	O
system	O
.	O
	
Adult	O
humans	O
certainly	O
are	O
less	O
susceptible	O
to	O
this	O
action	O
of	O
PCDDs/PCDFs	O
than	O
adolescent	O
Callithrix	O
jacchus	O
	
###MEDLINE:94031267	
	
Inhibition	O
of	O
HIV-1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O
	
The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O
	
HIV-1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O
	
However	O
,	O
activation	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
leading	O
to	O
enhanced	O
HIV-1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	B-protein
,	O
mitogens	O
,	O
and	O
cytokines	B-protein
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
[	O
TNF-alpha	B-protein
]	O
,	O
interleukin	B-protein
1	I-protein
,	O
and	O
interleukin-2	B-protein
)	O
.	O
	
Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV-1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV-6	O
)	O
can	O
also	O
enhance	O
HIV-1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV-1	O
harbored	O
in	O
chronically	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
monocytes	B-cell_type
,	O
or	O
macrophages	B-cell_type
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O
	
So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV-1	O
latency	O
reactivation	O
.	O
	
ACH-2	B-cell_line
,	O
derived	O
from	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
CEM	B-cell_line
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O
	
ACH-2	B-cell_line
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	B-protein
(	O
TNF-alpha	B-protein
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O
	
Therefore	O
the	O
ACH-2	B-cell_line
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV-1	O
activation	O
.	O
	
Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV-1	O
IIIB	O
replication	O
in	O
phytohemagglutinin-stimulated	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:93314685	
	
Occurrence	O
of	O
a	O
silencer	B-DNA
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
naive	O
but	O
not	O
in	O
memory	B-cell_type
resting	I-cell_type
T	I-cell_type
helper	I-cell_type
lymphocytes	I-cell_type
.	O
	
In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	B-cell_type
T	I-cell_type
cell	I-cell_type
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self-tolerance	O
.	O
	
In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
activation	O
shows	O
that	O
naive	B-cell_type
human	I-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
(	O
cord	B-cell_type
blood	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
adult	B-cell_type
CD4+CD45RO-	I-cell_type
T	I-cell_type
cells	I-cell_type
)	O
regulate	O
IL-2	B-protein
transcription	O
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	B-DNA
and	O
an	O
activator	B-DNA
acting	O
on	O
the	O
purine-rich	B-DNA
IL-2	I-DNA
promoter	I-DNA
elements	I-DNA
(	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
)	O
.	O
	
By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	B-cell_line
activated	I-cell_line
helper	I-cell_line
T	I-cell_line
cells	I-cell_line
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4+	B-cell_line
T	I-cell_line
(	I-cell_line
memory	I-cell_line
)	I-cell_line
clones	I-cell_line
,	O
or	O
CD4+CD45RO+	B-cell_line
T	I-cell_line
cells	I-cell_line
isolated	O
ex	O
vivo	O
,	O
no	O
longer	O
have	O
a	O
silencer	B-DNA
.	O
	
Their	O
IL-2	B-protein
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	B-protein
transcription	I-protein
factor	I-protein
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
the	O
activator	B-DNA
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	B-cell_line
cells	I-cell_line
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O
	
Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O
	
It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	B-DNA
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:93283670	
	
Expression	O
of	O
mRNA	B-RNA
for	O
the	O
GATA-binding	B-protein
proteins	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
and	O
basophils	B-cell_type
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O
	
The	O
expression	O
of	O
the	O
hematopoietic	B-protein
transcription	I-protein
factors	I-protein
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
and	O
GATA-3	B-protein
was	O
studied	O
in	O
eosinophils	B-cell_type
and	O
basophils	B-cell_type
.	O
	
Eosinophils	B-cell_type
express	O
mRNA	B-RNA
for	O
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
and	O
GATA-3	B-protein
.	O
	
Basophils	B-cell_type
express	O
GATA-2	B-protein
and	O
GATA-3	B-protein
.	O
	
Treatment	O
of	O
HL-60	B-cell_line
eosinophilic	I-cell_line
sublines	I-cell_line
with	O
either	O
interleukin-5	B-protein
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil-specific	B-DNA
genes	I-DNA
,	O
whereas	O
levels	O
of	O
GATA-2	B-RNA
mRNA	I-RNA
remained	O
relatively	O
constant	O
.	O
	
The	O
presence	O
of	O
mRNA	B-RNA
for	O
these	O
proteins	O
in	O
eosinophils	B-cell_type
and	O
basophils	B-cell_type
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA-binding	B-protein
proteins	I-protein
.	O
	
###MEDLINE:93266597	
	
Oxidoreductive	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O
	
Involvement	O
of	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B-protein
.	O
	
We	O
have	O
investigated	O
an	O
oxidoreductive	O
regulatory	O
pathway	O
for	O
the	O
DNA	O
binding	O
activity	O
of	O
a	O
pleiotropic	B-protein
cellular	I-protein
transcription	I-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
has	O
been	O
investigated	O
by	O
using	O
NF	B-protein
kappa	I-protein
B	I-protein
prepared	O
from	O
the	O
nucleus	O
and	O
the	O
cytosol	O
of	O
the	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B-protein
(	O
Trx	B-protein
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
-dependent	O
gene	O
expression	O
.	O
	
We	O
demonstrate	O
evidence	O
suggesting	O
that	O
redox	O
regulation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
by	O
Trx	B-protein
might	O
be	O
exerted	O
at	O
a	O
step	O
after	O
dissociation	O
of	O
the	O
inhibitory	O
molecule	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
cytosolic-anchoring	B-protein
protein	I-protein
for	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
To	O
examine	O
the	O
effect	O
of	O
Trx	B-protein
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	B-DNA
acetyltransferase-expressing	I-DNA
plasmid	I-DNA
under	O
the	O
control	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
an	O
effector	B-DNA
plasmid	I-DNA
expressing	O
human	B-protein
Trx	I-protein
.	O
	
The	O
promoter	O
activity	O
from	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
was	O
greatly	O
augmented	O
by	O
co-transfecting	O
the	O
Trx-expressing	B-DNA
plasmid	I-DNA
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
-binding	O
sites	O
.	O
	
These	O
findings	O
have	O
suggested	O
that	O
cysteine	O
residue	O
(	O
s	O
)	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
might	O
be	O
involved	O
in	O
the	O
DNA-recognition	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
that	O
the	O
redox	O
control	O
mechanism	O
mediated	O
by	O
Trx	B-protein
might	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O
	
These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O
	
###MEDLINE:93269273	
	
Synergism	O
between	O
the	O
CD3	O
antigen-	O
and	O
CD2	O
antigen-derived	O
signals	O
.	O
	
Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA-binding	B-protein
proteins	I-protein
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O
	
We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3/TCR	B-protein
complex	I-protein
with	O
the	O
CD2	B-protein
antigen	I-protein
results	O
in	O
the	O
proliferation	O
of	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O
	
To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA-binding	B-protein
proteins	I-protein
in	O
highly	O
purified	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
signaled	O
via	O
the	O
CD3	B-protein
and/or	O
CD2	B-protein
proteins	I-protein
.	O
	
The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
ionomycin	O
,	O
and/or	O
sn-1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O
	
The	O
emergence	O
of	O
nuclear	B-protein
binding	I-protein
proteins	I-protein
was	O
investigated	O
using	O
interleukin-2	B-DNA
sequence	I-DNA
specific	I-DNA
oligonucleotide	I-DNA
probes	I-DNA
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
	
Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	B-protein
antigen-derived	O
signals	O
and	O
CD2	B-protein
antigen	I-protein
-derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
NF-AT1	B-DNA
,	I-DNA
AP-1	I-DNA
,	I-DNA
and	I-DNA
NF-kB	I-DNA
sites	I-DNA
located	O
in	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
of	O
the	O
IL-2	B-protein
gene	O
.	O
	
Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA-binding	B-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen-dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O
	
###MEDLINE:93215800	
	
Induced	O
myeloid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
with	O
downregulation	O
of	O
erythroid	B-protein
and	I-protein
megakaryocytic	I-protein
transcription	I-protein
factors	I-protein
:	O
a	O
novel	O
experimental	O
model	O
for	O
hemopoietic	O
lineage	O
restriction	O
.	O
	
The	O
human	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	B-cell_line
cells	I-cell_line
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O
	
This	O
was	O
accompanied	O
by	O
downregulation	O
of	O
two	O
transcription	B-protein
factors	I-protein
normally	O
expressed	O
in	O
erythroid	B-cell_type
,	I-cell_type
mast	I-cell_type
and	I-cell_type
megakaryocyte	I-cell_type
lineages	I-cell_type
.	O
	
Northern	O
analysis	O
demonstrated	O
coordinate	O
downregulation	O
of	O
alpha	B-protein
globin	I-protein
and	O
gamma	B-protein
globin	I-protein
in	O
addition	O
to	O
the	O
two	O
lineage-restricted	O
transcription	B-protein
factors	I-protein
,	O
SCL	B-protein
and	O
GATA-1	B-protein
.	O
	
Proliferation	O
of	O
the	O
K562	B-cell_line
cells	I-cell_line
was	O
also	O
suppressed	O
.	O
	
Clonal	O
assay	O
showed	O
that	O
the	O
suppression	O
was	O
irreversible	O
and	O
appeared	O
analogous	O
to	O
the	O
commitment	O
of	O
murine	B-cell_line
erythroleukemia	I-cell_line
(	I-cell_line
MEL	I-cell_line
)	I-cell_line
cells	I-cell_line
to	O
terminal	O
differentiation	O
.	O
	
In	O
contrast	O
to	O
MEL	B-cell_line
cells	I-cell_line
,	O
however	O
,	O
K562	B-cell_line
cells	I-cell_line
acquired	O
a	O
macrophage-like	O
morphology	O
and	O
exhibited	O
a	O
complete	O
failure	O
to	O
generate	O
benzidine-positive	B-cell_line
cells	I-cell_line
.	O
	
Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	B-cell_type
.	O
	
Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA-induced	B-cell_line
cells	I-cell_line
expressed	O
reduced	O
levels	O
of	O
glycophorin	B-protein
A	I-protein
,	O
CD5	B-protein
,	O
CD7	B-protein
and	O
CD11b	B-protein
.	O
	
No	O
upregulation	O
of	O
megakaryocyte	B-protein
or	I-protein
lymphoid	I-protein
markers	I-protein
occurred	O
.	O
	
Thus	O
the	O
response	O
of	O
K562	B-cell_line
cells	I-cell_line
to	O
HMBA	O
may	O
provide	O
a	O
useful	O
experimental	O
system	O
for	O
studying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
downmodulation	O
of	O
lineage-restricted	O
transcription	B-protein
factors	I-protein
during	O
hemopoietic	O
lineage	O
commitment	O
.	O
	
###MEDLINE:93264305	
	
Activation	O
of	O
primary	B-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
through	O
CD2	B-protein
plus	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
long-term	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
Stimulation	O
of	O
highly	B-cell_type
purified	I-cell_type
human	I-cell_type
T-cells	I-cell_type
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O
	
This	O
potent	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-dependent	O
activation	O
does	O
not	O
require	O
monocytes	B-cell_type
or	O
accessory	B-cell_type
cells	I-cell_type
.	O
	
Long-lasting	O
IL-2	B-protein
receptivity	O
is	O
associated	O
with	O
high-level	O
expression	O
of	O
the	O
inducible	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
	
Increase	O
of	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
to	O
its	O
consensus	B-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
.	O
	
To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
we	O
analyzed	O
nuclear	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
a	O
radiolabeled	O
IL-2R	B-protein
alpha	I-protein
kappa	O
B-specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	B-protein
+	O
CD28	B-protein
activation	O
.	O
	
Resting	O
T-cell	O
nuclear	O
extracts	O
contained	O
KBF1/p50	B-protein
homodimer	I-protein
.	O
	
After	O
stimulation	O
,	O
two	O
new	O
kappa	B-protein
B-specific	I-protein
complexes	I-protein
were	O
identified	O
as	O
NF-kappa	B-protein
B	I-protein
p50-p65	B-protein
heterodimer	I-protein
and	O
putative	O
c-Rel	B-protein
homodimer	I-protein
or	O
c-Rel-p65	B-protein
heterodimer	I-protein
.	O
	
Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O
	
Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O
	
In	O
parallel	O
,	O
CD2	B-protein
+	O
CD28	B-protein
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	B-protein
molecules	I-protein
.	O
	
Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
T-lymphocytes	B-cell_type
,	O
also	O
inhibited	O
IL-2	B-protein
secretion	O
,	O
IL-2R	B-protein
alpha	I-protein
cell	O
surface	O
expression	O
,	O
and	O
T-cell	O
proliferation	O
.	O
	
Together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
long-term	O
activation	O
of	O
human	B-cell_type
primary	I-cell_type
T-lymphocytes	I-cell_type
via	O
CD2	B-protein
+	O
CD28	B-protein
.	O
	
###MEDLINE:93228833	
	
Immobilization	O
and	O
recovery	O
of	O
fusion	B-protein
proteins	I-protein
and	O
B-lymphocyte	B-cell_type
cells	I-cell_type
using	O
magnetic	O
separation	O
.	O
	
A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	B-protein
proteins	I-protein
and	O
selected	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
has	O
been	O
developed	O
.	O
	
Using	O
magnetic	O
beads	O
with	O
attached	O
DNA	O
containing	O
the	O
Escherichia	B-DNA
coli	I-DNA
lac	I-DNA
operator	I-DNA
,	O
fusion	B-protein
proteins	I-protein
comprising	O
the	O
DNA-binding	B-DNA
lac	I-DNA
repressor	I-DNA
could	O
be	O
affinity-purified	O
and	O
recovered	O
by	O
gentle	O
elution	O
conditions	O
,	O
such	O
as	O
with	O
a	O
lactose	O
analogue	O
or	O
by	O
enzymatic	O
means	O
using	O
either	O
deoxyribonuclease	B-protein
(	O
DNase	B-protein
)	O
or	O
restriction	B-protein
endonucleases	I-protein
.	O
	
The	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
DNA-binding	B-protein
protein	I-protein
can	O
be	O
used	O
for	O
affinity	O
purification	O
of	O
fusion	B-protein
proteins	I-protein
as	O
exemplified	O
by	O
the	O
specific	O
and	O
gentle	O
recovery	O
of	O
beta-galactosidase	B-protein
and	O
alkaline	B-protein
phosphatase	I-protein
from	O
bacterial	O
lysates	O
using	O
immunomagnetic	O
separation	O
.	O
	
The	O
approach	O
was	O
further	O
extended	O
to	O
cell	O
separation	O
by	O
the	O
efficient	O
recovery	O
and	O
elution	O
of	O
human	B-cell_line
CD37	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
from	O
peripheral	O
blood	O
.	O
	
###MEDLINE:93155082	
	
ras	B-protein
protein	I-protein
activity	O
is	O
essential	O
for	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
signal	O
transduction	O
.	O
	
In	O
a	O
Jurkat	B-cell_line
cell	I-cell_line
model	I-cell_line
of	O
T-cell	O
activation	O
an	O
interleukin-2	B-DNA
promoter/reporter	I-DNA
gene	I-DNA
construct	I-DNA
was	O
activated	O
by	O
antigen	B-protein
receptor	I-protein
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	B-protein
interleukin-1	B-protein
.	O
	
Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O
	
In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	B-protein
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin-1	B-protein
.	O
	
Activated	O
ras	B-protein
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	B-protein
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NF-AT	B-protein
.	O
	
A	O
dominant	B-protein
inhibitory	I-protein
ras	I-protein
mutant	I-protein
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	B-protein
activity	O
is	O
required	O
for	O
antigen	B-protein
receptor	I-protein
signaling	O
.	O
	
In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
blocked	O
both	O
activated	O
ras	B-protein
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B-protein
upstream	O
of	O
PKC	B-protein
.	O
	
###MEDLINE:93189882	
	
Expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
of	O
HIV1	O
in	O
human	B-cell_line
promonocytic	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
	
Numerous	O
studies	O
have	O
shown	O
that	O
,	O
upon	O
HIV1	O
infection	O
,	O
human	B-cell_line
promonocytic	I-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
,	O
as	O
indicated	O
,	O
for	O
example	O
,	O
by	O
increased	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
.	O
	
One	O
of	O
the	O
viral	O
proteins	O
involved	O
in	O
this	O
process	O
might	O
be	O
the	O
Tat	B-protein
protein	I-protein
.	O
	
Indeed	O
,	O
this	O
viral	B-protein
protein	I-protein
,	O
which	O
is	O
essential	O
for	O
productive	O
infection	O
,	O
has	O
also	O
been	O
shown	O
to	O
display	O
growth-stimulating	O
properties	O
and	O
immunomodulatory	O
activities	O
.	O
	
In	O
order	O
to	O
apprehend	O
the	O
role	O
of	O
the	O
HIV1	B-DNA
tat	I-DNA
gene	I-DNA
in	O
inducing	O
the	O
differentiation	O
of	O
HIV1-infected	B-cell_line
U937	I-cell_line
cells	I-cell_line
,	O
we	O
have	O
successfully	O
introduced	O
this	O
gene	O
into	O
U937	B-cell_line
cells	I-cell_line
by	O
infecting	O
them	O
with	O
retroviral	O
particles	O
transducing	O
tat	B-DNA
.	O
	
The	O
effect	O
of	O
the	O
Tat	B-protein
protein	I-protein
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
and	O
of	O
the	O
c-fms	B-DNA
proto-oncogenes	I-DNA
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O
	
Northern	O
blot	O
analysis	O
revealed	O
in	O
these	O
cells	O
,	O
an	O
increase	O
in	O
the	O
transcription	O
of	O
these	O
two	O
proto-oncogenes	B-DNA
,	O
and	O
this	O
increase	O
was	O
amplified	O
after	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
.	O
	
No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	B-cell_line
cells	I-cell_line
.	O
	
These	O
results	O
indicate	O
that	O
,	O
among	O
HIV1	B-protein
gene	I-protein
products	I-protein
,	O
the	O
Tat	B-protein
protein	I-protein
appears	O
to	O
trigger	O
monocytic	O
differentiation	O
,	O
and	O
suggests	O
that	O
this	O
viral	B-protein
protein	I-protein
directs	O
progenitors	O
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
towards	O
a	O
differentiation	O
stage	O
in	O
which	O
production	O
of	O
viral	B-protein
antigens	I-protein
and	O
virions	O
might	O
be	O
more	O
efficient	O
.	O
	
###MEDLINE:93329079	
	
Analysis	O
of	O
the	O
preexisting	O
and	O
nuclear	O
forms	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O
	
The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
3	O
is	O
an	O
inducible	O
DNA-binding	B-protein
protein	I-protein
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
during	O
T	O
cell	O
activation	O
.	O
	
NF-AT	B-protein
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	B-protein
,	I-protein
inducible	I-protein
nuclear	I-protein
component	I-protein
that	O
we	O
have	O
identified	O
as	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
,	O
and	O
a	O
preexisting	O
,	O
T	B-protein
cell-specific	I-protein
component	I-protein
(	O
NF-ATp	B-protein
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O
	
We	O
have	O
previously	O
shown	O
that	O
nuclear	O
extracts	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
form	O
two	O
inducible	O
NF-AT	B-protein
complexes	I-protein
with	O
an	O
oligonucleotide	O
corresponding	O
to	O
the	O
distal	B-DNA
NF-AT	I-DNA
site	I-DNA
of	O
the	O
murine	B-DNA
IL-2	I-DNA
promoter	I-DNA
,	O
although	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	B-cell_type
cells	I-cell_type
form	O
a	O
single	O
complex	O
containing	O
NF-ATp	B-protein
.	O
	
We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF-ATp	B-protein
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF-AT	B-protein
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O
	
Moreover	O
we	O
present	O
evidence	O
that	O
the	O
component	O
that	O
forms	O
the	O
faster-migrating	O
(	O
``	O
lower	O
''	O
)	O
nuclear	B-protein
NF-AT	I-protein
complex	I-protein
is	O
derived	O
by	O
a	O
calcium-dependent	O
,	O
cyclosporin-sensitive	O
,	O
posttranslational	O
modification	O
of	O
NF-ATp	B-protein
,	O
and	O
that	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
stabilize	O
its	O
interaction	O
with	O
DNA	O
.	O
	
The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
relating	O
the	O
two	O
nuclear	O
NF-AT	B-protein
complexes	I-protein
to	O
NF-ATp	B-protein
.	O
	
###MEDLINE:93309430	
	
Cell	O
cycle	O
analysis	O
of	O
E2F	B-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
reveals	O
novel	B-protein
E2F	I-protein
complexes	I-protein
and	O
biochemically	O
distinct	O
forms	O
of	O
free	O
E2F	B-protein
.	O
	
The	O
transcription	B-protein
factor	I-protein
E2F	B-protein
activates	O
the	O
expression	O
of	O
multiple	O
genes	B-DNA
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c-myc	B-DNA
and	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
.	O
	
Regulation	O
of	O
E2F	B-protein
involves	O
its	O
interactions	O
with	O
other	O
cellular	B-protein
proteins	I-protein
,	O
including	O
the	O
retinoblastoma	B-protein
protein	I-protein
(	O
Rb	B-protein
)	O
,	O
the	O
Rb-related	B-protein
protein	I-protein
p107	B-protein
,	O
cyclin	B-protein
A	I-protein
,	O
and	O
cdk2	B-protein
.	O
	
We	O
undertook	O
a	O
detailed	O
analysis	O
of	O
E2F	B-protein
DNA-binding	O
activities	O
and	O
their	O
cell	O
cycle	O
behavior	O
in	O
primary	O
human	O
T	B-cell_type
cells	I-cell_type
.	O
	
Three	O
E2F	B-protein
DNA-binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	B-cell_type
cells	I-cell_type
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	B-protein
complexes	O
.	O
	
One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb-	O
E2F	B-protein
complex	O
.	O
	
The	O
most	O
prominent	O
E2F	B-protein
activity	O
in	O
resting	O
T	B-cell_type
cells	I-cell_type
(	O
termed	O
complex	O
X	O
)	O
was	O
abundant	O
in	O
both	O
G0	O
and	O
G1	O
but	O
disappeared	O
as	O
cells	O
entered	O
S	O
phase	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
negatively	O
regulating	O
E2F	B-protein
function	O
.	O
	
Complex	B-protein
X	I-protein
could	O
be	O
dissociated	O
by	O
adenovirus	O
E1A	O
with	O
a	O
requirement	O
for	O
an	O
intact	O
E1A	B-DNA
conserved	I-DNA
region	I-DNA
2	I-DNA
.	O
	
However	O
,	O
X	B-protein
failed	O
to	O
react	O
with	O
a	O
variety	O
of	O
antibodies	O
against	O
Rb	B-protein
or	O
p107	B-protein
,	O
implicating	O
the	O
involvement	O
of	O
an	O
E1A-binding	B-protein
protein	I-protein
other	O
than	O
Rb	B-protein
or	O
p107	B-protein
.	O
	
In	O
addition	O
to	O
these	O
novel	B-protein
E2F	I-protein
complexes	I-protein
,	O
three	O
distinct	O
forms	O
of	O
unbound	O
(	O
free	O
)	O
E2F	B-protein
were	O
resolved	O
in	O
gel	O
shift	O
experiments	O
.	O
	
These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O
	
UV	O
cross-linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	B-protein
DNA-binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S-phase	B-protein
p107	I-protein
complex	I-protein
and	O
is	O
not	O
associated	O
with	O
Rb	B-protein
.	O
	
Together	O
,	O
these	O
results	O
suggest	O
that	O
E2F	B-protein
consists	O
of	O
multiple	O
,	O
biochemically	O
distinct	O
DNA-binding	B-protein
proteins	I-protein
which	O
function	O
at	O
different	O
points	O
in	O
the	O
cell	O
cycle	O
.	O
	
###MEDLINE:93286051	
	
Defective	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
multidrug-resistant	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
.	O
	
Previous	O
studies	O
have	O
demonstrated	O
that	O
human	B-cell_line
HL-60	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O
	
This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c-jun	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O
	
The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine-selected	O
,	O
multidrug	O
resistance	O
on	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
HL-60	O
cell	O
differentiation	O
.	O
	
The	O
results	O
demonstrate	O
that	O
multidrug-resistant	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
designated	O
HL-60/vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c-jun	B-RNA
transcripts	I-RNA
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O
	
By	O
contrast	O
,	O
treatment	O
of	O
HL-60/vinc	B-cell_line
cells	I-cell_line
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	B-protein
protein	I-protein
phosphatases	I-protein
,	O
induces	O
c-jun	B-DNA
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c-fms	B-DNA
gene	I-DNA
.	O
	
Studies	O
were	O
also	O
performed	O
with	O
an	O
HL-60/vinc	B-cell_line
revertant	I-cell_line
(	O
HL-60/vinc/R	B-cell_line
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O
	
The	O
finding	O
that	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c-jun	B-DNA
expression	O
,	O
suggests	O
that	O
c-jun	B-DNA
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O
	
Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun-B	B-DNA
and	O
fra-1	B-DNA
genes	B-DNA
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60/vinc	B-cell_line
and	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
,	O
whereas	O
c-fos	B-DNA
expression	O
is	O
attenuated	O
in	O
the	O
HL-60/vinc	O
line	O
.	O
	
Since	O
TPA	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	B-protein
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O
	
Although	O
HL-60	B-cell_line
and	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
demonstrated	O
translocation	O
of	O
PKC	B-protein
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL-60/vinc	B-cell_line
cells	I-cell_line
.	O
	
Activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
with	O
associated	O
phosphorylation	O
of	O
c-Jun	B-protein
Y-peptide	I-protein
was	O
markedly	O
diminished	O
in	O
TPA-treated	B-cell_line
HL-60/vinc	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O
	
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA-induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	B-protein
-mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun/fos	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:93281652	
	
Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O
	
We	O
have	O
previously	O
reported	O
that	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
that	O
include	O
IL2	B-DNA
,	O
IL3	B-DNA
,	O
IL4	B-DNA
,	O
and	O
IL5	B-DNA
,	O
which	O
encode	O
interleukins	B-protein
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	B-protein
,	O
-3	B-protein
,	O
-4	B-protein
,	O
and	O
-5	B-protein
)	O
.	O
	
To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
involved	O
a	O
trans-acting	B-protein
factor	I-protein
common	O
to	O
the	O
affected	O
lymphokine	B-DNA
genes	I-DNA
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	B-protein
factors	I-protein
from	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
IL2	B-DNA
.	O
	
Nuclear	B-protein
factor	I-protein
NF-kB	I-protein
,	O
activation	B-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
,	O
OCT-1	B-protein
,	O
and	O
NF-IL-2B	B-protein
binding	O
activity	O
were	O
normal	O
.	O
	
In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B-DNA
enhancer	I-DNA
and	O
to	O
an	O
NF-AT-like	B-DNA
response	I-DNA
element	I-DNA
present	O
in	O
the	O
IL4	B-DNA
enhancer	I-DNA
was	O
abnormal	O
.	O
	
To	O
ascertain	O
whether	O
the	O
abnormal	O
NF-AT	B-protein
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
of	O
multimers	O
of	O
individual	O
enhancer	B-DNA
sequences	I-DNA
.	O
	
CAT	O
expression	O
directed	O
by	O
the	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
by	O
a	O
multimer	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O
	
In	O
contrast	O
,	O
CAT	B-DNA
gene	I-DNA
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	B-DNA
proximal	I-DNA
(	I-DNA
OCT-1p	I-DNA
)	I-DNA
-binding	I-DNA
site	I-DNA
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O
	
These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of/or	O
influencing	O
NF-AT	B-protein
may	O
underlie	O
the	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
this	O
patient	O
.	O
	
###MEDLINE:94025289	
	
FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O
	
The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal-transduction	O
pathway	O
emanating	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second-messenger	O
Ca2+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL-2	B-protein
,	O
among	O
which	O
are	O
calmodulin	B-protein
,	O
calcineurin	B-protein
and	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
.	O
	
Hence	O
,	O
Ca2+	O
binds	O
to	O
calmodulin	B-protein
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	B-protein
to	O
calcineurin	B-protein
;	O
the	O
activated	O
calcineurin	B-protein
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	B-protein
subunit	I-protein
of	I-protein
NF-AT	I-protein
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	B-protein
transcriptional	I-protein
activator	I-protein
.	O
	
As	O
described	O
by	O
Jun	B-protein
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O
	
They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O
	
Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	B-protein
receptors	I-protein
called	O
immunophilins	B-protein
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	B-protein
prolyl	I-protein
cis-trans	I-protein
isomerase	I-protein
activities	O
.	O
	
The	O
two	O
structurally	O
distinct	O
immunophilin-drug	B-protein
complexes	I-protein
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	B-protein
activity	O
of	O
calcineurin	B-protein
.	O
	
###MEDLINE:93209552	
	
p105	B-protein
and	O
p98	B-protein
precursor	B-protein
proteins	I-protein
play	O
an	O
active	O
role	O
in	O
NF-kappa	B-protein
B	I-protein
-mediated	O
signal	O
transduction	O
.	O
	
The	O
Rel/NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
is	O
composed	O
of	O
two	O
distinct	O
subgroups	O
,	O
proteins	O
that	O
undergo	O
proteolytic	O
processing	O
and	O
contain	O
SWI6/ankyrin	B-protein
repeats	I-protein
in	O
their	O
carboxyl	B-protein
termini	I-protein
(	O
p105	B-protein
,	O
p98	B-protein
)	O
,	O
and	O
those	O
without	O
such	O
repeats	O
that	O
do	O
not	O
require	O
processing	O
(	O
p65	B-protein
,	O
c-Rel	B-protein
,	O
RelB	B-protein
,	O
and	O
Dorsal	B-protein
)	O
.	O
	
We	O
demonstrate	O
that	O
the	O
p105	B-protein
and	O
p98	B-protein
precursors	O
share	O
functional	O
properties	O
with	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
,	O
which	O
also	O
contain	O
SWI6/ankyrin	B-protein
repeats	I-protein
.	O
	
Both	O
p105	B-protein
and	O
p98	B-protein
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel/NF-kappa	B-protein
B	I-protein
family	I-protein
members	I-protein
,	O
including	O
p65	B-protein
and	O
c-Rel	B-protein
.	O
	
Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B-protein
or	O
c-Rel	B-protein
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O
	
These	O
complexes	O
undergo	O
stimulus-responsive	O
processing	O
to	O
produce	O
active	O
p50/c-Rel	B-protein
and	O
p55/c-Rel	B-protein
complexes	O
.	O
	
These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
plays	O
a	O
major	O
role	O
.	O
	
###MEDLINE:93206138	
	
NF-kappa	B-protein
B	I-protein
controls	O
expression	O
of	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O
	
The	O
eukaryotic	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
growth	O
.	O
	
Nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
Phorbol	O
ester	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
induction	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
the	O
activation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
gene	O
expression	O
.	O
	
Transfection	O
studies	O
indicate	O
that	O
the	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha	I-DNA
gene	I-DNA
is	O
specifically	O
induced	O
by	O
the	O
65-kilodalton	B-protein
transactivating	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
Association	O
of	O
the	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
with	O
p65	B-protein
restores	O
intracellular	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O
	
Together	O
,	O
these	O
results	O
show	O
that	O
NF-kappa	B-protein
B	I-protein
controls	O
the	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O
	
###MEDLINE:93180777	
	
The	O
human	B-DNA
prointerleukin	I-DNA
1	I-DNA
beta	I-DNA
gene	I-DNA
requires	O
DNA	O
sequences	O
both	O
proximal	O
and	O
distal	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
for	O
tissue-specific	O
induction	O
.	O
	
In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	B-DNA
sequences	I-DNA
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
prointerleukin	I-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
proIL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
.	O
	
A	O
cell-type-independent	B-DNA
lipopolysaccharide	I-DNA
(	I-DNA
LPS	I-DNA
)	I-DNA
-responsive	I-DNA
enhancer	I-DNA
element	I-DNA
located	O
between	O
-3757	B-DNA
and	I-DNA
-2729	I-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
cap	B-DNA
site	I-DNA
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	B-cell_line
monocytes	I-cell_line
.	O
	
The	O
enhancer	O
also	O
appeared	O
to	O
mediate	O
phorbol	O
myristate	O
acetate	O
induction	O
in	O
monocytes	B-cell_type
and	O
IL-1	B-protein
responsiveness	O
in	O
fibroblasts	B-cell_type
.	O
	
Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	B-DNA
binding	I-DNA
sequences	I-DNA
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	O
for	O
gene	O
induction	O
.	O
	
One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
both	O
IL-1	B-protein
-and	O
LPS-specific	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
(	O
i.e.	O
,	O
the	O
NF-IL6	B-DNA
proteins	I-DNA
)	O
.	O
	
When	O
ligated	O
to	O
the	O
proIL-1	B-DNA
beta	I-DNA
cap	I-DNA
site	I-DNA
-proximal	B-DNA
region	I-DNA
(	O
located	O
between	O
-131	O
to	O
+12	O
)	O
,	O
both	O
the	O
proIL-1	B-DNA
beta	I-DNA
and	I-DNA
the	I-DNA
simian	I-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
elements	I-DNA
functioned	O
more	O
efficiently	O
in	O
monocytes	B-cell_type
than	O
in	O
HeLa	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL-1	B-protein
beta	I-protein
expression	O
.	O
	
When	O
ligated	O
to	O
the	O
murine	B-DNA
c-fos	I-DNA
promoter	I-DNA
,	O
however	O
,	O
the	O
proIL-1	B-DNA
beta	I-DNA
enhancer	I-DNA
was	O
inducible	O
in	O
phorbol	B-cell_line
myristate	I-cell_line
acetate-stimulated	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
,	O
suggesting	O
the	O
existence	O
of	O
a	O
proIL-1	B-protein
beta	I-protein
promoter-proximal	O
requirement	O
for	O
tissue	O
specificity	O
.	O
	
###MEDLINE:93233083	
	
Lymphocytes	B-cell_type
from	O
the	O
site	O
of	O
disease	O
suggest	O
adenovirus	O
is	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
	
The	O
assessment	O
of	O
synovial	O
lymphocyte	O
reactivity	O
to	O
adenovirus	O
antigen	O
stimulation	O
was	O
undertaken	O
in	O
patients	O
with	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
	
The	O
3H-thymidine	O
uptake	O
procedure	O
was	O
employed	O
,	O
incorporating	O
multiple	O
microbiological	B-protein
antigens	I-protein
.	O
	
Five	O
patients	O
were	O
found	O
with	O
repeated	O
maximal	O
responses	O
to	O
adenovirus	B-protein
antigen	I-protein
;	O
in	O
one	O
of	O
these	O
adenovirus	B-DNA
nucleotide	I-DNA
sequences	I-DNA
were	O
present	O
in	O
a	O
synovial	O
biopsy	O
specimen	O
.	O
	
It	O
is	O
concluded	O
that	O
adenovirus	O
may	O
be	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
	
###MEDLINE:93183827	
	
Expression	O
of	O
PILOT	B-protein
,	O
a	O
putative	O
transcription	B-protein
factor	I-protein
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Few	O
known	O
genes	B-DNA
(	O
IL-2	B-protein
,	O
members	O
of	O
the	O
IL-8	B-DNA
family	I-DNA
,	O
interferon-gamma	B-DNA
)	O
are	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2+	O
)	O
-ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	B-DNA
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O
	
We	O
have	O
identified	O
a	O
putative	O
transcription	B-protein
factor	I-protein
,	O
designated	O
PILOT	B-protein
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	O
for	O
expression	O
.	O
	
Induction	O
of	O
the	O
PILOT	B-protein
gene	O
is	O
detectable	O
in	O
human	O
T	B-cell_type
cells	I-cell_type
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	O
by	O
CyA	O
.	O
	
The	O
PILOT	B-protein
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42.6	O
kDa	O
and	O
contains	O
three	O
zinc	B-protein
fingers	I-protein
of	O
the	O
C2H2-type	B-protein
at	O
the	O
carboxyl-terminus	B-protein
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	B-protein
finger	I-protein
regions	I-protein
of	O
the	O
transcription	B-protein
factors	I-protein
EGR1	B-protein
,	O
EGR2	B-protein
,	O
and	O
pAT	B-protein
133	I-protein
.	O
	
In	O
contrast	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
in	O
fibroblasts	B-cell_type
PILOT	B-protein
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O
	
This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2+	B-protein
signal-dependent	I-protein
regulatory	I-protein
element	I-protein
obligatory	O
for	O
expression	O
of	O
some	O
genes	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
fibroblasts	B-cell_type
.	O
	
This	O
differential	O
expression	O
model	O
will	O
be	O
valuable	O
in	O
the	O
dissection	O
of	O
the	O
dual	O
signal	O
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
the	O
effects	O
of	O
CyA	O
upon	O
it	O
.	O
	
###MEDLINE:93320446	
	
Antisense	O
oligonucleotides	O
to	O
the	O
p65	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
block	O
CD11b	B-protein
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL-60	B-cell_line
granulocytes	I-cell_line
.	O
	
NF-kappa	B-protein
B	I-protein
is	O
a	O
pleiotropic	B-protein
regulator	I-protein
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O
	
This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
distinct	O
regions	O
of	O
the	O
promoter	B-DNA
elements	I-DNA
of	O
numerous	O
genes	O
,	O
including	O
cytokines	B-protein
,	O
growth	B-protein
factor	I-protein
receptors	I-protein
,	O
and	O
adhesion	B-protein
molecules	I-protein
.	O
	
Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	B-protein
factor	I-protein
in	O
resting	B-cell_line
and	I-cell_line
stimulated	I-cell_line
granulocytes	I-cell_line
.	O
	
A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B-protein
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O
	
This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	B-cell_line
sulfoxide-differentiated	I-cell_line
HL-60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
stimulated	O
by	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O
	
These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B-protein
integrin	B-protein
expression	O
on	O
the	O
surface	O
of	O
treated	B-cell_line
cells	I-cell_line
.	O
	
Furthermore	O
,	O
the	O
p65	B-protein
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	B-protein
that	O
was	O
produced	O
by	O
formyl-met-leu-phe	O
and	O
TPA	O
.	O
	
However	O
,	O
the	O
p65	B-protein
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O
	
These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	B-protein
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	B-cell_type
.	O
	
###MEDLINE:93307660	
	
The	O
p65	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
regulates	O
I	B-protein
kappa	I-protein
B	I-protein
by	O
two	O
distinct	O
mechanisms	O
.	O
	
Transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
is	O
generally	O
localized	O
to	O
the	O
cytoplasm	O
by	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
.	O
	
Overproduced	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
free	O
from	O
NF-kappa	B-protein
B	I-protein
,	O
is	O
rapidly	O
degraded	O
.	O
	
Overexpression	O
of	O
p65	B-protein
increases	O
endogenous	O
I	B-protein
kappa	I-protein
B	I-protein
protein	O
in	O
both	O
carcinoma	B-cell_type
and	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
mRNA	I-RNA
.	O
	
In	O
contrast	O
,	O
p65	B-protein
delta	I-protein
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	B-protein
kappa	I-protein
B	I-protein
protein	O
levels	O
.	O
	
Both	O
overexpressed	O
p65	B-protein
and	O
coexpressed	O
p50	B-protein
are	O
cytoplasmic	O
,	O
whereas	O
p65	B-protein
delta	I-protein
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
induced	O
by	O
p65	B-protein
can	O
maintain	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O
	
Thus	O
,	O
p65	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
are	O
linked	O
in	O
an	O
autoregulatory	O
loop	O
,	O
ensuring	O
that	O
NF-kappa	B-protein
B	I-protein
is	O
held	O
in	O
the	O
cytoplasm	O
until	O
cells	O
are	O
specifically	O
induced	O
to	O
translocate	O
it	O
to	O
the	O
nucleus	O
.	O
	
###MEDLINE:93280143	
	
Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	B-protein
and	O
activation	O
of	O
c-Rel	B-protein
and	O
related	O
NF-kappa	B-protein
B	I-protein
proteins	O
in	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O
	
Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA-binding	O
proteins	O
.	O
	
However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS-generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O
	
Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c-Rel/p50	B-protein
heterodimers	I-protein
as	O
well	O
as	O
p50/p65	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
kappa	O
B	O
DNA-binding	O
complexes	O
in	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O
	
Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	B-protein
ester-sensitive	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
.	O
	
Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	B-protein
,	O
p105	B-protein
,	O
and	O
p50	B-protein
in	O
the	O
cytosol	O
.	O
	
The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	B-RNA
during	O
LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B-protein
(	O
an	O
I	B-protein
kappa	I-protein
B	I-protein
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	B-RNA
mRNA	I-RNA
,	O
and	O
an	O
increase	O
in	O
MAD3	B-protein
protein	O
by	O
2	O
h	O
.	O
	
Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
results	O
in	O
nuclear	O
expression	O
of	O
c-Rel/p50	B-protein
and	O
p50/p65	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B-protein
.	O
	
###MEDLINE:93252936	
	
A	O
chimeric	B-protein
type	I-protein
II/type	I-protein
I	I-protein
interleukin-1	I-protein
receptor	I-protein
can	O
mediate	O
interleukin-1	B-protein
induction	O
of	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
type	B-protein
I	I-protein
interleukin-1	I-protein
receptor	I-protein
(	O
IL-1R	B-protein
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	B-protein
domain	I-protein
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O
	
In	O
contrast	O
to	O
the	O
type	B-protein
I	I-protein
receptor	I-protein
,	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
has	O
a	O
small	O
cytoplasmic	B-protein
tail	I-protein
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal-transducing	B-protein
or	O
a	O
regulatory	B-protein
molecule	I-protein
.	O
	
Here	O
we	O
report	O
that	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
does	O
not	O
mediate	O
gene	O
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	I-protein
of	O
the	O
human	B-protein
type	I-protein
II	I-protein
interleukin-1	I-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
type	I-protein
I	I-protein
IL-1R	I-protein
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	B-protein
I	I-protein
IL-1R	I-protein
.	O
	
Our	O
results	O
indicated	O
that	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin-1	B-protein
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O
	
###MEDLINE:93253031	
	
A	O
mutation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
primary	O
cortisol	O
resistance	O
.	O
	
The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O
	
In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	B-protein
receptors	I-protein
(	O
hGR	B-protein
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O
	
We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	B-protein
glucocorticoid-binding	I-protein
domain	I-protein
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O
	
Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-DNA
cDNAs	I-DNA
,	O
and	O
the	O
entire	O
hGR	B-DNA
cDNA	I-DNA
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O
	
At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O
	
When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
COS-1	B-cell_line
cells	I-cell_line
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+/-	O
0.068	O
and	O
1.54	O
+/-	O
0.06	O
nM	O
(	O
mean	O
+/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O
	
When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
CV-1	B-cell_line
cells	I-cell_line
that	O
were	O
cotransfected	O
with	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
,	O
the	O
hGR-Ile	B-protein
729	I-protein
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B-protein
activity	O
.	O
	
The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-protein
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O
	
###MEDLINE:93205400	
	
The	O
transcriptionally	B-protein
active	I-protein
factors	I-protein
mediating	O
the	O
effect	O
of	O
the	O
HTLV-I	B-protein
Tax	I-protein
transactivator	I-protein
on	O
the	O
IL-2R	B-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
include	O
the	O
product	O
of	O
the	O
c-rel	B-DNA
proto-oncogene	I-DNA
.	O
	
The	O
transactivator	O
HTLV-I	B-protein
Tax	I-protein
activates	O
the	O
promoter	B-DNA
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B-protein
2	I-protein
alpha-chain	I-protein
receptor	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
via	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	B-protein
family	I-protein
.	O
	
Tax1	B-protein
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	B-cell_line
HeLa	I-cell_line
and	O
lymphoid	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
This	O
activation	O
was	O
not	O
observed	O
in	O
undifferentiated	O
embryocarcinoma	O
F9	O
cells	O
.	O
	
Overexpression	O
of	O
the	O
p50	B-protein
,	O
p65	B-protein
and	O
Rel	B-protein
proteins	I-protein
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	B-protein
alpha	I-protein
kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
observed	O
only	O
with	O
Rel	B-protein
and	O
Rel	B-protein
plus	O
p65	B-protein
.	O
	
Moreover	O
,	O
whereas	O
both	O
Tax	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
IL-2R	B-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O
	
Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B-protein
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O
	
This	O
established	O
a	O
clear	O
difference	O
between	O
both	O
stimuli	O
,	O
indicating	O
that	O
Rel	B-protein
is	O
the	O
functionally	B-protein
active	I-protein
factor	I-protein
.	O
	
We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	B-protein
family	I-protein
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	B-protein
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O
	
###MEDLINE:93203219	
	
Transcriptional	O
regulation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Role	O
of	O
AP-1-	B-protein
and	I-protein
octamer-binding	I-protein
proteins	I-protein
in	O
control	O
of	O
IL3	B-protein
gene	O
expression	O
.	O
	
We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
	
Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross-linking	O
studies	O
,	O
we	O
found	O
that	O
c-Jun	B-protein
,	O
c-Fos	B-protein
,	O
and	O
octamer-binding	B-protein
proteins	I-protein
play	O
a	O
major	O
role	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL3	B-DNA
gene	I-DNA
via	O
their	O
interaction	O
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	B-DNA
5'-flanking	I-DNA
sequence	I-DNA
.	O
	
Additionally	O
,	O
the	O
region	O
between	O
bases	O
-107	B-DNA
and	I-DNA
-59	I-DNA
of	O
the	O
IL3	B-DNA
promoter	I-DNA
containing	O
putative	O
AP-2	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
motifs	I-DNA
appears	O
necessary	O
for	O
basal	O
level	O
expression	O
of	O
the	O
IL3	B-protein
gene	O
.	O
	
The	O
data	O
also	O
indicate	O
that	O
CD2	B-protein
receptor	O
activation	O
and	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B-protein
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans-activating	O
signals	O
.	O
	
These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	B-protein
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
###MEDLINE:93180775	
	
Dimerization	O
of	O
NF-KB2	B-protein
with	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O
	
Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O
	
NF-kappa	B-protein
B	I-protein
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	B-DNA
(	O
p105	B-protein
)	O
,	O
NFKB2	B-DNA
(	O
p100	B-protein
)	O
,	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
,	O
c-rel	B-DNA
and	O
relB	B-DNA
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	B-DNA
B	I-DNA
DNA	I-DNA
elements	I-DNA
have	O
been	O
isolated	O
.	O
	
We	O
have	O
previously	O
found	O
that	O
NFKB2	B-protein
(	I-protein
p49/p52	I-protein
)	I-protein
acts	O
in	O
concert	O
with	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
to	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	O
T-leukemia	B-cell_line
cells	I-cell_line
.	O
	
Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	B-protein
.	O
	
Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	B-protein
p49	I-protein
and	O
heterodimeric	B-protein
p49/p65	I-protein
for	O
binding	O
to	O
the	O
HIV	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O
	
p49	B-protein
has	O
a	O
approximately	O
18-fold-lower	O
affinity	O
for	O
the	O
HIV	O
kappa	B-DNA
B	I-DNA
site	I-DNA
(	O
KD	O
=	O
69.1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50-kDa	O
protein	O
NFKB1	B-protein
(	I-protein
p50	I-protein
)	I-protein
derived	O
from	O
p105	B-protein
(	O
KD	O
=	O
3.9	O
pM	O
)	O
.	O
	
In	O
contrast	O
,	O
the	O
affinity	O
of	O
heterodimeric	B-protein
NFKB2	I-protein
(	I-protein
p49	I-protein
)	I-protein
/RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
for	O
this	O
site	O
is	O
approximately	O
6-fold	O
higher	O
(	O
KD	O
=	O
11.8	O
pM	O
)	O
than	O
that	O
of	O
p49	B-protein
alone	O
.	O
	
Consistent	O
with	O
these	O
findings	O
,	O
in	O
vitro	O
transcription	O
was	O
stimulated	O
18-fold	O
by	O
the	O
addition	O
of	O
preformed	O
,	O
heterodimeric	B-protein
NFKB2	I-protein
(	I-protein
p49	I-protein
)	I-protein
/RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
protein	I-protein
.	O
	
Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O
	
Recombinant	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	B-protein
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-protein
,	O
p49/p65	B-protein
,	O
and	O
p50/p65	B-protein
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B-protein
(	O
p49	B-protein
)	O
or	O
NFKB1	O
(	O
p50	O
)	O
.	O
	
Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49/p65	B-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T-leukemia	I-cell_line
cells	I-cell_line
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD-3	B-protein
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:93157335	
	
The	O
c-rel	B-protein
protooncogene	I-protein
product	I-protein
represses	O
NF-kappa	B-protein
B	I-protein
p65	B-protein
-mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O
	
The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
and	O
the	O
5	B-DNA
'	I-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
share	O
functional	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T-cell	O
activation	O
.	O
	
These	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
the	O
product	O
of	O
the	O
c-rel	B-DNA
protooncogene	I-DNA
(	O
c-Rel	B-protein
)	O
.	O
	
Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B-protein
and	O
p50	B-protein
form	O
the	O
prototypical	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T-cell	O
activation	O
.	O
	
This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B-directed	O
transcription	O
from	O
either	O
the	O
HIV-1	B-DNA
LTR	I-DNA
or	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B-protein
.	O
	
We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c-Rel	B-protein
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B-protein
,	O
markedly	O
represses	O
p65	B-protein
-mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O
	
These	O
inhibitory	O
effects	O
of	O
c-Rel	B-protein
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-protein
,	O
suggesting	O
that	O
c-Rel	B-protein
inhibition	O
involves	O
competition	O
with	O
p50/p65	B-protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O
	
Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	B-protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
and	O
IL-2R	B-protein
alpha	I-protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-protein
.	O
	
###MEDLINE:93141262	
	
Ras	B-DNA
oncogene	I-DNA
transformation	O
of	O
human	B-cell_type
B	I-cell_type
lymphoblasts	I-cell_type
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O
	
The	O
p21ras	B-protein
small	I-protein
GTP	I-protein
binding	I-protein
proteins	I-protein
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O
	
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	B-DNA
Ha-ras	I-DNA
oncogene	I-DNA
in	O
EBV-immortalized	B-cell_line
B	I-cell_line
lymphoblasts	I-cell_line
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
,	O
with	O
an	O
impaired	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O
	
Since	O
induction	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
is	O
a	O
hallmark	O
of	O
lymphocyte	B-cell_type
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B-protein
naturally	O
triggers	O
B	B-cell_type
cell	I-cell_type
activation	O
.	O
	
The	O
ras-transformed	B-cell_line
lymphocytes	I-cell_line
displayed	O
a	O
fully	O
functional	O
IL-2r	B-protein
,	O
as	O
assessed	O
by	O
c-fos	B-DNA
induction	O
following	O
treatment	O
with	O
IL-2	B-protein
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	B-protein
.	O
	
The	O
decreased	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
indicates	O
that	O
the	O
ras	B-DNA
oncogene	I-DNA
blocks	O
terminal	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte-specific	B-protein
transcription	I-protein
factors	I-protein
.	O
	
Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B-protein
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	B-protein
factors	I-protein
PEA1	B-protein
(	O
AP1	B-protein
)	O
,	O
PEA3	B-protein
,	O
Oct-2	B-protein
or	O
NF-kB	B-protein
	
###MEDLINE:93300824	
	
Comparative	O
analysis	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
complex	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell-specific	O
inducibility	O
of	O
IL-2	B-protein
expression	O
.	O
	
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	B-protein
binding	O
activity	O
could	O
also	O
be	O
induced	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
The	O
B	B-protein
cell	I-protein
NFAT	I-protein
complex	I-protein
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT-driven	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
construct	I-DNA
.	O
	
Competition	O
with	O
an	O
AP-1	B-DNA
motif	I-DNA
or	O
with	O
anti-Jun	B-protein
and	O
anti-Fos	B-protein
antibodies	I-protein
abolished	O
binding	O
to	O
the	O
NFAT	B-DNA
motif	I-DNA
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	B-protein
complex	I-protein
formation	O
in	O
both	O
cell	O
types	O
.	O
	
Purified	O
recombinant	O
Jun	B-protein
and	I-protein
Fos	I-protein
proteins	I-protein
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	B-DNA
motif	I-DNA
.	O
	
However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full-length	O
,	O
but	O
not	O
truncated	O
,	O
Jun/Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	B-protein
expressed	I-protein
nuclear	I-protein
factor	I-protein
(	O
s	O
)	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	B-protein
complex	I-protein
in	O
both	O
cell	O
types	O
.	O
	
An	O
NFAT	B-protein
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	B-DNA
'	I-DNA
purine-rich	I-DNA
part	I-DNA
of	O
the	O
NFAT	B-DNA
sequence	I-DNA
failed	O
to	O
form	O
a	O
complex	O
and	O
to	O
compete	O
with	O
the	O
wild	O
type	O
motif	O
for	O
NFAT	B-protein
complex	I-protein
formation	O
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	B-protein
complex	I-protein
consisting	O
of	O
Jun	B-protein
,	O
Fos	B-protein
,	O
and	O
a	O
constitutive	B-protein
nuclear	I-protein
factor	I-protein
is	O
formed	O
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post-translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	B-protein
.	O
	
###MEDLINE:93307152	
	
Differential	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_line
T-	I-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O
	
Regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	O
)	O
expression	O
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid-sensitive	B-cell_line
human	I-cell_line
leukemic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
6TG1.1	I-cell_line
and	O
in	O
the	O
human	B-cell_line
B-cell	I-cell_line
line	I-cell_line
IM-9	I-cell_line
.	O
	
In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	B-RNA
mRNA	I-RNA
seen	O
in	O
IM-9	B-cell_line
cells	I-cell_line
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16-18	O
h	O
,	O
treatment	O
of	O
6TG1.1	B-cell_line
cells	I-cell_line
resulted	O
in	O
an	O
8-fold	O
increase	O
in	O
GR	B-RNA
mRNA	I-RNA
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	B-protein
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3-	O
to	O
4-fold	O
increase	O
in	O
GR	B-protein
protein	I-protein
.	O
	
Half-maximal	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
was	O
observed	O
between	O
10-100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
is	O
a	O
receptor-mediated	O
response	O
.	O
	
Positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	B-cell_line
CEM-C1	I-cell_line
cells	I-cell_line
,	O
which	O
contain	O
functional	O
GR	B-protein
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O
	
Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	O
a	O
consequence	O
nor	O
the	O
sole	O
cause	O
of	O
growth	O
arrest	O
.	O
	
The	O
degree	O
of	O
negative	O
autoregulation	O
in	O
IM-9	B-cell_line
cells	I-cell_line
and	O
positive	O
autoregulation	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
was	O
unaffected	O
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O
	
Measurement	O
of	O
GR	B-RNA
mRNA	I-RNA
turnover	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
treated	O
with	O
actinomycin-D	O
revealed	O
a	O
half-life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O
	
A	O
similar	O
half-life	O
was	O
determined	O
in	O
IM-9	B-cell_line
cells	I-cell_line
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O
	
These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid-mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue-specific	O
primary	O
transcriptional	O
response	O
.	O
	
###MEDLINE:93280865	
	
Induction	O
of	O
CD8	B-protein
antigen	I-protein
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	B-cell_line
human	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
.	O
	
The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	B-protein
surface	I-protein
antigens	I-protein
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
C7	I-cell_line
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	B-cell_line
C1	I-cell_line
(	O
r+	O
,	O
ly-	O
)	O
.	O
	
The	O
reactivity	O
of	O
murine	B-protein
monoclonal	I-protein
antibodies	I-protein
,	O
anti-CD4-FITC	B-protein
,	O
anti-CD8-FITC	B-protein
,	O
anti-CD2-FITC	B-protein
and	O
anti-calla-FITC	B-protein
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O
	
The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin-activated	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O
	
Dexamethasone	O
treatment	O
of	O
a	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
CEM	I-cell_line
C7	I-cell_line
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	B-protein
antigen	I-protein
CD8	I-protein
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	B-cell_type
T-lymphocytes	I-cell_type
.	O
	
By	O
comparison	O
,	O
there	O
was	O
no	O
modification	O
of	O
the	O
expression	O
of	O
CD4	B-protein
antigen	I-protein
,	O
which	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
cells	O
.	O
	
After	O
two	O
days	O
of	O
treatment	O
with	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
dexamethasone	O
,	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
showed	O
a	O
two-fold	O
increase	O
in	O
suppressor	O
activity	O
compared	O
to	O
untreated	O
cells	O
.	O
	
In	O
contrast	O
,	O
there	O
was	O
no	O
regulation	O
by	O
glucocorticoids	O
of	O
either	O
the	O
CD8	B-protein
or	O
CD4	B-protein
antigens	I-protein
in	O
the	O
leukemic	B-cell_line
clone	I-cell_line
CEM	I-cell_line
C1	I-cell_line
.	O
	
Furthermore	O
,	O
no	O
modification	O
of	O
the	O
suppressor	O
function	O
in	O
CEM	B-cell_line
C1	I-cell_line
cells	I-cell_line
by	O
dexamethasone	O
was	O
observed	O
.	O
	
In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B-protein
antigen	I-protein
expression	O
in	O
a	O
CD4+	B-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B-cell_line
receptor	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
.	O
	
###MEDLINE:93246644	
	
Adenovirus	O
E1A	O
inhibits	O
IFN	B-protein
-induced	O
resistance	O
to	O
cytolysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
Infection	O
of	O
target	B-cell_type
cells	I-cell_type
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	B-protein
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell-mediated	O
cytolysis	O
[	O
IFN	B-protein
-mediated	O
cytoprotection	O
(	O
IFN	B-protein
-MCP	O
)	O
]	O
.	O
	
It	O
has	O
been	O
thought	O
that	O
the	O
virally	O
induced	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
is	O
secondary	O
to	O
the	O
shutdown	O
of	O
cellular	O
macromolecular	O
synthesis	O
that	O
accompanies	O
cytopathic	O
virus	O
infections	O
.	O
	
Group	O
C	O
,	O
adenovirus	O
serotype	O
5	O
(	O
Ad5	O
)	O
infection	O
inhibits	O
both	O
IFN	B-protein
-MCP	O
and	O
cellular	B-protein
protein	I-protein
synthesis	O
.	O
	
This	O
study	O
determined	O
if	O
the	O
Ad5-induced	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
was	O
independent	O
of	O
adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
secondary	O
only	O
to	O
the	O
expression	O
of	O
the	O
Ad	B-DNA
early	I-DNA
region	I-DNA
1A	I-DNA
gene	I-DNA
(	O
E1A	B-DNA
)	O
.	O
	
To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	B-cell_line
human	I-cell_line
cells	I-cell_line
infected	O
with	O
an	O
Ad5	O
E1A	B-DNA
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	B-DNA
E1A	I-DNA
gene	I-DNA
.	O
	
IFN	B-protein
-MCP	O
was	O
not	O
inhibited	O
by	O
infection	O
with	O
dl343	O
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	B-protein
,	O
p55	B-protein
)	O
and	O
late	O
(	O
hexon	B-protein
)	O
Ad	B-protein
proteins	I-protein
.	O
	
In	O
contrast	O
to	O
E1A-negative	B-cell_line
,	I-cell_line
parental	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IFN	B-protein
-MCP	O
was	O
blocked	O
in	O
Ad5	O
E1A-transfected	B-cell_line
epithelial	I-cell_line
and	O
fibroblastic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Genetic	O
mapping	O
studies	O
within	O
the	O
E1A	B-DNA
gene	I-DNA
demonstrated	O
that	O
expression	O
of	O
only	O
the	O
first	O
exon	O
of	O
E1A	B-DNA
was	O
sufficient	O
to	O
inhibit	O
IFN	B-protein
-MCP	O
.	O
	
DNA	O
sequence	O
homology	O
of	O
E1A	B-DNA
genes	O
between	O
different	O
Ad	O
groups	O
(	O
group	O
A	O
,	O
Ad12	O
;	O
group	O
C	O
,	O
Ad5	O
)	O
is	O
limited	O
almost	O
entirely	O
to	O
three	O
conserved	O
regions	O
located	O
within	O
the	O
first	O
exon	O
of	O
E1A	B-DNA
.	O
	
Because	O
IFN	B-protein
-MCP	O
was	O
also	O
blocked	O
in	O
Ad12	B-cell_line
E1A-transfected	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
E1A-conserved	B-DNA
regions	I-DNA
may	O
be	O
necessary	O
to	O
inhibit	O
IFN	B-protein
-MCP	O
.	O
	
In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	B-protein
gene	I-protein
products	I-protein
inhibited	O
IFN	B-protein
-MCP	O
independently	O
of	O
virus	O
infection	O
.	O
	
E1A	B-DNA
's	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell-mediated	O
clearance	O
of	O
Ad-infected	O
or	O
Ad-transformed	B-cell_line
human	I-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:93224733	
	
A	O
protein	O
of	O
the	O
AP-1	B-protein
family	I-protein
is	O
a	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O
	
Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
involved	O
in	O
the	O
induction	O
of	O
IL-2	B-protein
gene	O
expression	O
.	O
	
The	O
response	O
element	O
for	O
NF-AT	B-protein
is	O
a	O
sequence	O
localized	O
between	O
-285/-254	B-DNA
in	O
the	O
IL-2	B-DNA
regulatory	I-DNA
region	I-DNA
.	O
	
The	O
composition	O
of	O
NF-AT	B-protein
protein	O
is	O
still	O
not	O
fully	O
elucidated	O
.	O
	
We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
AP-1	B-protein
protein	I-protein
is	O
a	O
component	O
of	O
the	O
NF-AT	B-protein
protein	I-protein
complex	I-protein
.	O
	
This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
to	O
compete	O
with	O
the	O
NF-AT	B-protein
site	O
for	O
binding	O
to	O
NF-AT	B-protein
and	O
by	O
the	O
capacity	O
of	O
immobilized	B-protein
anti-Jun	I-protein
and	O
anti-Fos	B-protein
antibodies	O
to	O
deplete	O
NF-AT	B-protein
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
There	O
was	O
no	O
detectable	O
binding	O
of	O
in	O
vitro	O
translated	O
Jun/Fos	B-protein
heterodimer	I-protein
(	O
AP-1	B-protein
)	O
to	O
the	O
NF-AT	B-protein
sequence	O
,	O
and	O
the	O
NF-AT	B-DNA
sequence	I-DNA
was	O
unable	O
to	O
inhibit	O
the	O
binding	O
of	O
Jun/Fos	B-protein
to	O
the	O
AP-1	B-DNA
sequence	I-DNA
.	O
	
The	O
presence	O
of	O
an	O
AP-1	B-protein
protein	O
in	O
the	O
NF-AT	B-protein
protein	O
complex	O
may	O
regulate	O
NF-AT	B-protein
-binding	O
activity	O
through	O
protein-protein	O
interaction	O
.	O
	
###MEDLINE:93204999	
	
Interaction	O
between	O
NF-kappa	B-protein
B	I-protein
-and	O
serum	B-protein
response	I-protein
factor	I-protein
-binding	O
elements	O
activates	O
an	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
enhancer	I-DNA
specifically	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
preferentially	O
activated	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
IL-2R	B-protein
alpha	I-protein
enhancer	O
binds	O
NF-kappa	B-protein
B	I-protein
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
alone	O
.	O
	
Serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
binds	O
to	O
a	O
site	O
adjacent	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
IL-2R	B-DNA
enhancer	I-DNA
,	O
and	O
both	O
sites	O
together	O
have	O
strong	O
transcriptional	O
activity	O
specifically	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	B-protein
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O
	
Overexpression	O
of	O
SRF	B-protein
in	O
B	B-cell_type
cells	I-cell_type
causes	O
the	O
IL-2R	B-DNA
enhancer	I-DNA
to	O
function	O
as	O
well	O
as	O
it	O
does	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
the	O
high	O
level	O
of	O
SRF	B-protein
binding	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
functionally	O
important	O
.	O
	
###MEDLINE:93211996	
	
Mutual	O
regulation	O
of	O
the	O
transcriptional	B-protein
activator	I-protein
NF-kappa	B-protein
B	I-protein
and	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O
	
The	O
NK-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O
	
Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O
	
It	O
is	O
demonstrated	O
here	O
with	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
with	O
concomitant	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
protein	O
synthesis	O
.	O
	
Transfection	O
studies	O
reveal	O
that	O
the	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF-kappa	B-protein
B	I-protein
and	O
by	O
homodimers	O
of	O
p65	B-protein
and	O
of	O
c-Rel	B-protein
.	O
	
We	O
propose	O
a	O
model	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
Subsequently	O
,	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF-kappa	B-protein
B	I-protein
.	O
	
This	O
resurgence	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
is	O
again	O
inhibited	O
.	O
	
###MEDLINE:93172387	
	
Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	B-DNA
to	I-DNA
-130	I-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	B-DNA
gene	I-DNA
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	B-DNA
transcriptional	O
activity	O
in	O
a	O
T-cell	B-cell_line
line	I-cell_line
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65	O
:	O
2436-2444	O
,	O
1991	O
)	O
.	O
	
In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	B-DNA
to	I-DNA
-	I-DNA
184	I-DNA
,	O
-183	B-DNA
to	I-DNA
-166	I-DNA
,	O
-165	B-DNA
to	I-DNA
-148	I-DNA
,	O
and	O
-148	B-DNA
to	I-DNA
-130	I-DNA
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	B-cell_line
RD	I-cell_line
cells	I-cell_line
with	O
CEMx174	B-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	B-DNA
and	I-DNA
-76	I-DNA
and	O
between	O
-75	B-DNA
and	I-DNA
-58	I-DNA
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
-	I-DNA
and	I-DNA
Sp1-binding	I-DNA
sites	I-DNA
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O
	
Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O
	
Three	O
mutants	O
(	O
-201/-184	O
NXS	O
,	O
-165/-148	O
NXS	O
,	O
and	O
-147/-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201/-184	O
NXS	O
and	O
-183/-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O
	
In	O
addition	O
,	O
we	O
observed	O
cell	O
type-specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O
	
In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF-kappa	B-protein
B	I-protein
and	O
SP1-binding	B-DNA
sites	I-DNA
but	O
also	O
for	O
several	O
regions	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O
	
###MEDLINE:93141620	
	
Transcription	B-protein
factor	I-protein
GATA-1	B-protein
and	O
erythroid	O
development	O
.	O
	
In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	B-protein
in	O
red	B-cell_type
cell	I-cell_type
development	O
at	O
a	O
genetic	O
level	O
.	O
	
We	O
have	O
established	O
the	O
essential	O
nature	O
of	O
GATA-1	B-protein
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O
	
By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	B-DNA
gene	I-DNA
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	B-DNA
sequences	I-DNA
.	O
	
We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	O
been	O
possible	O
heretofore	O
.	O
	
Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O
	
The	O
ideal	O
situation	O
would	O
be	O
analyses	O
conducted	O
in	O
GATA-1	B-cell_line
-erythroid	I-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
these	O
cells	O
have	O
been	O
impossible	O
to	O
generate	O
given	O
the	O
requirement	O
of	O
GATA-1	B-protein
for	O
Epo	B-protein
receptor	I-protein
expression	O
and	O
red	B-cell_type
cell	I-cell_type
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O
	
It	O
may	O
be	O
possible	O
to	O
produce	O
such	O
cells	O
by	O
first	O
expressing	O
the	O
Epo	B-protein
receptor	I-protein
under	O
the	O
influence	O
of	O
a	O
constitutive	O
promoter	O
and	O
then	O
targeting	O
the	O
GATA-1	B-DNA
gene	I-DNA
.	O
	
If	O
GATA-1	B-cell_line
-red	I-cell_line
cells	I-cell_line
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	B-DNA
genes	I-DNA
.	O
	
Structure-function	O
studies	O
of	O
the	O
GATA-1	B-protein
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O
	
However	O
,	O
the	O
ES	O
cell	O
system	O
can	O
be	O
used	O
as	O
an	O
alternative	O
until	O
targeted	B-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
become	O
available	O
.	O
	
Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA-binding	B-protein
protein	I-protein
family	I-protein
members	I-protein
to	O
determine	O
whether	O
they	O
rescue	O
the	O
mutation	O
.	O
	
If	O
they	O
can	O
not	O
,	O
chimeric	B-protein
proteins	I-protein
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O
	
We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	B-protein
during	O
erythroid	O
ontogeny	O
.	O
	
How	O
does	O
GATA-1	B-protein
regulate	O
red	B-DNA
cell	I-DNA
genes	I-DNA
like	O
globin	B-DNA
or	O
the	O
Epo	B-protein
receptor	I-protein
?	O
Once	O
we	O
identify	O
the	O
functional	O
domains	O
of	O
the	O
GATA-binding	B-protein
proteins	I-protein
,	O
we	O
hope	O
to	O
learn	O
what	O
proteins	O
GATA-1	B-protein
binds	O
to	O
in	O
the	O
basic	O
transcription	O
machinery	O
or	O
in	O
chromatin	O
.	O
	
Is	O
GATA-1	B-protein
necessary	O
for	O
globin	O
gene	O
switching	O
?	O
GATA-1	B-protein
may	O
be	O
modified	O
differently	O
during	O
development	O
so	O
that	O
the	O
locus	O
control	O
region	O
can	O
interact	O
with	O
different	O
globin	B-DNA
promoters	I-DNA
.	O
	
We	O
may	O
find	O
that	O
one	O
region	O
of	O
the	O
protein	O
is	O
required	O
for	O
embryonic	O
expression	O
and	O
another	O
for	O
adult	O
globin	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:93135830	
	
A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
homologous	O
to	O
a	O
rodent	B-DNA
gene	I-DNA
encoding	O
a	O
zinc-binding	B-protein
potential	I-protein
transcription	I-protein
factor	I-protein
.	O
	
G0S24	B-DNA
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	B-DNA
G0/G1	I-DNA
switch	I-DNA
regulatory	I-DNA
genes	I-DNA
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B-protein
or	O
cycloheximide	O
to	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
Comparison	O
of	O
a	O
full-length	B-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	B-DNA
.	O
	
Potential	O
phosphorylation	B-protein
sites	I-protein
include	O
the	O
sequence	O
PSPTSPT	B-protein
,	O
which	O
resembles	O
an	O
RNA	B-protein
polymerase	I-protein
II	I-protein
repeat	I-protein
reported	O
to	O
be	O
a	O
target	O
of	O
the	O
cell	B-protein
cycle	I-protein
control	I-protein
kinase	I-protein
cdc2	I-protein
.	O
	
Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O
	
Group	O
1	O
contains	O
G0S24	B-DNA
and	O
the	O
rat	B-DNA
and	I-DNA
mouse	I-DNA
TIS11	I-DNA
genes	I-DNA
(	O
also	O
known	O
as	O
TTP	B-DNA
,	O
Nup475	B-DNA
,	O
and	O
Zfp36	B-DNA
)	O
.	O
	
Members	O
of	O
this	O
group	O
have	O
three	B-protein
tetraproline	I-protein
repeats	I-protein
.	O
	
Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	I-protein
and	O
an	O
``	O
arginine	B-protein
element	I-protein
``	O
(	O
RRLPIF	B-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	I-protein
.	O
	
All	O
groups	O
contain	O
cysteine-	B-protein
and	I-protein
histidine-rich	I-protein
putative	I-protein
zinc	I-protein
finger	I-protein
domains	I-protein
and	O
a	O
serine-phenylalanine	B-protein
``	I-protein
SFS	I-protein
''	I-protein
domain	I-protein
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	B-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
.	O
	
Comparison	O
of	O
group	O
1	O
human	B-DNA
and	I-DNA
mouse	I-DNA
genomic	I-DNA
sequences	I-DNA
shows	O
high	O
conservation	O
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
exons	B-DNA
.	O
	
A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O
	
G0S24	B-DNA
has	O
potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
intron	B-DNA
;	O
these	O
include	O
a	O
serum	B-DNA
response	I-DNA
element	I-DNA
.	O
	
Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	B-protein
product	I-protein
has	O
a	O
similar	O
role	O
.	O
	
###MEDLINE:93303626	
	
Regulation	O
of	O
lymphoid-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
enhancer	I-DNA
by	O
ETS-domain	O
proteins	O
.	O
	
The	O
enhancer	B-DNA
for	O
the	O
immunoglobulin	B-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
(	O
IgH	B-protein
)	O
activates	O
a	O
heterologous	B-DNA
gene	I-DNA
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	B-cell_type
lymphocyte	I-cell_type
differentiation	O
.	O
	
A	O
lymphoid-specific	B-DNA
element	I-DNA
,	O
microB	B-DNA
,	O
is	O
necessary	O
for	O
enhancer	B-DNA
function	O
in	O
pre-B	B-cell_type
cells	I-cell_type
.	O
	
A	O
microB	B-protein
binding	I-protein
protein	I-protein
is	O
encoded	O
by	O
the	O
PU.1/Spi-1	B-DNA
proto-oncogene	I-DNA
.	O
	
Another	O
sequence	B-DNA
element	I-DNA
,	O
microA	B-DNA
,	O
was	O
identified	O
in	O
the	O
mu	B-DNA
enhancer	I-DNA
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	B-DNA
proto-oncogene	I-DNA
.	O
	
The	O
microA	B-DNA
motif	O
was	O
required	O
for	O
microB-dependent	B-DNA
enhancer	I-DNA
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	B-DNA
B	I-DNA
cell-specific	I-DNA
enhancer	I-DNA
is	O
composed	O
of	O
both	O
the	O
PU.1	B-DNA
and	I-DNA
Ets-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O
	
Co-expression	O
of	O
both	O
PU.1	B-protein
and	O
Ets-1	B-protein
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
trans-activated	B-DNA
reporter	I-DNA
plasmids	I-DNA
that	O
contained	O
the	O
minimal	O
mu	B-DNA
enhancer	I-DNA
.	O
	
These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	B-protein
family	I-protein
in	O
the	O
activation	O
of	O
IgH	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:93300929	
	
1	O
,	O
25-Dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
synergistically	O
induce	O
monocytic	B-cell_type
cell	I-cell_type
differentiation	O
:	O
FOS	B-protein
and	O
RB	B-protein
expression	O
.	O
	
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
interact	O
synergistically	O
to	O
induce	O
monocytic	O
differentiation	O
of	O
U937	B-cell_line
histiocytic	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O
	
Addition	O
of	O
TPA	O
causes	O
an	O
otherwise	O
ineffective	O
dose	O
of	O
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
to	O
induce	O
differentiation	O
.	O
	
The	O
induced	O
differentiation	O
depends	O
on	O
the	O
simultaneous	O
(	O
vs.	O
sequential	O
)	O
presence	O
of	O
both	O
agents	O
.	O
	
The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O
	
The	O
induced	O
differentiation	O
occurs	O
with	O
down-regulation	O
of	O
c-fos	B-protein
protein	I-protein
and	O
an	O
accompanying	O
up-regulation	O
of	O
RB	B-protein
protein	I-protein
expression	O
,	O
consistent	O
with	O
a	O
possible	O
need	O
for	O
up-regulated	O
RB	B-protein
expression	O
to	O
maintain	O
a	O
given	O
differentiated	O
phenotype	O
and	O
suppress	O
transcriptional	B-protein
activators	I-protein
that	O
might	O
typically	O
be	O
associated	O
with	O
proliferation	O
.	O
	
###MEDLINE:93279468	
	
Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA-2/estrogen	B-protein
receptor	I-protein
chimera	I-protein
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone-dependent	O
manner	O
.	O
	
The	O
GATA	B-protein
factors	I-protein
are	O
a	O
family	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA-binding	B-protein
domains	I-protein
.	O
	
One	O
enigmatic	O
aspect	O
of	O
GATA	B-protein
factor	I-protein
expression	O
is	O
that	O
several	O
GATA	B-protein
proteins	I-protein
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA-binding	B-protein
site	I-protein
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O
	
To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	B-protein
factors	I-protein
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
and	O
GATA-3	B-protein
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
estrogen	I-protein
receptor	I-protein
(	O
ER	B-protein
)	O
.	O
	
These	O
GATA/ER	B-protein
chimeric	I-protein
factors	I-protein
were	O
shown	O
to	O
be	O
hormone-inducible	B-protein
trans-activating	I-protein
proteins	I-protein
in	O
transient	O
transfection	O
assays	O
.	O
	
When	O
stably	O
introduced	O
into	O
primary	B-cell_type
erythroblasts	I-cell_type
or	O
conditionally	B-cell_line
transformed	I-cell_line
erythroid	I-cell_line
progenitors	I-cell_line
cells	I-cell_line
,	O
exogenous	O
GATA-2/ER	B-protein
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen-dependent	O
manner	O
.	O
	
These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA-2/ER	B-protein
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA-2	B-protein
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	B-cell_line
progenitors	I-cell_line
expressing	O
either	O
Gal/ER	B-protein
or	O
GATA-3/ER	B-protein
do	O
not	O
display	O
a	O
hormone-responsive	O
block	O
in	O
differentiation	O
.	O
	
Thus	O
,	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self-renewal	O
capacity	O
of	O
early	B-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:93258811	
	
Mice	O
deficient	O
for	O
the	O
55	B-protein
kd	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O
	
The	O
multiple	O
biological	O
activities	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	B-protein
surface	I-protein
receptors	I-protein
of	O
55	B-protein
kd	I-protein
(	O
TNFRp55	B-protein
)	O
and	O
75	B-protein
kd	I-protein
(	O
TNFRp75	B-protein
)	O
.	O
	
Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-protein
-deficient	O
mouse	O
strain	O
.	O
	
Cells	O
from	O
TNFRp55-/-mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-protein
but	O
display	O
normal	O
numbers	O
of	O
high	B-protein
affinity	I-protein
TNFRp75	I-protein
molecules	I-protein
.	O
	
Thymocyte	B-cell_type
development	O
and	O
lymphocyte	B-cell_type
populations	I-cell_type
are	O
unaltered	O
,	O
and	O
clonal	O
deletion	O
of	O
potentially	O
self-reactive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
impaired	O
.	O
	
However	O
,	O
TNF	B-protein
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	B-protein
to	O
induce	O
NF-kappa	B-protein
B	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
TNFRp55	B-protein
-deficient	O
mice	O
.	O
	
The	O
loss	O
of	O
TNFRp55	B-protein
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S.	B-protein
aureus	I-protein
enterotoxin	I-protein
B	I-protein
.	O
	
In	O
contrast	O
,	O
TNFRp55-deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O
	
Thus	O
,	O
the	O
55	B-protein
kd	I-protein
TNFR	I-protein
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
's	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O
	
###MEDLINE:93224719	
	
Costimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
activation	O
by	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O
	
Enhanced	O
IL-2	B-protein
transcription	O
correlates	O
with	O
increased	O
c-fos	B-protein
synthesis	O
and	O
increased	O
Fos	B-protein
content	O
of	O
AP-1	B-protein
.	O
	
Endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
act	O
as	O
APC	O
for	O
resting	B-cell_type
PBL	I-cell_type
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O
	
We	O
previously	O
reported	O
that	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
EC	I-cell_type
provide	O
costimulatory	O
signals	O
to	O
PHA-stimulated	B-cell_type
PBL	I-cell_type
via	O
CD2	B-protein
:	I-protein
lymphocyte	I-protein
function-associated	I-protein
Ag-3	I-protein
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three-	O
to	O
eight-fold	O
enhancement	O
of	O
IL-2	B-protein
production	O
.	O
	
The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	B-cell_type
to	O
PBL	B-cell_type
suboptimally	O
stimulated	O
with	O
mAb	B-protein
OKT3	I-protein
.	O
	
We	O
now	O
report	O
that	O
EC	B-cell_type
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	B-RNA
mRNA	I-RNA
as	O
a	O
result	O
of	O
increased	O
IL-2	B-protein
transcription	O
in	O
PBL	B-cell_type
.	O
	
We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	B-cell_type
on	O
T	B-protein
cell	I-protein
nuclear	I-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
transcription	O
,	O
including	O
c-jun	B-protein
and	O
c-fos-two	B-protein
components	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
others	O
.	O
	
PBL	B-cell_type
constitutively	O
express	O
c-jun	B-protein
transcripts	I-protein
,	O
and	O
the	O
level	O
of	O
c-jun	B-RNA
mRNA	I-RNA
is	O
not	O
altered	O
by	O
PHA	B-protein
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	B-cell_type
.	O
	
In	O
contrast	O
,	O
c-fos	B-RNA
mRNA	I-RNA
is	O
absent	O
from	O
resting	O
T	B-cell_type
cells	I-cell_type
and	O
is	O
induced	O
on	O
PHA	B-protein
activation	O
.	O
	
EC	B-cell_type
alone	O
do	O
not	O
induce	O
c-fos	B-RNA
mRNA	I-RNA
but	O
augment	O
the	O
level	O
of	O
c-fos	B-RNA
mRNA	I-RNA
in	O
PHA-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
3-	O
to	O
10-fold	O
.	O
	
This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
pathway	O
.	O
	
Gel-shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	B-cell_type
PBL	I-cell_type
that	O
bind	O
to	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
that	O
contain	O
immunoreactive	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
protein	O
.	O
	
In	O
contrast	O
,	O
AP-1	B-protein
from	O
PHA-activated	B-cell_type
cells	I-cell_type
contains	O
c-Jun	B-protein
and	O
low	O
levels	O
of	O
c-Fos	B-protein
.	O
	
Strikingly	O
,	O
costimulation	O
with	O
EC	B-cell_type
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15-fold	O
)	O
in	O
the	O
c-Fos	B-protein
content	O
of	O
AP-1	B-protein
.	O
	
Levels	O
of	O
other	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
IL-2	B-protein
regulation	O
were	O
not	O
altered	O
by	O
EC	B-cell_type
,	O
although	O
NFAT-DNA	B-protein
complexes	I-protein
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O
	
In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	B-protein
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	B-cell_type
.	O
	
###MEDLINE:93204975	
	
Transcriptional	O
activation	O
of	O
human	B-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
by	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	B-protein
factor-DNA	I-protein
complexes	I-protein
.	O
	
We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
and	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
located	O
40	B-DNA
kb	I-DNA
upstream	I-DNA
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
.	O
	
It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	B-DNA
behaved	O
as	O
an	O
authentic	O
enhancer	B-DNA
for	O
high-level	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O
	
Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	B-DNA
plasmids	I-DNA
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	B-DNA
enhancer	I-DNA
-mediated	O
activity	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O
	
Site-directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	B-DNA
enhancer-	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O
	
The	O
functional	O
domains	O
of	O
HS-40	B-DNA
were	O
also	O
mapped	O
.	O
	
Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF-E2/AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	B-DNA
in	O
the	O
erythroid-specific	O
activation	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O
	
Site-directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
function	O
of	O
one	O
of	O
the	O
two	O
NF-E2/AP1	O
motifs	O
of	O
HS-40	B-DNA
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF-E2	B-protein
but	O
not	O
AP1	B-protein
transcription	I-protein
factor	I-protein
.	O
	
Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	B-DNA
enhancer	I-DNA
region	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
,	O
adult	B-cell_line
nucleated	I-cell_line
erythroblasts	I-cell_line
,	O
and	O
different	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O
	
All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS-40	B-DNA
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
in	O
living	O
K562	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O
	
On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	B-DNA
sequence	I-DNA
motifs	I-DNA
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O
	
In	O
comparison	O
to	O
K562	B-cell_line
,	O
nucleated	B-cell_line
erythroblasts	I-cell_line
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	B-protein
factor	I-protein
binding	O
in	O
vivo	O
at	O
the	O
HS-40	B-DNA
region	O
.	O
	
These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
and	O
the	O
fetal/adult	B-DNA
alpha	I-DNA
globin	I-DNA
genes	I-DNA
is	O
mediated	O
by	O
erythroid	O
cell-specific	O
and	O
developmental	B-protein
stage-specific	I-protein
nuclear	I-protein
factor-DNA	I-protein
complexes	I-protein
which	O
form	O
at	O
the	O
enhancer	B-DNA
(	O
HS-40	B-DNA
)	O
and	O
the	O
globin	B-DNA
promoters	I-DNA
.	O
	
###MEDLINE:93194832	
	
Transcriptional	O
regulation	O
of	O
the	O
pyruvate	B-DNA
kinase	I-DNA
erythroid-specific	I-DNA
promoter	I-DNA
.	O
	
Mammal	B-protein
pyruvate	I-protein
kinases	I-protein
are	O
encoded	O
by	O
two	O
genes	O
.	O
	
The	O
L	B-DNA
gene	I-DNA
produces	O
the	O
erythroid	B-protein
(	O
R-PK	B-protein
)	O
or	O
the	O
hepatic	B-protein
(	I-protein
L-PK	I-protein
)	I-protein
isozymes	I-protein
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	B-DNA
.	O
	
We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	B-DNA
and	I-DNA
trans-acting	I-DNA
elements	I-DNA
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	B-DNA
gene	I-DNA
erythroid	I-DNA
promoter	I-DNA
.	O
	
A	O
R-PK	B-DNA
DNA	I-DNA
fragment	I-DNA
extending	O
from	O
-870	O
to	O
+54	O
relative	O
to	O
the	O
cap	B-DNA
site	I-DNA
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	B-DNA
gene	I-DNA
.	O
	
Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	B-DNA
promoter	I-DNA
(	O
-62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid-specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O
	
One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	B-protein
family	I-protein
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O
	
Although	O
the	O
-20	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
,	O
it	O
does	O
not	O
bind	O
TFIID	B-protein
.	O
	
Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
by	O
a	O
canonical	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
suppresses	O
the	O
promoter	O
activity	O
.	O
	
Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	B-protein
and	O
GATA	B-DNA
binding	I-DNA
sites	I-DNA
can	O
drive	O
efficient	O
and	O
tissue-specific	O
expression	O
of	O
this	O
R-PK	B-protein
minimal	B-DNA
promoter	I-DNA
.	O
	
Finally	O
,	O
by	O
co-transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R-PK	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:93171603	
	
Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	B-protein
II	I-protein
MHC	I-protein
X1	I-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
wild-type	B-cell_line
and	I-cell_line
class	I-cell_line
II-deficient	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O
	
The	O
X	B-DNA
box	I-DNA
region	I-DNA
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
Although	O
several	O
class	B-protein
II	I-protein
promoter-specific	I-protein
DNA	I-protein
binding	I-protein
factors	I-protein
have	O
been	O
described	O
,	O
only	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
factor	O
,	O
RFX	B-protein
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
class	O
II-deficient	O
congenital	O
immunodeficiency	O
.	O
	
To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
,	O
the	O
role	O
of	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
was	O
examined	O
in	O
both	O
class	B-cell_line
II-positive	I-cell_line
and	O
-negative	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
to	O
the	O
wild-type	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
Raji	I-cell_line
,	O
two	B-cell_line
class	I-cell_line
II	I-cell_line
transcriptional	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SJO	B-cell_line
and	O
RJ2.2.5	B-cell_line
,	O
and	O
Jurkat	B-cell_line
,	O
a	O
class	B-cell_line
II	I-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
examined	O
.	O
	
In	O
contrast	O
to	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
neither	O
of	O
the	O
class	B-cell_line
II	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
use	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	B-DNA
gene	I-DNA
,	O
indicating	O
that	O
the	O
X	O
box-dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O
	
The	O
binding	O
activity	O
of	O
the	O
X1	B-protein
box	I-protein
DNA-binding	I-protein
protein	I-protein
RFX	B-protein
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
and	O
the	O
mutant	O
RJ2.2.5	B-cell_line
but	O
was	O
absent	O
in	O
SJO	B-cell_line
and	O
Jurkat	B-cell_line
.	O
	
However	O
,	O
other	O
X1	O
box-specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O
	
To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	B-protein
binding	I-protein
proteins	I-protein
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	B-protein
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA-binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1-specific	B-protein
factors	I-protein
.	O
	
One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	B-protein
activity	O
.	O
	
A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	B-protein
activity	O
.	O
	
In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	B-cell_line
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O
	
These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box-specific	O
DNA-binding	O
activities	O
exist	O
in	O
all	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	B-protein
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O
	
###MEDLINE:93124567	
	
Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	B-DNA
enhancer/promoters	I-DNA
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O
	
The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O
	
To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
inserted	O
into	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
place	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
.	O
	
The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	B-cell_line
cells	I-cell_line
and	O
on	O
HIV	O
infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
or	O
continuous	B-cell_line
T-leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
evaluated	O
.	O
	
HIVs	O
in	O
which	O
the	O
NF-kappa	B-DNA
B/Sp1	I-DNA
enhancer	I-DNA
plus	O
the	O
downstream	B-DNA
TATA	I-DNA
element	I-DNA
were	O
replaced	O
with	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
also	O
constructed	O
.	O
	
Viruses	O
containing	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
immediate-early	I-DNA
enhancer	I-DNA
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
AA2	B-cell_line
cells	I-cell_line
but	O
replicated	O
less	O
efficiently	O
in	O
H9	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
.	O
	
These	O
studies	O
indicate	O
that	O
heterologous	B-DNA
enhancer	I-DNA
elements	I-DNA
are	O
capable	O
of	O
restoring	O
Tat	B-protein
responsiveness	O
to	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
the	O
context	O
of	O
directing	O
reporter	B-DNA
gene	I-DNA
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O
	
###MEDLINE:93126354	
	
Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation-induced	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathway	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O
	
Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	B-protein
kinase	I-protein
regulatory	O
pathway	O
.	O
	
We	O
show	O
that	O
in	O
B-lymphocyte	B-cell_type
precursors	I-cell_type
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	B-protein
protein	I-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O
	
All	O
of	O
the	O
radiation-induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein-tyrosine	B-protein
kinase	I-protein
inhibitors	I-protein
genistein	I-protein
and	I-protein
herbimycin	I-protein
A	I-protein
.	O
	
Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
cascade	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
.	O
	
Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation-induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O
	
###MEDLINE:97218353	
	
Detection	O
of	O
adenovirus	B-DNA
DNA	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O
	
Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O
	
Lymphocytes	B-cell_type
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O
	
To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
.	O
	
Two	O
sets	O
of	O
nested	B-DNA
primers	I-DNA
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	B-DNA
E1A	I-DNA
and	I-DNA
hexon	I-DNA
genes	I-DNA
.	O
	
The	O
E1A	B-DNA
and	I-DNA
hexon	I-DNA
primers	I-DNA
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A-F	O
)	O
.	O
	
Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	I-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O
	
None	O
of	O
33	O
PBMC	B-cell_type
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	B-DNA
DNA	I-DNA
by	O
nested	O
PCR	O
assay	O
.	O
	
In	O
comparison	O
,	O
PBMC	B-cell_type
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	B-DNA
DNA	I-DNA
.	O
	
It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	B-cell_type
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O
	
In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O
	
###MEDLINE:93363253	
	
Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
expression	O
and	O
signal	O
transduction	O
in	O
HIV-1-infected	B-cell_type
cells	I-cell_type
.	O
	
OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter-relationship	O
between	O
HIV-1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV-1	O
replication	O
.	O
	
DESIGN	O
:	O
Infected	O
promyelocytic	B-cell_type
and	O
promonocytic	B-cell_type
cells	I-cell_type
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	B-protein
receptors	I-protein
.	O
	
METHODS	O
:	O
TNF	B-protein
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	B-protein
antibody	I-protein
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O
	
HIV-1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B-protein
transcriptase	I-protein
assay	O
.	O
	
RESULTS	O
:	O
In	O
the	O
OM-10.1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF-alpha-induced	O
HIV-1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B-protein
kd	I-protein
TNF	I-protein
receptor	I-protein
(	O
TR75	B-protein
)	O
expression	O
although	O
55	B-protein
kD	I-protein
TNF	I-protein
receptor	I-protein
(	O
TR55	B-protein
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O
	
A	O
series	O
of	O
uninfected	B-cell_line
parental	I-cell_line
HL-60	I-cell_line
subclones	I-cell_line
all	O
reduced	O
TR75	B-protein
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	B-protein
treatment	O
.	O
	
Enhanced	O
TR75	B-protein
expression	O
on	O
OM-10.1	O
cells	O
followed	O
the	O
same	O
TNF-alpha	B-protein
-dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV-1	O
production	O
.	O
	
An	O
increase	O
in	O
TR75	B-protein
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV-1	O
infection	O
of	O
HL-60	B-cell_line
promyelocytes	I-cell_line
.	O
	
Although	O
TR55	B-protein
expression	O
was	O
unaltered	O
during	O
TNF-alpha	B-protein
-induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O
	
Antibody	O
cross-linking	O
of	O
TR55	B-protein
,	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
TNF-alpha	I-protein
,	O
induced	O
maximal	O
HIV-1	O
expression	O
,	O
an	O
up-modulation	O
of	O
surface	O
TR75	B-protein
,	O
and	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
OM-10.1	O
cultures	O
.	O
	
Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B-protein
anti-TR55	I-protein
antibody	I-protein
was	O
used	O
.	O
	
Anti-TR55	B-protein
antibody	I-protein
cross-linking	O
in	O
chronically	B-cell_line
infected	I-cell_line
U1	I-cell_line
promonocytic	I-cell_line
cultures	I-cell_line
could	O
only	O
partially	O
substitute	O
for	O
TNF-alpha-induced	O
HIV-1	O
expression	O
.	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV-1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	B-protein
receptors	I-protein
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	B-protein
signal	O
transduction	O
.	O
	
###MEDLINE:94191916	
	
Comparative	O
mapping	O
of	O
SRY	B-DNA
in	O
the	O
great	O
apes	O
.	O
	
Cytogenetic	O
studies	O
of	O
the	O
primate	B-DNA
Y	I-DNA
chromosomes	I-DNA
have	O
suggested	O
that	O
extensive	O
rearrangements	O
have	O
occurred	O
during	O
evolution	O
of	O
the	O
great	O
apes	O
.	O
	
We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O
	
pHU-14	B-DNA
,	O
a	O
probe	O
including	O
sequences	O
from	O
the	O
sex	B-DNA
determining	I-DNA
gene	I-DNA
SRY	I-DNA
,	O
hybridizes	O
close	O
to	O
the	O
early	O
replicating	O
pseudoautosomal	O
segment	O
in	O
a	O
telomeric	O
or	O
subtelomeric	O
position	O
of	O
the	O
Y	B-DNA
chromosomes	I-DNA
of	O
all	O
great	O
apes	O
.	O
	
The	O
low	B-DNA
copy	I-DNA
repeat	I-DNA
detected	O
by	O
the	O
probe	O
Fr35-II	B-DNA
is	O
obviously	O
included	O
in	O
Y	O
chromosomal	O
rearrangements	O
during	O
hominid	O
evolution	O
.	O
	
These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	B-DNA
region	I-DNA
and	O
the	O
testis-determining	O
region	O
.	O
	
The	O
rest	O
of	O
the	O
Y	B-DNA
chromosome	I-DNA
has	O
undergone	O
several	O
rearrangements	O
in	O
the	O
different	O
great	O
apes	O
.	O
	
###MEDLINE:93272960	
	
Calcium	O
dependent	O
activation	O
of	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
by	O
p59fyn	B-protein
.	O
	
A	O
reporter	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
a	O
T-cell	B-DNA
antigen	I-DNA
receptor	I-DNA
element	I-DNA
was	O
activated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
a	O
calcium	O
ionophore	O
.	O
	
Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O
	
When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	B-protein
,	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
activated	O
by	O
PMA	B-protein
alone	O
.	O
	
Thus	O
p59fyn	B-protein
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O
	
The	O
activation	O
by	O
p59fyn	B-protein
plus	O
PMA	B-protein
was	O
blocked	O
by	O
EGTA	O
and	O
by	O
the	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
.	O
	
###MEDLINE:93292612	
	
Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B-protein
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
.	O
	
Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid-specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	B-DNA
genes	I-DNA
and	O
the	O
erythropoietin	B-DNA
receptor	I-DNA
(	I-DNA
Epo-R	I-DNA
)	I-DNA
gene	I-DNA
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
.	O
	
In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	O
of	O
GATA-1	B-protein
,	O
response	O
to	O
Epo	O
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
GATA-1	B-protein
,	O
Epo-R	B-protein
and	O
globin	B-DNA
genes	I-DNA
in	O
an	O
Epo-dependent	O
human	O
cell	O
line	O
,	O
UT-7	B-cell_line
Epo	O
.	O
	
The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	B-cell_line
granulocyte-macrophage	I-cell_line
colony-stimulating	I-cell_line
factor	I-cell_line
(	I-cell_line
GM-CSF	I-cell_line
)	I-cell_line
-dependent	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	B-protein
.	O
	
UT-7	B-protein
Epo	I-protein
and	O
UT-7	B-cell_line
expressed	O
similar	O
levels	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
and	O
binding	O
activity	O
.	O
	
The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo-R	B-RNA
mRNA	I-RNA
while	O
the	O
number	O
of	O
Epo	B-protein
-binding	O
sites	O
on	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
was	O
one-sixth	O
the	O
number	O
of	O
UT-7	B-cell_line
cells	I-cell_line
(	O
2400	O
+/-	O
3	O
vs.	O
13	O
,	O
800	O
+/-	O
300	O
)	O
.	O
	
This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	B-cell_line
cells	I-cell_line
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	B-cell_line
cells	I-cell_line
)	O
or	O
in	O
receptor	O
turnover	O
.	O
	
By	O
Northern	O
analysis	O
,	O
UT-7	B-cell_line
cells	I-cell_line
expressed	O
detectable	O
levels	O
of	O
beta-	B-protein
and	I-protein
gamma-globin	I-protein
but	O
not	O
alpha-globin	B-protein
.	O
	
In	O
comparison	O
,	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
expressed	O
alpha-globin	O
and	O
higher	O
levels	O
of	O
gamma-globin	B-protein
(	O
5-fold	O
)	O
and	O
beta-globin	B-protein
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O
	
Globin	B-protein
chains	I-protein
(	O
alpha	B-protein
,	O
beta	B-protein
and	O
gamma	B-protein
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	B-protein
Epo	I-protein
but	O
not	O
in	O
UT-7	B-cell_line
cells	I-cell_line
.	O
	
The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta-	B-DNA
and	I-DNA
gamma-	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta-	B-protein
and	I-protein
gamma-specific	I-protein
antibodies	I-protein
.	O
	
The	O
number	O
of	O
gamma-positive	B-cell_line
cells	I-cell_line
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT-7	B-protein
Epo	I-protein
than	O
in	O
UT-7	B-cell_line
cells	I-cell_line
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	B-RNA
mRNA	I-RNA
observed	O
in	O
UT-7	B-protein
Epo	I-protein
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma-globin	B-protein
.	O
	
The	O
levels	O
of	O
GATA-1	B-protein
,	O
Epo-R	B-protein
and	O
globin	B-RNA
mRNA	I-RNA
expressed	O
were	O
not	O
affected	O
by	O
a	O
24-hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	B-protein
,	O
GM-CSF	B-protein
or	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
	
###MEDLINE:93216805	
	
The	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
specifically	O
in	O
myeloid	O
cells	O
in	O
vivo	O
and	O
is	O
essential	O
for	O
myeloid-specific	B-DNA
promoter	I-DNA
activity	O
.	O
	
The	O
myeloid	B-protein
integrin	I-protein
CD11b	I-protein
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	B-cell_type
macrophages	I-cell_type
,	O
monocytes	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
Lineage-specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O
	
Recent	O
isolation	O
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	B-DNA
DNA	I-DNA
are	O
sufficient	O
to	O
direct	O
myeloid-specific	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
.	O
	
To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	B-DNA
CD11b	I-DNA
promoter	I-DNA
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	B-DNA
promoter	I-DNA
activity	O
.	O
	
We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
In	O
vivo	O
the	O
Sp1	B-DNA
site	I-DNA
is	O
bound	O
only	O
in	O
myeloid	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
not	O
in	O
cervical	B-cell_line
carcinoma	I-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	I-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	I-DNA
.	O
	
We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O
	
###MEDLINE:93202345	
	
Transcription	O
factor	O
jun-B	O
is	O
target	O
of	O
autoreactive	B-cell_type
T-cells	I-cell_type
in	O
IDDM	O
.	O
	
Target	O
antigens	O
defined	O
by	O
autoantibodies	B-protein
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	B-protein
cell	I-protein
antibodies	I-protein
,	O
and	O
a	O
64	B-protein
,	I-protein
000-M	I-protein
(	I-protein
r	I-protein
)	I-protein
protein	I-protein
recently	O
identified	O
as	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
.	O
	
In	O
addition	O
,	O
some	O
IDDM	O
sera	O
that	O
contain	O
antibodies	B-protein
to	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
also	O
coprecipitate	O
a	O
38	B-protein
,	I-protein
000-M	I-protein
(	I-protein
r	I-protein
)	I-protein
protein	I-protein
from	O
islets	O
.	O
	
This	O
study	O
used	O
a	O
high	O
titer	O
anti-38	O
,	O
000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	B-DNA
lambda	I-DNA
cDNA	I-DNA
expression	O
libraries	O
and	O
identified	O
human	B-cell_type
islet	I-cell_type
and	O
placental	B-cell_line
clones	I-cell_line
encoding	O
jun-B	B-protein
,	O
the	O
nuclear	B-protein
transcription	I-protein
protein	I-protein
,	O
of	O
predicted	O
38	O
,	O
000	O
M	O
(	O
r	O
)	O
.	O
	
Peripheral	B-cell_type
blood	I-cell_type
T-cells	I-cell_type
exhibited	O
significant	O
proliferation	O
in	O
response	O
to	O
a	O
recombinant	O
fragment	O
of	O
jun-B	B-protein
(	O
amino	O
acids	O
1-180	O
)	O
in	O
12	O
of	O
17	O
(	O
71	O
%	O
)	O
recent-onset	O
IDDM	O
subjects	O
,	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
ICA-positive	O
first-degree	O
relatives	O
of	O
IDDM	O
subjects	O
who	O
were	O
at	O
risk	O
,	O
3	O
of	O
12	O
(	O
25	O
%	O
)	O
other	O
autoimmune	O
disease	O
subjects	O
,	O
and	O
0	O
of	O
10	O
healthy	O
control	O
subjects	O
.	O
	
Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O
	
Responses	O
to	O
jun-B	B-protein
were	O
not	O
related	O
to	O
age	O
,	O
sex	O
,	O
or	O
human	B-protein
leukocyte	I-protein
antigen	I-protein
status	O
.	O
	
Thus	O
,	O
autoreactive	B-cell_type
T-cells	I-cell_type
identify	O
a	O
novel	B-protein
antigen	I-protein
,	O
p38	B-protein
jun-B	I-protein
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O
	
###MEDLINE:93194883	
	
Stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
and	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
.	O
	
Protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O
	
In	O
human	B-cell_type
monocytes	I-cell_type
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	B-protein
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-1	B-protein
alpha	I-protein
.	O
	
The	O
increased	O
mRNA	B-RNA
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin-1	B-DNA
genes	I-DNA
.	O
	
Stimulation	O
of	O
interleukin-1	B-DNA
gene	I-DNA
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	B-protein
factor	I-protein
activities	O
,	O
including	O
those	O
of	O
AP-1	B-protein
,	O
by	O
these	O
protein	B-protein
phosphatase	I-protein
inhibitors	O
.	O
	
Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	B-protein
beta	I-protein
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O
	
This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	B-RNA
beta	I-RNA
convertase	I-RNA
mRNA	I-RNA
accumulation	O
.	O
	
The	O
stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	B-protein
beta	I-protein
.	O
	
However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	B-protein
interleukin-1	I-protein
alpha	I-protein
cytokine	I-protein
was	O
increased	O
.	O
	
These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
suggest	O
that	O
these	O
two	O
phosphatases	B-protein
play	O
important	O
roles	O
in	O
regulating	O
interleukin-1	B-protein
production	O
.	O
	
###MEDLINE:93189564	
	
The	O
interleukin	B-protein
2	I-protein
CD28-responsive	I-protein
complex	I-protein
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
family	I-protein
:	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O
	
Optimal	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
.	O
	
One	O
signal	O
can	O
be	O
delivered	O
by	O
the	O
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
,	O
and	O
the	O
second	O
signal	O
is	O
provided	O
by	O
the	O
costimulatory	O
molecule	O
(	O
s	O
)	O
delivered	O
by	O
the	O
antigen-presenting	B-cell_type
cell	I-cell_type
.	O
	
CD28	B-protein
is	O
a	O
T-cell	B-protein
surface	I-protein
molecule	I-protein
and	O
stimulation	O
through	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
delivering	O
the	O
second	O
activation	O
signal	O
.	O
	
In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	B-protein
family	I-protein
proteins	I-protein
--	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O
	
Treatment	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
results	O
in	O
augmentation	O
of	O
nuclear	B-protein
c-Rel	I-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O
	
It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA/anti-CD28	B-protein
mAb	I-protein
or	O
anti-CD3/anti-CD28	B-protein
mAb	I-protein
,	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
are	O
associated	O
with	O
CD28-responsive	B-DNA
element	I-DNA
present	O
in	O
the	O
promoter	B-DNA
of	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
.	O
	
The	O
functional	O
significance	O
of	O
c-Rel	B-protein
involvement	O
in	O
the	O
CD28-responsive	B-protein
complex	I-protein
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	B-protein
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
CD28-responsive	B-DNA
element	I-DNA
.	O
	
###MEDLINE:93152834	
	
Expression	O
of	O
tal-1	B-protein
and	O
GATA-binding	B-protein
proteins	I-protein
during	O
human	O
hematopoiesis	O
.	O
	
Tal-1	B-protein
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O
	
Tal-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	O
transcription	B-protein
factor	I-protein
with	O
a	O
basic	B-protein
helix-loop-helix	I-protein
domain	I-protein
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O
	
We	O
investigated	O
the	O
pattern	O
of	O
tal-1	B-protein
expression	O
in	O
purified	B-cell_type
human	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
by	O
in	O
situ	O
hybridization	O
and	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
analysis	O
.	O
	
Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	B-protein
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	B-cell_type
granulocytes	I-cell_type
.	O
	
In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal-1	B-DNA
1A	I-DNA
promoter	I-DNA
,	O
which	O
contains	O
two	O
consensus	O
GATA-binding	B-DNA
sites	I-DNA
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O
	
Because	O
the	O
GATA-1	B-DNA
gene	I-DNA
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mastocytic/basophilic	I-cell_type
lineages	I-cell_type
,	O
we	O
studied	O
GATA-1	B-protein
expression	O
in	O
these	O
purified	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O
	
We	O
found	O
that	O
GATA-1	B-DNA
and	I-DNA
tal-1	I-DNA
genes	I-DNA
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O
	
Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O
	
In	O
immature	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
,	O
tal-1	B-DNA
and	I-DNA
GATA-1	I-DNA
genes	I-DNA
are	O
coexpressed	O
in	O
committed	B-cell_type
progenitors	I-cell_type
cells	I-cell_type
(	O
CD34+/CD38	B-cell_line
(	I-cell_line
2+	I-cell_line
)	I-cell_line
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	B-cell_type
cells	I-cell_type
(	O
CD34	B-cell_line
(	I-cell_line
2+	I-cell_line
)	I-cell_line
/CD38-	I-cell_line
)	O
.	O
	
In	O
contrast	O
,	O
GATA-2	B-protein
is	O
strongly	O
expressed	O
in	O
both	O
most	B-cell_type
primitive	I-cell_type
and	I-cell_type
committed	I-cell_type
progenitors	I-cell_type
cells	I-cell_type
,	O
whereas	O
GATA-3	B-protein
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O
	
Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	B-protein
modulates	O
the	O
transcription	O
of	O
tal-1	B-protein
during	O
the	O
differentiation	O
of	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
basosophilic	I-cell_type
lineages	I-cell_type
.	O
	
###MEDLINE:93228445	
	
The	O
lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	B-cell_line
B-cells	I-cell_line
.	O
	
Lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O
	
We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O
	
Two	O
stable	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
:	O
R59Z	B-cell_line
activator	I-cell_line
cells	I-cell_line
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B-protein
1	I-protein
trans-activator	I-protein
(	O
Zta	B-protein
)	O
.	O
	
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	B-DNA
origin	I-DNA
of	I-DNA
EBV	I-DNA
replication	I-DNA
(	O
ori	B-DNA
Lyt	I-DNA
)	O
.	O
	
Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans-activation	O
converted	O
the	O
recombinant	B-DNA
ori	I-DNA
Lyt	I-DNA
element	I-DNA
in	O
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
.	O
	
BZLF	B-protein
1	I-protein
,	O
transiently	O
expressed	O
in	O
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
was	O
the	O
only	O
EBV	B-protein
trans-activator	I-protein
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O
	
Basing	O
on	O
these	O
experiments	O
,	O
trans-cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	B-cell_type
1-expressing	I-cell_type
R59Z	I-cell_type
activator	I-cell_type
cells	I-cell_type
with	O
the	O
R7-57	B-cell_line
reporter	I-cell_line
line	I-cell_line
.	O
	
No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	B-cell_line
cells	I-cell_line
nor	O
by	O
coincubation	O
of	O
BZLF	B-protein
1	I-protein
-containing	O
cell	O
lysates	O
.	O
	
Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	B-cell_line
to	O
reporter	B-cell_line
cells	I-cell_line
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O
	
The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	B-DNA
gene	I-DNA
BZLF	I-DNA
1	I-DNA
	
###MEDLINE:93321228	
	
Costimulation	O
of	O
cAMP	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
pathways	O
inhibits	O
the	O
CD3	B-protein
-dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O
	
The	O
effects	O
mediated	O
by	O
a	O
combined	O
stimulation	O
of	O
cAMP	O
-and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-dependent	O
pathways	O
have	O
been	O
investigated	O
in	O
different	O
cellular	O
systems	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
they	O
may	O
complement	O
each	O
other	O
in	O
activating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
	
In	O
this	O
report	O
,	O
we	O
show	O
that	O
upon	O
the	O
stimulation	O
of	O
both	O
pathways	O
T	B-cell_type
lymphocytes	I-cell_type
became	O
refractory	O
to	O
activation	O
via	O
the	O
CD3/T	B-protein
cell	I-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
complex	O
.	O
	
T	B-cell_type
cells	I-cell_type
preincubated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
dibutyryl	O
cAMP	O
(	O
Bt2cAMP	O
)	O
displayed	O
a	O
deficient	O
proliferative	O
ability	O
in	O
response	O
to	O
anti-CD3	B-protein
mAb	I-protein
stimulation	O
,	O
whereas	O
lymphocytes	B-cell_type
treated	O
individually	O
with	O
either	O
Bt2cAMP	O
or	O
PMA	O
responded	O
comparably	O
to	O
untreated	O
samples	O
.	O
	
We	O
detected	O
an	O
association	O
between	O
the	O
reduced	O
mitogenic	O
response	O
and	O
low	O
expression	O
of	O
both	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
the	O
alpha	B-protein
chain	I-protein
(	O
CD25	B-protein
)	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
.	O
	
Analysis	O
of	O
intracellular	O
Ca2+	O
mobilization	O
suggested	O
that	O
the	O
CD3	B-protein
/	O
TcR	B-protein
-dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA/Bt2cAMP-treated	B-cell_line
cells	I-cell_line
.	O
	
Remarkably	O
,	O
we	O
observed	O
that	O
these	O
samples	O
displayed	O
a	O
persistent	O
expression	O
of	O
the	O
c-fos	B-DNA
protooncogene	I-DNA
,	O
associated	O
to	O
an	O
increased	O
AP-1	B-protein
DNA-binding	O
activity	O
,	O
whereas	O
no	O
variations	O
of	O
CREB	B-protein
or	O
NF-kB	B-protein
were	O
detected	O
.	O
	
Neither	O
Bt2cAMP	O
nor	O
PMA	O
individually	O
mediated	O
these	O
sustained	O
effects	O
,	O
which	O
therefore	O
appear	O
as	O
a	O
consequence	O
of	O
the	O
interplay	O
between	O
both	O
metabolic	O
stimuli	O
.	O
	
Altogether	O
,	O
the	O
data	O
provide	O
the	O
evidence	O
that	O
both	O
pathways	O
complement	O
each	O
other	O
in	O
regulating	O
gene	O
expression	O
and	O
,	O
conversely	O
,	O
downregulate	O
the	O
TcR	B-protein
transduction	O
mechanisms	O
.	O
	
###MEDLINE:94083530	
	
The	O
lymphotoxin	B-DNA
promoter	I-DNA
is	O
stimulated	O
by	O
HTLV-I	B-protein
tax	I-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
HTLV-I	B-protein
transcriptional	I-protein
activator	I-protein
tax	I-protein
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	B-DNA
(	I-DNA
LT	I-DNA
;	I-DNA
TNF-beta	I-DNA
)	I-DNA
gene	I-DNA
induction	O
.	O
	
Tax-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
produce	O
LT	B-protein
biologic	O
activity	O
.	O
	
An	O
LT	B-DNA
promoter	I-DNA
(	I-DNA
LT-293	I-DNA
)	I-DNA
CAT	I-DNA
construct	I-DNA
that	O
contained	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
active	O
in	O
the	O
LT-producing	B-cell_line
C81-66-45	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
contains	O
defective	O
HTLV-I	O
but	O
expresses	O
tax	B-protein
.	O
	
The	O
observation	O
that	O
a	O
mutated	B-DNA
LT-kappa	I-DNA
B	I-DNA
construct	I-DNA
(	O
M1-CAT	B-DNA
)	O
was	O
inactive	O
in	O
C81-66-45	B-cell_line
,	O
confirmed	O
the	O
importance	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
LT	B-protein
gene	O
expression	O
.	O
	
Tax	B-protein
was	O
transfected	O
into	O
HTLV-I-negative	B-cell_line
human	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stably	O
expressing	O
tax	B-protein
contained	O
elevated	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
that	O
directly	O
bound	O
to	O
the	O
LT-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O
	
Tax	B-protein
co-transfected	O
with	O
reporter	B-DNA
constructs	I-DNA
into	O
Jurkat	B-cell_line
cells	I-cell_line
maximally	O
activated	O
HTLV-I-LTR-CAT	B-protein
and	O
kappa	B-protein
B-fos-CAT	I-protein
and	O
also	O
activated	O
LT-293	B-DNA
to	O
a	O
lesser	O
extent	O
.	O
	
In	O
JM	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
tax	B-protein
induced	O
LT-293	B-DNA
activity	O
by	O
two-	O
to	O
four-fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1-CAT	B-protein
.	O
	
The	O
increase	O
in	O
LT-293	B-DNA
CAT	B-protein
activity	O
mirrored	O
the	O
increase	O
in	O
LT	B-protein
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O
	
These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	B-DNA
promoter	I-DNA
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV-I	B-protein
tax	I-protein
causes	O
low-level	O
activation	O
of	O
both	O
endogenous	O
LT	B-protein
and	O
the	O
LT	B-DNA
promoter	I-DNA
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
###MEDLINE:93276575	
	
A	O
concatenated	O
form	O
of	O
Epstein-Barr	B-DNA
viral	I-DNA
DNA	I-DNA
in	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
induced	O
by	O
transfection	O
with	O
BZLF1	B-protein
.	O
	
The	O
replicative	O
form	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
DNA	O
was	O
studied	O
using	O
two	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
X50-7	O
and	O
6F11	O
,	O
which	O
are	O
latently	O
infected	O
by	O
Epstein-Barr	O
virus	O
.	O
	
The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1/BZLF1	B-DNA
coding	I-DNA
region	I-DNA
of	O
the	O
P3HR-1	B-DNA
defective	I-DNA
genome	I-DNA
.	O
	
We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein-Barr	B-DNA
viral	I-DNA
DNA	I-DNA
in	O
the	O
lytic	B-cell_line
cycle-induced	I-cell_line
cells	I-cell_line
.	O
	
Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	I-DNA
.	O
	
This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	B-DNA
DNA	I-DNA
or	O
concatameric	B-DNA
linear	I-DNA
DNA	I-DNA
.	O
	
Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	B-DNA
EBV	I-DNA
DNA	I-DNA
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O
	
We	O
propose	O
from	O
these	O
results	O
that	O
the	O
source	O
of	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	I-DNA
is	O
a	O
concatenated	B-DNA
linear	I-DNA
EBV	I-DNA
DNA	I-DNA
molecule	I-DNA
,	O
and	O
that	O
such	O
a	O
concatenated	O
molecule	O
most	O
likely	O
represents	O
a	O
replicative	O
form	O
of	O
EBV	B-DNA
DNA	I-DNA
in	O
productively	O
infected	O
cells	O
.	O
	
###MEDLINE:93266777	
	
Expression	O
levels	O
of	O
the	O
thyrotropin	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	O
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
classes	I-protein
I	I-protein
and	I-protein
II	I-protein
.	O
	
Using	O
a	O
human	B-DNA
TSH	I-DNA
receptor	I-DNA
(	I-DNA
TSH-R	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
,	O
we	O
investigated	O
TSH-R	B-protein
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O
	
TSH-R	B-protein
expression	O
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	O
of	O
thyroid	B-protein
peroxidase	I-protein
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.05	O
)	O
,	O
thyroglobulin	B-protein
(	O
r	O
=	O
0.817	O
;	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
nuclear	B-DNA
oncogene	I-DNA
c-fos	I-DNA
(	O
r	O
=	O
0.935	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
c-myc	B-protein
.	O
	
Overall	O
,	O
TSH-R	B-protein
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
(	O
MHC	B-protein
I	I-protein
or	I-protein
II	I-protein
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	B-protein
I	I-protein
,	O
r	O
=	O
-0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	B-protein
II	I-protein
,	O
r	O
=	O
-0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O
	
In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	B-cell_type
,	O
thyroid	B-cell_type
cells	I-cell_type
themselves	O
were	O
the	O
source	O
of	O
MHC	B-protein
II	I-protein
transcripts	I-protein
.	O
	
gamma-Interferon	B-protein
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O
	
Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	B-cell_type
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH-R	B-protein
,	O
thyroid	B-protein
peroxidase	I-protein
,	O
thyroglobulin	B-protein
,	O
and	O
c-fos	O
)	O
and	O
immunological	O
markers	O
(	O
MHC	B-protein
I	I-protein
and	I-protein
II	I-protein
)	O
.	O
	
###MEDLINE:93224755	
	
Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	O
and	O
CD23	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
cells	I-cell_line
.	O
	
1	O
,	O
25	O
alpha-Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O
	
This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte-macrophage	B-protein
Ag	I-protein
,	O
CD14	B-protein
,	O
and	O
the	O
low	O
affinity	B-protein
Fc	I-protein
receptor	I-protein
for	O
IgE	B-protein
,	O
CD23	B-protein
,	O
were	O
inversely	O
regulated	O
during	O
VitD3	O
-and	O
RA-induced	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
monoblasts	I-cell_line
.	O
	
PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	B-protein
and	O
CD23	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O
	
Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O
	
The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	O
the	O
VitD3	O
induction	O
of	O
CD14	B-RNA
mRNA	I-RNA
expression	O
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	O
on	O
ongoing	O
protein	O
synthesis	O
.	O
	
While	O
inducing	O
CD14	B-protein
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA-	O
,	O
and	O
RA-inducible	O
CD23	B-protein
expression	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
In	O
contrast	O
,	O
U-937	B-cell_line
cells	I-cell_line
induced	O
by	O
RA	O
strongly	O
increased	O
their	O
expression	O
of	O
CD23	B-RNA
mRNA	I-RNA
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	O
detectable	O
CD14	O
cell	O
surface	O
or	O
mRNA	O
expression	O
.	O
	
Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA-induced	O
CD14	B-protein
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O
	
The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O
	
###MEDLINE:93275333	
	
Cell-specific	O
bifunctional	O
role	O
of	O
Jun	B-DNA
oncogene	I-DNA
family	I-DNA
members	I-DNA
on	O
glucocorticoid	B-protein
receptor	I-protein
-dependent	O
transcription	O
.	O
	
Interaction	O
between	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-	O
and	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
-mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	B-protein
activating	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B-protein
-dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone-induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	B-DNA
LTR	I-DNA
in	O
several	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
was	O
inhibitory	O
in	O
NIH-3T3	B-cell_line
fibroblasts	I-cell_line
.	O
	
TPA-GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR-responsive	B-DNA
element	I-DNA
(	O
GRE	B-DNA
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	B-DNA
mutants	I-DNA
or	O
synthetic	B-DNA
GRE	I-DNA
oligonucleotides	I-DNA
driving	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
expression	O
.	O
	
Synergism	O
required	O
an	O
intact	O
GR	B-protein
DNA-binding	I-protein
domain	I-protein
,	O
whereas	O
amino-	B-protein
or	I-protein
carboxyl-terminal	I-protein
domains	I-protein
were	O
dispensable	O
.	O
	
The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	B-protein
.	O
	
Increased	O
c-jun	B-protein
,	O
jun-B	B-protein
,	O
and	O
jun-D	B-protein
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP-1/TPA	B-DNA
responsive	I-DNA
elements	I-DNA
fused	O
to	O
chloramphenicol	B-DNA
acetyl-transferase	I-DNA
vectors	I-DNA
were	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O
	
The	O
ability	O
of	O
Jun	B-protein
proteins	I-protein
to	O
cooperate	O
with	O
GR	B-protein
in	O
T	B-cell_type
cells	I-cell_type
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
or	I-DNA
jun-D	I-DNA
expression	I-DNA
vectors	I-DNA
,	O
which	O
augmented	O
GR	B-protein
-dependent	O
transcription	O
from	O
either	O
MMTV	B-DNA
LTR	I-DNA
or	O
GRE	B-DNA
.	O
	
Conversely	O
,	O
c-jun	B-protein
and	O
jun-B	B-protein
transfection	O
blunted	O
GR	B-protein
-dependent	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
The	O
presence	O
of	O
c-fos	B-protein
had	O
a	O
negative	O
influence	O
on	O
GR	B-protein
function	O
and	O
correlated	O
with	O
the	O
cell-specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	B-protein
with	O
respect	O
to	O
GR	B-protein
;	O
high	O
basal	O
expression	O
of	O
c-fos	B-protein
as	O
well	O
as	O
AP-1	B-protein
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Furthermore	O
overexpression	O
of	O
exogenous	B-protein
c-fos	I-protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-protein
-dependent	O
transcription	O
from	O
GRE	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
We	O
propose	O
that	O
Jun	B-protein
plays	O
a	O
bifunctional	O
role	O
on	O
GR	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
GRE	B-DNA
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell-specific	O
microenvironment	O
.	O
	
In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c-fos	B-protein
appear	O
to	O
be	O
influential	O
.	O
	
###MEDLINE:93194904	
	
Cell	O
type-	O
and	O
stage-specific	O
expression	O
of	O
the	O
CD20/B1	B-protein
antigen	I-protein
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	B-DNA
.	O
	
The	O
CD20	B-DNA
(	I-DNA
B1	I-DNA
)	I-DNA
gene	I-DNA
encodes	O
a	O
B	B-protein
cell-specific	I-protein
protein	I-protein
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
	
Studies	O
with	O
5	B-DNA
'	I-DNA
deletion	I-DNA
CD20	I-DNA
promoter-CAT	I-DNA
constructs	I-DNA
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	B-DNA
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O
	
In	O
this	O
study	O
we	O
identified	O
a	O
sequence	B-DNA
element	I-DNA
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B-protein
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B-protein
in	O
pre-B	B-cell_type
cells	I-cell_type
.	O
	
This	O
sequence	B-DNA
element	I-DNA
was	O
referred	O
to	O
as	O
the	O
BAT	B-DNA
box	I-DNA
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter-CAT	O
construct	O
in	O
B	O
cells	O
.	O
	
Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O
	
Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B-DNA
box	I-DNA
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	B-DNA
promoter	I-DNA
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B-protein
proteins	I-protein
suggesting	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O
	
Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O
	
The	O
affinity	O
of	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
for	O
the	O
BAT	B-DNA
box	I-DNA
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	B-DNA
sequence	I-DNA
and	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
dissociated	O
from	O
the	O
BAT	B-DNA
box	I-DNA
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	B-DNA
sequence	I-DNA
.	O
	
Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	B-DNA
box	I-DNA
sequence	I-DNA
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	B-DNA
expression	I-DNA
vector	I-DNA
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	B-DNA
sequence	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
The	O
BAT	B-DNA
box	I-DNA
and	O
Oct-2	B-protein
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B-protein
in	O
the	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PB-697	B-cell_line
,	O
via	O
phorbol	O
esters	O
.	O
	
The	O
induction	O
of	O
CD20	B-RNA
mRNA	I-RNA
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
a	O
BAT	B-DNA
box-deleted	I-DNA
CD20-CAT	I-DNA
construct	I-DNA
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O
	
Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B-protein
and	O
perhaps	O
CD21	B-protein
.	O
	
###MEDLINE:93184333	
	
Human	B-cell_type
CD4	I-cell_type
lymphocytes	I-cell_type
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	B-protein
protein	I-protein
pml/RAR	B-protein
alpha	I-protein
present	O
in	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O
	
Fusion	O
proteins	O
present	O
in	O
leukemic	B-cell_type
cells	I-cell_type
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B-protein
point	I-protein
.	O
	
We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1/25	O
)	O
encompassing	O
the	O
fusion	B-protein
region	I-protein
of	O
the	O
hybrid	O
molecule	O
pml/RAR	B-protein
alpha	I-protein
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
(	I-cell_type
APL	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
can	O
be	O
recognized	O
by	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O
	
CD4+	B-cell_type
lymphocytes	I-cell_type
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	B-protein
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	B-cell_type
antigen-presenting	I-cell_type
cell	I-cell_type
(	O
APC	B-cell_type
)	O
or	O
by	O
APC	B-cell_type
expressing	O
the	O
HLA-DR11	B-protein
restricting	I-protein
molecule	I-protein
.	O
	
Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B-protein
and	O
RAR	B-protein
alpha	I-protein
proteins	I-protein
were	O
not	O
recognized	O
.	O
	
One	O
clone	O
(	O
DEG5	B-cell_line
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B-cell_line
cells	I-cell_line
pulsed	O
with	O
BCR1/25	O
.	O
	
The	O
autologous	B-cell_line
DE	I-cell_line
LCL	I-cell_line
containing	O
a	O
transduced	O
pml/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml/RAR	B-protein
alpha	I-protein
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	B-cell_line
anti-BCR1/25	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O
	
It	O
is	O
concluded	O
that	O
the	O
bcr1	B-protein
type-pml/RAR	I-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
of	O
APL	B-cell_line
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	B-cell_line
CD4+	I-cell_line
lymphocytes	I-cell_line
.	O
	
###MEDLINE:93145322	
	
The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O
	
We	O
have	O
isolated	O
cDNA	B-DNA
clones	I-DNA
of	O
myeloid	B-DNA
differentiation	I-DNA
primary	I-DNA
response	I-DNA
(	I-DNA
MyD	I-DNA
)	I-DNA
genes	I-DNA
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	B-cell_type
or	O
granulocyte	B-cell_type
lineage	I-cell_type
in	O
human	O
myeloblastic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O
	
One	O
cDNA	B-DNA
clone	I-DNA
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B-protein
,	O
a	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
.	O
	
The	O
Egr-1	B-DNA
gene	I-DNA
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
active	O
in	O
U-937	B-cell_line
and	O
M1	B-cell_line
cells	I-cell_line
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O
	
Egr-1	B-protein
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
myeloblasts	B-cell_type
.	O
	
HL-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
an	O
Egr-1	B-DNA
transgene	I-DNA
(	O
HL-60Egr-1	B-DNA
)	O
could	O
be	O
induced	O
for	O
macrophage	B-cell_type
,	O
but	O
not	O
granulocyte	B-cell_type
,	O
differentiation	O
.	O
	
These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	B-cell_type
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O
	
###MEDLINE:93154317	
	
The	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
interacts	O
with	O
an	O
EBNA2	B-DNA
responsive	I-DNA
cis-element	I-DNA
of	O
the	O
terminal	B-DNA
protein	I-DNA
1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O
	
The	O
Epstein-Barr	B-protein
virus	I-protein
protein	I-protein
EBNA2	I-protein
acts	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
immortalization	O
of	O
human	B-cell_type
primary	I-cell_type
B-cells	I-cell_type
by	O
EBV	O
.	O
	
We	O
have	O
shown	O
previously	O
that	O
EBNA2	B-protein
transactivates	O
the	O
promoters	O
of	O
the	O
latent	B-protein
membrane	I-protein
antigens	I-protein
LMP	B-protein
,	O
TP1	B-protein
and	O
TP2	B-protein
.	O
	
The	O
promoter	B-DNA
of	O
the	O
TP1	B-DNA
gene	I-DNA
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	B-protein
mediated	O
transactivation	O
.	O
	
To	O
identify	O
an	O
EBNA2	B-DNA
dependent	I-DNA
cis-acting	I-DNA
element	I-DNA
,	O
various	O
TP1	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
established	O
B-cell	B-cell_line
line	I-cell_line
BL41-P3HR1	I-cell_line
.	O
	
We	O
were	O
able	O
to	O
delineate	O
an	O
81	B-DNA
bp	I-DNA
EBNA2	I-DNA
responsive	I-DNA
region	I-DNA
between	O
-258	O
and	O
-177	O
relative	O
to	O
the	O
TP1	B-DNA
RNA	I-DNA
start	I-DNA
site	I-DNA
.	O
	
The	O
element	O
worked	O
in	O
either	O
orientation	O
and	O
could	O
mediate	O
EBNA2	B-protein
dependent	O
transactivation	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O
	
Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein-DNA	B-protein
complexes	I-protein
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	B-DNA
responsive	I-DNA
element	I-DNA
.	O
	
Two	O
of	O
these	O
were	O
not	O
cell	O
type	O
specific	O
,	O
but	O
the	O
third	O
was	O
detected	O
only	O
in	O
EBNA2	B-protein
positive	O
cell	O
extracts	O
.	O
	
Gel-shift	O
analysis	O
in	O
the	O
presence	O
of	O
EBNA2	B-protein
specific	O
monoclonal	O
antibodies	O
revealed	O
that	O
EBNA2	B-protein
is	O
a	O
component	O
of	O
the	O
third	O
complex	O
.	O
	
Thus	O
,	O
these	O
experiments	O
demonstrate	O
that	O
EBNA2	B-protein
interacts	O
with	O
an	O
EBNA2	B-DNA
responsive	I-DNA
cis-element	I-DNA
of	O
the	O
TP1	B-DNA
promoter	I-DNA
	
###MEDLINE:93315684	
	
Minimally	O
modified	O
low	O
density	O
lipoprotein	B-protein
-induced	O
inflammatory	O
responses	O
in	O
endothelial	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O
	
We	O
have	O
previously	O
shown	O
that	O
minimally	B-cell_line
oxidized	I-cell_line
LDL	I-cell_line
(	I-cell_line
MM-LDL	I-cell_line
)	I-cell_line
activated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
to	O
increase	O
their	O
interaction	O
with	O
monocytes	B-cell_type
but	O
not	O
neutrophils	B-cell_type
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
.	O
	
In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O
	
Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M-CSF	B-protein
by	O
MM-LDL	B-protein
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C-depleted	O
endothelial	B-cell_type
cells	I-cell_type
.	O
	
A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM-LDL	B-protein
cited	O
above	O
.	O
	
Incubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
MM-LDL	B-protein
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O
	
Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	B-protein
.	O
	
Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O
	
Although	O
endothelial	B-RNA
leukocyte	I-RNA
adhesion	I-RNA
molecule	I-RNA
(	I-RNA
ELAM	I-RNA
)	I-RNA
mRNA	I-RNA
synthesis	O
can	O
be	O
regulated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
ELAM	B-protein
was	O
not	O
expressed	O
and	O
ELAM	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM-LDL	B-protein
.	O
	
We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	B-cell_type
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O
	
###MEDLINE:93324366	
	
Human	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
GATA-3	B-protein
stimulates	O
HIV-1	O
expression	O
.	O
	
A	O
family	O
of	O
transcriptional	O
activating	O
proteins	O
,	O
the	O
GATA	B-protein
factors	I-protein
,	O
has	O
been	O
shown	O
to	O
bind	O
to	O
a	O
consensus	O
motif	O
through	O
a	O
highly	B-protein
conserved	I-protein
C4	I-protein
zinc	I-protein
finger	I-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O
	
One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O
	
In	O
vitro	O
DNase	B-protein
I	I-protein
footprinting	O
analysis	O
revealed	O
six	O
hGATA-3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
(	O
the	O
transcriptional	B-DNA
regulatory	I-DNA
domain	I-DNA
)	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O
	
Cotransfection	O
of	O
an	O
hGATA-3	B-DNA
expression	I-DNA
plasmid	I-DNA
with	O
a	O
reporter	B-DNA
plasmid	I-DNA
whose	O
transcription	O
is	O
directed	O
by	O
the	O
HIV-1	B-DNA
LTR	I-DNA
resulted	O
in	O
6-	O
to	O
10-fold	O
stimulation	O
of	O
LTR	B-DNA
-mediated	O
transcription	O
,	O
whereas	O
site	O
specific	O
mutation	O
of	O
these	O
GATA	B-DNA
sites	I-DNA
resulted	O
in	O
virtual	O
abrogation	O
of	O
the	O
activation	O
by	O
hGATA-3	B-protein
.	O
	
Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	B-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
abolished	O
GATA-dependent	O
HIV-1	O
trans-activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	B-protein
hGATA-3	I-protein
.	O
	
Introduction	O
of	O
the	O
HIV-1	B-DNA
plasmids	I-DNA
in	O
which	O
the	O
GATA	B-DNA
sites	I-DNA
have	O
been	O
mutated	O
into	O
human	O
T	B-cell_type
lymphocytes	I-cell_type
also	O
caused	O
a	O
significant	O
reduction	O
in	O
LTR	B-DNA
-mediated	O
transcription	O
at	O
both	O
the	O
basal	O
level	O
and	O
in	O
(	O
PHA-	O
plus	O
PMA-	O
)	O
stimulated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
These	O
observations	O
suggest	O
that	O
in	O
addition	O
to	O
its	O
normal	O
role	O
in	O
T	B-cell_type
lymphocyte	I-cell_type
gene	O
regulation	O
,	O
hGATA-3	B-protein
may	O
also	O
play	O
a	O
significant	O
role	O
in	O
HIV-1	O
transcriptional	O
activation	O
.	O
	
###MEDLINE:93350203	
	
Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O
	
Cytokines	B-protein
,	O
the	O
peptide	B-protein
hormones	I-protein
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O
	
Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
Conversely	O
,	O
several	O
cytokines	B-protein
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
mononuclear	I-cell_type
phagocytic	I-cell_type
lineage	I-cell_type
.	O
	
Activated	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
particularly	O
B	B-cell_type
cells	I-cell_type
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV-inductive	B-protein
cytokines	I-protein
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O
	
###MEDLINE:93259462	
	
Cloning	O
and	O
functional	O
characterization	O
of	O
early	B-protein
B-cell	I-protein
factor	I-protein
,	O
a	O
regulator	O
of	O
lymphocyte-specific	O
gene	O
expression	O
.	O
	
Early	B-protein
B-cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue-specific	O
and	O
differentiation	O
stage-specific	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre-B	B-DNA
and	I-DNA
B	I-DNA
lymphocyte-specific	I-DNA
mb-1	I-DNA
gene	I-DNA
.	O
	
Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	B-protein
were	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	I-DNA
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	B-protein
.	O
	
The	O
recombinant	B-protein
polypeptide	I-protein
formed	O
sequence-specific	O
complexes	O
with	O
the	O
EBF-binding	B-DNA
site	I-DNA
in	O
the	O
mb-1	B-DNA
promoter	I-DNA
.	O
	
The	O
cDNA	B-DNA
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre-B	B-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
but	O
transcripts	O
were	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
plasmacytoma	B-cell_line
,	O
T-cell	B-cell_line
,	O
and	O
nonlymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Expression	O
of	O
recombinant	O
EBF	B-protein
in	O
transfected	B-cell_line
nonlymphoid	I-cell_line
cells	I-cell_line
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF-binding	B-DNA
sites	I-DNA
.	O
	
Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	B-protein
identified	O
an	O
amino-terminal	B-protein
cysteine-rich	I-protein
DNA-binding	I-protein
domain	I-protein
lacking	O
obvious	O
sequence	O
similarity	O
to	O
known	O
transcription	B-protein
factors	I-protein
.	O
	
DNA-binding	O
assays	O
with	O
cotranslated	O
wild-type	O
and	O
truncated	O
forms	O
of	O
EBF	B-protein
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	B-protein
.	O
	
Deletions	O
delineated	O
a	O
carboxy-terminal	B-protein
dimerization	I-protein
region	I-protein
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	B-protein
domains	I-protein
of	O
basic-helix-loop-helix	B-protein
proteins	I-protein
.	O
	
Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte-specific	O
gene	O
expression	O
.	O
	
###MEDLINE:93241941	
	
Cell-specific	O
expression	O
of	O
helix-loop-helix	B-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	B-DNA
gene	I-DNA
.	O
	
The	O
E2A	B-DNA
gene	I-DNA
encodes	O
transcription	B-protein
factors	I-protein
of	O
the	O
helix-loop-helix	B-protein
family	I-protein
that	O
are	O
implicated	O
in	O
cell-specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	B-protein
complexes	I-protein
that	O
interact	O
with	O
E	B-DNA
box	I-DNA
enhancer	I-DNA
elements	I-DNA
.	O
	
It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	B-DNA
gene	I-DNA
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O
	
We	O
have	O
now	O
examined	O
expression	O
of	O
the	O
mouse	B-DNA
E2A	I-DNA
gene	I-DNA
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	B-protein
protein	I-protein
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O
	
A	O
73	B-protein
kDa	I-protein
protein	I-protein
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	B-cell_line
lines	I-cell_line
of	I-cell_line
B	I-cell_line
lymphoid	I-cell_line
origin	I-cell_line
as	O
compared	O
to	O
pancreatic	B-cell_type
beta-cells	I-cell_type
and	O
fibroblast	B-cell_type
cells	I-cell_type
.	O
	
The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	B-DNA
box	I-DNA
-binding	O
activity	O
LEF1/BCF1	B-protein
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	B-protein
gene	I-protein
products	I-protein
.	O
	
Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-DNA
cDNA	I-DNA
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	B-protein
on	O
mobility	O
shift	O
analysis	O
.	O
	
Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA-binding	O
activity	O
LEF1/BCF1	B-protein
is	O
a	O
homodimer	B-protein
of	I-protein
E2A	I-protein
proteins	I-protein
;	O
the	O
selective	O
appearance	O
of	O
this	O
putative	O
cell-specific	O
transcription	O
factor	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
seems	O
to	O
be	O
attributable	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	O
E2A	B-protein
protein	I-protein
concentrations	O
in	O
these	O
cells	O
.	O
	
###MEDLINE:93244226	
	
Hypertension	O
in	O
pregnancy	O
.	O
	
Pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O
	
In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O
	
Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O
	
To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy-corticosterone	O
(	O
18-OH-B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O
	
Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
count	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O
	
The	O
MR-count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH-group	O
.	O
	
The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH-B	O
were	O
also	O
low	O
.	O
	
These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
level	O
of	O
mineralocorticoids	O
of	O
the	O
zona	O
glomerulosa	O
.	O
	
Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
-status	O
.	O
	
The	O
first	O
results	O
of	O
continuous	O
blood	O
pressure	O
measurements	O
with	O
a	O
noninvasive	O
,	O
real-time	O
blood	O
pressure	O
monitor	O
(	O
Finapres	O
)	O
are	O
presented	O
.	O
	
The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O
	
We	O
also	O
report	O
on	O
the	O
first	O
experiences	O
with	O
Urapidil	O
in	O
the	O
treatment	O
of	O
hypertension	O
in	O
severe	O
preeclampsia	O
.	O
	
The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex-tachycardia	O
.	O
	
Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O
	
###MEDLINE:93186822	
	
Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
NF-E2	B-protein
)	O
to	O
an	O
enhancer	B-DNA
element	I-DNA
required	O
for	O
expression	O
of	O
an	O
erythroid-specific	B-DNA
gene	I-DNA
.	O
	
Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid-specific	B-DNA
gene	I-DNA
expression	O
in	O
the	O
human	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O
	
We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	B-protein
factors	I-protein
at	O
a	O
regulatory	B-DNA
element	I-DNA
found	O
within	O
the	O
transcriptional	B-DNA
regulatory	I-DNA
sequences	I-DNA
of	O
many	O
erythroid-specific	B-DNA
genes	I-DNA
.	O
	
TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	B-protein
AP-1	I-protein
factors	I-protein
to	O
this	O
element	O
.	O
	
TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	B-protein
to	O
this	O
transcriptional	B-DNA
control	I-DNA
element	I-DNA
.	O
	
Hemin	O
induction	O
of	O
K562	B-cell_line
cells	I-cell_line
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF-E2	B-protein
to	O
its	O
recognition	O
site	O
.	O
	
Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O
	
Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	B-protein
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	O
.	O
	
The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	B-cell_line
cells	I-cell_line
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
NF-E2	B-protein
.	O
	
###MEDLINE:93152894	
	
Interleukin-3	B-protein
expression	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
involves	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
and	O
an	O
octamer	B-protein
binding	I-protein
protein	I-protein
.	O
	
Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
exclusively	O
expressed	O
by	O
activated	B-cell_type
T	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage-specific	O
and	O
in	O
a	O
stimulation-dependent	O
manner	O
.	O
	
We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	B-DNA
region	I-DNA
of	O
the	O
IL-3	B-protein
promoter	O
.	O
	
This	O
region	O
binds	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
over	O
its	O
5	B-DNA
'	I-DNA
end	I-DNA
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	B-protein
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O
	
Over	O
its	O
3	B-DNA
'	I-DNA
end	I-DNA
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O
	
This	O
factor	O
is	O
Oct-1	B-protein
or	O
an	O
immunologically	B-protein
related	I-protein
octamer-binding	I-protein
protein	I-protein
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	B-DNA
elements	I-DNA
.	O
	
These	O
characteristics	O
make	O
the	O
ACT-1	B-DNA
site	I-DNA
analogous	O
to	O
the	O
activating	O
ARRE-1	B-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL-3	B-protein
and	O
IL-2	B-protein
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T-cell-specific	O
expression	O
of	O
these	O
genes	O
.	O
	
###MEDLINE:93136418	
	
Interleukin-4	B-protein
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	B-RNA
and	I-RNA
c-fos	I-RNA
messenger	I-RNA
RNA	I-RNA
and	O
activator	B-protein
protein-1	I-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
We	O
studied	O
the	O
effect	O
of	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O
	
These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	B-protein
complex	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	B-protein
factor	I-protein
.	O
	
Maximal	O
accumulation	O
of	O
either	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
messenger	I-RNA
RNA	I-RNA
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O
	
When	O
cells	O
were	O
treated	O
with	O
IL-4	B-protein
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c-fos	O
and	O
the	O
c-jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O
	
The	O
inhibition	O
of	O
c-fos	B-DNA
and	O
c-jun	O
expression	O
by	O
IL-4	B-protein
in	O
LPS-treated	B-cell_type
cells	I-cell_type
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c-fos	B-DNA
and	I-DNA
c-jun	I-DNA
genes	I-DNA
.	O
	
IL-4	B-protein
did	O
not	O
affect	O
the	O
stability	O
of	O
the	O
c-fos	B-protein
and	O
c-jun	B-protein
transcripts	I-protein
.	O
	
Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	B-protein
inhibits	O
LPS-induced	O
expression	O
of	O
AP-1	B-protein
protein	O
.	O
	
These	O
data	O
indicate	O
that	O
IL-4	B-protein
suppresses	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
activated	I-cell_type
monocytes	I-cell_type
.	O
	
###MEDLINE:94085904	
	
Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	B-protein
aldosterone	I-protein
receptors	I-protein
.	O
	
Results	O
in	O
two	O
affected	O
infants	O
.	O
	
We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O
	
Both	O
patients	O
presented	O
with	O
a	O
salt-losing	O
episode	O
simulating	O
adrenal	O
insufficiency	O
.	O
	
In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B-protein
receptors	I-protein
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O
	
Aldosterone	B-protein
receptors	I-protein
were	O
normal	O
in	O
both	O
patients	O
	
###MEDLINE:93246027	
	
Aldosterone-specific	B-protein
membrane	I-protein
receptors	I-protein
and	O
rapid	O
non-genomic	O
actions	O
of	O
mineralocorticoids	O
.	O
	
Functional	O
studies	O
in	O
extrarenal	B-cell_type
,	I-cell_type
non-epithelial	I-cell_type
cells	I-cell_type
such	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
more	O
recently	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O
	
These	O
involve	O
activation	O
of	O
the	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
min	O
.	O
	
A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O
	
Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O
	
The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor-effector	O
mechanisms	O
involved	O
.	O
	
The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O
	
###MEDLINE:92408021	
	
Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Nef	I-protein
protein	I-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
W.C.Greene	O
,	O
N.Engl.J.	O
Med.324	O
:	O
308-317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305-308	O
,	O
1989	O
)	O
.	O
	
Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	B-protein
mitogens	I-protein
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O
	
This	O
activation	O
is	O
mediated	O
by	O
the	O
host	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711-717	O
,	O
1987	O
]	O
.	O
	
We	O
report	O
here	O
that	O
the	O
HIV-1-encoded	B-protein
Nef	I-protein
protein	I-protein
inhibits	O
the	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
by	O
T-	B-protein
cell	I-protein
mitogens	I-protein
.	O
	
However	O
,	O
Nef	B-protein
does	O
not	O
affect	O
the	O
DNA-binding	O
activity	O
of	O
other	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
HIV-1	O
regulation	O
,	O
including	O
SP-1	B-protein
,	O
USF	B-protein
,	O
URS	B-protein
,	O
and	O
NF-AT	B-protein
.	O
	
Additionally	O
,	O
Nef	B-protein
inhibits	O
the	O
induction	O
of	O
HIV-1-	O
and	O
interleukin	O
2-directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV-1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF-kappa	B-DNA
B-binding	I-DNA
site	I-DNA
.	O
	
These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF-kappa	B-protein
B	I-protein
may	O
underlie	O
Nef	B-protein
's	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV-1	B-DNA
and	I-DNA
interleukin	I-DNA
2	I-DNA
promoters	I-DNA
.	O
	
Further	O
evidence	O
suggests	O
that	O
Nef	B-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
.	O
	
###MEDLINE:93061407	
	
Expression	O
of	O
c-fos	B-DNA
,	O
c-jun	B-DNA
and	O
jun	B-DNA
B	I-DNA
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O
	
The	O
expression	O
of	O
c-fos	B-DNA
,	I-DNA
c-jun	I-DNA
and	I-DNA
jun	I-DNA
B	I-DNA
proto-oncogenes	I-DNA
was	O
studied	O
in	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
activated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
(	O
PBL	B-cell_type
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O
	
Specific	O
mRNAs	B-RNA
for	O
c-fos	B-DNA
and	O
c-jun	B-DNA
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O
	
Both	O
c-fos	B-RNA
and	I-RNA
jun	I-RNA
B	I-RNA
mRNAs	I-RNA
decreased	O
to	O
pre-activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c-jun	B-RNA
mRNA	I-RNA
remained	O
elevated	O
.	O
	
In	O
PHA-activated	B-cell_line
PBL	I-cell_line
,	O
no	O
age-related	O
differences	O
were	O
observed	O
in	O
c-fos	O
or	O
jun	O
B	O
mRNA	O
expression	O
.	O
	
However	O
,	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
decreased	O
significantly	O
(	O
1.73	O
+/-	O
0.08	O
vs.	O
1.16	O
+/-	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	B-cell_type
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B-protein
.	O
	
Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti-CD2	B-protein
pathway	O
,	O
c-jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti-CD2-activated	B-cell_line
purified	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
No	O
age-related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto-oncogenes	B-DNA
by	O
anti-CD2	O
activated	O
T	O
cells	O
.	O
	
These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL-2	B-protein
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA-activated	B-cell_line
PBL	I-cell_line
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age-related	O
changes	O
in	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
and	O
in	O
the	O
ratio	O
of	O
c-fos	O
to	O
c-jun	B-RNA
mRNA	I-RNA
.	O
	
###MEDLINE:92318928	
	
Oct2	B-protein
transactivation	O
from	O
a	O
remote	B-DNA
enhancer	I-DNA
position	I-DNA
requires	O
a	O
B-cell-restricted	O
activity	O
.	O
	
Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	B-protein
could	O
efficiently	O
activate	O
a	O
promoter	B-DNA
containing	O
an	O
octamer	O
motif	O
.	O
	
Oct2	B-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
however	O
.	O
	
We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B-protein
isoforms	I-protein
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	B-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
and	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O
	
Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	I-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O
	
This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	B-protein
cofactor	I-protein
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B-protein
or	O
the	O
Oct2	B-protein
protein	I-protein
in	O
Oct2	B-protein
-mediated	O
enhancer	O
activation	O
.	O
	
Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy-terminal	B-protein
domain	I-protein
of	O
Oct2	B-protein
is	O
critical	O
for	O
enhancer	O
activation	O
.	O
	
Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B-protein
protein	I-protein
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O
	
The	O
glutamine-rich	B-protein
activation	I-protein
domain	I-protein
present	O
in	O
the	O
amino-terminal	B-protein
portion	I-protein
of	I-protein
Oct2	I-protein
and	O
the	O
POU	B-protein
domain	I-protein
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O
	
###MEDLINE:92269839	
	
The	O
promoter	B-DNA
of	O
the	O
CD19	B-DNA
gene	I-DNA
is	O
a	O
target	O
for	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
.	O
	
The	O
CD19	B-protein
protein	I-protein
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B-lymphoid	B-cell_type
cells	I-cell_type
with	O
the	O
exception	O
of	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
and	O
has	O
been	O
implicated	O
as	O
a	O
signal-transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O
	
Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
and	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
in	O
a	O
large	O
panel	O
of	O
B-lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
human	B-DNA
CD19	I-DNA
gene	I-DNA
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	B-DNA
sites	I-DNA
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O
	
In	O
particular	O
,	O
a	O
high-affinity	B-DNA
BSAP-binding	I-DNA
site	I-DNA
instead	O
of	O
a	O
TATA	B-DNA
sequence	I-DNA
is	O
located	O
in	O
the	O
-30	B-DNA
promoter	I-DNA
region	I-DNA
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O
	
Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	B-protein
in	O
vivo	O
in	O
a	O
CD19-expressing	B-cell_line
B-cell	I-cell_line
line	I-cell_line
but	O
not	O
in	O
plasma	B-cell_type
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
This	O
high-affinity	B-DNA
site	I-DNA
has	O
been	O
conserved	O
in	O
the	O
promoters	B-DNA
of	O
both	O
human	B-DNA
and	I-DNA
mouse	I-DNA
CD19	I-DNA
genes	I-DNA
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B-cell	O
specificity	O
to	O
a	O
beta-globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O
	
In	O
addition	O
,	O
BSAP	B-protein
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B-DNA
promoter	I-DNA
.	O
	
Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	B-protein
in	O
the	O
regulation	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
.	O
	
###MEDLINE:92294188	
	
Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O
	
In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	B-cell_type
aggregation	O
.	O
	
Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O
	
Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O
	
Eicosanoids	O
were	O
measured	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O
furthermore	O
,	O
TXA2	O
,	O
6-keto-PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O
	
Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O
PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O
	
Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O
	
Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	O
detectable	O
quantities	O
of	O
eicosanoids	O
were	O
found	O
in	O
the	O
non-tumor	O
material	O
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O
	
Statistically	O
significant	O
correlations	O
could	O
be	O
established	O
between	O
patient/histopathology	O
data	O
and	O
the	O
results	O
of	O
the	O
platelet	B-cell_type
aggregation	O
assays	O
,	O
e.g.	O
between	O
menopausal	O
status	O
and	O
ADP	O
aggregation	O
;	O
oestrogen	B-protein
receptor	I-protein
(	O
+/-	O
)	O
and	O
collagen	B-protein
and	O
arachidonic	O
acid	O
aggregation	O
,	O
inflammatory	O
cell	O
infiltration	O
score	O
and	O
arachidonic	O
acid	O
aggregation	O
and	O
fibrosis	O
score	O
and	O
ADP	O
aggregation	O
.	O
	
The	O
results	O
show	O
that	O
eicosanoid	O
synthesis	O
in	O
material	O
from	O
mammary	O
cancer	O
patients	O
is	O
different	O
from	O
that	O
in	O
benign	O
mammary	O
tissue	O
.	O
	
The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O
	
###MEDLINE:92193465	
	
Mineralocorticoids	O
and	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
pregnancy-induced	O
hypertension	O
.	O
	
To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxycorticosterone	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O
	
Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
status	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O
	
MR	B-protein
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
+/-	O
9	O
binding	O
sites/cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+/-	O
17	O
binding	O
sites/cell	O
;	O
mean	O
+/-	O
SEM	O
)	O
.	O
	
Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
+/-	O
61	O
pmol/L	O
;	O
in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
+/-	O
172	O
pmol/L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O
	
Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
+/-	O
149	O
pmol/L	O
;	O
controls	O
,	O
1907	O
+/-	O
318	O
pmol/L	O
)	O
.	O
	
These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O
	
These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
status	O
.	O
	
###MEDLINE:92147648	
	
Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O
	
Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O
	
Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O
	
Their	O
affinity	O
for	O
the	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O
	
The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	B-cell_type
cell	I-cell_type
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
	
The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O
	
The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
(	O
HL-60	B-cell_line
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O
	
Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
.	O
	
The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	B-cell_line
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O
	
###MEDLINE:92213189	
	
Glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	O
of	O
evidence	O
of	O
receptor	O
binding	O
defect	O
.	O
	
1	O
.	O
	
In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
,	O
circadian	O
variation	O
in	O
cortisol	O
concentration	O
,	O
dexamethasone	O
suppression	O
and	O
glucocorticoid	O
receptor	O
binding	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
,	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
were	O
measured	O
in	O
rigidly	O
defined	O
major	O
depressive	O
disorder	O
patients	O
and	O
non-depressed	O
psychiatric	O
controls	O
.	O
	
2	O
.	O
	
Mononuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O
	
3	O
.	O
	
Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non-depressed	O
control	O
subjects	O
.	O
	
4	O
.	O
	
The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O
	
###MEDLINE:92109743	
	
High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	I-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	I-protein
for	O
mineralocorticoids	O
?	O
	
In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	B-protein
have	O
been	O
described	O
in	O
intact	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O
	
In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	B-cell_type
was	O
studied	O
.	O
	
High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O
	
Aldosterone	O
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O
	
Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O
	
The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	O
for	O
cortisol	O
.	O
	
These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	B-protein
in	O
HML	B-cell_type
and	O
thus	O
very	O
likely	O
represent	O
membrane	B-protein
receptors	I-protein
for	O
aldosterone	O
.	O
	
###MEDLINE:93079901	
	
Natural	O
variants	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
:	O
analysis	O
of	O
promoters	B-DNA
with	O
duplicated	O
DNA	B-DNA
regulatory	I-DNA
motifs	I-DNA
.	O
	
Sequence	O
variation	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
region	I-DNA
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O
	
Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O
	
One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O
	
Another	O
LTR	B-DNA
size	I-DNA
variation	I-DNA
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O
	
This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	B-DNA
DNA	I-DNA
sequence	I-DNA
(	O
CTG-motif	B-DNA
)	O
.	O
	
Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	B-DNA
sites	I-DNA
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	B-DNA
control	I-DNA
LTR	I-DNA
with	O
three	O
Sp1	B-DNA
sites	I-DNA
.	O
	
No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG-motif	B-DNA
could	O
be	O
detected	O
.	O
	
In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild-type	B-DNA
plasmid	I-DNA
were	O
cotransfected	O
into	O
T-cells	B-cell_type
.	O
	
The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O
	
Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5-10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	B-DNA
variants	I-DNA
when	O
compared	O
to	O
that	O
of	O
wild-type	O
.	O
	
###MEDLINE:93046624	
	
A	O
novel	B-protein
B	I-protein
cell-derived	I-protein
coactivator	I-protein
potentiates	O
the	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	I-DNA
by	O
octamer-binding	B-protein
transcription	I-protein
factors	I-protein
.	O
	
A	O
novel	O
B	O
cell-restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	B-DNA
/	O
Oct	B-DNA
-dependent	O
transcription	O
from	O
an	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
promoter	I-DNA
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	B-cell_line
cell	I-cell_line
-derived	O
extracts	O
complemented	O
with	O
fractionated	B-protein
B	I-protein
cell	I-protein
nuclear	I-protein
proteins	I-protein
.	O
	
The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	B-protein
coactivator	I-protein
from	O
B	B-cell_type
cells	I-cell_type
(	O
OCA-B	B-protein
)	O
.	O
	
OCA-B	B-protein
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	B-DNA
promoter	I-DNA
in	O
conjunction	O
with	O
either	O
Oct-1	B-protein
or	O
Oct-2	B-protein
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	B-DNA
/	O
Oct	B-DNA
-dependent	O
transcription	O
of	O
the	O
ubiquitously	B-DNA
expressed	I-DNA
histone	I-DNA
H2B	I-DNA
promoter	I-DNA
and	O
the	O
transcription	O
of	O
USF-	B-DNA
and	I-DNA
Sp1-regulated	I-DNA
promoters	I-DNA
.	O
	
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA-B	B-protein
is	O
a	O
tissue-	B-protein
,	I-protein
promoter-	I-protein
,	I-protein
and	I-protein
factor-specific	I-protein
coactivator	I-protein
and	O
that	O
OCA-B	B-protein
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell-specific	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	I-DNA
.	O
	
In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	B-protein
factors	I-protein
and	O
OCA-B	B-protein
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA-B	B-protein
and	O
discuss	O
the	O
implications	O
of	O
OCA-B	B-protein
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue-specific	B-DNA
promoters	I-DNA
.	O
	
###MEDLINE:93085167	
	
SCL	B-protein
and	O
related	O
hemopoietic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factors	I-protein
.	O
	
The	O
helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
proteins	I-protein
are	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O
	
Five	O
members	O
of	O
this	O
family	O
(	O
MYC	B-protein
,	O
SCL	B-protein
,	O
TAL-2	B-protein
,	O
LYL-1	B-protein
and	O
E2A	B-protein
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O
	
Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B-protein
and	O
LYL-1	B-protein
is	O
low	O
or	O
undetectable	O
in	O
normal	B-cell_type
T	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O
	
SCL	B-protein
is	O
expressed	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
populations	I-cell_type
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	B-protein
,	O
a	O
zinc-finger	B-protein
transcription	I-protein
factor	I-protein
)	O
.	O
	
In	O
addition	O
,	O
both	O
SCL	B-protein
and	O
GATA-1	B-protein
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
and	O
are	O
down-modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	B-protein
in	O
erythroid	O
differentiation	O
events	O
.	O
	
However	O
,	O
in	O
contrast	O
to	O
GATA-1	B-protein
,	O
SCL	B-protein
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O
	
Studies	O
of	O
the	O
function	O
of	O
SCL	B-protein
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self-renewal	O
events	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:92318932	
	
Induction	O
of	O
the	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
during	O
T-cell	B-cell_type
activation	O
by	O
cognate	O
antigen	O
.	O
	
Oct-2	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
that	O
binds	O
specifically	O
to	O
octamer	B-DNA
DNA	I-DNA
motifs	I-DNA
in	O
the	O
promoters	B-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
.	O
	
All	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
a	O
few	O
from	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
express	O
Oct-2	B-protein
.	O
	
To	O
address	O
the	O
role	O
of	O
Oct-2	B-protein
in	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
nontransformed	B-cell_line
human	I-cell_line
and	I-cell_line
mouse	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Oct-2	B-protein
was	O
found	O
in	O
CD4+	B-cell_line
and	I-cell_line
CD8+	I-cell_line
T	I-cell_line
cells	I-cell_line
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	B-cell_type
lymph	I-cell_type
node	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
a	O
T-cell	B-cell_line
clone	I-cell_line
specific	O
for	O
pigeon	B-protein
cytochrome	I-protein
c	I-protein
in	O
the	O
context	O
of	O
I-Ek	B-protein
,	O
Oct-2	B-protein
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	B-protein
protein	I-protein
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O
	
Oct-2	B-RNA
mRNA	I-RNA
induction	O
during	O
antigen-driven	O
T-cell	B-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O
	
These	O
results	O
suggest	O
that	O
Oct-2	B-protein
participates	O
in	O
transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
activation.	O
The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	B-protein
induction	O
suggests	O
that	O
Oct-2	B-protein
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
###MEDLINE:93020778	
	
Glucocorticoid	B-protein
receptor	I-protein
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O
	
We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O
	
Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O
	
Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
MNL	B-cell_type
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O
	
In	O
summary	O
,	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O
	
###MEDLINE:92320321	
	
[	O
Changes	O
in	O
plasma	B-protein
interleukin-1	I-protein
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
in	O
aged	O
long-distance	O
runner	O
]	O
	
For	O
the	O
study	O
of	O
the	O
changes	O
in	O
plasma	B-protein
interleukin-1	I-protein
(	O
IL-1	B-protein
)	O
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
,	O
plasma	B-protein
IL-1	I-protein
and	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
long-distance	O
runner	O
were	O
measured	O
simultaneously	O
.	O
	
The	O
activity	O
of	O
IL-1	B-protein
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H-TdR	B-protein
incorporation	O
in	O
the	O
thymocytes	B-cell_type
of	O
C57	O
mice	O
.	O
	
GR	B-protein
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H-Dex	O
.	O
	
The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	B-protein
in	O
aged	O
long-distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7-18.7	O
,	O
3.8-7.0	O
and	O
1.5-2.6	O
KD	O
fractions	O
.	O
	
The	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O
	
Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	B-protein
and	O
GR	B-protein
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O
	
###MEDLINE:92193472	
	
Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O
	
Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
mononuclear	B-cell_type
leucocytes	I-cell_type
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O
	
Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	B-protein
(	O
preeclampsia	O
,	O
81	O
+/-	O
44	O
receptors/cell	O
;	O
controls	O
,	O
306	O
+/-	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
+/-	O
7	O
mV	O
;	O
controls	O
,	O
12	O
+/-	O
5	O
mV	O
)	O
.	O
	
In	O
six	O
cases	O
we	O
determined	O
MR	B-protein
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O
	
MR	B-protein
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+/-	O
27	O
receptors/cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B-protein
,	O
242	O
+/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+/-	O
4	O
mV	O
)	O
.	O
	
Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O
	
These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	O
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	O
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O
	
###MEDLINE:92215726	
	
Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
human	B-cell_line
HL60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
--	O
coincident	O
rise	O
of	O
DNA-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O
	
High	B-protein
affinity	I-protein
receptors	I-protein
(	O
VDR	B-protein
)	O
for	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O
	
HL60	B-cell_line
cells	I-cell_line
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	B-cell_line
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O
	
Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
examined	O
after	O
exposure	O
of	O
whole	B-cell_type
cells	I-cell_type
to	O
10	O
(	O
-9	O
)	O
M/l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O
	
Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites/nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites/nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	B-cell_type
.	O
	
Pulse	O
exposure	O
of	O
HL60	B-cell_line
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B-protein
radiolabeled	I-protein
VDR	I-protein
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B-protein
by	O
24	O
h	O
.	O
	
Radiolabeled	B-protein
VDR	I-protein
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse/chase-experiments	O
)	O
.	O
	
No	O
difference	O
of	O
VDR	B-protein
retention	O
in	O
pulse	O
and	O
pulse/chase-experiments	O
was	O
seen	O
in	O
PBL	B-cell_type
,	O
where	O
VDR	B-protein
halflife	O
was	O
approximately	O
30	O
min	O
.	O
	
No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O
	
Radiolabeled	B-protein
hormone/receptor	I-protein
complexes	I-protein
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O
	
The	O
activity	O
of	O
DNA	B-protein
relaxing	I-protein
enzymes	I-protein
(	O
e.g	O
.	O
topoisomerases	B-protein
I	I-protein
and	I-protein
II	I-protein
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation-assay	O
.	O
	
Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v/v	O
)	O
in	O
HL60	B-cell_line
and	O
PBL	B-cell_type
.	O
	
The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	B-cell_type
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	B-cell_line
.	O
	
No	O
effect	O
was	O
seen	O
in	O
ethanol	B-cell_line
treated	I-cell_line
controls	I-cell_line
.	O
	
We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B-protein
proteins	I-protein
after	O
hormone	O
binding	O
.	O
	
Translocated	B-protein
hormone/receptor	I-protein
complexes	I-protein
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O
	
Enhanced	O
activity	O
of	O
topoisomerases	B-protein
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B-protein
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O
	
###MEDLINE:92135176	
	
Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O
	
Estrogen	B-cell_line
receptor	I-cell_line
positive	I-cell_line
(	I-cell_line
ER+	I-cell_line
:	I-cell_line
MCF-7	I-cell_line
)	I-cell_line
and	I-cell_line
negative	I-cell_line
(	I-cell_line
ER-	I-cell_line
:	I-cell_line
MDA-MB-231	I-cell_line
)	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
(	I-cell_type
LAK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O
	
E2-stimulated	B-cell_line
ER+	I-cell_line
cells	I-cell_line
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	B-cell_type
cells	I-cell_type
than	O
corresponding	O
TAM-treated	B-cell_line
or	O
control	B-cell_type
cells	I-cell_type
,	O
while	O
treatment	O
of	O
ER-	B-cell_line
cells	I-cell_line
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune-mediated	O
lysis	O
.	O
	
All	O
ER+	B-cell_line
and	I-cell_line
ER-	I-cell_line
cells	I-cell_line
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	B-cell_type
cells	I-cell_type
.	O
	
In	O
addition	O
,	O
an	O
adenocarcinoma	B-protein
reactive	I-protein
human-mouse	I-protein
chimeric	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
ING-1	B-protein
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell-mediated	O
lysis	O
of	O
control	B-cell_line
,	I-cell_line
E2-treated	I-cell_line
,	I-cell_line
and	I-cell_line
TAM-treated	I-cell_line
ER+	I-cell_line
and	I-cell_line
ER-	I-cell_line
cells	I-cell_line
.	O
	
These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O
	
###MEDLINE:92107162	
	
The	O
cellular	B-DNA
oncogene	I-DNA
c-myb	B-DNA
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
genome	I-DNA
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B-protein
encoded	I-protein
transcription	I-protein
factor	I-protein
,	O
Z	B-protein
(	O
BZLF1	B-protein
)	O
.	O
	
We	O
have	O
shown	O
that	O
the	O
Z	B-protein
gene	I-protein
product	I-protein
,	O
which	O
binds	O
to	O
AP-1	B-DNA
sites	I-DNA
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	B-DNA
,	O
can	O
efficiently	O
activate	O
the	O
EBV	B-DNA
early	I-DNA
promoter	I-DNA
,	O
BMRF1	B-DNA
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	B-cell_line
cells	I-cell_line
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
which	O
is	O
itself	O
a	O
DNA-binding	B-protein
protein	I-protein
and	O
transcriptional	B-protein
transactivator	I-protein
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-protein
in	O
activating	O
the	O
BMRF1	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
T-cell	B-cell_line
line	I-cell_line
)	O
or	O
Raji	B-cell_line
cells	I-cell_line
(	O
an	O
EBV-positive	B-cell_line
B-cell	I-cell_line
)	O
,	O
whereas	O
the	O
c-myb	B-protein
gene	I-protein
product	I-protein
by	O
itself	O
has	O
little	O
effect	O
.	O
	
The	O
simian	B-DNA
virus	I-DNA
40	I-DNA
early	I-DNA
promoter	I-DNA
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
.	O
	
Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-DNA
promoter	I-DNA
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-protein
protein	I-protein
but	O
not	O
the	O
c-myb	B-protein
protein	I-protein
.	O
	
A	O
30-bp	B-DNA
sequence	I-DNA
in	O
the	O
BMRF1	B-DNA
promoter	I-DNA
which	O
contains	O
a	O
Z	B-DNA
binding	I-DNA
site	I-DNA
(	O
a	O
consensus	B-DNA
AP-1	I-DNA
site	I-DNA
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z/c-myb	B-protein
combination	I-protein
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O
	
That	O
the	O
c-myb	B-protein
oncogene	I-protein
product	I-protein
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	B-protein
member	I-protein
of	O
the	O
leucine	B-protein
zipper	I-protein
protein	I-protein
family	I-protein
suggests	O
c-myb	B-DNA
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	B-protein
encoded	I-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:93129248	
	
Alpha-lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O
	
The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
region	I-DNA
of	O
HIV	B-DNA
proviral	I-DNA
DNA	I-DNA
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
and	O
this	O
transcriptional	B-protein
activator	I-protein
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O
	
Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O
	
Incubation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells/ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha-lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
25	O
ng/ml	O
)	O
or	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
50	O
ng/ml	O
)	O
.	O
	
The	O
inhibitory	O
action	O
of	O
alpha-lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N-acetylcysteine	O
.	O
	
These	O
results	O
indicate	O
that	O
alpha-lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O
	
###MEDLINE:93077034	
	
Reticuloendotheliosis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
elements	I-DNA
are	O
efficient	O
promoters	B-DNA
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
Promiscuous	O
transcriptional	O
activity	O
of	O
the	O
reticuloendotheliosis	B-DNA
virus	I-DNA
(	I-DNA
REV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
was	O
detected	O
in	O
transient	O
expression	O
assays	O
using	O
LTR-chloramphenicol	B-DNA
acetyltransferase-encoding	I-DNA
gene	I-DNA
chimeras	I-DNA
,	O
and	O
cells	O
of	O
diverse	O
species	O
and	O
tissue	O
type	O
;	O
levels	O
of	O
expression	O
from	O
two	O
different	O
REV	B-DNA
LTRs	I-DNA
correlate	O
with	O
reports	O
of	O
pathogenicity	O
of	O
the	O
respective	O
viruses	O
in	O
vivo	O
.	O
	
REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	B-DNA
LTR	I-DNA
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	B-DNA
sarcoma/leukemia	I-DNA
virus	I-DNA
LTRs	I-DNA
.	O
	
REV	B-DNA
LTRs	I-DNA
work	O
efficiently	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	B-DNA
commonly	O
used	O
for	O
expression	O
of	O
cloned	B-DNA
genes	I-DNA
.	O
	
They	O
may	O
also	O
prove	O
useful	O
in	O
the	O
identification	O
of	O
new	O
,	O
ubiquitous	B-protein
cellular	I-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:92407982	
	
A	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
to	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O
	
Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O
	
The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O
	
In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O
	
In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
specifically	O
to	O
two	B-DNA
purine-rich	I-DNA
motifs	I-DNA
in	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
.	O
	
Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O
	
Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
Thus	O
,	O
Elf-1	B-protein
is	O
a	O
novel	B-protein
transcription	I-protein
factor	I-protein
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor-mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O
	
These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV-1	O
and	O
HIV-2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV-2	O
infection	O
.	O
	
###MEDLINE:92392375	
	
Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
Treatment	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
AP-1	B-protein
and	O
a	O
marked	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
levels	O
.	O
	
In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	B-protein
binding	I-protein
proteins	I-protein
,	O
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
were	O
found	O
.	O
	
Since	O
both	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF-alpha	B-RNA
mRNA	I-RNA
levels	O
.	O
	
Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF-alpha	B-RNA
mRNA	I-RNA
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF-alpha	B-protein
were	O
released	O
into	O
the	O
culture	O
media	O
.	O
	
Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	B-protein
secretion	O
.	O
	
###MEDLINE:92317168	
	
Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
.	O
	
The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
proteins	I-protein
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B-protein
related	I-protein
polypeptides	I-protein
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
In	O
this	O
study	O
multiple	O
NF-kappa	B-protein
B	I-protein
related	I-protein
polypeptides	I-protein
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
interferon	B-DNA
beta	I-DNA
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
and	O
form	O
multiple	B-protein
DNA	I-protein
binding	I-protein
homo-	I-protein
and	I-protein
heterodimer	I-protein
complexes	I-protein
in	O
co-renaturation	O
experiments	O
.	O
	
Furthermore	O
,	O
using	O
DNA	B-DNA
templates	I-DNA
containing	O
two	O
copies	O
of	O
the	O
PRDII	B-DNA
domain	I-DNA
linked	O
to	O
the	O
rabbit	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	B-protein
B	I-protein
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B-protein
homodimers	I-protein
.	O
	
These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	B-protein
proteins	I-protein
.	O
	
###MEDLINE:92309248	
	
c-myc	B-RNA
mRNA	I-RNA
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
's	O
syndrome	O
.	O
	
c-myc	B-DNA
protooncogene	I-DNA
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B	O
cell	O
lymphoid	O
malignancies	O
and	O
high	O
levels	O
of	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
are	O
observed	O
in	O
activated	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
lymphocytic	B-cell_type
infiltrates	I-cell_type
of	O
exocrine	O
glands	O
,	O
remarkable	O
B	O
cell	O
hyperreactivity	O
and	O
a	O
strong	O
predisposition	O
to	O
B	O
cell	O
neoplasia	O
.	O
	
In	O
this	O
study	O
,	O
c-myc	B-RNA
protooncogene	I-RNA
mRNA	I-RNA
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O
	
Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	B-DNA
and	I-DNA
the	I-DNA
2nd	I-DNA
exon	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O
	
To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c-myc	B-DNA
probe	I-DNA
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O
	
High	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
detected	O
on	O
acinar	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O
	
c-myc	B-protein
did	O
not	O
correlate	O
with	O
c-fos	B-protein
and	O
c-jun	B-protein
protein	O
expression	O
.	O
	
Stronger	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
detected	O
in	O
labial	O
salivary	O
glands	O
of	O
patients	O
with	O
longer	O
disease	O
duration	O
(	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.002	O
)	O
and	O
more	O
intense	O
T	B-cell_type
lymphocyte	I-cell_type
infiltrates	I-cell_type
(	O
p	O
less	O
than	O
0.05	O
)	O
although	O
these	O
patients	O
revealed	O
no	O
hypergammaglobulinemia	O
.	O
	
No	O
correlation	O
was	O
observed	O
between	O
c-myc	B-RNA
mRNA	I-RNA
and	O
B	O
lymphocyte	O
monoclonicity	O
or	O
lymphoma	O
.	O
	
In	O
conclusion	O
,	O
strong	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
observed	O
on	O
epithelial	B-cell_type
cells	I-cell_type
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O
	
Our	O
findings	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
reactivated	O
virus	O
hosted	O
in	O
these	O
cells	O
.	O
	
###MEDLINE:92230800	
	
Corticosteroid	B-protein
receptors	I-protein
and	O
lymphocyte	B-cell_type
subsets	I-cell_type
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
aging	O
.	O
	
Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O
	
In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	B-cell_type
subsets	I-cell_type
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O
	
The	O
mean	O
number	O
of	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
receptors	I-protein
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
+/-	O
96	O
and	O
272	O
+/-	O
97	O
receptors	B-protein
/cell	O
for	O
type	B-protein
I	I-protein
,	O
and	O
1	O
,	O
794	O
+/-	O
803	O
and	O
3	O
,	O
339	O
+/-	O
918	O
for	O
type	O
II	B-protein
receptors	I-protein
)	O
.	O
	
Plasma	O
aldosterone	O
and	O
cortisol	O
and	O
lymphocyte	B-cell_type
subsets	I-cell_type
were	O
not	O
different	O
in	O
the	O
two	O
groups	O
.	O
	
All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	B-protein
I	I-protein
and	O
type	B-protein
II	I-protein
receptors	I-protein
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	B-cell_type
and	O
age	O
and	O
CD4/CD8	B-cell_type
in	O
the	O
aged	O
group	O
.	O
	
These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	B-protein
receptors	I-protein
that	O
are	O
not	O
associated	O
with	O
increase	O
of	O
related	O
steroids	O
and	O
that	O
this	O
situation	O
probably	O
represents	O
a	O
concomitant	O
of	O
the	O
normal	O
aging	O
process	O
.	O
	
###MEDLINE:92176657	
	
T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B-protein
cytokine	I-protein
IL-4	I-protein
.	O
	
IL-4	B-protein
secreted	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
pleiotropic	B-protein
cytokine	I-protein
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O
	
We	O
investigated	O
the	O
upstream	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O
	
A	O
novel	B-DNA
T	I-DNA
cell-specific	I-DNA
negative	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
composed	O
of	O
two	O
protein-binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
:	O
-311CTCCCTTCT-303	O
(	O
NRE-I	B-DNA
)	O
and	O
-288CTTTTTGCTT-TGC-300	O
(	O
NRE-II	B-DNA
)	O
.	O
	
A	O
T	B-protein
cell-specific	I-protein
protein	I-protein
Neg-1	B-protein
and	O
a	O
ubiquitous	B-protein
protein	I-protein
Neg-2	B-protein
binding	O
to	O
NRE-I	B-DNA
and	O
NRE-II	B-DNA
,	O
respectively	O
,	O
were	O
identified	O
.	O
	
Furthermore	O
,	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
was	O
found	O
45	B-DNA
bp	I-DNA
downstream	I-DNA
of	O
the	O
NRE	B-DNA
.	O
	
The	O
enhancer	O
activity	O
of	O
the	O
PRE	B-DNA
was	O
completely	O
suppressed	O
when	O
the	O
NRE	B-DNA
was	O
present	O
.	O
	
These	O
data	O
suggest	O
that	O
IL-4	B-DNA
promoter	I-DNA
activity	O
is	O
normally	O
down-regulated	O
by	O
an	O
NRE	B-DNA
via	O
repression	O
of	O
the	O
enhancer	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
.	O
	
These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:92164748	
	
Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
into	O
IgM-secreting	B-cell_type
plasma	I-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
c-fos	B-DNA
.	O
	
The	O
role	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
6	I-protein
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O
	
Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	B-protein
6	I-protein
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	B-RNA
sense	I-RNA
mRNA	I-RNA
expression	O
.	O
	
The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O
	
The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c-fos	B-DNA
significantly	O
inhibited	O
IL	B-protein
6	I-protein
-induced	O
IgM	B-protein
production	O
by	O
SKW	B-cell_line
6.4	I-cell_line
cells	I-cell_line
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O
	
These	O
results	O
indicate	O
that	O
activation	O
of	O
c-fos	B-DNA
is	O
involved	O
in	O
IL	B-protein
6	I-protein
-induced	O
differentiation	O
of	O
SKW	B-cell_line
6.4	I-cell_line
cells	I-cell_line
into	O
IgM-secreting	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:92153263	
	
Transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
development	O
:	O
the	O
alpha	B-DNA
TCR	I-DNA
gene	I-DNA
as	O
a	O
molecular	O
model	O
.	O
	
The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	B-cell_type
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	B-DNA
positive	I-DNA
and	I-DNA
negative	I-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O
	
In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	B-DNA
T-cell-specific	I-DNA
gene	I-DNA
,	O
alpha	B-DNA
TCR	I-DNA
,	O
is	O
discussed	O
.	O
	
Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	B-DNA
factors	I-DNA
that	O
regulate	O
multiple	O
T-cell	B-DNA
genes	I-DNA
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	B-cell_type
activation	O
,	O
are	O
described	O
.	O
	
###MEDLINE:93129206	
	
Photoaffinity	O
labeling	O
of	O
plasma	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
Non-genomic	O
effects	O
of	O
aldosterone	O
on	O
the	O
sodium-proton-antiport	B-protein
have	O
been	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
which	O
could	O
be	O
related	O
to	O
a	O
new	O
aldosterone	B-protein
membrane	I-protein
receptor	I-protein
.	O
	
In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
derivative	O
.	O
	
Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O
	
The	O
presence	O
of	O
the	O
sulfhydryl	O
agent	O
dithiothreitol	O
did	O
not	O
affect	O
results	O
suggesting	O
the	O
absence	O
of	O
disulfide	B-protein
bridges	I-protein
in	O
the	O
steroid	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
receptor	O
.	O
	
These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	B-protein
receptor	I-protein
for	O
aldosterone	O
.	O
	
###MEDLINE:93056505	
	
Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
and	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
activity	O
in	O
human	B-cell_line
T	I-cell_line
and	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O
	
We	O
used	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha-tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	B-cell_line
and	I-cell_line
PMA-	I-cell_line
or	I-cell_line
TNF-stimulated	I-cell_line
cells	I-cell_line
blocks	O
the	O
functions	O
depending	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
both	O
lymphoblastoid	B-cell_line
T	I-cell_line
(	O
J.Jhan	B-cell_line
)	O
and	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Secretion	O
of	O
TNF	B-protein
,	O
the	O
product	O
of	O
another	O
NF-kappa	B-DNA
B-dependent	I-DNA
gene	I-DNA
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA-stimulated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
	
The	O
anti-oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	B-cell_line
and	I-cell_line
unstimulated	I-cell_line
T	I-cell_line
cell	I-cell_line
,	O
whereas	O
TNF	B-protein
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O
	
Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	B-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
could	O
not	O
by	O
itself	O
induce	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
These	O
observations	O
suggest	O
that	O
TNF	B-protein
and	O
PMA	B-protein
do	O
not	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O
	
Rather	O
,	O
TNF	B-protein
and	O
PMA	B-protein
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O
	
It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF-kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
.	O
	
###MEDLINE:93024383	
	
Selection	O
of	O
optimal	O
kappa	O
B/Rel	O
DNA-binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O
	
Analysis	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O
	
In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O
	
However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O
	
Using	O
purified	O
recombinant	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
proteins	I-protein
,	O
optimal	O
DNA-binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O
	
Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	B-protein
Rel-related	I-protein
proteins	I-protein
,	O
and	O
DNA-protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O
	
Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	B-protein
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	O
recognized	O
by	O
p50	B-protein
homodimers	I-protein
.	O
	
Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50-	B-DNA
and	I-DNA
c-Rel-selected	I-DNA
sequences	I-DNA
.	O
	
Using	O
either	O
a	O
p50-	O
or	O
p65-	O
selected	O
kappa	O
B	O
motif	O
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
.	O
	
Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
,	O
the	O
p65	B-DNA
-and	I-DNA
p50-selected	I-DNA
motifs	I-DNA
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	B-protein
and	O
p50/65	B-protein
(	O
a	O
chimeric	B-protein
protein	I-protein
with	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
and	O
p65	B-protein
activation	I-protein
domain	I-protein
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	O
demonstrated	O
a	O
significant	O
response	O
to	O
stimuli	O
that	O
induce	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O
	
These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	B-protein
proteins	I-protein
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O
	
###MEDLINE:92366555	
	
NF-kappa	B-protein
B	I-protein
-dependent	O
induction	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-DNA
subunit	I-DNA
gene	I-DNA
promoter	I-DNA
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O
	
The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
observed	O
in	O
U937	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O
	
The	O
activity	O
of	O
the	O
promoter	B-DNA
regulating	O
the	O
synthesis	O
of	O
the	O
p105	B-protein
precursor	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
subunit	I-protein
was	O
enhanced	O
in	O
these	O
cells	O
.	O
	
Deletions	O
in	O
this	O
promoter	B-DNA
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF-kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	B-DNA
motif	I-DNA
,	O
by	O
bona	O
fide	O
p50/p65	B-protein
heterodimers	I-protein
.	O
	
Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF-kappa	B-protein
B	I-protein
levels	O
were	O
increased	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B-protein
isoenzymes	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O
	
These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	B-cell_line
cells	I-cell_line
,	O
continuous	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF-kappa	B-protein
B	I-protein
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O
	
This	O
HIV-mediated	O
mechanism	O
results	O
in	O
a	O
self-perpetuating	O
loop	O
of	O
NF-kappa	B-protein
B	I-protein
production	O
.	O
	
###MEDLINE:93041375	
	
Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
interleukin	B-protein
2	I-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
	
We	O
report	O
here	O
that	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
acts	O
on	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	O
p55	B-protein
)	O
.	O
	
Similarly	O
,	O
IL-2	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U	I-cell_line
937	I-cell_line
,	O
but	O
not	O
in	O
resting	B-cell_type
human	I-cell_type
T-cells	I-cell_type
.	O
	
This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	B-protein
.	O
	
Enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
is	O
mediated	O
by	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sequence	I-DNA
(	O
-291	B-DNA
to	I-DNA
-245	I-DNA
)	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
is	O
activated	O
.	O
	
In	O
addition	O
,	O
IL-2	B-protein
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B-protein
gene	O
coding	O
for	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B-protein
NF-kappa	B-DNA
B	I-DNA
gene	I-DNA
remained	O
unchanged	O
.	O
	
###MEDLINE:92235212	
	
Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O
	
Hepatic	B-cell_type
microsomes	I-cell_type
and	O
isolated	B-cell_type
hepatocytes	I-cell_type
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O
	
We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	O
T3SO4	O
could	O
mimic	O
the	O
action	O
of	O
thyroid	O
hormone	O
in	O
vitro	O
.	O
	
T3SO4	O
had	O
no	O
thyromimetic	O
effect	O
on	O
the	O
activity	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10	O
,	O
000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
.	O
	
In	O
GH4C1	B-cell_line
pituitary	I-cell_line
cells	I-cell_line
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	B-protein
receptors	I-protein
in	O
intact	B-cell_line
cells	I-cell_line
or	O
soluble	O
preparations	O
.	O
	
Thus	O
,	O
T3SO4	O
was	O
not	O
directly	O
thyromimetic	O
in	O
either	O
an	O
isolated	O
human	O
membrane	O
system	O
or	O
a	O
pituitary	O
cell	O
system	O
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O
	
Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
fibroblasts	I-cell_line
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O
	
Human	B-cell_type
fibroblasts	I-cell_type
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p-nitrophenyl	B-protein
sulfatase	I-protein
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	B-cell_type
microsomes	I-cell_type
.	O
	
Propylthiouracil	O
(	O
50	O
mumol/L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O
	
Thus	O
,	O
it	O
appears	O
T3SO4	O
has	O
no	O
intrinsic	O
biological	O
activity	O
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	O
be	O
reactivated	O
by	O
desulfation	O
.	O
	
###MEDLINE:92185243	
	
Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	B-protein
molecule/CD69	I-protein
enhances	O
the	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O
	
The	O
induction	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O
	
We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B-protein
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	B-protein
activation	O
pathway	O
.	O
	
Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM/CD69	B-protein
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
conjunction	O
with	O
anti-AIM	B-protein
mAb	I-protein
.	O
	
Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	B-protein
mAb	I-protein
to	O
PMA-treated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	B-protein
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	B-DNA
ester	I-DNA
response	I-DNA
element	I-DNA
.	O
	
In	O
contrast	O
,	O
anti-AIM	B-protein
mAb	I-protein
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O
	
The	O
increase	O
in	O
AP-1	B-protein
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	B-protein
but	O
not	O
that	O
of	O
c-jun	B-protein
.	O
	
Blockade	O
of	O
the	O
DNA-binding	B-protein
complexes	I-protein
with	O
an	O
anti-Fos	B-protein
mAb	I-protein
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	B-protein
in	O
the	O
AP-1	B-protein
complexes	I-protein
induced	O
by	O
anti-AIM	B-protein
mAb	I-protein
.	O
	
Most	O
of	O
the	O
AP-1	B-protein
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	B-protein
mAb	I-protein
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	B-protein
-binding	O
activity	O
.	O
	
These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	B-protein
.	O
	
Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O
	
###MEDLINE:92176633	
	
Gangliosides	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
Both	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O
	
We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	O
on	O
the	O
expression	O
of	O
TNF	B-protein
in	O
blood	B-cell_type
monocytes	I-cell_type
and	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
.	O
	
Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms/ml	O
)	O
suppressed	O
LPS-stimulated	O
TNF	B-protein
production	O
5-fold	O
in	O
PBMC	B-cell_type
and	O
10-fold	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum-free	O
conditions	O
.	O
	
Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	B-protein
production	O
in	O
PBMC	B-cell_type
,	O
and	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
by	O
factor	O
10	O
to	O
50	O
.	O
	
The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	O
moiety	O
.	O
	
Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	B-RNA
transcripts	I-RNA
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
was	O
blocked	O
.	O
	
Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	O
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	O
,	O
but	O
not	O
thereafter	O
.	O
	
However	O
,	O
the	O
expression	O
of	O
the	O
CD14	B-protein
Ag	I-protein
,	O
a	O
receptor	B-protein
molecule	I-protein
for	O
LPS-LPS	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O
	
Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	B-protein
activating	I-protein
factor	I-protein
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	B-protein
production	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O
	
Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	B-protein
gene	O
expression	O
in	O
monocytes	B-cell_type
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O
	
###MEDLINE:92123193	
	
A	O
novel	O
mitogen-inducible	B-protein
gene	I-protein
product	I-protein
related	O
to	O
p50/p105-NF-kappa	B-protein
B	I-protein
participates	O
in	O
transactivation	O
through	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
.	O
	
A	O
Rel-related	B-protein
,	I-protein
mitogen-inducible	I-protein
,	I-protein
kappa	I-protein
B-binding	I-protein
protein	I-protein
has	O
been	O
cloned	O
as	O
an	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
The	O
cDNA	B-DNA
has	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
900	B-DNA
amino	I-DNA
acids	I-DNA
capable	O
of	O
encoding	O
a	O
97-kDa	B-protein
protein	I-protein
.	O
	
This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	B-protein
B	I-protein
.	O
	
Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino-terminal	B-protein
Rel-related	I-protein
domain	I-protein
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy-terminal	B-protein
domain	I-protein
containing	O
six	O
full	B-protein
cell	I-protein
cycle	I-protein
or	O
ankyrin	B-protein
repeats	I-protein
.	O
	
In	O
vitro-translated	B-protein
proteins	I-protein
,	O
truncated	O
downstream	O
of	O
the	O
Rel	B-DNA
domain	I-DNA
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O
	
We	O
refer	O
to	O
the	O
kappa	B-protein
B-binding	I-protein
,	I-protein
truncated	I-protein
protein	I-protein
as	O
p50B	B-protein
by	O
analogy	O
with	O
p50-NF-kappa	B-protein
B	I-protein
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	B-protein
.	O
	
p50B	B-protein
is	O
able	O
to	O
form	O
heteromeric	B-protein
kappa	I-protein
B-binding	I-protein
complexes	I-protein
with	O
RelB	B-protein
,	O
as	O
well	O
as	O
with	O
p65	B-protein
and	O
p50	B-protein
,	O
the	O
two	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
Transient-transfection	O
experiments	O
in	O
embryonal	B-cell_line
carcinoma	I-cell_line
cells	I-cell_line
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B-protein
and	O
RelB	B-protein
or	O
p65	B-protein
in	O
transactivation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
dependent	O
on	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
.	O
	
The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:93153207	
	
Surrogate	O
thyroglobulin	B-protein
receptors	I-protein
and	O
T	O
cell	O
proliferation	O
in	O
Hashimoto	O
's	O
thyroiditis	O
.	O
	
Immunoglobulin	B-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
a	O
B	B-cell_type
lymphocyte	I-cell_type
are	O
the	O
endogenous	O
``	O
receptors	O
''	O
to	O
which	O
specific	O
antigens	O
bind	O
.	O
	
Studies	O
in	O
mice	O
have	O
shown	O
that	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
conjugated	O
with	O
palmitate	O
to	O
provide	O
a	O
lipid	O
tail	O
,	O
can	O
be	O
inserted	O
into	O
the	O
cell	O
membrane	O
to	O
provide	O
a	O
``	O
surrogate	O
''	O
antigen	O
receptor	O
.	O
	
We	O
have	O
investigated	O
whether	O
a	O
palmitate	B-protein
conjugate	I-protein
of	O
a	O
human	B-protein
monoclonal	I-protein
antibody	I-protein
specific	O
for	O
thyroglobulin	B-protein
(	O
TG	B-protein
)	O
could	O
function	O
as	O
a	O
surrogate	B-protein
TG	I-protein
receptor	I-protein
on	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
separated	O
into	O
fractions	O
enriched	O
for	O
T	B-cell_type
cells	I-cell_type
or	O
depleted	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
non-T	B-cell_type
cells	I-cell_type
)	O
.	O
	
Using	O
flow	O
cytometry	O
,	O
we	O
detected	O
surrogate	B-protein
TG	I-protein
receptors	I-protein
on	O
non-T	B-cell_type
(	I-cell_type
but	I-cell_type
not	I-cell_type
on	I-cell_type
T	I-cell_type
)	I-cell_type
cells	I-cell_type
from	O
11	O
of	O
11	O
individuals	O
studied	O
(	O
5	O
Hashimoto	O
patients	O
and	O
6	O
control	O
donors	O
)	O
.	O
	
In	O
contrast	O
,	O
endogenous	B-protein
TG	I-protein
receptors	I-protein
could	O
only	O
be	O
detected	O
on	O
non-T	B-cell_type
cells	I-cell_type
from	O
1	O
of	O
3	O
Hashimoto	O
patients	O
and	O
from	O
0	O
of	O
4	O
control	O
donors	O
.	O
	
Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	B-protein
by	O
surrogate	B-protein
receptors	I-protein
on	O
non-T	B-cell_type
cells	I-cell_type
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	B-protein
to	O
T	B-cell_type
cells	I-cell_type
.	O
	
Proliferation	O
in	O
response	O
to	O
TG	B-protein
was	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O
	
This	O
low	O
frequency	O
of	O
response	O
was	O
no	O
different	O
from	O
that	O
previously	O
detected	O
using	O
cultures	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
autologous	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
.	O
	
Therefore	O
,	O
the	O
successful	O
generation	O
of	O
surrogate	B-protein
receptors	I-protein
on	O
non-T	B-cell_type
cells	I-cell_type
is	O
not	O
associated	O
with	O
more	O
efficient	O
TG	B-protein
presentation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
Furthermore	O
,	O
the	O
significance	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
,	O
not	O
the	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
are	O
likely	O
to	O
be	O
the	O
limiting	O
element	O
in	O
the	O
T	O
cell	O
proliferative	O
response	O
to	O
TG	B-protein
and	O
other	O
thyroid	B-protein
autoantigens	I-protein
.	O
	
###MEDLINE:93110357	
	
Targeted	O
degradation	O
of	O
c-Fos	B-protein
,	O
but	O
not	O
v-Fos	B-protein
,	O
by	O
a	O
phosphorylation-dependent	B-protein
signal	I-protein
on	O
c-Jun	B-protein
.	O
	
The	O
proto-oncogene	B-protein
products	I-protein
c-Fos	B-protein
and	O
c-Jun	B-protein
heterodimerize	O
through	O
their	O
leucine	B-protein
zippers	I-protein
to	O
form	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O
	
The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal-dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O
	
The	O
stability	O
of	O
c-Fos	B-protein
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O
	
In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c-Fos	B-protein
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	B-protein
c-Jun	I-protein
.	O
	
c-Jun	B-protein
protein	O
isolated	O
from	O
phorbol	B-cell_line
ester-induced	I-cell_line
cells	I-cell_line
did	O
not	O
target	O
c-Fos	B-protein
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c-Fos	B-protein
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O
	
v-Fos	B-protein
protein	I-protein
,	O
the	O
retroviral	O
counterpart	O
of	O
c-Fos	B-protein
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c-Jun	B-protein
.	O
	
###MEDLINE:93054486	
	
The	O
regulation	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
promoter	I-DNA
region	I-DNA
in	O
macrophage	B-cell_line
,	O
T	B-cell_line
cell	I-cell_line
,	O
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
1311-base	B-DNA
pair	I-DNA
human	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
(	I-DNA
TNF	I-DNA
)	I-DNA
alpha	I-DNA
promoter	I-DNA
region	I-DNA
was	O
fused	O
to	O
the	O
luciferase	B-DNA
(	I-DNA
Luc	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	B-cell_line
producing	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
U937	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
the	O
MLA	B-cell_line
144	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
the	O
729-6	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O
	
Analysis	O
of	O
a	O
series	O
of	O
5'-truncations	B-DNA
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	B-DNA
and	O
negative	O
regulatory	O
elements	O
.	O
	
A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
was	O
localized	O
to	O
a	O
region	O
between	O
-95	B-DNA
and	I-DNA
-36	I-DNA
bp	I-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O
	
Within	O
this	O
region	O
,	O
single	O
AP-2-	B-DNA
and	I-DNA
AP-1-	I-DNA
like	I-DNA
consensus	I-DNA
sequences	I-DNA
were	O
noted	O
.	O
	
These	O
AP-2	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O
	
A	O
modest	O
(	O
20-50	O
%	O
)	O
reduction	O
in	O
TNF	B-DNA
promoter	I-DNA
activity	O
was	O
observed	O
with	O
the	O
AP-2	B-DNA
site	I-DNA
mutation	I-DNA
.	O
	
However	O
,	O
mutation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA-activated	O
promoter	O
activity	O
.	O
	
Also	O
co-transfections	O
of	O
the	O
wild-type	B-DNA
promoter	I-DNA
construct	I-DNA
with	O
an	O
AP-1/c-jun	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
augmented	O
basal	O
and	O
PMA-induced	O
promoter	O
activity	O
.	O
	
###MEDLINE:93018835	
	
Stable	O
expression	O
of	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O
	
The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B-protein
protein	I-protein
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B-protein
,	O
Pol	B-protein
,	O
and	O
Env	B-protein
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O
	
In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B-protein
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	B-protein
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O
	
To	O
determine	O
whether	O
such	O
transdominant	B-protein
Rev	I-protein
proteins	I-protein
could	O
provide	O
long-term	O
protection	O
against	O
HIV	O
infection	O
without	O
affecting	O
T	O
cell	O
function	O
,	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
stably	O
transduced	O
with	O
a	O
retroviral	B-DNA
vector	I-DNA
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	B-protein
protein	I-protein
,	O
M10	B-protein
.	O
	
While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O
	
In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	B-cell_line
CEM	I-cell_line
clones	I-cell_line
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O
	
Expression	O
of	O
M10	B-protein
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
regulatory	I-DNA
element	I-DNA
or	O
Tat	B-protein
.	O
	
Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B-protein
M10	I-protein
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B-protein
2	I-protein
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	B-cell_line
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O
	
###MEDLINE:92366521	
	
Simple	O
derivation	O
of	O
TFIID-dependent	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O
	
Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	B-protein
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
.	O
	
This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O
	
TFIIDs	B-protein
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O
	
The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	B-protein
activator	I-protein
proteins	I-protein
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O
	
This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	B-protein
initiation	I-protein
factors	I-protein
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	B-protein
activators	I-protein
.	O
	
###MEDLINE:93041372	
	
Regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O
	
The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-protein
1	I-protein
and	I-protein
2A	I-protein
protein	I-protein
phosphatases	I-protein
,	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O
	
The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	B-protein
cell	I-protein
surface	I-protein
antigen	I-protein
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	B-protein
transcripts	I-protein
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
gene	I-DNA
expression	O
.	O
	
This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O
	
Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c-fos	B-DNA
gene	I-DNA
.	O
	
Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-DNA
transcription	O
in	O
U-937	B-cell_line
cells	I-cell_line
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O
	
c-jun	B-RNA
mRNA	I-RNA
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid-induced	O
c-jun	B-DNA
transcription	O
.	O
	
The	O
half-life	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	B-cell_line
acid-induced	I-cell_line
cells	I-cell_line
.	O
	
In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	B-protein
transcripts	I-protein
.	O
	
Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c-jun	B-DNA
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O
	
Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	B-DNA
gene	I-DNA
is	O
autoinduced	O
by	O
Jun/AP-1	B-protein
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	B-DNA
promoter	I-DNA
(	I-DNA
positions	I-DNA
-132/+170	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
with	O
and	O
without	O
a	O
mutated	O
AP-1	B-DNA
element	I-DNA
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:92378895	
	
Mitogen	O
stimulation	O
of	O
T-cells	O
increases	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O
	
We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T-cells	O
.	O
	
Both	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O
	
Since	O
T-cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	O
of	O
these	O
intracellular	O
messengers	O
in	O
c-Fos	B-protein
and	O
c-Jun	B-protein
induction	O
was	O
tested	O
.	O
	
PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	B-protein
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O
	
The	O
mitogen-induced	O
increase	O
of	O
c-Fos	B-protein
and	O
c-Jun	B-protein
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O
	
Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP-1	O
to	O
the	O
AP-1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP-1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O
	
We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	O
.	O
	
###MEDLINE:92212930	
	
An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	B-DNA
interleukin	I-DNA
4	I-DNA
gene	I-DNA
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O
	
We	O
have	O
identified	O
a	O
DNA	B-DNA
segment	I-DNA
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
4	I-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
The	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	B-DNA
and	O
three	O
introns	B-DNA
.	O
	
A	O
cis-acting	B-DNA
element	I-DNA
(	O
P	B-DNA
sequence	I-DNA
)	O
resides	O
in	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
region	I-DNA
;	O
no	O
additional	O
DNA	B-DNA
segments	I-DNA
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
.	O
	
For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	B-DNA
promoter	I-DNA
was	O
constructed	O
with	O
the	O
granulocyte/macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
basic	I-DNA
promoter	I-DNA
containing	O
60	B-DNA
base	I-DNA
pairs	I-DNA
of	I-DNA
sequence	I-DNA
upstream	O
from	O
the	O
cap	B-DNA
site	I-DNA
of	O
the	O
mouse	B-DNA
granulocyte/macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
various	O
lengths	O
of	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
.	O
	
The	O
P	B-DNA
sequence	I-DNA
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base-substitution	O
mutations	O
.	O
	
The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	B-DNA
sequence	I-DNA
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O
	
The	O
binding	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
recognize	O
the	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O
	
The	O
binding	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
(	O
a	O
DNA	B-protein
binding	I-protein
protein	I-protein
that	O
specifically	O
recognizes	O
the	O
P	B-DNA
sequence	I-DNA
)	O
to	O
the	O
P	B-DNA
sequence	I-DNA
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
interaction	O
is	O
sequence-specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	B-protein
expression	O
in	O
vivo	O
.	O
	
The	O
P	B-DNA
sequence	I-DNA
does	O
not	O
share	O
homology	O
with	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
share	O
high	O
homology	O
with	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O
	
We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	B-protein
recognize	O
IL-2	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
.	O
	
###MEDLINE:92207144	
	
Leukotriene	O
B4	O
stimulates	O
c-fos	O
and	O
c-jun	O
gene	O
transcription	O
and	O
AP-1	B-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	B-protein
mediator	I-protein
,	O
on	O
the	O
expression	O
of	O
the	O
proto-oncogenes	B-DNA
c-jun	I-DNA
and	I-DNA
c-fos	I-DNA
.	O
	
In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B-protein
factors	I-protein
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
after	O
LTB4	O
stimulation	O
.	O
	
LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O
	
The	O
c-jun	B-RNA
mRNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	B-cell_type
peripheral-blood	I-cell_type
monocytes	I-cell_type
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	B-DNA
.	O
	
The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c-fos	B-RNA
mRNA	I-RNA
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c-jun	B-DNA
at	O
30	O
min	O
.	O
	
Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O
	
Stability	O
of	O
the	O
c-fos	B-DNA
and	O
c-jun	B-RNA
mRNA	I-RNA
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O
	
Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
7-fold	O
and	O
the	O
c-jun	B-DNA
gene	I-DNA
1.4-fold	O
.	O
	
Resting	B-cell_type
monocytes	I-cell_type
contained	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
,	O
but	O
stimulation	O
of	O
monocytes	B-cell_type
with	O
LTB4	O
induced	O
greater	O
AP-1	B-protein
-binding	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
.	O
	
These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	B-protein
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
-binding	O
proto-oncogene	B-protein
products	I-protein
.	O
	
###MEDLINE:92195648	
	
Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
:	O
a	O
possible	O
target	O
for	O
v-erbA	B-DNA
oncogene	I-DNA
action	O
.	O
	
The	O
v-erbA	B-DNA
oncogene	I-DNA
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
alpha	I-protein
(	O
c-erbA/TR-alpha	B-protein
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	B-DNA
genes	I-DNA
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto-oncogene	B-DNA
c-erbA	I-DNA
in	O
erythropoiesis	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
alpha	I-protein
(	O
c-erbA/TR-alpha	B-protein
)	O
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR-alpha	B-protein
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O
	
Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	B-DNA
kinase	I-DNA
oncogene	I-DNA
.	O
	
When	O
added	O
pulsewise	O
to	O
immature	B-cell_type
cells	I-cell_type
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	B-cell_type
cells	I-cell_type
underwent	O
premature	O
cell	O
death	O
.	O
	
Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O
	
Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O
	
Expression	O
of	O
the	O
human	B-protein
RAR-alpha	I-protein
in	O
receptor-negative	B-cell_line
erythroblasts	I-cell_line
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	B-cell_type
cells	I-cell_type
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	B-protein
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O
	
Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	B-protein
c-erbA/TR-alpha	I-protein
in	O
erythroblasts	B-cell_type
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O
	
###MEDLINE:93150054	
	
Activation	O
of	O
lymphokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
:	O
role	O
of	O
cis-acting	B-DNA
DNA	I-DNA
elements	I-DNA
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O
	
Activation	O
of	O
T	B-cell_type
cells	I-cell_type
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
	
Two	O
types	O
of	O
helper	B-cell_line
T	I-cell_line
cell	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	I-cell_line
(	O
Th1	B-cell_line
and	O
Th2	B-cell_line
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	B-protein
(	O
lymphokine	B-protein
)	O
secretion	O
.	O
	
They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell-mediated	O
immunity	O
.	O
	
Although	O
lymphokine	B-DNA
genes	I-DNA
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O
	
For	O
most	O
lymphokine	B-DNA
genes	I-DNA
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O
	
Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	B-protein
.	O
	
The	O
production	O
of	O
the	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O
	
We	O
have	O
previously	O
found	O
a	O
cis-acting	B-DNA
region	I-DNA
spanning	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
region	I-DNA
(	O
positions	O
-95	O
to	O
+27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	B-DNA
genes	I-DNA
in	O
transient	O
transfection	O
assays	O
.	O
	
Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	B-DNA
,	O
GC-box	B-DNA
and	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
(	O
CLE0	B-DNA
)	O
.	O
	
GM2	B-DNA
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O
	
One	O
protein	O
,	O
NF-GM2	B-protein
is	O
similar	O
to	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
.	O
	
GC-box	B-DNA
is	O
a	O
binding	B-DNA
site	I-DNA
for	O
constitutively	B-protein
bound	I-protein
proteins	I-protein
.	O
	
CLEO	O
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O
	
Viral	B-protein
trans-activators	I-protein
such	O
as	O
Tax	B-protein
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	B-protein
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	B-DNA
gene	I-DNA
expression	O
by	O
bypassing	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
mediated	O
signaling	O
.	O
	
The	O
trans-activation	O
domain	O
of	O
E2	B-protein
and	O
Tax	B-protein
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O
	
The	O
viral	B-protein
trans-activators	I-protein
appear	O
to	O
target	O
specific	O
DNA	B-protein
binding	I-protein
protein	I-protein
such	O
as	O
NF-kB	B-protein
and	O
Sp1	B-protein
to	O
cis-acting	B-DNA
DNA	I-DNA
site	I-DNA
and	O
promote	O
lymphokine	B-DNA
gene	I-DNA
expression	O
without	O
TCR	B-protein
-mediated	O
stimulation	O
.	O
	
###MEDLINE:93112057	
	
Mutations	O
in	O
the	O
Pit-1	B-DNA
gene	I-DNA
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O
	
Pit-1	B-protein
is	O
a	O
pituitary-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
and	O
transactivates	O
promoters	B-DNA
of	O
growth	B-DNA
hormone	I-DNA
and	I-DNA
prolactin	I-DNA
genes	I-DNA
.	O
	
In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	B-DNA
gene	I-DNA
,	O
Pro24Leu	B-DNA
,	O
Arg143Gln	B-DNA
,	O
and	O
Arg271Trp	B-DNA
,	O
located	O
on	O
the	O
major	B-DNA
transactivation	I-DNA
region	I-DNA
,	O
POU-specific	B-DNA
domain	I-DNA
,	O
and	O
POU-homeodomain	B-DNA
,	O
respectively	O
.	O
	
###MEDLINE:93114357	
	
Activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c-Fos	B-protein
and	O
AP-1	B-protein
activity	O
in	O
Jurkat	O
cells	O
.	O
	
We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B-protein
.	O
	
Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	B-protein
and	O
a	O
combination	O
of	O
the	O
adenosine	B-protein
receptor	I-protein
agonist	O
NECA	O
(	O
5'-	O
(	O
N-ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	B-protein
and	O
Jun	B-protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O
	
PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time-dependent	O
increase	O
in	O
both	O
c-Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O
	
Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c-Fos	B-protein
)	O
or	O
decrease	O
(	O
Jun	B-protein
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	B-protein
binding	O
,	O
as	O
judged	O
by	O
gel-shift	O
assay	O
,	O
and	O
AP-1	B-protein
transcriptional	O
activity	O
.	O
	
Furthermore	O
there	O
was	O
a	O
clear-cut	O
synergy	O
between	O
the	O
PKC	B-protein
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O
	
The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B-protein
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	B-protein
transcriptional	O
activity	O
in	O
a	O
T-leukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
	
###MEDLINE:93105477	
	
Inhibition	O
of	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O
	
1	O
.	O
	
The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O
	
The	O
former	O
two	O
substances	O
interact	O
with	O
T	B-cell_type
cells	I-cell_type
via	O
the	O
glucocorticoid	B-protein
and	I-protein
beta-adrenergic	I-protein
receptors	I-protein
respectively	O
.	O
	
When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T-cell	O
function	O
during	O
stress	O
.	O
	
During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	B-cell_type
cells	I-cell_type
and	O
thus	O
alter	O
responsiveness	O
.	O
	
Proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
was	O
induced	O
by	O
immobilized	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	B-protein
mAb	I-protein
.	O
	
2	O
.	O
	
Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	B-cell_type
cells	I-cell_type
was	O
determined	O
.	O
	
The	O
results	O
demonstrate	O
that	O
physiologic	O
concentrations	O
of	O
all	O
three	O
of	O
these	O
agents	O
inhibit	O
the	O
anti-CD3	B-protein
mAb	I-protein
-induced	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
3	O
.	O
	
Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T-cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O
	
4	O
.	O
	
Because	O
concomitant	O
elevations	O
in	O
the	O
peripheral	O
levels	O
of	O
these	O
substances	O
may	O
occur	O
,	O
experiments	O
were	O
performed	O
to	O
determine	O
the	O
T-cell	O
inhibitory	O
effects	O
of	O
DEX	O
together	O
with	O
either	O
PGE2	O
or	O
ISO	O
.	O
	
Synergistic	O
suppression	O
of	O
T-cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	O
DEX	O
and	O
ISO	O
,	O
were	O
added	O
to	O
cultures	O
.	O
	
This	O
synergistic	O
suppression	O
could	O
not	O
be	O
explained	O
by	O
an	O
increase	O
in	O
cAMP	O
accumulation	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
DEX	O
and	O
PGE2	O
.	O
	
5	O
.	O
	
Finally	O
,	O
the	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3	B-cell_type
mAb-stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O
	
###MEDLINE:92366509	
	
In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
promoter	I-DNA
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B-protein
gamma	I-protein
.	O
	
Analysis	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
promoter	I-DNA
DRA	B-DNA
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	B-DNA
regions	I-DNA
required	O
for	O
maximal	O
expression	O
.	O
	
We	O
have	O
examined	O
the	O
DRA	B-DNA
promoter	I-DNA
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	B-cell_type
cell	I-cell_type
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O
	
Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	B-cell_line
lines	I-cell_line
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
the	O
Y	B-DNA
,	I-DNA
X1	I-DNA
,	I-DNA
and	I-DNA
X2	I-DNA
boxes	I-DNA
.	O
	
Class	B-cell_line
II	I-cell_line
antigen	I-cell_line
expressing	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
maintained	O
contacts	O
identical	O
to	O
B-cell	B-cell_line
lines	I-cell_line
,	O
while	O
class	B-cell_line
II-negative	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
exhibited	O
no	O
interactions	O
.	O
	
In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
octamer	B-DNA
site	I-DNA
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O
	
This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid-specific	B-protein
OTF-2	I-protein
factor	I-protein
.	O
	
In	O
contrast	O
,	O
the	O
class	B-cell_line
II-positive	I-cell_line
nonlymphoid	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
does	O
not	O
exhibit	O
interactions	O
at	O
the	O
octamer	B-DNA
site	I-DNA
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	B-protein
OTF-1	I-protein
factor	I-protein
and	O
an	O
open	B-DNA
binding	I-DNA
site	I-DNA
.	O
	
Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O
	
Interferon	B-protein
gamma	I-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O
	
These	O
results	O
suggest	O
that	O
interferon	B-protein
gamma	I-protein
functions	O
on	O
a	O
poised	B-DNA
promoter	I-DNA
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	B-DNA
boxes	I-DNA
to	O
strong	O
interactions	O
.	O
	
These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	O
that	O
the	O
modulation	O
of	O
X1	B-DNA
and	O
X2	B-DNA
interactions	O
is	O
an	O
important	O
constituent	O
of	O
the	O
interferon	B-protein
gamma	I-protein
induction	O
pathway	O
.	O
	
###MEDLINE:93012816	
	
Estrogen	O
binding	O
sites	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O
	
1	O
.	O
	
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
presence	O
of	O
estrogen	O
type	O
I	O
(	O
high	O
affinity	O
,	O
low	O
capacity	O
)	O
and	O
type	O
II	O
(	O
low	O
affinity	O
,	O
high	O
capacity	O
)	O
binding	O
sites	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
the	O
effects	O
of	O
danazol	O
on	O
these	O
sites	O
.	O
	
2	O
.	O
	
These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
	
3	O
.	O
	
Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O
	
4	O
.	O
	
It	O
is	O
suggested	O
that	O
danazol	O
has	O
an	O
anti-estrogenic	O
action	O
to	O
the	O
monocytes	O
through	O
the	O
competition	O
and	O
suppression	O
of	O
estrogen	O
binding	O
sites	O
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O
	
###MEDLINE:93030402	
	
A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-protein
receptors	I-protein
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O
	
A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	O
receptor	O
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O
	
Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-protein
receptors	I-protein
which	O
is	O
a	O
whole-cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-dexamethasone	O
as	O
radioligand	O
.	O
	
This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O
	
Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	B-cell_type
samples	I-cell_type
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
is	O
altered	O
in	O
this	O
'stressful	O
'	O
disease	O
.	O
	
On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B-protein
receptor	I-protein
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor-ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O
	
This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O
	
###MEDLINE:92368408	
	
SRC-related	B-DNA
proto-oncogenes	I-DNA
and	O
transcription	B-protein
factors	I-protein
in	O
primary	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O
	
Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
transcription	O
of	O
genes	B-DNA
encoding	O
for	O
lymphokines	B-protein
.	O
	
Interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans-activating	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O
	
Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
	
A	O
member	O
of	O
the	O
src	B-DNA
gene	I-DNA
family	I-DNA
,	O
the	O
lymphocyte-specific	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
p56lck	B-protein
,	O
has	O
been	O
implicated	O
in	O
IL-2	B-protein
production	O
.	O
	
CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B-protein
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	B-DNA
gene	I-DNA
product	O
.	O
	
However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF-AT	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O
	
Since	O
the	O
induction	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	B-protein
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans-activating	B-protein
factors	I-protein
.	O
	
###MEDLINE:92156807	
	
The	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
,	O
but	O
not	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
.	O
	
Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	B-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation-related	O
genes	O
.	O
	
We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	B-protein
in	O
induction	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
.	O
	
We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
Ar-5	I-cell_line
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isozymes	I-protein
of	O
PKC	B-protein
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
.	O
	
Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
in	O
Ar-5	B-cell_line
cells	I-cell_line
transfected	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
linked	O
to	O
this	O
reporter	B-DNA
gene	I-DNA
.	O
	
The	O
IL-2	B-DNA
promoter	I-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
factors	I-protein
including	O
NFAT-1	B-protein
,	O
Oct	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
AP-1	B-protein
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B-protein
.	O
	
We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	B-DNA
and	I-DNA
Oct	I-DNA
sites	I-DNA
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	B-DNA
site	I-DNA
located	O
at	O
-150	B-DNA
bp	I-DNA
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
appearance	O
of	O
an	O
inducible	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	B-protein
depletion	O
.	O
	
Moreover	O
,	O
cotransfections	O
with	O
c-fos	O
and	O
c-jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
minimally	B-cell_line
stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
###MEDLINE:92408125	
	
[	O
Effect	O
of	O
antihypertensive	O
therapy	O
with	O
captopril	O
on	O
gluco-	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
hypertensive	O
patients	O
of	O
various	O
age	O
]	O
	
Binding	O
of	O
3H-dexamethasone	O
and	O
3H-aldosterone	O
by	O
peripheral	B-protein
lymphocyte	I-protein
receptors	I-protein
was	O
investigated	O
in	O
healthy	O
persons	O
and	O
hypertensive	O
patients	O
before	O
and	O
after	O
2-week	O
captopril	O
treatment	O
.	O
	
The	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O
	
The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O
	
There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	B-protein
in	O
middle-aged	O
(	O
44-55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61-80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O
	
###MEDLINE:93121695	
	
The	O
use	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
cells	I-cell_line
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	B-protein
cell	I-protein
,	I-protein
platelet	I-protein
and	I-protein
granulocyte	I-protein
antibodies	I-protein
of	O
potential	O
clinical	O
significance	O
.	O
	
The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
(	I-cell_line
IFN-U937	I-cell_line
)	I-cell_line
cells	I-cell_line
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	B-protein
cell	I-protein
,	O
platelet	B-protein
and	O
granulocyte	B-protein
antibodies	I-protein
.	O
	
A	O
clone	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
selected	O
which	O
expressed	O
Fc	B-protein
receptor	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN-gamma	B-protein
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin-enhanced	O
CL	O
.	O
	
The	O
CL	O
responses	O
of	O
IFN-U937	B-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
human	I-cell_type
monocytes	I-cell_type
to	O
sensitized	B-cell_type
red	I-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
were	O
then	O
compared	O
.	O
	
Assays	O
using	O
monocytes	B-cell_type
or	O
IFN-U937	B-cell_line
cells	I-cell_line
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	B-protein
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O
	
In	O
addition	O
,	O
the	O
use	O
of	O
IFN-U937	B-cell_line
cells	I-cell_line
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O
	
The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
to	O
respond	O
to	O
red	B-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O
	
In	O
addition	O
,	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
both	O
responded	O
to	O
red	B-cell_type
cells	I-cell_type
sensitized	O
with	O
antibodies	B-protein
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O
	
In	O
contrast	O
,	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
responded	O
only	O
weakly	O
to	O
red	B-cell_type
cells	I-cell_type
sensitized	O
with	O
either	O
anti-D	B-protein
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	B-protein
titre	I-protein
antibodies	I-protein
with	O
specificities	O
not	O
normally	O
associated	O
with	O
significantly	O
reduced	O
red	B-cell_type
cell	I-cell_type
survival	O
.	O
	
###MEDLINE:93101981	
	
Ablation	O
of	O
transplanted	O
HTLV-I	O
Tax-transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O
	
Mice	O
transgenic	O
for	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
leukemia	I-DNA
virus	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
Tax	I-DNA
gene	I-DNA
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF-kappa	B-DNA
B-inducible	I-DNA
early	I-DNA
genes	I-DNA
.	O
	
In	O
vitro	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	B-cell_line
Tax-transformed	I-cell_line
fibroblasts	I-cell_line
as	O
well	O
as	O
an	O
HTLV-I-transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
.	O
	
In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	B-protein
itself	O
had	O
no	O
apparent	O
effect	O
on	O
cell	O
growth	O
.	O
	
Mice	O
treated	O
with	O
antisense	O
to	O
NF-kappa	B-protein
B	I-protein
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O
	
This	O
suggests	O
that	O
NF-kappa	B-protein
B	I-protein
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O
	
###MEDLINE:93072349	
	
Membrane	B-protein
receptors	I-protein
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O
	
Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H+	I-protein
antiport	I-protein
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O
	
Binding	O
of	O
125I-labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	B-cell_type
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O
	
This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H	I-protein
(	I-protein
+	I-protein
)	I-protein
-antiport	I-protein
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O
	
Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O
	
Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O
	
These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O
	
###MEDLINE:93011470	
	
Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	B-protein
expression	O
involving	O
NK-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
.	O
	
Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O
	
It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	B-protein
cytokines	I-protein
.	O
	
Here	O
we	O
report	O
that	O
LTB4	O
induces	O
synthesis	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
by	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
through	O
transcriptional	O
activation	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
.	O
	
We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-chi	B-protein
B	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF-IL6	B-protein
,	O
while	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
shown	O
to	O
otherwise	O
confer	O
IL-6	B-protein
inducibility	O
,	O
appeared	O
to	O
be	O
unaffected	O
by	O
LTB4	O
.	O
	
Involvement	O
of	O
NF-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
in	O
induction	O
of	O
IL-6	B-protein
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O
	
Activation	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
by	O
LTB4	O
was	O
not	O
only	O
associated	O
with	O
accumulation	O
of	O
the	O
respective	O
transcripts	O
but	O
resulted	O
in	O
synthesis	O
of	O
functional	O
IL-6	B-protein
protein	I-protein
as	O
well	O
.	O
	
In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
the	O
NF-chi	B-DNA
B	I-DNA
or	O
the	O
NF-IL6	B-DNA
enhancer	I-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
enhancer	I-DNA
.	O
	
The	O
signaling	O
events	O
mediating	O
this	O
effect	O
appeared	O
to	O
involve	O
the	O
release	O
of	O
H2O2	O
,	O
since	O
LTB4	O
failed	O
to	O
induce	O
NF-chi	B-protein
B	I-protein
or	O
NF-IL6	B-protein
in	O
the	O
presence	O
of	O
the	O
scavenger	O
of	O
H2O2	O
,	O
N-acetyl-L-cysteine	O
.	O
	
###MEDLINE:92378748	
	
Bcl-2	B-protein
:	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
.	O
	
The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O
	
The	O
bcl-2	B-DNA
gene	I-DNA
,	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
,	O
is	O
perhaps	O
the	O
best	O
understood	O
of	O
the	O
programmed	O
cell	O
death	O
associated	O
genes	O
.	O
	
Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	B-protein
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B-	O
and	O
T-cell	O
development	O
and	O
in	O
oncogenesis	O
.	O
	
###MEDLINE:92311659	
	
Cytoplasmic	O
domain	O
heterogeneity	O
and	O
functions	O
of	O
IgG	B-protein
Fc	I-protein
receptors	I-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
B	B-cell_type
lymphocytes	I-cell_type
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	B-protein
G	I-protein
(	I-protein
IgG	I-protein
)	I-protein
Fc	I-protein
receptors	I-protein
(	O
Fc	B-protein
gamma	I-protein
RII	I-protein
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	B-protein
domains	I-protein
.	O
	
Because	O
of	O
cell	O
type-specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B-cell	B-protein
Fc	I-protein
gamma	I-protein
RII	I-protein
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O
	
Transfection	O
of	O
an	O
Fc	B-cell_line
gamma	I-cell_line
RII-negative	I-cell_line
B-cell	I-cell_line
line	I-cell_line
with	O
complementary	O
DNA	O
's	O
encoding	O
the	O
two	O
splice	O
products	O
and	O
various	O
receptor	O
mutants	O
indicated	O
that	O
the	O
insertion	O
was	O
responsible	O
for	O
preventing	O
both	O
Fc	B-protein
gamma	I-protein
RII	I-protein
-mediated	O
endocytosis	O
and	O
Fc	B-protein
gamma	I-protein
RII	I-protein
-mediated	O
antigen	O
presentation	O
.	O
	
The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B-protein
gamma	I-protein
RII	I-protein
to	O
modulate	O
surface	B-protein
immunoglobulin	I-protein
-triggered	O
B-cell	O
activation	O
.	O
	
Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
common	O
to	O
both	O
the	O
lymphocyte	B-protein
and	I-protein
macrophage	I-protein
receptor	I-protein
isoforms	I-protein
.	O
	
In	O
contrast	O
,	O
the	O
insertion	O
did	O
contribute	O
to	O
the	O
formation	O
of	O
caps	O
in	O
response	O
to	O
receptor	O
cross-linking	O
,	O
consistent	O
with	O
suggestions	O
that	O
the	O
lymphocyte	O
but	O
not	O
macrophage	O
form	O
of	O
the	O
receptor	O
can	O
associate	O
with	O
the	O
detergent-insoluble	O
cytoskeleton	O
.	O
	
###MEDLINE:92362919	
	
[	O
Age-related	O
changes	O
in	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O
	
It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O
	
The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
grows	O
in	O
hypertensive	O
patients	O
.	O
	
Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid-age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O
	
###MEDLINE:92255823	
	
The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O
	
CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	B-DNA
genes	I-DNA
.	O
	
Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	B-protein
intracellular	I-protein
receptors	I-protein
,	O
the	O
immunophilins	B-protein
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	B-protein
phosphatase	I-protein
,	I-protein
calcineurin	B-protein
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O
	
###MEDLINE:92156797	
	
Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O
	
The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O
	
PLB-985	B-cell_line
cells	I-cell_line
represent	O
a	O
bipotential	B-cell_line
myelomonoblastic	I-cell_line
cell	I-cell_line
population	I-cell_line
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O
	
By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-protein
on	O
the	O
cell	O
surface	O
,	O
PLB-985	B-cell_line
cells	I-cell_line
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O
	
PLB-IIIB	B-cell_line
cells	I-cell_line
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	B-cell_type
myeloblasts	I-cell_type
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	B-protein
surface	I-protein
markers	I-protein
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-DNA
proto-oncogene	I-DNA
.	O
	
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
inducible	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	B-cell_line
.	O
	
However	O
,	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O
	
These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	I-DNA
from	O
the	O
interferon	B-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
promoter	I-DNA
.	O
	
Mutations	O
affecting	O
the	O
5	B-DNA
'	I-DNA
guanine	I-DNA
residues	I-DNA
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
were	O
unable	O
to	O
compete	O
for	O
these	O
NF-kappa	B-protein
B-related	I-protein
proteins	I-protein
.	O
	
Inducibility	O
of	O
endogenous	O
IFN-beta	B-RNA
and	I-RNA
IFN-alpha	I-RNA
RNA	I-RNA
was	O
also	O
increased	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
.	O
	
These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
may	O
contribute	O
to	O
differential	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O
	
###MEDLINE:92113075	
	
Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O
	
Primary	O
(	O
partial	O
)	O
cortisol	B-protein
receptor	I-protein
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O
	
Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O
	
In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O
	
The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O
	
Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life-threatening	O
hypokalemia	O
.	O
	
The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	O
hypokalemia	O
.	O
	
All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O
	
Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1-1.5	O
mg/day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O
	
All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O
	
The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O
	
There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin-induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O
	
Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O
	
Glucocorticoid	B-protein
receptors	I-protein
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O
	
In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O
	
A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O
	
In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O
	
As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O
	
In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O
	
Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O
	
In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O
	
Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O
	
###MEDLINE:92367617	
	
The	O
development	O
of	O
functionally	O
responsive	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O
	
First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	B-protein
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O
	
This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O
	
However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O
	
Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	B-DNA
gene	I-DNA
rearrangement	O
.	O
	
The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	B-DNA
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O
	
It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	B-DNA
gamma	I-DNA
loci	I-DNA
in	O
the	O
gamma	B-cell_type
delta	I-cell_type
lineage	I-cell_type
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	B-DNA
beta	I-DNA
in	O
the	O
alpha	B-cell_type
beta	I-cell_type
lineage	I-cell_type
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O
	
In	O
the	O
TCR	B-cell_type
alpha	I-cell_type
beta	I-cell_type
lineage	I-cell_type
,	I-cell_type
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O
	
The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O
	
Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O
	
Whereas	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O
	
Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	O
of	O
antigen	O
responsiveness	O
:	O
instead	O
of	O
turning	O
on	O
IL-2	B-protein
expression	O
,	O
the	O
activated	B-cell_type
cell	I-cell_type
destroys	O
its	O
own	O
chromatin	B-DNA
.	O
	
The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O
	
It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	B-cell_type
thymocytes	I-cell_type
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	B-protein
alpha	I-protein
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	B-protein
IL-2	I-protein
is	O
provided	O
.	O
	
Perhaps	O
murine	B-cell_type
thymocytes	I-cell_type
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL-2R	B-protein
beta	I-protein
chain	I-protein
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl-2	B-protein
deficient	O
(	O
cf.	O
Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O
	
Even	O
so	O
,	O
medullary	B-cell_type
thymocytes	I-cell_type
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O
	
###MEDLINE:93153017	
	
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
requires	O
the	O
transactivation	B-protein
domain	I-protein
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
DNA	O
binding	O
.	O
	
The	O
active	O
nuclear	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
composed	O
of	O
two	O
DNA	B-protein
binding	I-protein
subunits	I-protein
,	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
,	O
both	O
of	O
which	O
share	O
extensive	O
N-terminal	O
sequence	O
homology	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O
	
The	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
subunit	I-protein
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
termed	O
I	O
kappa	O
B	O
.	O
	
In	O
contrast	O
,	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
alone	O
fails	O
to	O
stimulate	O
kappa	O
B-directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
.	O
	
To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
a	O
series	O
of	O
human	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
mutants	I-protein
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
,	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O
	
Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
mutants	I-protein
revealed	O
the	O
following	O
:	O
1	O
)	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
completely	O
inhibits	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
-dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
2	O
)	O
the	O
binding	O
of	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
to	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
is	O
sufficient	O
to	O
retarget	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	B-protein
homology	I-protein
domain	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
disrupts	O
its	O
ability	O
to	O
engage	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
and	O
4	O
)	O
the	O
unique	O
C-terminus	B-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
DNA	O
binding	O
activity	O
.	O
	
Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	B-protein
domain	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
.	O
	
Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
binds	O
directly	O
to	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
.	O
	
This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O
	
However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C-terminal	B-protein
domain	I-protein
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
.	O
	
###MEDLINE:93024468	
	
Characterization	O
of	O
a	O
new	O
tissue-specific	O
transcription	B-protein
factor	I-protein
binding	O
to	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
TC-II	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
element	I-DNA
.	O
	
We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	B-protein
factor	I-protein
,	O
NP-TCII	B-protein
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
but	O
is	O
not	O
found	O
in	O
nonhematopoietic	B-cell_type
cells	I-cell_type
.	O
	
This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	B-protein
proteins	I-protein
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O
	
It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O
	
###MEDLINE:93024882	
	
The	O
candidate	B-protein
oncoprotein	I-protein
Bcl-3	I-protein
is	O
an	O
antagonist	O
of	O
p50/NF-kappa	B-protein
B	I-protein
-mediated	O
inhibition	O
.	O
	
The	O
candidate	B-DNA
oncogene	I-DNA
bcl-3	I-DNA
was	O
discovered	O
as	O
a	O
translocation	O
into	O
the	O
immunoglobulin	B-DNA
alpha-locus	I-DNA
in	O
some	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukaemias	O
.	O
	
The	O
protein	B-protein
Bcl-3	I-protein
contains	O
seven	O
so-called	O
ankyrin	B-protein
repeats	I-protein
.	O
	
Similar	O
repeat	B-protein
motifs	I-protein
are	O
found	O
in	O
a	O
number	O
of	O
diverse	B-protein
regulatory	I-protein
proteins	I-protein
but	O
the	O
motifs	O
of	O
Bcl-3	B-protein
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
in	O
which	O
the	O
ankyrin	B-protein
repeat	I-protein
domain	O
is	O
thought	O
to	O
be	O
directly	O
involved	O
in	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O
	
No	O
biological	O
function	O
has	O
yet	O
been	O
described	O
for	O
Bcl-3	B-protein
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	B-protein
interferes	O
with	O
DNA-binding	O
of	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
in	O
vitro	O
.	O
	
Here	O
we	O
demonstrate	O
that	O
Bcl-3	B-protein
can	O
aid	O
kappa	B-DNA
B	I-DNA
site	I-DNA
-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50/NF-kappa	B-protein
B	I-protein
homodimers	I-protein
.	O
	
Bcl-3	B-protein
may	O
therefore	O
aid	O
activation	O
of	O
select	O
NF-kappa	B-DNA
B-regulated	I-DNA
genes	I-DNA
,	O
including	O
those	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
.	O
	
###MEDLINE:93013114	
	
[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones.	O
I.	O
Estrogens	O
]	O
	
The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O
although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O
	
Their	O
action	O
mechanism	O
is	O
not	O
completely	O
cleared	O
.	O
	
The	O
estrogens	O
participate	O
in	O
the	O
regulation	O
of	O
practically	O
all	O
the	O
reproductive	O
and	O
sexual	O
events	O
of	O
the	O
female	O
,	O
although	O
the	O
intracellular	O
actions	O
by	O
which	O
they	O
take	O
place	O
are	O
not	O
well	O
known	O
and	O
the	O
proposed	O
models	O
do	O
not	O
adequately	O
satisfy	O
the	O
questions	O
.	O
	
Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	B-protein
and/or	I-protein
nuclear	I-protein
receptor	I-protein
,	O
without	O
explaining	O
satisfactorily	O
how	O
the	O
hormones	O
come	O
to	O
the	O
nucleus	O
.	O
	
The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	O
interaction	O
with	O
cellular	O
membrane	O
.	O
	
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O
	
###MEDLINE:92291523	
	
Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl-methanesulfonate-treated	B-cell_line
CEM	I-cell_line
subclones	I-cell_line
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathway	O
.	O
	
We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	B-cell_line
subclones	I-cell_line
that	O
express	O
CD4	B-protein
receptors	I-protein
and	O
bind	O
soluble	O
gp120	B-protein
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O
	
Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activator	O
PMA	O
.	O
	
PMA	O
treatment	O
induced	O
CD3	B-protein
and	I-protein
CD25	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
receptors	I-protein
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl-methanesulfonate-derived	B-cell_line
subclones	I-cell_line
,	O
but	O
not	O
on	O
these	O
two	O
mutants	O
.	O
	
Direct	O
assays	O
of	O
PKC	B-protein
activity	O
were	O
conducted	O
.	O
	
Total	O
cellular	O
PKC	B-protein
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O
	
PMA-induced	O
CD4	B-protein
down-modulation	O
occurred	O
normally	O
.	O
	
In	O
addition	O
,	O
activation	O
of	O
c-raf	B-protein
kinase	I-protein
was	O
normal	O
.	O
	
Since	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
contains	O
two	O
functional	O
nuclear	B-DNA
factor	I-DNA
kB	I-DNA
(	I-DNA
NF-kB	I-DNA
)	I-DNA
regulatory	I-DNA
elements	I-DNA
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	B-protein
binding	O
activity	O
by	O
different	O
assays	O
.	O
	
Chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
assays	O
using	O
the	O
HIV-1	B-DNA
(	I-DNA
-139	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat-CAT	I-DNA
construct	I-DNA
showed	O
no	O
PMA	O
induction	O
of	O
CAT	B-protein
activity	O
in	O
these	O
subclones	O
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O
	
Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
did	O
not	O
overcome	O
the	O
defect	O
in	O
these	O
subclones	O
.	O
	
Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P-probe	O
containing	O
the	O
HIV-1	O
NF-kB	B-protein
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_type
cells	I-cell_type
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	B-protein
NF-kB	I-protein
binding	I-protein
proteins	I-protein
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	B-protein
type	I-protein
CEM	I-protein
and	O
a	O
control	O
subclone	O
.	O
	
Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	B-protein
binding	I-protein
proteins	I-protein
from	O
their	O
cytoplasmic	O
pools	O
.	O
	
Thus	O
,	O
reduced	O
levels	O
of	O
PKC	B-protein
-induced	O
nuclear	O
NF-kB	B-protein
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	O
affect	O
their	O
normal	O
cell	O
growth	O
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O
	
###MEDLINE:92244343	
	
Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
contains	O
Fos	B-protein
and	O
Jun	B-protein
.	O
	
The	O
nuclear	B-protein
factor	I-protein
NF-AT	I-protein
(	O
ref.	O
1	O
)	O
is	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T-cell	B-protein
receptor/CD3	I-protein
complex	I-protein
,	O
and	O
is	O
required	O
for	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
induction	O
.	O
	
Although	O
NF-AT	B-protein
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O
	
NF-AT	B-protein
induction	O
may	O
require	O
two	O
activation-dependent	O
events	O
:	O
the	O
CsA-sensitive	O
translocation	O
of	O
a	O
pre-existing	O
component	O
and	O
the	O
CsA-resistant	O
synthesis	O
of	O
a	O
nuclear	B-protein
component	I-protein
.	O
	
Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	B-protein
component	I-protein
of	O
NF-AT	B-protein
is	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O
	
We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF-AT	B-protein
contains	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O
	
Furthermore	O
,	O
we	O
identify	O
a	O
pre-existing	B-protein
NF-AT-binding	I-protein
factor	I-protein
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	O
that	O
activation	O
of	O
NF-AT	B-protein
occurs	O
in	O
at	O
least	O
two	O
stages	O
:	O
a	O
CsA-sensitive	O
stage	O
involving	O
modification	O
and/or	O
translocation	O
of	O
the	O
pre-existing	O
NF-AT	B-protein
complex	I-protein
,	O
and	O
a	O
CsA-insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	B-protein
or	O
Fos/Jun	B-protein
proteins	I-protein
to	O
the	O
pre-existing	B-protein
complex	I-protein
.	O
	
###MEDLINE:92195320	
	
A	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
containing	O
c-Rel-like	B-protein
proteins	I-protein
preferentially	O
interacts	O
with	O
interleukin-6	B-DNA
kappa	I-DNA
B-related	I-DNA
motifs	I-DNA
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
The	O
proto-oncoprotein	B-protein
c-Rel	I-protein
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
which	O
includes	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O
	
We	O
show	O
here	O
that	O
c-Rel	B-protein
binds	O
to	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
as	O
homodimers	B-protein
as	O
well	O
as	O
heterodimers	B-protein
with	O
p50	B-protein
.	O
	
These	O
homodimers	B-protein
and	O
heterodimers	B-protein
show	O
distinct	O
DNA-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
.	O
	
In	O
particular	O
,	O
the	O
c-Rel	B-protein
homodimer	I-protein
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
beta	B-DNA
interferon	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
.	O
	
In	O
spite	O
of	O
its	O
association	O
with	O
p50	B-protein
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
in	O
vivo	O
that	O
contains	O
c-Rel	B-protein
but	O
not	O
p50	B-protein
epitopes	I-protein
;	O
this	O
factor	O
,	O
termed	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
,	O
appears	O
to	O
contain	O
the	O
c-Rel	B-protein
homodimer	I-protein
and	O
preferentially	O
recognizes	O
several	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
.	O
	
Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	B-DNA
kappa	I-DNA
B	I-DNA
motif	I-DNA
functions	O
as	O
a	O
potent	O
IL-1/tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
element	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
such	O
as	O
a	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O
	
We	O
also	O
present	O
evidence	O
that	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:92156261	
	
Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O
	
This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O
	
All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O
	
An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O
	
We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	I-protein
activation	O
.	O
	
Glucocorticoid	B-protein
receptor	I-protein
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+/-	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+/-	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
+/-	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O
	
The	O
affinity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O
	
[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
abnormality	O
.	O
	
In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B-protein
glucocorticoid	I-protein
receptors	I-protein
on	O
lymphocytes	B-cell_type
.	O
	
Resistance	O
to	O
glucocorticoids	O
implies	O
a	O
complex	O
change	O
in	O
immune-endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	O
syndrome	O
.	O
	
###MEDLINE:92134262	
	
A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
families	O
with	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O
	
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
.	O
	
We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O
	
After	O
the	O
DNA	B-DNA
fragment	I-DNA
containing	O
the	O
CAG	B-DNA
repeats	I-DNA
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end-labelled	B-DNA
reverse	I-DNA
primer	I-DNA
adjacent	O
to	O
3	B-DNA
'	I-DNA
end	I-DNA
of	O
CAG	B-DNA
repeats	I-DNA
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	B-DNA
repeats	I-DNA
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O
	
The	O
resultant	O
primer	B-DNA
products	I-DNA
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O
	
This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	B-DNA
repeats	I-DNA
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	B-DNA
dinucleotide	I-DNA
and	O
trinucleotide	B-DNA
repeats	I-DNA
.	O
	
###MEDLINE:94051535	
	
Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	B-protein
factor	I-protein
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O
	
Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	B-cell_type
cells	I-cell_type
in	O
the	O
cellular	O
immune	O
response	O
.	O
	
In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	B-protein
effector	I-protein
gene	I-protein
products	I-protein
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O
	
The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	B-protein
.	O
	
We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	B-DNA
Factor	I-DNA
(	I-DNA
TF	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
function	O
of	O
the	O
TF	B-protein
protein	I-protein
.	O
	
The	O
enhanced	O
initiation	O
of	O
transcription	O
of	O
the	O
TF	O
gene	O
appears	O
to	O
require	O
engagement	O
of	O
a	O
56	O
bp	O
LPS	B-DNA
Response	I-DNA
Element	I-DNA
,	O
an	O
enhancer	O
that	O
is	O
engaged	O
by	O
both	O
AP-1	B-protein
type	I-protein
heterodimeric	I-protein
complexes	I-protein
as	O
well	O
as	O
NF	B-protein
kappa	I-protein
B	I-protein
like	I-protein
heterodimeric	I-protein
complexes	I-protein
.	O
	
Dissociation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
Ig	B-protein
kappa	I-protein
B	I-protein
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	B-DNA
and	I-DNA
other	I-DNA
inflammatory	I-DNA
genes	I-DNA
.	O
	
Enhancement	O
of	O
expression	O
of	O
TF	B-protein
is	O
observed	O
upon	O
adhesion	O
of	O
Mo	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
extracellular	O
matrix	O
proteins	O
,	O
as	O
well	O
as	O
upon	O
engagement	O
of	O
leukocyte	B-protein
integrins	I-protein
.	O
	
The	O
biological	O
effects	O
that	O
follow	O
from	O
expression	O
of	O
TF	B-protein
by	O
vascular	O
cells	O
have	O
been	O
resolved	O
by	O
analysis	O
of	O
function	O
aided	O
by	O
the	O
use	O
of	O
recombinant	B-protein
full	I-protein
length	I-protein
TF	I-protein
and	O
truncated	B-protein
surface	I-protein
domain	I-protein
of	O
TF	B-protein
.	O
	
The	O
rules	O
of	O
assembly	O
of	O
the	O
cognate	O
ligands	O
of	O
TF	B-protein
,	O
namely	O
the	O
zymogen	B-protein
plasma	I-protein
factors	I-protein
VII	I-protein
and	O
the	O
serine	B-protein
protease	I-protein
factor	I-protein
VIIa	I-protein
,	O
with	O
the	O
soluble	B-protein
surface	I-protein
domain	I-protein
of	O
TF	B-protein
in	O
free	O
solution	O
,	O
in	O
the	O
presence	O
of	O
phospholipid	O
surfaces	O
and	O
cell	O
surface	O
and	O
of	O
the	O
anchored	B-protein
TF	I-protein
molecule	I-protein
have	O
been	O
described	O
.	O
	
It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B-protein
domain	I-protein
of	O
TF	B-protein
with	O
VIIa	B-protein
to	O
form	O
the	O
binary	O
TF.VIIa	B-protein
complex	I-protein
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B-protein
domain	I-protein
of	O
VIIa	B-protein
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B-protein
substrate	I-protein
.	O
	
This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	B-protein
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	B-protein
,	O
its	O
cognate	O
catalytic	O
cofactor	B-protein
.	O
	
It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	B-protein
complex	I-protein
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	B-protein
plasma	I-protein
factor	I-protein
X	I-protein
to	O
the	O
serine	B-protein
protease	I-protein
Xa	I-protein
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	B-protein
complex	I-protein
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	B-protein
recognition	I-protein
structure	I-protein
.	O
	
It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	B-protein
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	B-protein
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O
	
###MEDLINE:93100507	
	
Phorbol	O
ester	O
reduces	O
constitutive	B-protein
nuclear	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
and	O
inhibits	O
HIV-1	O
production	O
in	O
mature	B-cell_type
human	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
NF	B-protein
kappa	I-protein
B	I-protein
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV-1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O
	
There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
to	O
cytokines	B-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O
	
We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	B-protein
factor	I-protein
.	O
	
Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
extracts	O
of	O
nuclei	O
from	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O
	
Treatment	O
of	O
normal	B-cell_type
monocytes	I-cell_type
with	O
12-0-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
for	O
4-24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O
	
A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O
	
The	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
SP1	B-protein
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O
	
The	O
disappearance	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng/ml	O
of	O
phorbol	O
ester	O
.	O
	
In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster-migrating	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
species	I-protein
not	O
induced	O
in	O
monocytes	B-cell_type
.	O
	
Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	O
cyclic	O
nucleotide-dependent	O
protein	O
kinase	O
inhibitor	O
HA-1004	O
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O
	
Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	B-cell_type
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	B-protein
transcriptase	I-protein
assays	O
,	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
	
These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
U937	I-cell_line
and	O
HL-60	B-cell_line
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	B-protein
regulation	O
of	O
HIV-1	O
in	O
normal	B-cell_type
monocytes	I-cell_type
.	O
	
###MEDLINE:93066282	
	
A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
expression	O
of	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
.	O
	
Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O
	
The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	B-cell_type
leukocytes	I-cell_type
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B-protein
molecules	I-protein
for	O
leukocytes	B-cell_type
[	O
e.g.	O
,	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ELAM-1	B-protein
)	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ICAM-1	B-protein
)	O
]	O
.	O
	
We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
for	O
neutrophils	B-cell_type
(	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
)	O
.	O
	
Preincubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram/ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O
	
Moreover	O
,	O
the	O
steroid	B-protein
receptor	I-protein
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O
	
Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	B-protein
receptors	I-protein
[	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
hGRs	B-protein
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O
	
RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	B-protein
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	B-protein
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O
	
Treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B-protein
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	B-protein
ELAM-1	I-protein
and	O
ICAM-1	B-protein
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O
	
Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	B-protein
and	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O
	
As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O
	
In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
.	O
	
These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B-protein
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
a	O
hormone-dependent	O
regulator	O
of	O
transcription	O
.	O
	
###MEDLINE:92387536	
	
Pax-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
and	O
is	O
expressed	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
developing	O
CNS	O
,	O
and	O
adult	O
testis	O
.	O
	
BSAP	B-protein
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	O
late	O
,	O
stages	O
of	O
B-cell	O
differentiation	O
.	O
	
Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	B-protein
belongs	O
to	O
the	O
family	O
of	O
paired	B-protein
domain	I-protein
proteins	I-protein
.	O
	
BSAP	B-protein
is	O
encoded	O
by	O
the	O
Pax-5	B-DNA
gene	I-DNA
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O
	
An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	B-protein
.	O
	
Binding	O
studies	O
with	O
several	O
BSAP	B-DNA
recognition	I-DNA
sequences	I-DNA
demonstrated	O
that	O
the	O
sequence	O
specificity	O
of	O
BSAP	B-protein
differs	O
from	O
that	O
of	O
the	O
distantly	O
related	O
paired	B-protein
domain	I-protein
protein	I-protein
Pax-1	I-protein
.	O
	
During	O
embryogenesis	O
,	O
the	O
BSAP	B-DNA
gene	I-DNA
is	O
transiently	O
expressed	O
in	O
the	O
mesencephalon	O
and	O
spinal	O
cord	O
with	O
a	O
spatial	O
and	O
temporal	O
expression	O
pattern	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
	
Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	B-DNA
gene	I-DNA
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O
	
BSAP	B-protein
expression	O
persists	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O
	
All	O
of	O
this	O
evidence	O
indicates	O
that	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
may	O
not	O
only	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
differentiation	O
but	O
also	O
in	O
neural	O
development	O
and	O
spermatogenesis	O
.	O
	
###MEDLINE:92335296	
	
Cell	O
cycle-dependent	O
initiation	O
and	O
lineage-dependent	O
abrogation	O
of	O
GATA-1	B-protein
expression	O
in	O
pure	B-cell_type
differentiating	I-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
.	O
	
The	O
programmed	O
activation/repression	O
of	O
transcription	B-protein
factors	I-protein
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O
	
The	O
DNA-binding	B-protein
protein	I-protein
GATA-1	B-protein
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid-expressed	B-DNA
genes	I-DNA
in	O
maturing	B-cell_type
erythroblasts	I-cell_type
.	O
	
We	O
analyzed	O
GATA-1	B-protein
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
``	O
pure	O
''	O
early	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte-macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
	
The	O
GATA-1	B-DNA
gene	I-DNA
,	O
though	O
virtually	O
silent	O
in	O
quiescent	B-cell_type
progenitors	I-cell_type
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
	
Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte-macrophage	B-cell_type
lineage	I-cell_type
.	O
	
These	O
results	O
suggest	O
a	O
microenvironment-directed	O
,	O
two-step	O
model	O
for	O
GATA-1	B-protein
expression	O
in	O
differentiating	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
that	O
involves	O
(	O
i	O
)	O
cycle-dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage-dependent	O
maintenance	O
or	O
suppression	O
.	O
	
Hypothetically	O
,	O
on/off	O
switches	O
of	O
lineage-restricted	B-protein
transactivators	I-protein
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O
	
###MEDLINE:92260664	
	
Specific	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
act	O
in	O
concert	O
with	O
Tat	B-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O
	
NF-kappa	B-protein
B	I-protein
is	O
a	O
protein	B-protein
complex	I-protein
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	I-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O
	
To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
to	O
act	O
with	O
Tat-I	B-protein
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	B-cell_type
T-leukemia	I-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
found	O
that	O
the	O
p49	B-protein
(	I-protein
100	I-protein
)	I-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
,	O
together	O
with	O
p65	B-protein
,	O
can	O
act	O
in	O
concert	O
with	O
Tat-I	B-protein
to	O
stimulate	O
the	O
expression	O
of	O
HIV-CAT	B-DNA
plasmid	I-DNA
.	O
	
Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B-protein
forms	I-protein
of	O
p105	B-protein
NF-kappa	B-protein
B	I-protein
or	O
rel	B-protein
,	O
in	O
combination	O
with	O
p65	B-protein
or	O
full-length	B-protein
c-rel	I-protein
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
these	O
cells	O
.	O
	
These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B-protein
(	I-protein
100	I-protein
)	I-protein
and	O
p65	B-protein
NF-kappa	B-protein
B	I-protein
can	O
act	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	I-protein
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	B-RNA
RNA	I-RNA
.	O
	
###MEDLINE:92235036	
	
Stable	O
expression	O
of	O
HB24	B-DNA
,	O
a	O
diverged	B-DNA
human	I-DNA
homeobox	I-DNA
gene	I-DNA
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O
	
A	O
diverged	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
which	O
is	O
known	O
to	O
be	O
induced	O
following	O
lymphocyte	O
activation	O
,	O
was	O
introduced	O
into	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
under	O
the	O
control	O
of	O
a	O
constitutive	B-DNA
promoter	I-DNA
.	O
	
Stable	O
transfectants	O
of	O
HB24	B-DNA
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	B-RNA
mRNA	I-RNA
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	B-cell_line
,	O
including	O
c-fos	B-DNA
,	O
c-myc	B-DNA
,	O
c-myb	B-DNA
,	O
HLA-DR	B-DNA
,	O
lck	B-DNA
,	O
NF-kappa	B-protein
B	I-protein
,	O
interleukin-2	B-DNA
and	O
interleukin-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	O
IL-2R	B-DNA
alpha	I-DNA
)	O
.	O
	
Analysis	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
into	O
the	O
HB24	B-cell_line
transfectants	I-cell_line
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin-	B-cell_line
and	I-cell_line
phorbol	I-cell_line
ester-activated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O
	
Furthermore	O
,	O
as	O
a	O
consequence	O
of	O
the	O
increased	O
HB24	B-RNA
mRNA	I-RNA
levels	O
,	O
the	O
Jurkat	B-cell_line
HB24	I-cell_line
transfectants	I-cell_line
proliferated	O
more	O
rapidly	O
than	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Thus	O
,	O
stable	O
expression	O
of	O
HB24	B-DNA
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B-protein
factor	I-protein
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O
	
###MEDLINE:92385366	
	
Functional	O
interaction	O
between	O
the	O
two	O
zinc	B-protein
finger	I-protein
domains	I-protein
of	O
the	O
v-erb	B-protein
A	I-protein
oncoprotein	I-protein
.	O
	
The	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	B-DNA
cell	I-DNA
gene	I-DNA
encoding	O
a	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
.	O
	
The	O
protein	O
expressed	O
by	O
the	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O
	
The	O
v-erb	B-protein
A	I-protein
protein	I-protein
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA-binding	B-protein
domain	I-protein
relative	O
to	O
that	O
of	O
c-erb	B-protein
A	I-protein
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v-erb	B-protein
A	I-protein
function	O
in	O
the	O
neoplastic	B-cell_type
cell	I-cell_type
.	O
	
We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	B-protein
A	I-protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	B-protein
A	I-protein
protein	I-protein
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	B-protein
61	I-protein
.	O
	
Threonine	O
78	O
lies	O
within	O
the	O
D-box	B-protein
of	O
the	O
v-erb	B-protein
A	I-protein
protein	I-protein
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor-receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	B-protein
61	I-protein
.	O
	
It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v-erb	B-protein
A	I-protein
function	O
.	O
	
###MEDLINE:92186836	
	
cis-acting	B-DNA
sequences	I-DNA
required	O
for	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
bind	O
a	O
novel	O
Ets-related	B-protein
protein	I-protein
,	O
Elf-1	B-protein
.	O
	
The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	B-DNA
binding	I-DNA
sequence	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	I-DNA
.	O
	
In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
,	O
EBS1	O
and	O
EBS2	B-DNA
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
interleukin-2	I-DNA
enhancers	I-DNA
.	O
	
Within	O
the	O
human	B-DNA
enhancer	I-DNA
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-protein
I	I-protein
footprints	O
,	O
NFAT-1	B-DNA
and	O
NFIL-2B	B-DNA
,	O
respectively	O
.	O
	
Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	B-DNA
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	B-protein
and	I-protein
NFIL-2B	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
.	O
	
Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	B-DNA
.	O
	
Two	O
well-characterized	O
Ets	B-protein
family	I-protein
members	I-protein
,	O
Ets-1	B-protein
and	O
Ets-2	B-protein
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O
	
Surprisingly	O
,	O
however	O
,	O
neither	O
of	O
these	O
proteins	O
bound	O
in	O
vitro	O
to	O
EBS1	O
or	O
EBS2	B-DNA
.	O
	
We	O
therefore	O
screened	O
a	O
T-cell	B-DNA
cDNA	I-DNA
library	O
under	O
low-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
Ets-1	B-protein
and	O
isolated	O
a	O
novel	B-protein
Ets	I-protein
family	I-protein
member	I-protein
,	O
Elf-1	B-protein
.	O
	
Elf-1	B-protein
contains	O
a	O
DNA	B-protein
binding	I-protein
domain	I-protein
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B-protein
,	O
the	O
ecdysone-inducible	B-protein
Drosophila	I-protein
transcription	I-protein
factor	I-protein
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B-protein
,	O
for	O
E74-like	B-protein
factor	I-protein
1	I-protein
)	O
.	O
	
Elf-1	B-protein
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	B-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
It	O
also	O
bound	O
to	O
the	O
purine-rich	B-DNA
CD3R	I-DNA
element	I-DNA
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	B-protein
receptor	I-protein
.	O
	
Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	B-protein
Ets	I-protein
family	I-protein
members	I-protein
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:92165059	
	
Binding	O
of	O
erythroid	B-protein
and	I-protein
non-erythroid	I-protein
nuclear	I-protein
proteins	I-protein
to	O
the	O
silencer	B-DNA
of	O
the	O
human	B-DNA
epsilon-globin-encoding	I-DNA
gene	I-DNA
.	O
	
To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin-encoding	B-DNA
genes	I-DNA
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	B-DNA
in	O
human	B-cell_type
cells	I-cell_type
in	O
continuous	O
culture	O
.	O
	
We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	B-DNA
control	I-DNA
element	I-DNA
with	O
the	O
properties	O
of	O
a	O
silencer	B-DNA
extending	O
from	O
-392	B-DNA
to	I-DNA
-177	I-DNA
bp	I-DNA
relative	O
to	O
the	O
cap	B-DNA
site	I-DNA
of	O
the	O
human	B-DNA
epsilon-globin-encoding	I-DNA
gene	I-DNA
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306-5309	O
]	O
.	O
	
We	O
also	O
showed	O
that	O
this	O
silencer	B-DNA
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
as	O
compared	O
to	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O
	
Using	O
deletion	B-DNA
mutants	I-DNA
and	O
cis-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	B-DNA
to	I-DNA
-251	I-DNA
bp	I-DNA
.	O
	
Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B-protein
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O
	
Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon-globin-encoding	B-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
are	O
discussed	O
.	O
	
###MEDLINE:93113611	
	
Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O
	
A	O
MEDLINE	O
search	O
of	O
the	O
English-language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O
	
Sixty-six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O
	
Forty-five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O
	
The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O
	
No	O
unifying	O
hypothesis	O
has	O
yet	O
emerged	O
explaining	O
this	O
collection	O
of	O
data	O
.	O
	
This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O
	
###MEDLINE:93087498	
	
Transcription	O
of	O
the	O
hypersensitive	B-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
In	O
the	O
human	B-DNA
genome	I-DNA
,	O
the	O
erythroid-specific	B-DNA
hypersensitive	I-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
regulates	O
the	O
transcription	O
of	O
the	O
downstream	B-DNA
beta-like	I-DNA
globin	I-DNA
genes	I-DNA
10-50	B-DNA
kilobases	I-DNA
away	O
.	O
	
The	O
mechanism	O
of	O
HS2	B-DNA
enhancer	I-DNA
function	O
is	O
not	O
known	O
.	O
	
The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	B-DNA
enhancer	I-DNA
in	O
transfected	B-DNA
recombinant	I-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
plasmids	I-DNA
.	O
	
In	O
erythroid	B-cell_line
K562	I-cell_line
cells	I-cell_line
in	O
which	O
the	O
HS2	B-DNA
enhancer	I-DNA
is	O
active	O
,	O
the	O
HS2	B-DNA
sequence	I-DNA
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	B-DNA
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis-linked	B-DNA
CAT	I-DNA
gene	I-DNA
.	O
	
In	O
nonerythroid	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
in	O
which	O
the	O
HS2	B-DNA
enhancer	I-DNA
is	O
inactive	O
,	O
long	B-RNA
enhancer	I-RNA
transcripts	I-RNA
are	O
not	O
detectable	O
.	O
	
Splitting	O
the	O
HS2	B-DNA
enhancer	I-DNA
between	O
two	O
tandem	B-DNA
Ap1	I-DNA
sites	I-DNA
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	B-RNA
enhancer	I-RNA
transcripts	I-RNA
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis-linked	O
CAT	O
gene	O
.	O
	
In	O
directing	O
the	O
synthesis	O
of	O
RNA	B-RNA
through	O
the	O
intervening	O
DNA	B-DNA
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	B-DNA
enhancer	I-DNA
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	B-DNA
structure	I-DNA
of	O
a	O
gene	B-DNA
domain	I-DNA
and	O
(	O
ii	O
)	O
deliver	O
enhancer	B-protein
binding	I-protein
proteins	I-protein
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	B-DNA
site	I-DNA
.	O
	
###MEDLINE:93065212	
	
Characterization	O
of	O
a	O
novel	B-protein
T	I-protein
lymphocyte	I-protein
protein	I-protein
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
receptor	I-DNA
response	I-DNA
elements	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
sequence	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
We	O
have	O
previously	O
identified	O
a	O
T	B-protein
lymphocyte	I-protein
protein	I-protein
which	O
binds	O
to	O
a	O
site	O
within	O
the	O
LTR	B-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
virus	O
gene	O
expression	O
.	O
	
The	O
palindromic	B-DNA
site	I-DNA
(	O
site	B-DNA
B	I-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O
	
Here	O
we	O
characterize	O
the	O
T	B-protein
cell	I-protein
protein	I-protein
binding	O
to	O
this	O
site	O
as	O
a	O
100	O
kD	O
protein	O
which	O
is	O
most	O
abundant	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
which	O
binds	O
to	O
site	B-DNA
B	I-DNA
as	O
a	O
200	B-protein
kD	I-protein
complex	I-protein
.	O
	
This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
including	O
the	O
COUP	B-protein
protein	I-protein
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O
	
###MEDLINE:92371447	
	
TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O
	
The	O
Tat	B-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O
	
Tat	B-protein
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	B-DNA
promoter	I-DNA
.	O
	
This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O
	
Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	B-protein
with	O
a	O
specific	O
RNA	B-RNA
target	I-RNA
termed	O
TAR	B-RNA
(	O
transactivation	B-RNA
responsive	I-RNA
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	B-RNA
mRNAs	I-RNA
.	O
	
This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O
	
In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS-derived	B-cell_line
cells	I-cell_line
Tat	B-protein
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	B-DNA
-independent	O
pathway	O
.	O
	
A	O
Tat-responsive	B-DNA
element	I-DNA
is	O
found	O
upstream	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
that	O
in	O
glial-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	B-RNA
.	O
	
Deletion	O
mapping	O
and	O
hybrid	B-DNA
promoter	I-DNA
constructs	I-DNA
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat-responsive	B-DNA
element	I-DNA
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
previously	O
identified	O
as	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
,	O
or	O
NF-kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O
	
DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
Further	O
,	O
we	O
observe	O
that	O
TAR-deleted	B-DNA
mutants	I-DNA
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B-protein
p24	I-protein
antigen	I-protein
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:92331609	
	
Transcription	B-protein
factor	I-protein
AP-2	I-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O
	
The	O
HTLV-I	B-DNA
LTR	I-DNA
contains	O
three	O
conserved	O
regulatory	B-DNA
elements	I-DNA
known	O
as	O
21	B-DNA
base	I-DNA
pair	I-DNA
repeats	I-DNA
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	B-protein
protein	I-protein
tax	B-protein
.	O
	
Mutagenesis	O
indicates	O
that	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B-protein
activation	O
.	O
	
The	O
A	B-DNA
site	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
AP-2	I-protein
.	O
	
We	O
demonstrated	O
that	O
AP-2	B-RNA
mRNA	I-RNA
was	O
present	O
in	O
T-lymphocytes	B-cell_type
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	B-cell_type
specifically	O
bound	O
to	O
the	O
consensus	B-DNA
motif	I-DNA
for	O
AP-2	B-protein
in	O
each	O
21	O
bp	O
.	O
	
To	O
determine	O
the	O
role	O
of	O
AP-2	B-protein
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	B-DNA
cDNA	I-DNA
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O
	
Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B-protein
produced	I-protein
AP-2	I-protein
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
,	O
and	O
that	O
it	O
required	O
the	O
core	B-DNA
sequence	I-DNA
AGGC	O
for	O
specific	O
binding	O
.	O
	
Binding	O
of	O
AP-2	B-protein
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	B-protein
family	I-protein
to	O
an	O
adjacent	B-DNA
regulatory	I-DNA
motif	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
.	O
	
Transfection	O
of	O
an	O
AP-2	B-DNA
expression	I-DNA
construct	I-DNA
into	O
T-lymphocytes	B-cell_type
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
.	O
	
At	O
least	O
two	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	B-protein
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	B-DNA
consensus	I-DNA
binding	I-DNA
sequences	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
eliminate	O
this	O
activation	O
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:92260679	
	
Activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
is	O
not	O
dependent	O
on	O
NFAT-1	B-protein
.	O
	
The	O
function	O
of	O
a	O
putative	B-DNA
NFAT-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
has	O
been	O
analyzed	O
.	O
	
Activation	O
by	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
is	O
minimal	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
is	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O
	
The	O
putative	B-DNA
NFAT-1	I-DNA
region	I-DNA
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti-CD3	B-protein
or	O
to	O
mitogens	B-protein
in	O
T-cell	B-cell_line
,	O
B-cell	B-cell_line
,	O
or	O
monocyte/macrophage	B-cell_line
leukemia	I-cell_line
lines	I-cell_line
,	O
nor	O
is	O
it	O
a	O
cis-acting	B-DNA
negative	I-DNA
regulatory	I-DNA
element	I-DNA
.	O
	
###MEDLINE:92218428	
	
The	O
B	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
OTF-2	B-protein
positively	O
regulates	O
transcription	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
transplantation	I-DNA
gene	I-DNA
,	O
DRA	B-DNA
.	O
	
The	O
promoter	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
DRA	B-DNA
contains	O
an	O
octamer	B-DNA
element	I-DNA
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
Several	O
DNA-binding	B-protein
proteins	I-protein
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O
	
The	O
best	O
characterized	O
are	O
the	O
B	B-protein
cell-specific	I-protein
OTF-2	I-protein
and	O
the	O
ubiquitous	O
OTF-1	B-protein
.	O
	
This	O
report	O
directly	O
demonstrates	O
that	O
OTF-2	B-protein
but	O
not	O
OTF-1	B-protein
regulates	O
the	O
DRA	B-DNA
gene	I-DNA
.	O
	
In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer-binding	O
protein	O
OTF-2	B-protein
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF-2	B-protein
in	O
DRA	B-DNA
gene	I-DNA
transcription	O
.	O
	
In	O
contrast	O
,	O
OTF-1	B-protein
-enriched	O
protein	O
fractions	O
did	O
not	O
affect	O
DRA	B-DNA
gene	I-DNA
transcription	O
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O
	
Recombinant	B-protein
OTF-2	I-protein
protein	I-protein
produced	O
by	O
in	O
vitro	O
transcription/translation	O
could	O
also	O
enhance	O
DRA	B-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
.	O
	
In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	B-protein
protein	I-protein
enhanced	O
DRA	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	B-DNA
element	I-DNA
.	O
	
Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	B-protein
octamer-binding	I-protein
factor	I-protein
in	O
DRA	O
gene	O
transcription	O
.	O
	
###MEDLINE:92251244	
	
Interferon-gamma	B-protein
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon-stimulated	B-DNA
genes	I-DNA
induced	O
by	O
interferon-alpha	B-cell_line
in	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
	
Binding	O
of	O
type	B-protein
I	I-protein
interferon	I-protein
(	I-protein
IFN-alpha/beta	I-protein
)	I-protein
to	I-protein
specific	I-protein
receptors	I-protein
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN-alpha-stimulated	B-DNA
genes	I-DNA
(	O
ISGs	B-DNA
)	O
in	O
human	B-cell_type
fibroblasts	I-cell_type
and	O
HeLa	B-cell_line
and	O
Daudi	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
binding	O
of	O
ISGF3	B-protein
(	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
)	O
to	O
the	O
conserved	O
IFN-stimulated	B-DNA
response	I-DNA
element	I-DNA
(	O
ISRE	B-DNA
)	O
results	O
in	O
transcriptional	O
activation	O
.	O
	
This	O
factor	O
is	O
composed	O
of	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
ISGF3	B-protein
gamma	I-protein
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha-activated	B-protein
proteins	I-protein
which	O
preexist	O
as	O
latent	B-protein
cytoplasmic	I-protein
precursors	I-protein
(	O
ISGF3	B-protein
alpha	I-protein
)	O
.	O
	
We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
differs	O
from	O
most	O
cell	B-cell_line
lines	I-cell_line
previously	O
examined	O
.	O
	
U937	B-cell_line
cells	I-cell_line
express	O
both	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFN	I-protein
receptors	I-protein
,	O
but	O
only	O
IFN-alpha	B-protein
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O
	
Pretreatment	O
with	O
IFN-gamma	B-protein
potentiates	O
the	O
IFN-alpha	B-protein
-induced	O
protection	O
,	O
but	O
IFN-gamma	B-protein
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O
	
ISG15	B-RNA
mRNA	I-RNA
accumulation	O
in	O
U937	B-cell_line
cells	I-cell_line
is	O
not	O
detectable	O
before	O
6	O
h	O
of	O
IFN-alpha	B-protein
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O
	
Although	O
IFN-gamma	B-protein
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN-gamma	B-protein
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O
	
Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	B-protein
binding	I-protein
factors	I-protein
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	B-protein
is	O
induced	O
by	O
IFN-alpha	B-protein
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Activation	O
of	O
ISGF3	B-protein
alpha	I-protein
,	O
the	O
latent	O
component	O
of	O
ISGF3	B-protein
,	O
occurs	O
rapidly	O
.	O
	
However	O
,	O
the	O
increase	O
in	O
ISGF3	B-protein
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	B-protein
gamma	I-protein
induced	O
by	O
IFN-alpha	B-protein
or	O
IFN-gamma	B-protein
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:93043110	
	
Single	O
point	O
estimation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O
	
A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
human	O
lymphocytes	B-cell_type
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi-point	O
Scatchard	O
analysis	O
.	O
	
The	O
assay	O
conditions-concentration	O
of	O
the	O
ligand	O
20	O
nmol/l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2-6	O
mil	O
.	O
	
cells/tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O
	
An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O
	
Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole-cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non-applicable	O
for	O
receptor	O
quantitation	O
.	O
	
The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	B-protein
concentration	O
7131	O
+/-	O
1256	O
sites/cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O
	
The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O
	
The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
found	O
in	O
these	O
children	O
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O
	
###MEDLINE:92142646	
	
Glucocorticoid	B-protein
receptor	I-protein
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O
	
We	O
have	O
measured	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
in	O
mononuclear	B-cell_type
and	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O
	
In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O
	
The	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
correlated	O
with	O
those	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
glucocorticoid-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O
	
When	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo-cAMP	O
,	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O-methyl-D-glucose	O
.	O
	
We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O
	
###MEDLINE:92224250	
	
Transcription	B-protein
factor	I-protein
activation	O
and	O
functional	O
stimulation	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
Activation	O
of	O
expression	O
of	O
genes	B-DNA
encoding	O
transcription	B-protein
factors	I-protein
:	O
c-fos	B-DNA
and	O
c-jun	B-DNA
and	O
formation	O
of	O
AP1	B-protein
transcriptional	I-protein
complex	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
investigated	O
.	O
	
It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	B-DNA
and	O
c-jun	B-DNA
expression	O
as	O
well	O
as	O
AP1	B-protein
formation	O
.	O
	
Interferon	B-protein
gamma	I-protein
activated	O
strongly	O
c-fos	B-DNA
and	O
weakly	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O
	
Tumor	B-protein
necrosis	I-protein
factor	I-protein
induced	O
slightly	O
c-fos	B-DNA
and	O
had	O
almost	O
no	O
effect	O
on	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O
	
The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	B-cell_type
by	O
all	O
three	O
factors	B-protein
may	O
be	O
dependent	O
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	B-protein
.	O
	
###MEDLINE:92062170	
	
Regulation	O
of	O
interleukin-1	B-protein
beta	I-protein
production	O
by	O
glucocorticoids	O
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O
	
Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
.	O
	
Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O
	
When	O
human	B-cell_type
monocytes	I-cell_type
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide-induced	O
interleukin-1	B-protein
beta	I-protein
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate-induced	O
production	O
was	O
increased	O
3-10	O
fold	O
.	O
	
This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O
	
When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	B-RNA
mRNA	I-RNA
)	O
.	O
	
Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate-induced	O
signal	O
(	O
prolonged	O
protein	B-protein
kinase	I-protein
C	I-protein
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	B-RNA
mRNA	I-RNA
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O
	
###MEDLINE:92013087	
	
Nuclear	B-protein
transcription	I-protein
factors	I-protein
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
Induction	O
requirements	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
the	O
stimulated	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
.	O
	
The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
AP-3	B-protein
,	O
OCT-1	B-protein
,	O
and	O
NF-AT	B-protein
.	O
	
The	O
latter	O
``	O
nuclear	B-protein
factor	I-protein
for	I-protein
activated	I-protein
T	I-protein
cells	I-protein
``	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O
	
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	B-protein
factors	I-protein
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O
	
All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	B-cell_type
cells	I-cell_type
upon	O
activation	O
with	O
mitogens	B-protein
but	O
not	O
with	O
exogenous	B-protein
IL-2	I-protein
growth	I-protein
factor	I-protein
.	O
	
However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O
	
Only	O
the	O
activities	O
for	O
NF-AT	B-DNA
and	I-DNA
AP-1	I-DNA
sites	I-DNA
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	B-protein
or	O
antibody	B-protein
to	O
the	O
CD3	B-protein
or	O
CD28	B-protein
surface	I-protein
molecules	I-protein
.	O
	
Other	O
factors	O
are	O
induced	O
by	O
lectin	B-protein
,	O
antibody	B-protein
,	O
and/or	O
PMA	O
alone	O
.	O
	
After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	B-protein
and	O
AP-1	B-protein
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O
	
Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:91361546	
	
NF-kappa	B-protein
B	I-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
stably	O
expressing	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O
	
The	O
effect	O
of	O
constitutive	O
Tax	B-protein
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
its	O
recognition	B-DNA
sequence	I-DNA
and	O
on	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	B-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
19D	B-cell_line
and	O
9J	B-cell_line
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-DNA
expression	I-DNA
vector	I-DNA
.	O
	
Tax	B-cell_line
expressing	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
contained	O
a	O
constitutive	O
level	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross-linking	O
using	O
a	O
palindromic	B-DNA
NF-kappa	I-DNA
B	I-DNA
probe	I-DNA
homologous	O
to	O
the	O
interferon	B-DNA
beta	I-DNA
PRDII	I-DNA
site	I-DNA
.	O
	
In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	B-protein
binding	I-protein
proteins	I-protein
of	O
85	B-protein
,	I-protein
75	I-protein
,	I-protein
and	I-protein
54	I-protein
kDa	I-protein
,	O
whereas	O
in	O
Tax	B-cell_line
expressing	I-cell_line
cells	I-cell_line
the	O
85-kDa	B-protein
protein	I-protein
and	O
a	O
92-kDa	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
were	O
constitutively	O
induced	O
.	O
	
Expression	O
of	O
Tax	B-protein
protein	I-protein
in	O
19D	B-cell_line
and	O
9J	B-cell_line
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	B-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
granulocyte-macrophage	I-DNA
colony	I-DNA
stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O
	
Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O
	
Tax	B-protein
expression	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
may	O
alter	O
the	O
stoichiometry	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	B-protein
binding	I-protein
proteins	I-protein
and	O
thus	O
change	O
the	O
expression	O
of	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O
	
###MEDLINE:92001749	
	
A	O
nuclear	B-protein
factor	I-protein
NF-GM2	B-protein
that	O
interacts	O
with	O
a	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	B-cell_line
leukemia	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
and	O
similarity	O
to	O
NF-kappa	B-protein
B	I-protein
.	O
	
Activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
antigen	O
,	O
lectin	B-protein
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	B-protein
,	O
including	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O
	
We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	B-DNA
region	I-DNA
of	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
at	O
positions	O
between	O
-95	B-DNA
and	I-DNA
-73	I-DNA
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA/A23187	O
.	O
	
This	O
region	O
contains	O
two	O
DNA-binding	B-DNA
motifs	I-DNA
,	O
GM2	B-DNA
and	O
GC-box	B-DNA
.	O
	
The	O
GM2	B-DNA
sequence	I-DNA
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	B-protein
factors	I-protein
A1	B-protein
,	O
A2	B-protein
,	O
and	O
B	B-protein
.	O
	
To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	B-protein
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	B-cell_line
cells	I-cell_line
on	O
the	O
basis	O
of	O
specific	O
DNA-binding	O
activity	O
.	O
	
The	O
purified	O
NF-GM2	B-protein
consists	O
of	O
50	O
(	O
p50	B-protein
)	O
and	O
65	O
kDa	O
(	O
p65	B-protein
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM-CSF	B-protein
and	O
immunoglobulin	B-DNA
kappa	I-DNA
(	I-DNA
GGAAAGTCCC	I-DNA
)	I-DNA
enhancers	I-DNA
.	O
	
Electrophoretically	O
purified	O
p50	B-protein
alone	O
can	O
form	O
a	O
protein-DNA	B-protein
complex	I-protein
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B-protein
associates	O
preferentially	O
with	O
p65	B-protein
to	O
form	O
the	O
NF-GM2	B-protein
complex	I-protein
.	O
	
In	O
addition	O
,	O
p65	B-protein
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein-DNA	B-protein
complex	I-protein
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF-GM2	B-protein
complex	I-protein
.	O
	
Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B-protein
(	O
identical	O
to	O
50	B-protein
kDa	I-protein
NF-kappa	I-protein
B	I-protein
protein	I-protein
)	O
reacted	O
with	O
the	O
p50	B-protein
of	O
NF-GM2	B-protein
,	O
indicating	O
that	O
the	O
NF-GM2	B-protein
polypeptide	I-protein
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	B-protein
kDa	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
The	O
purified	O
NF-GM2	B-protein
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
harboring	O
the	O
GM2	O
sequence	O
.	O
	
This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
through	O
the	O
GM2/GC-box	B-DNA
sequence	I-DNA
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
alone	O
.	O
	
###MEDLINE:91292530	
	
Characterization	O
of	O
an	O
immediate-early	B-DNA
gene	I-DNA
induced	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
that	O
encodes	O
I	B-protein
kappa	I-protein
B	I-protein
-like	O
activity	O
.	O
	
We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	B-DNA
representing	O
mRNAs	B-RNA
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	B-RNA
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	B-protein
tandem	I-protein
repeats	I-protein
of	O
the	O
cdc10/ankyrin	B-protein
motif	I-protein
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	B-protein
repeat	I-protein
region	I-protein
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B/KBF1	I-protein
p50	I-protein
.	O
	
The	O
C-terminus	B-protein
has	O
a	O
putative	O
protein	B-protein
kinase	I-protein
C	I-protein
phosphorylation	I-protein
site	I-protein
.	O
	
In	O
vitro	O
translated	O
MAD-3	B-protein
protein	I-protein
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
the	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
but	O
not	O
that	O
of	O
the	O
p50/p50	B-protein
KBF1	I-protein
factor	I-protein
or	O
of	O
other	O
DNA-binding	B-protein
proteins	I-protein
.	O
	
The	O
MAD-3	B-DNA
cDNA	I-DNA
encodes	O
an	O
I	B-protein
kappa	I-protein
B-like	I-protein
protein	I-protein
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF-kappa	B-protein
B	I-protein
,	O
including	O
adhesion-dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O
	
###MEDLINE:91248763	
	
Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	B-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
in	O
wild-type	B-cell_line
and	O
dexamethasone-resistant	B-cell_line
human	I-cell_line
leukemic	I-cell_line
(	I-cell_line
CEM	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O
	
Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O
	
In	O
both	O
wild-type	B-cell_line
and	O
highly	O
dexamethasone	B-cell_line
(	I-cell_line
dex	I-cell_line
)	I-cell_line
-resistant	I-cell_line
clones	I-cell_line
of	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
CEM	I-cell_line
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O
	
It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	B-cell_line
CEM	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
a	O
dex-resistant	B-cell_line
,	I-cell_line
glucocorticoid	I-cell_line
receptor	I-cell_line
(	I-cell_line
GR	I-cell_line
)	I-cell_line
-defective	I-cell_line
clone	I-cell_line
ICR-27	B-cell_line
TK-3	I-cell_line
,	O
dex	O
induces	O
GR	B-RNA
mRNA	I-RNA
.	O
	
To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex-resistant	B-cell_line
cells	I-cell_line
by	O
making	O
use	O
of	O
the	O
residual	O
GR	B-protein
found	O
there	O
,	O
wild-type	O
and	O
dex-resistant	B-cell_line
clones	I-cell_line
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
was	O
studied	O
.	O
	
Cortivazol	O
significantly	O
induced	O
GR	B-RNA
mRNA	I-RNA
in	O
the	O
normal	B-cell_line
CEM-C7	I-cell_line
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex-resistant	B-cell_line
clones	I-cell_line
,	O
although	O
the	O
dex-resistant	B-cell_line
clones	I-cell_line
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_type
cells	I-cell_type
for	O
significant	O
GR	B-RNA
mRNA	I-RNA
induction	O
.	O
	
Increased	O
levels	O
of	O
GR	B-RNA
mRNA	I-RNA
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O
	
A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex-resistant	B-cell_line
cells	I-cell_line
was	O
found	O
.	O
	
Positive	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	B-cell_line
and	I-cell_line
dex-resistant	I-cell_line
CEM	I-cell_line
cells	I-cell_line
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O
	
However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex-resistant	B-cell_line
cells	I-cell_line
is	O
defective	O
in	O
that	O
dex-resistant	B-cell_line
clones	I-cell_line
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_line
cells	I-cell_line
for	O
lysis	O
of	O
the	O
cells	O
.	O
	
###MEDLINE:91218850	
	
HIV	B-DNA
enhancer	I-DNA
activity	O
perpetuated	O
by	O
NF-kappa	B-protein
B	I-protein
induction	O
on	O
infection	O
of	O
monocytes	B-cell_type
[	O
see	O
comments	O
]	O
	
Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O
	
In	O
T	B-cell_type
cells	I-cell_type
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O
	
Cloned	O
,	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
low	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
potent	B-protein
transcriptional	I-protein
activator	I-protein
of	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O
	
In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	B-cell_type
express	O
detectable	O
HIV	B-protein
proteins	I-protein
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O
	
One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	B-cell_type
could	O
be	O
sustained	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O
	
However	O
,	O
the	O
U937	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O
	
We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B-protein
factor	I-protein
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
permanently	O
increased	O
HIV	B-DNA
enhancer	I-DNA
activity	O
.	O
	
This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	B-cell_type
.	O
	
###MEDLINE:91173312	
	
Isolation	O
of	O
a	O
rel-related	B-DNA
human	I-DNA
cDNA	I-DNA
that	O
potentially	O
encodes	O
the	O
65-kD	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O
	
A	O
DNA	B-DNA
probe	I-DNA
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
,	O
the	O
Drosophila	B-protein
morphogen	I-protein
dorsal	I-protein
,	O
and	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
was	O
generated	O
from	O
Jurkat	B-DNA
T	I-DNA
cell	I-DNA
complementary	I-DNA
DNA	I-DNA
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O
	
This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	B-DNA
complementary	I-DNA
DNA	I-DNA
that	O
hybridized	O
to	O
a	O
2.6-kilobase	B-RNA
messenger	I-RNA
RNA	I-RNA
present	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B-protein
kilodaltons	I-protein
(	O
kD	O
)	O
.	O
	
The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O
	
This	O
protein-DNA	B-protein
complex	I-protein
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	B-protein
human	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunit	I-protein
and	O
binding	O
was	O
inhibited	O
by	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
-beta	O
proteins	O
.	O
	
In	O
addition	O
,	O
the	O
65-kD	B-protein
protein	I-protein
associated	O
with	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
kappa	B-DNA
B	I-DNA
probe	I-DNA
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	B-protein
B-DNA	I-protein
complex	I-protein
.	O
	
Therefore	O
the	O
rel-related	B-protein
65-kD	I-protein
protein	I-protein
may	O
represent	O
the	O
p65	B-protein
subunit	I-protein
of	O
the	O
active	B-protein
NF-kappa	I-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
.	O
	
###MEDLINE:91246215	
	
The	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide-stimulated	B-RNA
interleukin-1	I-RNA
beta	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O
	
The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte/macrophage	O
function	O
in	O
vitro	O
.	O
	
To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
U-937	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
HL-60	B-cell_line
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	B-RNA
beta	I-RNA
(	I-RNA
IL-1	I-RNA
beta	I-RNA
)	I-RNA
mRNA	I-RNA
and	O
IL-1	B-protein
beta	I-protein
protein	I-protein
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
	
All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
LPS	O
.	O
	
Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
only	O
in	O
U-937	B-cell_line
and	O
HL-60	B-cell_line
cells	O
.	O
	
From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	B-cell_line
was	O
chosen	O
over	O
HL-60	B-cell_line
and	O
THP-1	B-cell_line
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O
	
In	O
U-937	B-cell_line
cells	I-cell_line
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12-24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O
	
Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
appearance	O
in	O
response	O
to	O
LPS	O
.	O
	
However	O
,	O
exposure	O
of	O
U-937	B-cell_line
cells	I-cell_line
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	B-cell_line
cells	I-cell_line
not	O
preincubated	O
with	O
the	O
hormone.2+o	O
	
###MEDLINE:91354520	
	
Regulation	O
of	O
M-CSF	B-protein
expression	O
by	O
M-CSF	B-protein
:	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O
	
Macrophage-colony-stimulating	B-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	B-protein
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	B-cell_type
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	B-DNA
protooncogene	I-DNA
.	O
	
The	O
detection	O
of	O
both	O
M-CSF	O
and	O
c-fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	B-cell_type
lineage	I-cell_type
has	O
suggested	O
that	O
M-CSF	B-protein
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O
	
Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M-CSF	B-protein
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O
	
Although	O
sensitivity	O
to	O
M-CSF	B-protein
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	B-protein
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O
	
To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	B-protein
signal	O
transduction	O
.	O
	
We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	B-cell_type
to	O
M-CSF	B-protein
.	O
	
We	O
show	O
that	O
M-CSF	B-protein
activates	O
and	O
translocates	O
PKC	B-protein
.	O
	
Inhibition	O
of	O
PKC	B-protein
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	B-protein
by	O
M-CSF	B-protein
.	O
	
Furthermore	O
,	O
activation	O
of	O
PKC	B-protein
was	O
pertussis-toxin-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	B-protein
kappa	I-protein
B	I-protein
protein	I-protein
in	O
nuclear	O
extracts	O
of	O
M-CSF-induced	B-cell_line
blood	I-cell_line
monocytes	I-cell_line
but	O
not	O
in	O
monocytes	B-cell_type
exposed	O
to	O
medium	O
treatment	O
only	O
.	O
	
The	O
results	O
suggest	O
that	O
M-CSF	B-protein
induction	O
of	O
M-CSF	B-protein
involves	O
G	B-protein
proteins	I-protein
,	O
PKC	B-protein
and	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
###MEDLINE:92052214	
	
Clone	B-DNA
pAT	I-DNA
133	I-DNA
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	B-DNA
factor-induced	I-DNA
genes	I-DNA
with	O
almost	O
identical	O
zinc-finger	B-protein
domains	I-protein
.	O
	
We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	B-DNA
pAT	I-DNA
133	I-DNA
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O
	
The	O
pAT	B-DNA
133	I-DNA
gene	I-DNA
is	O
immediately	O
induced	O
,	O
with	O
FOS	B-protein
-like	O
kinetics	O
,	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
fibroblasts	B-cell_type
.	O
	
Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	B-protein
zinc-finger	I-protein
sequences	I-protein
of	O
the	O
type	O
Cys2-Xaa12-His2	B-protein
.	O
	
This	O
zinc-finger	B-protein
region	I-protein
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	B-protein
factors	I-protein
pAT	B-protein
225/EGR1	I-protein
and	O
pAT	O
591/EGR2	B-protein
.	O
	
Except	O
for	O
the	O
conserved	O
zinc-finger	B-protein
domains	I-protein
,	O
the	O
amino	B-protein
acid	I-protein
sequences	I-protein
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O
	
This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	B-DNA
133	I-DNA
gene	I-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
with	O
a	O
specific	O
biological	O
function	O
.	O
	
Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc-finger-encoding	B-DNA
genes	I-DNA
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
of	O
resting	B-cell_type
fibroblasts	I-cell_type
.	O
	
However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O
	
In	O
human	B-RNA
histiocytic	I-RNA
U937	I-RNA
cells	I-RNA
mRNA	I-RNA
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	B-RNA
of	O
pAT	B-protein
225/EGR1	I-protein
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O
	
In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	B-protein
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O
	
This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O
	
###MEDLINE:92038993	
	
v-erbA	B-protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	B-protein
function	O
in	O
erythroid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B-DNA
target	I-DNA
gene	I-DNA
CAII	B-DNA
.	O
	
The	O
v-erbA	B-protein
oncoprotein	I-protein
represents	O
a	O
retrovirus-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B-protein
hormone	I-protein
(	I-protein
T3/T4	I-protein
)	I-protein
receptor	I-protein
c-erbA	B-protein
(	I-protein
type	I-protein
alpha	I-protein
)	I-protein
.	O
	
It	O
contributes	O
to	O
virus-induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte-specific	B-DNA
genes	I-DNA
.	O
	
Here	O
,	O
we	O
show	O
that	O
v-erbA	B-protein
and	O
c-erbA	B-protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	B-DNA
of	O
the	O
erythrocyte-specific	B-protein
carbonic	I-protein
anhydrase	I-protein
II	I-protein
(	O
CAII	B-DNA
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	B-protein
.	O
	
This	O
erbA-binding	B-DNA
site	I-DNA
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down-regulation	O
of	O
CAII	B-DNA
transcription	O
by	O
the	O
v-erbA	B-protein
oncoprotein	I-protein
.	O
	
In	O
stably	B-cell_line
transformed	I-cell_line
erythroblasts	I-cell_line
coexpressing	O
the	O
v-erbA	B-protein
oncoprotein	I-protein
and	O
the	O
c-erbA/T3	B-protein
receptor	I-protein
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	B-protein
activity	O
is	O
dominant	O
over	O
v-erbA	B-protein
.	O
	
T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA	B-protein
-mediated	O
differentiation	O
arrest	O
.	O
	
Likewise	O
,	O
T3	O
activated	O
CAII	B-DNA
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	B-DNA
reporter	I-DNA
gene	I-DNA
containing	O
the	O
CAII-specific	B-DNA
erbA-binding	I-DNA
site	I-DNA
.	O
	
The	O
c-erbA	B-protein
-dependent	O
activation	O
of	O
this	O
CAII	B-DNA
reporter	I-DNA
construct	I-DNA
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v-erbA	B-protein
.	O
	
Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	B-protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	B-protein
.	O
	
###MEDLINE:92013023	
	
Anti-CD2	B-protein
receptor	I-protein
antibodies	I-protein
activate	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
CD2	B-protein
T	I-protein
lymphocyte	I-protein
glycoprotein	I-protein
surface	I-protein
molecule	I-protein
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O
	
Treatment	O
of	O
chronically	B-cell_line
HIV-infected	I-cell_line
PBMC	I-cell_line
with	O
anti-CD2	B-protein
mAb	I-protein
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O
	
In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	B-protein
antibodies	I-protein
stimulate	O
viral	O
production	O
.	O
	
We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
anti-CD2	B-protein
antibodies	I-protein
results	O
in	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
Furthermore	O
,	O
CAT	B-protein
assays	O
using	O
mutated	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat-CAT	I-DNA
constructs	I-DNA
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O
	
These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-protein
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B-protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O
	
###MEDLINE:91293101	
	
Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
and	O
HIV-1	O
.	O
	
Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O
	
In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
The	O
effect	O
is	O
mediated	O
by	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	B-protein
cytoplasmic	I-protein
form	I-protein
.	O
	
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
H2O2	O
.	O
	
NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
cycloheximide	O
,	O
double-stranded	B-RNA
RNA	I-RNA
,	O
calcium	O
ionophore	O
,	O
TNF-alpha	B-protein
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	B-protein
,	O
lipopolysaccharide	O
and	O
lectin	B-protein
.	O
	
This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O
	
ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
I	B-protein
kappa	I-protein
B	I-protein
from	O
NF-kappa	B-protein
B	I-protein
.	O
	
###MEDLINE:91266912	
	
Inhibition	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
by	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
.	O
	
The	O
KBF1	B-protein
factor	I-protein
,	O
which	O
binds	O
to	O
the	O
enhancer	B-DNA
A	I-DNA
located	O
in	O
the	O
promoter	B-DNA
of	O
the	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
I	I-DNA
gene	I-DNA
H-2Kb	B-DNA
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
	
The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O
	
The	O
dimerization	B-protein
domain	I-protein
of	O
KBF1/p50	B-protein
is	O
contained	O
between	B-protein
amino	I-protein
acids	I-protein
201	I-protein
and	I-protein
367	I-protein
.	O
	
A	O
mutant	O
of	O
KBF1/p50	B-protein
(	O
delta	B-protein
SP	I-protein
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B-protein
,	O
has	O
been	O
constructed	O
.	O
	
This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	B-protein
proteins	I-protein
of	O
the	O
same	O
family	O
(	O
KBF1/p50	B-protein
,	O
c-	B-protein
and	I-protein
v-rel	I-protein
)	O
.	O
	
This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans-acting	B-protein
dominant	I-protein
negative	I-protein
regulator	I-protein
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	B-protein
B	I-protein
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co-transfected	O
into	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
the	O
delta	B-protein
SP	I-protein
mutant	O
.	O
	
Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B-protein
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	B-DNA
class	I-DNA
I	I-DNA
H-2Kb	I-DNA
promoter	I-DNA
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	B-cell_line
lines	I-cell_line
.	O
	
These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
.	O
	
###MEDLINE:91224990	
	
Tissue-specific	O
expression	O
of	O
the	O
platelet	B-DNA
GPIIb	I-DNA
gene	I-DNA
.	O
	
One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	B-cell_type
progenitor	I-cell_type
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	B-cell_type
lineage	I-cell_type
.	O
	
Recent	O
development	O
of	O
primary	B-cell_line
cultures	I-cell_line
of	O
human	B-cell_line
megakaryocytes	I-cell_line
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O
	
One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B-DNA
IIb	I-DNA
(	I-DNA
GPIIb	I-DNA
)	I-DNA
gene	I-DNA
;	O
GPIIb	B-DNA
,	O
the	O
alpha	B-protein
subunit	I-protein
of	O
the	O
platelet	B-protein
cytoadhesin	I-protein
GPIIb-IIIa	I-protein
,	O
is	O
produced	O
in	O
megakaryocytes	B-cell_line
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B-protein
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O
	
For	O
these	O
reasons	O
,	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
GPIIb	B-DNA
gene	I-DNA
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	B-protein
nuclear	I-protein
factors	I-protein
.	O
	
A	O
fragment	O
extending	O
from	O
-643	B-DNA
to	I-DNA
+33	I-DNA
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	B-DNA
gene	I-DNA
in	O
transfection	O
experiments	O
.	O
	
Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	B-protein
I	I-protein
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O
	
One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	B-DNA
factor	I-DNA
E1-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	B-DNA
motif	I-DNA
.	O
	
Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	B-cell_line
cells	I-cell_line
and	O
nonrelated	B-cell_type
cells	I-cell_type
as	O
well	O
.	O
	
Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	B-cell_line
cells	I-cell_line
.	O
	
In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	B-DNA
activity	O
.	O
	
It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	B-protein
nuclear	I-protein
proteins	I-protein
acting	O
as	O
positive	B-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:91349414	
	
Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O
	
Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O
	
Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O
	
No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
and	O
antidepressant	O
medication	O
.	O
	
These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand-induced	O
plasticity	O
of	O
glucocorticoid	B-protein
receptor	I-protein
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
during	O
depression	O
.	O
	
###MEDLINE:92314696	
	
Every	O
enhancer	O
works	O
with	O
every	O
promoter	B-DNA
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O
	
The	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	B-DNA
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	B-DNA
.	O
	
While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O
	
A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	B-DNA
and	O
enhancers	B-DNA
were	O
tested	O
by	O
transfection	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O
	
We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	B-DNA
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	B-DNA
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer/	O
promoter	B-DNA
combination	O
.	O
	
Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
enhancer	I-DNA
(	O
or	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	B-DNA
.	O
	
We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/	O
promoter	B-DNA
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O
	
###MEDLINE:91282927	
	
Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O
	
Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O
	
Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell-specific	B-protein
membrane	I-protein
proteins	I-protein
allows	O
the	O
identification	O
of	O
transcription	B-protein
factors	I-protein
that	O
control	O
the	O
expression	O
of	O
these	O
T-cell	B-DNA
genes	I-DNA
.	O
	
Such	O
transcription	B-protein
factors	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T-cell	O
phenotype	O
by	O
functioning	O
as	O
'master	O
regulators	O
of	O
T-cell	O
differentiation'	O
.	O
	
###MEDLINE:91187152	
	
A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O
	
Circadian	O
rhythm	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
was	O
studied	O
in	O
the	O
rat	B-cell_type
liver	I-cell_type
and	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
.	O
	
For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	B-protein
GR	I-protein
were	O
detected	O
between	O
23	O
:	O
00	O
and	O
02	O
:	O
00	O
h	O
.	O
	
Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	B-protein
GR	I-protein
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18	O
:	O
30	O
and	O
06	O
:	O
30	O
h	O
)	O
.	O
	
In	O
human	B-cell_type
leukocytes	I-cell_type
,	O
the	O
peak	O
value	O
of	O
GR	B-protein
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	O
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04	O
:	O
00-08	O
:	O
00	O
h	O
and	O
23	O
:	O
00-24	O
:	O
00	O
h	O
,	O
respectively	O
.	O
	
In	O
patients	O
suffering	O
from	O
Cushing	O
's	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	B-protein
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O
	
For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	B-protein
was	O
abolished	O
.	O
	
Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O
	
Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	B-protein
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	O
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'circadian	O
pacemaker	O
'	O
located	O
in	O
the	O
human	O
basal	O
brain	O
.	O
	
These	O
diurnal	O
variations	O
in	O
GR	B-protein
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	B-cell_type
cells	I-cell_type
to	O
cortisol	O
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR	B-protein
-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	B-protein
.	O
	
###MEDLINE:92112059	
	
Transcription	B-protein
factor	I-protein
requirements	O
for	O
U2	B-RNA
snRNA	I-RNA
-encoding	O
gene	O
activation	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
Transcription	O
of	O
a	O
human	O
U2	B-DNA
small	I-DNA
nuclear	I-DNA
RNA	I-DNA
(	I-DNA
snRNA	I-DNA
)	I-DNA
-encoding	I-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
requires	O
a	O
distal	B-DNA
enhancer	I-DNA
element	I-DNA
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	B-DNA
motif	I-DNA
(	O
Oct	B-DNA
)	O
and	O
three	O
Sp	B-DNA
1-binding	I-DNA
sites	I-DNA
.	O
	
To	O
study	O
the	O
transcription	B-protein
factor	I-protein
requirement	O
in	O
B-cells	B-cell_type
,	O
different	O
U2	B-DNA
enhancer	I-DNA
constructions	I-DNA
were	O
transfected	O
into	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
.	O
	
The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B-cells	B-cell_type
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	B-DNA
and	O
at	O
least	O
one	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O
	
Deletion	O
of	O
all	O
the	O
Sp	B-DNA
1-binding	I-DNA
sites	I-DNA
from	O
the	O
enhancer	B-DNA
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer-binding	B-DNA
site	I-DNA
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O
	
Enhancers	O
containing	O
a	O
single	O
Oct	B-DNA
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	B-RNA
snRNA	I-RNA
transcription	O
in	O
both	O
HeLa	B-cell_line
cells	I-cell_line
,	O
in	O
which	O
only	O
OTF-1	O
is	O
expressed	O
,	O
and	O
in	O
BJA-B	B-cell_line
cells	I-cell_line
in	O
which	O
OTF-2	B-protein
is	O
the	O
predominantly	O
expressed	O
octamer-binding	B-protein
factor	I-protein
.	O
	
The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	B-protein
factor	I-protein
,	O
OTF-1	B-protein
,	O
and	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
OTF-2	B-protein
,	O
can	O
activate	O
U2	B-RNA
snRNA	I-RNA
transcription	O
.	O
	
The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	B-DNA
and	O
the	O
adjacent	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	B-DNA
expresses	O
wild-type	O
levels	O
of	O
U2	B-RNA
snRNA	I-RNA
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer-binding	B-DNA
site	I-DNA
is	O
combined	O
with	O
a	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O
	
###MEDLINE:92051383	
	
One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell-restricted	O
activity	O
of	O
a	O
kB-like	B-DNA
proto-enhancer	I-DNA
element	I-DNA
from	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
.	O
	
The	O
inducible	O
,	O
T	B-DNA
cell-specific	I-DNA
enhancers	I-DNA
of	O
murine	B-DNA
and	I-DNA
human	I-DNA
Interleukin	I-DNA
2	I-DNA
(	I-DNA
Il-2	I-DNA
)	I-DNA
genes	I-DNA
contain	O
the	O
kB-like	B-DNA
sequence	I-DNA
GGGATTTCACC	O
as	O
an	O
essential	B-DNA
cis-acting	I-DNA
enhancer	I-DNA
motif	I-DNA
.	O
	
When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so-called	O
TCEd	B-DNA
(	O
distal	B-DNA
T	I-DNA
cell	I-DNA
element	I-DNA
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	B-DNA
element	I-DNA
in	O
E14	B-cell_line
T	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
In	O
extracts	O
of	O
induced	O
,	O
Il-2	B-cell_line
secreting	I-cell_line
El4	I-cell_line
cells	I-cell_line
three	O
individual	O
protein	B-protein
factors	I-protein
bind	O
to	O
TCEd	B-DNA
DNA	I-DNA
.	O
	
The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	B-protein
(	O
T	B-protein
cell	I-protein
factor	I-protein
1	I-protein
)	O
,	O
is	O
correlated	O
with	O
the	O
proto-enhancer	O
activity	O
of	O
TCEd	O
.	O
	
TCF-1	B-protein
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	B-protein
kD	I-protein
polypeptide	I-protein
of	O
NF-kB	B-protein
.	O
	
Purified	B-protein
NF-kB	I-protein
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	B-DNA
,	O
but	O
TCF-1	B-protein
binds	O
stronger	O
than	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	O
.	O
	
The	O
conversion	O
of	O
the	O
TCEd	B-DNA
to	O
a	O
'perfect	B-DNA
'	I-DNA
NF-kB	I-DNA
binding	I-DNA
site	I-DNA
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	I-DNA
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	B-DNA
'	I-DNA
TCEd	I-DNA
motifs	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	B-DNA
motif	I-DNA
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	B-cell_line
cells	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
These	O
results	O
indicate	O
that	O
lymphocyte-specific	O
factors	O
binding	O
to	O
the	O
TCEd	B-DNA
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific-transcription	O
of	O
the	O
Il-2	B-DNA
gene	I-DNA
.	O
	
###MEDLINE:92020218	
	
An	O
erythroid	B-DNA
specific	I-DNA
enhancer	I-DNA
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell-type	B-protein
specific	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O
	
The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O
	
We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	B-DNA
genes	I-DNA
.	O
	
A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-protein
or	O
to	O
the	O
SV40	O
promoter	O
.	O
	
The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	B-DNA
GATA-1	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
###MEDLINE:92020850	
	
Demonstration	O
of	O
a	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3-responsive	I-protein
protein	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
.	O
	
Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
recognizing	O
a	O
17-amino	B-protein
acid	I-protein
epitope	I-protein
of	O
the	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
,	O
we	O
have	O
detected	O
two	O
crossreacting	B-protein
proteins	I-protein
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	B-protein
kDa	I-protein
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
	
The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	O
to	O
be	O
specific	O
for	O
activated	B-cell_type
lymphocytes	I-cell_type
since	O
it	O
was	O
not	O
detected	O
in	O
several	O
other	O
human	B-cell_type
cells	I-cell_type
including	O
monocytes	B-cell_type
.	O
	
More	O
strikingly	O
,	O
the	O
80-kDa	B-protein
protein	I-protein
was	O
downregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O
	
However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	B-protein
protein	I-protein
.	O
	
###MEDLINE:91363265	
	
Regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O
	
Glucocorticoid	B-protein
receptors	I-protein
(	O
GcR	B-protein
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	B-cell_type
mononulear	I-cell_type
leukocytes	I-cell_type
(	O
hMNL	B-cell_type
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O
	
Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	B-protein
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B-protein
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O
	
In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O
	
Furthermore	O
,	O
GcR	B-protein
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O
	
We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	B-protein
in	O
intact	B-cell_type
cells	I-cell_type
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O
	
The	O
results	O
suggested	O
that	O
GcR	B-protein
in	O
hMNL	B-cell_type
are	O
down-regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O
	
Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up-regulation	O
or	O
antagonism	O
of	O
GcR	B-protein
by	O
ketoconazole	O
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	O
levels	O
of	O
patients	O
with	O
Cushing	O
's	O
disease	O
were	O
reduced	O
.	O
	
This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	B-protein
of	O
target	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
the	O
process	O
of	O
GcR	B-protein
regulation	O
in	O
hMNL	B-cell_type
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O
	
###MEDLINE:91296379	
	
HTLV-1	B-protein
Tax	I-protein
induces	O
expression	O
of	O
various	O
immediate	B-DNA
early	I-DNA
serum	I-DNA
responsive	I-DNA
genes	I-DNA
.	O
	
Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
	
We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	B-cell_line
lines	I-cell_line
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B-protein
activities	O
.	O
	
Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	B-RNA
encoding	O
the	O
AP-1	B-protein
proteins	I-protein
,	O
c-Fos	B-protein
,	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	O
JunD	B-protein
.	O
	
Previously	O
,	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B-protein
transcription	I-protein
factor	I-protein
,	O
Tax1	B-protein
.	O
	
By	O
using	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
(	O
JPX-9	B-cell_line
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-protein
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	B-RNA
for	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
JunD	B-protein
was	O
also	O
transactivated	O
by	O
Tax1	B-protein
.	O
	
Moreover	O
,	O
Tax1	B-protein
activated	O
expression	O
of	O
two	O
other	O
transcription	B-protein
factors	I-protein
having	O
zinc	B-protein
finger	I-protein
motifs	I-protein
,	O
Egr-1	B-protein
and	O
Egr-2	B-protein
,	O
in	O
the	O
same	O
cells	O
.	O
	
The	O
Tax1-inducible	B-protein
transcription	I-protein
factors	I-protein
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O
	
Thus	O
,	O
Tax1	B-protein
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O
	
###MEDLINE:91221358	
	
Glucocorticoid	B-protein
receptor	I-protein
characteristics	O
in	O
monocytes	B-cell_type
of	O
patients	O
with	O
corticosteroid-resistant	O
bronchial	O
asthma	O
.	O
	
The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
isolated	O
from	O
corticosteroid-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	B-protein
)	O
generation	O
by	O
human	B-cell_type
neutrophils	I-cell_type
(	O
PMN	B-cell_type
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O
	
In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	B-cell_type
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O
	
The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	B-cell_type
from	O
CS	O
individuals	O
.	O
	
There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O
	
The	O
dexamethasone	O
Kd	O
was	O
2.45	O
+/-	O
0.58	O
nM	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
+/-	O
0.35	O
nM	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O
	
The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3	O
,	O
605	O
+/-	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4	O
,	O
757	O
+/-	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O
	
These	O
findings	O
indicate	O
that	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	O
receptor	O
characteristics	O
.	O
	
###MEDLINE:91210272	
	
Vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O
	
Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O
	
The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	B-protein
protein	I-protein
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
were	O
examined	O
.	O
	
Lymphocytes	B-cell_type
activated	O
with	O
the	O
OKT3	B-protein
antibody	I-protein
to	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	B-cell_type
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
.	O
	
However	O
,	O
combination	O
of	O
OKT3	B-protein
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA-activated	B-cell_line
cells	I-cell_line
.	O
	
The	O
receptor	O
from	O
OKT3	B-protein
and	O
OKT3	B-protein
+	O
phorbol	O
myristate	O
acetate	O
-activated	B-cell_type
lymphocytes	I-cell_type
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	B-cell_type
lymphocytes	I-cell_type
.	O
	
In	O
lymphocytes	B-cell_type
activated	O
either	O
by	O
PHA	B-protein
or	O
OKT3	B-protein
(	O
but	O
not	O
in	O
resting	B-cell_type
cells	I-cell_type
)	O
,	O
a	O
50-kDa	B-protein
species	I-protein
cross-reacting	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
against	O
the	O
intestinal	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
was	O
detected	O
.	O
	
Finally	O
,	O
RNA	O
from	O
activated	B-cell_type
lymphocytes	I-cell_type
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	B-DNA
base	I-DNA
pair	I-DNA
long	I-DNA
region	I-DNA
encoding	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O
	
The	O
amplified	O
product	O
showed	O
an	O
identical	B-DNA
nucleotide	I-DNA
sequence	I-DNA
to	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O
	
These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
in	O
lymphocytes	B-cell_type
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	B-RNA
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
.	O
	
###MEDLINE:91172768	
	
Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	B-DNA
B-related	I-DNA
sequences	I-DNA
:	O
modulation	O
of	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
tax	I-DNA
gene	I-DNA
.	O
	
The	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O
	
For	O
example	O
,	O
kappa	B-DNA
B-related	I-DNA
sequences	I-DNA
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
and	O
the	O
beta-interferon	B-DNA
gene	I-DNA
.	O
	
However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O
	
We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	B-DNA
B-related	I-DNA
sequence	I-DNA
elements	I-DNA
in	O
two	O
different	O
cell	O
types	O
.	O
	
We	O
show	O
that	O
in	O
S194	B-cell_line
plasma	I-cell_line
cells	I-cell_line
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell-derived	B-protein
NF-kappa	I-protein
B	I-protein
for	O
that	O
element	O
.	O
	
This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
or	O
T-cell	B-DNA
receptor	I-DNA
genes	I-DNA
in	O
S194	B-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
in	O
either	O
EL-4	B-cell_line
(	I-cell_line
T	I-cell_line
)	I-cell_line
cells	I-cell_line
or	O
S194	B-cell_line
cells	I-cell_line
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B-protein
gene	I-protein
product	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	B-protein
B	I-protein
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O
	
###MEDLINE:91110562	
	
Specific	O
depletion	O
of	O
the	O
B-cell	B-cell_line
population	I-cell_line
induced	O
by	O
aberrant	O
expression	O
of	O
human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
1	I-DNA
gene	I-DNA
in	O
transgenic	O
mice	O
.	O
	
Interferons	B-protein
(	O
IFNs	B-protein
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B-protein
proteins	I-protein
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O
	
In	O
fact	O
,	O
IFNs	B-protein
inhibit	O
growth	O
of	O
various	O
normal	B-cell_type
and	O
transformed	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O
	
Previously	O
,	O
a	O
nuclear	B-protein
factor	I-protein
,	O
IRF-1	B-protein
(	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
)	O
,	O
which	O
binds	O
to	O
type	B-DNA
I	I-DNA
IFN	I-DNA
and	O
some	O
IFN-inducible	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
was	O
identified	O
and	O
cloned	O
.	O
	
Since	O
the	O
IRF-1	B-protein
gene	O
is	O
both	O
virus	O
and	O
IFN	B-protein
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-DNA
gene	I-DNA
is	O
functioning	O
in	O
IFN	B-protein
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O
	
In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-DNA
IRF-1	I-DNA
gene	I-DNA
linked	O
to	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O
	
In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
B	B-cell_type
cells	I-cell_type
)	O
.	O
	
Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	I-cell_type
.	O
	
In	O
fact	O
,	O
transgenic	B-cell_line
bone	I-cell_line
marrow	I-cell_line
cells	I-cell_line
cocultured	O
with	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
revealed	O
an	O
altered	O
B-cell	B-cell_type
maturation	O
pattern	O
.	O
	
###MEDLINE:92108417	
	
Characterization	O
of	O
a	O
cofactor	B-protein
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	B-protein
homeodomain	I-protein
protein	I-protein
.	O
	
Dimerization	O
among	O
transcription	B-protein
factors	I-protein
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O
	
Hepatocyte	B-protein
nuclear	I-protein
factor-1	I-protein
alpha	I-protein
(	O
HNF-1	B-protein
alpha	I-protein
)	O
is	O
a	O
homeodomain-containing	B-protein
protein	I-protein
that	O
functions	O
as	O
a	O
dimer	B-protein
.	O
	
A	O
dimerization	B-protein
cofactor	I-protein
of	O
HNF-1	B-protein
alpha	I-protein
(	O
DCoH	B-protein
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	B-protein
alpha	I-protein
dimers	I-protein
.	O
	
The	O
formation	O
of	O
a	O
stable	O
tetrameric	B-protein
DCoH-HNF-1	I-protein
alpha	I-protein
complex	I-protein
,	O
which	O
required	O
the	O
dimerization	B-protein
domain	I-protein
of	O
HNF-1	B-protein
alpha	I-protein
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	B-protein
alpha	I-protein
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O
	
However	O
,	O
DCoH	B-protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O
	
These	O
results	O
indicate	O
that	O
DCoH	B-protein
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	B-protein
complexes	I-protein
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	B-protein
.	O
	
###MEDLINE:92060325	
	
Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O
	
Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O
	
A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	O
obstruction	O
were	O
classified	O
as	O
glucocorticoid-sensitive	O
or	O
-resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	O
.	O
	
The	O
resistant	O
patients	O
showed	O
no	O
significant	O
improvements	O
in	O
airflow	O
limitation	O
.	O
	
Phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
-induced	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O
	
When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
	
No	O
differences	O
were	O
observed	O
between	O
six	O
of	O
the	O
sensitive	O
and	O
resistant	O
patients	O
in	O
the	O
clearance	O
of	O
plasma	O
prednisolone	O
derived	O
from	O
orally	O
administered	O
prednisone	O
.	O
	
Peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O
	
The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	B-protein
could	O
not	O
account	O
for	O
the	O
observed	O
difference	O
in	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
functional	O
inhibition	O
by	O
dexamethasone	O
in	O
vitro	O
.	O
	
These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
glucocorticoids	O
.	O
	
This	O
lack	O
of	O
sensitivity	O
is	O
unexplained	O
but	O
is	O
not	O
attributable	O
to	O
abnormalities	O
of	O
cellular	B-protein
glucocorticoid	I-protein
receptors	I-protein
.	O
	
###MEDLINE:92042309	
	
Inhibition	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	B-DNA
and	O
c-jun	B-DNA
(	O
AP-1	B-DNA
)	O
.	O
	
Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-DNA
and	I-DNA
c-fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O
	
The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O
	
These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	B-cell_type
phenotype	I-cell_type
,	O
including	O
inhibition	O
of	O
TPA-induced	O
increases	O
in	O
lamin	B-RNA
A	I-RNA
,	I-RNA
lamin	I-RNA
C	I-RNA
,	I-RNA
and	I-RNA
vimentin	I-RNA
transcripts	I-RNA
.	O
	
Other	O
studies	O
have	O
demonstrated	O
that	O
TPA-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-DNA
and	O
c-fos	B-DNA
genes	I-DNA
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O
	
The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA-induced	O
activation	O
of	O
PKC	B-protein
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	B-protein
.	O
	
Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	O
and	O
c-fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA-induced	O
expression	O
of	O
c-jun	B-DNA
and	O
c-fos	B-protein
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O
	
To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
.	O
	
Increases	O
in	O
CAT	B-protein
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
cells	I-cell_line
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	B-DNA
that	O
contains	O
the	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
.	O
	
This	O
induction	O
of	O
CAT	B-protein
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O
	
These	O
findings	O
suggest	O
that	O
dexamethasone	O
down-regulates	O
TPA-induced	O
transcription	O
of	O
the	O
c-jun	B-DNA
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
.	O
	
###MEDLINE:91366165	
	
Tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
mRNA	I-RNA
accumulation	O
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	B-DNA
sequence	I-DNA
motifs	I-DNA
and	O
mRNA	O
stabilization	O
.	O
	
The	O
cytokine	B-protein
TNF	B-protein
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O
	
The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-protein
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
PMA	O
stimulation	O
.	O
	
The	O
cell	B-cell_line
lines	I-cell_line
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-RNA
mRNA	I-RNA
expression	O
.	O
	
Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-RNA
mRNA	I-RNA
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O
	
This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O
	
At	O
the	O
level	O
of	O
the	O
genomic	B-DNA
TNF	I-DNA
gene	I-DNA
,	O
a	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
is	O
detected	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O
	
Although	O
absent	O
in	O
nonexpressing	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
DNase	B-DNA
I	I-DNA
site	I-DNA
is	O
present	O
in	O
uninduced	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O
	
The	O
PMA	O
induction	O
of	O
c-fos	B-RNA
mRNA	I-RNA
correlated	O
well	O
with	O
TNF	B-protein
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	B-protein
complex	I-protein
(	O
junB	B-protein
and	O
junD	B-protein
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O
	
The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	B-cell_line
ML-1	I-cell_line
cells	I-cell_line
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
,	I-DNA
AP-2	I-DNA
,	I-DNA
and	I-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
sequence	I-DNA
located	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
.	O
	
PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	B-protein
binding	I-protein
complexes	I-protein
relative	O
to	O
the	O
resting	B-cell_type
cells	I-cell_type
.	O
	
The	O
regulatory	O
mechanisms	O
of	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
TNF	I-DNA
genes	I-DNA
are	O
discussed	O
.	O
	
###MEDLINE:91319738	
	
Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	B-cell_type
by	O
1	O
,	O
25-dihydroxycholecalciferol	O
.	O
	
Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O
	
We	O
demonstrate	O
that	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10	O
,	O
000-fold	O
in	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
and	O
unfractionated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O
	
Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
intracellular	I-protein
receptor	I-protein
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O
	
These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O
	
###MEDLINE:91237114	
	
Transforming	B-protein
growth	I-protein
factor-beta	I-protein
suppresses	O
human	B-protein
B	I-protein
lymphocyte	I-protein
Ig	I-protein
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
form	I-RNA
of	O
Ig	B-RNA
mRNA	I-RNA
.	O
	
Transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
inhibits	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
secretion	O
and	O
reduces	O
B	B-cell_type
cell	I-cell_type
membrane	O
Ig	B-protein
expression	O
.	O
	
The	O
addition	O
of	O
TGF-beta	B-protein
to	O
human	B-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	B-protein
completely	O
inhibited	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	B-cell_type
cell	I-cell_type
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O
	
In	O
contrast	O
,	O
TGF-beta	B-protein
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	B-protein
cell	I-protein
membrane	I-protein
proteins	I-protein
,	O
HLA-DR	B-protein
and	O
CD20	B-protein
.	O
	
Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti-IgM	B-protein
,	O
anti-kappa	B-protein
,	O
and	O
anti-lambda	B-protein
antibodies	I-protein
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	B-protein
L	I-protein
chain	I-protein
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O
	
A	O
less	O
pronounced	O
reduction	O
in	O
lambda	B-protein
L	I-protein
chain	I-protein
and	O
microH	B-protein
chain	I-protein
was	O
also	O
noted	O
.	O
	
Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	B-cell_type
cells	I-cell_type
treated	O
with	O
TGF-beta	B-protein
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O
	
Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	O
gamma	B-RNA
to	O
their	O
respective	O
secreted	B-RNA
forms	I-RNA
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O
	
Nuclear	O
run-on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	B-protein
L	I-protein
chain	I-protein
.	O
	
The	O
effects	O
of	O
TGF-beta	B-protein
on	O
two	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
Oct-2	B-protein
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
kappa	I-protein
B	I-protein
,	O
known	O
to	O
be	O
important	O
in	O
Ig	B-protein
gene	O
transcription	O
were	O
examined	O
.	O
	
Oct-2	B-RNA
mRNA	I-RNA
levels	O
and	O
both	O
Oct-2	B-protein
and	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF-beta	B-protein
.	O
	
In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
AP-1	I-protein
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
production	O
,	O
were	O
reduced	O
by	O
TGF-beta	B-protein
.	O
	
These	O
findings	O
demonstrate	O
that	O
TGF-beta	B-protein
decreases	O
B	O
lymphocyte	O
Ig	B-protein
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	B-RNA
mRNA	I-RNA
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	I-RNA
gamma	I-RNA
mRNA	I-RNA
.	O
	
The	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
Oct-2	B-protein
to	O
their	O
respective	O
target	O
sequences	O
.	O
	
###MEDLINE:91203899	
	
Murine	B-protein
and	I-protein
human	I-protein
T-lymphocyte	I-protein
GATA-3	I-protein
factors	I-protein
mediate	O
transcription	O
through	O
a	O
cis-regulatory	B-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O
	
A	O
family	O
of	O
transcriptional	B-protein
activators	I-protein
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	B-protein
activators	I-protein
recognize	O
a	O
common	O
consensus	B-DNA
motif	I-DNA
(	O
WGATAR	B-DNA
)	O
through	O
a	O
conserved	O
C4	B-protein
zinc	I-protein
finger	I-protein
DNA-binding	I-protein
domain	I-protein
.	O
	
One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O
	
Analysis	O
of	O
human	B-protein
and	I-protein
murine	I-protein
GATA-3	I-protein
factors	I-protein
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O
	
The	O
murine	B-protein
and	I-protein
human	I-protein
factors	I-protein
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	B-DNA
GATA-binding	I-DNA
site	I-DNA
identified	O
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O
	
We	O
infer	O
that	O
the	O
murine	B-protein
and	I-protein
human	I-protein
GATA-3	I-protein
proteins	I-protein
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell-specific	O
transcriptional	O
regulation	O
.	O
	
###MEDLINE:91204058	
	
Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
the	O
HIV-1	B-protein
protease	I-protein
during	O
acute	O
infection	O
.	O
	
Transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
is	O
regulated	O
in	O
part	O
by	O
cellular	B-protein
factors	I-protein
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
This	O
factor	O
consists	O
of	O
two	O
DNA-binding	B-protein
subunits	I-protein
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	B-protein
subunits	I-protein
.	O
	
It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	B-protein
cytoplasmic	I-protein
complex	I-protein
.	O
	
External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	B-cell_type
cells	I-cell_type
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
.	O
	
The	O
cloning	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
for	O
the	O
50K	B-protein
subunit	I-protein
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	B-protein
105K	I-protein
precursor	I-protein
(	O
p105	B-protein
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O
	
The	O
expression	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B-protein
.	O
	
Because	O
HIV-1	O
requires	O
active	O
NF-kappa	B-protein
B	I-protein
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	B-protein
105K	I-protein
precursor	I-protein
.	O
	
We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	B-protein
and	O
increases	O
levels	O
of	O
active	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
.	O
	
###MEDLINE:91159628	
	
1	B-RNA
,	I-RNA
25-Dihydroxyvitamin	I-RNA
D3	I-RNA
receptor	I-RNA
RNA	I-RNA
:	O
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O
	
1	O
,	O
25-Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O
	
Little	O
is	O
known	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O
	
We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
various	O
proliferating	B-cell_type
and	I-cell_type
nonproliferating	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O
	
Constitutive	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
macrophages	O
and	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	B-cell_line
(	O
myeloblasts	B-cell_line
)	O
,	O
HL-60	B-cell_line
(	O
promyelocytes	B-cell_line
)	O
,	O
ML-3	B-cell_line
(	O
myelomonoblasts	B-cell_line
)	O
,	O
U937	B-cell_line
,	O
THP-1	B-cell_line
(	O
monoblasts	B-cell_line
)	O
,	O
K562	B-cell_line
(	O
erythroblasts	B-cell_line
)	O
,	O
and	O
S-LB1	B-cell_line
(	O
HTLV-1-transfected	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
)	O
.	O
	
Receptor	B-RNA
transcripts	I-RNA
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O
	
All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O
	
Most	O
B	B-cell_line
lymphocyte	I-cell_line
lines	I-cell_line
expressed	O
negligible	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid/myeloid	B-cell_line
somatic	I-cell_line
hybrid	I-cell_line
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
a	O
dominant	O
characteristic	O
.	O
	
HL-60	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
10	O
(	O
-7	O
)	O
mol/L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
and	O
its	O
RNA	O
were	O
examined	O
.	O
	
Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	B-protein
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O
	
Levels	O
of	O
occupied	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
protein	I-protein
increased	O
in	O
these	O
HL-60	B-cell_line
cells	I-cell_line
;	O
but	O
the	O
total	O
number	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O
	
Steady-state	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL-60	B-cell_line
toward	O
either	O
granulocytes	B-cell_type
or	O
macrophages	B-cell_type
.	O
	
Nondividing	O
macrophages	B-cell_type
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
.	O
	
In	O
contrast	O
,	O
nondividing	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
markedly	O
.	O
	
Half-life	O
(	O
t1/2	O
)	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O
	
Consistent	O
with	O
this	O
short	O
t1/2	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O
	
Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
and	O
proliferating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
###MEDLINE:91119580	
	
Expression	O
of	O
c-jun	B-DNA
,	I-DNA
jun	I-DNA
B	I-DNA
and	I-DNA
jun	I-DNA
D	I-DNA
proto-oncogenes	I-DNA
in	O
human	B-cell_type
peripheral-blood	I-cell_type
granulocytes	I-cell_type
.	O
	
We	O
have	O
found	O
that	O
purified	B-cell_type
human	I-cell_type
peripheral-blood	I-cell_type
granulocytes	I-cell_type
express	O
constitutively	O
significant	O
levels	O
of	O
proto-oncogenes	B-DNA
c-jun	B-RNA
,	I-RNA
jun	I-RNA
B	I-RNA
and	I-RNA
jun	I-RNA
D	I-RNA
mRNA	I-RNA
.	O
	
Upon	O
functional	O
activation	O
of	O
granulocytes	B-cell_type
by	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c-jun	B-RNA
,	I-RNA
jun	I-RNA
B	I-RNA
and	I-RNA
jun	I-RNA
D	I-RNA
transcripts	I-RNA
were	O
increased	O
.	O
	
The	O
three	O
jun	B-DNA
genes	I-DNA
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O
	
These	O
results	O
suggest	O
that	O
expression	O
of	O
c-jun	B-DNA
,	O
jun	B-DNA
B	I-DNA
and	O
jun	B-DNA
D	I-DNA
genes	I-DNA
might	O
be	O
involved	O
in	O
terminal	B-cell_type
granulocyte	I-cell_type
differentiation	O
or	O
in	O
regulating	O
granulocyte	B-cell_type
functionality	O
.	O
	
###MEDLINE:92107919	
	
The	O
29-kDa	B-protein
proteins	I-protein
phosphorylated	O
in	O
thrombin-activated	B-cell_line
human	I-cell_line
platelets	I-cell_line
are	O
forms	O
of	O
the	O
estrogen	B-protein
receptor-related	I-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O
	
Thrombin	B-protein
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O
	
Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	B-protein
proteins	I-protein
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O
	
We	O
have	O
characterized	O
several	O
29-kDa	B-protein
proteins	I-protein
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	B-cell_type
human	I-cell_type
platelets	I-cell_type
to	O
thrombin	B-protein
.	O
	
A	O
murine	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
to	O
an	O
unidentified	B-protein
estrogen	I-protein
receptor-related	I-protein
29-kDa	I-protein
protein	I-protein
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B-protein
27-kDa	I-protein
protein	I-protein
.	O
	
Cellular	O
activation	O
by	O
thrombin	B-protein
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	B-protein
unphosphorylated	I-protein
form	I-protein
to	O
the	O
29-kDa	B-protein
phosphoprotein	I-protein
species	I-protein
.	O
	
Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	B-DNA
clone	I-DNA
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	B-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
HSP27	B-protein
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O
	
The	O
29-kDa	B-protein
proteins	I-protein
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	B-protein
by	O
immunoprecipitation	O
studies	O
.	O
	
Thus	O
,	O
the	O
``	O
estrogen	O
receptor-related	O
protein	O
''	O
is	O
HSP27	B-protein
,	O
and	O
the	O
three	O
major	O
29-kDa	B-protein
proteins	I-protein
phosphorylated	O
in	O
thrombin-activated	B-cell_type
platelets	I-cell_type
are	O
forms	O
of	O
HSP27	B-protein
.	O
	
These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	B-protein
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	B-cell_type
activation	O
.	O
	
###MEDLINE:92052179	
	
Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF-E1	B-protein
(	O
YY-1	B-protein
,	O
delta	B-protein
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O
	
We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
(	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	B-DNA
and	I-DNA
negative-acting	I-DNA
elements	I-DNA
.	O
	
We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	B-DNA
negative-acting	I-DNA
elements	I-DNA
.	O
	
The	O
negative-acting	B-DNA
sequences	I-DNA
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O
	
We	O
have	O
isolated	O
a	O
human	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
a	O
zinc	B-protein
finger	I-protein
protein	I-protein
(	O
NF-E1	B-protein
)	O
that	O
binds	O
to	O
the	O
negative-acting	B-DNA
segment	I-DNA
of	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
.	O
	
This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O
	
NF-E1	B-protein
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	B-protein
protein	I-protein
,	O
which	O
binds	O
to	O
the	O
adeno-associated	B-DNA
virus	I-DNA
P5	I-DNA
promoter	I-DNA
.	O
	
NF-E1	B-protein
is	O
also	O
the	O
human	B-protein
homologue	I-protein
of	O
the	O
mouse	B-DNA
delta	I-DNA
protein	I-DNA
,	O
which	O
binds	O
to	O
ribosomal	B-DNA
protein	I-DNA
gene	I-DNA
promoters	I-DNA
.	O
	
The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	B-protein
activators	I-protein
as	O
well	O
as	O
transcriptional	B-protein
repressors	I-protein
.	O
	
Cotransfection	O
studies	O
with	O
this	O
cDNA	B-DNA
indicate	O
that	O
it	O
can	O
repress	O
basal	B-DNA
promoter	I-DNA
activity	O
.	O
	
The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O
	
###MEDLINE:92029620	
	
A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
containing	O
a	O
CpG-rich	B-DNA
island	I-DNA
encodes	O
a	O
small	B-protein
basic	I-protein
protein	I-protein
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O
	
Genes	O
actively	O
involved	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
(	O
G0S	B-RNA
genes	I-RNA
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	B-protein
-induced	O
switch	O
of	O
lymphocytes	B-cell_type
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O
	
This	O
paper	O
presents	O
studies	O
of	O
G0S2	B-DNA
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	B-RNA
genes	I-RNA
,	O
for	O
which	O
cDNAs	B-DNA
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O
	
G0S2	B-RNA
mRNA	I-RNA
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B-protein
or	O
cycloheximide	O
to	O
cultured	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
	
Comparison	O
of	O
a	O
nearly	B-DNA
full-length	I-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	B-DNA
sequence	I-DNA
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
in	O
the	O
second	O
exon	B-DNA
.	O
	
The	O
derived	O
103-amino-acid	B-protein
basic	I-protein
protein	I-protein
has	O
two	O
potential	O
alpha-helical	B-protein
domains	I-protein
separated	O
by	O
a	O
hydrophobic	B-protein
region	I-protein
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O
	
Consistent	O
with	O
involvement	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
casein	B-protein
kinase	I-protein
II	I-protein
.	O
	
The	O
gene	O
contains	O
a	O
CpG-rich	B-protein
island	I-protein
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O
	
An	O
upstream	B-DNA
segment	I-DNA
contains	O
tandem	B-DNA
dinucleotide	I-DNA
repeats	I-DNA
(	B-DNA
CT	I-DNA
)	I-DNA
19/	I-DNA
(	I-DNA
CA	I-DNA
)	I-DNA
16	I-DNA
.	O
	
There	O
is	O
a	O
suitably	O
located	O
TATA	B-DNA
box	I-DNA
,	O
but	O
potential	O
sites	O
for	O
CCAAT-box	B-protein
binding	I-protein
factors	I-protein
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	B-DNA
repeat	I-DNA
element	I-DNA
.	O
	
Potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
AP1	B-protein
,	O
AP2	B-protein
,	O
and	O
AP3	B-protein
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O
	
###MEDLINE:91367666	
	
USF-related	B-protein
transcription	I-protein
factor	I-protein
,	O
HIV-TF1	B-protein
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O
	
The	O
transcription	B-protein
factor	I-protein
HIV-TF1	B-protein
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
HIV-TF1	B-protein
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O
	
Binding	O
of	O
HIV-TF1	B-protein
to	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
activated	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O
	
The	O
HIV-TF1-binding	B-DNA
site	I-DNA
in	O
HIV	B-DNA
LTR	I-DNA
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
(	O
USF	B-protein
)	O
in	O
the	O
adenovirus	B-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
.	O
	
DNA-binding	O
properties	O
of	O
HIV-TF1	B-protein
suggested	O
that	O
HIV-TF1	B-protein
might	O
be	O
identical	O
or	O
related	O
to	O
USF	B-protein
.	O
	
Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	B-protein
by	O
phosphatase	B-protein
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV-TF1	B-protein
was	O
essential	O
for	O
DNA	O
binding	O
.	O
	
The	O
disruption	O
of	O
HIV-TF1-binding	B-DNA
site	I-DNA
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vivo	O
.	O
	
These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O
	
###MEDLINE:91292396	
	
Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
deficiency	O
.	O
	
A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O
	
This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	O
catabolism	O
and	O
its	O
association	O
with	O
drug-induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	O
(	O
FUra	O
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	O
carcinoma	O
.	O
	
The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O
	
The	O
activity	O
of	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
(	O
DPD	B-protein
)	O
,	O
the	O
initial	O
enzyme	B-protein
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O
	
The	O
proband	O
had	O
no	O
detectable	O
DPD	B-protein
activity	O
.	O
	
When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O
	
This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O
	
Monitoring	O
DPD	B-protein
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O
	
###MEDLINE:91237803	
	
Transactivation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
identification	O
of	O
transactivating	B-DNA
HHV-6	I-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
gene	I-DNA
fragments	I-DNA
.	O
	
Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
promoter	I-DNA
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O
	
Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
.	O
	
The	O
GS	O
strain	O
transactivated	O
the	O
promoter	B-DNA
in	O
both	O
stimulated	O
and	O
resting	O
T	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	B-DNA
promoter	I-DNA
activity	O
only	O
in	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
Three	O
DNA	O
clones	O
containing	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
genomic	I-DNA
fragments	I-DNA
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
cotransfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
A	O
21.4-kb	B-DNA
DNA	I-DNA
clone	I-DNA
,	O
pZVB70	B-DNA
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	B-DNA
fragments	I-DNA
,	O
pZVB10	B-DNA
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	B-DNA
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O
	
One	O
of	O
these	O
clones	O
,	O
pZVH14	B-DNA
,	O
activated	O
the	O
HIV	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
a	O
mutation	O
in	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O
	
However	O
,	O
this	O
mutated	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
promoter	I-DNA
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	B-DNA
or	O
pZVB10	B-DNA
.	O
	
These	O
data	O
indicate	O
that	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
of	O
the	O
HIV	B-DNA
promoter	I-DNA
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O
	
By	O
increasing	O
HIV	B-DNA
promoter	I-DNA
activity	O
in	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:91321794	
	
Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O
	
HIV-1	B-DNA
proviral	I-DNA
DNA	I-DNA
contains	O
two	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O
	
HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O
	
We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O
	
The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N-acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O
	
Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
binding	B-DNA
sites	I-DNA
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O
	
This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV-1-infected	O
individuals	O
may	O
cause	O
an	O
over-expression	O
of	O
NF-kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
and	O
enhance	O
HIV-1	O
replication	O
.	O
	
NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1-infected	O
individuals	O
.	O
	
###MEDLINE:91184620	
	
A	O
thymus-specific	B-protein
member	I-protein
of	O
the	O
HMG	B-protein
protein	I-protein
family	I-protein
regulates	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
enhancer	I-DNA
.	O
	
The	O
human	B-protein
T	I-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
TCF-1	B-protein
alpha	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine-rich	B-DNA
elements	I-DNA
(	O
5'-PyCTTTG-3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	B-DNA
cell-specific	I-DNA
control	I-DNA
regions	I-DNA
.	O
	
Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	B-protein
affinity-purified	I-protein
protein	I-protein
,	O
we	O
have	O
now	O
isolated	O
cDNA	B-DNA
clones	I-DNA
encoding	O
TCF-1	B-protein
alpha	I-protein
.	O
	
The	O
TCF-1	B-DNA
alpha	I-DNA
cDNA	I-DNA
contains	O
a	O
single	O
68-amino-acid	B-protein
domain	I-protein
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	B-protein
group	I-protein
(	O
HMG	B-protein
)	O
and	O
nonhistone	B-protein
chromosomal	I-protein
proteins	I-protein
.	O
	
Expression	O
of	O
full-length	B-DNA
and	O
mutant	B-DNA
cDNA	I-DNA
clones	I-DNA
in	O
bacteria	O
reveal	O
that	O
the	O
single	B-protein
HMG	I-protein
motif	I-protein
,	O
which	O
is	O
predicted	O
to	O
contain	O
two	O
extended	O
alpha-helical	B-protein
segments	I-protein
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence-specific	O
binding	O
of	O
TCF-1	B-protein
alpha	I-protein
to	O
DNA	O
.	O
	
Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	I-RNA
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	B-cell_line
or	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
immature	B-cell_line
CEM	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	I-RNA
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O
	
Interestingly	O
,	O
the	O
cloned	O
TCF-1	B-protein
alpha	I-protein
protein	I-protein
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
human	B-DNA
TCR	I-DNA
alpha	I-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	B-protein
protein	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	B-cell_line
cell-specific	I-cell_line
protein	I-cell_line
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O
	
TCF-1	B-protein
alpha	I-protein
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	B-protein
regulatory	I-protein
proteins	I-protein
that	O
share	O
the	O
HMG	B-protein
motif	I-protein
in	O
that	O
it	O
is	O
a	O
highly	B-protein
tissue-specific	I-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
transcription	B-protein
factor	I-protein
.	O
	
###MEDLINE:91134976	
	
A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
.	O
	
Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	B-DNA
LTR	I-DNA
.	O
	
Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O
	
These	O
changes	O
in	O
the	O
enhancer	B-DNA
element	I-DNA
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O
	
Subcloning	O
of	O
the	O
variant	B-DNA
NF-kappa	I-DNA
B	I-DNA
segments	I-DNA
into	O
LTR-driven	B-DNA
CAT	I-DNA
expression	I-DNA
vectors	I-DNA
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative/cytopathic	O
capacity	O
.	O
	
###MEDLINE:91187647	
	
Multiple	O
Oct2	B-protein
isoforms	I-protein
are	O
generated	O
by	O
alternative	O
splicing	O
.	O
	
The	O
interaction	O
of	O
the	O
Oct2	B-protein
transcription	I-protein
factor	I-protein
with	O
the	O
cognate	B-DNA
octamer	I-DNA
motif	I-DNA
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
	
Ectopic	O
expression	O
of	O
cloned	B-DNA
Oct2	I-DNA
cDNA	I-DNA
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	B-cell_type
cells	I-cell_type
.	O
	
We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	B-DNA
cDNAs	I-DNA
encoding	O
mouse	B-protein
Oct2	I-protein
from	O
a	O
mature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	B-protein
factor	I-protein
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O
	
All	O
the	O
isoforms	B-protein
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	B-DNA
motif	I-DNA
.	O
	
Different	O
amounts	O
of	O
the	O
various	O
isoforms	B-protein
are	O
present	O
within	O
the	O
same	O
B-cell	B-cell_type
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	B-protein
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O
	
In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B-protein
are	O
able	O
to	O
activate	O
an	O
octamer	B-DNA
containing	O
promoter	B-DNA
element	I-DNA
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O
	
Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	B-protein
encodes	O
the	O
previously	O
described	O
lymphoid-specific	B-protein
Oct2B	I-protein
protein	I-protein
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
.	O
	
###MEDLINE:92223210	
	
[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O
	
The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	B-cell_type
lymphocytes	I-cell_type
and	O
skin	B-cell_type
fibroblasts	I-cell_type
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O
	
The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O
	
In	O
fibroblasts	B-cell_type
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
did	O
not	O
exceed	O
10	O
%	O
of	O
their	O
content	O
in	O
normal	B-cell_type
cells	I-cell_type
.	O
	
The	O
decrease	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
seems	O
to	O
be	O
a	O
compensatory	O
response	O
of	O
cells	O
culminating	O
in	O
activation	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O
	
###MEDLINE:92052106	
	
Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	B-protein
plus	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
dimer	I-protein
.	O
	
Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O
	
These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O
	
In	O
THP-1	B-cell_line
cells	I-cell_line
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	B-protein
binding	I-protein
complex	I-protein
formation	O
with	O
the	O
HIV-1	B-DNA
promoter-enhancer	I-DNA
associated	O
with	O
markedly	O
less	O
viral	B-RNA
RNA	I-RNA
production	O
.	O
	
This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
region	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
;	O
the	O
65-kDa	B-protein
plus	I-protein
50-kDa	I-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
was	O
preferentially	O
lost	O
.	O
	
Adding	O
purified	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O
	
In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	B-protein
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O
	
Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O
	
Antiserum	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
,	O
but	O
not	O
c-rel-specific	O
antiserum	O
,	O
disrupted	O
heterodimer	B-protein
complex	I-protein
formation	O
.	O
	
Thus	O
,	O
both	O
NF-kappa	B-protein
B-binding	I-protein
complexes	I-protein
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O
	
Binding	O
of	O
the	O
65-kDa	B-protein
plus	O
50-kDa	B-protein
heterodimer	I-protein
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	B-cell_type
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:92006162	
	
Glucocorticoid	B-protein
receptors	I-protein
in	O
normal	B-cell_type
leukocytes	I-cell_type
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O
	
We	O
measured	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O
	
An	O
age-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B-protein
.	O
	
Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	B-protein
.	O
	
Eight	O
patients	O
with	O
dermatomyositis/polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
could	O
be	O
down-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O
	
The	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O
	
However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B-protein
in	O
MNL	B-cell_type
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O
	
###MEDLINE:92031293	
	
Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
during	O
activation	O
by	O
the	O
trans-activator	B-protein
of	O
HTLV-I	O
.	O
	
We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	B-DNA
elements	I-DNA
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
using	O
the	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
Jurkat	B-cell_line
and	O
MOLT	B-cell_line
4	I-cell_line
,	O
which	O
are	O
negative	O
for	O
HTLV-I	O
,	O
and	O
MT-2	O
and	O
TL-Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV-I	O
.	O
	
Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
.	O
	
One	O
is	O
the	O
21-base-pair	B-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
core	I-DNA
element	I-DNA
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	O
trans-activator	B-protein
p40tax	B-protein
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	B-protein
responsive	I-protein
element	I-protein
binding	I-protein
factor	I-protein
(	I-protein
CREB	I-protein
)	I-protein
-like	I-protein
factor	I-protein
(	O
s	O
)	O
.	O
	
The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	B-DNA
elements	I-DNA
.	O
	
In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	B-DNA
elements	I-DNA
is	O
involved	O
in	O
trans-activation	O
by	O
p40tax	B-protein
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF-kappa	B-protein
B-like	I-protein
nuclear	I-protein
factor	I-protein
or	O
factors	O
.	O
	
Formation	O
of	O
the	O
protein-DNA	B-protein
complex	I-protein
with	O
the	O
C26	B-protein
subfragment	I-protein
was	O
positively	O
affected	O
by	O
p40tax	B-protein
.	O
	
The	O
C26	B-DNA
element	I-DNA
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B-protein
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	B-DNA
element	I-DNA
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B-protein
.	O
	
However	O
,	O
the	O
C26	B-DNA
element	I-DNA
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B-protein
,	O
unlike	O
other	O
NF-kappa	B-DNA
B-binding	I-DNA
elements	I-DNA
.	O
	
In	O
contrast	O
,	O
the	O
C26	B-DNA
element	I-DNA
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O
	
These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
contains	O
multiple	B-DNA
functional	I-DNA
elements	I-DNA
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B-protein
and	I-protein
NF-kappa	I-protein
B-like	I-protein
factors	I-protein
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
in	O
response	O
to	O
p40tax	B-protein
.	O
	
Our	O
results	O
also	O
demonstrate	O
that	O
TPA-dependent	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
may	O
be	O
mediated	O
through	O
the	O
C26	B-DNA
element	I-DNA
.	O
	
###MEDLINE:91277630	
	
Human	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
minimal	O
region	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
lines	I-cell_line
has	O
been	O
localized	O
between	O
-52	B-DNA
and	I-DNA
+89	I-DNA
nucleotides	I-DNA
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O
	
Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O
	
Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF-kappa	B-protein
B	I-protein
binding	O
activities	O
displayed	O
by	O
different	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Moreover	O
,	O
kappa	B-DNA
1-kappa	I-DNA
3	I-DNA
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	O
.	O
	
Therefore	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	O
not	O
primarily	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	B-protein
factors	I-protein
.	O
	
Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
in	O
a	O
B	B-cell_line
(	I-cell_line
Raji	I-cell_line
)	I-cell_line
,	I-cell_line
but	I-cell_line
not	I-cell_line
a	I-cell_line
T	I-cell_line
(	I-cell_line
HUT78	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF-alpha	B-DNA
promoter	I-DNA
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
.	O
	
###MEDLINE:91237800	
	
Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
protein	I-protein
in	O
oral	O
hairy	O
leukoplakia	O
.	O
	
The	O
BZLF1	B-protein
protein	I-protein
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	B-protein
protein	I-protein
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O
	
Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	B-protein
monoclonal	B-protein
antibody	I-protein
.	O
	
A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	B-protein
expression	O
was	O
observed	O
,	O
BZ1	B-protein
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O
	
This	O
finding	O
suggests	O
that	O
the	O
BZLF1	B-DNA
promoter	I-DNA
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O
	
A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	B-DNA
DNA	I-DNA
and	O
viral	B-protein
capsid	I-protein
antigen	I-protein
staining	O
with	O
BZ1	B-protein
reactivity	O
suggested	O
that	O
BZLF1	B-protein
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O
	
The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	O
hairy	O
leukoplakia	O
raises	O
questions	O
concerning	O
the	O
nature	O
of	O
EBV	O
latency	O
and	O
persistence	O
in	O
stratified	O
squamous	O
epithelium	O
.	O
	
###MEDLINE:91347784	
	
[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O
	
The	O
number	O
of	O
estrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O
	
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	O
diabetes	O
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O
	
It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-protein
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O
	
Our	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-protein
level	O
in	O
leukocytes	B-cell_type
may	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
type	O
II	O
diabetes	O
in	O
menopausal	O
period	O
.	O
	
###MEDLINE:91174087	
	
Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O
	
OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O
	
METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O
	
RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning-to-afternoon	O
decline	O
in	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O
	
The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O
	
No	O
group	O
differences	O
in	O
cortisol	O
levels	O
were	O
observed	O
,	O
nor	O
were	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
cortisol	O
levels	O
correlated	O
.	O
	
The	O
number	O
of	O
morning	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O
	
The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O
	
Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O
	
The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O
	
###MEDLINE:91376384	
	
Induction	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O
	
Cells	O
of	O
the	O
monocyte-macrophage	B-cell_type
lineage	I-cell_type
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O
	
We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O
	
In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O
	
Also	O
,	O
in	O
a	O
promonocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	B-protein
B	I-protein
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B-protein
alpha	I-protein
.	O
	
Thus	O
,	O
stimulation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
phorbol	O
esters	O
or	O
TNF	B-protein
alpha	I-protein
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O
	
Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	B-cell_type
.	O
	
###MEDLINE:91236793	
	
Demonstration	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
as	O
well	O
as	O
Ki-67	B-protein
and	I-protein
p-145	I-protein
antigens	I-protein
in	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O
	
We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	B-protein
localized	O
in	O
the	O
nucleus	O
from	O
isolated	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
from	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
derived	O
from	O
malignant	O
effusions	O
.	O
	
With	O
the	O
antibodies	O
Ki-67	B-protein
and	O
anti-p-145	B-protein
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O
	
An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	B-cell_type
cells	I-cell_type
from	O
malignant	O
effusions	O
were	O
tested	O
.	O
	
Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	O
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	B-cell_type
mesothelial	I-cell_type
cells	I-cell_type
from	O
non-tumorous	O
cavity	O
fluids	O
.	O
	
The	O
detection	O
of	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
(	O
ER	B-protein
and	O
PR	B-protein
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O
	
The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	B-cell_type
cells	I-cell_type
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O
	
Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O
	
ER	B-protein
was	O
positive	O
in	O
13	O
and	O
PR	B-protein
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O
	
In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	B-protein
and	O
PR	B-protein
antibody	O
.	O
	
The	O
hormone	B-protein
receptors	I-protein
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	B-protein
)	O
and	O
14	O
(	O
PR	B-protein
)	O
patients	O
,	O
respectively	O
.	O
	
In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	B-cell_type
cells	I-cell_type
from	O
the	O
pleural	O
effusions	O
.	O
	
These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	B-protein
receptor	I-protein
proteins	I-protein
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O
	
###MEDLINE:92068245	
	
Constitutive	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O
	
NF-kB	B-protein
is	O
a	O
eukaryotic	B-protein
transcription	I-protein
regulatory	I-protein
factor	I-protein
.	O
	
In	O
T	B-cell_type
cells	I-cell_type
and	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
NF-kB	B-protein
is	O
bound	O
to	O
a	O
cytoplasmic	B-protein
proteic	I-protein
inhibitor	I-protein
,	O
the	O
IkB	B-protein
.	O
	
Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	B-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
induces	O
NF-kB	B-protein
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF-kB	B-DNA
dependent	I-DNA
T	I-DNA
cell	I-DNA
genes	I-DNA
.	O
	
Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
thymic	I-cell_type
progenitors	I-cell_type
.	O
	
We	O
report	O
differences	O
in	O
(	O
Ca2+	O
)	O
i	O
requirement	O
for	O
NF-kB	B-protein
activation	O
in	O
thymocytes	B-cell_type
as	O
compared	O
to	O
mature	O
T	B-cell_type
cells	I-cell_type
.	O
	
Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	B-cell_type
have	O
a	O
constitutively	B-protein
active	I-protein
form	I-protein
of	O
NF-kB	B-protein
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O
	
###MEDLINE:92103005	
	
TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
of	O
the	O
HMG	B-protein
box	I-protein
family	I-protein
,	O
interacts	O
with	O
sequence	B-DNA
motifs	I-DNA
in	O
the	O
TCR	B-DNA
beta	I-DNA
and	I-DNA
TCR	I-DNA
delta	I-DNA
enhancers	I-DNA
.	O
	
We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	B-DNA
motif	I-DNA
in	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O
	
TCF-1	B-protein
belongs	O
to	O
the	O
family	O
of	O
transcription-regulating	B-protein
proteins	I-protein
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	B-protein
.	O
	
Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	B-protein
specifically	O
recognizes	O
the	O
T	B-DNA
beta	I-DNA
5	I-DNA
element	I-DNA
of	O
the	O
TCR	B-DNA
beta	I-DNA
enhancer	I-DNA
and	O
the	O
T	B-DNA
delta	I-DNA
7	I-DNA
element	I-DNA
of	O
the	O
TCR	B-DNA
delta	I-DNA
enhancer	I-DNA
.	O
	
Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	B-DNA
recognized	O
by	O
TCF-1	B-protein
defines	O
a	O
consensus	B-DNA
motif	I-DNA
A/T	B-DNA
A/T	I-DNA
C	I-DNA
A	I-DNA
A/G	I-DNA
A	I-DNA
G	I-DNA
.	O
	
These	O
observations	O
imply	O
that	O
TCF-1	B-protein
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O
	
###MEDLINE:92179751	
	
[	O
Regulatory	O
effect	O
of	O
insulin	B-protein
on	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
]	O
	
The	O
regulatory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
was	O
assessed	O
by	O
the	O
unoccupied	B-protein
receptor	I-protein
sites	I-protein
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B-protein
added	O
to	O
the	O
medium	O
.	O
	
After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
+/-	O
10.0	O
,	O
32.2	O
+/-	O
13.2	O
and	O
54.3	O
+/-	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B-protein
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU/L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU/L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU/L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B-protein
in	O
the	O
incubation	O
medium	O
.	O
	
After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
+/-	O
19.0	O
,	O
56.1	O
+/-	O
20.7	O
and	O
80.2	O
+/-	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O
	
Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
GR	B-protein
binding	O
power	O
is	O
both	O
dose-	O
and	O
time-dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	B-protein
is	O
tonically	O
controlled	O
by	O
insulin	B-protein
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O
	
###MEDLINE:91369589	
	
The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
levels	O
in	O
breast	O
cancer	O
.	O
	
Estrogens	O
and	O
anti-estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
-secreting	I-cell_type
cells	I-cell_type
in	O
pokeweed	B-cell_line
mitogen	I-cell_line
(	I-cell_line
PWM	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
.	O
	
Lymphocytes	B-cell_type
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig-secreting	B-cell_type
cells	I-cell_type
after	O
PWM	B-protein
stimulation	O
.	O
	
In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
(	O
IgA	B-protein
,	O
IgM	B-protein
,	O
IgG	B-protein
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O
	
Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O
	
An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O
	
This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	O
.	O
	
###MEDLINE:91266919	
	
Human	B-protein
erythroid	I-protein
5-aminolevulinate	I-protein
synthase	I-protein
:	O
promoter	B-DNA
analysis	O
and	O
identification	O
of	O
an	O
iron-responsive	B-DNA
element	I-DNA
in	O
the	O
mRNA	B-RNA
.	O
	
5-Aminolevulinate	B-protein
synthase	I-protein
(	O
ALAS	B-protein
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O
	
cDNA	B-DNA
clones	I-DNA
for	O
the	O
human	B-protein
erythroid	I-protein
ALAS	I-protein
isozyme	I-protein
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O
	
It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B-protein
ALAS	I-protein
precursor	I-protein
protein	I-protein
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B-protein
housekeeping	I-protein
ALAS	I-protein
precursor	I-protein
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O
	
The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	I-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O
	
The	O
two	O
isozymes	B-protein
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	B-protein
signal	I-protein
sequences	I-protein
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	B-protein
two-thirds	I-protein
of	O
their	O
proteins	O
.	O
	
An	O
analysis	O
of	O
the	O
immediate	B-DNA
promoter	I-DNA
of	O
the	O
human	B-DNA
erythroid	I-DNA
ALAS	I-DNA
gene	I-DNA
revealed	O
several	O
putative	O
erythroid-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
including	O
both	O
a	O
GATA-1	B-DNA
and	O
an	O
NF-E2	B-DNA
binding	I-DNA
site	I-DNA
.	O
	
An	O
iron-responsive	B-RNA
element	I-RNA
(	I-RNA
IRE	I-RNA
)	I-RNA
motif	I-RNA
has	O
been	O
identified	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	B-RNA
erythroid	I-RNA
ALAS	I-RNA
mRNA	I-RNA
,	O
but	O
is	O
not	O
present	O
in	O
the	O
housekeeping	B-RNA
ALAS	I-RNA
mRNA	I-RNA
.	O
	
Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	B-RNA
motif	I-RNA
formed	O
a	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	I-protein
with	O
cytosolic	O
extracts	O
from	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	B-RNA
transcripts	I-RNA
from	O
ferritin	B-RNA
or	I-RNA
transferrin	I-RNA
receptor	I-RNA
mRNAs	I-RNA
.	O
	
A	O
transcript	O
of	O
the	O
ALAS	B-DNA
IRE	I-DNA
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	B-DNA
,	O
did	O
not	O
readily	O
form	O
this	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	I-protein
.	O
	
These	O
results	O
suggest	O
that	O
the	O
IRE	B-RNA
motif	I-RNA
in	O
the	O
ALAS	B-RNA
mRNA	I-RNA
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	B-RNA
is	O
controlled	O
by	O
cellular	O
iron	O
availability	O
during	O
erythropoiesis	O
.	O
	
###MEDLINE:91291720	
	
Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O
	
The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O
	
However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O
	
The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	B-protein
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O
	
Low	O
levels	O
of	O
c-jun	B-protein
transcripts	I-protein
were	O
detectable	O
in	O
resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
	
Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units/ml	O
human	B-protein
recombinant	I-protein
M-CSF	I-protein
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
.	O
	
Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	B-protein
regulates	O
c-jun	B-DNA
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	B-RNA
transcripts	I-RNA
.	O
	
M-CSF	B-protein
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun-B	B-DNA
gene	I-DNA
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c-jun	B-DNA
.	O
	
We	O
further	O
demonstrate	O
that	O
M-CSF	B-protein
increases	O
c-fos	B-RNA
mRNA	I-RNA
levels	O
in	O
human	B-cell_type
monocytes	I-cell_type
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
	
Maximal	O
induction	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	B-DNA
gene	I-DNA
.	O
	
Moreover	O
,	O
M-CSF	B-protein
-induced	O
expression	O
of	O
the	O
fos-related	B-DNA
gene	I-DNA
,	O
fra-1	B-DNA
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	B-DNA
and	O
fos-B	B-DNA
.	O
	
Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M-CSF	B-protein
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun/fos	B-DNA
family	I-DNA
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O
	
###MEDLINE:91325181	
	
Glucocorticoid	B-protein
receptors	I-protein
in	O
systemic	O
lupus	O
erythematosus	O
.	O
	
Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O
	
Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-protein
receptors	I-protein
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O
	
We	O
studied	O
glucocorticosteroid	B-protein
receptor	I-protein
density	O
and	O
affinity	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	O
glucocorticosteroid	O
for	O
the	O
previous	O
6	O
months	O
and	O
in	O
32	O
healthy	O
controls	O
.	O
	
Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O
	
Glucocorticosteroid	B-protein
receptors	I-protein
on	O
leukocytes	B-cell_type
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
+/-	O
306	O
vs	O
3369	O
+/-	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O
	
The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O
	
There	O
was	O
no	O
correlation	O
between	O
glucocorticosteroid	B-protein
receptor	I-protein
number	O
and	O
SLE	O
disease	O
activity	O
.	O
	
###MEDLINE:91170801	
	
Kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	B-cell_line
autocrine	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
The	O
IL-2	B-DNA
and	I-DNA
the	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
are	O
both	O
expressed	O
transiently	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O
	
In	O
contrast	O
,	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
IARC	B-cell_line
301	I-cell_line
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
and	O
high	B-protein
affinity	I-protein
IL-2R	I-protein
.	O
	
To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
in	O
these	O
IARC	B-cell_line
301	I-cell_line
T	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	B-protein
expressed	I-protein
nuclear	I-protein
proteins	I-protein
with	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
regions	I-DNA
of	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
using	O
both	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O
	
We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	B-DNA
alpha	I-DNA
and	O
-203	O
to	O
-183	O
for	O
IL-2	B-DNA
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
element	I-DNA
,	I-DNA
is	O
specifically	O
protected	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IARC	B-cell_line
301	I-cell_line
.	O
	
In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
promoters	I-DNA
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	B-cell_line
301	I-cell_line
cells	I-cell_line
.	O
	
In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	B-protein
B	I-protein
enhancer	I-protein
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	B-DNA
.	O
	
Two	O
proteins	O
binding	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
,	O
NF-kappa	B-protein
B	I-protein
and	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	B-cell_line
301	I-cell_line
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	B-protein
in	O
Jurkat	B-cell_line
.	O
	
They	O
bind	O
to	O
the	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	B-DNA
.	O
	
###MEDLINE:91376383	
	
HIV1	O
infection	O
of	O
human	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB-related	B-protein
factors	I-protein
.	O
	
In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	B-protein
,	O
B2	B-protein
and	O
B3	B-protein
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	B-DNA
target	I-DNA
sequence	I-DNA
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O
	
The	O
B2	B-protein
factor	I-protein
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O
	
The	O
B3	B-protein
factor	I-protein
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	B-cell_type
cells	I-cell_type
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	B-cell_type
monocytes	I-cell_type
.	O
	
Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	B-cell_type
macrophages	I-cell_type
.	O
	
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	B-protein
factor	I-protein
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
as	O
a	O
DNA-binding	B-protein
protein	I-protein
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O
	
This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O
	
The	O
B3	B-protein
factor	I-protein
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O
	
The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O
	
###MEDLINE:91114695	
	
Identification	O
and	O
cloning	O
of	O
TCF-1	B-protein
,	O
a	O
T	B-protein
lymphocyte-specific	I-protein
transcription	I-protein
factor	I-protein
containing	O
a	O
sequence-specific	B-protein
HMG	I-protein
box	I-protein
.	O
	
CD3	B-protein
-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	B-DNA
T	I-DNA
lymphocyte-specific	I-DNA
enhancer	I-DNA
element	I-DNA
.	O
	
We	O
report	O
the	O
identification	O
of	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
binding	O
to	O
this	O
element	O
.	O
	
The	O
multimerized	B-protein
recognition	I-protein
motif	I-protein
of	O
TCF-1	B-protein
constituted	O
a	O
T	O
cell-specific	O
enhancer	O
.	O
	
Subsequent	O
cloning	O
of	O
TCF-1	B-protein
identified	O
three	O
splice	B-protein
alternatives	I-protein
.	O
	
TCF-1	B-protein
contained	O
a	O
single	O
DNA-binding	B-protein
HMG	I-protein
box	I-protein
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	B-DNA
mammalian	I-DNA
sex-determining	I-DNA
gene	I-DNA
SRY	B-DNA
and	O
in	O
the	O
Schizosaccharomyces	B-DNA
pombe	I-DNA
Mc	I-DNA
mating	I-DNA
type	I-DNA
gene	I-DNA
.	O
	
TCF-1	B-RNA
mRNA	I-RNA
was	O
expressed	O
uniquely	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Upon	O
cotransfection	O
into	O
non-T	B-cell_type
cells	I-cell_type
,	O
TCF-1	B-protein
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O
	
These	O
results	O
identify	O
TCF-1	B-protein
as	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O
	
###MEDLINE:92066454	
	
Identification	O
of	O
transcriptional	B-protein
suppressor	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
	
Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus-infected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	B-DNA
dyad	I-DNA
symmetrical	I-DNA
sequence	I-DNA
.	O
	
This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
retinoblastoma	I-DNA
gene	I-DNA
.	O
	
Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus-uninfected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O
	
The	O
other	O
factor	O
bound	O
to	O
a	O
putative	B-DNA
AP-1	I-DNA
recognition	I-DNA
sequence	I-DNA
predicted	O
for	O
the	O
HIV-1	O
NRE	B-DNA
.	O
	
However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP-1	B-DNA
site	I-DNA
.	O
	
The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
site	I-DNA
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	B-DNA
promoter	I-DNA
reduced	O
the	O
promoter	O
activity	O
to	O
one-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O
	
Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	B-protein
negative	I-protein
regulator	I-protein
of	O
transcription	O
.	O
	
###MEDLINE:92265660	
	
Protein	B-protein
kinase	I-protein
C	I-protein
activation	O
and	O
protooncogene	B-DNA
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O
	
Human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
differentiate	O
along	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
following	O
3-day	O
exposures	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
	
This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression/repression	O
of	O
differentiation-associated	B-DNA
genes	I-DNA
.	O
	
Long	O
term	O
culture	O
of	O
TPA-differentiated	B-cell_type
U-937	I-cell_type
cells	I-cell_type
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O
	
The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O
	
Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	B-protein
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	B-cell_type
cells	I-cell_type
.	O
	
Treatment	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O
	
Increased	O
levels	O
of	O
membrane-associated	O
PKC	B-protein
activity	O
persisted	O
until	O
17-29	O
days	O
.	O
	
However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	B-protein
in	O
control	O
cells	O
.	O
	
Activation	O
of	O
PKC	B-protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c-fos	B-DNA
and	O
c-jun	B-DNA
gene	I-DNA
expression	I-DNA
.	O
	
Levels	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
transcripts	I-RNA
remained	O
elevated	O
during	O
periods	O
of	O
PKC	B-protein
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30-36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O
	
Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	B-protein
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:92118719	
	
Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O
	
Kappa	B-protein
B	I-protein
(	I-protein
kappa	I-protein
B	I-protein
)	I-protein
enhancer	I-protein
binding	I-protein
proteins	I-protein
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
produce	O
two	O
distinct	O
nucleoprotein	B-protein
complexes	I-protein
when	O
incubated	O
with	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor-alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
.	O
	
These	O
two	O
DNA-protein	B-protein
complexes	I-protein
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
p85	B-protein
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O
	
Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
p55/p75	B-protein
early	I-protein
and	O
p50/p85	B-protein
late	I-protein
)	O
.	O
	
DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	B-protein
complex	I-protein
contains	O
both	O
p50	B-protein
and	O
p55	B-protein
while	O
the	O
more	O
slowly	O
migrating	O
B1	B-protein
complex	I-protein
is	O
composed	O
of	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
and	O
p85	B-protein
.	O
	
Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	B-DNA
IL-2R	I-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	B-protein
(	O
B2	B-protein
complex	I-protein
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	B-DNA
'	I-DNA
triplet	I-DNA
of	O
deoxyguanosine	O
residues	O
.	O
	
In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	B-protein
complex	I-protein
,	O
reflecting	O
the	O
binding	O
of	O
p75	B-protein
and	O
p85	B-protein
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	B-DNA
element	I-DNA
.	O
	
DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel-related	B-protein
factors	I-protein
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
.	O
	
Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O
	
In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B-protein
oxidase	I-protein
selectively	O
inhibits	O
p75	B-protein
and	O
p85	B-protein
binding	O
while	O
not	O
blocking	O
p50	B-protein
and	O
p55	B-protein
interactions	O
.	O
	
These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel-related	B-protein
transcription	I-protein
factors	I-protein
.	O
	
###MEDLINE:92127655	
	
[	O
Changes	O
in	O
leucocytic	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O
	
The	O
numbers	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O
	
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child-bearing-age	O
women	O
.	O
	
It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	B-protein
ER	I-protein
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child-bearing-age	O
women	O
.	O
	
The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O
	
The	O
numbers	O
of	O
leucocytic	B-protein
ER	I-protein
were	O
significantly	O
increased	O
after	O
treatment	O
.	O
	
The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-protein
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O
	
LDP	O
not	O
only	O
increases	O
plasma	O
estradiol	O
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	O
ER	B-protein
levels	O
.	O
	
This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O
	
###MEDLINE:92049367	
	
Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
human	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O
	
We	O
have	O
used	O
a	O
DNA-binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
hGR	B-protein
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O
	
In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
indistinguishable	O
from	O
native	B-protein
hGR	I-protein
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	B-protein
antibodies	I-protein
generated	O
against	O
hGR	B-protein
.	O
	
In	O
addition	O
,	O
cell-free	B-protein
synthesized	I-protein
hGR	I-protein
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
GRE	I-DNA
)	I-DNA
-containing	I-DNA
DNA	I-DNA
fragments	I-DNA
.	O
	
Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	B-protein
receptors	I-protein
.	O
	
In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O
	
Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA-binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O
	
In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat-activated	O
unliganded	B-protein
receptors	I-protein
.	O
	
Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O
	
DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
GR	I-protein
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O
	
Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA-	O
receptor	B-protein
complex	I-protein
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O
	
The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	B-protein
synthesized	I-protein
hGR	I-protein
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	B-DNA
DNAs	I-DNA
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	B-DNA
found	O
in	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
Oligonucleotides	O
containing	O
the	O
consensus	B-DNA
GRE	I-DNA
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	B-DNA
sequences	I-DNA
from	O
glucocorticoid-repressible	B-DNA
genes	I-DNA
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O
	
Together	O
these	O
studies	O
indicate	O
that	O
hGR	B-protein
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	B-DNA
-specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	B-protein
receptor	I-protein
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	B-cell_type
cells	I-cell_type
and	O
tissues	O
.	O
	
Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O
	
###MEDLINE:91264362	
	
Expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
alveolar	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O
	
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O
	
In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O
	
Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor-positive	B-cell_type
lymphocytes	I-cell_type
:	O
sarcoidosis	O
,	O
20	O
+/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+/-	O
17	O
%	O
)	O
.	O
	
In	O
contrast	O
,	O
blood	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
granulomatous	O
diseases	O
did	O
not	O
express	O
detectable	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O
	
The	O
percentage	O
of	O
lavage	B-cell_type
T-lymphocytes	I-cell_type
expressing	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O
	
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
than	O
on	O
CD4+	B-cell_type
T-lymphocytes	I-cell_type
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	B-cell_type
than	O
of	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O
	
These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	B-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	B-cell_type
populations	I-cell_type
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	B-protein
molecule	I-protein
is	O
likely	O
different	O
in	O
sarcoidosis	O
and	O
tuberculosis	O
.	O
	
###MEDLINE:91219488	
	
Role	O
for	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
in	O
viral	B-DNA
promoter	I-DNA
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O
	
During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
six	B-protein
viral	I-protein
nuclear	I-protein
antigen	I-protein
(	O
EBNAs	B-protein
)	O
are	O
expressed	O
from	O
long	B-RNA
primary	I-RNA
transcripts	I-RNA
by	O
means	O
of	O
alternative	B-RNA
splicing	I-RNA
and	O
alternative	B-RNA
polyadenylylation	I-RNA
sites	I-RNA
.	O
	
These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	B-DNA
,	O
Cp	B-DNA
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O
	
Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	B-DNA
usage	O
.	O
	
These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B-protein
2	I-protein
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	B-DNA
usage	O
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	B-DNA
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	B-DNA
to	I-DNA
-245	I-DNA
base	I-DNA
pairs	I-DNA
upstream	O
of	O
Cp	B-DNA
is	O
essential	O
for	O
Cp	B-DNA
activity	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
;	O
and	O
(	O
iv	O
)	O
DNase	B-protein
I	I-protein
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
revealed	O
a	O
B-cell-specific	B-DNA
footprint	I-DNA
in	O
the	O
region	O
of	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O
	
These	O
results	O
support	O
a	O
model	O
for	O
viral	B-DNA
promoter	I-DNA
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	B-protein
2	I-protein
,	O
followed	O
by	O
activation	O
of	O
Cp	B-DNA
through	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O
	
###MEDLINE:91184714	
	
Immune	O
response	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
to	O
HBx-antigen	B-protein
of	O
hepatitis	O
B	O
virus	O
.	O
	
The	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	I-DNA
encodes	O
a	O
transcriptional	B-protein
transactivator	I-protein
protein	I-protein
designated	O
HBxAg	B-protein
.	O
	
We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	B-cell_type
T-lymphocytes	I-cell_type
.	O
	
Using	O
recombinant	B-protein
HBxAg	I-protein
protein	I-protein
,	O
we	O
found	O
HBxAg	B-protein
-specific	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O
	
With	O
HBxAg	B-protein
-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T-cell	O
epitopes	O
were	O
identified	O
.	O
	
Most	O
were	O
located	O
in	O
the	O
carboxyterminal	B-protein
half	I-protein
of	O
the	O
HBxAg	B-protein
protein	I-protein
.	O
	
Five	O
T-cell	B-cell_line
clones	I-cell_line
specific	O
for	O
a	O
T-cell	B-protein
epitope	I-protein
located	O
at	O
the	O
carboxyterminal	B-protein
region	I-protein
of	O
HBxAg	B-protein
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	B-cell_line
,	I-cell_line
CD8-negative	I-cell_line
subtype	I-cell_line
.	O
	
These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	B-protein
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O
	
###MEDLINE:91339573	
	
[	O
Changes	O
in	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O
	
The	O
number	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex-and	O
age-matched	O
healthy	O
subjects	O
.	O
	
It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-protein
in	O
leucocytes	B-cell_type
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	B-cell_type
were	O
1054	O
+/-	O
254	O
sites/cell	O
)	O
.	O
	
It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O
	
###MEDLINE:91101115	
	
The	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
independent	I-DNA
cis-acting	I-DNA
sequences	I-DNA
in	O
HIV-1	B-DNA
LTR	I-DNA
responsive	O
to	O
T-cell	O
activation	O
.	O
	
The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B-protein
or	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
The	O
rate	O
of	O
LTR	B-DNA
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
if	O
either	O
the	O
NFAT-1	B-protein
or	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O
	
The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
NFAT-1	I-DNA
deletion	I-DNA
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B-protein
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
Neither	O
deletion	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
nor	O
deletion	O
of	O
NFAT-1	B-protein
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O
	
###MEDLINE:92052243	
	
cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-protein
and	O
JunB	B-protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B-protein
proteins	I-protein
.	O
	
We	O
demonstrate	O
that	O
JunD	B-protein
,	O
a	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
,	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
proenkephalin	I-DNA
gene	I-DNA
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O
	
Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	B-DNA
,	I-DNA
phorbol	I-DNA
ester-	I-DNA
,	I-DNA
and	I-DNA
Ca	I-DNA
(	I-DNA
2+	I-DNA
)	I-DNA
-inducible	I-DNA
enhancer	I-DNA
,	O
and	O
JunD	B-protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	B-DNA
as	O
a	O
homodimer	B-protein
.	O
	
Another	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
complex	I-protein
,	O
JunB	B-protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-protein
.	O
	
As	O
a	O
homodimer	O
JunB	B-protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-protein
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O
	
Furthermore	O
,	O
JunD	B-protein
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	B-DNA
elements	I-DNA
.	O
	
These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B-protein
protein	I-protein
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-protein
and	O
other	O
AP-1-related	B-protein
proteins	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O
	
###MEDLINE:92257680	
	
[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O
	
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O
	
As	O
a	O
result	O
,	O
the	O
cases	O
of	O
deficiency-cold	O
syndrome	O
(	O
DCS	O
)	O
had	O
a	O
normal	O
concentration	O
of	O
plasma	O
cortisol	O
but	O
a	O
lowered	O
content	O
of	O
GCR	B-protein
in	O
leukocytes	B-cell_type
when	O
compared	O
with	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
;	O
the	O
cases	O
of	O
deficiency-heat	O
syndrome	O
(	O
DHS	O
)	O
had	O
a	O
higher	O
concentration	O
of	O
plasma	O
cortisol	O
than	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
a	O
slightly	O
higher	O
content	O
of	O
GCR	B-protein
in	O
leukocytes	B-cell_type
.	O
	
It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O
	
###MEDLINE:92088960	
	
The	O
role	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O
	
Terminal	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
U-937	B-cell_line
and	O
HL-60	B-cell_line
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O
	
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c-jun	B-DNA
expression	O
best	O
paralleling	O
differentiation	O
.	O
	
The	O
generation	O
of	O
AP-1	B-protein
complexes	I-protein
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O
	
Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	B-DNA
driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	B-DNA
AP-1	I-DNA
regulated	I-DNA
genes	I-DNA
.	O
	
Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B-protein
appears	O
.	O
	
This	O
tight	O
correlation	O
between	O
c-jun	B-DNA
expression	O
,	O
the	O
generation	O
of	O
AP-1	B-protein
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B-protein
complex	I-protein
during	O
this	O
process	O
.	O
	
###MEDLINE:91351285	
	
Nuclear	O
association	O
of	O
a	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
blocked	O
by	O
FK-506	O
and	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O
	
Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O
	
In	O
T	B-cell_type
lymphocytes	I-cell_type
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
to	O
cytokine	B-DNA
genes	I-DNA
that	O
coordinate	O
the	O
immune	O
response	O
.	O
	
The	O
putative	B-protein
intracellular	I-protein
receptors	I-protein
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O
	
Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	B-protein
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	B-protein
inhibitors	O
and	O
analysis	O
of	O
cyclosporin-resistant	B-cell_line
mutants	I-cell_line
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	B-protein
complex	I-protein
between	O
the	O
drug	O
and	O
isomerase	B-protein
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	B-protein
activity	O
.	O
	
A	O
transcription	B-protein
factor	I-protein
,	O
NF-AT	B-protein
,	O
which	O
is	O
essential	O
for	O
early	O
T-cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O
	
Here	O
we	O
demonstrate	O
that	O
NF-AT	B-protein
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	B-protein
receptor	I-protein
induces	O
a	O
pre-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	B-protein
.	O
	
FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	B-protein
component	I-protein
without	O
affecting	O
synthesis	O
of	O
the	O
nuclear	B-protein
subunit	I-protein
.	O
	
###MEDLINE:91364264	
	
Glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
in	O
anorexia	O
nervosa	O
.	O
	
OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O
	
DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	O
determination	O
and	O
blood	B-cell_type
lymphocytes	I-cell_type
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O
	
PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
+/-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+/-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O
	
Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O
	
MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
with	O
dexamethasone	O
as	O
ligand	O
on	O
lymphocytes	B-cell_type
.	O
	
RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+/-	O
1750	O
vs	O
7347	O
+/-	O
1285	O
sites/cell	O
;	O
Kd	O
:	O
7.7	O
+/-	O
2.4	O
vs	O
7.4	O
+/-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O
	
After	O
weight	O
gain	O
(	O
14	O
+/-	O
2	O
to	O
16	O
+/-	O
2	O
kg/m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
+/-	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
+/-	O
500	O
(	O
post	O
)	O
sites/cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O
the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
+/-	O
2.6	O
vs	O
9.2	O
+/-	O
2.4	O
nM	O
)	O
.	O
	
CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down-regulate	O
the	O
lymphocyte	O
glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
a	O
post-receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O
	
###MEDLINE:91236696	
	
Inhibition	O
of	O
protein	B-protein
phosphatases	I-protein
by	O
okadaic	O
acid	O
induces	O
AP1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
	
To	O
examine	O
the	O
role	O
of	O
protein	B-protein
phosphatases	I-protein
in	O
T	O
cell	O
activation	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-protein
1	I-protein
and	I-protein
2A	I-protein
phosphatases	I-protein
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	B-protein
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O
	
Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	B-protein
.	O
	
In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
family	I-DNA
of	O
proto-oncogenes	B-DNA
.	O
	
Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B-protein
further	O
enhanced	O
the	O
induction	O
of	O
AP1	B-protein
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O
	
Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	B-RNA
transcripts	I-RNA
of	O
the	O
jun	B-DNA
family	I-DNA
of	I-DNA
proto-oncogenes	I-DNA
including	O
c-jun	B-DNA
,	O
junD	B-DNA
,	O
and	O
junB	B-DNA
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	B-DNA
family	I-DNA
including	O
c-fos	B-DNA
and	O
fra-1	B-DNA
.	O
	
By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	B-DNA
gene	I-DNA
family	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	B-RNA
mRNA	I-RNA
by	O
okadaic	O
acid	O
.	O
	
Transfection	O
of	O
c-jun	B-DNA
promoter	I-DNA
constructs	I-DNA
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c-jun	B-DNA
transcription	O
.	O
	
The	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
(	O
PP1	B-protein
and	O
PP2A	B-protein
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	B-protein
.	O
	
###MEDLINE:91217625	
	
Cloning	O
of	O
murine	B-protein
TCF-1	I-protein
,	O
a	O
T	O
cell-specific	O
transcription	B-protein
factor	I-protein
interacting	O
with	O
functional	B-DNA
motifs	I-DNA
in	O
the	O
CD3-epsilon	B-DNA
and	I-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
enhancers	I-DNA
.	O
	
CD3	B-protein
-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	B-cell_line
cell	I-cell_line
lineage	I-cell_line
.	O
	
We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O
	
In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	B-protein
expression	O
was	O
restricted	O
to	O
T	B-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O
	
TCF-1	B-protein
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so-called	O
high	O
mobility	B-DNA
group	I-DNA
1	I-DNA
(	I-DNA
HMG	I-DNA
)	I-DNA
box	I-DNA
.	O
	
Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	B-protein
TCF-1	I-protein
.	O
	
Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B-protein
TCF-1	I-protein
.	O
	
Murine	B-protein
and	I-protein
human	I-protein
TCF-1	I-protein
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O
	
Recombinant	B-protein
murine	I-protein
and	I-protein
human	I-protein
TCF-1	I-protein
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	B-DNA
enhancer	I-DNA
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O
	
With	O
the	O
murine	B-DNA
cDNA	I-DNA
clones	I-DNA
several	O
aspects	O
of	O
TCF-1	B-protein
were	O
analyzed	O
.	O
	
First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	B-protein
containing	O
the	O
HMG	B-DNA
box	I-DNA
was	O
sufficient	O
for	O
sequence-specific	O
binding	O
.	O
	
Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	B-protein
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O
	
Third	O
,	O
TCF-1	B-protein
bound	O
specifically	O
to	O
a	O
functional	O
T	B-DNA
cell-specific	I-DNA
element	I-DNA
in	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR-alpha	I-DNA
)	I-DNA
enhancer	I-DNA
.	O
	
The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	B-DNA
and	I-DNA
CD3-epsilon	I-DNA
enhancers	I-DNA
imply	O
an	O
important	O
role	O
for	O
TCF-1	B-protein
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O
	
###MEDLINE:91291757	
	
Cloning	O
of	O
a	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
that	O
resembles	O
a	O
diverged	B-DNA
Drosophila	I-DNA
homeobox	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	B-cell_type
.	O
	
A	O
new	O
homeobox	B-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O
	
Northern	O
blot	O
analysis	O
of	O
polyadenylated	B-RNA
RNA	I-RNA
purified	O
from	O
activated	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
revealed	O
a	O
single	B-RNA
mRNA	I-RNA
transcript	I-RNA
of	O
approximately	O
2.3	O
kb	O
.	O
	
Two	O
cDNA	B-DNA
clones	I-DNA
were	O
sequenced	O
and	O
provided	O
2	O
,	O
250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	B-DNA
sequence	I-DNA
information	O
.	O
	
There	O
is	O
a	O
single	O
methionine	B-DNA
codon-initiated	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B-DNA
and	O
a	O
CAX	B-DNA
repeat	I-DNA
,	O
and	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O
	
When	O
the	O
homeodomain	B-DNA
from	O
HB24	B-DNA
was	O
compared	O
to	O
known	O
mammalian	B-DNA
and	I-DNA
Drosophila	I-DNA
homeodomains	I-DNA
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	B-DNA
homeodomain	I-DNA
,	O
H2.0	O
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O
	
The	O
HB24	B-RNA
mRNA	I-RNA
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	B-cell_type
lymphocytes	I-cell_type
;	O
however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	B-RNA
mRNA	I-RNA
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
	
Characterization	O
of	O
HB24	B-DNA
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O
	
Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O
	
HB24	B-DNA
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O
	
###MEDLINE:91132035	
	
Platelet-activating	B-protein
factor	I-protein
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	B-DNA
expression	O
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Platelet-activating	B-protein
factor	I-protein
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O
	
Studies	O
of	O
the	O
actions	O
of	O
platelet-activating	B-protein
factor	I-protein
have	O
centered	O
mainly	O
around	O
neutrophils	B-cell_type
,	O
monocytes	B-cell_type
,	O
and	O
platelets	B-cell_type
.	O
	
In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
Employing	O
the	O
EBV-transformed	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
SKW6.4	B-cell_line
,	O
we	O
demonstrate	O
that	O
platelet-activating	B-protein
factor	I-protein
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-9	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
.	O
	
The	O
inactive	O
precursor	O
,	O
lyso-platelet-activating	B-protein
factor	I-protein
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O
	
We	O
also	O
show	O
that	O
platelet-activating	B-protein
factor	I-protein
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	O
platelet-activating	B-protein
factor	I-protein
was	O
again	O
ineffective	O
.	O
	
We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	B-protein
factor	I-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
by	O
measuring	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O
	
Moreover	O
,	O
platelet-activating	B-protein
factor	I-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O
	
Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	B-protein
activity	O
modulates	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B-protein
A2	I-protein
.	O
	
In	O
summary	O
,	O
platelet-activating	B-protein
factor	I-protein
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
###MEDLINE:91094881	
	
Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
by	O
a	O
novel	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
.	O
	
A	O
new	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
has	O
been	O
identified	O
3	O
'	O
of	O
E4	B-DNA
and	I-DNA
the	I-DNA
octamerlike	I-DNA
motifs	I-DNA
in	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O
	
Tandem	O
copies	O
of	O
this	O
67-bp	B-DNA
MnlI-AluI	I-DNA
fragment	I-DNA
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
driven	O
by	O
the	O
conalbumin	B-DNA
promoter	I-DNA
,	O
stimulated	O
transcription	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B-DNA
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
or	O
HeLa	O
cells	O
.	O
	
Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	B-DNA
E6	I-DNA
motif	I-DNA
detected	O
a	O
B-cell-specific	B-protein
complex	I-protein
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B-DNA
motif	I-DNA
stimulated	O
transcription	O
in	O
ARH77	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
Jurkat	B-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
Furthermore	O
,	O
a	O
mutant	B-DNA
E6	I-DNA
motif	I-DNA
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O
	
In	O
striking	O
contrast	O
to	O
the	O
mouse	B-DNA
Ig	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
,	O
in	O
which	O
the	O
octamer	B-DNA
motif	I-DNA
acts	O
as	O
a	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
,	O
the	O
human	B-DNA
enhancer	I-DNA
contains	O
an	O
octamerlike	B-DNA
sequence	I-DNA
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer-binding	B-protein
proteins	I-protein
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O
	
Interestingly	O
,	O
the	O
MnlI-AluI	B-DNA
fragment	I-DNA
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	B-DNA
promoter	I-DNA
in	O
both	O
Jurkat	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O
	
Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	B-DNA
fragment	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
factors	I-protein
.	O
	
###MEDLINE:92043714	
	
Charybdotoxin-sensitive	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	B-cell_type
or	I-cell_type
B	I-cell_type
cell	I-cell_type
activation	O
and	O
proliferation	O
.	O
	
The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	B-protein
binding	O
.	O
	
Human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O
	
Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O
	
We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
K+	I-protein
channels	I-protein
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O
	
We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
a	O
dose-dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2+	O
.	O
	
However	O
,	O
blockade	O
of	O
the	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channel	I-protein
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	O
gene	O
activation	O
,	O
IL-2	B-protein
production	O
,	O
IL-2R	B-protein
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O
	
These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channels	I-protein
are	O
not	O
involved	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
activation	O
and	O
mitogenesis	O
.	O
	
###MEDLINE:92135145	
	
Activity	O
of	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
The	O
two	B-protein
nuclear	I-protein
proteins	I-protein
NF-kappa	B-protein
B	I-protein
(	O
consisting	O
of	O
subunits	O
p50	B-protein
an	O
dp65	B-protein
)	O
and	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
IARC	B-cell_line
301.5	I-cell_line
.	O
	
In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	B-protein
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	B-DNA
B	I-DNA
enhancers	I-DNA
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	B-cell_line
301.5	I-cell_line
and	O
a	O
murine	B-cell_line
myeloma	I-cell_line
.	O
	
Most	O
hybrids	O
express	O
both	O
KBF1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B-protein
.	O
	
The	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	B-cell_line
expressing	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O
	
These	O
findings	O
show	O
that	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
is	O
necessary	O
to	O
activate	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
,	O
while	O
KBF1	B-protein
by	O
itself	O
is	O
not	O
sufficient	O
.	O
	
We	O
propose	O
that	O
KBF1	B-protein
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B-protein
and	O
IL-2	B-protein
alpha	I-protein
genes	O
during	O
the	O
immune	O
response	O
.	O
	
###MEDLINE:92022337	
	
T-helper-cell	B-protein
determinants	I-protein
in	O
protein	B-protein
antigens	I-protein
are	O
preferentially	O
located	O
in	O
cysteine-rich	B-protein
antigen	I-protein
segments	I-protein
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O
	
We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	B-protein
epitopes	I-protein
in	O
protein	B-protein
antigen	I-protein
(	O
Ag	B-protein
)	O
by	O
analysing	O
the	O
Ag	B-protein
amino	B-protein
acid	I-protein
sequence	I-protein
.	O
	
The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	B-protein
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O
	
These	O
are	O
prominent	O
enzymes	B-protein
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B-protein
protein	I-protein
Ag	I-protein
enter	O
APC	B-protein
,	O
and	O
resistant	B-protein
segments	I-protein
in	O
Ag	B-protein
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	B-protein
determinants	I-protein
than	O
susceptible	B-protein
segments	I-protein
.	O
	
From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	B-protein
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	O
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	B-protein
,	I-protein
S1	I-protein
,	I-protein
S1	I-protein
'	I-protein
,	I-protein
and	I-protein
S2	I-protein
'	I-protein
subsites	I-protein
of	O
cathepsin	B-protein
B	I-protein
and	I-protein
L	I-protein
,	O
and	O
not	O
in	O
the	O
S1	B-protein
and	O
S1	B-protein
'	I-protein
subsites	O
of	O
cathepsin	B-protein
D	I-protein
.	O
	
Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine-containing	B-protein
T-cell	I-protein
determinants	I-protein
in	O
a	O
number	O
of	O
protein	B-protein
Ag	I-protein
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O
	
By	O
searching	O
protein	O
Ag	B-protein
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
in	O
the	O
Ag	B-protein
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O
	
Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	B-protein
for	O
potential	O
amphipatic	B-protein
alpha-helical	I-protein
protein	I-protein
segments	I-protein
.	O
	
Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O
	
###MEDLINE:91303691	
	
Contribution	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
motifs	I-DNA
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	B-cell_type
types	I-cell_type
.	O
	
Starting	O
with	O
a	O
replication-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
present	O
in	O
the	O
native	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
proviruses	O
containing	O
reconstructed	B-DNA
LTRs	I-DNA
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
elements	I-DNA
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection-cocultivation	O
.	O
	
Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	B-cell_type
T-cell	I-cell_type
types	I-cell_type
depending	O
on	O
which	O
element	B-DNA
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	B-DNA
.	O
	
For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	B-DNA
containing	O
one	O
or	O
two	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
(	O
and	O
no	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
=	O
MT4	B-cell_line
greater	O
than	O
H9	B-cell_line
greater	O
than	O
CEM	B-cell_line
greater	O
than	O
Jurkat	B-cell_line
)	O
was	O
observed	O
.	O
	
Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	B-DNA
LTR	I-DNA
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	B-DNA
box	I-DNA
.	O
	
These	O
results	O
suggest	O
that	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
LTR	I-DNA
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B-cell_type
types	I-cell_type
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B-protein
factors	I-protein
present	O
.	O
	
###MEDLINE:92144438	
	
Stimulation	O
of	O
interferon	B-DNA
beta	I-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
by	O
purified	O
NF-kappa	B-protein
B	I-protein
and	O
a	O
novel	O
TH	B-protein
protein	I-protein
.	O
	
The	O
human	B-DNA
interferon	I-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
regulatory	I-DNA
element	I-DNA
consists	O
of	O
multiple	O
enhanson	B-DNA
domains	I-DNA
which	O
are	O
targets	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B-DNA
.	O
	
To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	B-protein
induction	O
,	O
positive	B-protein
regulatory	I-protein
domain	I-protein
(	I-protein
PRD	I-protein
)	I-protein
II	I-protein
binding	I-protein
proteins	I-protein
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	B-cell_line
T-cells	I-cell_line
and	O
from	O
IFN	B-cell_line
primed	I-cell_line
,	I-cell_line
cycloheximide/polyinosinic-polycytidylic	I-cell_line
acid	I-cell_line
treated	I-cell_line
HeLa	I-cell_line
S3	I-cell_line
cells	I-cell_line
.	O
	
From	O
HeLa	B-cell_line
cells	I-cell_line
,	O
two	O
major	O
proteins	O
of	O
52	B-protein
and	I-protein
45	I-protein
kilodaltons	I-protein
(	I-protein
kD	I-protein
)	I-protein
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	B-cell_type
,	O
four	O
proteins	O
--	O
a	O
major	B-protein
protein	I-protein
of	O
52	B-protein
kD	I-protein
and	O
three	O
minor	B-protein
proteins	I-protein
of	O
82	B-protein
,	O
67	B-protein
,	O
and	O
43-47	B-protein
kD	I-protein
--	O
were	O
purified	O
.	O
	
Also	O
,	O
an	O
induction	O
specific	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
was	O
purified	O
from	O
HeLa	B-cell_line
cells	I-cell_line
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	B-DNA
sequence	I-DNA
and	O
the	O
PRDI	B-DNA
domain	I-DNA
.	O
	
This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	B-protein
.	O
	
Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B-DNA
beta	I-DNA
promoter	I-DNA
deletions	I-DNA
.	O
	
Deletions	O
upstream	O
of	O
the	O
PRDII	B-DNA
element	I-DNA
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	B-DNA
.	O
	
A	O
2-4-fold	O
increase	O
in	O
IFN-beta	B-DNA
promoter	I-DNA
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	B-DNA
and	O
PRDII	B-DNA
elements	I-DNA
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O
	
When	O
purified	O
PRDII	B-protein
and	I-protein
tetrahexamer	I-protein
binding	I-protein
proteins	I-protein
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O
	
These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	B-protein
transcription	O
.	O
	
###MEDLINE:91239569	
	
The	O
rhombotin	B-DNA
family	I-DNA
of	O
cysteine-rich	B-DNA
LIM-domain	I-DNA
oncogenes	I-DNA
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	B-DNA
translocations	I-DNA
to	O
human	B-DNA
chromosomes	I-DNA
11p15	I-DNA
and	I-DNA
11p13	I-DNA
.	O
	
A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	B-DNA
arm	I-DNA
of	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p15	I-DNA
disrupts	O
the	O
rhombotin	B-DNA
gene	I-DNA
.	O
	
This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	B-protein
regions	I-protein
called	O
LIM	B-protein
domains	I-protein
,	O
which	O
show	O
homology	O
to	O
zinc-binding	B-protein
proteins	I-protein
and	O
to	O
iron-sulfur	B-protein
centers	I-protein
of	O
ferredoxins	B-protein
.	O
	
Two	O
homologues	O
of	O
the	O
rhombotin	B-DNA
gene	I-DNA
have	O
now	O
been	O
isolated	O
.	O
	
One	O
of	O
these	O
,	O
designated	O
Rhom-2	B-DNA
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p13	I-DNA
,	O
where	O
a	O
cluster	O
of	O
T-cell	B-DNA
leukemia-specific	I-DNA
translocations	I-DNA
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	B-DNA
are	O
upstream	O
of	O
the	O
Rhom-2	B-DNA
gene	I-DNA
.	O
	
Human	B-DNA
and	I-DNA
mouse	I-DNA
Rhom-2	I-DNA
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-DNA
,	O
encode	O
two	O
tandem	B-DNA
cysteine-rich	I-DNA
LIM	I-DNA
domains	I-DNA
.	O
	
Rhom-2	B-RNA
mRNA	I-RNA
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O
	
The	O
other	O
gene	O
,	O
designated	O
Rhom-3	B-DNA
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	B-DNA
domain	I-DNA
of	O
rhombotin	B-DNA
.	O
	
Since	O
the	O
Rhom-2	B-DNA
gene	I-DNA
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	B-cell_type
tumors	I-cell_type
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B-DNA
gene	I-DNA
was	O
further	O
examined	O
.	O
	
A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-DNA
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O
	
Therefore	O
,	O
chromosome	B-DNA
bands	I-DNA
11p15	I-DNA
(	O
rhombotin	B-DNA
)	O
and	O
11p13	B-DNA
(	O
Rhom-2	B-DNA
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	B-DNA
target	I-DNA
more	O
rarely	O
involved	O
.	O
	
The	O
results	O
define	O
the	O
rhombotin	B-DNA
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	B-DNA
oncogenes	I-DNA
with	O
duplicated	O
cysteine-rich	B-DNA
LIM	I-DNA
domains	I-DNA
.	O
	
###MEDLINE:91355651	
	
NF-kappa	B-protein
B	I-protein
activation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
is	O
independent	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-regulated	I-protein
kinases	I-protein
.	O
	
NF-kappa	B-protein
B	I-protein
is	O
a	O
DNA-binding	B-protein
regulatory	I-protein
factor	I-protein
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
genes	I-DNA
.	O
	
In	O
T	B-cell_type
cells	I-cell_type
,	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
.	O
	
In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
TNF	B-protein
alpha	I-protein
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
and	O
its	O
subclone	O
JCT6	B-cell_line
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	B-protein
transduction	O
pathway	O
.	O
	
We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B-protein
alpha	I-protein
were	O
able	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O
	
Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	B-protein
alpha	I-protein
activation	O
was	O
not	O
.	O
	
Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B-protein
alpha	I-protein
effect	O
was	O
unchanged	O
.	O
	
TNF	B-protein
alpha	I-protein
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O
	
Moreover	O
,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
Thus	O
,	O
TNF	B-protein
alpha	I-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal-mediating	B-protein
kinases	I-protein
such	O
as	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
or	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-regulated	I-protein
kinases	I-protein
.	O
	
Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
both	O
TNF	B-protein
alpha	I-protein
and	O
PKC	B-protein
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B-protein
B	I-protein
/I	B-protein
kappa	I-protein
B	I-protein
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B-protein
B	I-protein
translocation	O
step	O
.	O
	
###MEDLINE:91172211	
	
The	O
functional	O
domains	O
of	O
the	O
murine	B-DNA
Thy-1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O
	
The	O
Thy-1	B-DNA
gene	I-DNA
promoter	I-DNA
resembles	O
a	O
``	B-DNA
housekeeping	I-DNA
''	I-DNA
promoter	I-DNA
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	B-DNA
island	I-DNA
,	O
lacks	O
a	O
canonical	B-DNA
TATA	I-DNA
box	I-DNA
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	B-RNA
termini	I-RNA
of	O
the	O
mRNA	B-RNA
.	O
	
Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	B-DNA
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position-dependent	O
manner	O
.	O
	
It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B-DNA
site	I-DNA
.	O
	
We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	B-DNA
Thy-1	I-DNA
promoter	I-DNA
and	O
show	O
that	O
the	O
dominant	B-DNA
promoter	I-DNA
elements	I-DNA
consist	O
of	O
multiple	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
,	O
an	O
inverted	O
CCAAT	B-DNA
box	I-DNA
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O
	
DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B-protein
factors	I-protein
to	O
these	O
elements	B-DNA
,	O
including	O
Sp1	B-protein
and	O
CP1	B-protein
.	O
	
Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	B-DNA
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
CP1	B-protein
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B-DNA
sequences	I-DNA
.	O
	
###MEDLINE:91117203	
	
Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
activates	O
proenkephalin	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Upon	O
activation	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-RNA
mRNA	I-RNA
in	O
the	O
cells	O
.	O
	
Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O
	
The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	B-DNA
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O
	
Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
an	O
NF-kappa	B-protein
B	I-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	B-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
.	O
	
Mutations	O
at	O
the	O
B2	B-DNA
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O
	
The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O
	
Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
.	O
	
However	O
,	O
as	O
NF-kappa	B-protein
B	I-protein
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	B-DNA
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	B-protein
factor	I-protein
which	O
synergizes	O
with	O
NF-kappa	B-protein
B	I-protein
should	O
be	O
considered	O
.	O
	
###MEDLINE:91079577	
	
Induction	O
of	O
NF-KB	B-protein
during	O
monocyte	B-cell_type
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O
	
The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	I-cell_type
macrophages	I-cell_type
.	O
	
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B-protein
transactivation	I-protein
factor	I-protein
NF-KB	B-protein
to	O
the	O
double	B-DNA
repeat-KB	I-DNA
enhancer	I-DNA
sequence	I-DNA
located	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	B-cell_line
cells	I-cell_line
acts	O
in	O
inducing	O
NF-KB	B-protein
expression	O
in	O
the	O
nuclei	O
.	O
	
In	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
or	O
macrophages	B-cell_type
,	O
induction	O
of	O
NF-KB	B-protein
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O
	
When	O
U937	B-cell_line
cells	I-cell_line
were	O
infected	O
with	O
HIV-1	O
,	O
no	O
induction	O
of	O
NF-KB	B-protein
factor	I-protein
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O
	
These	O
results	O
indicate	O
that	O
in	O
monocytic	B-cell_line
cell	I-cell_line
lineage	I-cell_line
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation/activation	O
stimuli	O
allowing	O
nuclear	O
NF-KB	B-protein
expression	O
.	O
	
###MEDLINE:91075236	
	
Disruption	O
of	O
the	O
human	B-DNA
SCL	I-DNA
locus	I-DNA
by	O
``	O
illegitimate	O
''	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
.	O
	
A	O
fusion	B-DNA
complementary	I-DNA
DNA	I-DNA
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
HSB-2	I-cell_line
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
SCL	B-protein
.	O
	
The	O
fusion	B-DNA
cDNA	I-DNA
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	B-DNA
locus	I-DNA
,	O
SIL	B-DNA
(	O
SCL	B-DNA
interrupting	I-DNA
locus	I-DNA
)	O
,	O
and	O
the	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
of	O
SCL	B-protein
.	O
	
Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-DNA
5	I-DNA
'	I-DNA
regulatory	I-DNA
region	I-DNA
.	O
	
This	O
event	O
is	O
probably	O
mediated	O
by	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B-protein
or	O
a	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O
	
Two	O
other	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
and	O
RPMI	B-cell_line
8402	I-cell_line
,	O
have	O
essentially	O
identical	O
deletions	O
.	O
	
Thus	O
,	O
in	O
lymphocytes	B-cell_type
,	O
growth-affecting	B-DNA
genes	I-DNA
other	O
than	O
immune	B-protein
receptors	I-protein
risk	O
rearrangements	O
.	O
	
###MEDLINE:91125342	
	
Thyroid	B-protein
hormone	I-protein
receptors	I-protein
form	O
distinct	O
nuclear	B-protein
protein-dependent	I-protein
and	I-protein
independent	I-protein
complexes	I-protein
with	O
a	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
.	O
	
We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
and	O
recombinant	B-protein
thyroid	I-protein
hormone	I-protein
receptors	I-protein
(	O
TRs	B-protein
)	O
to	O
the	O
palindromic	B-DNA
thyroid	I-DNA
hormone	I-DNA
responsive	I-DNA
element	I-DNA
AGGTCATGACCT	O
(	O
TREp	B-DNA
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
	
Four	O
specific	O
protein-DNA	B-protein
complexes	I-protein
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B-cell_line
pituitary	I-cell_line
(	I-cell_line
GH3	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
a	O
TREp-containing	B-DNA
DNA	I-DNA
fragment	I-DNA
.	O
	
This	O
was	O
compared	O
with	O
the	O
TREp	B-DNA
binding	O
of	O
reticulocyte	B-protein
lysate-synthesized	I-protein
TRs	I-protein
.	O
	
TR	B-protein
alpha	I-protein
1	I-protein
and	O
TR	B-protein
beta	I-protein
2	I-protein
each	O
formed	O
a	O
single	O
major	O
TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-protein
beta	I-protein
1	I-protein
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	B-DNA
as	O
an	O
oligomer	B-protein
.	O
	
Interestingly	O
,	O
coincubation	O
of	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	B-DNA
resulted	O
in	O
not	O
only	O
the	O
35S-TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O
	
Incubation	O
of	O
each	O
of	O
the	O
TRs	B-protein
with	O
NE	O
from	O
COS-7	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	B-protein
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	B-protein
shifted	I-protein
complex	I-protein
.	O
	
A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-protein
:	I-protein
TRE	I-protein
complex	I-protein
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B-cell_line
JEG-3	I-cell_line
cells	I-cell_line
.	O
	
At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B-protein
bound	O
to	O
TREp	B-DNA
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O
	
Truncation	O
of	O
TR	B-protein
alpha	I-protein
1	I-protein
at	O
amino	B-protein
acid	I-protein
210	I-protein
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl-terminus	B-protein
of	O
the	O
TRs	B-protein
is	O
essential	O
for	O
interaction	O
with	O
nuclear	B-protein
proteins	I-protein
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:90376424	
	
Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	B-DNA
B	I-DNA
regulatory	I-DNA
elements	I-DNA
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
and	I-DNA
beta	I-DNA
interferon	I-DNA
promoters	I-DNA
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
.	O
	
Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O
	
Tumor	B-RNA
necrosis	I-RNA
factor	I-RNA
alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
mRNA	I-RNA
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
and	O
in	O
a	O
chronically	B-cell_line
HIV	I-cell_line
infected	I-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U9-IIIB	B-cell_line
)	O
.	O
	
TNF-alpha	B-RNA
RNA	I-RNA
was	O
undetectable	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
.	O
	
Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	I-RNA
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
compared	O
with	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-protein
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O
	
The	O
effects	O
of	O
TNF-alpha	B-protein
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
plasmids	I-DNA
linked	O
to	O
regulatory	B-DNA
elements	I-DNA
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
.	O
	
In	O
U937	B-cell_line
and	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	B-DNA
promoters	I-DNA
by	O
TNF-alpha	B-protein
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B-DNA
B-containing	I-DNA
plasmids	I-DNA
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O
	
Although	O
the	O
intact	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	B-protein
,	O
multimers	O
of	O
the	O
PRDII	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
domain	I-DNA
were	O
inducible	O
by	O
both	O
agents	O
.	O
	
TNF-alpha	B-protein
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	B-protein
did	O
not	O
induce	O
the	O
HIV	B-DNA
LTR	I-DNA
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O
	
This	O
level	O
of	O
NF-kappa	B-protein
B	I-protein
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF-alpha	B-protein
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	B-RNA
RNA	I-RNA
production	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
However	O
,	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
TNF-alpha	B-protein
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	B-RNA
RNA	I-RNA
synthesis	O
,	O
indicating	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	B-protein
treatment	O
.	O
	
###MEDLINE:91118160	
	
Functional	O
analysis	O
of	O
cis-linked	B-DNA
regulatory	I-DNA
sequences	I-DNA
in	O
the	O
HLA	B-DNA
DRA	I-DNA
promoter	I-DNA
by	O
transcription	O
in	O
vitro	O
.	O
	
Two	O
consensus	O
sequences	O
,	O
called	O
X	B-DNA
and	I-DNA
Y	I-DNA
boxes	I-DNA
,	O
capable	O
of	O
binding	O
nuclear	B-protein
proteins	I-protein
and	O
regulating	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
.	O
	
Unlike	O
other	O
class	B-DNA
II	I-DNA
promoters	I-DNA
,	O
the	O
HLA-DR	B-DNA
alpha	I-DNA
(	I-DNA
DRA	I-DNA
)	I-DNA
promoter	I-DNA
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
of	O
immunoglobulin	B-DNA
variable	I-DNA
region	I-DNA
promoters	I-DNA
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O
	
This	O
``	O
octamer	B-DNA
``	O
in	O
the	O
context	O
of	O
DRA	B-protein
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	B-protein
(	O
OTF-1	B-protein
)	O
and	O
lymphoid-specific	B-protein
(	I-protein
OTF-2	I-protein
)	I-protein
``	I-protein
octamer	I-protein
''	I-protein
binding	I-protein
proteins	I-protein
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
``	B-protein
octamer	I-protein
''	I-protein
complex	I-protein
was	O
found	O
.	O
	
In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	B-DNA
elements	I-DNA
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-DNA
promoter	I-DNA
construct	I-DNA
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
than	O
in	O
extracts	O
from	O
class	B-cell_line
II-negative	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O
	
5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	B-DNA
box	I-DNA
,	O
but	O
retained	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
and	O
TATA	B-DNA
box	I-DNA
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	B-DNA
box	I-DNA
reduced	O
transcription	O
by	O
95	O
%	O
.	O
	
Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	B-DNA
consensus	I-DNA
element	I-DNA
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	B-DNA
box	I-DNA
sequences	I-DNA
in	O
transient	O
expression	O
assays	O
.	O
	
Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	B-DNA
box	I-DNA
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
the	O
DRA	B-DNA
``	I-DNA
octamer	I-DNA
''	I-DNA
does	O
not	O
utilize	O
OTF-2	B-protein
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B-DNA
promoters	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:90293687	
	
Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O
	
Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
HIV-1-LTR	I-DNA
)	I-DNA
CAT	I-DNA
constructs	I-DNA
transfected	O
into	O
monocyte/macrophage-like	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O
	
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-protein
B	I-protein
in	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocyte/macrophage-like	I-cell_line
cloned	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U1	B-cell_line
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O
	
The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
before	O
treatment	O
with	O
LPS	O
.	O
	
This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B-RNA
RNA	I-RNA
and	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O
	
###MEDLINE:90285430	
	
Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O
	
Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O
	
This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O
	
Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O
	
The	O
suppression	O
of	O
basophils	B-cell_type
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O
	
The	O
37.5	O
%	O
reduction	O
in	O
dose	O
produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O
	
A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O
	
A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	B-cell_type
cell	I-cell_type
return	O
to	O
blood	O
.	O
	
The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng/ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O
	
The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O
	
The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng/ml	O
.	O
	
Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
``	O
dose-sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O
	
This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O
	
###MEDLINE:90237240	
	
1	O
,	O
25	O
(	O
OH	O
)	O
2D2	O
production	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis	O
.	O
	
To	O
compare	O
extra-renal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible	O
,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D3	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
uncultured	B-cell_type
cells	I-cell_type
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis	O
.	O
	
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	B-cell_type
cells	I-cell_type
(	O
12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
	
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
lavage	B-cell_type
cells	I-cell_type
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8+	O
T	B-cell_type
lymphocytes	I-cell_type
present	O
but	O
not	O
other	O
cell	O
types	O
.	O
	
T	B-cell_type
lymphocytes	I-cell_type
appeared	O
to	O
be	O
an	O
important	O
source	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
,	O
since	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	O
lavage	B-cell_type
cells	I-cell_type
.	O
	
Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	B-cell_type
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O
	
###MEDLINE:90206049	
	
Megakaryocytic	B-cell_line
and	I-cell_line
erythrocytic	I-cell_line
lineages	I-cell_line
share	O
specific	O
transcription	B-protein
factors	I-protein
.	O
	
Erythroid-specific	B-DNA
genes	I-DNA
contain	O
binding	O
sites	O
for	O
NF-E1	B-protein
(	O
also	O
called	O
GF-1	B-protein
and	O
Eryf-1	B-protein
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA-binding	B-protein
protein	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O
	
NF-E1	B-protein
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O
	
A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	B-cell_line
megakaryocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
purified	B-cell_line
human	I-cell_line
megakaryocytes	I-cell_line
;	O
it	O
binds	O
to	O
promoter	B-DNA
regions	I-DNA
of	O
two	O
megakaryocytic-specific	B-DNA
genes	I-DNA
.	O
	
The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B-protein
protein	I-protein
;	O
also	O
,	O
NF-E1	B-RNA
messenger	I-RNA
RNA	I-RNA
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	B-cell_line
and	I-cell_line
erythroid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF-E1	B-protein
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic-specific	B-DNA
promoter	I-DNA
.	O
	
We	O
also	O
find	O
that	O
NF-E2	B-protein
,	O
another	O
trans-acting	B-protein
factor	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
,	O
is	O
present	O
in	O
megakaryocytes	B-cell_line
.	O
	
Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans-acting	B-protein
factors	I-protein
.	O
	
Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	B-cell_line
and	I-cell_line
the	I-cell_line
megakaryocytic	I-cell_line
lineages	I-cell_line
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
in	O
most	O
erythroblastic	B-cell_line
and	I-cell_line
megakaryoblastic	I-cell_line
permanent	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
###MEDLINE:91175478	
	
Transcriptional	O
down-regulation	O
of	O
c-myc	B-DNA
expression	O
by	O
protein	O
synthesis-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
We	O
show	O
that	O
in	O
the	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	I-cell_line
Molt4	B-RNA
c-myc	I-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
is	O
down-regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O
	
A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B-DNA
transcription	O
.	O
	
Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O
	
The	O
calcium	O
ionophore-induced	O
c-myc	B-DNA
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O
	
Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	B-DNA
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O
	
The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium-dependent	B-protein
induced	I-protein
gene	I-protein
product	I-protein
.	O
	
###MEDLINE:91124866	
	
Oestrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
analysis	O
in	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O
	
Oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
are	O
present	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O
	
Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	O
and	O
Hodgkin	O
's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O
	
Until	O
now	O
,	O
ER	B-protein
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O
	
Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	B-protein
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O
	
We	O
studied	O
49	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O
	
In	O
30	O
of	O
these	O
cases	O
ER	B-protein
enzyme	O
immunoassay	O
(	O
ER	B-protein
-EIA	O
)	O
was	O
also	O
performed	O
.	O
	
Cultured	B-cell_line
MCF-7	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O
a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B-protein
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40-48	O
%	O
ER	B-cell_type
positive	I-cell_type
cells	I-cell_type
by	O
immunocytochemistry	O
;	O
200	O
fmol/mg	O
protein	O
by	O
EIA	O
)	O
.	O
	
All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(	O
96	O
%	O
)	O
were	O
negative	O
for	O
ER	B-protein
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol/mg	O
protein	O
)	O
.	O
	
The	O
two	O
positive	O
cases	O
expressed	O
granular	O
ER	B-protein
staining	O
over	O
the	O
nucleus	O
(	O
9.2	O
and	O
12.1	O
%	O
positive	O
cells	O
)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O
	
It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	O
rarely	O
express	O
ER	B-protein
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B-protein
.	O
	
It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	O
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O
	
###MEDLINE:91065749	
	
Type-II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
a	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
growth-inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti-estrogen	O
and	O
bioflavonoids	O
.	O
	
Type-II	B-protein
estrogen-binding	I-protein
sites	I-protein
(	O
type-II	B-protein
EBS	I-protein
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
IM-9	B-cell_line
using	O
a	O
whole-cell	O
assay	O
with	O
(	O
6	O
,	O
7-3H	O
)	O
estradiol	O
(	O
3H-E2	O
)	O
as	O
tracer	O
.	O
	
Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type-II	B-protein
EBS	I-protein
.	O
	
Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O
	
The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type-II	B-protein
EBS	I-protein
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O
	
Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type-II	B-protein
EBS	I-protein
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O
	
Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O
	
Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti-estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	B-cell_line
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	B-protein
EBS	I-protein
.	O
	
###MEDLINE:91132900	
	
[	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O
	
Quantitation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B-protein
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O
	
It	O
is	O
stated	O
that	O
GCR	B-protein
of	O
healthy	O
controls	O
and	O
GCS-untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol-dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O
	
Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B-protein
count	O
in	O
cortisol-dependent	O
BA	O
tends	O
to	O
rise	O
.	O
	
Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B-protein
level	O
estimated	O
by	O
3H-triamcinolone	O
acetonide	O
.	O
	
###MEDLINE:90382324	
	
Two	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
on	O
the	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
.	O
	
Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	B-cell_type
cells	I-cell_type
via	O
interactions	O
with	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O
	
Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B-protein
with	O
one-site	O
kinetics	O
.	O
	
Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A-ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
(	O
a	O
human	B-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
)	O
.	O
	
It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O
	
The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O
	
In	O
mutant	O
leukemic	B-cell_type
cells	I-cell_type
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
.	O
	
We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B-protein
affinity	I-protein
CVZ	I-protein
binding	I-protein
site	I-protein
.	O
	
We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B-cell	B-cell_line
line	I-cell_line
,	O
IM-9	B-cell_line
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B-protein
's	I-protein
binding	I-protein
sites	I-protein
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B-protein
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ-resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O
	
These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
on	O
the	O
human	O
GR	B-protein
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O
	
###MEDLINE:90381363	
	
Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B-DNA
genes	I-DNA
in	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B-protein
activity	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
.	O
	
In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B-DNA
promoter	I-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O
	
The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	B-DNA
promoter-driven	I-DNA
beta-galactosidase	I-DNA
gene	I-DNA
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	B-protein
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O
	
A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-DNA
gene	I-DNA
with	O
an	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
,	O
results	O
in	O
beta-galactosidase	B-protein
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	B-cell_line
and	O
primary	B-cell_type
cells	I-cell_type
.	O
	
Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	I-protein
.	O
	
###MEDLINE:91049522	
	
[	O
The	O
effect	O
of	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O
	
Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O
	
The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B-cell_type
and	I-cell_type
0-lymphocytes	I-cell_type
.	O
	
Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	B-cell_type
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O
	
Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O
	
###MEDLINE:91013631	
	
[	O
The	O
role	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
HLA	B-protein
antigens	I-protein
in	O
the	O
pathogenesis	O
of	O
Cushing	O
's	O
syndrome	O
]	O
	
Lymphocytic	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-Cushing	O
's	O
syndrome	O
.	O
	
Incidence	O
of	O
HLA	B-protein
antigens	I-protein
was	O
determined	O
in	O
94	O
of	O
them	O
.	O
	
A	O
significant	O
rise	O
of	O
A10	B-protein
and	O
B27	B-protein
antigen	I-protein
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko-Cushing	O
's	O
syndrome	O
.	O
	
The	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O
	
The	O
patients	O
carrying	O
B27	B-protein
antigen	I-protein
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O
	
Antigen	B-protein
B27	I-protein
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
blood	B-cell_type
lymphocytes	I-cell_type
.	O
	
###MEDLINE:90242285	
	
Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
RWLeu-4	B-cell_line
.	O
	
The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B-cell_line
chromosome-positive	I-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RWLeu-4	B-cell_line
,	O
were	O
investigated	O
.	O
	
Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites/cell	O
,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM	O
.	O
	
Treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
induced	O
24R-hydroxylase	B-protein
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O
	
Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O
	
Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage/monocyte	B-cell_type
type	I-cell_type
cells	I-cell_type
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O
	
Progressive	O
expression	O
of	O
cell	B-protein
surface	I-protein
maturation-specific	I-protein
antigens	I-protein
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O
	
c-myc	B-RNA
RNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B-cell_line
cells	I-cell_line
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O
	
Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-protein
oncogene	I-protein
product	I-protein
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O
	
Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O
	
###MEDLINE:90208323	
	
A	O
new	O
member	O
of	O
the	O
leucine	B-protein
zipper	I-protein
class	I-protein
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-DNA
DR	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O
	
Several	O
mutants	O
derived	O
from	O
transformed	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
defective	O
in	O
expressing	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O
	
The	O
failure	O
to	O
express	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
in	O
at	O
least	O
one	O
such	O
mutant	B-cell_line
line	I-cell_line
has	O
been	O
mapped	O
to	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
X	I-DNA
box	I-DNA
,	O
a	O
conserved	B-DNA
transcriptional	I-DNA
element	I-DNA
in	O
the	O
promoter	B-DNA
region	I-DNA
.	O
	
A	O
complementary	B-DNA
DNA	I-DNA
encoding	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
human	B-protein
X	I-protein
box	I-protein
binding	I-protein
protein	I-protein
,	O
hXBP-1	B-protein
)	O
whose	O
target	O
is	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
X	I-DNA
box	I-DNA
and	O
the	O
3	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
now	O
been	O
cloned	O
.	O
	
This	O
complementary	B-DNA
DNA	I-DNA
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	B-DNA
target	I-DNA
sequence	I-DNA
of	O
c-jun	B-DNA
.	O
	
Mutation	O
of	O
the	O
hXBP-1	B-DNA
DNA	I-DNA
target	I-DNA
sequence	I-DNA
decreased	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
vivo	O
.	O
	
These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B-protein
protein	I-protein
acts	O
as	O
a	O
transcription	B-protein
factor	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:90171176	
	
Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O
	
Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O
	
The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O
	
Absent	O
or	O
greatly	O
diminished	O
type	O
I	B-protein
aldosterone	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O
	
We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O
	
There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O
	
In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B-protein
receptor	I-protein
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O
	
In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O
	
These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O
	
In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O
	
It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O
	
###MEDLINE:90161003	
	
Perceived	O
social	O
support	O
and	O
tumor	O
estrogen/progesterone	B-protein
receptor	I-protein
status	O
as	O
predictors	O
of	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
activity	O
in	O
breast	O
cancer	O
patients	O
.	O
	
This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	B-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O
	
All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O
	
A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
``	O
stress	O
''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O
	
In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables	O
.	O
	
Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B-protein
receptor	I-protein
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O
	
Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O
	
###MEDLINE:91215472	
	
[	O
Estrogen	B-protein
receptor	I-protein
content	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O
	
ER	O
content	O
in	O
lymphocytes	B-cell_type
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran-coated	O
charcoal	O
assay	O
.	O
	
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol/mg	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
protein	I-protein
and	O
fmol/micrograms	O
of	O
lymphocyte	B-DNA
DNA	I-DNA
.	O
	
The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B-protein
content	O
of	O
lymphocytes	B-cell_type
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O
	
But	O
the	O
logarithmic	O
mean	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-protein
protein	I-protein
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
	
The	O
normal	O
upper	O
limit	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O
	
The	O
elevated	O
rate	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
in	O
14	O
active	O
SLE	O
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O
	
Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	B-protein
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B-protein
antibody	I-protein
and	O
hypocomplementemia	O
.	O
	
###MEDLINE:91099657	
	
An	O
in	O
vitro	O
globin	B-DNA
gene	I-DNA
switching	O
model	O
based	O
on	O
differentiated	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O
	
We	O
used	O
mouse	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
(	I-cell_type
ES	I-cell_type
)	I-cell_type
cells	I-cell_type
to	O
study	O
globin	B-DNA
gene	I-DNA
expression	O
and	O
switching	O
in	O
vitro	O
.	O
	
We	O
show	O
that	O
ES-derived	B-cell_type
embryoid	I-cell_type
bodies	I-cell_type
express	O
the	O
full	O
complement	O
of	O
mouse	B-DNA
embryonic	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B-DNA
genes	I-DNA
.	O
	
In	O
addition	O
,	O
the	O
erythroid-specific	B-protein
transcription	I-protein
factor	I-protein
NF-E1	B-protein
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B-protein
in	O
embryoid	B-cell_type
bodies	I-cell_type
.	O
	
We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O
	
When	O
the	O
human	B-DNA
epsilon-	I-DNA
or	I-DNA
beta-globin	I-DNA
genes	I-DNA
driven	O
by	O
the	O
dominant	B-DNA
control	I-DNA
region	I-DNA
(	O
DCR	B-DNA
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
,	O
in	O
contrast	O
to	O
the	O
beta-globin	B-DNA
gene	I-DNA
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	B-DNA
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B-DNA
gene	I-DNA
.	O
	
We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-globin	B-DNA
gene	I-DNA
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
.	O
	
###MEDLINE:91043047	
	
Cloning	O
of	O
a	O
mitogen-inducible	B-DNA
gene	I-DNA
encoding	O
a	O
kappa	B-protein
B	I-protein
DNA-binding	I-protein
protein	I-protein
with	O
homology	O
to	O
the	O
rel	B-DNA
oncogene	I-DNA
and	O
to	O
cell-cycle	B-DNA
motifs	I-DNA
.	O
	
We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	B-DNA
gene	I-DNA
isolated	O
from	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
predicts	O
a	O
protein	O
of	O
968	B-protein
amino	I-protein
acids	I-protein
.	O
	
The	O
amino-terminal	B-protein
domain	I-protein
has	O
regions	O
homologous	O
to	O
the	O
oncogene	B-DNA
rel	I-DNA
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	B-DNA
of	O
Drosophila	O
.	O
	
The	O
carboxy-terminal	B-protein
domain	I-protein
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	B-DNA
human	I-DNA
oncogene	I-DNA
bcl-3	I-DNA
and	O
in	O
the	O
ankyrin	B-protein
protein	I-protein
.	O
	
A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B-protein
protein	I-protein
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
found	O
in	O
many	O
inducible	B-DNA
genes	I-DNA
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O
	
This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O
	
###MEDLINE:91050279	
	
Extrarenal	O
receptor-effector-mechanisms	O
for	O
aldosterone	O
:	O
the	O
sequence	O
of	O
effects	O
on	O
the	O
cellular	O
electrolyte	O
transport	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
their	O
implications	O
for	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balances	O
.	O
	
High	O
affinity	O
aldosterone	O
binding	O
sites	O
have	O
not	O
only	O
been	O
described	O
in	O
the	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
renal	O
tubules	O
,	O
but	O
also	O
in	O
non-classic	O
target	O
tissues	O
such	O
as	O
the	O
hippocampus	O
,	O
mammary	O
gland	O
,	O
endothelial	B-cell_type
cells	I-cell_type
and	O
,	O
recently	O
,	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
In	O
the	O
absence	O
of	O
aldosterone	O
,	O
the	O
intracellular	O
Na+	O
,	O
K+	O
and	O
Ca2+	O
concentrations	O
and	O
the	O
cell	O
volume	O
decreased	O
significantly	O
,	O
but	O
remained	O
constant	O
when	O
aldosterone	O
(	O
1.4	O
nmol/l	O
)	O
was	O
added	O
to	O
the	O
incubation	O
medium	O
.	O
	
These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol/l	O
)	O
.	O
	
The	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
could	O
be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action	O
,	O
possibly	O
non-genomically	O
mediated	O
through	O
membrane	B-protein
receptors	I-protein
.	O
	
The	O
clinical	O
significance	O
of	O
this	O
model	O
was	O
underlined	O
by	O
the	O
demonstration	O
of	O
absent	O
or	O
a	O
decreased	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
and	O
the	O
lack	O
of	O
electrolyte	O
response	O
to	O
aldosterone	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
pseudohypoaldosteronism	O
and	O
aldosteronism	O
.	O
	
Additionally	O
,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
from	O
essential	O
hypertensives	O
.	O
	
These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
extrarenal	B-protein
,	I-protein
nonepithelial	I-protein
mineralocorticoid	I-protein
receptors	I-protein
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O
	
###MEDLINE:91037456	
	
Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O
	
Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti-sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O
	
Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O
	
Immunostained	B-cell_type
tumor	I-cell_type
cells	I-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O
	
The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O
in	O
female	O
cases	O
.	O
	
Furthermore	O
,	O
the	O
existence	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
estrogen	O
binding	O
activity	O
)	O
was	O
examined	O
histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8	O
.	O
	
We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O
	
###MEDLINE:90287178	
	
Involvement	O
of	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	B-protein
.	O
	
Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	I-cell_line
blocked	O
IL-1-induced	B-DNA
gene	I-DNA
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	I-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
This	O
inhibitor	O
did	O
not	O
affect	O
protein	B-protein
kinase	I-protein
C	I-protein
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	B-protein
in	O
a	O
number	O
of	O
responsive	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O
	
###MEDLINE:90244395	
	
The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
ORI1yt	I-DNA
enhancer	I-DNA
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B-protein
transcription	I-protein
factors	I-protein
R	I-protein
and	I-protein
Z	I-protein
.	O
	
The	O
Epstein-Barr	B-DNA
virus	I-DNA
DR	I-DNA
promoter	I-DNA
is	O
located	O
upstream	O
of	O
the	O
PstI	B-DNA
repeats	I-DNA
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B-DNA
box	I-DNA
,	O
it	O
contains	O
an	O
upstream	B-DNA
region	I-DNA
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-protein
(	I-protein
Z	I-protein
)	I-protein
(	O
the	O
BZLF1-encoded	B-protein
transcription	I-protein
factor	I-protein
)	O
and	O
an	O
enhancer	B-DNA
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	B-DNA
.	O
	
Domain	B-DNA
B	I-DNA
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-DNA
EB1-responsive	I-DNA
element	I-DNA
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	B-protein
and	O
R	B-protein
,	O
an	O
EBV	B-protein
early	I-protein
product	I-protein
encoded	O
by	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
BRLF1	I-DNA
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O
	
We	O
show	O
here	O
that	O
domain	B-DNA
B	I-DNA
is	O
an	O
R-responsive	B-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	B-DNA
B-cell-specific	I-DNA
element	I-DNA
.	O
	
However	O
,	O
there	O
is	O
an	O
EB1-binding	B-DNA
site	I-DNA
(	O
ZRE-B	B-DNA
)	O
located	O
within	O
the	O
R-responsive	B-DNA
enhancer	I-DNA
region	I-DNA
.	O
	
ZRE-B	B-DNA
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	O
enhancer	O
activity	O
.	O
	
Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B-protein
and	O
EB1	B-protein
when	O
activating	O
the	O
B	B-DNA
domain	I-DNA
(	O
ZRE-B	B-DNA
plus	O
the	O
R-responsive	B-DNA
element	I-DNA
)	O
positioned	O
as	O
an	O
enhancer	B-DNA
.	O
	
ZRE-B	B-DNA
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-DNA
inducible	I-DNA
enhancer	I-DNA
.	O
	
We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	I-DNA
B	B-DNA
domain	I-DNA
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	I-DNA
.	O
	
We	O
found	O
that	O
the	O
R-responsive	B-DNA
element	I-DNA
is	O
composed	O
of	O
four	O
protoenhancers	B-DNA
that	O
span	O
the	O
whole	O
B	B-DNA
domain	I-DNA
.	O
	
These	O
protoenhancers	B-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-protein
.	O
	
One	O
of	O
the	O
protoenhancers	B-DNA
contains	O
the	O
overlapping	B-DNA
palindromes	I-DNA
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O
	
However	O
,	O
one	O
palindrome	B-DNA
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B-DNA
palindromes	I-DNA
did	O
not	O
respond	O
to	O
R	O
.	O
	
###MEDLINE:90360678	
	
Nuclear	O
3	B-protein
,	I-protein
5	I-protein
,	I-protein
3'-triiodothyronine	I-protein
receptors	I-protein
(	O
T3R	B-protein
)	O
of	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
in	O
hyper-	O
and	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
.	O
	
The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B-protein
alterations	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O
	
Nuclear	O
T3R	B-protein
in	O
lymphocytes	B-cell_type
was	O
determined	O
by	O
radio-ligand	O
binding	O
analysis	O
.	O
	
The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O
	
In	O
hyperthyroidism	O
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased	O
.	O
	
In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	B-protein
T3R	I-protein
MBC	O
of	O
lymphocytes	B-cell_type
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O
	
It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B-protein
T3R	I-protein
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O
	
###MEDLINE:90255794	
	
Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-protein
alpha	I-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptor	I-protein
.	O
	
Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D-dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR-II	O
)	O
.	O
	
These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T-lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O
	
Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T-lymphocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
S-LB1	B-cell_line
)	O
from	O
a	O
normal	O
individual	O
.	O
	
The	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
of	O
S-LB1	B-cell_line
was	O
comparable	O
to	O
the	O
well-characterized	O
chick	B-protein
intestinal	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5-20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O
	
Three	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
VDDR-II	O
(	O
Rh-	O
VDR	B-protein
,	O
Sh-	O
VDR	B-protein
,	O
and	O
Ab-	O
VDR	B-protein
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	B-protein
and	O
treatment	O
of	O
the	O
cultured	B-cell_line
cells	I-cell_line
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25-dihydroxy-vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O
	
In	O
a	O
fourth	O
cell	B-cell_line
line	I-cell_line
,	O
A1-VDR	B-cell_line
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-protein
(	I-protein
OH	I-protein
)	I-protein
D3-24-hydroxylase	I-protein
activity	O
was	O
not	O
detectable	O
.	O
	
Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	B-cell_line
line	I-cell_line
,	O
designated	O
Ro-VDR	B-cell_line
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
a	O
normal	O
donor	O
.	O
	
The	O
capacity	O
of	O
the	O
receptor	B-protein
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro-VDR	B-cell_line
.	O
	
In	O
all	O
cell	B-cell_line
lines	I-cell_line
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	B-protein
was	O
detectable	O
,	O
the	O
receptor	B-protein
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O
	
Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	B-cell_line
and	O
A1-VDR	B-cell_line
cells	I-cell_line
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O
	
While	O
Ro-VDR	B-cell_line
cells	I-cell_line
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	B-protein
from	O
A1-VDR	B-cell_line
cells	I-cell_line
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O
	
In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	B-RNA
coding	O
for	O
both	O
the	O
c-myc	B-DNA
oncogene	I-DNA
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte-monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
status	O
of	O
these	O
cells	O
.	O
	
Use	O
of	O
these	O
cell	B-cell_line
lines	I-cell_line
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	B-protein
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O
	
###MEDLINE:90153985	
	
Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
.	O
	
AP-1	B-protein
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	B-DNA
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	B-DNA
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
	
We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	I-cell_line
during	O
monocytic	O
differentiation	O
.	O
	
Low	O
levels	O
of	O
c-jun	B-RNA
transcripts	I-RNA
were	O
detectable	O
in	O
untreated	B-cell_line
HL-60	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O
	
Similar	O
kinetics	O
of	O
c-jun	B-DNA
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B-cell_line
U-937	I-cell_line
and	O
THP-1	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O
	
Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O
	
Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B-DNA
expression	O
.	O
	
TPA	O
treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	B-DNA
transcripts	O
.	O
	
Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-DNA
gene	O
transcription	O
in	O
untreated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O
	
Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B-DNA
transcription	O
.	O
	
The	O
half-life	O
of	O
c-jun	B-RNA
RNA	I-RNA
as	O
determined	O
by	O
treating	O
HL-60	B-cell_line
cells	I-cell_line
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O
	
In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	B-RNA
RNA	I-RNA
in	O
TPA-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O
	
These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	B-RNA
RNA	I-RNA
observed	O
during	O
TPA-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O
	
###MEDLINE:92213636	
	
[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O
	
As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O
	
Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2	O
)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3	O
)	O
low	O
content	O
of	O
T3	O
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O
	
It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O
	
It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O
	
###MEDLINE:91092268	
	
Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	I-DNA
.	O
	
A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
However	O
,	O
analysis	O
of	O
the	O
viral	B-DNA
control	I-DNA
elements	I-DNA
and	O
the	O
cellular	B-protein
factors	I-protein
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	B-cell_type
has	O
not	O
been	O
reported	O
.	O
	
The	O
adenovirus	B-protein
early	I-protein
region	I-protein
3	I-protein
(	I-protein
ES	I-protein
)	I-protein
gene	I-protein
products	I-protein
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B-protein
I	I-protein
MHC	I-protein
antigens	I-protein
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O
	
To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	I-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	B-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	I-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O
	
These	O
studies	O
detected	O
two	O
novel	B-DNA
domains	I-DNA
referred	O
to	O
as	O
L1	B-DNA
and	O
L2	B-DNA
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O
	
Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O
	
Transfections	O
of	O
E3	B-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L2	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L1	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
when	O
coupled	O
to	O
the	O
L2	B-DNA
mutation	O
.	O
	
Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	B-DNA
and	O
L2	B-DNA
domains	I-DNA
indicated	O
that	O
the	O
primary	B-DNA
sequence	I-DNA
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B-DNA
promoter	I-DNA
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:91034184	
	
Characterization	O
of	O
defensin	B-protein
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-DNA
virulence	I-DNA
regulon	I-DNA
of	O
Salmonella	O
typhimurium	O
.	O
	
The	O
defensin	B-protein
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	B-DNA
two-component	I-DNA
virulence	I-DNA
regulon	I-DNA
were	O
tested	O
by	O
using	O
purified	B-protein
defensins	I-protein
NP-1	B-protein
and	O
NP-2	B-protein
.	O
	
Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	B-DNA
pair	I-DNA
(	O
phoP	B-DNA
[	O
transcriptional	B-DNA
activator	I-DNA
]	O
or	O
phoQ	B-DNA
[	O
membrane	B-protein
sensor	I-protein
kinase	I-protein
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	B-protein
.	O
	
The	O
predicted	O
periplasmic	B-protein
domain	I-protein
of	O
the	O
PhoQ	B-protein
protein	I-protein
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B-protein
proteins	I-protein
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B-protein
.	O
	
Because	O
insertion	O
mutations	O
in	O
phoP	B-DNA
are	O
polar	O
on	O
phoQ	B-DNA
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-protein
protein	I-protein
in	O
the	O
absence	O
of	O
PhoP	B-protein
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B-protein
gene	I-protein
product	I-protein
.	O
	
We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B-protein
without	O
PhoP	B-protein
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B-protein
.	O
	
This	O
implied	O
that	O
a	O
pag	B-protein
(	I-protein
phoP-activated	I-protein
gene	I-protein
)	I-protein
product	I-protein
is	O
responsible	O
for	O
defensin	B-protein
resistance	O
.	O
	
We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B-protein
NP-1	B-protein
,	O
NP-5	B-protein
,	O
and	O
HNP-1	B-protein
to	O
activate	O
pag	B-DNA
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O
	
Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	B-protein
regulon	I-protein
because	O
mutations	O
in	O
pagC	B-DNA
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-DNA
locus	I-DNA
that	O
resulted	O
in	O
constitutive	O
pag	B-DNA
activation	O
(	O
phenotype	O
PhoPc	B-protein
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	B-protein
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	B-cell_type
.	O
	
The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-DNA
-phoQ	B-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-protein
proteins	I-protein
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	B-cell_type
.	O
	
###MEDLINE:91045897	
	
Stimulation	O
of	O
a	O
human	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
with	O
anti-CD3	B-protein
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
induces	O
NF-kappa	B-protein
B	I-protein
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O
	
The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	B-DNA
sequence	I-DNA
and	O
the	O
translocation	O
of	O
the	O
HIV	B-protein
enhancer-binding	I-protein
protein	I-protein
NF-kappa	B-protein
B	I-protein
were	O
analyzed	O
in	O
two	O
human	O
T-cell	B-cell_line
clones	I-cell_line
stimulated	O
through	O
their	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
or	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
	
We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	I-DNA
or	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O
	
Interleukin	B-protein
2	I-protein
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-protein
B	I-protein
translocation	O
or	O
LTR	B-DNA
transactivation	O
.	O
	
Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B-DNA
LTR	I-DNA
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	O
to	O
CD3	B-protein
did	O
not	O
.	O
	
The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O
	
Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	B-protein
to	I-protein
CD3	I-protein
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B-DNA
enhancer	I-DNA
-dependent	O
transcription	O
in	O
cloned	B-cell_line
T	I-cell_line
cells	I-cell_line
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
indicates	O
that	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
differ	O
from	O
tumoral	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
terms	O
of	O
requirements	O
for	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O
	
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O
	
###MEDLINE:91028334	
	
Decreased	O
concentration	O
of	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
X-linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O
	
Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O
	
However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
can	O
not	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O
	
Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-protein
)	O
,	O
abnormalities	O
of	O
VDR	B-protein
have	O
been	O
postulated	O
in	O
XLH	O
.	O
	
In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-protein
in	O
PHA-activated	B-cell_line
peripheral	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
from	O
10	O
XLH	O
patients	O
.	O
	
Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+/-	O
5.1	O
fmol/mg	O
protein	O
,	O
mean	O
+/-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+/-	O
4.0	O
)	O
.	O
	
On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate-supplemented	O
patients	O
(	O
58.3	O
+/-	O
2.7	O
)	O
and	O
controls	O
.	O
	
There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-protein
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
	
In	O
two	O
patients	O
,	O
VDR	B-protein
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O
	
These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O
	
###MEDLINE:90319091	
	
Two	O
distinct	O
forms	O
of	O
active	B-protein
transcription	I-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
.	O
	
Mammalian	B-cell_type
cells	I-cell_type
express	O
two	O
distinct	O
forms	O
of	O
transcription	B-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-RNA
gene	I-RNA
transcript	I-RNA
.	O
	
The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	B-protein
acid	I-protein
serine-rich	I-protein
insertion	I-protein
present	O
in	O
one	O
of	O
the	O
CREB	B-protein
isoforms	I-protein
.	O
	
We	O
show	O
that	O
both	O
CREB	B-protein
isoforms	I-protein
are	O
expressed	O
in	O
many	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
mammalian	O
species	O
.	O
	
Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
in	I-DNA
vitro	I-DNA
.	O
	
As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-protein
proteins	I-protein
bind	O
DNA	O
as	O
dimers	O
.	O
	
Both	O
proteins	O
impart	O
cAMP-regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-protein
.	O
	
The	O
presence	O
of	O
multiple	O
CREB	B-protein
isoforms	I-protein
with	O
identical	O
DNA-binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	B-protein
domain	I-protein
raises	O
the	O
possibility	O
that	O
CREB	B-protein
proteins	I-protein
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
	
###MEDLINE:90244434	
	
Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion-associated	B-protein
regulatory	I-protein
protein	I-protein
.	O
	
The	O
vpr	B-protein
product	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	I-protein
.	O
	
The	O
vpr	B-protein
product	I-protein
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O
	
This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	B-DNA
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O
	
###MEDLINE:90337320	
	
A	O
novel	O
B-cell	B-protein
lineage-specific	I-protein
transcription	I-protein
factor	I-protein
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O
	
A	O
novel	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
,	O
was	O
identified	O
as	O
a	O
mammalian	B-protein
homolog	I-protein
of	O
the	O
sea	B-protein
urchin	I-protein
protein	I-protein
TSAP	B-protein
,	O
which	O
interacts	O
with	O
the	O
promoters	B-DNA
of	O
four	O
tissue-specific	B-DNA
late	I-DNA
histone	I-DNA
H2A-2	I-DNA
and	I-DNA
H2B-2	I-DNA
genes	I-DNA
.	O
	
As	O
shown	O
by	O
mobility-shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B-protein
protein	I-protein
BSAP	B-protein
recognizes	O
all	O
four	O
sea	B-DNA
urchin	I-DNA
binding	I-DNA
sites	I-DNA
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	B-protein
;	O
however	O
,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O
weight	O
.	O
	
BSAP	B-protein
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O
	
Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O
	
Moreover	O
,	O
BSAP	B-protein
is	O
clearly	O
a	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
a	O
wild-type	B-DNA
but	O
not	O
a	O
mutant	B-DNA
TSAP-binding	I-DNA
site	I-DNA
of	O
the	O
sea	O
urchin	O
functions	O
only	O
in	O
transfected	B-cell_line
B	I-cell_line
cells	I-cell_line
as	O
an	O
upstream	B-DNA
promoter	I-DNA
element	I-DNA
.	O
	
Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
for	O
BSAP	B-protein
in	O
known	O
regulatory	B-DNA
regions	I-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
class	I-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
BSAP	B-protein
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B-lymphoid-specific	B-DNA
genes	I-DNA
.	O
	
###MEDLINE:90169371	
	
Octamer	B-protein
transcription	I-protein
factors	I-protein
and	O
the	O
cell	B-DNA
type-specificity	I-DNA
of	I-DNA
immunoglobulin	I-DNA
gene	I-DNA
expression	O
.	O
	
Antibodies	B-protein
are	O
produced	O
exclusively	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
The	O
expression	O
of	O
the	O
antibody-encoding	B-DNA
genes	I-DNA
,	O
the	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
,	O
is	O
also	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O
	
The	O
octamer	B-DNA
sequence	I-DNA
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	B-DNA
and	O
the	O
enhancer	B-DNA
of	O
Ig	B-DNA
genes	I-DNA
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O
	
This	O
sequence	B-DNA
motif	I-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-protein
proteins	I-protein
,	O
the	O
so-called	O
octamer	B-protein
transcription	I-protein
factors	I-protein
(	O
Oct	B-protein
or	O
OTF	B-protein
factors	I-protein
)	O
.	O
	
The	O
Oct-1	B-protein
protein	I-protein
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	B-protein
and	O
Oct-2B	B-protein
are	O
found	O
mainly	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O
	
It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	B-protein
Oct	I-protein
factors	I-protein
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B-protein
and	O
Oct-2	B-protein
factors	I-protein
.	O
	
Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	B-protein
factor	I-protein
variants	I-protein
were	O
identified	O
.	O
	
Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B-RNA
transcript	I-RNA
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O
	
###MEDLINE:90151654	
	
A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
only	O
in	O
lymphocytes	B-cell_type
is	O
a	O
ubiquitously	B-protein
active	I-protein
transcription	I-protein
factor	I-protein
.	O
	
The	O
transcriptional	B-DNA
enhancer	I-DNA
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
constant	I-DNA
region	I-DNA
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
	
Like	O
other	O
enhancers	B-DNA
,	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
contains	O
several	O
short	O
sequence	B-DNA
motifs	I-DNA
that	O
bind	O
specific	B-protein
transcription	I-protein
factors	I-protein
.	O
	
Each	O
binding	B-DNA
site	I-DNA
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	B-DNA
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O
	
For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
components	I-DNA
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	B-DNA
elements	I-DNA
.	O
	
We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B-DNA
enhancer	I-DNA
motif	I-DNA
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O
	
It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
non-B	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
in	O
non-lymphoid	B-cell_type
cells	I-cell_type
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF-muE3	B-protein
,	O
was	O
detected	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
non-B	B-cell_type
cells	I-cell_type
.	O
	
From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
:	O
(	O
a	O
)	O
cell-specific	B-protein
factors	I-protein
such	O
as	O
Oct-2A	B-protein
and	O
Oct-2B	B-protein
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	B-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
that	O
are	O
constitutively	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	B-protein
active	I-protein
factors	I-protein
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	B-DNA
sequence	I-DNA
motif	I-DNA
.	O
	
This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
in	O
non-B	B-cell_type
cells	I-cell_type
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	O
chromatin	B-DNA
structure	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
locus	I-DNA
.	O
	
###MEDLINE:92107586	
	
[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O
	
A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O
and	O
thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O
14	O
years	O
.	O
	
The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O
	
###MEDLINE:91092266	
	
TAR	B-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Multiple	B-DNA
regulatory	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV	B-DNA
LTR	I-DNA
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O
	
Previous	O
transfection	O
studies	O
of	O
HIV	B-DNA
LTR	I-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
indicated	O
that	O
multiple	O
regulatory	B-DNA
regions	I-DNA
including	O
the	O
enhancer	B-DNA
,	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
TAR	B-DNA
regions	I-DNA
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O
	
To	O
characterize	O
these	O
regulatory	B-DNA
elements	I-DNA
further	O
,	O
mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
HIV	B-DNA
LTRs	I-DNA
and	O
infectious	O
proviral	O
constructs	O
were	O
assembled	O
.	O
	
These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	B-cell_line
cells	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O
	
Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B-protein
gag	I-protein
protein	I-protein
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O
	
Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B-DNA
motif	I-DNA
or	O
TAR	B-DNA
primary	I-DNA
sequence	I-DNA
resulted	O
in	O
only	O
slight	O
decreases	O
.	O
	
However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	B-DNA
loop	I-DNA
sequences	I-DNA
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
HeLa	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
.	O
	
High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B-DNA
mutant	I-DNA
constructs	I-DNA
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B-DNA
region	I-DNA
or	O
by	O
disruption	O
of	O
the	O
tat	B-DNA
gene	I-DNA
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:91258741	
	
A	O
case	O
of	O
hypersensitivity	O
to	O
thyroid	O
hormones	O
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	O
triiodothyronine	B-protein
receptors	I-protein
.	O
	
A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O
	
Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded	O
.	O
	
The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O
	
The	O
lymphocyte	B-protein
nuclear	I-protein
T3	I-protein
receptor	I-protein
was	O
found	O
with	O
an	O
affinity	O
close	O
to	O
that	O
of	O
normal	O
volunteers	O
(	O
Ka	O
:	O
1.42	O
x	O
10	O
(	O
10	O
)	O
M-1	O
vs	O
1.95	O
+/-	O
0.35	O
x	O
10	O
(	O
10	O
)	O
M-1	O
)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O
(	O
9.9	O
vs	O
3.7	O
+/-	O
0.4	O
fmol	O
T3/100	O
micrograms	O
DNA	O
)	O
.	O
	
Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O
	
Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(	O
27.7	O
+/-	O
3.6	O
nmol/l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O
	
The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-protein
nuclear	I-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
.	O
	
###MEDLINE:90375934	
	
Induction	O
of	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
by	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O
	
A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	B-DNA
,	O
cytoskeletal	B-DNA
,	I-DNA
and	I-DNA
extracellular	I-DNA
matrix	I-DNA
genes	I-DNA
have	O
been	O
termed	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	B-protein
factor	I-protein
-stimulated	O
cell	O
proliferation	O
.	O
	
We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	B-protein
(	O
M-CSF	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	B-protein
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O
	
Normal	O
human	B-cell_type
monocytes	I-cell_type
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O
	
At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
M-CSF	B-protein
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O
	
RNA	O
from	O
control	O
resting	B-cell_type
cells	I-cell_type
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	B-RNA
,	O
fibronectin	B-RNA
receptor	I-RNA
,	O
and	O
actin	B-RNA
mRNA	I-RNA
.	O
	
Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	B-protein
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O
	
The	O
c-jun	B-DNA
gene	I-DNA
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B-protein
addition	O
.	O
	
In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	B-RNA
and	I-RNA
fibronectin	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	B-protein
addition	O
.	O
	
We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	B-DNA
specific	I-DNA
tyrosine	I-DNA
kinase	I-DNA
hck	I-DNA
gene	I-DNA
simultaneously	O
with	O
the	O
other	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O
	
The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super-induced	O
the	O
expression	O
of	O
c-jun	B-DNA
and	O
hck	B-DNA
.	O
	
Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	B-DNA
,	O
hck	B-DNA
,	O
and	O
actin	B-DNA
genes	I-DNA
.	O
	
Therefore	O
,	O
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
M-CSF	B-protein
induces	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
without	O
inducing	O
cell	O
proliferation	O
.	O
	
These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B-protein
.	O
	
###MEDLINE:90317911	
	
Inducible	O
nuclear	B-protein
factor	I-protein
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O
	
Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	B-DNA
genes	I-DNA
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B-protein
.	O
	
In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O
	
To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-protein
factors	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B-protein
DNA-binding	I-protein
complexes	I-protein
,	O
the	O
kappa	B-protein
B	I-protein
complex	I-protein
within	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
the	O
NFAT-1	B-protein
complex	I-protein
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O
	
The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B-protein
phytohemagglutinin	B-protein
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O
	
This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-protein
B	I-protein
complexes	I-protein
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O
	
###MEDLINE:91190842	
	
Purification	O
of	O
TCF-1	B-protein
alpha	I-protein
,	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
activates	O
the	O
T-cell	B-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
gene	I-DNA
enhancer	I-DNA
in	O
a	O
context-dependent	O
manner	O
.	O
	
The	O
differentiation	O
of	O
T	B-cell_type
cells	I-cell_type
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O
	
We	O
have	O
purified	O
a	O
new	O
T-cell-specific	B-protein
factor	I-protein
,	O
TCF-1	B-protein
alpha	I-protein
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B-protein
T-cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O
	
TCF-1	B-protein
alpha	I-protein
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	B-DNA
promoter	I-DNA
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
to	O
promoters	B-DNA
for	O
several	O
genes	B-DNA
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B-DNA
alpha	I-DNA
gene	I-DNA
(	O
e.g.	O
,	O
p56lck	B-DNA
and	O
CD3	B-DNA
delta	I-DNA
)	O
.	O
	
Sequences	O
related	O
to	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
motif	I-DNA
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	B-DNA
TCR	I-DNA
delta	I-DNA
(	O
and	O
possibly	O
TCR	B-DNA
beta	I-DNA
)	O
enhancers	B-DNA
.	O
	
Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	B-protein
alpha	I-protein
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57-	B-protein
to	I-protein
53-kD	I-protein
proteins	I-protein
that	O
are	O
abundantly	O
expressed	O
in	O
mature	B-cell_line
and	I-cell_line
immature	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
Jurkat	B-cell_line
,	O
CCRF-CEM	B-cell_line
)	O
and	O
not	O
in	O
mature	B-cell_line
B	I-cell_line
cells	I-cell_line
(	O
JY	B-cell_line
,	O
Namalwa	B-cell_line
)	O
or	O
nonlymphoid	B-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
A	O
small	O
95-bp	O
fragment	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
control	I-DNA
region	I-DNA
that	O
contains	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
juxtaposed	O
between	O
a	O
cAMP-response	B-DNA
element	I-DNA
(	O
the	O
CRE	B-DNA
or	O
T	B-DNA
alpha	I-DNA
1	I-DNA
motif	I-DNA
)	O
and	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
distinct	O
lymphoid-specific	B-protein
protein	I-protein
(	O
TCF-2	B-protein
alpha	I-protein
)	O
behaved	O
as	O
a	O
potent	O
T-cell-specific	B-DNA
enhancer	I-DNA
in	O
vivo	O
.	O
	
Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	B-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	B-cell_line
(	I-cell_line
CCRF-CEM	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
Mutation	O
of	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	B-DNA
enhancer	I-DNA
repeats	I-DNA
.	O
	
The	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
was	O
also	O
required	O
for	O
TCR	B-protein
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	B-cell_line
but	O
not	O
HeLa	B-cell_line
cells	I-cell_line
,	O
confirming	O
that	O
TCF-1	B-protein
alpha	I-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O
	
Curiously	O
,	O
the	O
TCF-1	B-protein
alpha	I-protein
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O
	
Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B-protein
alpha	I-protein
appears	O
to	O
depend	O
on	O
the	O
TCF-2	B-protein
alpha	I-protein
and	O
T	B-protein
alpha	I-protein
1	I-protein
(	O
CREB	B-protein
)	O
transcription	B-protein
factors	I-protein
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O
	
###MEDLINE:90346297	
	
Tandem	B-DNA
AP-1-binding	I-DNA
sites	I-DNA
within	O
the	O
human	B-DNA
beta-globin	I-DNA
dominant	I-DNA
control	I-DNA
region	I-DNA
function	O
as	O
an	O
inducible	B-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	B-DNA
DNA	I-DNA
segment	I-DNA
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
within	O
the	O
dominant	B-DNA
control	I-DNA
or	O
locus-activating	B-DNA
region	I-DNA
.	O
	
This	O
enhancer	B-DNA
is	O
inducible	O
in	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
,	O
increasing	O
linked	O
gamma-globin	B-DNA
promoter	I-DNA
/luciferase	B-protein
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	B-DNA
construct	I-DNA
.	O
	
The	O
enhancer	B-DNA
consists	O
of	O
tandem	B-DNA
AP-1-binding	I-DNA
sites	I-DNA
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O
	
DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B-protein
molecular	I-protein
weight	I-protein
complex	I-protein
on	O
the	O
enhancer	B-DNA
.	O
	
The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B-DNA
sites	I-DNA
and	O
correlates	O
with	O
maximal	O
enhancer	B-DNA
activity	O
.	O
	
Induction	O
of	O
the	O
enhancer	B-DNA
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O
	
Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
families	I-DNA
to	O
tandem	B-DNA
AP-1	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O
	
###MEDLINE:90220600	
	
Identification	O
of	O
a	O
novel	B-protein
factor	I-protein
that	O
interacts	O
with	O
an	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-protein
cell-specific	I-protein
factor	I-protein
OTF2	B-protein
.	O
	
The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	B-DNA
141	I-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O
	
B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	B-DNA
element	I-DNA
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	B-DNA
region	I-DNA
of	O
this	O
promoter	B-DNA
and	O
in	O
the	O
promoters	B-DNA
of	O
all	O
other	O
immunoglobulin	B-DNA
heavy-	I-DNA
and	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O
	
The	O
interaction	O
of	O
purified	O
octamer	B-protein
transcription	I-protein
factors	I-protein
1	O
and	O
2	O
(	O
OTF1	B-protein
and	O
OTF2	B-protein
)	O
with	O
the	O
MOPC	B-DNA
141	I-DNA
promoter	I-DNA
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B-protein
I	I-protein
footprinting	O
.	O
	
Purified	O
OTF1	B-protein
from	O
HeLa	B-cell_line
cells	I-cell_line
and	O
OTF1	B-protein
and	O
OTF2	B-protein
from	O
B	B-cell_type
cells	I-cell_type
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	B-DNA
promoter	I-DNA
.	O
	
The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O
	
In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
N	B-DNA
element	I-DNA
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O
	
The	O
N	B-DNA
element	I-DNA
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	B-DNA
element	I-DNA
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O
	
The	O
N	B-DNA
element	I-DNA
bound	O
a	O
transcription	B-protein
factor	I-protein
,	O
NTF	B-protein
,	O
that	O
is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	B-protein
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	B-protein
described	I-protein
proteins	I-protein
that	O
bind	O
to	O
similar	O
sequences	O
.	O
	
Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	B-protein
and	O
OTF2	B-protein
interactions	O
(	O
both	O
with	O
their	O
cognate	B-DNA
DNA	I-DNA
elements	I-DNA
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O
	
###MEDLINE:90158596	
	
NF-kappa	B-protein
B	I-protein
as	O
inducible	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
.	O
	
The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phytohemagglutinin	B-protein
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	B-protein
,	O
a	O
transactivating	B-protein
protein	I-protein
of	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O
	
The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
,	O
depending	O
on	O
promoter	B-DNA
elements	I-DNA
that	O
bind	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
(	O
or	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	I-protein
)	O
.	O
	
We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B-DNA
gene	I-DNA
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
.	O
	
A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol.	O
Cell.	O
Biol.	O
8	O
:	O
5581-5587	O
,	O
1988	O
)	O
described	O
a	O
short	B-DNA
promoter	I-DNA
region	I-DNA
in	O
the	O
GM-CSF	B-DNA
gene	I-DNA
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell-activating	O
signals	O
and	O
tax1	B-protein
,	O
but	O
no	O
NF-kappa	B-DNA
B-binding	I-DNA
motifs	I-DNA
were	O
identified	O
.	O
	
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B-protein
NF-kappa	I-protein
B	I-protein
and	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
activated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
element	I-DNA
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	B-protein
.	O
	
As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF-kappa	B-protein
B	I-protein
binds	O
at	O
positions	B-DNA
-82	I-DNA
to	I-DNA
-91	I-DNA
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	B-DNA
functional	I-DNA
kappa	I-DNA
B	I-DNA
motif	I-DNA
in	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
(	O
GGGAAATTCC	O
)	O
.	O
	
Two	O
kappa	B-DNA
B-like	I-DNA
motifs	I-DNA
at	O
positions	B-DNA
-98	I-DNA
to	I-DNA
-108	I-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O
	
Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
to	O
a	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O
	
###MEDLINE:90254291	
	
Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	I-cell_type
.	O
	
The	O
treatment	O
of	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	I-cell_type
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O
	
This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
	
Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O
	
PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B-protein
.	O
	
Alone	O
,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however	O
,	O
PMA-A23187	O
and	O
PMA	O
-PHA	B-protein
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O
	
###MEDLINE:92010096	
	
To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O
.	O
	
Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O
	
Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O
	
The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
haplotypes	I-protein
can	O
mount	O
T-cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B-protein
receptors	I-protein
are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	B-protein
of	O
class	B-protein
I	I-protein
or	O
class	O
II	O
MHC	O
molecules	O
.	O
	
At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self	O
,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous	O
,	O
hence	O
creating	O
responders	O
and	O
nonresponders	O
.	O
	
###MEDLINE:91067681	
	
Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B-protein
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O
	
Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	I-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O
	
On	O
the	O
other	O
hand	O
,	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O
	
Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B-protein
(	O
immunosuppressant	B-protein
binding	I-protein
protein	I-protein
)	O
.	O
	
We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B-protein
binding	I-protein
protein	I-protein
FKBP	B-protein
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B-protein
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O
	
However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	B-protein
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
,	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
necessary	O
for	O
IL-2	B-DNA
gene	I-DNA
activation	O
.	O
	
Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
proliferation	O
.	O
	
The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	B-protein
FKBP	B-protein
.	O
	
FKBP	B-protein
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	B-protein
amide	I-protein
bond	I-protein
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B-protein
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O
	
Neither	O
FKBP	B-protein
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	B-protein
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O
	
Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B-protein
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B-protein
receptor	I-protein
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	B-protein
interferes	O
with	O
IL-2	B-protein
-induced	O
signals	O
.	O
	
###MEDLINE:91035625	
	
Adherence-dependent	O
increase	O
in	O
human	B-RNA
monocyte	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
is	O
associated	O
with	O
increases	O
in	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
EGR2	I-RNA
mRNA	I-RNA
.	O
	
Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	B-cell_type
monocyte	I-cell_type
to	O
a	O
tissue	B-cell_type
macrophage	I-cell_type
.	O
	
This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	B-protein
factors	I-protein
.	O
	
We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	B-RNA
encoding	O
profibrotic	O
growth	B-protein
factors	I-protein
such	O
as	O
platelet-derived	B-protein
growth	I-protein
factor	I-protein
B	I-protein
subunit	I-protein
(	O
PDGF	B-protein
[	I-protein
B	I-protein
]	I-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
.	O
	
After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O
	
No	O
increase	O
in	O
TGF-beta	B-RNA
mRNA	I-RNA
was	O
observed	O
.	O
	
The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O
	
The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O
	
Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
accumulation	O
.	O
	
The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	I-DNA
c-fos	B-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O
	
The	O
increase	O
in	O
c-jun	O
and	O
EGR2	O
,	O
but	O
not	O
c-fos	B-DNA
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O
	
These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
.	O
	
In	O
addition	O
,	O
the	O
increases	O
in	O
c-jun	B-DNA
,	O
EGR2	B-DNA
,	O
and	O
PDGF	B-protein
(	I-protein
B	I-protein
)	I-protein
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O
	
Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O
	
###MEDLINE:91065527	
	
Single	O
cell	O
assay	O
of	O
a	O
transcription	B-protein
factor	I-protein
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O
	
Stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
through	O
their	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
NF-AT	B-protein
and	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O
	
To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B-protein
factor	I-protein
in	O
individual	B-cell_type
viable	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	B-protein
(	O
beta-gal	B-protein
)	O
.	O
	
We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	B-protein
transcriptional	O
activity	O
among	O
T	B-cell_type
cells	I-cell_type
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
directs	O
transcription	O
of	O
the	O
lacZ	B-DNA
gene	I-DNA
.	O
	
Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B-cell_line
stably	I-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B-protein
and	O
others	O
express	O
high	O
levels	O
.	O
	
This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation	O
.	O
	
Further	O
results	O
,	O
in	O
which	O
beta-gal	B-protein
activity	O
is	O
correlated	O
with	O
NF-AT	B-protein
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-protein
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O
	
This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	B-protein
concentration-dependent	O
assembly	O
of	O
transcription	B-protein
complexes	I-protein
at	O
the	O
promoter	B-DNA
.	O
	
Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	I-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	I-DNA
.	O
	
###MEDLINE:90317873	
	
The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
BMRF1	I-DNA
promoter	I-DNA
for	O
early	B-protein
antigen	I-protein
(	O
EA-D	B-protein
)	O
is	O
regulated	O
by	O
the	O
EBV	B-protein
transactivators	I-protein
,	O
BRLF1	B-protein
and	O
BZLF1	B-protein
,	O
in	O
a	O
cell-specific	O
manner	O
.	O
	
The	O
Epstein-Barr	B-protein
virus	I-protein
early	I-protein
antigen	I-protein
diffuse	I-protein
component	I-protein
(	O
EA-D	B-protein
)	O
is	O
essential	O
for	O
Epstein-Barr	O
virus	B-DNA
DNA	I-DNA
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O
	
We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B-DNA
(	O
BMRF1	B-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-protein
viral	I-protein
transactivators	I-protein
,	O
BZLF1	B-protein
(	O
Z	B-protein
)	O
and	O
BRLF1	B-protein
(	O
R	B-protein
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O
	
In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
Z	B-protein
or	O
R	B-protein
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B-DNA
promoter	I-DNA
activity	O
,	O
whereas	O
both	O
transactivators	B-protein
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O
	
In	O
epithelial	B-cell_type
cells	I-cell_type
,	O
the	O
Z	B-protein
transactivator	I-protein
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
;	O
the	O
effect	O
of	O
R	B-protein
and	O
Z	B-protein
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B-protein
alone	O
.	O
	
Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
demonstrated	O
that	O
in	O
epithelial	B-cell_type
cells	I-cell_type
the	O
potential	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
plays	O
an	O
essential	O
role	O
in	O
Z	B-protein
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O
	
In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
only	O
the	O
upstream	B-DNA
sequences	I-DNA
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	B-protein
combination	O
,	O
and	O
the	O
AP-1	B-protein
site	I-protein
is	O
dispensable	O
.	O
	
These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	I-DNA
regulation	O
by	O
Z	B-protein
and	O
R	B-protein
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O
	
###MEDLINE:90319127	
	
Complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
human	B-protein
T-cell	I-protein
FK506-binding	I-protein
protein	I-protein
,	O
a	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
distinct	O
from	O
cyclophilin	B-protein
.	O
	
The	O
recently	O
discovered	O
macrolide	O
FK506	O
has	O
been	O
demonstrated	O
to	O
have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	O
A	O
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O
such	O
as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O
	
After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B-protein
A-binding	I-protein
protein	I-protein
cyclophilin	B-protein
is	O
identical	O
to	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
,	O
a	O
cellular	B-protein
binding	I-protein
protein	I-protein
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B-protein
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O
	
In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	B-protein
)	O
from	O
human	O
peripheral	O
blood	O
T	B-cell_type
cells	I-cell_type
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	O
,	O
reported	O
for	O
bovine	B-protein
FKBP	I-protein
.	O
	
The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O
	
The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino-terminal	O
sequence	O
of	O
bovine	O
FKBP	B-protein
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	B-protein
.	O
	
Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B-protein
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B-protein
.	O
	
This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
,	O
evolved	O
independently	O
.	O
	
In	O
Northern	O
blot	O
analysis	O
,	O
mRNA	B-RNA
species	I-RNA
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	B-DNA
FKBP	I-DNA
cDNA	I-DNA
were	O
detected	O
in	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
+	I-RNA
RNAs	I-RNA
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	B-cell_type
cells	I-cell_type
and	O
leukocytes	B-cell_type
.	O
	
Induction	O
of	O
Jurkat	B-cell_line
leukemic	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-RNA
mRNA	I-RNA
.	O
	
Southern	O
blot	O
analysis	O
of	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
digested	O
with	O
different	O
restriction	B-protein
enzymes	I-protein
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	O
sequence	O
encoding	O
FKBP	B-protein
.	O
	
This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B-DNA
gene	I-DNA
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	B-DNA
genome	I-DNA
.	O
	
###MEDLINE:90258907	
	
Involvement	O
of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	I-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
expression	O
.	O
	
To	O
determine	O
whether	O
enhancer	B-DNA
elements	I-DNA
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
-nucleotide	I-DNA
motif	I-DNA
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
putative	B-protein
additional	I-protein
lymphoid-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
designated	O
NF-microB	B-protein
,	O
in	O
the	O
murine	B-DNA
IgH	I-DNA
enhancer	I-DNA
.	O
	
We	O
demonstrate	O
that	O
the	O
NF-microB-binding	B-DNA
site	I-DNA
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B-DNA
enhancer	I-DNA
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
in	O
cells	O
of	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
but	O
not	O
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
.	O
	
This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B-DNA
site	I-DNA
.	O
	
Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	B-DNA
and	O
OCTA	B-DNA
sites	I-DNA
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	B-DNA
or	O
E3	B-DNA
site	I-DNA
in	O
a	O
70-base-pair	B-DNA
fragment	I-DNA
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
completely	O
.	O
	
Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	B-DNA
motif	I-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O
	
DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B-protein
protein	I-protein
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	I-DNA
.	O
	
Our	O
results	O
suggest	O
that	O
the	O
microB	B-DNA
element	I-DNA
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	B-DNA
element	I-DNA
is	O
essential	O
for	O
its	O
activity	O
.	O
	
###MEDLINE:90298081	
	
Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	B-DNA
transactivator	I-DNA
gene	I-DNA
.	O
	
Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O
	
Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O
	
The	O
transactivator	B-DNA
(	I-DNA
IE-2	I-DNA
)	I-DNA
gene	I-DNA
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O
	
This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	B-DNA
tat	I-DNA
gene	I-DNA
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
.	O
	
While	O
the	O
HIV-2	O
and	O
HIV-1	B-DNA
tat	I-DNA
genes	I-DNA
and	O
T-cell	B-protein
activators	I-protein
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	B-DNA
transactivator	I-DNA
in	O
combination	O
with	O
the	O
HIV-2	B-DNA
tat	I-DNA
or	O
T-cell	B-protein
activators	I-protein
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O
	
Both	O
HIV-2	O
and	O
CMV	B-DNA
transactivators	I-DNA
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B-DNA
transactivator	I-DNA
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O
	
A	O
significant	O
proportion	O
of	O
transcripts	B-RNA
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	B-protein
.	O
	
Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
.	O
	
###MEDLINE:90244306	
	
Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	B-cell_type
infiltrates	I-cell_type
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O
	
Inflammatory	B-cell_type
infiltrates	I-cell_type
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	B-cell_type
,	O
IgA+	B-cell_type
and	I-cell_type
IgG+	I-cell_type
plasma	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
with	O
their	O
subpopulations	O
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O
	
These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O
	
A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B-protein
receptor	I-protein
(	O
OR	B-protein
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
	
The	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
suppressor/cytotoxic	I-cell_line
T	I-cell_line
cells	I-cell_line
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
	
The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
	
In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
T	I-cell_line
cells	I-cell_line
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7+	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O
	
###MEDLINE:90124644	
	
Reactivity	O
of	O
lymphocytes	B-cell_line
to	O
a	O
progesterone	B-protein
receptor-specific	I-protein
monoclonal	I-protein
antibody	I-protein
.	O
	
In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
not	O
nonpregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
progesterone	B-protein
receptor-specific	I-protein
monoclonal	I-protein
antibody	I-protein
mPRI	B-protein
.	O
	
Using	O
an	O
avidin	B-protein
-biotin	B-protein
peroxidase	I-protein
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
only	O
0.47	O
+/-	O
0.33	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	B-cell_type
lymphocytes	I-cell_type
reacted	O
with	O
the	O
antibody	O
.	O
	
To	O
characterize	O
the	O
receptor-bearing	O
subset	O
,	O
CD8+	B-cell_line
and	I-cell_line
CD4+	I-cell_line
cells	I-cell_line
were	O
depleted	O
by	O
complement-dependent	O
lysis	O
.	O
	
Depletion	O
of	O
CD8+	B-cell_line
cells	I-cell_line
was	O
accompanied	O
by	O
62	O
+/-	O
18	O
%	O
loss	O
of	O
progesterone	B-cell_line
receptor-bearing	I-cell_line
cells	I-cell_line
,	O
while	O
depletion	O
of	O
CD4+	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	B-cell_line
.	O
	
In	O
nonpregnancy	B-cell_line
lymphocytes	I-cell_line
a	O
3-day	O
PHA	B-protein
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B-cell_type
cells	I-cell_type
.	O
	
These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	B-cell_line
contain	O
progesterone	B-protein
binding	I-protein
structures	I-protein
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O
	
###MEDLINE:91079583	
	
Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Interaction	O
of	O
fibronectin	B-protein
with	O
VLA-5	B-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
induces	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O
	
Fibronectin	B-protein
synergized	O
with	O
anti-CD3	B-protein
antibody	I-protein
to	O
promote	O
CD4	B-protein
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
.	O
	
In	O
addition	O
,	O
anti-CD29	B-protein
(	O
integrin	B-protein
beta	I-protein
1	I-protein
)	O
as	O
well	O
as	O
anti-VLA-5	B-protein
(	O
human	B-protein
fibronectin	I-protein
receptor	I-protein
)	O
antibodies	O
blocked	O
this	O
CD4	B-cell_line
cell	I-cell_line
activation	O
in	O
this	O
system	O
.	O
	
Although	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
can	O
not	O
induce	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
,	O
the	O
combination	O
of	O
anti-CD3	B-protein
plus	O
fibronectin	B-protein
induced	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
.	O
	
In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-protein
-VLA-5	O
fibronectin	B-protein
receptor	I-protein
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-protein
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-protein
transcriptional	I-protein
factor	I-protein
.	O
	
Thus	O
the	O
VLA-5	B-protein
fibronectin	I-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B-protein
-	O
TCR	B-protein
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-protein
.	O
	
###MEDLINE:91164434	
	
Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
Alzheimer	O
's	O
disease	O
.	O
	
Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
	
In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O
	
GR	O
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O
	
These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	B-protein
deficiency	O
.	O
	
###MEDLINE:91100449	
	
Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
release	O
by	O
tumor	B-cell_type
cells	I-cell_type
?	O
	
One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c-erbB2	O
,	O
int-2	O
,	O
and	O
c-myc	O
gene	O
amplification	O
.	O
	
Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O
	
Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O
	
Amplified	O
c-erbB2	B-DNA
gene	I-DNA
sequences	I-DNA
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O
	
Int-2	B-DNA
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	B-DNA
was	O
amplified	O
in	O
10.3	O
%	O
.	O
	
In	O
a	O
non-parametric	O
test	O
(	O
Kruskal-Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c-erbB2	B-DNA
amplification	O
and	O
absence	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O
	
No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O
	
There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	B-DNA
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O
	
A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	B-DNA
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O
	
We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B-protein
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O
	
###MEDLINE:91175707	
	
Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-protein
Tax	I-protein
protein	I-protein
.	O
	
Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O
	
Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
the	O
nucleus	O
of	O
Namalwa	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
express	O
Tax	B-protein
.	O
	
In	O
contrast	O
,	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	B-protein
to	O
activate	O
NF-kappa	B-protein
B	I-protein
was	O
also	O
blocked	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
Tax	B-protein
.	O
	
However	O
,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	B-protein
transcription	I-protein
factors	I-protein
,	O
such	O
as	O
Fos	B-protein
and	O
Jun	B-protein
,	O
was	O
unaffected	O
.	O
	
Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	B-protein
expression	O
can	O
be	O
quite	O
different	O
.	O
	
Consequently	O
,	O
one	O
function	O
of	O
Tax	B-protein
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O
	
The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O
	
###MEDLINE:91041706	
	
Interferon-gamma	B-protein
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O
	
The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O
	
In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B-protein
interferon-gamma	B-protein
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O
	
Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B-protein
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O
	
###MEDLINE:90302010	
	
Cloning	O
of	O
a	O
transcriptionally	B-protein
active	I-protein
human	I-protein
TATA	I-protein
binding	I-protein
factor	I-protein
.	O
	
Transcription	B-protein
factor	I-protein
IID	I-protein
(	O
TFIID	B-protein
)	O
binds	O
to	O
the	O
TATA	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B-DNA
genes	I-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O
	
Complementary	B-DNA
DNA	I-DNA
(	O
cDNA	B-DNA
)	O
encoding	O
a	O
human	B-protein
TFIID	I-protein
protein	I-protein
has	O
been	O
cloned	O
.	O
	
The	O
human	B-protein
TFIID	I-protein
polypeptide	I-protein
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37	O
,	O
745	O
daltons	O
.	O
	
The	O
carboxyl-terminal	B-protein
181	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
human	B-protein
TFIID	I-protein
protein	I-protein
shares	O
80	O
%	O
identity	O
with	O
the	O
TFIID	B-protein
protein	O
from	O
Saccharomyces	O
cerevisiae	O
.	O
	
The	O
amino	B-protein
terminus	I-protein
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O
and	O
an	O
X-Thr-Pro	B-protein
repeat	I-protein
.	O
	
Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O
	
###MEDLINE:91208110	
	
A	O
novel	O
T-cell	B-protein
trans-activator	I-protein
that	O
recognizes	O
a	O
phorbol	B-DNA
ester-inducible	I-DNA
element	I-DNA
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O
	
The	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
recognized	O
by	O
several	O
cell-type-specific	B-protein
and	I-protein
ubiquitous	I-protein
transcriptional	I-protein
regulators	I-protein
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	B-protein
production	O
and	O
T-cell	B-cell_type
activation	O
.	O
	
Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B-protein
T-cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
TCF-1	B-protein
(	O
for	O
T-Cell	B-protein
Factor-1	I-protein
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA
response	I-DNA
element	I-DNA
(	O
TCE	B-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
	
Although	O
the	O
TCE	B-DNA
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	B-protein
is	O
distinct	O
from	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
However	O
,	O
like	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
TCF-1	B-protein
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O
	
###MEDLINE:90199680	
	
Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O
	
Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I-II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow-up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O
	
Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-protein
receptor	I-protein
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O
	
Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O
	
These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O
	
Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR/EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O
	
Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O
	
For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O
	
The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O
	
High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O
	
The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O
	
###MEDLINE:90191722	
	
Tax	B-protein
-independent	O
binding	O
of	O
multiple	O
cellular	B-protein
factors	I-protein
to	O
Tax-response	B-DNA
element	I-DNA
DNA	I-DNA
of	O
HTLV-I	O
.	O
	
The	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	B-DNA
(	O
Tax-response	B-DNA
element	I-DNA
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B-protein
encoded	I-protein
transactivator	I-protein
protein	I-protein
Tax	B-protein
.	O
	
We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-protein
proteins	I-protein
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	B-cell_line
immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	I-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	B-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	B-protein
.	O
	
The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O
	
Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O
	
First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	B-protein
proteins	I-protein
were	O
specifically	O
cross-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE-DNA	B-DNA
fragment	I-DNA
.	O
	
Second	O
,	O
TRE-DNA	B-protein
binding	I-protein
proteins	I-protein
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O
	
Third	O
,	O
only	O
the	O
50	B-protein
kD	I-protein
protein	I-protein
was	O
retained	O
on	O
a	O
biotinylated	O
DNA-streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE-DNA	B-DNA
.	O
	
Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	B-DNA
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B-protein
,	I-protein
36	I-protein
to	I-protein
42	I-protein
and	I-protein
110	I-protein
kD	I-protein
proteins	I-protein
and	O
to	O
less	O
extent	O
the	O
50	B-protein
kD	I-protein
factor	I-protein
.	O
	
Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I-C	O
)	O
]	O
in	O
all	O
reactions	O
.	O
	
The	O
cAMP-response	B-DNA
element	I-DNA
CRE	B-DNA
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B-DNA
base-pair	I-DNA
sequence	I-DNA
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	B-DNA
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O
	
This	O
result	O
suggests	O
that	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
,	O
CREB	B-protein
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	B-protein
complex	I-protein
and	O
in	O
mediating	O
the	O
Tax	B-protein
response	O
.	O
	
###MEDLINE:90140708	
	
Two	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
the	O
immunoglobulin	B-DNA
enhancer	I-DNA
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
.	O
	
Activity	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
enhancers	I-DNA
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B-protein
and	I-protein
developmentally	I-protein
regulated	I-protein
proteins	I-protein
.	O
	
Two	O
complementary	B-DNA
DNAs	I-DNA
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	B-protein
and	O
ITF-2	B-protein
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
found	O
in	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancers	I-DNA
.	O
	
The	O
complementary	B-DNA
DNAs	I-DNA
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B-protein
and	O
ITF-2	B-protein
are	O
structurally	O
and	O
functionally	O
similar	O
.	O
	
The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	B-protein
motifs	I-protein
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O
	
###MEDLINE:92077236	
	
Elevated	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O
	
The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O
	
Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B-protein
affinity	O
did	O
not	O
differ	O
.	O
	
Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-protein
sites	O
per	O
cell	O
in	O
the	O
steroid-treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O
	
The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O
	
In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP-phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	B-protein
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B-protein
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP-induced	O
GR	B-protein
expression	O
.	O
	
###MEDLINE:91092267	
	
The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	B-protein
produced	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B-protein
protein	I-protein
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O
	
Using	O
constructs	O
in	O
which	O
mRNA	B-RNA
production	O
controlled	O
by	O
a	O
specific	O
transcription	B-protein
factor	I-protein
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B-protein
,	O
NFIL2	B-protein
A	I-protein
,	O
NFIL2	B-protein
B	I-protein
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O
	
However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O
	
Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B-protein
factors	I-protein
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B-protein
factors	I-protein
.	O
	
###MEDLINE:90376447	
	
The	O
internal	O
methionine	O
codons	O
of	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
II	I-DNA
rex	I-DNA
gene	I-DNA
are	O
not	O
required	O
for	O
p24rex	B-protein
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O
	
Human	O
T-cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B-DNA
trans-acting	I-DNA
regulatory	I-DNA
genes	I-DNA
,	O
tax	B-DNA
and	O
rex	B-DNA
,	O
located	O
in	O
the	O
3	B-DNA
'	I-DNA
region	I-DNA
of	O
the	O
viral	B-DNA
genome	I-DNA
.	O
	
The	O
tax	B-protein
gene	I-protein
product	I-protein
(	O
HTLV-I	B-protein
p40tax	I-protein
and	O
HTLV-II	B-protein
p37tax	I-protein
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
The	O
rex	B-DNA
gene	I-DNA
encodes	O
two	O
protein	O
products	O
,	O
p27rex/p21rex	B-protein
and	O
p26rex/p24rex	B-protein
in	O
HTLV-I	O
and	O
HTLV-II	O
,	O
respectively	O
.	O
	
Rex	B-protein
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full-length	O
gag/pol	B-protein
and	O
singly	O
spliced	O
env	B-RNA
mRNA	I-RNA
in	O
the	O
cytoplasm	O
of	O
HTLV-infected	B-cell_type
cells	I-cell_type
.	O
	
Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-DNA
gene	I-DNA
is	O
critical	O
for	O
Rex	B-protein
production	O
and	O
function	O
.	O
	
The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-protein
function	O
is	O
not	O
known	O
.	O
	
However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	O
rex	B-DNA
gene	I-DNA
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-protein
,	O
and	O
by	O
analogy	O
HTLV-II	O
p24rex	B-protein
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax/rex	B-RNA
mRNA	I-RNA
.	O
	
By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-DNA
gene	I-DNA
on	O
Rex	B-protein
protein	O
production	O
and	O
function	O
.	O
	
Our	O
results	O
indicate	O
that	O
p24rex	B-protein
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-DNA
gene	I-DNA
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O
	
###MEDLINE:91016834	
	
Astrocytes	B-cell_type
and	O
glioblastoma	B-cell_type
cells	I-cell_type
express	O
novel	O
octamer-DNA	B-protein
binding	I-protein
proteins	I-protein
distinct	O
from	O
the	O
ubiquitous	B-protein
Oct-1	I-protein
and	I-protein
B	I-protein
cell	I-protein
type	I-protein
Oct-2	I-protein
proteins	I-protein
.	O
	
The	O
'octamer	B-DNA
'	I-DNA
sequence	I-DNA
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
B-lymphocytes	B-cell_type
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B-DNA
genes	I-DNA
in	O
all	O
cell	O
types	O
.	O
	
In	O
lymphocytes	B-cell_type
,	O
the	O
octamer-binding	B-protein
protein	I-protein
Oct-2A	B-protein
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	B-DNA
specific	I-DNA
gene	I-DNA
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	B-DNA
site	I-DNA
-dependent	O
transcription	O
.	O
	
Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	B-DNA
and	I-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
contain	O
an	O
octamer	B-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O
	
This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	B-protein
proteins	I-protein
in	O
the	O
latter	O
cells	O
.	O
	
Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B-protein
binding	I-protein
proteins	I-protein
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	B-cell_type
mouse	I-cell_type
astrocytes	I-cell_type
.	O
	
These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
nervous	B-protein
system-derived	I-protein
(	I-protein
N-Oct	I-protein
)	I-protein
proteins	I-protein
bound	O
to	O
the	O
octamer	B-DNA
DNA	I-DNA
sequence	I-DNA
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	I-protein
.	O
	
The	O
relationship	O
of	O
the	O
N-Oct	B-protein
proteins	I-protein
to	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct-factors	B-protein
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B-protein
Oct-1	I-protein
and	O
the	O
lymphoid-specific	B-protein
Oct-2A	I-protein
proteins	O
.	O
	
In	O
melanoma	B-cell_type
cells	I-cell_type
that	O
contain	O
the	O
N-Oct-3	B-protein
factor	I-protein
,	O
a	O
transfected	O
lymphocyte-specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	B-DNA
expression	I-DNA
vector	I-DNA
.	O
	
We	O
therefore	O
speculate	O
that	O
N-Oct-3	B-protein
and	O
other	O
N-Oct	B-protein
factors	I-protein
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O
	
###MEDLINE:90351381	
	
Detection	O
in	O
non-erythroid	B-cell_type
cells	I-cell_type
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
EF1	B-protein
.	O
	
The	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
erythroid	B-protein
factor-1	I-protein
(	O
EF1	B-protein
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
.	O
	
Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	B-protein
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O
	
This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-protein
-like	O
activity	O
in	O
non-erythroid	B-cell_type
cells	I-cell_type
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
expressed	O
in	O
such	O
cells	O
.	O
	
###MEDLINE:90290483	
	
Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	B-RNA
mRNA	I-RNA
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O
	
Rex	B-protein
,	O
the	O
post-transcriptional	B-protein
regulator	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	B-RNA
viral	I-RNA
gag-pol	I-RNA
mRNA	I-RNA
.	O
	
Rex	B-protein
is	O
a	O
phosphoprotein	B-protein
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O
	
We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-protein
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-	O
(	O
5-isoquinolinyl-sulfonyl	O
)	O
-2-methylpiperazine	O
]	O
.	O
	
Treatment	O
of	O
an	O
HTLV-I	B-cell_line
infected	I-cell_line
human	I-cell_line
T-cell	I-cell_line
line	I-cell_line
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	B-RNA
gag-pol	I-RNA
mRNA	I-RNA
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-protein
protein	I-protein
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-protein
.	O
	
In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	O
used	O
.	O
	
Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B-protein
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV-I	O
.	O
	
###MEDLINE:90292959	
	
Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4+	B-cell_line
T-cell	I-cell_line
clonal	I-cell_line
lines	I-cell_line
grown	O
in	O
serum-free	O
media	O
.	O
	
CEM-C7	B-cell_line
,	O
a	O
human	B-cell_line
leukemic	I-cell_line
CD4+	I-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	B-cell_line
,	O
CEM-3R43	B-cell_line
,	O
and	O
ICR-27	B-cell_line
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum-free	O
media	O
.	O
	
The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms/ml	O
each	O
transferrin	B-protein
and	O
insulin	B-protein
+	O
5	O
ng/ml	O
sodium	O
selenite	O
+/-	O
0.1	O
%	O
bovine	B-protein
serum	I-protein
albumin	I-protein
.	O
	
While	O
growing	O
either	O
with	O
or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	B-cell_line
lines	I-cell_line
of	O
CEM	B-cell_line
cells	O
displayed	O
growth	O
similar	O
to	O
serum-supplemented	O
cultures	O
.	O
	
Cell	O
proliferation	O
of	O
CEM-C7	B-cell_line
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O
	
with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum-supplemented	B-cell_line
and	I-cell_line
serum-free	I-cell_line
cultures	I-cell_line
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O
	
Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O
	
The	O
expression	O
of	O
CD4	B-protein
,	O
a	O
marker	O
for	O
T-derived	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O
	
When	O
grown	O
in	O
serum-free	O
medium	O
,	O
CEM-C7	B-cell_line
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O
	
Receptor	O
mutant	O
subclones	O
of	O
CEM-C7	B-cell_line
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O
	
The	O
increased	O
sensitivity	O
of	O
CEM-C7	B-cell_line
cells	I-cell_line
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O
	
Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O
	
###MEDLINE:90381807	
	
[	O
Glucocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O
	
It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
on	O
peripheral	B-cell_type
mixed	I-cell_type
leucocytes	I-cell_type
in	O
patients	O
with	O
Yang-deficiency	O
were	O
decreased	O
.	O
	
In	O
this	O
work	O
,	O
the	O
mixed	B-cell_type
leucocytes	I-cell_type
were	O
further	O
separated	O
into	O
mononuclear	B-cell_type
(	I-cell_type
MNL	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
(	I-cell_type
PML	I-cell_type
)	I-cell_type
leucocytes	I-cell_type
,	O
and	O
GCR	B-protein
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	B-cell_type
.	O
	
GCR	B-protein
on	O
MNL	B-cell_type
and	O
PML	B-cell_type
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+/-	O
413	O
and	O
4433	O
+/-	O
651	O
sites/cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+/-	O
962	O
and	O
5622	O
+/-	O
782	O
sites/cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O
	
GCR	B-protein
on	O
MNL	B-cell_type
,	O
PML	B-cell_type
and	O
mixed	B-cell_type
leucocytes	I-cell_type
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O
	
The	O
results	O
were	O
3369	O
+/-	O
370	O
,	O
4986	O
+/-	O
419	O
and	O
4524	O
+/-	O
852	O
sites/cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B-protein
on	O
MNL	B-cell_type
and	O
highest	O
on	O
PML	B-cell_type
.	O
	
###MEDLINE:90158614	
	
The	O
ubiquitous	B-protein
octamer-binding	I-protein
protein	I-protein
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
	
All	O
immunoglobulin	B-DNA
genes	I-DNA
contain	O
a	O
conserved	O
octanucleotide	B-DNA
promoter	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O
	
Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	B-DNA
encoding	O
octamer-binding	B-protein
proteins	I-protein
have	O
been	O
cloned	O
.	O
	
Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B-protein
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B-protein
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O
	
The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
is	O
unclear	O
.	O
	
We	O
have	O
identified	O
two	O
human	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	B-protein
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	B-RNA
immunoglobulin	I-RNA
heavy-chain	I-RNA
mRNA	I-RNA
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	B-DNA
gene	I-DNA
in	O
vitro	O
.	O
	
Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	B-protein
made	O
from	O
one	O
of	O
these	O
pre-B	B-cell_line
cells	I-cell_line
or	O
from	O
HeLa	B-cell_line
cells	I-cell_line
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
gene	I-DNA
.	O
	
Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B-protein
when	O
normalized	O
for	O
binding	O
activity	O
.	O
	
These	O
results	O
suggest	O
that	O
OTF-1	B-protein
,	O
without	O
OTF-2	B-protein
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
and	O
that	O
OTF-2	B-protein
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:90205027	
	
Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O
	
In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	B-cell_type
have	O
already	O
been	O
described	O
.	O
	
In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O
	
In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	B-cell_type
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O
	
A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
	
The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O
	
Plasma	B-protein
renin	I-protein
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O
	
The	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O
	
The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	B-cell_type
of	O
patients	O
with	O
essential	O
hypertension	O
.	O
	
###MEDLINE:91296472	
	
[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
]	O
	
The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
.	O
	
It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O
	
###MEDLINE:91048014	
	
Regulation	O
of	O
gene	O
expression	O
with	O
double-stranded	O
phosphorothioate	O
oligonucleotides	O
.	O
	
Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O
	
The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O
	
Inhibition	O
of	O
sequence-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
was	O
achieved	O
with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B-DNA
or	I-DNA
kappa	I-DNA
B	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O
	
The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B-protein
transcription	I-protein
factor	I-protein
or	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O
	
The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O
	
Octamer-dependent	O
activation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
or	O
NF-kappa	B-protein
B	I-protein
-dependent	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
enhancer	I-DNA
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	B-cell_line
transfected	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B-DNA
consensus	I-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
inhibited	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O
	
The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O
	
###MEDLINE:91098724	
	
[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney-tonifying	O
and	O
qi-invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-protein
receptor	I-protein
]	O
	
The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GCR	B-protein
)	O
in	O
the	O
peripheral	B-cell_type
lymphocytes	I-cell_type
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O
	
In	O
animal	O
experiment	O
,	O
GCR	B-protein
of	O
spleen	B-cell_type
lymphocytic	I-cell_type
cell	I-cell_type
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O
	
The	O
results	O
showed	O
that	O
GCR	B-protein
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O
	
So	O
we	O
think	O
that	O
GCR	B-protein
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O
	
After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney-tonifying	O
and	O
Qi-invigorating	O
,	O
the	O
GCR	B-protein
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O
	
###MEDLINE:90381353	
	
Interferon	O
affects	O
nuclear	B-protein
proteins	I-protein
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O
	
Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-cell_type
myelogenous	I-cell_type
leukemia	I-cell_type
(	I-cell_type
CML	I-cell_type
)	I-cell_type
cells	I-cell_type
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B-protein
proteins	I-protein
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O
	
Exposure	O
of	O
CML	B-cell_type
cells	I-cell_type
to	O
IFN-alpha	B-protein
diminished	O
the	O
effect	O
of	O
the	O
CML	B-protein
cytoplasmic	I-protein
proteins	I-protein
on	O
these	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O
	
The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	B-protein
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B-protein
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O
	
These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B-protein
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-protein
proteins	I-protein
.	O
	
###MEDLINE:90279073	
	
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
transactivates	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O
	
Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
or	O
leader	B-protein
protein	I-protein
(	O
EBNA-LP	B-protein
)	O
affects	O
expression	O
of	O
the	O
EBV	B-protein
latent	I-protein
infection	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O
	
We	O
now	O
demonstrate	O
the	O
following	O
.	O
	
(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B-protein
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	I-DNA
resulted	O
in	O
increased	O
LMP1	B-protein
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
the	O
P3HR-1	B-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	B-protein
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-protein
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
affect	O
LMP1	B-protein
expression	O
.	O
	
(	O
iii	O
)	O
LMP1	B-protein
expression	O
in	O
Daudi	B-cell_line
and	O
P3HR-1-infected	B-cell_line
cells	I-cell_line
was	O
controlled	O
at	O
the	O
mRNA	B-RNA
level	O
,	O
and	O
EBNA-2	B-protein
expression	O
in	O
Daudi	B-cell_line
cells	I-cell_line
increased	O
LMP1	B-RNA
mRNA	I-RNA
.	O
	
(	O
iv	O
)	O
No	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
required	O
for	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
since	O
cotransfection	O
of	O
recombinant	B-DNA
EBNA-2	I-DNA
expression	I-DNA
vectors	I-DNA
and	O
genomic	O
LMP1	B-DNA
DNA	I-DNA
fragments	I-DNA
enhanced	O
LMP1	B-protein
expression	O
in	O
the	O
EBV-negative	B-cell_line
B-lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
BJAB	B-cell_line
,	O
Louckes	B-cell_line
,	O
and	O
BL30	B-cell_line
.	O
	
(	O
v	O
)	O
An	O
EBNA-2-responsive	B-DNA
element	I-DNA
was	O
found	O
within	O
the	O
-512	B-DNA
to	I-DNA
+40	I-DNA
LMP1	I-DNA
DNA	I-DNA
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B-DNA
expression	I-DNA
vector	I-DNA
.	O
	
(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	B-protein
transactivated	O
LMP1	B-protein
as	O
well	O
as	O
the	O
EBV	B-protein
type	I-protein
1	I-protein
EBNA-2	I-protein
.	O
	
(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B-protein
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-protein
,	O
whereas	O
a	O
transformation-competent	B-DNA
EBNA-2	I-DNA
deletion	I-DNA
mutant	I-DNA
did	O
transactivate	O
LMP1	B-protein
.	O
	
LMP1	B-protein
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O
	
Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B-protein
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV-induced	O
growth	O
transformation	O
.	O
	
###MEDLINE:90278097	
	
The	O
expression	O
of	O
c-fos	B-DNA
,	O
c-jun	B-DNA
,	O
and	O
c-myc	B-DNA
genes	I-DNA
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B-DNA
protooncogenes	I-DNA
c-fos	B-DNA
,	O
c-jun	B-DNA
,	O
and	O
c-myc	B-DNA
was	O
studied	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
	
Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B-RNA
mRNA	I-RNA
levels	O
in	O
pre-B	B-cell_line
(	I-cell_line
Hyon	I-cell_line
)	I-cell_line
and	I-cell_line
T	I-cell_line
(	I-cell_line
DND-41	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O
	
The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	B-DNA
in	O
Hyon	B-cell_line
cells	I-cell_line
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O
	
Altered	O
transcription	O
of	O
c-fos	B-DNA
and	O
c-myc	B-DNA
genes	I-DNA
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O
	
Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	B-cell_line
cells	I-cell_line
stabilized	O
the	O
c-myc	B-RNA
mRNA	I-RNA
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O
	
The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B-RNA
mRNA	I-RNA
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O
	
These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	B-DNA
protooncogenes	I-DNA
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	B-DNA
protooncogenes	I-DNA
in	O
the	O
stress	O
response	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:90244394	
	
Mapping	O
of	O
B-cell	B-protein
epitopes	I-protein
of	O
the	O
human	B-protein
hepatitis	I-protein
B	I-protein
virus	I-protein
X	I-protein
protein	I-protein
.	O
	
The	O
immune	O
response	O
to	O
the	O
X	B-protein
protein	I-protein
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B-protein
fusion	I-protein
proteins	I-protein
and	O
synthetic	O
peptides	O
.	O
	
Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O
	
Each	O
serum	O
contained	O
antibodies	B-protein
to	O
a	O
different	O
set	O
of	O
epitopes	B-protein
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B-protein
sequence	I-protein
.	O
	
Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B-protein
proteins	I-protein
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O
	
The	O
carboxy-terminal	B-protein
half	I-protein
of	O
the	O
HBx	B-protein
protein	I-protein
was	O
preferentially	O
recognized	O
by	O
antibodies	B-protein
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B-protein
antigenic	I-protein
region	I-protein
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-protein
epitopes	I-protein
.	O
	
Anti-	O
HBx	B-protein
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O
	
The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B-protein
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B-protein
-specific	O
peptide	O
ELISAs	O
.	O
	
Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O
	
###MEDLINE:90327113	
	
[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B-cell_type
leukocytes	I-cell_type
]	O
	
Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O
	
Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O
	
Leukocytes	B-cell_type
migrated	O
most	O
rapidly	O
at	O
night	O
.	O
	
The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
	
ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol/L	O
)	O
which	O
was	O
dose-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O
	
The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol/L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O
	
It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	B-cell_type
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O
	
The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	B-protein
affinity	I-protein
specific	I-protein
binding	I-protein
sites	I-protein
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
	
###MEDLINE:90277507	
	
Heterogeneity	O
of	O
antigen	B-protein
molecules	I-protein
recognized	O
by	O
anti-tax1	B-protein
monoclonal	I-protein
antibody	I-protein
Lt-4	B-protein
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O
	
Using	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Lt-4	B-protein
,	O
directed	O
against	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
trans-activator	I-protein
(	I-protein
tax1	I-protein
)	I-protein
antigen	I-protein
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-protein
and	O
related	O
antigens	B-protein
in	O
a	O
variety	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O
	
Lt-4	B-protein
reacted	O
with	O
all	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II-bearing	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
Lt-4	B-protein
detected	O
40	O
kd	O
tax1	B-protein
antigen	I-protein
molecules	I-protein
in	O
most	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B-protein
kd	I-protein
tax1	I-protein
antigen	I-protein
.	O
	
In	O
the	O
STLV-I-bearing	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
tax1-related	B-protein
antigen	I-protein
molecules	I-protein
detected	O
by	O
Lt-4	B-protein
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O
	
###MEDLINE:90147621	
	
Characterization	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
enhancer-binding	I-protein
proteins	I-protein
from	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
.	O
	
The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
Among	O
the	O
protein-binding	O
regions	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
is	O
the	O
transcription-enhancer	B-DNA
region	I-DNA
.	O
	
We	O
show	O
that	O
at	O
least	O
one	O
inducible	B-protein
,	O
C1	B-protein
,	O
and	O
one	O
constitutive	B-protein
,	I-protein
C2	I-protein
,	I-protein
protein	I-protein
can	O
bind	O
to	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O
	
Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	I-DNA
.	O
	
Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O
	
The	O
inducible	B-protein
C1	I-protein
protein	I-protein
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B-protein
kDa	I-protein
protein	I-protein
.	O
	
###MEDLINE:91079526	
	
Differences	O
in	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
HIV-1	O
and	O
HIV-2	O
.	O
	
Response	O
to	O
T	B-cell_type
cell	I-cell_type
activation	O
signals	O
.	O
	
T	B-cell_type
cell	I-cell_type
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O
	
In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
comprise	O
the	O
transcriptional	B-DNA
enhancer	I-DNA
,	O
which	O
contains	O
two	O
conserved	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
.	O
	
The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
We	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
LTR	I-DNA
responds	O
better	O
than	O
the	O
HIV-2	B-DNA
LTR	I-DNA
to	O
T	O
cell	O
activation	O
signals	O
.	O
	
These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	B-cell_type
cell	I-cell_type
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	B-DNA
or	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
are	O
placed	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
but	O
also	O
when	O
these	O
enhancers	B-DNA
are	O
switched	O
between	O
their	O
respective	O
LTR	B-DNA
.	O
	
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
.	O
	
Instead	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
the	O
activator	B-protein
protein	I-protein
3	I-protein
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O
	
In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O
	
###MEDLINE:91036996	
	
NF-X2	B-protein
that	O
binds	O
to	O
the	O
DRA	B-DNA
X2-box	I-DNA
is	O
activator	B-protein
protein	I-protein
1	I-protein
.	O
	
Expression	O
cloning	O
of	O
c-Jun	B-protein
.	O
	
Human	B-protein
class	I-protein
II	I-protein
MHC	I-protein
Ag	I-protein
are	O
a	O
family	O
of	O
cell	B-protein
surface	I-protein
glycoproteins	I-protein
.	O
	
Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O
	
In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	B-protein
.	O
	
Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O
	
In	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
one	O
of	O
these	O
cis-acting	B-DNA
regulatory	I-DNA
motifs	I-DNA
is	O
the	O
X2-box	B-DNA
to	O
which	O
nuclear	B-protein
factor	I-protein
X2	I-protein
(	O
NF-X2	B-protein
)	O
binds	O
.	O
	
Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
NF-X2	B-protein
.	O
	
This	O
cDNA	B-DNA
clone	I-DNA
was	O
isolated	O
by	O
expression	O
cDNA	B-DNA
cloning	O
,	O
and	O
encodes	O
the	O
human	B-protein
c-Jun	I-protein
protein	I-protein
,	O
which	O
together	O
with	O
c-Fos	B-protein
forms	O
the	O
heterodimeric	B-protein
activator	I-protein
protein-1	I-protein
transcription	I-protein
complex	I-protein
.	O
	
Whereas	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
do	O
not	O
exist	O
in	O
B	B-cell_line
cells	I-cell_line
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	B-DNA
in	O
class	B-cell_line
II	I-cell_line
nonexpressing	I-cell_line
cells	I-cell_line
.	O
	
Thus	O
,	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-DNA
gene	I-DNA
expression	O
.	O
	
###MEDLINE:91098050	
	
Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O
	
Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B-protein
1	I-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
	
11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd-C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O
	
With	O
hot	O
acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd-C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O
	
Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O
	
Pd-C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O
	
When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B-protein
1	I-protein
receptor	I-protein
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O
	
For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O
	
###MEDLINE:90368794	
	
Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-protein
factor	I-protein
.	O
	
Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O
	
We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	B-protein
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O
	
The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B-protein
binding	O
motif	O
that	O
directs	O
transcription	B-protein
of	I-protein
SV40	I-protein
T-antigen	I-protein
in	O
transgenic	O
mice	O
.	O
	
This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O
	
NFAT-1	B-protein
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	B-cell_type
T-lymphocytes	I-cell_type
upon	O
release	O
of	O
intracellular	B-cell_type
calcium	I-cell_type
.	O
	
By	O
targeting	O
NFAT-1	B-protein
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B-protein
activity	O
.	O
	
Besides	O
in	O
T-lymphocytes	B-cell_type
NFAT-1	B-protein
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte-depleted	B-cell_type
spleen	I-cell_type
cells	I-cell_type
and	O
purified	B-cell_type
B-lymphocytes	I-cell_type
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O
	
A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B-protein
activity	O
between	O
T-lymphocytes	B-cell_type
and	O
non-T-lymphocytes	B-cell_type
was	O
revealed	O
.	O
	
Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O
	
Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	B-protein
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O
	
This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	B-protein
has	O
been	O
shown	O
to	O
bind	O
functional	B-DNA
sequences	I-DNA
in	O
HIV-LTR	B-DNA
suggest	O
a	O
role	O
for	O
NFAT-1	B-protein
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	B-DNA
.	O
	
###MEDLINE:90279052	
	
A	O
novel	O
T-cell	B-protein
protein	I-protein
which	O
recognizes	O
a	O
palindromic	B-DNA
sequence	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
Two	O
major	B-DNA
protein-binding	I-DNA
sites	I-DNA
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
have	O
been	O
identified	O
.	O
	
One	O
(	O
site	B-DNA
B	I-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	I-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	I-DNA
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O
	
A	O
novel	O
T-cell	B-protein
protein	I-protein
recognized	O
the	O
palindromic	B-DNA
sequence	I-DNA
within	O
site	B-DNA
B	I-DNA
and	O
also	O
bound	O
estrogen-	B-DNA
or	I-DNA
thyroid	I-DNA
hormone-response	I-DNA
elements	I-DNA
with	O
lower	O
affinity	O
.	O
	
A	O
7-base-pair	O
mutation	O
in	O
the	O
site	B-DNA
B	I-DNA
palindrome	I-DNA
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:91025498	
	
Progesterone	O
suppression	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O
	
This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
mediated	O
by	O
specific	O
progesterone	B-protein
receptors	I-protein
.	O
	
The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B-protein
factor	I-protein
by	O
progesterone-treated	B-cell_line
pregnancy	I-cell_line
lymphocytes	I-cell_line
.	O
	
RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B-protein
factor	I-protein
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O
	
These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B-protein
receptors	I-protein
and	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
are	O
not	O
involved	O
.	O
	
###MEDLINE:90335211	
	
The	O
56-59-kilodalton	B-protein
protein	I-protein
identified	O
in	O
untransformed	B-protein
steroid	I-protein
receptor	I-protein
complexes	I-protein
is	O
a	O
unique	B-protein
protein	I-protein
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B-protein
and	I-protein
90-kilodalton	I-protein
heat	I-protein
shock	I-protein
proteins	I-protein
.	O
	
It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B-protein
,	O
untransformed	B-protein
progestin	I-protein
,	I-protein
estrogen	I-protein
,	I-protein
androgen	I-protein
,	I-protein
and	I-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B-protein
protein	I-protein
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O
	
In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	B-protein
antibody	I-protein
KN	I-protein
382/EC1	I-protein
raised	O
against	O
the	O
rabbit	B-protein
59-kDa	I-protein
protein	I-protein
reacts	O
with	O
9S	B-protein
,	O
untransformed	B-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
in	O
cytosol	O
prepared	O
from	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	I-cell_line
but	O
not	O
with	O
4S	B-protein
salt-transformed	I-protein
receptors	I-protein
.	O
	
The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-protein
antibody	I-protein
is	O
a	O
56-kDa	B-protein
protein	I-protein
(	O
p56	B-protein
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O
	
There	O
are	O
at	O
least	O
six	O
isomorphs	B-protein
of	O
p56	B-protein
by	O
two-dimensional	O
gel	O
analysis	O
.	O
	
N-Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	B-protein
is	O
a	O
unique	B-protein
human	I-protein
protein	I-protein
.	O
	
When	O
p56	B-protein
is	O
immunoadsorbed	O
from	O
IM-9	B-cell_line
cell	I-cell_line
cytosol	O
,	O
both	O
the	O
70-	B-protein
and	I-protein
90-kDa	I-protein
heat	I-protein
shock	I-protein
proteins	I-protein
are	O
coadsorbed	O
in	O
an	O
immune-specific	O
manner	O
.	O
	
Neither	O
heat	B-protein
shock	I-protein
protein	I-protein
reacts	O
directly	O
with	O
the	O
EC1	B-protein
antibody	I-protein
.	O
	
We	O
conclude	O
that	O
p56	B-protein
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-protein
and	O
hsp90	B-protein
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B-protein
steroid	I-protein
receptors	I-protein
.	O
	
###MEDLINE:90299137	
	
Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B-protein
ets-1	B-protein
defines	O
a	O
transcriptional	B-DNA
activator	I-DNA
sequence	I-DNA
within	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O
	
The	O
ets	B-DNA
proto-oncogene	I-DNA
family	I-DNA
is	O
a	O
group	O
of	O
sequence-related	B-DNA
genes	I-DNA
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O
	
In	O
a	O
study	O
of	O
cellular	B-protein
proteins	I-protein
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
sequence-specific	B-protein
DNA-binding	I-protein
protein	I-protein
.	O
	
A	O
mouse	B-DNA
ets-1	I-DNA
cDNA	I-DNA
clone	I-DNA
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double-stranded	B-DNA
oligonucleotide	I-DNA
probe	I-DNA
representing	O
20	O
bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O
	
The	O
cDNA	B-DNA
sequence	I-DNA
has	O
an	O
813-bp	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
(	O
ORF	B-DNA
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	B-protein
carboxy-terminal	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
human	B-protein
ets-1	I-protein
protein	I-protein
.	O
	
The	O
ORF	B-DNA
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B-protein
protein	I-protein
product	I-protein
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O
	
A	O
mutant	B-DNA
LTR	I-DNA
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B-DNA
binding	I-DNA
site	I-DNA
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O
	
Transcriptional	O
efficiency	O
of	O
the	O
MSV	B-DNA
LTR	I-DNA
promoter	I-DNA
containing	O
this	O
disrupted	O
ets-1	B-DNA
binding	I-DNA
site	I-DNA
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild-type	B-DNA
promoter	I-DNA
in	O
mouse	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
culture	O
,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
was	O
observed	O
.	O
	
We	O
propose	O
that	O
ets-1	B-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B-DNA
genes	I-DNA
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O
	
###MEDLINE:90247097	
	
Type	B-protein
II	I-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O
	
We	O
have	O
previously	O
reported	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
contain	O
type	O
II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
(	O
type	B-protein
II	I-protein
EBS	I-protein
)	O
.	O
	
In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O
	
Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O
	
In	O
postmenopausal	O
women	O
the	O
mean	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O
	
However	O
,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
.	O
	
Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta-estradiol	O
for	O
type	B-protein
II	I-protein
EBS	I-protein
in	O
PBMC	B-cell_type
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O
	
###MEDLINE:90311515	
	
Mononuclear	B-cell_type
leukocyte	I-cell_type
glucocorticoid	B-protein
receptor	I-protein
binding	O
characteristics	O
and	O
down-regulation	O
in	O
major	O
depression	O
.	O
	
Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O
	
To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX-binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B-protein
receptor	I-protein
affinity	O
(	O
1/Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O
	
No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O
	
DEX	O
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	B-protein
GC	I-protein
receptor	I-protein
down-regulation	O
.	O
	
Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O
	
By	O
paired	O
t-test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O
	
Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down-regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O
	
These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor-binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC-mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O
	
###MEDLINE:98038598	
	
Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
and	O
leukocyte	B-cell_type
signal	O
transduction	O
.	O
	
Many	O
aspects	O
of	O
leukocyte	B-cell_type
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	B-protein
and	O
Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	B-cell_type
for	O
cell	O
killing	O
.	O
	
Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
by	O
the	O
Rac	B-protein
GTP-binding	I-protein
proteins	I-protein
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O
	
It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B-protein
oxidase	I-protein
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	O
state	O
of	O
Rac	B-protein
.	O
	
Proteins	O
exist	O
in	O
leukocytes	B-cell_type
able	O
to	O
modify	O
GTP-binding	B-protein
protein	I-protein
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O
	
Proteins	O
of	O
the	O
Ras	B-protein
superfamily	I-protein
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B-protein
filaments	I-protein
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O
	
###MEDLINE:96114389	
	
BSAP	B-protein
:	O
a	O
key	O
regulator	O
of	O
B-cell	B-cell_type
development	O
and	O
differentiation	O
.	O
	
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax-gene	B-DNA
family	I-DNA
of	O
transcription	B-protein
factors	I-protein
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	B-protein
is	O
produced	O
only	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
Here	O
,	O
Markus	O
Neurath	O
,	O
Eckhard	O
Stuber	O
and	O
Warren	O
Strober	O
describe	O
the	O
molecular	O
structure	O
of	O
BSAP	B-protein
and	O
focus	O
on	O
the	O
ability	O
of	O
this	O
protein	O
to	O
regulate	O
the	O
expression	O
of	O
B-cell-specific	B-DNA
genes	I-DNA
.	O
	
They	O
propose	O
that	O
BSAP	B-protein
is	O
a	O
key	B-protein
protein	I-protein
of	O
B	B-cell_type
cells	I-cell_type
and	O
that	O
it	O
not	O
only	O
influence	O
B-cell	O
development	O
but	O
also	O
influences	O
the	O
balance	O
between	O
B-cell	O
proliferation	O
and	O
immunoglobulin	B-protein
secretion	O
at	O
later	O
stages	O
of	O
B-cell	O
differentiation	O
.	O
	
###MEDLINE:96074632	
	
Down-regulation	O
of	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:	O
524	O
]	O
	
The	O
effect	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
proteins	O
was	O
examined	O
in	O
in	B-cell_line
vitro	I-cell_line
activated	I-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
by	O
Western	O
blot	O
analysis	O
.	O
	
Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
,	O
p50	B-protein
,	O
and	O
its	O
precursor	O
,	O
p105	B-protein
,	O
was	O
increased	O
progressively	O
.	O
	
When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O
	
The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	B-protein
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O
	
Besides	O
p50	B-protein
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
,	O
namely	O
c-rel	B-protein
.	O
	
In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	B-protein
DNA-protein	I-protein
complex	I-protein
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
.	O
	
Further	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
construct	B-DNA
containing	O
four	O
tandem	B-DNA
repeats	I-DNA
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
of	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O
	
These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O
	
###MEDLINE:96068726	
	
The	O
myeloid	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
,	O
MZF-1	B-DNA
,	O
regulates	O
the	O
CD34	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O
	
MZF-1	B-DNA
is	O
a	O
C2H2	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
encoding	O
a	O
putative	B-protein
transcriptional	I-protein
regulator	I-protein
of	O
myeloid	O
differentiation	O
.	O
	
The	O
MZF-1	B-DNA
protein	O
contains	O
13	O
C2H2	B-protein
zinc	I-protein
fingers	I-protein
arranged	O
in	O
bipartite	O
DNA	B-protein
binding	I-protein
domains	I-protein
containing	O
zinc	B-protein
fingers	I-protein
through	O
4	O
and	O
,	O
in	O
the	O
carboxy-terminus	B-protein
,	O
5	O
through	O
13	O
.	O
	
We	O
previously	O
identified	O
the	O
DNA	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
recognized	O
by	O
the	O
two	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O
	
To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	B-DNA
,	O
the	O
full-length	O
MZF-1	B-DNA
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
yeast	B-protein
transactivator	I-protein
GAL4	I-protein
.	O
	
The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
regulated	O
by	O
the	O
thymidine	B-DNA
kinase	I-DNA
promoter	I-DNA
containing	O
GAL4	B-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
into	O
NIH	B-cell_line
3T3	I-cell_line
,	O
293	B-cell_line
,	O
K562	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
MZF-1	B-DNA
represses	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
via	O
GAL4	B-protein
binding	O
sites	O
in	O
the	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
NIH	B-cell_line
3T3	I-cell_line
and	O
293	B-cell_line
.	O
	
In	O
contrast	O
,	O
MZF-1	B-DNA
activates	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
the	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
K562	B-cell_line
and	O
Jurkat	B-cell_line
.	O
	
The	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
present	O
in	O
the	O
promoters	B-DNA
of	O
several	O
genes	B-DNA
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B-DNA
promoter	I-DNA
.	O
	
MZF-1	B-DNA
transcriptional	O
regulation	O
of	O
this	O
physiologically	B-DNA
relevant	I-DNA
promoter	I-DNA
was	O
assessed	O
in	O
both	O
hematopoietic	B-cell_line
and	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Recombinant	B-protein
MZF-1	I-protein
protein	I-protein
specifically	O
binds	O
to	O
the	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
CD34	B-DNA
promoter	I-DNA
in	O
mobility	O
shift	O
assays	O
.	O
	
MZF-1	B-DNA
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
regulated	O
by	O
the	O
CD34	B-DNA
promoter	I-DNA
into	O
both	O
nonhematopoietic	B-cell_line
and	I-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
As	O
with	O
the	O
heterologous	O
DNA	B-protein
binding	I-protein
domain	I-protein
,	O
MZF-1	B-DNA
represses	O
reporter	B-DNA
gene	I-DNA
expression	O
in	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
activates	O
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Activation	O
of	O
CD34	B-protein
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
.	O
	
The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	B-DNA
promoter	I-DNA
by	O
MZF-1	B-DNA
suggests	O
the	O
presence	O
of	O
tissue-specific	O
regulators/adapters	O
or	O
differential	O
MZF-1	B-DNA
modifications	O
that	O
determine	O
MZF-1	B-DNA
transcriptional	O
regulatory	O
function	O
.	O
	
###MEDLINE:96038894	
	
The	O
murine	O
BCL6	B-DNA
gene	I-DNA
is	O
induced	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
.	O
	
The	O
chromosomal	O
translocation	O
involving	O
3q27	B-DNA
is	O
often	O
detected	O
in	O
human	B-cell_type
B-cell	I-cell_type
lymphomas	I-cell_type
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large-cell	O
component	O
.	O
	
The	O
BCL6	B-DNA
gene	I-DNA
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O
	
Here	O
we	O
cloned	O
the	O
murine	B-DNA
BCL6	I-DNA
(	I-DNA
mBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
from	O
the	O
muscle	B-DNA
cDNA	I-DNA
library	I-DNA
using	O
the	O
human	B-DNA
BCL6	I-DNA
(	I-DNA
hBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
as	O
a	O
probe	O
.	O
	
The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	B-protein
.	O
	
It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel-like	B-protein
zinc-finger	I-protein
motif	I-protein
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B-protein
,	O
indicating	O
that	O
the	O
BCL6	B-DNA
gene	I-DNA
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O
	
Expression	O
of	O
the	O
mBCL6	B-DNA
gene	I-DNA
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O
	
Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	B-cell_type
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O
	
This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O
	
These	O
results	O
suggest	O
that	O
BCL6	B-protein
plays	O
a	O
role	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	O
early	O
gene	O
.	O
	
###MEDLINE:96114497	
	
The	O
role	O
of	O
BSAP	B-protein
(	O
Pax-5	B-protein
)	O
in	O
B-cell	O
development	O
.	O
	
The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O
	
In	O
this	O
manner	O
,	O
the	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	I-DNA
Pax-5	B-DNA
,	O
encoding	O
the	O
B	B-protein
cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O
	
Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B-protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B-protein
heavy-chain	I-protein
gene	O
at	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
.	O
	
###MEDLINE:96009551	
	
The	O
DNA-binding	O
properties	O
of	O
two	B-protein
heat	I-protein
shock	I-protein
factors	I-protein
,	O
HSF1	B-protein
and	O
HSF3	B-protein
,	O
are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	I-cell_line
HD6	B-cell_line
.	O
	
Avian	O
cells	O
express	O
three	O
heat	B-DNA
shock	I-DNA
transcription	I-DNA
factor	I-DNA
(	I-DNA
HSF	I-DNA
)	I-DNA
genes	I-DNA
corresponding	O
to	O
a	O
novel	B-protein
factor	I-protein
,	O
HSF3	B-protein
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B-protein
and	O
HSF2	B-protein
.	O
	
Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B-protein
reveals	O
that	O
HSF3	B-protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-protein
and	O
HSF2	B-protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O
	
HSF3	B-protein
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	B-cell_line
cell	I-cell_line
line	I-cell_line
HD6	I-cell_line
,	O
the	O
lymphoblast	B-cell_line
cell	I-cell_line
line	I-cell_line
MSB	I-cell_line
,	O
and	O
embryo	B-cell_line
fibroblasts	I-cell_line
,	O
and	O
yet	O
its	O
DNA-binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O
	
Acquisition	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
in	O
HD6	B-cell_line
cells	I-cell_line
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B-protein
dimer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-protein
is	O
oligomerization	O
of	O
an	O
inert	B-protein
monomer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
.	O
	
Induction	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B-protein
.	O
	
As	O
occurs	O
for	O
HSF1	B-protein
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-protein
to	O
the	O
nucleus	O
.	O
	
HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	B-protein
activator	I-protein
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	B-protein
overexpressed	I-protein
HSF3	I-protein
measured	O
by	O
using	O
a	O
heat	B-DNA
shock	I-DNA
element-containing	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	B-protein
GAL4-HSF3	I-protein
protein	I-protein
on	O
a	O
GAL4	B-DNA
reporter	I-DNA
construct	I-DNA
.	O
	
These	O
results	O
reveal	O
that	O
HSF3	B-protein
is	O
negatively	O
regulated	O
in	O
avian	B-cell_type
cells	I-cell_type
and	O
acquires	O
DNA-binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O
	
###MEDLINE:95403468	
	
Direct	O
demonstration	O
of	O
NFATp	B-protein
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	B-cell_line
HT-2	I-cell_line
cells	I-cell_line
using	O
a	O
specific	O
NFATp	B-protein
polyclonal	I-protein
antibody	I-protein
.	O
	
Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B-protein
genes	I-protein
,	O
and	O
NFAT	B-protein
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O
	
Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	B-protein
is	O
a	O
substrate	O
for	O
calcineurin	B-protein
,	O
a	O
serine/threonine	B-protein
phosphatase	I-protein
.	O
	
Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	B-protein
NFATp	I-protein
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110-130-kDa	O
NFATp	B-protein
protein	I-protein
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O
	
Treatment	O
of	O
immunoprecipitated	O
NFATp	B-protein
from	O
untreated	O
HT-2	B-cell_line
cells	I-cell_line
with	O
calcineurin	B-protein
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B-protein
,	O
demonstrating	O
that	O
NFATp	B-protein
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B-protein
.	O
	
NFATp	B-protein
immunoprecipitated	O
from	O
32P-labeled	B-cell_line
HT-2	I-cell_line
cells	I-cell_line
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O
	
Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-protein
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-protein
dephosphorylation	O
.	O
	
The	O
dephosphorylation	O
of	O
NFATp	B-protein
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O
	
Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B-protein
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-protein
is	O
a	O
calcineurin	B-protein
substrate	O
in	O
cells	O
.	O
	
###MEDLINE:95378799	
	
Activation	O
and	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
in	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
:	O
regulation	O
upon	O
CD16	B-protein
ligand	O
binding	O
.	O
	
The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B-protein
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O
	
We	O
report	O
here	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFATp	B-protein
)	O
,	O
a	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
-sensitive	I-protein
factor	I-protein
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B-protein
,	O
mediates	O
CD16	B-protein
-induced	O
activation	O
of	O
cytokine	B-protein
genes	I-protein
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
.	O
	
CD16	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
)	O
-induced	O
expression	O
of	O
cytokine	B-RNA
mRNA	I-RNA
in	O
NK	B-cell_type
cells	I-cell_type
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O
	
Stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
CD16	B-protein
ligands	O
induces	O
NFAT	B-protein
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
	
This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O
	
NK	B-protein
cell	I-protein
NFAT	I-protein
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	B-cell_type
cells	I-cell_type
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	B-protein
.	O
	
Two	O
distinct	O
molecules	O
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	B-protein
activity	O
.	O
	
The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B-protein
and	I-protein
NFATc-	I-protein
specific	I-protein
antibodies	I-protein
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B-protein
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B-protein
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
NK	B-cell_type
cells	I-cell_type
do	O
not	O
express	O
NFATc	B-protein
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	I-RNA
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O
	
However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	B-protein
recognizing	O
the	O
T	B-protein
cell	I-protein
NFATc	I-protein
revealed	O
no	O
detectable	O
NFATc	B-protein
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B-cell_line
ester-stimulated	I-cell_line
cells	I-cell_line
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O
	
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA-sensitive	B-protein
transcription	I-protein
factors	I-protein
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
are	O
expressed	O
in	O
human	O
NK	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	B-cell_type
cells	I-cell_type
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B-protein
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B-RNA
mRNA	I-RNA
.	O
	
###MEDLINE:95372363	
	
Interleukin	O
2	O
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	B-protein
proteins	I-protein
.	O
	
One	O
of	O
the	O
most	O
important	O
cytokines	B-protein
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O
	
While	O
the	O
binding	O
of	O
IL-2	B-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B-protein
,	O
Jak-1	B-protein
and	O
Jak-3	B-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O
	
Since	O
many	O
cytokines	B-protein
that	O
activate	O
Jak	B-protein
kinases	I-protein
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
the	O
ability	O
of	O
IL-2	B-protein
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O
	
Exposure	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NKL	B-cell_line
)	O
to	O
IL-2	B-protein
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-protein
alpha	I-protein
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B-protein
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B-protein
proteins	I-protein
,	O
p94	B-protein
and	O
p95	B-protein
.	O
	
p94	B-protein
and	O
p95	B-protein
share	O
homology	O
with	O
Stat1	B-protein
at	O
the	O
phosphorylation	B-protein
site	I-protein
and	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-protein
.	O
	
These	O
Stat	B-protein
proteins	I-protein
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	B-DNA
DNA	I-DNA
sequence	I-DNA
.	O
	
These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	B-protein
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	B-DNA
genes	I-DNA
involved	O
in	O
immune	O
cell	O
function	O
.	O
	
###MEDLINE:98029486	
	
Expression	O
of	O
c-fos	B-DNA
correlates	O
with	O
IFN-alpha	B-protein
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O
	
This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	B-DNA
and	O
p53	B-RNA
transcripts	I-RNA
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B-protein
2c	I-protein
.	O
	
Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmc	B-cell_type
)	O
and	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
of	O
26	O
patients	O
were	O
examined	O
for	O
c-fos	O
,	O
c-myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	O
.	O
	
Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c-fos	B-RNA
transcript	I-RNA
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	B-protein
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	B-cell_type
cells	I-cell_type
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	B-cell_type
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	B-RNA
mRNA	I-RNA
levels	O
of	O
the	O
hybrid	B-DNA
bcr/abl	I-DNA
,	O
c-myc	B-DNA
and	O
p53	B-DNA
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	B-protein
is	O
accompanied	O
by	O
upregulation	O
of	O
c-fos	B-DNA
and	O
downregulation	O
of	O
c-myc	B-RNA
mRNA	I-RNA
levels	O
in	O
responder	O
patients	O
.	O
	
###MEDLINE:96191817	
	
Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O
	
PROBLEM	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
evaluated	O
.	O
	
METHOD	O
:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O
	
In	O
addition	O
,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine	O
.	O
	
RESULTS	O
:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	B-cell_type
positive	I-cell_type
monocytes	I-cell_type
,	O
and	O
an	O
increase	O
in	O
blood	B-cell_type
monocyte	I-cell_type
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young	O
.	O
	
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O
the	O
monocyte	B-cell_type
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	B-protein
in	O
the	O
monocytes	B-cell_type
.	O
	
###MEDLINE:96074633	
	
Staphylococcal	B-protein
enterotoxins	I-protein
modulate	O
interleukin	B-protein
2	I-protein
receptor	I-protein
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
proteins	I-protein
)	O
.	O
	
Staphylococcal	B-protein
enterotoxins	I-protein
(	O
SE	B-protein
)	O
stimulate	O
T	B-cell_type
cells	I-cell_type
expressing	O
the	O
appropriate	O
variable	B-protein
region	I-protein
beta	I-protein
chain	I-protein
of	I-protein
(	I-protein
V	I-protein
beta	I-protein
)	I-protein
T-cell	I-protein
receptors	I-protein
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O
	
Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	B-protein
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
In	O
addition	O
,	O
SE	B-protein
can	O
induce	O
an	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O
	
Here	O
,	O
we	O
show	O
that	O
SE	B-protein
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
chains	I-protein
(	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-protein
and	O
SEB	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
was	O
down-regulated	O
,	O
IL-2R	B-protein
gamma	I-protein
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-protein
alpha	I-protein
remained	O
largely	O
unaffected	O
.	O
	
The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	B-protein
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
called	O
Stat3	B-protein
and	O
Stat5	B-protein
.	O
	
In	O
parallel	O
experiments	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O
	
After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
was	O
further	O
up-regulated	O
,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
Stat	B-protein
proteins	I-protein
was	O
partly	O
normalized	O
.	O
	
Yet	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-protein
/Stat	B-protein
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B-protein
stimulation	O
.	O
	
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	B-protein
can	O
modulate	O
IL-2R	B-protein
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak/Stat	B-protein
pathway	O
in	O
CD4+	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O
	
###MEDLINE:96086826	
	
Constitutive	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-deficient	O
mice	O
.	O
	
Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
are	O
controlled	O
by	O
inhibitory	B-protein
I	I-protein
kappa	I-protein
B	I-protein
proteins	I-protein
,	O
mainly	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
.	O
	
Apparently	O
normal	O
at	O
birth	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-/-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O
	
Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
and	O
mRNAs	B-RNA
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	B-protein
B	I-protein
.	O
	
NF-kappa	B-protein
B	I-protein
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O
	
In	O
contrast	O
to	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
I	B-cell_line
kappa	I-cell_line
B	I-cell_line
alpha-/-	I-cell_line
embryonic	I-cell_line
fibroblasts	I-cell_line
show	O
minimal	O
constitutive	B-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
that	O
is	O
concomitant	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
degradation	O
.	O
	
Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O
	
However	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O
	
These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
	
###MEDLINE:96085174	
	
Interleukin-7	B-protein
can	O
induce	O
the	O
activation	O
of	O
Jak	B-protein
1	I-protein
,	O
Jak	B-protein
3	I-protein
and	O
STAT	B-protein
5	I-protein
proteins	I-protein
in	O
murine	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
activation	O
of	O
Janus	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
and	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B-protein
.	O
	
IL-7	B-protein
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-protein
1	I-protein
and	O
Jak	B-protein
3	I-protein
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B-protein
proteins	I-protein
.	O
	
The	O
STAT	B-protein
proteins	I-protein
utilized	O
by	O
IL-7	B-protein
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	B-protein
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B-protein
5	I-protein
isoforms	I-protein
.	O
	
Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B-protein
1	I-protein
and	I-protein
3	I-protein
,	O
and	O
STAT	B-protein
5	I-protein
activity	O
strongly	O
correlated	O
with	O
the	O
growth-promoting	O
effects	O
of	O
IL-7	B-protein
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	B-protein
-induced	O
proliferation	O
.	O
	
###MEDLINE:96288304	
	
Cytokine	B-protein
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O
	
Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	O
anti-inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O
	
It	O
has	O
been	O
shown	O
to	O
possess	O
anti-inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	B-protein
induced	O
signal	O
transduction	O
.	O
	
The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	B-protein
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O
	
In	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	B-cell_type
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O
	
Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	B-protein
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	B-protein
IL-2	B-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
(	O
IC50	O
=	O
10-12	O
microM	O
)	O
.	O
	
Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O
	
Add-back	O
experiments	O
with	O
either	O
cytokines	B-protein
(	O
IL-2	B-protein
or	O
IL-6	B-protein
)	O
,	O
LTB4	B-protein
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O
	
However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O
	
Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
which	O
acts	O
on	O
several	O
cytokine	B-DNA
genes	I-DNA
.	O
	
Tepoxalin	O
's	O
effect	O
on	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O
	
These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	B-cell_type
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
subsequent	O
inhibition	O
of	O
cytokine	B-protein
production	O
.	O
	
###MEDLINE:96009559	
	
N-	B-protein
and	I-protein
C-terminal	I-protein
sequences	I-protein
control	O
degradation	O
of	O
MAD3/I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O
	
The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	B-protein
protein	I-protein
MAD3/I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O
	
Analysis	O
of	O
the	O
expression	O
of	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
in	O
stable	O
transfectants	O
of	O
mouse	B-cell_line
70Z/3	I-cell_line
cells	I-cell_line
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O
	
In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	B-protein
inhibitor	O
N-Ac-Leu-Leu-norleucinal	O
inhibits	O
this	O
ligand-induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
.	O
	
By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	I-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
molecule	O
up	O
to	O
amino	B-protein
acid	I-protein
279	I-protein
abolishes	O
constitutive	O
but	O
not	O
ligand-inducible	O
phosphorylation	O
and	O
inhibits	O
ligand-inducible	O
degradation	O
.	O
	
Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
maps	O
to	O
two	O
serines	O
in	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand-induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:95403403	
	
Microtubules	B-protein
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
The	O
genomic	O
actions	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O
	
Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol-VDR	B-protein
complex	I-protein
,	O
the	O
role	O
of	O
microtubules	B-protein
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	B-cell_type
cells	I-cell_type
.	O
	
Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24-hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
	
Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B-protein
binding	O
.	O
	
Thus	O
,	O
intact	O
microtubules	B-protein
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O
	
Interestingly	O
,	O
microtubule	B-protein
disruption	O
also	O
decreased	O
monocyte	B-cell_type
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B-protein
mitochondrial	I-protein
1	I-protein
alpha-hydroxylase	I-protein
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
	
We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O
	
Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O
	
Thus	O
,	O
microtubules	B-protein
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O
	
###MEDLINE:95382761	
	
Relationship	O
between	O
Rap1	B-protein
protein	I-protein
phosphorylation	O
and	O
regulation	O
of	O
Ca2+	O
transport	O
in	O
platelets	B-cell_type
:	O
a	O
new	O
approach	O
.	O
	
Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O
	
We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	B-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPases	I-protein
by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
using	O
a	O
pathological	O
model	O
.	O
	
We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca	O
(	O
2+	O
)	O
-transport	O
by	O
platelet	O
membrane	O
vesicles	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
.	O
	
Then	O
,	O
we	O
studied	O
platelets	B-cell_type
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O
potential	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
target	I-protein
of	O
regulation	O
through	O
the	O
Rap1	B-protein
protein	I-protein
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
using	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
the	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
C.	B-protein
Sub	I-protein
.	I-protein
)	O
.	O
	
In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B-protein
430	I-protein
monoclonal	I-protein
antibody	I-protein
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O
	
In	O
contrast	O
,	O
the	O
Rap1	B-protein
protein	I-protein
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms/ml	O
of	O
the	O
C.	B-protein
Sub	I-protein
.	I-protein
	
These	O
results	O
allowed	O
us	O
to	O
use	O
these	O
pathological	O
platelets	B-cell_type
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	B-protein
protein	I-protein
and	O
the	O
regulation	O
of	O
Ca2+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O
	
We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B-protein
protein	I-protein
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B-protein
Sub	I-protein
.	I-protein
on	O
Ca2+	O
transport	O
.	O
	
Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B-protein
protein	I-protein
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	B-protein
protein	I-protein
with	O
the	O
stimulatory	O
effect	O
of	O
C.	B-protein
Sub	I-protein
.	I-protein
on	O
Ca2+	O
transport	O
.	O
	
Besides	O
the	O
evidence	O
for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	B-protein
protein	I-protein
in	O
platelets	B-cell_type
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2+	O
transport	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
.	O
	
###MEDLINE:95364954	
	
An	O
IRF-1	B-protein
-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Lymphocytes	B-cell_line
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O
	
The	O
tumour	B-protein
suppressor	I-protein
p53	I-protein
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	B-cell_type
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	B-protein
-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	B-cell_line
mature	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Here	O
we	O
show	O
DNA	O
damage-induced	O
apoptosis	O
in	O
these	O
T	B-cell_type
lymphocytes	I-cell_type
is	O
dependent	O
on	O
the	O
antioncogenic	B-protein
transcription	I-protein
factor	I-protein
interferon	I-protein
regulatory	I-protein
factor	I-protein
(	B-protein
IRF	I-protein
)	I-protein
-1	I-protein
.	O
	
Thus	O
two	O
different	O
anti-onco-genic	B-protein
transcription	I-protein
factors	I-protein
,	O
p53	B-protein
and	O
IRF-1	B-protein
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
converting	I-DNA
enzyme	I-DNA
(	I-DNA
ICE	I-DNA
)	I-DNA
gene	I-DNA
,	O
a	O
mammalian	B-protein
homologue	I-protein
of	O
the	O
Caenorhabditis	B-DNA
elegans	I-DNA
cell	I-DNA
death	I-DNA
gene	I-DNA
ced-3	B-DNA
,	O
is	O
IRF-1	B-protein
-dependent	O
.	O
	
Ectopic	O
overexpression	O
of	O
IRF-1	B-protein
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B-DNA
gene	I-DNA
for	O
ICE	B-protein
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O
	
###MEDLINE:91017623	
	
Circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O
	
1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B-protein
in	O
human	B-cell_type
leukocytes	I-cell_type
,	O
PMN	B-cell_type
,	O
and	O
monocytes	B-cell_type
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O
	
The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O
	
2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	B-cell_type
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-protein
.	O
	
This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B-protein
may	O
be	O
of	O
functional	O
significance	O
.	O
	
3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O
	
This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B-protein
from	O
that	O
of	O
cortisol	O
.	O
	
4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
``	O
circadian	O
pacemaker	O
''	O
of	O
GR	B-protein
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O
	
###MEDLINE:98005316	
	
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
multiple	O
sclerosis	O
patients	O
and	O
a	O
healthy	O
control	O
producing	O
a	O
putative	O
new	O
human	O
retrovirus	O
and	O
Epstein-Barr	O
virus	O
.	O
	
On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
from	O
a	O
patient	O
with	O
MS	O
.	O
	
Later	O
we	O
established	O
spontaneously	O
formed	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCLs	B-cell_line
)	O
from	O
a	O
patient	O
with	O
an	O
MS-like	O
disease	O
and	O
from	O
another	O
patient	O
with	O
MS	O
who	O
had	O
a	O
reactivated	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O
	
Both	O
LCLs	B-cell_line
were	O
found	O
by	O
EM	O
to	O
produce	O
RVLP	O
and	O
EBV	O
particles	O
.	O
	
Reverse	O
transcriptase	O
(	O
RT	O
)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	B-cell_line
.	O
	
To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O
culturing	O
procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	B-cell_line
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O
healthy	O
controls	O
.	O
	
All	O
LCLs	B-cell_line
were	O
found	O
to	O
produce	O
both	O
RVLP	O
and	O
EBV	O
particles	O
by	O
EM	O
.	O
	
Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O
	
###MEDLINE:96140672	
	
Identification	O
of	O
an	O
ionomycin/cyclosporin	B-DNA
A-responsive	I-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
enhancer	I-DNA
.	O
	
Activation	O
through	O
the	O
Ca2+/	O
calcineurin	B-protein
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
.	O
	
The	O
conserved	B-DNA
cis-acting	I-DNA
sequence	I-DNA
,	O
GGAAAA	O
,	O
and	O
transcription	B-protein
factors	I-protein
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O
	
Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	B-DNA
gene	I-DNA
,	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
(	I-DNA
TCRG	I-DNA
)	I-DNA
enhancer	I-DNA
.	O
	
Results	O
from	O
site-directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin-induced	O
activation	O
of	O
the	O
TCRG	B-DNA
enhancer	I-DNA
.	O
	
Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B-RNA
mRNA	I-RNA
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
alpha	I-protein
and	I-protein
-beta	I-protein
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O
	
###MEDLINE:96074623	
	
Coexpression	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O
	
Productive	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O
	
This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
,	O
which	O
synergizes	O
with	O
the	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
to	O
drive	O
the	O
HIV-1	B-DNA
promoter	I-DNA
.	O
	
Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
syncytium	O
formation	O
with	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
.	O
	
These	O
syncytia	O
lack	O
activated	B-cell_type
cells	I-cell_type
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	O
cell	O
cycle	O
antigen	O
.	O
	
The	O
expression	O
and	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-protein
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	B-cell_type
cells	I-cell_type
and	O
DCs	B-cell_type
from	O
humans	O
and	O
mice	O
.	O
	
We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O
	
T	B-cell_type
cells	I-cell_type
lack	O
active	O
NF-kappa	B-protein
B	I-protein
but	O
express	O
Sp1	B-protein
as	O
expected	O
.	O
	
DCs	B-cell_type
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	B-protein
proteins	I-protein
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O
	
However	O
,	O
DCs	B-cell_type
lack	O
Sp1	B-protein
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	O
DCs	B-cell_type
.	O
	
Coexpression	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-protein
occurs	O
in	O
the	O
heterologous	B-cell_type
DC-T-cell	I-cell_type
syncytia	I-cell_type
that	O
are	O
induced	O
by	O
HIV-1	O
.	O
	
Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O
	
Since	O
DCs	B-cell_type
and	O
memory	O
T	B-cell_type
cells	I-cell_type
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	B-cell_type
syncytia	I-cell_type
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O
	
###MEDLINE:96063646	
	
Cupric	O
ion	O
blocks	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
A	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	B-DNA
genes	I-DNA
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
.	O
	
Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
release	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
	
Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
TPA	O
,	O
or	O
H2O2	O
.	O
	
Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF-alpha	B-protein
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B-protein
kappa	I-protein
B-I	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
.	O
	
Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
was	O
observed	O
upon	O
TNF-alpha	B-protein
stimulation	O
in	O
the	O
presence	O
of	O
Cu2+	O
.	O
	
These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
###MEDLINE:96038813	
	
Cloning	O
a	O
cDNA	B-DNA
from	O
human	O
NK/T	B-cell_type
cells	I-cell_type
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O
	
A	O
cDNA	B-DNA
clone	I-DNA
,	O
B4-2	B-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA
)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	I-DNA
.	O
	
The	O
B4-2	B-DNA
clone	O
coded	O
for	O
an	O
mRNA	B-RNA
of	O
2061	O
bp	O
in	O
length	O
.	O
	
It	O
encodes	O
a	O
deduced	O
327	B-protein
aa	I-protein
protein	I-protein
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35.2	O
kDa	O
.	O
	
Searching	O
of	O
B4-2	B-DNA
DNA	I-DNA
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O
	
However	O
,	O
B4-2	B-DNA
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O
,	O
contains	O
a	O
putative	O
nuclear	B-protein
targeting	I-protein
sequence	I-protein
,	O
and	O
has	O
several	O
SPXX	B-protein
motifs	I-protein
which	O
are	O
frequently	O
found	O
in	O
gene	B-protein
regulatory	I-protein
proteins	I-protein
.	O
	
One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4-2	B-DNA
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	B-protein
domains	I-protein
.	O
	
Northern	O
hybridization	O
data	O
showed	O
that	O
B4-2	B-DNA
is	O
not	O
a	O
lymphoid	B-DNA
specific	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
a	O
hepatoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O
	
A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-protein
B4-2	I-protein
recognizes	O
a	O
32-34	B-protein
kDa	I-protein
protein	I-protein
in	O
lymphocytes	B-cell_type
.	O
	
###MEDLINE:96127450	
	
Activation	O
of	O
JAK3	B-protein
,	O
but	O
not	O
JAK1	B-protein
,	O
is	O
critical	O
for	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
STAT5	B-protein
recruitment	O
by	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O
	
A	O
number	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
use	O
the	O
JAK	B-protein
-STAT	B-protein
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O
	
While	O
homodimerizing	B-protein
cytokine	I-protein
receptors	I-protein
may	O
transmit	O
signal	O
via	O
a	O
single	O
form	O
of	O
JAK	B-protein
(	O
i.e	O
.	O
growth	B-protein
hormone	I-protein
receptors	I-protein
)	O
,	O
several	O
multicomponent	B-protein
cytokine	I-protein
receptors	I-protein
have	O
been	O
shown	O
to	O
require	O
simultaneous	O
activation	O
of	O
pairs	O
of	O
different	O
JAK	B-protein
kinases	I-protein
(	O
i.e	O
.	O
interferon	B-protein
receptors	I-protein
)	O
.	O
	
Recent	O
evidence	O
for	O
a	O
preferential	O
coupling	O
of	O
JAK3	B-protein
to	O
interleukin-2	B-protein
receptor-gamma	I-protein
(	O
IL-2R	B-protein
gamma	I-protein
)	O
and	O
JAK1	B-protein
to	O
IL-2R	B-protein
beta	I-protein
supports	O
the	O
concept	O
of	O
heterotrans-activation	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
caused	O
by	O
IL-2	B-protein
-induced	O
heterodimerization	O
of	O
their	O
receptor	O
partners	O
.	O
	
The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL-2	B-protein
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
,	O
but	O
demonstrated	O
that	O
IL-2	B-protein
stimulated	O
JAK3	B-protein
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
the	O
YT	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
This	O
conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria	O
,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	B-protein
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	B-protein
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	B-protein
in	O
activated	O
IL-2	B-protein
receptor	I-protein
complexes	I-protein
.	O
	
Furthermore	O
,	O
when	O
human	B-protein
IL-2R	I-protein
beta	I-protein
was	O
stably	O
expressed	O
in	O
murine	B-cell_line
BA/F3	I-cell_line
cells	I-cell_line
,	O
robust	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
JAK3	B-protein
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B-protein
,	O
JAK2	B-protein
or	O
TYK2	B-protein
.	O
	
We	O
therefore	O
propose	O
that	O
IL-2	B-protein
receptor	I-protein
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
following	O
IL-2	B-protein
-induced	O
heterodimerization	O
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
.	O
	
Nonetheless	O
,	O
a	O
membrane-proximal	B-protein
region	I-protein
of	O
human	O
IL-2R	B-protein
beta	I-protein
(	O
Asn240-Leu335	B-protein
)	O
was	O
critical	O
for	O
JAK3	B-protein
activation	O
,	O
and	O
the	O
amount	O
of	O
JAK3	B-protein
present	O
in	O
activated	O
IL-2	B-protein
receptor	I-protein
complexes	I-protein
increased	O
with	O
time	O
,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	B-protein
binding	O
to	O
the	O
receptor	B-protein
complex	I-protein
relies	O
on	O
both	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
.	O
	
Moreover	O
,	O
STAT5	B-protein
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B-protein
transcription	I-protein
factor	I-protein
used	O
by	O
IL-2	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
specifically	O
required	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
IL-2R	B-protein
beta	I-protein
(	O
Ser386-Val525	B-protein
)	O
,	O
while	O
STAT5	B-protein
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B-protein
gamma	I-protein
or	O
JAK3	B-protein
.	O
	
###MEDLINE:96001293	
	
Up-regulation	O
of	O
high-affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O
	
DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L	O
,	O
mean	O
+/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187	O
.	O
	
Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O
	
These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B-protein
receptor	I-protein
,	O
but	O
also	O
suggest	O
that	O
T	B-cell_type
cells	I-cell_type
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O
	
###MEDLINE:95394931	
	
Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	B-protein
B	I-protein
transcriptional	B-protein
activator	I-protein
precursor	I-protein
p105	B-protein
.	O
	
Reconstitution	O
of	O
a	O
cell-free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin-carrier	B-protein
protein	I-protein
,	O
E2	B-protein
,	O
and	O
a	O
novel	O
ubiquitin-protein	B-protein
ligase	I-protein
,	O
E3	B-protein
,	O
involved	O
in	O
conjugation	O
.	O
	
In	O
most	O
cases	O
,	O
the	O
transcriptional	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
a	O
heterodimer	B-protein
consisting	O
of	O
two	O
subunits	O
,	O
p50	B-protein
and	O
p65	B-protein
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	B-DNA
family	I-DNA
.	O
	
p50	B-protein
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	B-protein
kDa	I-protein
.	O
	
The	O
C-terminal	B-protein
domain	I-protein
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B-protein
p50	I-protein
subunit	I-protein
consisted	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
molecule	O
.	O
	
The	O
mechanism	O
of	O
generation	O
of	O
p50	B-protein
is	O
not	O
known	O
.	O
	
It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B-protein
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O
	
Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O
,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773-785	O
)	O
have	O
shown	O
that	O
ubiquitin	B-protein
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell-free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60-kDa	B-protein
precursor	I-protein
.	O
	
They	O
have	O
also	O
shown	O
that	O
proteasome	B-protein
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B-protein
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	B-protein
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin-carrier	B-protein
protein	I-protein
,	O
E2-F1	B-protein
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B-protein
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B-protein
precursor	I-protein
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	B-protein
species	I-protein
of	O
ubiquitin-protein	B-protein
ligase	I-protein
,	O
is	O
involved	O
in	O
the	O
process	O
.	O
	
This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	B-protein
,	O
the	O
p53-conjugating	B-protein
ligase	I-protein
,	O
and	O
from	O
E3	B-protein
alpha	I-protein
,	O
the	O
``	B-protein
N-end	I-protein
rule	I-protein
''	I-protein
ligase	I-protein
.	O
	
###MEDLINE:95369491	
	
Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long-term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B-protein
receptor	I-protein
behavior	O
.	O
	
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-protein
receptor	I-protein
status	O
,	O
in	O
hirsute	O
women	O
.	O
	
DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O
	
Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O
	
Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O
	
Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O
	
Gonadotropin-releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O
	
In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O
	
RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	B-protein
transaminase	I-protein
after	O
8	O
months	O
of	O
therapy	O
.	O
	
Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+/-	O
0.5	O
versus	O
14.1	O
+/-	O
0.9	O
)	O
.	O
	
A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O
	
Cycles	O
remained	O
ovulatory	O
.	O
	
Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B-protein
receptors	I-protein
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O
	
This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O
	
CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O
	
Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O
	
Flutamide	O
affects	O
androgen	B-protein
receptor	I-protein
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O
	
The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O
	
###MEDLINE:90188846	
	
Constitutive	O
expression	O
of	O
HIV-1	B-protein
tat	I-protein
protein	I-protein
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
using	O
a	O
BK	O
virus	O
vector	O
.	O
	
The	O
production	O
and	O
characterization	O
of	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
constitutively	O
express	O
functional	O
human	B-protein
immune	I-protein
deficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
tat	I-protein
protein	I-protein
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	B-DNA
tat	I-DNA
cDNA	I-DNA
,	O
is	O
described	O
.	O
	
An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
observed	O
.	O
	
###MEDLINE:96125073	
	
A	O
PEBP2	B-protein
alpha/AML-1-related	I-protein
factor	I-protein
increases	O
osteocalcin	B-DNA
promoter	I-DNA
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
.	O
	
To	O
identify	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
and	O
trans-acting	B-protein
factors	I-protein
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	B-DNA
of	O
a	O
mouse	B-DNA
osteocalcin	I-DNA
gene	I-DNA
,	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
.	O
	
In	O
this	O
promoter	O
,	O
we	O
identified	O
two	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
(	O
Ducy	O
,	O
P.and	O
Karsenty	O
,	O
G.	O
(	O
1995	O
)	O
Mol.Cell.Biol.15	O
,	O
1858-1869	O
)	O
.	O
	
The	O
sequence	O
of	O
one	O
of	O
these	O
elements	B-DNA
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B-DNA
site	I-DNA
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mammalian	B-protein
homologues	I-protein
of	O
the	O
Drosophila	B-protein
Runt	I-protein
protein	I-protein
.	O
	
Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-protein
protein	I-protein
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B-protein
proteins	I-protein
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	B-protein
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B-protein
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O
	
By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	B-protein
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B-DNA
promoter	I-DNA
through	O
its	O
binding	O
to	O
OSE2	O
.	O
	
Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
compared	O
with	O
T-cell	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B-protein
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B-protein
alpha	I-protein
factors	I-protein
,	O
suggest	O
that	O
OSF2	B-protein
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B-protein
factors	I-protein
.	O
	
Thus	O
,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B-protein
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
and	O
presents	O
evidence	O
that	O
OSF2	B-protein
is	O
a	O
member	O
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
###MEDLINE:96069375	
	
Initiation	B-protein
binding	I-protein
repressor	I-protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
is	O
a	O
glycosylated	B-protein
member	I-protein
of	O
a	O
family	O
of	O
cell	B-protein
growth	I-protein
regulators	I-protein
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O
	
Initiation	B-protein
binding	I-protein
repressor	I-protein
[	O
corrected	O
]	O
(	O
IBR	B-protein
)	O
is	O
a	O
chicken	B-protein
erythrocyte	I-protein
factor	I-protein
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
repressing	O
its	O
transcription	O
.	O
	
A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
,	O
do	O
not	O
have	O
IBR	B-protein
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B-protein
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B-protein
sites	O
.	O
	
We	O
have	O
cloned	O
the	O
IBR	B-DNA
cDNA	I-DNA
and	O
studied	O
the	O
relationship	O
of	O
IBR	B-protein
and	O
IBF	B-protein
.	O
	
IBR	B-protein
is	O
a	O
503-amino-acid-long	B-protein
acidic	I-protein
protein	I-protein
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B-protein
NRF-1/alpha-Pal	I-protein
factor	I-protein
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B-protein
factors	I-protein
P3A2	B-protein
and	O
erected	B-protein
wing	I-protein
gene	I-protein
product	I-protein
(	O
EWG	B-protein
)	O
.	O
	
We	O
present	O
evidence	O
that	O
IBR	B-protein
and	O
IBF	B-protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O
	
We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	B-protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	B-protein
and	O
that	O
the	O
dimer	B-protein
is	O
the	O
relevant	B-protein
DNA-binding	I-protein
species	I-protein
.	O
	
The	O
evolutionarily	O
conserved	O
N-terminal	B-protein
half	I-protein
of	O
IBR/F	B-protein
harbors	O
the	O
DNA-binding/dimerization	B-protein
domain	I-protein
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B-protein
kinase	I-protein
II	I-protein
sites	I-protein
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	B-protein
nuclear	I-protein
localization	I-protein
signal	I-protein
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O
	
Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	B-protein
RCGCRYGCGY	I-protein
consensus	I-protein
constitutes	O
high-affinity	O
IBR/F	B-DNA
binding	I-DNA
sites	I-DNA
and	O
that	O
the	O
direct-repeat	B-DNA
palindrome	I-DNA
TGCGCATGCGCA	O
is	O
the	O
optimal	B-DNA
site	I-DNA
.	O
	
A	O
survey	O
of	O
genes	B-DNA
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	B-protein
primarily	O
revealed	O
genes	B-DNA
involved	O
in	O
growth-related	O
metabolism	O
.	O
	
###MEDLINE:96070930	
	
Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
.	O
	
We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
/	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
of	O
human	B-DNA
interleukin-6	I-DNA
(	I-DNA
IL-6	I-DNA
)	I-DNA
gene	I-DNA
in	O
THP-1	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
	
Functional	O
studies	O
with	O
IL-6	B-DNA
promoter	I-DNA
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN-gamma	B-protein
and/or	O
TNF-alpha	B-protein
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O
	
The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-73	O
and	O
-36	O
,	O
which	O
is	O
the	O
minimal	B-DNA
element	I-DNA
inducible	O
by	O
LPS	O
or	O
TNF-alpha	B-protein
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-181	O
and	O
-73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	B-DNA
element	I-DNA
upstream	I-DNA
of	O
-224	O
,	O
which	O
was	O
inducible	O
by	O
IFN-gamma	B-protein
alone	O
.	O
	
LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
by	O
the	O
p50/p65	B-protein
heterodimers	I-protein
.	O
	
Synergistic	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
,	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	B-protein
and	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	I-protein
homodimers	I-protein
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	B-DNA
control	I-DNA
element	I-DNA
present	O
in	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O
	
This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B-protein
Sp1	I-protein
factor	I-protein
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	B-protein
.	O
	
###MEDLINE:96055115	
	
Mutation	O
of	O
Jak3	B-protein
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B-protein
in	O
lymphoid	O
development	O
.	O
	
Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-DNA
receptor	I-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	I-DNA
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
.	O
	
The	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
Jak3	B-protein
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-protein
c	I-protein
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B-protein
might	O
cause	O
an	O
XSCID-like	O
phenotype	O
.	O
	
A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O
	
An	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
her	O
lymphocytes	B-cell_type
had	O
normal	O
gamma	B-protein
c	I-protein
expression	O
but	O
lacked	O
Jak3	B-protein
protein	I-protein
and	O
had	O
greatly	O
diminished	O
Jak3	B-RNA
messenger	I-RNA
RNA	I-RNA
.	O
	
Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-protein
JH4	I-protein
domain	I-protein
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B-protein
JH2	O
domain	O
.	O
	
The	O
lack	O
of	O
Jak3	B-protein
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	B-protein
to	O
activate	O
Stat6	B-protein
in	O
the	O
EBV-transformed	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-protein
c	I-protein
are	O
dependent	O
on	O
Jak3	B-protein
and	O
that	O
Jak3	B-protein
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O
	
###MEDLINE:96017245	
	
Constitutive	O
overexpression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
.	O
	
L-selectin	B-protein
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O
	
Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O
	
To	O
understand	O
the	O
mechanism	O
of	O
leukemic	B-cell_type
cell	I-cell_type
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L-selectin	B-RNA
mRNA	I-RNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
to	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	I-protein
,	O
which	O
is	O
a	O
viral	B-protein
transcriptional	I-protein
transactivator	I-protein
.	O
	
Flow	O
cytometry	O
showed	O
that	O
L-selectin	B-protein
was	O
expressed	O
on	O
fresh	O
ATL	B-cell_line
cells	I-cell_line
along	O
with	O
other	O
activation	B-protein
antigens	I-protein
.	O
	
Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B-cell_line
cells	I-cell_line
overexpressed	O
that	O
L-selectin	B-RNA
mRNA	I-RNA
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O
	
Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L-selectin	B-RNA
mRNA	I-RNA
in	O
the	O
infiltrating	O
leukemic	B-cell_type
cells	I-cell_type
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O
	
Intravenous	O
injection	O
of	O
a	O
rat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
that	O
overexpresses	O
L-selectin	B-protein
showed	O
increased	O
organ	O
infiltration	O
.	O
	
The	O
induction	O
of	O
Tax	B-protein
expression	O
in	O
JPX9	B-cell_line
cells	I-cell_line
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	B-RNA
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O
	
Chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
by	O
Tax	B-protein
.	O
	
The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	B-protein
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+/-	O
SD	O
,	O
4	O
,	O
215.4	O
+/-	O
4	O
,	O
111	O
ng/mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+/-	O
SD	O
,	O
1	O
,	O
148.0	O
+/-	O
269.0	O
ng/mL	O
and	O
991.9	O
+/-	O
224	O
ng/mL	O
,	O
respectively	O
)	O
.	O
	
These	O
results	O
indicated	O
that	O
ATL	B-cell_line
cells	I-cell_line
constitutively	O
overexpress	O
the	O
L-selectin	B-DNA
gene	I-DNA
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	O
Tax	B-protein
.	O
	
The	O
overexpression	O
of	O
L-selectin	B-protein
,	O
as	O
well	O
as	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
by	O
ATL	B-cell_line
cells	I-cell_line
may	O
provide	O
a	O
basis	O
for	O
ATL	B-cell_line
cells	I-cell_line
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O
	
###MEDLINE:96157213	
	
Human	O
herpesvirus	O
6	O
variant	O
A	O
,	O
but	O
not	O
variant	O
B	O
,	O
infects	O
EBV-positive	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
activating	O
the	O
latent	B-DNA
EBV	I-DNA
genome	I-DNA
through	O
a	O
BZLF-1	B-protein
-dependent	O
mechanism	O
.	O
	
Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV-positive	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O
	
Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O
	
The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	B-cell_line
cells	I-cell_line
,	O
in	O
which	O
,	O
however	O
,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B-protein
antigens	I-protein
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	O
sites	O
and	O
the	O
percentage	O
of	O
infectable	B-cell_type
cells	I-cell_type
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(	O
3	O
)	O
HHV-6	B-cell_line
infected	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
plasmids	B-DNA
bearing	O
the	O
promoter	B-DNA
regions	I-DNA
of	O
the	O
EBV	O
early	O
genes	O
BZLF1	O
and	O
BMRF1	B-DNA
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	O
promoters	B-DNA
.	O
	
###MEDLINE:96001288	
	
Evidence	O
for	O
normal	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O
	
Absorptive	O
hypercalciuria	O
(	O
a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O
	
Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O
	
We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-DNA
gene	I-DNA
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age-matched	O
control	O
subjects	O
.	O
	
There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B-protein
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O
	
The	O
coding	O
region	O
of	O
VDR	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	B-DNA
sequence	I-DNA
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B-protein
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B-DNA
genotype	I-DNA
.	O
	
###MEDLINE:95394907	
	
Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B-protein
C-type	I-protein
lectin	I-protein
leukocyte	I-protein
receptor	I-protein
AIM/CD69	B-protein
and	O
functional	O
characterization	O
of	O
its	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha-responsive	I-DNA
elements	I-DNA
.	O
	
The	O
human	B-protein
activation	I-protein
antigen	I-protein
CD69	B-protein
is	O
a	O
member	O
of	O
the	O
C-type	B-protein
animal	I-protein
lectin	I-protein
superfamily	I-protein
that	O
functions	O
as	O
a	O
signal-transmitting	B-protein
receptor	I-protein
.	O
	
Although	O
the	O
expression	O
of	O
CD69	B-protein
can	O
be	O
induced	O
in	O
vitro	O
on	O
cells	O
of	O
most	O
hematopoietic	O
lineages	O
with	O
a	O
wide	O
variety	O
of	O
stimuli	O
,	O
in	O
vivo	O
it	O
is	O
mainly	O
expressed	O
by	O
T-lymphocytes	B-cell_type
located	O
in	O
the	O
inflammatory	O
infiltrates	O
of	O
several	O
human	O
diseases	O
.	O
	
To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	B-protein
by	O
leukocytes	B-cell_type
,	O
we	O
isolated	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
CD69	B-protein
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O
	
Sequence	O
analysis	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
CD69	B-DNA
gene	I-DNA
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B-DNA
element	I-DNA
30	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B-protein
factors	I-protein
(	O
NF-kappa	B-protein
B	I-protein
,	O
Egr-1	B-protein
,	O
AP-1	B-protein
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O
	
Transient	O
expression	O
of	O
CD69	B-DNA
promoter-based	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
indicated	O
that	O
the	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
spanning	O
positions	O
-78	O
to	O
+16	O
contained	O
the	O
cis-acting	B-DNA
sequences	I-DNA
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate-inducible	O
transcription	O
of	O
the	O
CD69	B-DNA
gene	I-DNA
.	O
	
Removal	O
of	O
the	O
upstream	O
sequences	O
located	O
between	O
positions	O
-78	O
and	O
-38	O
resulted	O
in	O
decreased	O
promoter	O
strength	O
and	O
abolished	O
the	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
	
We	O
also	O
found	O
that	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O
CD69	B-protein
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	O
plasmids	O
that	O
contain	O
5'-flanking	O
sequences	O
of	O
the	O
CD69	B-protein
gene	O
,	O
suggesting	O
that	O
this	O
cytokine	O
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	B-protein
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
	
###MEDLINE:95368765	
	
Characterization	O
of	O
5	B-DNA
'	I-DNA
end	I-DNA
of	I-DNA
human	I-DNA
thromboxane	I-DNA
receptor	I-DNA
gene	I-DNA
.	O
	
Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	B-DNA
kinase	I-DNA
C	I-DNA
--	I-DNA
responsive	I-DNA
elements	I-DNA
regulating	O
expression	O
in	O
platelets	B-cell_type
.	O
	
Platelet	B-protein
thromboxane	I-protein
receptors	I-protein
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O
	
To	O
determine	O
if	O
platelet	O
thromboxane	B-protein
receptors	I-protein
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
clones	I-DNA
containing	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
.	O
	
The	O
exon-intron	B-DNA
structure	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	B-DNA
sequence	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
genomic	I-DNA
clone	I-DNA
with	O
that	O
of	O
a	O
novel	B-DNA
human	I-DNA
uterine	I-DNA
thromboxane	I-DNA
receptor	I-DNA
cDNA	I-DNA
that	O
extended	O
the	O
mRNA	B-RNA
141	B-DNA
bp	I-DNA
further	I-DNA
upstream	I-DNA
than	O
the	O
previously	B-DNA
identified	I-DNA
human	I-DNA
placental	I-DNA
cDNA	I-DNA
.	O
	
A	O
major	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
and	O
380	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
any	O
previously	O
identified	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O
	
The	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
has	O
neither	O
a	O
TATA	B-DNA
nor	O
a	O
CAAT	B-DNA
consensus	I-DNA
site	I-DNA
.	O
	
Promoter	O
function	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
chimera	I-DNA
plasmids	I-DNA
into	O
platelet-like	O
K562	B-cell_line
cells	I-cell_line
.	O
	
Thromboxane	O
receptor	B-DNA
promoter	I-DNA
activity	O
,	O
as	O
assessed	O
by	O
CAT	B-protein
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O
	
Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	I-DNA
in	O
transfected	O
K562	B-cell_line
cells	I-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	I-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O
	
These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
and	O
demonstrate	O
that	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
via	O
induction	O
of	O
an	O
AP-2-like	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
upstream	B-DNA
promoter	I-DNA
elements	I-DNA
.	O
	
These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B-protein
thromboxane	I-protein
receptors	I-protein
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
in	O
platelet-progenitor	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:91172250	
	
Estrogen	B-protein
receptor	I-protein
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early-stage	O
breast	O
cancer	O
patients	O
.	O
	
Confirmation	O
of	O
a	O
model	O
.	O
	
Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O
	
As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O
	
It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow-up	O
was	O
tumor	O
ER	B-protein
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	B-protein
-status	O
.	O
	
In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O
	
If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	B-protein
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	B-cell_type
cells	I-cell_type
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	B-cell_type
cells	I-cell_type
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O
	
The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O
	
This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O
	
Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O
	
###MEDLINE:96107207	
	
Solution	O
structure	O
of	O
the	O
sequence-specific	B-DNA
HMG	I-DNA
box	I-DNA
of	O
the	O
lymphocyte	B-protein
transcriptional	I-protein
activator	I-protein
Sox-4	B-protein
.	O
	
Two	O
groups	O
of	O
HMG	B-protein
box	I-protein
proteins	I-protein
are	O
distinguished	O
.	O
	
Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B-protein
boxes	I-protein
,	O
are	O
non-sequence-specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B-DNA
DNA	I-DNA
and	O
cross-over	B-DNA
DNA	I-DNA
.	O
	
The	O
abundant	O
chromosomal	B-protein
protein	I-protein
HMG-1	B-protein
belongs	O
to	O
this	O
subgroup	O
.	O
	
Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B-protein
HMG	I-protein
box	I-protein
with	O
affinity	O
for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	B-DNA
motif	I-DNA
AACAAAG	O
or	O
variations	O
thereof	O
.	O
	
A	O
solution	O
structure	O
for	O
the	O
non-sequence-specific	O
C-terminal	B-protein
HMG	I-protein
box	I-protein
of	O
HMG-1	B-protein
has	O
recently	O
been	O
proposed	O
.	O
	
Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B-protein
HMG-box	I-protein
of	O
the	O
SRY-related	B-protein
protein	I-protein
Sox-4	B-protein
.	O
	
NMR	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
three	O
alpha-helices	B-protein
(	O
Val10-Gln22	B-protein
,	O
Glu30-Leu41	B-protein
and	O
Phe50-Tyr65	B-protein
)	O
connected	O
by	O
loop	B-protein
regions	I-protein
(	O
Ser23-Ala49	B-protein
and	O
Leu42-Pro49	B-protein
)	O
.	O
	
Helices	B-protein
I	I-protein
and	I-protein
II	I-protein
are	O
positioned	O
in	O
an	O
antiparallel	B-protein
mode	I-protein
and	O
form	O
one	O
arm	O
of	O
the	O
HMG	B-protein
box	I-protein
.	O
	
Helix	B-protein
III	I-protein
is	O
less	O
rigid	O
,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B-protein
I	I-protein
and	I-protein
II	I-protein
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule	O
.	O
	
As	O
in	O
HMG1B	B-protein
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	B-protein
HMG	B-protein
box	I-protein
is	O
L-shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O
	
###MEDLINE:96072803	
	
Nuclear	B-protein
factor-IL6	I-protein
activates	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
Positive	B-DNA
regulatory	I-DNA
element	I-DNA
I	I-DNA
(	O
PRE-I	B-DNA
)	O
is	O
a	O
strong	O
enhancer	B-DNA
element	I-DNA
essential	O
for	O
expression	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
.	O
	
To	O
identify	O
transcription	B-protein
factors	I-protein
binding	O
to	O
PRE-I	B-DNA
,	O
we	O
screened	O
a	O
cDNA	B-DNA
expression	I-DNA
library	I-DNA
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
isolated	O
a	O
cDNA	B-DNA
encoding	O
nuclear	B-protein
factor	I-protein
(	B-protein
NF	I-protein
)	I-protein
-IL6	I-protein
(	O
also	O
known	O
as	O
C/EBP	B-protein
beta	I-protein
)	O
.	O
	
NF-IL6	B-RNA
mRNA	I-RNA
was	O
found	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
mouse	B-cell_line
Th2	I-cell_line
clone	I-cell_line
D10	B-cell_line
,	O
but	O
not	O
in	O
Th1	B-cell_line
clone	I-cell_line
29	I-cell_line
.	O
	
rNF-IL6	B-protein
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	B-DNA
.	O
	
PRE-I	B-DNA
forms	O
multiple	B-protein
DNA-protein	I-protein
complexes	I-protein
with	O
nuclear	O
extracts	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B-protein
by	O
using	O
anti-C/EBP	B-protein
beta	I-protein
Abs	I-protein
.	O
	
Overexpression	O
of	O
NF-IL6	B-protein
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
PRE-I-thymidine	B-protein
kinase	I-protein
or	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
more	O
than	O
10-fold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O
	
Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	B-protein
proximal	I-protein
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-protein
medial	I-protein
)	O
,	O
respectively	O
.	O
	
Our	O
results	O
demonstrate	O
that	O
NF-IL6	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:96070929	
	
Identification	O
of	O
an	O
I	B-protein
kappa	I-protein
B	I-protein
alpha-associated	I-protein
protein	I-protein
kinase	I-protein
in	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
determination	O
of	O
its	O
phosphorylation	B-protein
sites	I-protein
on	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
.	O
	
Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O
	
We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
.	O
	
In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	B-protein
in	O
cell	O
extracts	O
from	O
the	O
LPS-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-bound	B-protein
kinase	I-protein
activity	O
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
Mutational	O
analyses	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B-protein
sites	I-protein
by	O
the	O
bound	O
kinase	B-protein
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
	
Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
blocked	O
the	O
LPS-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
a	O
cell-free	O
system	O
using	O
THP-1	B-cell_line
cells	I-cell_line
.	O
	
These	O
results	O
suggested	O
that	O
the	O
bound	B-protein
kinase	I-protein
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
.	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
complex	I-protein
.	O
	
###MEDLINE:96068922	
	
Bik	B-protein
,	O
a	O
novel	O
death-inducing	B-protein
protein	I-protein
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B-protein
family	I-protein
proteins	I-protein
and	O
interacts	O
with	O
viral	O
and	O
cellular	B-protein
survival-promoting	I-protein
proteins	I-protein
.	O
	
The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B-protein
proteins	I-protein
.	O
	
We	O
have	O
identified	O
a	O
novel	O
cellular	B-protein
protein	I-protein
,	O
Bik	B-protein
,	O
that	O
interacts	O
with	O
the	O
cellular	B-protein
survival-promoting	I-protein
proteins	I-protein
,	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
,	O
as	O
well	O
as	O
the	O
viral	B-protein
survival-promoting	I-protein
proteins	I-protein
,	O
Epstein	B-protein
Barr	I-protein
virus-BHRF1	I-protein
and	O
adenovirus	B-protein
E1B-19	I-protein
kDa	I-protein
.	O
	
In	O
transient	O
transfection	O
assays	O
,	O
Bik	B-protein
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death-promoting	B-protein
members	I-protein
of	O
the	O
Bcl-2	B-protein
family	I-protein
,	O
Bax	B-protein
and	O
Bak	B-protein
.	O
	
This	O
death-promoting	O
activity	O
of	O
Bik	B-protein
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl-2	B-protein
,	O
Bcl-XL	B-protein
,	O
EBV-BHRF1	B-protein
and	O
E1B-19	B-protein
kDa	I-protein
proteins	O
suggesting	O
that	O
Bik	B-protein
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B-protein
and	I-protein
viral	I-protein
anti-apoptotic	I-protein
proteins	I-protein
.	O
	
While	O
Bik	B-protein
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B-protein
and	O
BH2	B-protein
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
,	O
it	O
does	O
share	O
a	O
9	O
amino	B-protein
acid	I-protein
domain	I-protein
(	O
BH3	B-protein
)	O
with	O
Bax	B-protein
and	O
Bak	B-protein
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death-promoting	O
activity	O
of	O
these	O
proteins	O
.	O
	
###MEDLINE:96017239	
	
The	O
human	B-DNA
TCF-1	I-DNA
gene	I-DNA
encodes	O
a	O
nuclear	B-protein
DNA-binding	I-protein
protein	I-protein
uniquely	O
expressed	O
in	O
normal	B-cell_line
and	I-cell_line
neoplastic	I-cell_line
T-lineage	I-cell_line
lymphocytes	I-cell_line
.	O
	
The	O
TCF-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	B-protein
transcription	I-protein
factor	I-protein
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T-cell	B-DNA
enhancers	I-DNA
.	O
	
TCF-1	B-RNA
mRNA	I-RNA
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O
	
We	O
have	O
now	O
raised	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B-protein
TCF-1	I-protein
protein	I-protein
.	O
	
As	O
expected	O
,	O
the	O
TCF-1	B-protein
protein	I-protein
was	O
detectable	O
only	O
in	O
cell	B-cell_line
lines	I-cell_line
of	I-cell_line
T	I-cell_line
lineage	I-cell_line
.	O
	
Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O
	
Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B-protein
protein	I-protein
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3+	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
peripheral	O
lymphoid	O
tissues	O
.	O
	
Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O
	
The	O
TCF-1	B-protein
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T-cell	B-cell_type
malignancies	I-cell_type
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	B-cell_type
neoplasms	I-cell_type
.	O
	
These	O
observations	O
imply	O
a	O
T	O
cell-specific	O
function	O
for	O
TCF-1	B-protein
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	O
knock-out	O
mice	O
.	O
	
In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	B-protein
expression	O
can	O
serve	O
as	O
a	O
pan-T-lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O
	
###MEDLINE:96128660	
	
Cross-linking	O
of	O
Fc	B-protein
gamma	I-protein
receptors	I-protein
activates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
	
Elevation	O
of	O
the	O
levels	O
of	O
circulating	B-protein
immune	I-protein
complexes	I-protein
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O
	
Here	O
we	O
report	O
that	O
cross-linking	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
or	O
Fc	B-protein
gamma	I-protein
RII	I-protein
by	O
adherent	B-protein
human	I-protein
IgG	I-protein
or	O
by	O
specific	O
anti-Fc	B-protein
gamma	I-protein
R	I-protein
mAb	I-protein
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
BF24	B-cell_line
and	O
increased	O
HIV	B-RNA
RNA	I-RNA
expression	O
in	O
monocytes	B-cell_type
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O
	
In	O
THP-1	B-cell_line
cells	I-cell_line
,	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
induced	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti-TNF-alpha	B-protein
antibody	I-protein
but	O
not	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
.	O
	
These	O
results	O
indicate	O
that	O
Fc	B-protein
gamma	I-protein
R	I-protein
can	O
mediate	O
a	O
TNF-alpha	B-protein
-dependent	O
induction	O
of	O
HIV-1	B-DNA
gene	I-DNA
transcription	O
and	O
suggest	O
that	O
immune	B-protein
complexes	I-protein
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	B-cell_type
.	O
	
###MEDLINE:96003970	
	
Signalling	O
via	O
CD28	B-protein
of	O
human	B-cell_line
naive	I-cell_line
neonatal	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O
	
Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O
	
We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B-protein
in	O
modulating	O
the	O
'naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti-CD2	B-protein
-mediated	O
activation	O
.	O
	
To	O
compare	O
the	O
role	O
of	O
CD28	B-protein
,	O
neonatal	B-cell_type
and	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	B-protein
anti-CD2	I-protein
antibodies	I-protein
in	O
the	O
presence	O
or	O
absence	O
of	O
anti-CD28	B-protein
MoAb	I-protein
.	O
	
With	O
anti-CD2	B-protein
alone	O
,	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL-2	B-protein
,	O
whereas	O
adult	O
T	B-cell_type
cells	I-cell_type
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL-2	B-protein
production	O
.	O
	
Costimulation	O
with	O
anti-CD28	B-protein
MoAb	I-protein
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
only	O
slight	O
increases	O
.	O
	
Although	O
IL-2	B-protein
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti-CD28	B-protein
MoAb	I-protein
,	O
neonatal	B-cell_type
T	I-cell_type
cell	I-cell_type
IL-2	B-protein
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O
	
In	O
contrast	O
,	O
enhancement	O
of	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O
	
Anti-	O
CD28	B-protein
MoAb	I-protein
costimulation	O
increased	O
NF	B-protein
kappa	I-protein
B	I-protein
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O
	
The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
to	O
anti-CD2	B-protein
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B-protein
kappa	I-protein
B	I-protein
induction	O
,	O
reduced	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
and	O
deficient	O
IL-2	B-protein
production	O
.	O
	
Although	O
anti-CD28	B-protein
MoAb	I-protein
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O
	
###MEDLINE:95391995	
	
TCL1	O
oncogene	O
activation	O
in	O
preleukemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O
	
The	O
TCL1	B-DNA
oncogene	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
14q32.1	B-DNA
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	B-DNA
(	I-DNA
14	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
and	O
t	B-DNA
(	I-DNA
7	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q35	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
]	O
and	O
inversions	O
[	O
inv14	B-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
]	O
with	O
TCR	B-DNA
alpha/beta	I-DNA
loci	I-DNA
in	O
T-cell	O
leukemias	O
,	O
such	O
as	O
T-prolymphocytic	O
(	O
T-PLL	O
)	O
.	O
	
It	O
is	O
also	O
involved	O
in	O
T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia-telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O
	
Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	B-cell_type
cells	I-cell_type
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O
	
We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O
	
We	O
found	O
that	O
the	O
TCL1	B-DNA
gene	I-DNA
was	O
overexpressed	O
in	O
the	O
PBLs	B-cell_type
of	O
an	O
AT	O
patient	O
with	O
a	O
large	B-cell_line
clonal	I-cell_line
T-cell	I-cell_line
population	I-cell_line
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	B-cell_type
of	O
the	O
other	O
cases	O
.	O
	
Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	I-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA
locus	I-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	I-DNA
of	O
chromosome	B-DNA
14	I-DNA
.	O
	
These	O
data	O
indicate	O
that	O
TCL1	B-DNA
is	O
activated	O
in	O
preleukemic	B-cell_line
clonal	I-cell_line
cells	I-cell_line
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	B-DNA
locus	I-DNA
at	O
14q11	B-DNA
.	O
	
Deregulation	O
of	O
TCL1	B-DNA
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O
	
###MEDLINE:95363941	
	
C/EBP	B-protein
proteins	I-protein
activate	O
transcription	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
macrophages/	O
monocytes	B-cell_type
.	O
	
Three	O
binding	O
sites	O
for	O
C/EBP	B-protein
proteins	I-protein
are	O
found	O
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
(	O
V.M.	O
Tesmer	O
,	O
A.Rajadhyaksha	O
,	O
J.Babin	O
,	O
and	O
M.Bina	O
,	O
Proc.Natl.Acad.Sci.	O
USA	O
90	O
:	O
7298-7302	O
,	O
1993	O
)	O
.	O
	
We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B-protein
proteins	I-protein
and	O
C/EBP	B-DNA
sites	I-DNA
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B-DNA
1	I-DNA
LTR	I-DNA
in	O
monocytes/macrophages	B-cell_type
.	O
	
Inhibition	O
of	O
endogenous	B-protein
C/EBP	I-protein
proteins	I-protein
,	O
using	O
either	O
an	O
excess	O
of	O
C/EBP	B-DNA
binding	I-DNA
sites	I-DNA
or	O
a	O
trans-	B-DNA
dominant	I-DNA
negative	I-DNA
inhibitor	I-DNA
,	O
demonstrated	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
in	O
the	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O
	
Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF-IL6	B-protein
is	O
the	O
only	O
known	O
C/EBP	B-protein
family	I-protein
member	I-protein
which	O
is	O
increased	O
when	O
U937	B-cell_line
cells	I-cell_line
are	O
activated	O
.	O
	
Mutational	O
analyses	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
showed	O
that	O
one	O
C/EBP	B-DNA
site	I-DNA
is	O
required	O
for	O
normal	O
LTR	B-DNA
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C/EBP	B-DNA
sites	I-DNA
are	O
functionally	O
equivalent	O
.	O
	
However	O
,	O
transcription	O
from	O
crippled	B-DNA
HIV-1	I-DNA
LTRs	I-DNA
lacking	O
C/EBP	B-DNA
sites	I-DNA
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF-IL6	B-protein
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	B-protein
expression	O
,	O
and	O
HIV	O
replication	O
.	O
	
###MEDLINE:91175694	
	
Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	B-DNA
and	O
their	O
activation	O
by	O
T-cell	B-cell_type
activators	O
.	O
	
The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O
	
Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	I-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTRs	B-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	I-DNA
in	O
the	O
HIV-2	B-DNA
LTR	I-DNA
.	O
	
The	O
HIV-2	B-DNA
LTR	I-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	B-DNA
.	O
	
One	O
of	O
these	O
enhancers	B-DNA
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
.	O
	
This	O
enhancer	B-DNA
in	O
HIV-1	O
is	O
the	O
T-cell	B-DNA
activation	I-DNA
response	I-DNA
element	I-DNA
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	B-DNA
enhancer	I-DNA
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O
	
The	O
second	O
enhancer	B-DNA
interacts	O
with	O
two	O
nuclear	B-protein
binding	I-protein
proteins	I-protein
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O
	
Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O
	
###MEDLINE:96134911	
	
NF-M	B-protein
(	O
chicken	B-protein
C/EBP	I-protein
beta	I-protein
)	O
induces	O
eosinophilic	O
differentiation	O
and	O
apoptosis	O
in	O
a	O
hematopoietic	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
	
CAAT/enhancer	B-protein
binding	I-protein
proteins	I-protein
(	O
C/EBPs	B-protein
)	O
are	O
transcriptional	O
activators	O
implicated	O
in	O
the	O
differentiation	O
processes	O
of	O
various	O
cell	O
lineages	O
.	O
	
We	O
have	O
shown	O
earlier	O
that	O
NF-M	B-protein
,	O
the	O
chicken	B-protein
homolog	I-protein
of	O
C/EBP	B-protein
beta	I-protein
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
cells	I-cell_type
of	O
the	O
hematopoietic	O
system	O
.	O
	
To	O
investigate	O
the	O
role	O
of	O
NF-M	B-protein
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lineage	I-cell_line
commitment	O
,	O
we	O
constructed	O
a	O
conditional	O
form	O
of	O
the	O
protein	O
by	O
fusing	O
it	O
to	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
human	B-protein
estrogen	I-protein
receptor	I-protein
.	O
	
This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	I-cell_line
transformed	O
by	O
the	O
Myb-Ets	B-protein
oncoprotein	I-protein
.	O
	
We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	I-cell_line
.	O
	
At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B-protein
surface	I-protein
markers	I-protein
and	O
the	O
up-regulation	O
of	O
differentiation	B-protein
markers	I-protein
restricted	O
to	O
the	O
eosinophil	B-cell_type
and	O
myeloid	B-cell_type
lineages	I-cell_type
.	O
	
In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O
	
Our	O
results	O
suggest	O
that	O
NF-M	B-protein
plays	O
an	O
important	O
role	O
in	O
commitment	O
along	O
the	O
eosinophil	B-cell_type
lineage	I-cell_type
and	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O
	
###MEDLINE:96079922	
	
Prolactin	B-protein
and	O
interleukin-2	B-protein
receptors	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
signal	O
through	O
a	O
MGF-STAT5-like	B-protein
transcription	I-protein
factor	I-protein
.	O
	
The	O
cell	O
surface	O
receptors	O
for	O
PRL	B-protein
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over-lapping	O
sets	O
of	O
genes	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
	
PRL	B-protein
and	O
IL-2	B-protein
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak/Stat	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
pathway	O
.	O
	
We	O
investigated	O
the	O
ability	O
of	O
PRL	B-protein
and	O
IL-2	B-protein
to	O
activate	O
Stat	B-protein
proteins	I-protein
in	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat-specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	B-protein
-and	O
PRL-induced	B-protein
DNA-binding	I-protein
proteins	I-protein
in	O
Nb2	B-cell_line
and	I-cell_line
C196	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
investigated	O
.	O
	
A	O
comparison	O
with	O
the	O
Stat	B-protein
proteins	I-protein
induced	O
by	O
interferon-gamma	B-protein
,	O
PRL	B-protein
,	O
and	O
IL-6	B-protein
in	O
T47D	B-cell_line
mammary	I-cell_line
tumor	I-cell_line
cells	I-cell_line
was	O
made	O
.	O
	
We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	B-protein
and	I-protein
IL-2-induced	I-protein
factors	I-protein
.	O
	
A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	B-protein
gland	I-protein
factor-Stat5	I-protein
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	B-protein
and	O
PRL	B-protein
with	O
their	O
respective	O
receptors	O
.	O
	
Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	B-protein
was	O
also	O
observed	O
.	O
	
Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B-protein
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B-protein
factors	I-protein
mammary	B-protein
gland	I-protein
factor-Stat5	I-protein
and	O
Stat1	B-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O
	
###MEDLINE:96074843	
	
ETS1	B-protein
transactivates	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O
	
Activation	O
of	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B-protein
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O
	
Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
one	O
such	O
cytokine	B-protein
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O
	
Cis-acting	B-DNA
elements	I-DNA
with	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
AP-1	B-protein
and	O
ETS-like	B-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O
	
A	O
number	O
of	O
the	O
ETS	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
including	O
ETS1	B-protein
and	O
ELF1	B-protein
.	O
	
Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	B-DNA
)	O
,	O
located	O
within	O
the	O
CLE0	B-DNA
element	I-DNA
,	O
-47	B-DNA
to	I-DNA
-40	I-DNA
upstream	I-DNA
of	O
the	O
GM-CSF	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O
	
Exogenous	O
ETS1	B-protein
,	O
but	O
not	O
ELF1	B-protein
,	O
can	O
transactivate	O
GM-CSF	B-protein
,	O
through	O
the	O
GM5	B-DNA
site	O
,	O
in	O
a	O
PMA/ionomycin	O
dependent	O
manner	O
.	O
	
Other	O
unidentified	O
ETS-like	B-protein
factors	I-protein
present	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
are	O
also	O
capable	O
of	O
binding	O
GM5	B-DNA
.	O
	
Mutation	O
of	O
the	O
core	O
ETS	B-DNA
binding	I-DNA
site	I-DNA
from	O
-GGAA-	B-DNA
to	I-DNA
-GGAT-	I-DNA
prevents	O
the	O
binding	O
of	O
ETS-like	B-protein
factors	I-protein
with	O
the	O
exception	O
of	O
ETS1	B-protein
.	O
	
The	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O
	
Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	B-protein
production	O
associated	O
with	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
	
###MEDLINE:96379940	
	
Quantitation	O
of	O
beta	B-RNA
1	I-RNA
triiodothyronine	I-RNA
receptor	I-RNA
mRNA	I-RNA
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
	
Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
,	O
the	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
(	I-protein
TR	I-protein
)	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
.	O
	
Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	B-protein
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O
	
To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	B-protein
expression	O
occur	O
in	O
humans	O
,	O
we	O
determined	O
the	O
mRNA	O
levels	O
of	O
the	O
hTR	B-protein
beta	I-protein
1	I-protein
in	O
various	O
thyroid	O
states	O
.	O
	
Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O
	
For	O
comparison	O
,	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
determined	O
in	O
lymphocytes	B-cell_type
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O
	
Human	B-RNA
TR	I-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
lymphocytes	B-cell_type
were	O
1.8	O
+/-	O
0.4	O
,	O
1.9	O
+/-	O
0.5	O
,	O
1.1	O
+/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol/microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O
	
Although	O
the	O
mean	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O
	
Similar	O
levels	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O
	
In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O
	
Absolute	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	B-RNA
being	O
present	O
in	O
a	O
mononuclear	B-cell_type
blood	I-cell_type
cell	I-cell_type
or	O
thyrocyte	B-cell_type
.	O
	
No	O
up-regulation	O
of	O
hTR	B-protein
beta	I-protein
1	I-protein
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O
	
However	O
,	O
there	O
is	O
a	O
non-significant	O
trend	O
towards	O
a	O
down-regulation	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
hyperthyroid	O
patients	O
.	O
	
###MEDLINE:96025857	
	
Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	B-DNA
inhibitory	I-DNA
protein	I-DNA
repressor	I-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin-3	I-DNA
promoter	I-DNA
.	O
	
T	O
cell	O
expression	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
directed	O
by	O
positive	B-DNA
and	I-DNA
negative	I-DNA
cis-acting	I-DNA
DNA	I-DNA
elements	I-DNA
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O
	
A	O
strong	O
repressor	B-protein
element	I-protein
,	O
termed	O
nuclear	B-protein
inhibitory	I-protein
protein	I-protein
(	O
NIP	B-protein
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL-3	B-DNA
promoter	I-DNA
between	O
nucleotides	B-DNA
-271	I-DNA
and	I-DNA
-250	I-DNA
.	O
	
Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O
	
DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O
	
Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B-DNA
region	I-DNA
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O
	
Complex	B-protein
1	I-protein
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O
	
Complex	B-protein
2	I-protein
corresponds	O
to	O
binding	O
of	O
transcription	B-protein
factor	I-protein
(	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
)	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
the	O
NIP	B-DNA
region	I-DNA
.	O
	
DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
but	O
is	O
clearly	O
distinct	O
.	O
	
To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	B-protein
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	B-DNA
site	I-DNA
of	O
an	O
IL-3	B-DNA
promoter-linked	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
examined	O
their	O
effects	O
on	O
NIP	B-protein
-mediated	O
repression	O
.	O
	
Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B-protein
3	I-protein
;	O
both	O
repressor	O
activity	O
and	O
complex	B-protein
3	I-protein
binding	O
require	O
the	O
consensus	B-DNA
sequence	I-DNA
CTCACNTNC	O
.	O
	
###MEDLINE:95399778	
	
The	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
is	O
downregulated	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
PU.1	B-protein
is	O
a	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
belonging	O
to	O
the	O
Ets-family	B-protein
.	O
	
It	O
is	O
identical	O
to	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O
	
PU.1	B-protein
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	B-cell_type
hematopoietic	I-cell_type
lineages	I-cell_type
,	O
but	O
its	O
expression	O
in	O
mature	B-cell_type
cells	I-cell_type
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B-cell_type
monocyte/macrophage-differentiation	I-cell_type
lineage	I-cell_type
.	O
	
It	O
binds	O
the	O
so-called	O
Pu	B-DNA
box	I-DNA
,	O
an	O
important	O
tissue-specific	B-DNA
regulatory	I-DNA
DNA	I-DNA
element	I-DNA
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	B-cell_type
lineages	I-cell_type
.	O
	
We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B-protein
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	B-cell_line
precursors	I-cell_line
to	O
differentiated	B-cell_line
plasma	I-cell_line
cells	I-cell_line
.	O
	
PU.1	B-RNA
mRNA	I-RNA
expression	O
and	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	B-cell_line
lines	I-cell_line
representing	O
pro-B	B-cell_line
,	I-cell_line
pre-B	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O
	
We	O
could	O
also	O
show	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O
	
In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
representing	O
differentiated	B-cell_type
,	I-cell_type
plasma	I-cell_type
cell-like	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O
	
In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O
	
The	O
findings	O
in	O
the	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represent	O
the	O
first	O
examples	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
downregulated	O
PU.1	B-protein
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B-protein
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	B-protein
expression	O
and	O
activity	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:95399771	
	
Regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
E-selectin	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
by	O
cyclosporin	O
A	O
and	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NFAT	B-protein
.	O
	
Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
athat	O
supported	O
the	O
activation	O
of	O
cytokine	B-protein
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	B-protein
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
	
As	O
we	O
observed	O
that	O
activated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
also	O
expressed	O
NFAT	B-protein
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O
	
Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
use	O
NFAT	B-protein
by	O
60	O
%	O
.	O
	
CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65	O
%	O
in	O
GM-CSF	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
in	O
activated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O
	
CsA	O
also	O
suppressed	O
E-selectin	B-protein
,	O
but	O
not	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
expression	O
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E-selectin	B-DNA
promoter	I-DNA
is	O
activated	O
by	O
NF-kappa	B-protein
B	I-protein
rather	O
than	O
NFAT	B-protein
.	O
	
Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	B-cell_type
adhesion	O
.	O
	
The	O
effects	O
of	O
CsA	O
on	O
endothelial	B-cell_type
cells	I-cell_type
were	O
also	O
detected	O
at	O
the	O
chromatin	B-DNA
structure	O
level	O
,	O
as	O
DNasel	B-DNA
hypersensitive	I-DNA
sites	I-DNA
within	O
both	O
the	O
GM-CSF	B-protein
enhancer	O
and	O
the	O
E-selectin	B-DNA
promoter	I-DNA
were	O
suppressed	O
by	O
CsA	O
.	O
	
This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O
	
###MEDLINE:96049646	
	
Costimulation	O
requirement	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
requires	O
T-cell	B-cell_type
costimulation	O
delivered	O
by	O
the	O
TCR	B-protein
and	O
the	O
auxiliary	B-protein
receptor	I-protein
CD28	I-protein
.	O
	
Several	O
transcription	B-protein
factors	I-protein
participate	O
in	O
IL-2	B-protein
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1-like	B-protein
factors	I-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O
	
Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B-protein
protein	I-protein
c-Jun	B-protein
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
from	O
NF-kappa	B-protein
B	I-protein
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O
	
We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O
	
Furthermore	O
,	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O
	
According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O
	
Whereas	O
TPCK	B-protein
inhibits	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B-protein
,	O
the	O
MAP	B-protein
kinase-related	I-protein
kinase	I-protein
that	O
phosphorylates	O
the	O
transactivation	B-protein
domain	I-protein
of	O
c-Jun	B-protein
.	O
	
We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T-cell	O
costimulation	O
.	O
	
Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
,	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O
	
Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B-protein
and	O
CD28	B-protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
phosphorylation	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	B-protein
activation	O
and	O
c-Jun	B-protein
phosphorylation	O
on	O
the	O
other	O
.	O
	
We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	B-protein
/	O
NF-kappa	B-protein
B	I-protein
pathway	O
.	O
	
###MEDLINE:96035700	
	
Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
by	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	B-protein
factors	I-protein
.	O
	
CD4+	B-cell_line
macrophages	I-cell_line
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O
	
HIV-1-infected	O
myeloid	B-cell_type
cells	I-cell_type
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O
	
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B-protein
receptors	I-protein
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B-protein
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O
	
Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
.	O
	
NF-kappa	B-protein
B	I-protein
binds	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
region	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O
	
Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O
	
Both	O
N-	O
and	O
C-terminal	O
residues	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O
	
Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
leads	O
to	O
constitutive	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O
	
Increased	O
intracellular	O
stores	O
of	O
latent	B-protein
NF-kappa	I-protein
B	I-protein
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B-protein
B	I-protein
-dependent	O
cytokine	B-protein
gene	O
expression	O
.	O
	
In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	B-protein
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
compared	O
with	O
uninfected	B-cell_type
cells	I-cell_type
.	O
	
Elevated	O
levels	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O
	
Secretion	O
of	O
myeloid	B-protein
cell-derived	I-protein
cytokines	I-protein
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O
	
###MEDLINE:90173249	
	
Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	B-cell_type
requires	O
the	O
DNA	O
binding	O
region	O
of	O
the	O
steroid	O
hormone	O
receptor	O
.	O
	
Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	B-cell_type
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O
	
It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O
	
In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B-protein
receptor	I-protein
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	B-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O
	
CEM-ICR	B-cell_line
27	I-cell_line
leukemic	I-cell_line
lymphoblasts	I-cell_line
,	O
a	O
clone	O
of	O
CEM	B-cell_line
cells	I-cell_line
which	O
lack	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B-protein
synthetase	I-protein
induction	O
,	O
were	O
provided	O
with	O
steroid	B-protein
receptors	I-protein
by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O
	
We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
in	O
the	O
transfected	B-cell_line
cells	I-cell_line
.	O
	
Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	B-cell_line
lymphoblasts	I-cell_line
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O
	
The	O
DNA	B-protein
binding	I-protein
region	I-protein
specifying	O
high	O
affinity	O
for	O
GRE	B-DNA
sites	I-DNA
is	O
required	O
.	O
	
Lysis	O
is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O
	
Our	O
data	O
support	O
the	O
view	O
that	O
steroid-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid-receptor	B-protein
complexes	I-protein
with	O
the	O
genome	O
.	O
	
###MEDLINE:96102041	
	
Functional	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
of	O
the	O
B	B-protein
cell-specific	I-protein
coactivator	I-protein
BOB.1/OBF.1	B-protein
.	O
	
B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	I-DNA
requires	O
the	O
Oct1	B-protein
or	O
Oct2	B-protein
protein	I-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	I-protein
.	O
	
One	O
such	O
cofactor	B-protein
,	O
BOB.1/OBF.1	B-protein
,	O
was	O
recently	O
isolated	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
	
Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
.	O
	
Full-length	O
cDNAs	B-DNA
and	O
genomic	B-DNA
clones	I-DNA
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined.	O
Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	B-protein
and	I-protein
human	I-protein
BOB.1/OBF.1	I-protein
.	O
	
The	O
NH2-terminal	B-protein
126	I-protein
amino	I-protein
acids	I-protein
of	O
BOB.1/OBF.1	B-protein
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B-protein
domains	I-protein
of	O
either	O
Oct1	B-protein
or	O
Oct2	B-protein
.	O
	
This	O
protein-protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-protein
proteins	I-protein
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B-DNA
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	B-protein
to	O
Oct1	B-protein
or	O
Oct2	B-protein
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O
	
BOB.1/OBF.1	B-protein
can	O
efficiently	O
activate	O
octamer-dependent	O
promoters	O
in	O
fibroblasts	B-cell_type
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
activity	O
.	O
	
Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	B-protein
with	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
reveals	O
that	O
both	O
NH2-	B-protein
and	I-protein
COOH-terminal	I-protein
domains	I-protein
of	O
BOB.1/OBF.1	B-protein
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	B-protein
domain	I-protein
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O
	
Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-protein
BOB.1/OBF.1	I-protein
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
elements	I-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
the	O
GAL4	B-protein
fusions	I-protein
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O
	
###MEDLINE:96096469	
	
Anti-immunoglobulin	B-protein
M	I-protein
activates	O
nuclear	B-protein
calcium/calmodulin-dependent	I-protein
protein	I-protein
kinase	I-protein
II	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
	
We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B-protein
protein	I-protein
,	O
Ets-1	B-protein
,	O
is	O
phosphorylated	O
in	O
a	O
calcium-dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O
	
As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	O
CaM	B-protein
kinase	I-protein
)	O
might	O
phosphorylate	O
the	O
Ets-1	B-protein
protein	I-protein
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O
	
The	O
dephosphorylated	O
form	O
of	O
Ets-1	B-protein
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	B-protein
kinase	I-protein
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O
	
We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B-protein
protein	O
.	O
	
Activity	O
of	O
the	O
CaM	B-protein
kinases	I-protein
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B-protein
kinase	I-protein
family	I-protein
,	O
KN-62	O
.	O
	
Stimulation	O
of	O
cells	O
with	O
anti-IgM	B-protein
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B-protein
kinase	I-protein
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O
	
Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B-protein
specific	O
for	O
CaM	B-protein
kinase	I-protein
II	I-protein
.	O
	
Two-dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets-1	B-protein
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti-IgM	B-protein
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O
	
Incubation	O
of	O
isolated	B-protein
Ets-1	I-protein
protein	I-protein
with	O
purified	O
CaM	B-protein
kinase	I-protein
II	I-protein
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti-IgM	B-protein
or	O
ionomycin	O
.	O
	
These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	B-protein
receptor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	B-protein
CaM	I-protein
kinase	I-protein
II	I-protein
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA-binding	B-protein
proteins	I-protein
.	O
	
###MEDLINE:96096754	
	
Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
.	O
	
The	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
contains	O
two	O
transcriptional	B-protein
activation	I-protein
domains	I-protein
which	O
are	O
located	O
within	O
the	O
N-terminal	B-protein
and	O
C-terminal	B-protein
regions	I-protein
.	O
	
To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	B-protein
domains	I-protein
to	O
the	O
GAL4	B-protein
DNA-binding	I-protein
domain	I-protein
.	O
	
We	O
have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	B-protein
,	O
isolated	O
from	O
their	O
natural	O
context	O
,	O
can	O
activate	O
transcription	O
as	O
promoter	B-protein
factors	I-protein
.	O
	
In	O
contrast	O
to	O
the	O
C-terminus	B-protein
,	O
activation	O
by	O
the	O
N-terminal	B-protein
domain	I-protein
is	O
dependent	O
on	O
a	O
yet	O
unidentified	O
factor	O
(	O
s	O
)	O
binding	O
to	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
.	O
	
The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	B-protein
domains	I-protein
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent	O
.	O
	
However	O
,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C-terminus	B-protein
of	O
Oct-2a	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O
	
In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B-protein
cofactors	I-protein
in	O
concert	O
with	O
the	O
effector	B-protein
domains	I-protein
of	O
Oct-2a	B-protein
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O
	
Furthermore	O
,	O
we	O
identified	O
a	O
repression	O
domain	O
at	O
the	O
N-terminus	O
of	O
Oct-2a	B-protein
.	O
	
When	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently	O
.	O
	
These	O
results	O
underscore	O
the	O
modular	O
structure	O
of	O
Oct-2a	B-protein
with	O
separable	O
domains	O
for	O
activation	O
and	O
repression	O
and	O
suggest	O
that	O
Oct-2a	B-protein
might	O
have	O
complex	O
regulatory	O
functions	O
in	O
vivo	O
.	O
	
###MEDLINE:96029754	
	
Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	B-cell_type
and	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O
	
Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O
	
To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B-protein
sigma	I-protein
factor	I-protein
were	O
undertaken	O
.	O
	
The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	B-protein
adhesins	I-protein
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	B-cell_type
and	O
neutrophils	B-cell_type
.	O
	
Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O
	
The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	B-cell_type
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O
	
###MEDLINE:96025852	
	
Identification	O
of	O
essential	O
GATA	B-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	I-DNA
within	O
the	O
promoter	O
of	O
the	O
platelet	B-DNA
glycoprotein	I-DNA
Ib	I-DNA
alpha	I-DNA
gene	I-DNA
.	O
	
Platelet	B-protein
glycoprotein	I-protein
(	O
GP	B-protein
)	O
Ib-IX-V	B-protein
is	O
a	O
multisubunit	B-protein
adhesion	I-protein
receptor	I-protein
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O
	
The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
``	B-cell_type
giant	I-cell_type
''	I-cell_type
platelets	I-cell_type
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O
	
To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	B-protein
Ib-IX-V	I-protein
complex	I-protein
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	B-DNA
elements	I-DNA
supporting	O
the	O
expression	O
of	O
the	O
alpha-subunit	B-protein
of	O
the	O
complex	O
(	O
GP	B-protein
Ib	I-protein
alpha	I-protein
)	O
.	O
	
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	B-protein
,	O
luciferase	B-protein
.	O
	
Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O
	
In	O
cells	O
of	O
nonhematopoietic	B-cell_type
lineage	I-cell_type
,	O
human	B-cell_type
endothelial	I-cell_type
and	O
HeLa	B-cell_type
cells	I-cell_type
,	O
the	O
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	B-DNA
constructs	I-DNA
.	O
	
Gel	O
shift	O
assays	O
and	O
site-directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	B-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	I-DNA
93	B-DNA
and	I-DNA
150	I-DNA
nucleotides	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O
	
The	O
results	O
define	O
essential	O
cis-acting	B-DNA
elements	I-DNA
responsible	O
for	O
the	O
expression	O
of	O
GP	B-protein
Ib	I-protein
alpha	I-protein
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	B-cell_type
platelets	I-cell_type
into	O
the	O
bloodstream	O
.	O
	
###MEDLINE:96062038	
	
CD30	B-protein
ligation	O
induces	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
CD30	B-protein
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor/nerve	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O
	
In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B-cell_line
cells	I-cell_line
(	O
Hodgkin	B-cell_line
's	I-cell_line
disease-derived	I-cell_line
,	I-cell_line
T	I-cell_line
cell-like	I-cell_line
,	I-cell_line
CD30+	I-cell_line
cells	I-cell_line
)	O
with	O
the	O
agonistic	B-protein
anti-CD30	I-protein
monoclonal	I-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
M44	B-protein
and	O
M67	B-protein
,	O
two	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O
	
The	O
effect	O
of	O
the	O
mAb	B-protein
towards	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O
	
By	O
comparison	O
,	O
an	O
isotype-matched	B-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
Moreover	O
,	O
in	O
human	B-cell_line
T	I-cell_line
helper	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	I-cell_line
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	B-protein
-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	B-cell_line
cells	I-cell_line
.	O
	
In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
induced	O
following	O
CD30	B-protein
engagement	O
were	O
shown	O
to	O
contain	O
p50	B-protein
NF-kappa	I-protein
B1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and	O
possibly	O
other	O
transcription	B-protein
factors	I-protein
.	O
	
Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B-protein
ligation	O
.	O
	
###MEDLINE:96016217	
	
Pathogenesis	O
of	O
atherosclerosis	O
.	O
	
The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O
	
This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O
subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O
	
The	O
trapped	O
LDL	O
is	O
seeded	O
with	O
oxidative	O
species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	O
particle.	O
Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB-like	B-protein
transcription	I-protein
factors	I-protein
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	B-protein
products	I-protein
mediate	O
monocyte	O
binding	O
,	O
monocyte	B-cell_type
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	B-cell_type
.	O
	
At	O
least	O
1	O
major	B-DNA
gene	I-DNA
modulates	O
the	O
oxidation	O
of	O
LDL	O
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids	O
.	O
	
The	O
inverse	O
relation	O
between	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
atherosclerotic	O
events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	B-protein
associated	O
with	O
HDL	O
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	O
.	O
	
###MEDLINE:97252236	
	
Estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
in	O
vernal	O
keratoconjunctivitis	O
.	O
	
PURPOSE	O
:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O
	
METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
by	O
using	O
monoclonal	B-protein
antibodies	I-protein
with	O
a	O
peroxidase-antiperoxidase	O
technique	O
.	O
	
RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B-protein
receptors	I-protein
.	O
	
Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
with	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	B-cell_type
cells	I-cell_type
were	O
eosinophils	B-cell_type
.	O
	
CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	B-protein
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	B-cell_type
in	O
patients	O
with	O
VKC	O
.	O
	
###MEDLINE:96091806	
	
CIITA	B-protein
activates	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
mouse	O
T	O
cells	O
.	O
	
It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
are	O
expressed	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
activation	O
but	O
not	O
in	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O
	
Recently	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	B-protein
regulatory	I-protein
factor	I-protein
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O
	
Here	O
we	O
show	O
that	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	B-protein
transcripts	O
while	O
MHC	O
class	O
II-negative	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
.	O
	
The	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	B-DNA
CIITA	I-DNA
cDNA	I-DNA
.	O
	
These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B-protein
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
in	O
human	B-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
respectively	O
.	O
	
###MEDLINE:90110496	
	
Anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
autoantibodies	I-protein
are	O
associated	O
with	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
beta	I-DNA
genes	I-DNA
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O
	
Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B-protein
.	O
	
Associations	O
between	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
autoantibodies	B-protein
to	O
the	O
ribonucleoproteins	B-protein
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
and	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O
	
Because	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
present	O
antigen	O
to	O
T	B-protein
cell	I-protein
receptors	I-protein
(	O
TCRs	B-protein
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B-DNA
gene	I-DNA
associated	O
with	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O
	
A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
(	O
RFLPs	B-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	I-DNA
and	O
the	O
other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	I-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	I-DNA
.	O
	
This	O
RFLP	B-DNA
pair	I-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
-positive	O
patients	O
lacking	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
precipitins	B-protein
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B-protein
(	O
P	O
=	O
0.0004	O
)	O
.	O
	
This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O
indicates	O
that	O
these	O
RFLPs	B-DNA
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B-DNA
genes	I-DNA
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O
	
The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B-DNA
and	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B-DNA
occur	I-DNA
in	O
response	O
to	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
.	O
	
###MEDLINE:96102166	
	
Inhibition	O
of	O
NF-AT	B-protein
-dependent	O
transcription	O
by	O
NF-kappa	B-protein
B	I-protein
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O
	
Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
results	O
in	O
differential	O
lymphokine	B-protein
expression	O
:	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	B-protein
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	I-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O
	
The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
factor	I-protein
NF-ATp	B-protein
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	B-DNA
genes	I-DNA
.	O
	
However	O
,	O
while	O
IL2	B-protein
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B-protein
IL4	I-protein
transcription	O
through	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
	
This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	B-protein
and	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
P	B-DNA
sequence	I-DNA
,	O
an	O
element	O
located	O
69	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
IL4	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O
	
Human	B-DNA
IL4	I-DNA
promoter	I-DNA
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
stimulated	O
with	O
the	O
NF-kappa	B-protein
B-activating	I-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
suppressed	O
in	O
RelA-overexpressing	B-cell_line
cells	I-cell_line
.	O
	
In	O
contrast	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
or	O
RelA	B-protein
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	B-DNA
IL4	I-DNA
promoter	I-DNA
containing	O
a	O
mouse	B-DNA
P	I-DNA
sequence	I-DNA
,	O
which	O
is	O
a	O
higher-affinity	B-DNA
site	I-DNA
for	O
NF-ATp	B-protein
and	O
a	O
lower-affinity	B-DNA
site	I-DNA
for	O
RelA	B-protein
.	O
	
Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	B-protein
activators	I-protein
,	O
RelA	B-protein
and	O
NF-ATp	B-protein
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
on	O
IL4	B-protein
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B-cell_line
cells	I-cell_line
.	O
	
###MEDLINE:96096457	
	
Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B-protein
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B-protein
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B-protein
and	O
inflammatory	O
synovial	O
fluids	O
.	O
	
The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B-protein
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O
	
Many	O
cytokines	B-protein
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activation	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O
	
We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line
priming	I-cell_line
cultures	I-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	I-cell_type
(	O
SFs	B-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B-protein
production	O
and	O
STAT	B-protein
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O
	
Exposure	O
to	O
SFs	B-cell_type
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
,	O
but	O
not	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
4	I-protein
,	O
production	O
by	O
effector	B-cell_type
cells	I-cell_type
generated	O
in	O
priming	O
cultures	O
.	O
	
SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
and	O
inhibition	O
of	O
IL-12	B-protein
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O
	
SFs	B-cell_type
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B-protein
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B-protein
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN-gamma	B-protein
production	O
.	O
	
Active	O
Stat3	B-protein
,	O
but	O
not	O
Stat1	B-protein
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O
	
These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	B-cell_type
cell	I-cell_type
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O
	
###MEDLINE:96062305	
	
Triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Monocyte/macrophages	B-cell_type
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O
	
Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	B-protein
such	O
as	O
TNF-alpha	B-protein
in	O
vitro	O
.	O
	
The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	B-protein
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	B-protein
heterodimer	I-protein
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O
	
The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O
	
Monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B-protein
(	I-protein
ab	I-protein
'	I-protein
)	I-protein
2	I-protein
fragments	I-protein
of	O
monoclonal	B-protein
anti-CR1	I-protein
or	O
anti-CR3	B-protein
Abs	I-protein
or	O
with	O
C3	B-protein
fragments	I-protein
.	O
	
Stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	B-protein
Ag	I-protein
in	O
cell	B-cell_line
cultures	I-cell_line
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	B-cell_line
cultures	I-cell_line
triggered	O
with	O
LPS	O
.	O
	
We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
induces	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
in	O
infected	B-cell_type
cells	I-cell_type
.	O
	
Translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
of	O
uninfected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
from	O
HIV-seronegative	O
donors	O
.	O
	
The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF-alpha	B-protein
.	O
	
TNF-alpha	B-protein
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
induced	O
by	O
triggering	O
of	O
complement	B-protein
receptors	I-protein
.	O
	
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B-cell_type
monocytes	I-cell_type
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	B-protein
particles	I-protein
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B-protein
receptor	I-protein
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O
	
###MEDLINE:96029750	
	
Attenuation	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	B-protein
kinases	I-protein
and	O
Stat1	B-protein
.	O
	
The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-protein
interferon	I-protein
is	O
impaired	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O
	
The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-protein
interferon	I-protein
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak2	B-protein
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
.	O
	
To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-protein
interferon	I-protein
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B-protein
and	O
Jak2	B-protein
and	O
phosphorylation	O
of	O
Stat1	B-protein
was	O
developed	O
in	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate-differentiated	I-cell_line
U-937	I-cell_line
cells	I-cell_line
.	O
	
Analysis	O
of	O
whole-cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-protein
interferon	I-protein
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O
	
Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	B-cell_type
cells	I-cell_type
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O
	
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon-treated	B-cell_line
cells	I-cell_line
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O
	
Tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
increased	O
markedly	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
in	O
U-937	B-cell_line
cells	I-cell_line
incubated	O
with	O
gamma	B-protein
interferon	I-protein
.	O
	
In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
was	O
markedly	O
impaired	O
.	O
	
This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O
	
Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B-cell_line
cells	I-cell_line
were	O
also	O
obtained	O
with	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
	
These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B-protein
interferon	I-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	B-protein
pathway	O
.	O
	
Unresponsiveness	O
to	O
gamma	B-protein
interferon	I-protein
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania-infected	B-cell_type
cells	I-cell_type
.	O
	
###MEDLINE:96025779	
	
Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B-protein
attachment	I-protein
region	I-protein
binding	I-protein
protein	I-protein
and	O
the	O
NF-muNR	B-protein
enhancer	I-protein
repressor	I-protein
.	O
	
Implications	O
for	O
regulation	O
of	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
expression	O
.	O
	
The	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
(	O
IgH	B-protein
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	O
promoters	O
in	O
B	O
lymphocytes	O
but	O
not	O
other	O
cell	O
types	O
.	O
	
The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B-protein
factor-mu	I-protein
negative	I-protein
regulator	I-protein
(	I-protein
NF-muNR	I-protein
)	I-protein
enhancer	I-protein
repressor	I-protein
overlap	I-protein
nuclear	I-protein
matrix	I-protein
attachment	I-protein
regions	I-protein
(	O
MARs	B-protein
)	O
in	O
this	O
enhancer	B-DNA
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	B-DNA
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O
&	O
Dev.	O
3	O
,	O
1255-1266	O
)	O
.	O
	
To	O
understand	O
the	O
role	O
of	O
MARs	B-protein
in	O
IgH	B-DNA
enhancer	I-DNA
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR-binding	B-protein
protein	I-protein
,	O
MAR-BP1	B-protein
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	B-protein
associated	O
with	O
the	O
IgH	B-DNA
enhancer	I-DNA
.	O
	
Purified	O
MAR-BP1	B-protein
migrates	O
as	O
a	O
33-kDa	B-protein
protein	I-protein
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF-muNR	B-protein
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR-BP1	B-protein
binding	O
.	O
	
Indeed	O
,	O
binding	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR-BP1	B-protein
is	O
mutually	O
exclusive	O
to	O
NF-muNR	B-protein
binding	O
.	O
	
These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell-type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF-muNR	B-protein
repressor	I-protein
to	O
the	O
IgH	B-DNA
enhancer	I-DNA
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR-BP1	B-protein
/enhancer	B-DNA
interaction	O
.	O
	
###MEDLINE:96009612	
	
PU.1	B-protein
(	O
Spi-1	B-protein
)	O
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O
	
Growth	B-protein
factor	I-protein
receptors	I-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O
	
In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B-protein
factors	I-protein
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O
	
Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O
	
The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	I-DNA
.	O
	
We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
.	O
	
Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	I-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
.	O
	
C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O
	
Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B-protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B-protein
)	O
when	O
binding	O
the	O
GM-CSF	B-protein
receptor	I-protein
alpha	I-protein
promoter	O
PU.1	B-DNA
site	I-DNA
.	O
	
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O
	
The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B-DNA
cell	I-DNA
enhancer	I-DNA
sites	I-DNA
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B-protein
to	O
extracts	O
from	O
certain	O
nonmyeloid	B-cell_type
cell	I-cell_type
types	I-cell_type
which	O
do	O
not	O
express	O
PU.1	B-protein
,	O
including	O
T	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
from	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B-protein
complex	I-protein
binds	O
to	O
PU.1	B-protein
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	B-DNA
promoters	I-DNA
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B-DNA
site	I-DNA
adjacent	O
to	O
a	O
single-stranded	O
region	O
.	O
	
Expression	O
of	O
PU.1	B-protein
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O
	
Deletion	O
of	O
the	O
amino-terminal	B-protein
region	I-protein
of	O
PU.1	B-protein
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	B-protein
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU-SF	B-protein
complex	I-protein
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O
	
Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O
	
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
	
###MEDLINE:96024587	
	
HMG-I	B-protein
binds	O
to	O
GATA	B-DNA
motifs	I-DNA
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O
	
We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B-protein
protein	I-protein
HMG-I	B-protein
to	O
the	O
human	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
.	O
	
We	O
find	O
that	O
HMG-I	B-protein
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	B-DNA
motifs	I-DNA
in	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O
	
A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	B-protein
results	O
in	O
overexpression	O
of	O
gamma-globin	B-protein
in	O
adult	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
HPFH	B-cell_type
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	B-protein
does	O
not	O
bind	O
to	O
this	O
mutant	B-DNA
sequence	I-DNA
.	O
	
A	O
survey	O
of	O
GATA	B-DNA
motifs	I-DNA
from	O
other	O
globin	B-DNA
cis-elements	I-DNA
demonstrates	O
HMG-I	B-protein
binding	O
to	O
most	O
of	O
them	O
.	O
	
These	O
findings	O
implicate	O
HMG-I	B-protein
in	O
the	O
HPFH	B-cell_type
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B-protein
complexes	I-protein
that	O
regulate	O
globin	O
gene	O
expression	O
.	O
	
###MEDLINE:95386713	
	
Constitutive	O
activation	O
of	O
different	O
Jak	B-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
tax	I-protein
protein	I-protein
or	O
virus-transformed	B-cell_line
cells	I-cell_line
.	O
	
HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O
	
The	O
viral	B-protein
encoded	I-protein
protein	I-protein
tax	B-protein
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O
	
Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B-protein
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B-protein
transforms	O
mouse	B-cell_type
fibroblasts	I-cell_type
but	O
not	O
thymocytes	B-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	B-protein
expression	O
in	O
both	O
tissues	O
.	O
	
Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B-protein
protein	I-protein
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B-protein
transformed	B-cell_line
fibroblast	I-cell_line
B	I-cell_line
line	I-cell_line
and	O
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
thymocytes	B-cell_type
from	O
Thy-tax	O
transgenic	O
mice	O
.	O
	
Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B-protein
kinase	I-protein
specific	I-protein
antibodies	I-protein
,	O
identified	O
p130	O
as	O
Jak2	B-protein
in	O
the	O
tax	B-protein
transformed	O
mouse	B-cell_line
fibroblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
Jak3	B-protein
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Phosphorylation	O
of	O
Jak2	B-protein
in	O
tax	B-cell_line
transformed	I-cell_line
cells	I-cell_line
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O
	
Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B-cell_line
cells	I-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	I-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O
	
Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B-protein
neutralizing	I-protein
antibodies	I-protein
.	O
	
Constitutive	O
phosphorylation	O
of	O
Jak	B-protein
kinases	I-protein
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B-cell_type
infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
the	O
transgenic	O
mouse	O
model	O
.	O
	
###MEDLINE:95367587	
	
Regulation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
hydroxyurea	O
in	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O
	
Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O
	
In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-protein
hemoglobin	I-protein
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O
	
To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	B-DNA
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O
	
HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	B-DNA
synthesis	O
.	O
	
The	O
levels	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O
	
This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O
	
Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c-jun	B-RNA
mRNA	I-RNA
.	O
	
In	O
addition	O
,	O
the	O
level	O
of	O
jun	B-protein
protein	I-protein
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	B-cell_line
treated	I-cell_line
cells	I-cell_line
.	O
	
Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B-protein
/CAT	B-protein
activity	O
.	O
	
These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B-DNA
during	O
erythroid	O
differentiation	O
.	O
	
###MEDLINE:92187059	
	
In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B-protein
receptors	I-protein
.	O
	
Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O
	
While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O
	
To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B-protein
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	B-protein
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O
	
Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O
	
There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B-protein
-induced	O
B-cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O
	
These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
.	O
	
The	O
decrease	O
in	O
PWM	B-protein
-generated	O
B-cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid-mediated	O
induction	O
of	O
interleukin-1	B-protein
receptor	I-protein
synthesis	O
.	O
	
###MEDLINE:96356325	
	
Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O
	
Application	O
of	O
a	O
``	O
formamide	O
free	O
''	O
and	O
thus	O
``	O
material	O
preserving	O
''	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	B-DNA
of	O
the	O
myf3	B-DNA
gene	I-DNA
revealed	O
the	O
following	O
results	O
:	O
Human	B-cell_type
rhabdomyosarcoma	I-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	B-DNA
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O
	
RNase	B-protein
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O
	
In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O
	
Correspondingly	O
,	O
RNase	B-protein
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O
	
In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O
	
###MEDLINE:96079009	
	
Oncogenicity	O
of	O
human	B-cell_line
papillomavirus-	I-cell_line
or	I-cell_line
adenovirus-transformed	I-cell_line
cells	I-cell_line
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
	
The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-protein
and	O
E7	B-protein
proteins	I-protein
to	O
target	B-cell_type
cells	I-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
response	O
.	O
	
As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-protein
-and	O
E7	B-protein
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	I-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	B-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O
	
Cells	O
expressing	O
the	O
E1A	B-protein
oncoprotein	I-protein
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
while	O
the	O
same	O
parental	B-cell_type
cells	I-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-protein
oncoprotein	I-protein
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O
	
The	O
ability	O
of	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	B-protein
's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i.e.	O
,	O
non-viral	B-cell_line
oncogene-expressing	I-cell_line
)	O
but	O
not	O
virally	B-cell_line
transformed	I-cell_line
cells	I-cell_line
.	O
	
E1A	B-protein
blocked	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O
	
The	O
extent	O
of	O
IFN	B-protein
-induced	O
NK	O
cell	O
killing	O
of	O
E1A-expressing	B-cell_line
cells	I-cell_line
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B-protein
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B-protein
to	O
block	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
in	O
target	B-cell_type
cells	I-cell_type
.	O
	
In	O
contrast	O
,	O
E7	B-protein
blocked	O
neither	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
nor	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O
	
In	O
conclusion	O
,	O
E1A	B-protein
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	B-cell_type
cell	I-cell_type
response	O
,	O
whereas	O
the	O
E7	B-protein
oncoprotein	I-protein
lacks	O
this	O
activity	O
.	O
	
###MEDLINE:96062284	
	
Regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O
	
The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
	
While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
calcineurin	B-protein
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O
	
Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
.	O
	
While	O
PKC	B-protein
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
co-activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O
	
Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
or	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O
	
Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	B-protein
alpha	I-protein
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
a	O
PKC	B-protein
-independent	O
stimulus	O
.	O
	
Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B-protein
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	B-protein
not	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O
	
These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B-protein
calcineurin	B-protein
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B-protein
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
degradation	O
.	O
	
###MEDLINE:96054968	
	
Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
binding	O
.	O
	
Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O
	
Oxidative	O
stress	O
enhances	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activity	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-protein
cytokines	I-protein
.	O
	
Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O
	
This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O
	
Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O
	
In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O
	
Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O
	
These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O
	
It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B-protein
cytokine	I-protein
synthesis	O
.	O
	
###MEDLINE:96026328	
	
Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
through	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
synthesis	O
[	O
see	O
comments	O
]	O
	
Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O
	
They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	B-protein
and	O
of	O
several	O
cell	B-protein
surface	I-protein
molecules	I-protein
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
mice	O
and	O
cultured	B-cell_line
cells	I-cell_line
.	O
	
This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
inactive	B-protein
cytoplasmic	I-protein
complexes	I-protein
.	O
	
Because	O
NF-kappa	B-protein
B	I-protein
activates	O
many	O
immunoregulatory	B-DNA
genes	I-DNA
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O
	
###MEDLINE:96009608	
	
Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
by	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
.	O
	
T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O
	
We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O
	
We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	B-protein
expression	O
by	O
cotransfecting	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
IL-2	B-DNA
promoter/reporter	I-DNA
constructs	I-DNA
and	O
a	O
VDR	B-DNA
overexpression	I-DNA
vector	I-DNA
and	O
by	O
DNA	O
binding	O
.	O
	
We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	I-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
NF-AT-1	B-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
NFATp	B-protein
,	O
as	O
well	O
as	O
by	O
AP-1	B-protein
.	O
	
VDR	B-protein
DNA-binding	I-protein
mutants	I-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	I-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B-protein
expression	O
.	O
	
These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O
	
By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O
	
Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
heterodimer	I-protein
blocks	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B-DNA
element	I-DNA
.	O
	
This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O
	
###MEDLINE:96017769	
	
Tissue-specific	O
regulation	O
of	O
the	O
rabbit	B-DNA
15-lipoxygenase	I-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
a	O
transcriptional	B-DNA
silencer	I-DNA
.	O
	
The	O
15-lipoxygenase	B-DNA
(	I-DNA
lox	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B-cell_type
cells	I-cell_type
but	O
also	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
.	O
	
We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
of	O
the	O
15-lox	B-DNA
gene	I-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	B-DNA
'silencer	I-DNA
'	I-DNA
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O
	
The	O
main	O
activity	O
of	O
the	O
silencer	B-DNA
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	B-protein
factor	I-protein
present	O
in	O
non-	O
erythroid	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
	
These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	I-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O
	
The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
GATA	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
	
###MEDLINE:95386516	
	
Phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFATp	B-protein
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	B-cell_line
A-treated	I-cell_line
human	I-cell_line
B	I-cell_line
and	O
T	B-cell_type
cells	I-cell_type
.	O
	
Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O
	
This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B-protein
component	O
to	O
the	O
nucleus	O
.	O
	
Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O
	
Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-protein
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O
	
Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O
	
These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA-sensitive	O
regulation	O
of	O
NFATp	B-protein
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O
	
###MEDLINE:95367586	
	
Transcription	B-protein
factors	I-protein
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O
	
We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O
	
In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O
	
Treatment	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O
	
This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O
	
It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O
	
Taking	O
the	O
IL-2	B-DNA
gene	I-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	I-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
and	O
Oct1	B-protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B-protein
mRNA	O
.	O
	
Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	B-RNA
mRNA	I-RNA
and	O
secretion	O
of	O
IL-2	B-protein
into	O
the	O
culture	O
medium	O
.	O
	
The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B-protein
factor	I-protein
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
extracted	O
from	O
mitogen-stimulated	B-cell_type
cells	I-cell_type
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O
	
Interestingly	O
,	O
Oct1	O
and	O
NF-AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O
	
The	O
identification	O
of	O
regulatory	B-protein
proteins	I-protein
,	O
such	O
as	O
transcription	B-protein
factors	I-protein
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
	
###MEDLINE:91175240	
	
Sex	O
and	O
age	O
distribution	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
human	O
subjects	O
.	O
	
Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O
	
We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O
	
Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(	O
38.9	O
+/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O
	
The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O
	
Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O
	
No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O
	
Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B-protein
receptors	I-protein
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O
	
###MEDLINE:96226053	
	
Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O
	
Helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O
	
The	O
Id	B-protein
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B-protein
proteins	I-protein
,	O
in	O
a	O
dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B-protein
HLH	I-protein
proteins	I-protein
.	O
	
We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	I-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	I-cell_line
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	B-cell_type
)	O
.	O
	
The	O
Id2	B-RNA
mRNA	I-RNA
was	O
abundantly	O
expressed	O
in	O
5/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
and	O
Id3	B-RNA
mRNA	I-RNA
was	O
detected	O
in	O
4/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O
	
Interestingly	O
,	O
Id2	B-RNA
,	O
but	O
not	O
Id3	B-RNA
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	B-cell_line
,	O
MT-2	B-cell_line
,	O
S-LB1	B-cell_line
)	O
and	O
type	O
II	O
(	O
Mo	B-cell_line
)	O
.	O
	
Another	O
unexpected	O
finding	O
was	O
that	O
T-cell	O
leukemias	O
and	O
T-cell	B-cell_line
lines	I-cell_line
often	O
expressed	O
either	O
Id2	B-RNA
or	O
Id3	B-RNA
mRNA	I-RNA
.	O
	
In	O
addition	O
,	O
resting	B-cell_type
PBL	I-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	I-RNA
.	O
	
Upon	O
PHA	B-protein
-stimulation	O
,	O
Id2	B-protein
expression	O
decreased	O
and	O
Id3	B-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O
	
Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	B-RNA
mRNA	I-RNA
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T-cells	O
usually	O
express	O
either	O
Id2	B-protein
or	O
Id3	B-RNA
mRNA	I-RNA
,	O
but	O
B-cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non-dividing	O
,	O
normal	O
PBL	B-cell_type
express	O
high	O
levels	O
of	O
Id2	B-protein
and	O
no	O
Id3	B-RNA
mRNA	I-RNA
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
decrease	O
while	O
levels	O
of	O
Id3	B-RNA
mRNA	I-RNA
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	B-DNA
is	O
disparate	O
.	O
	
###MEDLINE:96082168	
	
Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
	
Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	I-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	I-protein
initiates	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O
	
TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O
	
Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O
	
Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O
	
Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O
	
In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O
	
These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O
	
The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O
	
###MEDLINE:96062272	
	
Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B-protein
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
	
Critical	O
role	O
for	O
IL-6	B-protein
.	O
	
The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O
	
The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
primary	O
TCR	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
have	O
been	O
explored	O
.	O
	
In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	I-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	I-protein
.	O
	
These	O
STAT	B-protein
proteins	I-protein
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
	
Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-protein
Abs	I-protein
indicated	O
that	O
they	O
contained	O
STAT-3	B-protein
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B-protein
family	I-protein
.	O
	
The	O
induction	O
of	O
STAT	B-protein
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-protein
factor	I-protein
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O
	
As	O
neutralizing	B-protein
anti-IL-6	I-protein
Abs	I-protein
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	B-protein
proteins	I-protein
and	O
as	O
exogenously	O
added	O
IL-6	B-protein
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B-protein
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	B-protein
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
	
###MEDLINE:96046572	
	
The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
.	O
	
B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O
	
Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B-DNA
cycle-associated	I-DNA
genes	I-DNA
in	O
quiescent	B-cell_type
and	I-cell_type
stimulated	I-cell_type
cells	I-cell_type
.	O
	
We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B-DNA
genes	I-DNA
,	O
cdc-2	B-DNA
,	O
cyclin	B-DNA
E	I-DNA
,	O
CD23	B-DNA
,	O
and	O
cyclin	B-DNA
D2	I-DNA
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O
	
Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O
	
Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B-protein
,	O
anti-IgM	B-protein
,	O
and	O
IL4	B-protein
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	B-cell_type
cell	O
cycle	O
activation	O
.	O
	
###MEDLINE:96011839	
	
Expression	O
of	O
the	O
chemokine	B-protein
receptor	I-protein
BLR2/EBI1	B-protein
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
.	O
	
In	O
our	O
attempt	O
to	O
identify	O
chemokine	B-protein
receptors	I-protein
that	O
are	O
related	O
to	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
receptor	I-protein
1	I-protein
(	O
BLR1	B-protein
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-protein
transmembrane	I-protein
receptor	I-protein
termed	O
BLR2	B-protein
.	O
	
The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-protein
coupled	I-protein
chemokine	I-protein
receptors	I-protein
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-protein
EBI1	I-protein
.	O
	
Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-RNA
mRNA	I-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O
	
BLR2-specific	B-RNA
mRNA	I-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
	
We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-DNA
gene	I-DNA
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
negative	I-cell_line
BL	I-cell_line
41	I-cell_line
cells	I-cell_line
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
,	O
a	O
key	O
regulator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
in	O
immortalized	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O
	
Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B-protein
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
viral	O
pathogenesis	O
.	O
	
###MEDLINE:96009598	
	
A	O
central	O
role	O
for	O
a	O
single	B-DNA
c-Myb	I-DNA
binding	I-DNA
site	I-DNA
in	O
a	O
thymic	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O
	
Locus	B-DNA
control	I-DNA
regions	I-DNA
(	O
LCRs	B-DNA
)	O
are	O
powerful	O
assemblies	O
of	O
cis	B-DNA
elements	I-DNA
that	O
organize	O
the	O
actions	O
of	O
cell-type-specific	B-protein
trans-acting	I-protein
factors	I-protein
.	O
	
A	O
2.3-kb	B-protein
LCR	I-protein
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	I-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	B-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	I-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	B-DNA
.	O
	
Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	I-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	I-DNA
.	O
	
We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	I-DNA
.	O
	
In	O
both	O
transiently	B-cell_line
cotransfected	I-cell_line
human	I-cell_line
cells	I-cell_line
and	O
stable	O
chromatin-integrated	B-cell_line
yeast	I-cell_line
cells	I-cell_line
,	O
c-Myb	B-protein
strongly	O
transactivated	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
contained	O
polymerized	B-DNA
core	I-DNA
sequences	I-DNA
.	O
	
c-Myb	B-protein
protein	I-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	I-cell_type
in	O
which	O
the	O
enhancer	B-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O
	
Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	B-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	I-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	I-DNA
-directed	O
transgene	O
expression	O
.	O
	
Point	O
mutation	O
of	O
the	O
c-Myb	B-DNA
site	I-DNA
within	O
the	O
intact	O
2.3-kb	B-protein
LCR	I-protein
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	B-DNA
activity	O
in	O
transgenic	B-cell_line
thymocytes	I-cell_line
.	O
	
Within	O
the	O
context	O
of	O
a	O
complex	B-DNA
enhancer	I-DNA
and	O
LCR	B-DNA
,	O
c-Myb	B-protein
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	B-DNA
gene	I-DNA
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O
	
###MEDLINE:95403454	
	
A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
zinc	B-protein
finger	I-protein
proteins	I-protein
Sp1	B-protein
and	O
EGR-1	B-protein
.	O
	
Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O
	
Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-protein
factors	I-protein
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
stimulated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
	
Here	O
we	O
describe	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
domain	I-DNA
.	O
	
This	O
region	O
(	O
termed	O
the	O
zinc	B-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
region	I-DNA
(	O
ZIP	B-DNA
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B-protein
finger	I-protein
proteins	I-protein
:	O
the	O
constitutively	B-protein
expressed	I-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
and	O
the	O
inducible	B-protein
early	I-protein
growth	I-protein
response	I-protein
protein	I-protein
EGR-1	B-protein
.	O
	
In	O
unstimulated	B-cell_type
cells	I-cell_type
which	O
do	O
not	O
secrete	O
IL-2	B-protein
,	O
only	O
Sp1	B-protein
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-cell_line
IL-2	I-cell_line
secreting	I-cell_line
cells	I-cell_line
the	O
inducible	B-protein
EGR-1	I-protein
protein	I-protein
recognizes	O
this	O
element	O
.	O
	
In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
the	O
ZIP	B-DNA
site	I-DNA
serves	O
as	O
an	O
activator	O
for	O
IL-2	B-protein
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	B-DNA
and	O
NFAT	B-DNA
binding	I-DNA
sites	I-DNA
is	O
required	O
for	O
maximal	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O
	
These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	B-DNA
site	I-DNA
for	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O
	
###MEDLINE:95385995	
	
Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
by	O
the	O
LEF-1	B-protein
HMG	I-protein
protein	I-protein
on	O
nucleosome-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O
	
Lymphoid	B-protein
enhancer-binding	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	B-protein
)	O
is	O
a	O
regulatory	B-protein
high	I-protein
mobility	I-protein
group	I-protein
(	I-protein
HMG	I-protein
)	I-protein
protein	I-protein
that	O
activates	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
in	O
a	O
context-restricted	O
manner	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
	
In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
which	O
contains	O
DNA-binding	B-DNA
sites	I-DNA
for	O
LEF-1	B-protein
and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B-protein
.	O
	
First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	I-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
LEF-1/GAL4	B-protein
can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	I-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O
	
Second	O
,	O
recombinant	B-protein
LEF-1	I-protein
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O
	
By	O
using	O
a	O
nucleosome	B-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B-protein
(	O
or	O
LEF-1	B-protein
and	O
Ets-1	B-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	I-protein
,	O
Sp1	B-protein
.	O
	
Addition	O
of	O
TFE-3	B-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	I-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O
	
Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer-binding	B-protein
proteins	I-protein
(	O
LEF-1	B-protein
,	O
Ets-1	B-protein
,	O
and	O
TFE-3	B-protein
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B-protein
.	O
	
A	O
truncation	B-protein
mutant	I-protein
of	O
LEF-1	B-protein
(	O
HMG-88	B-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	I-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	I-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	I-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	I-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O
	
We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B-protein
in	O
vitro	O
is	O
a	O
chromatin	B-DNA
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B-protein
domain	I-protein
in	O
addition	O
to	O
the	O
HMG	B-protein
domain	I-protein
.	O
	
###MEDLINE:95370270	
	
HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
induce	O
activation	O
of	O
activated	O
protein-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O
	
Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV	O
,	O
gp	B-protein
160	I-protein
,	O
can	O
induce	O
activation	O
of	O
transcription	B-protein
factor	I-protein
,	I-protein
activated	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O
	
The	O
stimulatory	O
effects	O
of	O
gp160	B-protein
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
treatment	O
of	O
gp160	B-protein
with	O
soluble	O
CD4-IgG	B-protein
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-protein
.	O
	
Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O
	
The	O
gp160-induced	B-protein
AP-1	I-protein
complex	I-protein
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O
	
This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O
	
This	O
gp160	B-protein
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B-cell_type
cells	I-cell_type
:	O
pre-treatment	O
of	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
gp160	B-protein
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti-CD3	B-protein
-induced	O
interleukin-2	B-protein
secretion	O
.	O
	
Effects	O
similar	O
to	O
gp160	B-protein
were	O
seen	O
with	O
anti-CD4	B-protein
mAb	I-protein
.	O
	
The	O
aberrant	O
activation	O
of	O
AP-1	B-protein
by	O
gp160	B-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B-protein
containing	O
AP-1	B-DNA
sites	I-DNA
,	O
e.g	O
.	O
interleukin-3	B-protein
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	I-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B-protein
secretion	O
.	O
	
